<SEC-DOCUMENT>0000950170-24-091193.txt : 20240806
<SEC-HEADER>0000950170-24-091193.hdr.sgml : 20240806
<ACCEPTANCE-DATETIME>20240806070023
ACCESSION NUMBER:		0000950170-24-091193
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		58
CONFORMED PERIOD OF REPORT:	20240630
FILED AS OF DATE:		20240806
DATE AS OF CHANGE:		20240806

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Pediatrix Medical Group, Inc.
		CENTRAL INDEX KEY:			0000893949
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-HOSPITALS [8060]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		IRS NUMBER:				263667538
		STATE OF INCORPORATION:			FL
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-12111
		FILM NUMBER:		241177014

	BUSINESS ADDRESS:	
		STREET 1:		1301 CONCORD TERRACE
		CITY:			SUNRISE
		STATE:			FL
		ZIP:			33323
		BUSINESS PHONE:		9543840175

	MAIL ADDRESS:	
		STREET 1:		1301 CONCORD TERRACE
		CITY:			SUNRISE
		STATE:			FL
		ZIP:			33323

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	MEDNAX, INC.
		DATE OF NAME CHANGE:	20090102

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PEDIATRIX MEDICAL GROUP INC
		DATE OF NAME CHANGE:	19950801
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>md-20240630.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- DFIN New ActiveDisclosure (SM) Inline XBRL Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2024-08-05T14:02:49.3777+00:00 -->
<!-- Copyright (c) 2024 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:md="http://www.mednax.com/20240630" xmlns:calc="https://xbrl.org/2023/calculation-1.1" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ecd-sub="http://xbrl.sec.gov/ecd-sub/2024" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16" xmlns:srt="http://fasb.org/srt/2024" xmlns:utr="http://www.xbrl.org/2009/utr">
 <head>
  <title>10-Q</title>
  <meta http-equiv="Content-Type" content="text/html"/>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric id="F_b8aeeed6-e408-4eb5-973c-15d85dbd4147" name="dei:AmendmentFlag" contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf">false</ix:nonNumeric><ix:nonNumeric id="F_fdecb36e-d533-4416-9a31-4b9149c64ca1" name="dei:EntityCentralIndexKey" contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf">0000893949</ix:nonNumeric><ix:nonNumeric id="F_91680b13-2b28-4ece-b9f1-d83205e91a05" name="dei:DocumentFiscalPeriodFocus" contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf">Q2</ix:nonNumeric><ix:nonNumeric id="F_5a1747dc-191d-4580-8b2a-c28d00f9f79c" name="dei:CurrentFiscalYearEndDate" contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf">--12-31</ix:nonNumeric><ix:nonFraction id="F_63ef34ef-3859-4003-9f94-acd5a8cf0ae8" name="us-gaap:CommitmentsAndContingencies" contextRef="C_378538d0-b7e1-4ecd-af00-bb424f0b1747" unitRef="U_USD" xsi:nil="true"/><ix:nonFraction id="F_2480f1a6-5340-4f8f-9b78-b9de431629ea" name="us-gaap:CommitmentsAndContingencies" contextRef="C_01d46517-67df-489d-b34d-e087cf6dadaf" unitRef="U_USD" xsi:nil="true"/><ix:nonFraction id="F_4ef21d0f-768e-4fd9-ac98-0f999e424f57" name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="C_378538d0-b7e1-4ecd-af00-bb424f0b1747" unitRef="U_USDollarShare" decimals="2" scale="0" format="ixt:num-dot-decimal">0.01</ix:nonFraction><ix:nonFraction id="F_aa5b77d8-2818-431e-b57f-9e1e031ea043" name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="C_01d46517-67df-489d-b34d-e087cf6dadaf" unitRef="U_USDollarShare" decimals="INF" format="ixt:num-dot-decimal">0.01</ix:nonFraction><ix:nonFraction id="F_e97295ab-73a6-4c14-8a53-7e8ab77b99d6" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="C_378538d0-b7e1-4ecd-af00-bb424f0b1747" unitRef="U_USDollarShare" decimals="2" scale="0" format="ixt:num-dot-decimal">0.01</ix:nonFraction><ix:nonFraction id="F_4b51cbce-e856-447d-8cac-01d0d16055b3" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="C_01d46517-67df-489d-b34d-e087cf6dadaf" unitRef="U_USDollarShare" decimals="INF" format="ixt:num-dot-decimal">0.01</ix:nonFraction></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="md-20240630.xsd"/></ix:references><ix:resources><xbrli:context id="C_82895573-2795-4732-b42c-4cd5883caf98"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">md:UnnamedCorporateJointVentureOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_85f3a02e-88e7-4e7f-b8f5-7e31732a7772"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">md:ContractedManagedCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8693cd13-0631-41d8-8347-98d3ec5b732d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_86bb4acc-ec76-4db5-933a-a771e7cd3750"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8c03e792-f7c1-4fa1-9f86-8c10e39fa1ac"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8d682d9c-f4a6-4720-b0e5-6aba644d655b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:HealthCarePatientServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_925f1f8e-686d-4cc3-b111-72650c3e2456"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9478e6ac-d067-47ed-985a-d3a75cbb347e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">md:RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9909352a-5fba-478d-bc57-50fb72a6c67d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9949ee77-7752-43b8-9d0b-21296bfbc11e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_999199c5-cb3d-47a6-abb8-3629d31afbe9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AllOtherCorporateBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9997289e-fdb8-486e-acac-cb788b4f8239"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">md:RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9a4ff3c3-70d2-4f27-923d-76e5a8c48431"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:GovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9d8d79b8-258d-4977-8e93-a832860452f4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">md:RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9f05953b-1f07-4686-942c-7b1d7943d27f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a03ab9fe-6fdf-4312-9317-7df9fc924d88"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">md:TwoZeroThreeZeroMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a04037ee-9a78-4964-9e1c-74fa20cac8af"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a0685afe-439a-454c-a102-de37c36a07ad"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">md:FivePointThreeSevenFivePercentUnsecuredSeniorNotesDueTwoThousandThirtyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a20b1ed9-1ed7-4cc0-9d05-984cabc1cbec"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">md:ContractedManagedCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a20e0eec-fcf2-491f-ad41-9a428f13e263"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a23f2efb-8927-4491-a7c8-c1b619aa2e83"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">md:RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a24c8561-3fe8-4ee9-9a5f-3650008ddd53"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a3930cd6-349a-4a67-8e41-4578fe93ff88"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a816572a-ebf4-473a-a445-92cc3d3335f4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_aab2ef2b-f5d5-463b-af2e-d14d85478a3f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">md:MaternalFetalMedicinePracticeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_aacf8890-734e-41da-b969-870124e61507"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ab52b5b0-1d74-4f4b-8f22-0ab60d83e515"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ac837f6b-5715-4c36-8c4a-be2ace21a7e2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">md:ContractedManagedCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_aea590f4-2725-4610-b86d-be28415452fc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b2e57193-b6ec-4e23-91dd-bd0d8c1391a7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b55fcf9b-75fb-43d4-8441-f6cc48e23e07"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b76e1e1c-7e08-49c4-ba42-36b7776b9c77"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">md:RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b87610a2-4379-4ba9-97b7-9e4606d8ef5c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bbfdd70c-5aff-4803-b853-9aed8b435db7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bf0934a0-5844-404d-a376-9a2eb1aa3de7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">md:RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c38ac2d9-9615-4715-baeb-08e4368151a9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c4efd93d-fa74-4b60-99aa-628c88395267"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c97ff8ba-a0bb-4c2f-9d12-7e68bbd283c7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ca171fc2-2432-408d-b564-cd2e7563ba71"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">md:RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ca383e94-5006-4063-9440-291a788feb2a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cc98a5b3-d80a-4eb1-aeee-1a0e562d5e27"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:SelfPayMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cd8a1422-f4cb-4c26-b354-491001ddef25"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d2b8faaa-e3b4-40e7-b170-e0b31556d8c0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d3b7b754-9615-4731-9358-8ab2afbdb4a3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d408367b-f06f-4217-a293-02fa802d8521"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">md:CreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d564d4a9-a926-457b-80b1-01fa631a1e4f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d65f3724-0e7f-4c6c-b50d-444cfddf4c6b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d6aad445-12fd-4b00-8591-81e1e41d8cfd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">md:HospitalsContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d6bf2c94-ac55-40fc-90b0-8184b979a967"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_dc0ea4b3-aac8-4793-b9f2-f1f63e43c02c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">md:NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_dec064d9-341f-4d43-8d13-9380383f1ea2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:HealthCarePatientServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e0420691-52ea-4671-94fc-b8e7b69e3142"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">md:FivePointThreeSevenFivePercentUnsecuredSeniorNotesDueTwoThousandThirtyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-11</xbrli:startDate><xbrli:endDate>2022-02-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e050a756-0027-4664-943e-74db5426b7c8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">md:CreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e1d34d08-f45e-4aed-a85a-ba2eecf7da87"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e3eb8c28-c7e1-4a49-b42b-e63f13e290c4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:GovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e6d4fa65-6594-4957-b174-3dcd01093f75"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:SelfPayMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_eb6de81c-9c30-48c6-8848-0a4491bbd3cf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_edb2e0fd-b34b-4b67-8c89-128090856b98"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ef12bbdb-7da5-4d1d-98f3-f1b0c3da31ba"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ef9ac9e9-8f0b-4197-8eb4-12ca2061e14f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">md:RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f2de318d-f0fc-45fc-a7dd-1d90eebc8aff"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f58ff9fd-0a96-40d3-97e1-a038b63ab720"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f80a1315-a5a6-418b-98c4-fc56bd22ae95"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f8ba14c0-203a-4abe-895a-7068e0d681d9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f9deda8d-474c-400c-8f2b-c04bdaea334d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_feaa2e55-4022-4e2f-abe1-edb33b1f5e36"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0037f299-00cc-441c-a3a7-d37288934aaf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_01c11cbc-05a6-4e7d-bb87-a2a2acb9a949"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_01d46517-67df-489d-b34d-e087cf6dadaf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_055fb263-9778-4cf7-8395-b3db5ae74ab3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0971ef72-7587-4d12-8daf-522e84254143"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_097f26a0-c77e-4f84-b663-38d6391e01e6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0b63294a-0107-49a4-a13e-bda5f278d21c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-11</xbrli:startDate><xbrli:endDate>2022-02-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0ca0f3da-cd87-48f0-9af2-4b8a86903bc0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">md:AmendedAndRestatedTwoThousandEightPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_12147e67-2e9c-4442-8daa-56def203d5b7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:HealthCarePatientServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_121e7382-aaaf-4b4b-b85f-ca7209a14358"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_13c390ad-a46f-4851-8328-8c24f9da6308"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">md:FivePointThreeSevenFivePercentUnsecuredSeniorNotesDueTwoThousandThirtyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_156059b8-27ec-4255-9fd4-8a26b81f0b31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1786cd13-4a3f-41ee-8fba-517746735e35"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1c3d0626-f775-4377-9dde-87804a3a8785"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1e093f6f-db74-422e-95ac-c5b0a5e76558"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">md:RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_207dae80-b868-42b4-8f60-529bb2da464b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_21d152cb-f002-4995-a0e6-8a4087443620"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_21dc151c-5f14-4067-a9f0-945b9851cd13"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-02-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2656143a-67b9-4650-b483-9f48b62093d5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_26ef4d6b-17ee-42a8-8ef0-3a3202107d61"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">md:HospitalsContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_270805f0-aab2-410a-81a6-0fd72e3a746a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2bb8a119-7219-4b9c-be50-62118be95425"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2d25298d-eb54-4bce-a6ef-521cc063eeb3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">md:NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_31b43498-9159-4c16-bd8b-ab5cef5e0575"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_322f434d-d131-49bb-a0d5-c51c55aa30d0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">md:ContractedManagedCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_32a74e36-4b2a-435f-abc7-46f886f94451"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">md:TwoThousandFifteenNonQualifiedStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_35df4ea0-7c25-462a-83e1-ff1079f8091e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3610c317-f612-4c22-9d38-5d8900ab3930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_378538d0-b7e1-4ecd-af00-bb424f0b1747"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3c0663a6-a6a7-4ee3-809d-8c8aeb1fca8a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:GovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3c7dc91a-a1a8-4164-8011-aa824e2173f1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3c816b3b-c82c-4a26-bf82-3219ef7103e7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:HealthCarePatientServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3f38e980-706e-4b34-b4a0-c3cf6a91f926"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">md:HospitalsContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_407e9c0c-05d2-4164-85d8-d7f2fdffa0b3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">md:SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-02-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_44713f7f-0be3-44e5-8ff8-456f9638bcb6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AllOtherCorporateBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4506227b-6467-48fd-bf2a-12d647f3a96a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">md:CreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_45e7bb15-6f89-4eb6-9120-7ec8d161f85b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4753588f-87b9-420c-894d-f10c964db638"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_47c0d2ef-584a-4c5e-ae36-b63c1c605bcc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4ddfa92a-fd22-4353-88c1-befe81c45dca"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">md:RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4fd51aa1-699c-4d1f-a3f5-aa92a33bc175"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">md:MaternalFetalMedicinePracticeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_51999449-03d0-412b-a0e1-24677d710d3a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">md:FivePointThreeSevenFivePercentUnsecuredSeniorNotesDueTwoThousandThirtyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-02-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5207957e-5a84-4d96-961c-054e57351b74"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_57ad6014-6b49-4fd8-b8f7-ae2932078fd6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5875e45d-cd89-498d-903a-55b9e7739c94"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_594a2ea7-65e0-4290-83d4-8be74d122ddc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5a5fa8ad-967b-444b-af35-7dd7a8bf7ba3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5b39fcf4-ee54-4657-b078-1fee2e008ed8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:SelfPayMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5dea8f8c-6ce2-4ac6-b2b8-2c6020fb27ef"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">md:NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5f0c50a0-53ad-41c3-8101-90e7e5cacb14"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_601000a8-e8a9-4fb8-a90f-f1923b0d6484"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-08-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_60b78123-38d8-4d05-8a9b-e087fe9016a9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_671fe710-eb0a-40ea-9b5f-3fc84da58634"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_690872af-c97c-4e54-9314-3d7d7de3a6f3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">md:NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6ac5d2f3-36f9-4043-a22d-1a055bff677d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:GovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6cc6fddd-3fb2-40be-bc2f-d396ff6d56c5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:SelfPayMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_70422dcf-ff02-49e5-8b94-24099256e942"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">md:AmendedAndRestatedTwoThousandEightPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_73da6023-b99b-4424-9d33-e387db8c2e30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">md:HospitalsContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_74e636e1-15c7-4b53-87ca-8d27ceeed147"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">md:TwoZeroThreeZeroMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7c834d47-d5d5-4daa-8490-432e04b450c3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7cf5d7c6-f082-42c8-aa0e-fe1ed65ec2d0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="U_pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="U_shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="U_USDollarShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="U_Number"><xbrli:measure>md:Number</xbrli:measure></xbrli:unit><xbrli:unit id="U_USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="FNT_744c8b1e-b9b8-41e6-bb9a-b20ca1c97fb6" fromRefs="F_66ce8c6b-bf02-4620-aebb-b797c84e03c0 F_366def61-6f60-45f1-ba3d-c025beb3a2f3 F_57572a1b-018e-4ddb-a8a8-a910ae1e8652 F_76080b36-bd54-43be-8e29-8555378a28cc"/></ix:resources></ix:header></div>
  <div style="padding-top:0.5in;min-height:0.63in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:2.25pt double;text-align:center;"><span style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:16pt;font-family:Times New Roman;min-width:fit-content;">UNITED STATES</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:16pt;font-family:Times New Roman;min-width:fit-content;">SECURITIES AND EXCHANGE COMMISSION</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Washington, D.C. 20549</span></p>
  <p style="margin-left:26.667%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;margin-right:26.667%;text-align:center;"><span style="white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:16pt;font-family:Times New Roman;min-width:fit-content;">FORM </span><span style="font-size:16pt;font-family:Times New Roman;"><ix:nonNumeric id="F_878c859f-ed24-4599-ad73-2b01483005a4" contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf" name="dei:DocumentType"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:16pt;font-family:Times New Roman;min-width:fit-content;">10-Q</span></ix:nonNumeric></span></p>
  <p style="margin-left:26.667%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;margin-right:26.667%;text-align:center;"><span style="white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:-4.895%;padding-left:4.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:11pt;font-family:Times New Roman;"><ix:nonNumeric id="F_abe76e55-9124-47dc-9414-e810df560035" contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf" name="dei:DocumentQuarterlyReport" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">    QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></p>
  <p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For the quarterly period ended </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2815cd63-c384-44bb-81e0-f3796d624791" contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">June 30, </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f6be0db4-9723-44dc-b4de-370c7e8e016a" contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf" name="dei:DocumentFiscalYearFocus"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2024</span></ix:nonNumeric></span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">OR</span></p>
  <p style="text-indent:-4.895%;padding-left:4.667%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:11pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d441f37b-01bc-41d4-a069-e9759e531b74" contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">     TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></p>
  <p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For the transition period from ______ to ______</span></p>
  <p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Commission File Number: </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2af863cd-0ab4-41cb-9f60-96b99e1d3172" contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf" name="dei:EntityFileNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">001-12111</span></ix:nonNumeric></span></p>
  <p style="margin-left:26.667%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;margin-right:26.667%;text-align:center;"><span style="white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img260269913_0.jpg" alt="img260269913_0.jpg" style="width:134px;height:84px;"/>&#160;</p>
  <p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:14.5pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a942fa3f-1fd2-4126-92be-4c0b81c647ab" contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf" name="dei:EntityRegistrantName"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:14.5pt;font-family:Times New Roman;min-width:fit-content;">Pediatrix Medical Group, Inc.</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">(Exact name of registrant as specified in its charter)</span></p>
  <p style="margin-left:26.667%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;margin-right:26.667%;text-align:center;"><span style="white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:47.71%;"/>
    <td style="width:3.821%;"/>
    <td style="width:48.47%;"/>
   </tr>
   <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><ix:nonNumeric id="F_071fb06a-a537-4070-a7b4-3e11c4206a96" contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Florida</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><ix:nonNumeric id="F_72f58580-758b-4312-a3cf-dd7d8917f6f7" contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf" name="dei:EntityTaxIdentificationNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">26-3667538</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(State or other jurisdiction of</span></p><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Incorporation or organization)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(I.R.S. Employer</span></p><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Identification No.)</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;text-indent:48.95pt;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="margin-left:48.95pt;text-indent:0;font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><ix:nonNumeric id="F_f7b1e011-a2c0-4024-a5de-b0bd3cfbec9b" contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf" name="dei:EntityAddressAddressLine1"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">1301 Concord Terrace</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><ix:nonNumeric id="F_623670a5-e201-47d6-8438-7c89499c81c0" contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf" name="dei:EntityAddressCityOrTown"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Sunrise</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;min-width:fit-content;">, </span><span style="font-size:9pt;"><ix:nonNumeric id="F_96dcc374-78df-481a-9e4d-5dd997370b78" contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Florida</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><ix:nonNumeric id="F_6fa493bf-5a29-47ff-8110-180df21d129b" contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf" name="dei:EntityAddressPostalZipCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">33323</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Address of principal executive offices)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Zip Code)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_02e38c25-cb75-45a4-a1d2-574a092dd90a" contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf" name="dei:CityAreaCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">954</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">) </span><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f926ce2a-b916-42ed-b95f-a9d74852618a" contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf" name="dei:LocalPhoneNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">384-0175</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">(Registrant's telephone number, including area code)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Not Applicable</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">(Former name, former address and former fiscal year, if changed since last report)</span></p>
  <p style="margin-left:26.667%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;margin-right:26.667%;text-align:center;"><span style="white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:4pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:4pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Securities registered pursuant to Section 12(b) of the Act:</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:39.76%;"/>
    <td style="width:1%;"/>
    <td style="width:18.08%;"/>
    <td style="width:1.06%;"/>
    <td style="width:40.1%;"/>
   </tr>
   <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-left:0.06in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.06in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Title of each class</span></p></td>
    <td style="text-indent:31.5pt;padding-left:0.06in;vertical-align:top;border-bottom:0.5pt solid #ffffff03;padding-right:0.06in;"><p style="text-indent:-31.5pt;padding-left:31.5pt;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="text-indent:31.5pt;padding-left:0.06in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.06in;"><p style="text-indent:-31.5pt;padding-left:31.5pt;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Trading Symbol</span></p></td>
    <td style="text-indent:31.5pt;padding-left:0.06in;vertical-align:top;border-bottom:0.5pt solid #ffffff03;padding-right:0.06in;"><p style="text-indent:-31.5pt;padding-left:31.5pt;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-left:0.06in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.06in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Name of each exchange on which registered</span></p></td>
   </tr>
   <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-left:0.06in;vertical-align:top;padding-right:0.06in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><ix:nonNumeric id="F_4fe3de21-ad84-411c-a9a7-1b8fb7a26390" contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf" name="dei:Security12bTitle"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Common Stock, par value $.01 per share</span></ix:nonNumeric></span></p></td>
    <td style="text-indent:4.5pt;padding-left:0.06in;vertical-align:top;padding-right:0.06in;"><p style="margin-left:4.5pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="text-indent:4.5pt;padding-left:0.06in;vertical-align:top;padding-right:0.06in;"><p style="margin-left:4.5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><ix:nonNumeric id="F_4141d140-2a7a-4e5e-b541-39c8fddd4089" contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf" name="dei:TradingSymbol"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">MD</span></ix:nonNumeric></span></p></td>
    <td style="text-indent:4.5pt;padding-left:0.06in;vertical-align:top;padding-right:0.06in;"><p style="margin-left:4.5pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-left:0.06in;vertical-align:top;padding-right:0.06in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><ix:nonNumeric id="F_43843b92-51d6-425b-9d1e-c33e7c35ce46" contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">New York Stock Exchange</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. </span><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c83ce910-dc22-4a3c-a4d3-88cedccc8f42" contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf" name="dei:EntityCurrentReportingStatus"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">   &#9745;  No   &#9744;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). </span><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f638644d-d65c-467f-b9a1-66e53834fc1a" contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf" name="dei:EntityInteractiveDataCurrent"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">   &#9745;  No   &#9744;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:18.455%;"/>
    <td style="width:1.946%;"/>
    <td style="width:55.527%;"/>
    <td style="width:22.066%;"/>
    <td style="width:2.006%;"/>
   </tr>
   <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;"><ix:nonNumeric id="F_67e3563b-07c6-4da0-b305-6a0c088bf233" contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Large accelerated filer</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#9745;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accelerated filer</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#9744;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Non-accelerated filer</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#9744;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Smaller reporting company</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;"><ix:nonNumeric id="F_03719006-f0c6-4c3c-b2e4-7b6f07d3f8e0" contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Emerging growth company</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;"><ix:nonNumeric id="F_fe810309-c01a-4685-9df1-8d64b5264f0d" contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.63in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.   &#9744;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes &#9744; No   </span><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_cd022a49-36a4-4276-afaf-21a55bf75f4d" contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf" name="dei:EntityShellCompany" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#9745;</span></ix:nonNumeric></span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">On August 2, 2024, the registrant had outstanding </span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a8df0810-800b-491e-8f06-c5e55306d211" contextRef="C_601000a8-e8a9-4fb8-a90f-f1923b0d6484" name="dei:EntityCommonStockSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">85,865,841</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> shares of Common Stock, par value $.01 per share.</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:2.25pt double;text-align:left;"><span style="white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pediatrix Medical Group, Inc.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">INDEX</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:10.74%;"/>
    <td style="width:84%;"/>
    <td style="width:5.26%;"/>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;min-width:fit-content;">Page</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">PART I - FINANCIAL INFORMATION</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#financial_statements"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Item 1.</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#financial_statements"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Financial Statements</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#balance_sheet"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Consolidated Balance Sheets as of June 30, 2024 and December 31, 2023 (Unaudited)</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#statements_income"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Consolidated Statements of Income and Comprehensive Income for the Three and Six Months</span><span style="color:#0000ff;white-space:pre-wrap;min-width:fit-content;"> </span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#statements_income"><span style="color:#0000ff;white-space:pre-wrap;min-width:fit-content;">   </span><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Ende</span></a><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">d </span><a href="#statements_income"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">June 30, 2024 and 2023 (Unaudited)</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#statements_equity"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Consolidated Statements of Equity for the Three and Six Months Ended</span></a></p><p style="text-indent:7.2pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#statements_equity"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">June 30, 2024 and 2023 (Unaudited)</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#statements_cash_flows"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Consolidated Statements of Cash Flows for the Six Months Ended</span></a></p><p style="text-indent:7.2pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#statements_cash_flows"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">June 30, 2024 and 2023 (Unaudited)</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#notes_financial_statements"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Notes to Consolidated Financial Statements (Unaudited)</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#mda"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Item 2.</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#mda"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_3"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Item 3.</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_3"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Quantitative and Qualitative Disclosures About Market Risk</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_4"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Item 4.</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_4"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Controls and Procedures</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#part_ii"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline;min-width:fit-content;">PART II - OTHER INFORMATION</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Item 1.</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Legal Proceedings</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">22</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1a"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Item 1A.</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1a"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Risk Factors</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">22</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_2"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Item 2.</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_2"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Unregistered Sales of Equity Securities and Use of Proceeds</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">22</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_5"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Item 5.</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_5"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Other Information</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">22</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#exhibit_index"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Item 6.</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#exhibit_index"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Exhibits</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">23</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#signatures"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline;min-width:fit-content;">SIGNATURES</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">24</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">2</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.3in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="financial_statements"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">P</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">e</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">diatrix Medical Group, Inc.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="balance_sheet"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Consolidated</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Balance Sheets</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">(in thousands, except share data)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">(Unaudited)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:67.287%;"/>
    <td style="width:1.46%;"/>
    <td style="width:1%;"/>
    <td style="width:12.897%;"/>
    <td style="width:1%;"/>
    <td style="width:1.46%;"/>
    <td style="width:1%;"/>
    <td style="width:12.897%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">June 30, 2024</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">ASSETS</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:10pt;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Current assets:</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash and cash equivalents</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c2e8e59e-36ab-4b92-be60-7f44f4a7bb07" contextRef="C_378538d0-b7e1-4ecd-af00-bb424f0b1747" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19,402</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b8692d79-01fd-4bed-917e-aa4c52e2652b" contextRef="C_01d46517-67df-489d-b34d-e087cf6dadaf" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">73,258</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Short-term investments</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b46a0fac-6be4-4f58-843e-633f101b25d1" contextRef="C_378538d0-b7e1-4ecd-af00-bb424f0b1747" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">113,795</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fa835bb8-9cd5-4c64-b198-45eca3ff8d44" contextRef="C_01d46517-67df-489d-b34d-e087cf6dadaf" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">104,485</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accounts receivable, net</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_30b50649-f7f1-461e-937c-471a10b2b5f2" contextRef="C_378538d0-b7e1-4ecd-af00-bb424f0b1747" name="us-gaap:AccountsReceivableNetCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">274,164</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1af21e01-0aee-4e25-bfa3-913fe9ca8b6f" contextRef="C_01d46517-67df-489d-b34d-e087cf6dadaf" name="us-gaap:AccountsReceivableNetCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">272,313</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Prepaid expenses</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d42ab78d-dbc9-4217-9575-bec6943114a7" contextRef="C_378538d0-b7e1-4ecd-af00-bb424f0b1747" name="us-gaap:PrepaidExpenseCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,910</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_081afc76-4fe7-403e-98ee-ddb167e3ecc2" contextRef="C_01d46517-67df-489d-b34d-e087cf6dadaf" name="us-gaap:PrepaidExpenseCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,525</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Income taxes receivable</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e7b713aa-2910-4e42-b174-ea90897b030e" contextRef="C_378538d0-b7e1-4ecd-af00-bb424f0b1747" name="us-gaap:IncomeTaxReceivable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6d2e74c1-5bc3-408c-a4d0-fd9b2f775267" contextRef="C_01d46517-67df-489d-b34d-e087cf6dadaf" name="us-gaap:IncomeTaxReceivable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,565</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other current assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5373c66c-e7ad-4576-8b5b-7a3a2a8f6716" contextRef="C_378538d0-b7e1-4ecd-af00-bb424f0b1747" name="us-gaap:OtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,941</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e40e0741-b23e-421a-a871-bcd0d9cf6504" contextRef="C_01d46517-67df-489d-b34d-e087cf6dadaf" name="us-gaap:OtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,308</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:30pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:30pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total current assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_db316433-c05d-491c-962e-970d6565b2b0" contextRef="C_378538d0-b7e1-4ecd-af00-bb424f0b1747" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">429,212</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1974b26e-7ad4-4975-a884-5d2e48e32cc5" contextRef="C_01d46517-67df-489d-b34d-e087cf6dadaf" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">483,454</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Property and equipment, net</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f74107c8-2c3e-4d40-af29-ab56845b1c4b" contextRef="C_378538d0-b7e1-4ecd-af00-bb424f0b1747" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">47,893</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_70ada1f9-6082-44ad-938d-c2842f16c53b" contextRef="C_01d46517-67df-489d-b34d-e087cf6dadaf" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">75,639</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Goodwill</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_99f608db-5888-447e-b515-1af3e26da74e" contextRef="C_378538d0-b7e1-4ecd-af00-bb424f0b1747" name="us-gaap:Goodwill" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,239,007</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_36e4179c-fbd1-48c1-8c2c-0cca4a8604f6" contextRef="C_01d46517-67df-489d-b34d-e087cf6dadaf" name="us-gaap:Goodwill" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,384,166</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Intangible assets, net</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f142b4a9-dc90-40fe-a4d9-ba77cdbf4fb8" contextRef="C_378538d0-b7e1-4ecd-af00-bb424f0b1747" name="us-gaap:FiniteLivedIntangibleAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,193</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_90351aa9-02dc-41c1-aefb-3cebc67eb103" contextRef="C_01d46517-67df-489d-b34d-e087cf6dadaf" name="us-gaap:FiniteLivedIntangibleAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21,240</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating and finance lease right-of-use assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3e55c185-2cdb-4df7-89cc-2982934e7626" contextRef="C_378538d0-b7e1-4ecd-af00-bb424f0b1747" name="md:OperatingAndFinanceLeaseRightOfUseAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">65,392</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a6c20bf3-0487-4582-ba9d-9f6ece39edb3" contextRef="C_01d46517-67df-489d-b34d-e087cf6dadaf" name="md:OperatingAndFinanceLeaseRightOfUseAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">70,294</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred income tax assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0fffbc99-02d0-45c0-922e-bf6fda49b41c" contextRef="C_378538d0-b7e1-4ecd-af00-bb424f0b1747" name="us-gaap:DeferredIncomeTaxAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">124,115</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fb8d8785-2961-4b5d-a92f-5659c91fdfdf" contextRef="C_01d46517-67df-489d-b34d-e087cf6dadaf" name="us-gaap:DeferredIncomeTaxAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">102,852</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e6e4f006-f5aa-4faa-b9f2-adfe5da57721" contextRef="C_378538d0-b7e1-4ecd-af00-bb424f0b1747" name="us-gaap:OtherAssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">79,539</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f1db2186-34ef-4c19-82fe-bbe2d2cde230" contextRef="C_01d46517-67df-489d-b34d-e087cf6dadaf" name="us-gaap:OtherAssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">82,165</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f62b32e2-547e-4159-8b23-22d3ddf4dbd9" contextRef="C_378538d0-b7e1-4ecd-af00-bb424f0b1747" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,995,351</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b89edfa6-ed55-4e26-8cfd-c3ee299b6a77" contextRef="C_01d46517-67df-489d-b34d-e087cf6dadaf" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,219,810</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">LIABILITIES AND SHAREHOLDERS' EQUITY</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Current liabilities:</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accounts payable and accrued expenses</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a80a6143-0356-4a77-b74d-f82736dbe1a6" contextRef="C_378538d0-b7e1-4ecd-af00-bb424f0b1747" name="md:AccountsPayableAndAccruedLiabilitiesExcludingAccruedIncomeTaxesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">267,333</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_91f483fb-9fec-4275-ab6b-a93480a3c1e2" contextRef="C_01d46517-67df-489d-b34d-e087cf6dadaf" name="md:AccountsPayableAndAccruedLiabilitiesExcludingAccruedIncomeTaxesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">350,798</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Current portion of debt and finance lease liabilities, net</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5bcfbc95-3e8d-472d-af31-789e3bc31cab" contextRef="C_378538d0-b7e1-4ecd-af00-bb424f0b1747" name="us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,730</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e02d36ea-f4d6-42f2-9e6c-788f441a5742" contextRef="C_01d46517-67df-489d-b34d-e087cf6dadaf" name="us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,913</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Current portion of operating lease liabilities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_64dd5627-bc84-434c-9b11-00f87addafa8" contextRef="C_378538d0-b7e1-4ecd-af00-bb424f0b1747" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">18,764</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2c17fb10-ec48-43bb-8711-03e6f156e7e4" contextRef="C_01d46517-67df-489d-b34d-e087cf6dadaf" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21,076</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Income taxes payable</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_307948ff-9c18-4486-9b5f-7a17a8392a24" contextRef="C_378538d0-b7e1-4ecd-af00-bb424f0b1747" name="us-gaap:AccruedIncomeTaxesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,329</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9bfb9bde-7f56-4821-a7c9-f5b48c5f10ec" contextRef="C_01d46517-67df-489d-b34d-e087cf6dadaf" name="us-gaap:AccruedIncomeTaxesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,159</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total current liabilities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9f237141-6422-41cc-9660-6004ce8a3fe2" contextRef="C_378538d0-b7e1-4ecd-af00-bb424f0b1747" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">310,156</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_74f1a89e-b486-4c99-af1e-8ada466d1c7e" contextRef="C_01d46517-67df-489d-b34d-e087cf6dadaf" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">388,946</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Long-term debt and finance lease liabilities, net</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4508757b-5d91-4614-9ef3-50f237cc251f" contextRef="C_378538d0-b7e1-4ecd-af00-bb424f0b1747" name="md:LongTermDebtAndCapitalLeaseObligationsExcludingLongTermLineOfCredit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">612,640</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ec1e097f-e076-4975-bfb7-18c6acabe253" contextRef="C_01d46517-67df-489d-b34d-e087cf6dadaf" name="md:LongTermDebtAndCapitalLeaseObligationsExcludingLongTermLineOfCredit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">618,421</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Long-term operating lease liabilities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2bc8b425-5784-455d-bdcc-edb19bdda607" contextRef="C_378538d0-b7e1-4ecd-af00-bb424f0b1747" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">49,176</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_15677f25-a14f-4a9e-8cc1-23388ac597ab" contextRef="C_01d46517-67df-489d-b34d-e087cf6dadaf" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">47,238</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Long-term professional liabilities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9f84396c-e56f-42aa-babc-ea14c8a12948" contextRef="C_378538d0-b7e1-4ecd-af00-bb424f0b1747" name="us-gaap:MalpracticeLossContingencyAccrualUndiscountedNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">254,770</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ce1aede2-1e21-426b-a907-bc5bb4e48d49" contextRef="C_01d46517-67df-489d-b34d-e087cf6dadaf" name="us-gaap:MalpracticeLossContingencyAccrualUndiscountedNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">251,284</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred income tax liabilities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_64aaa779-7047-4460-a080-655c8248f00f" contextRef="C_378538d0-b7e1-4ecd-af00-bb424f0b1747" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">30,627</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_213330b2-381c-4efc-a96e-1954c84aec33" contextRef="C_01d46517-67df-489d-b34d-e087cf6dadaf" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">34,308</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other liabilities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_81cfc01f-6201-4260-9f25-d871df542b5d" contextRef="C_378538d0-b7e1-4ecd-af00-bb424f0b1747" name="us-gaap:OtherLiabilitiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">31,521</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d858a81d-f22e-4086-8ca5-4f994c5aabfe" contextRef="C_01d46517-67df-489d-b34d-e087cf6dadaf" name="us-gaap:OtherLiabilitiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">30,552</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total liabilities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_88e66442-fb90-49b1-ac40-a22d530b6efc" contextRef="C_378538d0-b7e1-4ecd-af00-bb424f0b1747" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,288,890</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_83df0e70-19b3-4ca4-8259-2190aa33c52b" contextRef="C_01d46517-67df-489d-b34d-e087cf6dadaf" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,370,749</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;"><span style="-sec-ix-hidden:F_63ef34ef-3859-4003-9f94-acd5a8cf0ae8;"><span style="-sec-ix-hidden:F_2480f1a6-5340-4f8f-9b78-b9de431629ea;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Commitments and contingencies</span></span></span></span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:10pt;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Shareholders&#8217; equity:</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:middle;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:middle;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">Preferred stock; $</span><span style="font-size:9pt;"><span style="-sec-ix-hidden:F_4ef21d0f-768e-4fd9-ac98-0f999e424f57;"><span style="-sec-ix-hidden:F_aa5b77d8-2818-431e-b57f-9e1e031ea043;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">.01</span></span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">&#160;par value; </span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bd55ad26-5a9e-4558-94c3-c9ce92a3623f" contextRef="C_378538d0-b7e1-4ecd-af00-bb424f0b1747" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_ede18482-5037-4758-bf27-bc45801374d1" contextRef="C_01d46517-67df-489d-b34d-e087cf6dadaf" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,000,000</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">&#160;shares authorized; </span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5597f6e8-7e8b-41c9-bc08-0640937019a7" contextRef="C_378538d0-b7e1-4ecd-af00-bb424f0b1747" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" scale="3" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_fdf94180-3c45-4153-9ee2-2a922a64196b" contextRef="C_01d46517-67df-489d-b34d-e087cf6dadaf" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" scale="3" decimals="INF" format="ixt-sec:numwordsen">none</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">&#160;issued</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_94dc7f69-eb8f-4f47-9e02-e3644eca836a" contextRef="C_378538d0-b7e1-4ecd-af00-bb424f0b1747" name="us-gaap:PreferredStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_70098b04-9218-40a5-a421-bb200d0acda2" contextRef="C_01d46517-67df-489d-b34d-e087cf6dadaf" name="us-gaap:PreferredStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">Common stock; $</span><span style="font-size:9pt;"><span style="-sec-ix-hidden:F_e97295ab-73a6-4c14-8a53-7e8ab77b99d6;"><span style="-sec-ix-hidden:F_4b51cbce-e856-447d-8cac-01d0d16055b3;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">.01</span></span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">&#160;par value; </span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ab55feb3-b1a0-4779-abaf-e4b5896c6a5b" contextRef="C_378538d0-b7e1-4ecd-af00-bb424f0b1747" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_df11290a-b78f-42a9-8e62-d9d100998711" contextRef="C_01d46517-67df-489d-b34d-e087cf6dadaf" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">200,000,000</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">&#160;shares authorized; </span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bda8fcab-8ebf-4a41-8fc9-7c09217fb7c2" contextRef="C_378538d0-b7e1-4ecd-af00-bb424f0b1747" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_c6c38fd1-1148-45cd-a0dc-f49daa9e7740" contextRef="C_378538d0-b7e1-4ecd-af00-bb424f0b1747" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">85,753,258</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">&#160;and </span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dd928b24-1e44-4cad-b867-b8fd07c5220a" contextRef="C_01d46517-67df-489d-b34d-e087cf6dadaf" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_00e899be-8570-4483-8769-5ab315c30074" contextRef="C_01d46517-67df-489d-b34d-e087cf6dadaf" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">84,018,023</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">&#160;shares<br/>&#160;&#160;&#160;issued and outstanding, respectively</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dd7241f2-c9e3-4604-879a-8f508bac5888" contextRef="C_378538d0-b7e1-4ecd-af00-bb424f0b1747" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">858</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2164e190-cdbc-44d2-8d37-144992ebe7cf" contextRef="C_01d46517-67df-489d-b34d-e087cf6dadaf" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">840</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Additional paid-in capital</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4205b746-a6f0-4cc8-acbb-5b84312e743a" contextRef="C_378538d0-b7e1-4ecd-af00-bb424f0b1747" name="us-gaap:AdditionalPaidInCapitalCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,006,018</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ac8f8624-5b8f-4b76-8fb7-7bb76f8870cd" contextRef="C_01d46517-67df-489d-b34d-e087cf6dadaf" name="us-gaap:AdditionalPaidInCapitalCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">999,906</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accumulated other comprehensive loss</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_235e469d-7e70-45c3-8e78-51bf2c89597c" contextRef="C_378538d0-b7e1-4ecd-af00-bb424f0b1747" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,954</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_eb47bcca-6c00-497e-b73e-9a6645745967" contextRef="C_01d46517-67df-489d-b34d-e087cf6dadaf" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">2,214</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Retained deficit</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1b4ce053-f198-4c6f-974b-ae60d0dd0c30" contextRef="C_378538d0-b7e1-4ecd-af00-bb424f0b1747" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">298,461</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_882b3d3b-c730-4ca3-ace5-3355bdd629c6" contextRef="C_01d46517-67df-489d-b34d-e087cf6dadaf" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">149,471</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total shareholders&#8217; equity</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8d1cd3d8-af4b-400b-890d-187294727219" contextRef="C_378538d0-b7e1-4ecd-af00-bb424f0b1747" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">706,461</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_51a93754-e687-472f-b524-228ca46d5c0c" contextRef="C_01d46517-67df-489d-b34d-e087cf6dadaf" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">849,061</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total liabilities and shareholders' equity</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_236ff1e4-252b-4050-a04d-5b0b4ab38629" contextRef="C_378538d0-b7e1-4ecd-af00-bb424f0b1747" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,995,351</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_21290644-7d18-4df5-95d1-65c51ce5c735" contextRef="C_01d46517-67df-489d-b34d-e087cf6dadaf" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,219,810</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The accompanying notes are an integral part of these Consolidated Financial Statements.</span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.3in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">3</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.3in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pediatrix Medical Group, Inc.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="statements_income"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Consolidated Sta</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">tements of Income and Comprehensive Income</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">(in thousands, except per share data)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(Unaudited)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:51.97%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:9.782%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:9.222%;"/>
    <td style="width:1%;"/>
    <td style="width:1.58%;"/>
    <td style="width:1%;"/>
    <td style="width:8.302000000000001%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:8.142%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Three Months Ended<br/>June 30,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Six Months Ended<br/>June 30,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net revenue</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7a99f5eb-dbad-498d-96ff-e1e85b535667" contextRef="C_f8ba14c0-203a-4abe-895a-7068e0d681d9" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">504,296</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_df6fdb3c-cd6a-4515-afdb-682f761466e2" contextRef="C_5a5fa8ad-967b-444b-af35-7dd7a8bf7ba3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">500,577</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7e59e707-00a9-468e-9c73-7b5387e79b17" contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">999,397</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_84cd525b-fdff-4089-914c-7ac5dea93791" contextRef="C_57ad6014-6b49-4fd8-b8f7-ae2932078fd6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">991,585</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating expenses:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Practice salaries and benefits</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_123572a4-6a0a-425a-b8c6-5a17e52f3ab6" contextRef="C_f8ba14c0-203a-4abe-895a-7068e0d681d9" name="md:PracticeSalariesAndBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">357,808</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6756d97e-afc4-4538-b842-5699c01401c3" contextRef="C_5a5fa8ad-967b-444b-af35-7dd7a8bf7ba3" name="md:PracticeSalariesAndBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">354,032</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b0e669b1-edd8-43b4-89a4-3381cbc2c50f" contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf" name="md:PracticeSalariesAndBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">726,946</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c99ba539-c9ba-4630-8009-b998601bcc7e" contextRef="C_57ad6014-6b49-4fd8-b8f7-ae2932078fd6" name="md:PracticeSalariesAndBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">716,267</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Practice supplies and other operating expenses</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f6fb2ae4-0509-41b7-8e08-ab66bfcc2ae1" contextRef="C_f8ba14c0-203a-4abe-895a-7068e0d681d9" name="md:PracticeSuppliesAndOtherOperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">32,369</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8c269e90-a7b5-4176-b3b1-8a988706c3cc" contextRef="C_5a5fa8ad-967b-444b-af35-7dd7a8bf7ba3" name="md:PracticeSuppliesAndOtherOperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">31,089</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e681b381-dfb0-4a9a-a4a7-8ad1df8f0d3d" contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf" name="md:PracticeSuppliesAndOtherOperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">63,454</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_68436388-6382-415d-a62d-ca781144a765" contextRef="C_57ad6014-6b49-4fd8-b8f7-ae2932078fd6" name="md:PracticeSuppliesAndOtherOperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">61,809</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">General and administrative expenses</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bfc25329-f6f7-43af-960c-91c8ec6e361e" contextRef="C_f8ba14c0-203a-4abe-895a-7068e0d681d9" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">56,565</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cc04c812-a8cf-42ea-85c6-b9c136fab7ed" contextRef="C_5a5fa8ad-967b-444b-af35-7dd7a8bf7ba3" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">58,013</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_51fd2fb5-fbda-4839-ad20-f952fc00ec1e" contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">116,763</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bdd318af-5334-44d3-b3de-6e4c26a16ae4" contextRef="C_57ad6014-6b49-4fd8-b8f7-ae2932078fd6" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">117,072</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Depreciation and amortization</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_02754bcd-2361-4e38-85fb-83532d078c77" contextRef="C_f8ba14c0-203a-4abe-895a-7068e0d681d9" name="us-gaap:DepreciationDepletionAndAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,791</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_05d5be3c-5b56-4ad4-a680-24059e51c3c8" contextRef="C_5a5fa8ad-967b-444b-af35-7dd7a8bf7ba3" name="us-gaap:DepreciationDepletionAndAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,945</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_902a5ce0-d23c-4e68-b28d-0c90e8663751" contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf" name="us-gaap:DepreciationDepletionAndAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19,099</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3d2f0f91-f696-4176-9426-5419fb92eeb3" contextRef="C_57ad6014-6b49-4fd8-b8f7-ae2932078fd6" name="us-gaap:DepreciationDepletionAndAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,898</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Transformational and restructuring related expenses</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b520e213-257b-476a-8f39-0220ef5c1706" contextRef="C_f8ba14c0-203a-4abe-895a-7068e0d681d9" name="us-gaap:RestructuringCharges" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,579</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c2b58806-7209-4cc0-b156-d32801927f27" contextRef="C_5a5fa8ad-967b-444b-af35-7dd7a8bf7ba3" name="us-gaap:RestructuringCharges" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ca097d32-f358-478e-89f4-de4ca9576aa5" contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf" name="us-gaap:RestructuringCharges" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">22,059</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_95c0fee6-86ba-4bab-8d9a-4fee96429ac3" contextRef="C_57ad6014-6b49-4fd8-b8f7-ae2932078fd6" name="us-gaap:RestructuringCharges" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Goodwill impairment</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b1f8dd9f-1224-4c5f-868c-6b6070dd17a4" contextRef="C_f8ba14c0-203a-4abe-895a-7068e0d681d9" name="us-gaap:GoodwillImpairmentLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">154,243</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_634b0e25-28f2-4f68-8f8e-22334aa43aef" contextRef="C_5a5fa8ad-967b-444b-af35-7dd7a8bf7ba3" name="us-gaap:GoodwillImpairmentLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_93907e04-2ae0-426f-8b23-059c667c9689" contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf" name="us-gaap:GoodwillImpairmentLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">154,243</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_704e413b-5178-4ef3-a60e-248556431c97" contextRef="C_57ad6014-6b49-4fd8-b8f7-ae2932078fd6" name="us-gaap:GoodwillImpairmentLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Fixed assets impairments</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5991b3ce-bd0b-4db7-ac5a-efd39cb2a2f3" contextRef="C_f8ba14c0-203a-4abe-895a-7068e0d681d9" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">20,112</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9e112529-f2f0-4d14-9dc1-605ae0e8c03c" contextRef="C_5a5fa8ad-967b-444b-af35-7dd7a8bf7ba3" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_32a6ebcd-943b-46e8-87ee-47c5523b0c1c" contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">20,112</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ed6da3e4-bccc-4f49-adea-ff314422179e" contextRef="C_57ad6014-6b49-4fd8-b8f7-ae2932078fd6" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Intangible assets impairments</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e332291b-3797-48f0-805d-20cb8cf1d0dd" contextRef="C_f8ba14c0-203a-4abe-895a-7068e0d681d9" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,679</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3d7c96b9-144f-4c47-8f4a-60fe0aca8a16" contextRef="C_5a5fa8ad-967b-444b-af35-7dd7a8bf7ba3" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9a294df7-ad25-4b68-af99-b55023a0b995" contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,679</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_16a409f2-482b-4fb1-971c-51eaa4d32894" contextRef="C_57ad6014-6b49-4fd8-b8f7-ae2932078fd6" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Loss on disposal of businesses</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6ab7c523-0812-4136-b585-10f8391fd51d" contextRef="C_f8ba14c0-203a-4abe-895a-7068e0d681d9" name="us-gaap:GainLossOnSaleOfBusiness" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">10,873</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_21555f8c-440e-420a-a99d-4b0e28dbe4e0" contextRef="C_5a5fa8ad-967b-444b-af35-7dd7a8bf7ba3" name="us-gaap:GainLossOnSaleOfBusiness" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_12ed119d-b195-4da1-89bc-1770ffcdfd62" contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf" name="us-gaap:GainLossOnSaleOfBusiness" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">10,873</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5129b3df-8b0d-4e82-9b01-d1eb03d0fc0d" contextRef="C_57ad6014-6b49-4fd8-b8f7-ae2932078fd6" name="us-gaap:GainLossOnSaleOfBusiness" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total operating expenses</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_16e8b0eb-666a-4a9e-ac31-f1e9104c3e9e" contextRef="C_f8ba14c0-203a-4abe-895a-7068e0d681d9" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">662,019</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bf324807-47b4-413f-9c37-2555d2081b73" contextRef="C_5a5fa8ad-967b-444b-af35-7dd7a8bf7ba3" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">452,079</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7f9bbb83-605d-498c-a76d-2ed4d06ee97d" contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,141,228</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2a209760-1871-4108-b2a0-922ba1d44853" contextRef="C_57ad6014-6b49-4fd8-b8f7-ae2932078fd6" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">913,046</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(Loss) income from operations</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5042a68e-0b92-4be4-8d0a-b12779bc8acc" contextRef="C_f8ba14c0-203a-4abe-895a-7068e0d681d9" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">157,723</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2f6967d3-4b02-44cd-8151-5e76cbbbd6c3" contextRef="C_5a5fa8ad-967b-444b-af35-7dd7a8bf7ba3" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">48,498</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c68ef2ad-8ab3-4f0a-a3a8-31f6c94b4d62" contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">141,831</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d4b31528-62cf-42e2-a743-e7194ae6f75f" contextRef="C_57ad6014-6b49-4fd8-b8f7-ae2932078fd6" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">78,539</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Investment and other (loss) income</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_84741e03-3176-48bd-8426-042786e57b40" contextRef="C_f8ba14c0-203a-4abe-895a-7068e0d681d9" name="us-gaap:InvestmentIncomeNet" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">161</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2f14ea32-1043-4e8f-b7ac-4e334b1a11e9" contextRef="C_5a5fa8ad-967b-444b-af35-7dd7a8bf7ba3" name="us-gaap:InvestmentIncomeNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,189</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_176fa6e7-7321-451d-b29d-5447eb3d6e53" contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf" name="us-gaap:InvestmentIncomeNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,852</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b768e05a-4370-4c5c-a90f-84d0fd92508d" contextRef="C_57ad6014-6b49-4fd8-b8f7-ae2932078fd6" name="us-gaap:InvestmentIncomeNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,823</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Interest expense</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_502a7f02-3d66-40e6-8e99-01d64f45324e" contextRef="C_f8ba14c0-203a-4abe-895a-7068e0d681d9" name="us-gaap:InterestExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,308</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2879028f-4f15-4697-8cda-b65ecac77af2" contextRef="C_5a5fa8ad-967b-444b-af35-7dd7a8bf7ba3" name="us-gaap:InterestExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,230</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f69147e8-dfa5-4447-81fd-6175cf426a95" contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf" name="us-gaap:InterestExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">20,907</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_73dc6929-83d4-48e5-b791-6ea19d6a6e51" contextRef="C_57ad6014-6b49-4fd8-b8f7-ae2932078fd6" name="us-gaap:InterestExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21,620</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Equity in earnings of unconsolidated affiliate</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9715b650-b285-47b1-b365-8217b2eece9f" contextRef="C_f8ba14c0-203a-4abe-895a-7068e0d681d9" name="us-gaap:IncomeLossFromEquityMethodInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">464</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_97f25645-9daf-4c8b-8c7c-4a4072be7758" contextRef="C_5a5fa8ad-967b-444b-af35-7dd7a8bf7ba3" name="us-gaap:IncomeLossFromEquityMethodInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">490</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0d1457e0-083b-406d-8617-25e740654e01" contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf" name="us-gaap:IncomeLossFromEquityMethodInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">982</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_72761670-756a-489b-9c76-497cc2f9a155" contextRef="C_57ad6014-6b49-4fd8-b8f7-ae2932078fd6" name="us-gaap:IncomeLossFromEquityMethodInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">917</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total non-operating expenses</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2286c26b-5142-4e28-a9e2-5daa41ae3984" contextRef="C_f8ba14c0-203a-4abe-895a-7068e0d681d9" name="us-gaap:NonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">10,005</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_71e2ae36-501b-485c-9658-1cbe5ec778f6" contextRef="C_5a5fa8ad-967b-444b-af35-7dd7a8bf7ba3" name="us-gaap:NonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">9,551</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4ff605bf-4f42-41b9-b2b7-3b3205d08e58" contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf" name="us-gaap:NonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">18,073</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5ad71eb7-75ea-4d50-80e7-beaf1772b3d4" contextRef="C_57ad6014-6b49-4fd8-b8f7-ae2932078fd6" name="us-gaap:NonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">18,880</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(Loss) income before income taxes</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7411ec82-55a9-489b-9e42-ad195db34aaf" contextRef="C_f8ba14c0-203a-4abe-895a-7068e0d681d9" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">167,728</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_707e517e-e083-4e05-bc10-1085514c67be" contextRef="C_5a5fa8ad-967b-444b-af35-7dd7a8bf7ba3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">38,947</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_41a37d81-dfdc-49ce-94e3-3860da71ea9e" contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">159,904</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_66bc080c-4f7a-4c53-a2f3-e9d98b12854a" contextRef="C_57ad6014-6b49-4fd8-b8f7-ae2932078fd6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">59,659</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Income tax benefit (provision)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_aceac554-87b6-461d-9530-dd7700fcb291" contextRef="C_f8ba14c0-203a-4abe-895a-7068e0d681d9" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">14,703</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8c8aa03f-e8bf-4869-b124-147012ce7967" contextRef="C_5a5fa8ad-967b-444b-af35-7dd7a8bf7ba3" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,665</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_54e00b57-46f7-4a65-8f21-ff62a16ee4b4" contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">10,914</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1a69a900-b60f-4c10-b64a-335c7116f02e" contextRef="C_57ad6014-6b49-4fd8-b8f7-ae2932078fd6" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,171</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net (loss) income</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4b4d22e2-1e7d-4da1-83eb-9a82796f3503" contextRef="C_f8ba14c0-203a-4abe-895a-7068e0d681d9" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">153,025</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_40e0cc12-fd52-4281-b86c-4fb5e14a87e6" contextRef="C_5a5fa8ad-967b-444b-af35-7dd7a8bf7ba3" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">28,282</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e7d0ec2d-bcfd-4733-acbc-7e2b53dc6030" contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">148,990</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_93c378de-a8b3-47f7-9f52-d0eb04642ce8" contextRef="C_57ad6014-6b49-4fd8-b8f7-ae2932078fd6" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">42,488</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other comprehensive (loss) income, net of tax</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">Unrealized holding gain (loss) on investments, net of tax of $</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_18714c5a-15f1-4275-9146-b35258cfc14a" contextRef="C_f8ba14c0-203a-4abe-895a-7068e0d681d9" name="md:NetOfTaxUnrealizedHoldingGainLossOnInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">66</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">, $</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3699bfa2-aab4-49b1-84ef-d34970cf8735" contextRef="C_5a5fa8ad-967b-444b-af35-7dd7a8bf7ba3" name="md:NetOfTaxUnrealizedHoldingGainLossOnInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">126</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">, $</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_39c22187-b770-4405-ac56-9fc664b34869" contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf" name="md:NetOfTaxUnrealizedHoldingGainLossOnInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">86</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">&#160;and $</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_56ec7fa3-f3e2-445c-b325-ac6fa53e6bd9" contextRef="C_57ad6014-6b49-4fd8-b8f7-ae2932078fd6" name="md:NetOfTaxUnrealizedHoldingGainLossOnInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">353</ix:nonFraction></span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1dbbcd2b-5c38-4436-ada3-ce8ab4c1825c" contextRef="C_f8ba14c0-203a-4abe-895a-7068e0d681d9" name="us-gaap:UnrealizedGainLossOnInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">200</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9f567b36-dbe5-47ae-b364-14855618907d" contextRef="C_5a5fa8ad-967b-444b-af35-7dd7a8bf7ba3" name="us-gaap:UnrealizedGainLossOnInvestments" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">387</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3e3b13c8-956e-4ae9-b897-32cae7773414" contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf" name="us-gaap:UnrealizedGainLossOnInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">260</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_517364d4-e286-48f9-8165-d870e272fb85" contextRef="C_57ad6014-6b49-4fd8-b8f7-ae2932078fd6" name="us-gaap:UnrealizedGainLossOnInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">217</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total comprehensive (loss) income</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d5d61069-f94e-42ec-9988-bda22fd027c7" contextRef="C_f8ba14c0-203a-4abe-895a-7068e0d681d9" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">152,825</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_10e6ea74-ccdd-427a-a3c7-e47df663440b" contextRef="C_5a5fa8ad-967b-444b-af35-7dd7a8bf7ba3" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">27,895</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ce8c60f1-39eb-40a1-9a1d-32b1d0967ab4" contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">148,730</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ecadbb01-4995-4e9c-af96-fd0940cd4bd3" contextRef="C_57ad6014-6b49-4fd8-b8f7-ae2932078fd6" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">42,705</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Per common and common equivalent share data:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net (loss) income:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Basic</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dfdc46c7-28c7-450f-8353-b481100dfce8" contextRef="C_f8ba14c0-203a-4abe-895a-7068e0d681d9" name="us-gaap:EarningsPerShareBasic" unitRef="U_USDollarShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">1.84</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cbbe38da-80e1-4b94-94b1-6cad1d25da60" contextRef="C_5a5fa8ad-967b-444b-af35-7dd7a8bf7ba3" name="us-gaap:EarningsPerShareBasic" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:num-dot-decimal">0.34</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5ede3980-6d2b-4f06-8c62-ae9f6a425345" contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf" name="us-gaap:EarningsPerShareBasic" unitRef="U_USDollarShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">1.79</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_61f74dd3-c974-47d0-a457-24acb8fa9bec" contextRef="C_57ad6014-6b49-4fd8-b8f7-ae2932078fd6" name="us-gaap:EarningsPerShareBasic" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:num-dot-decimal">0.52</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Diluted</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7bc7e3d7-ede8-4e2e-b9c1-44ff3561a7f0" contextRef="C_f8ba14c0-203a-4abe-895a-7068e0d681d9" name="us-gaap:EarningsPerShareDiluted" unitRef="U_USDollarShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">1.84</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f436b0ba-4e2e-4ed0-aa50-6973fce2dad1" contextRef="C_5a5fa8ad-967b-444b-af35-7dd7a8bf7ba3" name="us-gaap:EarningsPerShareDiluted" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:num-dot-decimal">0.34</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ad180b7c-ba85-4b98-8762-7e934cb01fa1" contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf" name="us-gaap:EarningsPerShareDiluted" unitRef="U_USDollarShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">1.79</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f0bdc3db-b66d-4f08-979f-282474f927d6" contextRef="C_57ad6014-6b49-4fd8-b8f7-ae2932078fd6" name="us-gaap:EarningsPerShareDiluted" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:num-dot-decimal">0.52</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted average common shares:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Basic</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_459ab46e-f278-4170-b64f-299825b83f5c" contextRef="C_f8ba14c0-203a-4abe-895a-7068e0d681d9" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">83,332</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f6aa01f5-614d-45cf-af36-73fb3de81835" contextRef="C_5a5fa8ad-967b-444b-af35-7dd7a8bf7ba3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">82,399</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2215b0c1-357f-4041-af33-54ce0c944527" contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">83,074</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d4bf882d-a5d7-488c-8a66-5a60bd01131e" contextRef="C_57ad6014-6b49-4fd8-b8f7-ae2932078fd6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">82,033</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Diluted</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e55ef5ba-2730-42dd-bf00-0c0635e516d7" contextRef="C_f8ba14c0-203a-4abe-895a-7068e0d681d9" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">83,332</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_71fcb6e2-e888-40d7-bd72-9e3946cc8083" contextRef="C_5a5fa8ad-967b-444b-af35-7dd7a8bf7ba3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">82,664</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_84fc3e91-3edd-4bbb-887c-005a36b853a1" contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">83,074</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_447c0fdb-8b30-46fb-b0d9-529086ad0e3f" contextRef="C_57ad6014-6b49-4fd8-b8f7-ae2932078fd6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">82,377</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The accompanying notes are an integral part of these Consolidated Financial Statements.</span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.3in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">4</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.3in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pediatrix Medical Group, Inc.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="statements_equity"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Consolidated Sta</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">tements of Shareholders' Equity</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(in thousands)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(Unaudited)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:29.976%;"/>
    <td style="width:0.999%;"/>
    <td style="width:1%;"/>
    <td style="width:6.553%;"/>
    <td style="width:1%;"/>
    <td style="width:1.019%;"/>
    <td style="width:1%;"/>
    <td style="width:8.651%;"/>
    <td style="width:1%;"/>
    <td style="width:1.019%;"/>
    <td style="width:1%;"/>
    <td style="width:8.651%;"/>
    <td style="width:1%;"/>
    <td style="width:1.019%;"/>
    <td style="width:1%;"/>
    <td style="width:11.229%;"/>
    <td style="width:1%;"/>
    <td style="width:1.019%;"/>
    <td style="width:1%;"/>
    <td style="width:8.651%;"/>
    <td style="width:1%;"/>
    <td style="width:1.019%;"/>
    <td style="width:1%;"/>
    <td style="width:8.190999999999999%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Common Stock</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Number of</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Additional<br/>Paid-in</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Accumulated<br/>Other<br/>Comprehensive</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Retained</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total<br/>Shareholders'</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Shares</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amount</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Capital</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Loss</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Deficit</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Equity</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;min-width:fit-content;">2024</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance at January 1, 2024</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_60cc24cb-8b99-49f4-8b3c-b5f81f707b5d" contextRef="C_bbfdd70c-5aff-4803-b853-9aed8b435db7" name="us-gaap:SharesIssued" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">84,018</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_57afd45f-d6ae-4abf-aecf-249dfbd46c8e" contextRef="C_bbfdd70c-5aff-4803-b853-9aed8b435db7" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">840</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3d0b0af1-6f3b-40d4-966e-b59bd57b8a92" contextRef="C_feaa2e55-4022-4e2f-abe1-edb33b1f5e36" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">999,906</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2b6eed39-a5cc-47b4-a78c-818d610432a0" contextRef="C_cd8a1422-f4cb-4c26-b354-491001ddef25" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">2,214</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d6db44b1-c2c9-4f2e-ab36-5de966351f28" contextRef="C_b76e1e1c-7e08-49c4-ba42-36b7776b9c77" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">149,471</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8d401c0e-cf97-4ab1-aeba-2376b17e7e3b" contextRef="C_01d46517-67df-489d-b34d-e087cf6dadaf" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">849,061</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net income</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0e662654-6d9c-403c-8991-91ac49c6b6db" contextRef="C_a23f2efb-8927-4491-a7c8-c1b619aa2e83" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,035</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_226a40fc-93f3-4c3d-a22d-bb1855973840" contextRef="C_01c11cbc-05a6-4e7d-bb87-a2a2acb9a949" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,035</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unrealized holding gain on investments, net of tax</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8fdb171e-6080-414d-9a60-db90bead08db" contextRef="C_a04037ee-9a78-4964-9e1c-74fa20cac8af" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">60</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a1f4e6df-134e-4de0-a79b-b206d81d321e" contextRef="C_01c11cbc-05a6-4e7d-bb87-a2a2acb9a949" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">60</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Common stock issued under employee stock purchase plan</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9303bd94-44d7-46f7-bbdd-5f96c0fe50da" contextRef="C_055fb263-9778-4cf7-8395-b3db5ae74ab3" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">108</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_99821ef8-d2d5-4785-8793-5445d2732fce" contextRef="C_055fb263-9778-4cf7-8395-b3db5ae74ab3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bcca2d43-d58a-4769-b2c9-3df615a5a196" contextRef="C_207dae80-b868-42b4-8f60-529bb2da464b" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">859</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0ef715e2-48dd-4e6c-b6e7-eb3432dc0ed6" contextRef="C_01c11cbc-05a6-4e7d-bb87-a2a2acb9a949" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">860</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Forfeitures of restricted stock</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d90e4b4f-6a91-49a4-a2fd-a21be07de954" contextRef="C_055fb263-9778-4cf7-8395-b3db5ae74ab3" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" unitRef="U_shares" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">21</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock-based compensation expense</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fca8169f-c20a-4c53-bced-5f2f19567fb7" contextRef="C_207dae80-b868-42b4-8f60-529bb2da464b" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,067</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_02711fa6-8322-41fc-9fc3-4d9f6591f251" contextRef="C_01c11cbc-05a6-4e7d-bb87-a2a2acb9a949" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,067</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Repurchased common stock</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_997bbeab-24d9-43c8-93cd-41f54f1a7fd8" contextRef="C_055fb263-9778-4cf7-8395-b3db5ae74ab3" name="us-gaap:StockRepurchasedDuringPeriodShares" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">97</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ad887e07-059a-4aa2-a05f-598f013a4c6a" contextRef="C_055fb263-9778-4cf7-8395-b3db5ae74ab3" name="us-gaap:StockRepurchasedDuringPeriodValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2a37c032-62f0-4879-83ad-b60a09976220" contextRef="C_207dae80-b868-42b4-8f60-529bb2da464b" name="us-gaap:StockRepurchasedDuringPeriodValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">886</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b0a23a23-336c-4dfc-9a30-04d12b50fc00" contextRef="C_01c11cbc-05a6-4e7d-bb87-a2a2acb9a949" name="us-gaap:StockRepurchasedDuringPeriodValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">887</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance at March 31, 2024</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8eb4719d-948c-4a7e-bfcc-a0fb75db0112" contextRef="C_8693cd13-0631-41d8-8347-98d3ec5b732d" name="us-gaap:SharesIssued" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">84,008</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_01683239-a700-4526-abec-c31965ac7648" contextRef="C_8693cd13-0631-41d8-8347-98d3ec5b732d" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">840</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_974567a9-31eb-48fa-87cc-f0295431cda3" contextRef="C_d6bf2c94-ac55-40fc-90b0-8184b979a967" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,002,946</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7c3250cf-40d6-4af1-b0e3-0e4a02ac281e" contextRef="C_7c834d47-d5d5-4daa-8490-432e04b450c3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">2,154</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_82c34756-4a3a-4d29-b0f8-9a54181555d4" contextRef="C_9997289e-fdb8-486e-acac-cb788b4f8239" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">145,436</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e54b3ee4-7fcb-4e2f-a966-e11f95f09e71" contextRef="C_f80a1315-a5a6-418b-98c4-fc56bd22ae95" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">856,196</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9e6c5d71-e8a6-440a-b64e-f108e282360c" contextRef="C_9d8d79b8-258d-4977-8e93-a832860452f4" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">153,025</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_490c9058-5063-4a72-a8d0-ba4150c57f4f" contextRef="C_f8ba14c0-203a-4abe-895a-7068e0d681d9" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">153,025</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unrealized holding gain on investments, net of tax</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a2a59b0c-4b56-4c88-817c-d1540891e75c" contextRef="C_594a2ea7-65e0-4290-83d4-8be74d122ddc" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">200</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_66ccca52-2522-4767-94b6-e7799375ca9b" contextRef="C_f8ba14c0-203a-4abe-895a-7068e0d681d9" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">200</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Common stock issued under employee stock purchase plan</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_addd5c1e-3b77-42ea-b00c-6ead8a07ffde" contextRef="C_86bb4acc-ec76-4db5-933a-a771e7cd3750" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">139</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ce1e1dad-e2fa-4b4e-9f37-0711b250b716" contextRef="C_86bb4acc-ec76-4db5-933a-a771e7cd3750" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f88bfb98-8aec-4aef-abb1-df9611f883f1" contextRef="C_35df4ea0-7c25-462a-83e1-ff1079f8091e" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,147</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d1bf67d4-a875-4b29-9dd0-69123666bdd0" contextRef="C_f8ba14c0-203a-4abe-895a-7068e0d681d9" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,149</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Issuance of restricted stock</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3aefb809-b848-48b1-a7df-9cf1bef17789" contextRef="C_86bb4acc-ec76-4db5-933a-a771e7cd3750" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,630</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d995133f-3ac9-4b8a-9990-25b83657dcf7" contextRef="C_86bb4acc-ec76-4db5-933a-a771e7cd3750" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6ab2d3ae-763b-4615-a519-950f1f6ee178" contextRef="C_35df4ea0-7c25-462a-83e1-ff1079f8091e" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">16</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Forfeitures of restricted stock</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_54125c18-985c-4af5-a24b-e3ca175f6f13" contextRef="C_86bb4acc-ec76-4db5-933a-a771e7cd3750" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" unitRef="U_shares" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">22</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock-based compensation expense</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2041b7ea-1657-4aee-b824-dd83e936124b" contextRef="C_35df4ea0-7c25-462a-83e1-ff1079f8091e" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,952</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a94b7636-8a37-4244-a5d0-55d8e1f4533d" contextRef="C_f8ba14c0-203a-4abe-895a-7068e0d681d9" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,952</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Repurchased common stock</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fa393c19-b95f-454e-a72a-3dac69262b77" contextRef="C_86bb4acc-ec76-4db5-933a-a771e7cd3750" name="us-gaap:StockRepurchasedDuringPeriodShares" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">2</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0f85f907-04b1-430b-b8e2-0c3bffc9bd3d" contextRef="C_35df4ea0-7c25-462a-83e1-ff1079f8091e" name="us-gaap:StockRepurchasedDuringPeriodValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e68ad259-7f11-4954-8027-08abc4683e4a" contextRef="C_f8ba14c0-203a-4abe-895a-7068e0d681d9" name="us-gaap:StockRepurchasedDuringPeriodValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance at June 30, 2024</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9b742f63-e7ca-4a73-8bd6-b162633108cd" contextRef="C_a20e0eec-fcf2-491f-ad41-9a428f13e263" name="us-gaap:SharesIssued" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">85,753</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_76ca9f43-930c-4064-9dfe-39207b71f9f5" contextRef="C_a20e0eec-fcf2-491f-ad41-9a428f13e263" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">858</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_50077b20-a5c6-4330-94fc-c2e29a162cfb" contextRef="C_5207957e-5a84-4d96-961c-054e57351b74" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,006,018</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3419a1a1-f9fd-498e-b132-b5bb4fe9a88e" contextRef="C_121e7382-aaaf-4b4b-b85f-ca7209a14358" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,954</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_175495f8-becf-4889-a8f4-8efe0b11f438" contextRef="C_9478e6ac-d067-47ed-985a-d3a75cbb347e" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">298,461</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1ef50ec2-7d6a-4c5c-8637-2fc7ea912186" contextRef="C_378538d0-b7e1-4ecd-af00-bb424f0b1747" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">706,461</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance at January 1, 2023</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dfaeed9d-4046-4f95-bb0f-4d66d9e94697" contextRef="C_d564d4a9-a926-457b-80b1-01fa631a1e4f" name="us-gaap:SharesIssued" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">82,947</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_85a30032-2a55-435a-8efc-b557d67b0391" contextRef="C_d564d4a9-a926-457b-80b1-01fa631a1e4f" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">829</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_abe95c30-fe63-42d0-8361-a1d627e9bb6f" contextRef="C_f9deda8d-474c-400c-8f2b-c04bdaea334d" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">983,601</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_37c91e05-3c2f-453f-8bd3-4ec503b2dbce" contextRef="C_aea590f4-2725-4610-b86d-be28415452fc" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">3,735</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a25e21a2-8a1f-4800-a0b2-31941371fdd2" contextRef="C_4ddfa92a-fd22-4353-88c1-befe81c45dca" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">89,063</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_30350dc6-5aac-4067-a663-15deaebf35ef" contextRef="C_097f26a0-c77e-4f84-b663-38d6391e01e6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">891,632</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net income</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_733c394a-f2c5-4311-ba2f-14f0363b808f" contextRef="C_1e093f6f-db74-422e-95ac-c5b0a5e76558" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,206</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c15045b7-2be5-4f3a-bb98-319aff35468e" contextRef="C_31b43498-9159-4c16-bd8b-ab5cef5e0575" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,206</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unrealized holding gain on investments, net of tax</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_53646c34-0cdb-443c-9f88-78d4ce119ca2" contextRef="C_edb2e0fd-b34b-4b67-8c89-128090856b98" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">604</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_90d318ab-697c-434a-baa1-77a43431e24c" contextRef="C_31b43498-9159-4c16-bd8b-ab5cef5e0575" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">604</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Common stock issued under employee stock purchase plan</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a6386da0-5d2d-494f-9679-f6f06d389b98" contextRef="C_5f0c50a0-53ad-41c3-8101-90e7e5cacb14" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">86</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_de50d025-3f39-4279-9d11-cd8061d02d83" contextRef="C_a24c8561-3fe8-4ee9-9a5f-3650008ddd53" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,095</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4fbeeeb3-7fd0-47d5-86dc-9e3b9e19d1c9" contextRef="C_31b43498-9159-4c16-bd8b-ab5cef5e0575" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,095</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Issuance of restricted stock</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_66424206-08cf-4e95-a1b0-93bced896810" contextRef="C_5f0c50a0-53ad-41c3-8101-90e7e5cacb14" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">871</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0563a0d9-1d28-46b3-b834-950321cdf821" contextRef="C_5f0c50a0-53ad-41c3-8101-90e7e5cacb14" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_619f2ca0-5aa6-48c7-9d41-10e953e8a740" contextRef="C_a24c8561-3fe8-4ee9-9a5f-3650008ddd53" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">9</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Forfeitures of restricted stock</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_949b2ec5-96e1-49e6-a491-7aba3d906ff8" contextRef="C_5f0c50a0-53ad-41c3-8101-90e7e5cacb14" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" unitRef="U_shares" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">221</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_45bf7d33-953a-48e2-b85e-74f14c3225df" contextRef="C_5f0c50a0-53ad-41c3-8101-90e7e5cacb14" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">2</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7fabaa1f-3d2c-4185-86c6-8559c93019b3" contextRef="C_a24c8561-3fe8-4ee9-9a5f-3650008ddd53" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock-based compensation expense</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_eda69540-ce85-4540-9d9c-b42784b336b0" contextRef="C_a24c8561-3fe8-4ee9-9a5f-3650008ddd53" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,009</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_844a8692-ab71-4cfc-a517-f9a057812fcc" contextRef="C_31b43498-9159-4c16-bd8b-ab5cef5e0575" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,009</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Repurchased common stock</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_49031508-c750-4bd3-a319-fd72b0938aaf" contextRef="C_5f0c50a0-53ad-41c3-8101-90e7e5cacb14" name="us-gaap:StockRepurchasedDuringPeriodShares" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">49</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3823b637-fc12-4b79-9162-ead29a2f3c88" contextRef="C_a24c8561-3fe8-4ee9-9a5f-3650008ddd53" name="us-gaap:StockRepurchasedDuringPeriodValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">775</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0215c999-e842-4f61-a08a-99014053abaf" contextRef="C_31b43498-9159-4c16-bd8b-ab5cef5e0575" name="us-gaap:StockRepurchasedDuringPeriodValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">775</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance at March 31, 2023</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fdf9b003-3d69-4524-8bad-5efa6fa246d4" contextRef="C_b87610a2-4379-4ba9-97b7-9e4606d8ef5c" name="us-gaap:SharesIssued" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">83,634</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9ea703f1-a9de-4e0f-ab18-951dcdd909dc" contextRef="C_b87610a2-4379-4ba9-97b7-9e4606d8ef5c" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">836</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f43ff5f5-60b1-4493-9455-6ffe8293359c" contextRef="C_5875e45d-cd89-498d-903a-55b9e7739c94" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">986,923</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e2f056d2-3ebd-44ad-8981-87d55d730a79" contextRef="C_9f05953b-1f07-4686-942c-7b1d7943d27f" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">3,131</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_28f163cb-426c-40e1-ab29-b5a1b1f661b2" contextRef="C_ca171fc2-2432-408d-b564-cd2e7563ba71" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">74,857</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7b34037e-a188-4c1a-84c3-46d087113e7e" contextRef="C_a3930cd6-349a-4a67-8e41-4578fe93ff88" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">909,771</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net income</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2efc3264-c821-4e08-8b70-913dae915aaf" contextRef="C_ef9ac9e9-8f0b-4197-8eb4-12ca2061e14f" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">28,282</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7a0a1956-eb07-4d76-8240-888223938610" contextRef="C_5a5fa8ad-967b-444b-af35-7dd7a8bf7ba3" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">28,282</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unrealized holding loss on investments, net of tax</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e0749bea-9e2d-49cb-b742-82b1ed1639ad" contextRef="C_d3b7b754-9615-4731-9358-8ab2afbdb4a3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">387</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c55ed278-1a48-4e8d-b0e5-3f2d342626f6" contextRef="C_5a5fa8ad-967b-444b-af35-7dd7a8bf7ba3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">387</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Common stock issued under employee stock purchase plan</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7ac4399d-a43d-458d-9de0-4ac8f5d20694" contextRef="C_47c0d2ef-584a-4c5e-ae36-b63c1c605bcc" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">126</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6f85d6c1-6efe-4f06-8bc8-5e30ac4f43e5" contextRef="C_47c0d2ef-584a-4c5e-ae36-b63c1c605bcc" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_df59075d-959f-4a4f-80c5-259df4e9a689" contextRef="C_eb6de81c-9c30-48c6-8848-0a4491bbd3cf" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,593</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7bb01184-4cd2-441e-91d0-d3b3b591393a" contextRef="C_5a5fa8ad-967b-444b-af35-7dd7a8bf7ba3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,594</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Issuance of restricted stock</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6eae5993-8c85-4a52-9b0f-e562295ec149" contextRef="C_47c0d2ef-584a-4c5e-ae36-b63c1c605bcc" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">93</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_54352b48-71d9-4e9c-bb97-994eebc5ea3a" contextRef="C_47c0d2ef-584a-4c5e-ae36-b63c1c605bcc" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f936c975-9254-429b-9f07-95360d34d850" contextRef="C_eb6de81c-9c30-48c6-8848-0a4491bbd3cf" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Forfeitures of restricted stock</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a6b52d1c-8205-4bf7-9d23-0ef15c691c0e" contextRef="C_47c0d2ef-584a-4c5e-ae36-b63c1c605bcc" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" unitRef="U_shares" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">11</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock-based compensation expense</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a15edb90-01a3-4094-9e4a-b9fc694efbd7" contextRef="C_eb6de81c-9c30-48c6-8848-0a4491bbd3cf" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,126</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_45f24a93-28b8-405f-ba1c-e95da4b0d507" contextRef="C_5a5fa8ad-967b-444b-af35-7dd7a8bf7ba3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,126</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Repurchased common stock</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_db8fadeb-e1bf-4750-8413-1cb2b7d8a104" contextRef="C_47c0d2ef-584a-4c5e-ae36-b63c1c605bcc" name="us-gaap:StockRepurchasedDuringPeriodShares" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fdaf3762-bc86-4839-ac9e-f10b9a497f18" contextRef="C_eb6de81c-9c30-48c6-8848-0a4491bbd3cf" name="us-gaap:StockRepurchasedDuringPeriodValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_48c3c792-669a-4812-9f36-8850a6ac26be" contextRef="C_5a5fa8ad-967b-444b-af35-7dd7a8bf7ba3" name="us-gaap:StockRepurchasedDuringPeriodValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance at June 30, 2023</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_aa50ce5b-c7c8-4645-9140-8c026664af95" contextRef="C_45e7bb15-6f89-4eb6-9120-7ec8d161f85b" name="us-gaap:SharesIssued" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">83,841</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b15095a4-72ac-40f4-8c92-a1a59d36754c" contextRef="C_45e7bb15-6f89-4eb6-9120-7ec8d161f85b" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">838</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d3fbc7e1-01a7-42a1-90d6-bda10ea1072a" contextRef="C_3610c317-f612-4c22-9d38-5d8900ab3930" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">991,630</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6f3d1060-cf9f-4546-a05a-aae1a3eebc83" contextRef="C_1786cd13-4a3f-41ee-8fba-517746735e35" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">3,518</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9df3fbbc-858f-4d2a-9964-64c7e8d338a7" contextRef="C_bf0934a0-5844-404d-a376-9a2eb1aa3de7" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">46,575</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9ce7e962-b4f3-494d-bddb-598e72eca754" contextRef="C_60b78123-38d8-4d05-8a9b-e087fe9016a9" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">942,375</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The accompanying notes are an integral part of these Consolidated Financial Statements.</span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.3in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">5</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.3in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Pediatrix Medical Group, Inc.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="statements_cash_flows"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Consolidated S</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">t</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">atements of Cash Flows</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">(in thousands)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">(Unaudited)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:67.287%;"/>
    <td style="width:1.46%;"/>
    <td style="width:1%;"/>
    <td style="width:12.897%;"/>
    <td style="width:1%;"/>
    <td style="width:1.46%;"/>
    <td style="width:1%;"/>
    <td style="width:12.897%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Six Months Ended June 30,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash flows from operating activities:</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net (loss) income</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0ef3d371-43f8-4697-a1f4-7e858cbca2af" contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">148,990</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3bb12444-d7ca-4633-b773-e9909aad8599" contextRef="C_57ad6014-6b49-4fd8-b8f7-ae2932078fd6" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">42,488</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:10pt;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Adjustments to reconcile net income to net cash from operating activities:</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Depreciation and amortization</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2b13be2e-5d03-4772-bc9c-57555e8fb0db" contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf" name="us-gaap:DepreciationDepletionAndAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19,099</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_31a50fb4-b0d5-4296-8ad9-98148fc6e935" contextRef="C_57ad6014-6b49-4fd8-b8f7-ae2932078fd6" name="us-gaap:DepreciationDepletionAndAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,898</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Amortization of premiums, discounts and issuance costs</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_69f65d4d-6770-4d13-9676-8e12a38c0773" contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">440</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0cba5eb6-9f6f-4843-99f1-4bfc6b5fa4b6" contextRef="C_57ad6014-6b49-4fd8-b8f7-ae2932078fd6" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">733</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Goodwill impairment</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5f6c66d2-89da-49de-a113-9f93bcfe1078" contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf" name="us-gaap:GoodwillImpairmentLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">154,243</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7a4b82ad-afee-4e9c-b945-4a5b1deb90c5" contextRef="C_57ad6014-6b49-4fd8-b8f7-ae2932078fd6" name="us-gaap:GoodwillImpairmentLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Fixed assets impairments</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a1bcf941-3917-4fac-a6cf-ff23d4129ce0" contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">20,112</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fa07e5f0-8f76-4c83-b7a3-b98b19cca07f" contextRef="C_57ad6014-6b49-4fd8-b8f7-ae2932078fd6" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Intangible assets impairments</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a0851738-69c0-4ba3-bea9-b397adfe1cc4" contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,679</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7ea4d44b-6af8-498e-8cab-69e38eebae23" contextRef="C_57ad6014-6b49-4fd8-b8f7-ae2932078fd6" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Loss on disposal of businesses</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dea4fb28-725e-422c-b770-5eadad74719c" contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf" name="us-gaap:GainLossOnSaleOfBusiness" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">10,873</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_56396ec4-6a75-4817-8e74-a460b7b3c55c" contextRef="C_57ad6014-6b49-4fd8-b8f7-ae2932078fd6" name="us-gaap:GainLossOnSaleOfBusiness" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock-based compensation expense</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4e4d26e3-c8f2-4f80-a6a5-5e01bf0f336e" contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,019</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d4438f8e-828a-443c-a145-590e6d8533e4" contextRef="C_57ad6014-6b49-4fd8-b8f7-ae2932078fd6" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,135</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred income taxes</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_309f63e8-31b7-4c26-a3aa-a6205ac98fde" contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf" name="us-gaap:DeferredIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">25,028</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7c0d82cc-1eda-4ea9-9da5-58981baacac7" contextRef="C_57ad6014-6b49-4fd8-b8f7-ae2932078fd6" name="us-gaap:DeferredIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,376</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f1dea87e-5e53-468f-9d51-de13499b4fc9" contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf" name="us-gaap:OtherNoncashIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,678</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_398e88cf-9e7f-4767-9c71-7bf8f147f078" contextRef="C_57ad6014-6b49-4fd8-b8f7-ae2932078fd6" name="us-gaap:OtherNoncashIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">900</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:20pt;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Changes in assets and liabilities:</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:30pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:30pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accounts receivable</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_916f2614-29a4-4905-af86-b867ffb06ebd" contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf" name="us-gaap:IncreaseDecreaseInAccountsReceivable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">934</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ac1117a2-f9ea-45f7-bbf8-2726a0713a11" contextRef="C_57ad6014-6b49-4fd8-b8f7-ae2932078fd6" name="us-gaap:IncreaseDecreaseInAccountsReceivable" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">28,900</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:30pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:30pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Prepaid expenses and other current assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f4592d53-9552-4cb9-bcf3-d9d9ef904799" contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">3,703</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_375c1d48-61c1-4721-b714-f47b67047a97" contextRef="C_57ad6014-6b49-4fd8-b8f7-ae2932078fd6" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">2,141</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:30pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:30pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other long-term assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c360dfa3-e285-4986-a380-a283e8bbff4f" contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">16,955</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7cd5c421-d22b-4eb2-8b95-fb8b58bb254e" contextRef="C_57ad6014-6b49-4fd8-b8f7-ae2932078fd6" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">5,052</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:30pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:30pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accounts payable and accrued expenses</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_007d2897-d843-46fb-98ab-a9342a59e3f3" contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">82,917</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cf03de60-28b1-4506-9ca7-47e11493f82b" contextRef="C_57ad6014-6b49-4fd8-b8f7-ae2932078fd6" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">97,315</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:30pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:30pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Income taxes payable</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d1e9978e-9fdb-4cfc-a360-f9905d019678" contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf" name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,735</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bb7ebd5a-fde7-4c4e-a7f8-d9b1df6e0970" contextRef="C_57ad6014-6b49-4fd8-b8f7-ae2932078fd6" name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">12,028</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:30pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:30pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Long-term professional liabilities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_90fc48ba-2022-436d-9a62-6c1640ccf07a" contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf" name="us-gaap:IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,039</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e2fdd7f5-9a51-44ed-b53f-6830dd13acf9" contextRef="C_57ad6014-6b49-4fd8-b8f7-ae2932078fd6" name="us-gaap:IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">838</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:30pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:30pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other liabilities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d85276f7-3a6d-441d-8caa-f28a81ed5a10" contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">11,630</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d3b5af24-4048-4597-9d2a-b3bf30d519f7" contextRef="C_57ad6014-6b49-4fd8-b8f7-ae2932078fd6" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">10,356</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net cash used in operating activities &#8211; continuing operations</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f916c3ed-08de-455d-b6e5-1a7b28bf9d0f" contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf" name="us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">13,280</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e4674178-032d-435a-9e42-efbabfb92593" contextRef="C_57ad6014-6b49-4fd8-b8f7-ae2932078fd6" name="us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">8,038</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net cash used in operating activities - discontinued operations</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_96918e4e-cb83-4819-82e4-ae2a86d4533b" contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf" name="us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">4,995</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f58e032e-7c42-40e7-9cad-6303d7f6cbc5" contextRef="C_57ad6014-6b49-4fd8-b8f7-ae2932078fd6" name="us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">3,825</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net cash used in operating activities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bf2973c1-5760-4218-971c-8a9613cc68c2" contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">18,275</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cf6aaf44-b4f0-4cc9-bdaa-36d3047605ce" contextRef="C_57ad6014-6b49-4fd8-b8f7-ae2932078fd6" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">11,863</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash flows from investing activities:</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Acquisition payments, net of cash acquired</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3558572b-675b-491c-bfec-5020046d4819" contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,167</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8fd84336-e48b-493c-8b25-a667b1ff0749" contextRef="C_57ad6014-6b49-4fd8-b8f7-ae2932078fd6" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,667</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Purchases of investments</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9dc50a92-2438-455d-909e-a0219af75749" contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf" name="us-gaap:PaymentsToAcquireInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">39,915</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_64f93a36-6e2b-4941-ad65-3390834a83ee" contextRef="C_57ad6014-6b49-4fd8-b8f7-ae2932078fd6" name="us-gaap:PaymentsToAcquireInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,761</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Proceeds from maturities or sales of investments</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_142e6a30-222c-44e2-803a-b6c0951913d2" contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf" name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">31,244</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0204ae7d-6e7a-4c7f-9f80-1bd09ff62393" contextRef="C_57ad6014-6b49-4fd8-b8f7-ae2932078fd6" name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,810</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Purchases of property and equipment</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b6b925aa-8183-4b87-863d-dfd5ada2b71c" contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf" name="us-gaap:PaymentsToAcquireOtherPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,292</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b421386a-df24-432a-8325-594362717ec8" contextRef="C_57ad6014-6b49-4fd8-b8f7-ae2932078fd6" name="us-gaap:PaymentsToAcquireOtherPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,130</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net cash used in investing activities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1cc0cf80-648b-4b56-88ff-c42d17990e15" contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">29,130</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b4933d93-b065-422a-b1d1-973c5bf21686" contextRef="C_57ad6014-6b49-4fd8-b8f7-ae2932078fd6" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">21,748</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash flows from financing activities:</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Borrowings on line of credit</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9608bbf4-df42-4425-9e93-c8be5777238b" contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf" name="us-gaap:ProceedsFromLinesOfCredit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">235,500</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6681bcf3-e46f-4f14-b476-5698ab88091a" contextRef="C_57ad6014-6b49-4fd8-b8f7-ae2932078fd6" name="us-gaap:ProceedsFromLinesOfCredit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">421,000</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Payments on line of credit</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_94c0c0b8-afb3-427a-b32e-bff19e1c99b7" contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf" name="us-gaap:RepaymentsOfLinesOfCredit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">235,500</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9d913398-bd89-4e47-bd01-105496b19426" contextRef="C_57ad6014-6b49-4fd8-b8f7-ae2932078fd6" name="us-gaap:RepaymentsOfLinesOfCredit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">384,000</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Payments on term loan</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b1747f6f-5eaf-475f-8462-103d0f9dddf9" contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf" name="md:PaymentsToTermLoan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,250</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c39d3bd9-9eac-42e1-a64a-2dce0b8679a6" contextRef="C_57ad6014-6b49-4fd8-b8f7-ae2932078fd6" name="md:PaymentsToTermLoan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,250</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Payments on finance lease obligations</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_12494ae0-58b1-4e99-b4e8-c1f20559a02e" contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf" name="md:RepaymentsOfLongTermCapitalLeaseObligation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,391</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a5e7464d-b3b6-4225-93fc-a27ece47701a" contextRef="C_57ad6014-6b49-4fd8-b8f7-ae2932078fd6" name="md:RepaymentsOfLongTermCapitalLeaseObligation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,404</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Proceeds from issuance of common stock</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_89cf1579-e4b3-4b2c-9633-54763cba71d3" contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,009</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_15ab3ad9-cb65-43f6-93ff-69e6ee0898c0" contextRef="C_57ad6014-6b49-4fd8-b8f7-ae2932078fd6" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,689</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Repurchases of common stock</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_05f2fb56-cf34-4d34-91ea-84f5c2fe82ba" contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf" name="us-gaap:PaymentsForRepurchaseOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">898</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7348e8c1-8a28-43d3-801b-d67d73cbaca5" contextRef="C_57ad6014-6b49-4fd8-b8f7-ae2932078fd6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">786</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_84e30022-f56f-4411-b957-3275e11f8030" contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">79</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5df6c633-112c-4562-a186-06cc3efa1825" contextRef="C_57ad6014-6b49-4fd8-b8f7-ae2932078fd6" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,613</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net cash (used in) provided by financing activities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e7e3720d-7f81-4395-887b-b73d55979c5d" contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">6,451</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_22cc7ff5-7b2c-40b8-91c3-68ab561d5799" contextRef="C_57ad6014-6b49-4fd8-b8f7-ae2932078fd6" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">29,636</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net decrease in cash and cash equivalents</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3a25cdf7-f3f9-4869-90c4-bc1c9862419c" contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">53,856</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_13314506-0f00-4566-8811-20a6022487c6" contextRef="C_57ad6014-6b49-4fd8-b8f7-ae2932078fd6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">3,975</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash and cash equivalents at beginning of period</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_98db8ff0-8ff3-4b1d-84ef-90372180f23f" contextRef="C_01d46517-67df-489d-b34d-e087cf6dadaf" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">73,258</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7af69c6a-54fe-4f68-969c-740c94ac3a9e" contextRef="C_097f26a0-c77e-4f84-b663-38d6391e01e6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,824</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash and cash equivalents at end of period</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_aa36d916-d9d6-492c-8d5a-3f341075667f" contextRef="C_378538d0-b7e1-4ecd-af00-bb424f0b1747" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19,402</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d85f4650-cf5d-476e-a1e2-80a593cdf4f2" contextRef="C_60b78123-38d8-4d05-8a9b-e087fe9016a9" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,849</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The accompanying notes are an integral part of these Consolidated Financial Statements.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.3in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">6</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.3in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pediatrix Medical Group, Inc.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="notes_financial_statements"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Notes to Consolidated </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial Statements</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">June 30, 2024</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(Unaudited)</span></p>
  <div style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5b9af3b4-638d-487c-baf9-b73ff9e3fdf9" contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf" name="us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">1.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">            Basis of Presentation:</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">The accompanying unaudited Consolidated Financial Statements of the Company and the notes thereto presented in this Form 10-Q have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission ("SEC") applicable to interim financial statements, and do not include all disclosures required by accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) for complete financial statements. In the opinion of management, these financial statements include all adjustments, consisting only of normal recurring adjustments, necessary for a fair statement of the results of interim periods. The financial statements include all the accounts of Pediatrix Medical Group, Inc. and its consolidated subsidiaries (collectively, &#8220;PMG&#8221;) together with the accounts of PMG&#8217;s affiliated business corporations or professional associations, professional corporations, limited liability companies and partnerships (the &#8220;affiliated professional contractors&#8221;). Certain subsidiaries of PMG have contractual management arrangements with its affiliated professional contractors, which are separate legal entities that provide physician services in certain states. The terms &#8220;Pediatrix&#8221; and the &#8220;Company&#8221; refer collectively to Pediatrix Medical Group Inc., its subsidiaries and the affiliated professional contractors.</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">The Compan</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">y is a party to a joint venture in which it owns a </span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b13dd794-172e-4a14-9daf-26db4dbe69f2" contextRef="C_82895573-2795-4732-b42c-4cd5883caf98" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">37.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">% economic interest.  The Company accounts for this joint venture under the equity method of accounting because the Company exercises significant influence over, but does not control, this entity.</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">  </span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">The consolidated results of operations for the interim periods presented are not necessarily indicative of the results to be experienced for the entire fiscal year. In addition, the accompanying unaudited Consolidated Financial Statements and the notes thereto should be read in conjunction with the Consolidated Financial Statements and the notes thereto included in the Company&#8217;s most recent Annual Report on Form 10-K (the &#8220;Form 10-K&#8221;).</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4cb3b5d4-4bb4-4aa1-9aa3-a1f44ea421d4" contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">2.            Cash Equivalents and Investments:</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">As of June 30, 2024 and December 31, 2023, the Company's cash equivalents consisted entirely of money market funds totaling $</span><span style="font-size:9pt;font-family:Times New Roman;white-space:pre-wrap;min-width:fit-content;color:#000000;"><ix:nonFraction id="F_35fb877b-dea8-40ea-9b4e-55aa647760b6" contextRef="C_e1d34d08-f45e-4aed-a85a-ba2eecf7da87" name="us-gaap:MoneyMarketFundsAtCarryingValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:9pt;font-family:Times New Roman;white-space:pre-wrap;min-width:fit-content;color:#000000;"><ix:nonFraction id="F_19594a85-17cf-4463-829d-7b9d59dd19b7" contextRef="C_a816572a-ebf4-473a-a445-92cc3d3335f4" name="us-gaap:MoneyMarketFundsAtCarryingValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">  </span></p><div style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7ab42ddb-a8c9-4967-abd3-5bf9d0b0f37f" contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf" name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock" escape="true"><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Investments held are all classified as current and at </span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">June 30, 2024 and December 31, 2023 are summarized as follows (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:72.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:56.529%;"/>
        <td style="width:1.42%;"/>
        <td style="width:1%;"/>
        <td style="width:18.316%;"/>
        <td style="width:1%;"/>
        <td style="width:1.42%;"/>
        <td style="width:1%;"/>
        <td style="width:18.316%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">June 30, 2024</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Corporate securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b07f34e9-1160-425b-8bca-c12ec196d133" contextRef="C_44713f7f-0be3-44e5-8ff8-456f9638bcb6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">55,777</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8483e884-ff5c-4840-af93-a548c984a45e" contextRef="C_999199c5-cb3d-47a6-abb8-3629d31afbe9" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">57,878</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. Treasury securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_463e3c56-407b-4dfc-bab6-dc85982a49d1" contextRef="C_2656143a-67b9-4650-b483-9f48b62093d5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">31,456</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_209f9834-94b9-4838-b19c-f9662e9045b3" contextRef="C_ca383e94-5006-4063-9440-291a788feb2a" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">22,674</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Municipal debt securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_854a8efb-9223-45f8-895f-7e6bd5181543" contextRef="C_8c03e792-f7c1-4fa1-9f86-8c10e39fa1ac" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,377</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0533f1f7-324b-4384-a009-1f96b15940bf" contextRef="C_925f1f8e-686d-4cc3-b111-72650c3e2456" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,649</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Federal home loan securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bb2b6ccf-3f66-4e90-bb7a-53245f44a8e6" contextRef="C_aacf8890-734e-41da-b969-870124e61507" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,503</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_be926a33-3e20-4433-8de8-6db44e48efe3" contextRef="C_d65f3724-0e7f-4c6c-b50d-444cfddf4c6b" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,670</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Certificates of deposit</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_969cc16a-41e1-4aeb-934c-d1843f4ebfc8" contextRef="C_4753588f-87b9-420c-894d-f10c964db638" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,682</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f8596908-8b5a-40b8-91b0-6870e6c6973a" contextRef="C_3c7dc91a-a1a8-4164-8011-aa824e2173f1" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,614</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f366eeaf-2431-428f-9d33-710f08b964b5" contextRef="C_378538d0-b7e1-4ecd-af00-bb424f0b1747" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">113,795</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cb9de403-5ef7-4933-be70-956fc29a75ea" contextRef="C_01d46517-67df-489d-b34d-e087cf6dadaf" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">104,485</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_dba11174-e972-44db-801a-d9eaa9996247" contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf" name="us-gaap:FairValueDisclosuresTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">3.            Fair Value Measurements:</span></p><p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">The accounting guidance establishes a fair value hierarchy that prioritizes valuation inputs into three levels based on the extent to which inputs used in measuring fair value are observable in the market. Each fair value measurement is reported in one of three levels:</span></p><p style="margin-left:6.667%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Level 1 &#8211; inputs are based upon unadjusted quoted prices for identical instruments traded in active markets.</span></p><p style="margin-left:6.667%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Level 2 &#8211; inputs are based upon quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, and model-based valuation techniques for which all significant assumptions are observable in the market or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span></p><p style="margin-left:6.667%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Level 3 &#8211; inputs are generally unobservable and typically reflect management&#8217;s estimates of assumptions that market participants would use in pricing the asset or liability. The fair values are therefore determined using model-based techniques that include option pricing models, discounted cash flow models, and similar techniques.</span></p><div style="font-size:12pt;font-family:Arial;"><ix:nonNumeric id="F_e54c1428-2fa5-4a79-a91b-f188e87f6a95" contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" escape="true"><p style="text-indent:6.667%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">The following table presents information about the Company&#8217;s financial instruments that are accounted for at fair value on a recurring basis at </span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">June 30, 2024 and December 31, 2023 (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><ix:exclude><div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">7</span></p></div></div></ix:exclude><ix:exclude>
       <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.3in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</span></p></div></ix:exclude>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.54%;"/>
        <td style="width:1.32%;"/>
        <td style="width:13%;"/>
        <td style="width:1.26%;"/>
        <td style="width:1%;"/>
        <td style="width:13.54%;"/>
        <td style="width:1%;"/>
        <td style="width:1.26%;"/>
        <td style="width:1%;"/>
        <td style="width:15.08%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair Value<br/>Category</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">June 30, 2024</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Assets:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Money market funds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Level 1</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_286113c8-8f62-45aa-ae27-79eb7696ffb6" contextRef="C_c97ff8ba-a0bb-4c2f-9d12-7e68bbd283c7" name="md:MoneyMarketFundsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">397</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2b16a090-0d2f-4849-8d39-e78d861216ca" contextRef="C_f2de318d-f0fc-45fc-a7dd-1d90eebc8aff" name="md:MoneyMarketFundsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,814</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Short-term investments</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Level 2</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1e8ce852-712f-4695-a1c1-a567a82147e9" contextRef="C_b2e57193-b6ec-4e23-91dd-bd0d8c1391a7" name="us-gaap:InvestmentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">113,795</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3d2f8051-defe-471e-9c6e-d991a22071a9" contextRef="C_c4efd93d-fa74-4b60-99aa-628c88395267" name="us-gaap:InvestmentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">104,485</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Mutual Funds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Level 1</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_590490bc-d30f-4e9d-bf6a-790f4f5c84a1" contextRef="C_c97ff8ba-a0bb-4c2f-9d12-7e68bbd283c7" name="md:MutualFundsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19,002</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7eead798-0e0b-43ef-9faa-86ca2c83a83b" contextRef="C_f2de318d-f0fc-45fc-a7dd-1d90eebc8aff" name="md:MutualFundsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,687</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_94814d31-db0d-4a40-a22b-1a17460c49ea" contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf" name="md:FinancialInstrumentsMeasuredAtCarryingAmountTableTextBlock" escape="true"><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">The following table presents information about the Company&#8217;s financial instruments that are not carried at fair value at </span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">June 30, 2024 and December 31, 2023 (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.72%;"/>
        <td style="width:1.08%;"/>
        <td style="width:1%;"/>
        <td style="width:9.24%;"/>
        <td style="width:1%;"/>
        <td style="width:1.08%;"/>
        <td style="width:1%;"/>
        <td style="width:9.24%;"/>
        <td style="width:1%;"/>
        <td style="width:1.08%;"/>
        <td style="width:1%;"/>
        <td style="width:9.24%;"/>
        <td style="width:1%;"/>
        <td style="width:1.08%;"/>
        <td style="width:1%;"/>
        <td style="width:9.24%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">June 30, 2024</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Carrying<br/>Amount</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair<br/>Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Carrying<br/>Amount</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair<br/>Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Liabilities:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2030 Notes</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e69dcac9-4c18-4922-af5f-7cbf0f8e8c4b" contextRef="C_74e636e1-15c7-4b53-87ca-8d27ceeed147" name="us-gaap:NotesPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">400,000</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bb9f78db-30d1-4380-b8a3-c491cae73812" contextRef="C_74e636e1-15c7-4b53-87ca-8d27ceeed147" name="us-gaap:NotesPayableFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">353,760</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_08769550-9557-4fa6-9a43-0366f5205a51" contextRef="C_a03ab9fe-6fdf-4312-9317-7df9fc924d88" name="us-gaap:NotesPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">400,000</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fb70aac4-8b07-44ed-a727-bbdde9ac8108" contextRef="C_a03ab9fe-6fdf-4312-9317-7df9fc924d88" name="us-gaap:NotesPayableFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">357,000</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">The carrying amounts of cash equivalents, accounts receivable and accounts payable and accrued expenses approximate fair value due to the short maturities of the respective instruments. The carrying value of the line of credit approximates fair value.  If the Company&#8217;s line of credit was measured at fair value, it would be categorized as Level 2 in the fair value hierarchy.</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">  </span></p></ix:nonNumeric></div>
  <p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:12pt;font-family:Arial;"><ix:nonNumeric id="F_fb3b0887-1b33-435d-8ce8-93bddcd8c4ac" contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf" name="md:AccountsReceivableAndNetRevenueDisclosureTextBlock" escape="true"><p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">4. </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Arial;min-width:fit-content;">            </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Accounts Receivable and Net Revenue:</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_70c6d452-0446-46b8-8fe8-713a0e488152" contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf" name="us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" escape="true"><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Accounts receivable, net consists of the following (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:93.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:63.441%;"/>
        <td style="width:2.151%;"/>
        <td style="width:1%;"/>
        <td style="width:14.128%;"/>
        <td style="width:1%;"/>
        <td style="width:2.151%;"/>
        <td style="width:1%;"/>
        <td style="width:14.128%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">June 30, 2024</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Gross accounts receivable</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bb38042d-bf48-4a9e-a198-dc394e8549cd" contextRef="C_378538d0-b7e1-4ecd-af00-bb424f0b1747" name="us-gaap:AccountsReceivableGrossCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,490,865</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a4602581-9452-49eb-ac14-c8287c3d3112" contextRef="C_01d46517-67df-489d-b34d-e087cf6dadaf" name="us-gaap:AccountsReceivableGrossCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,379,213</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Allowance for contractual adjustments and uncollectibles</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c88a9ef5-5c5b-4c48-b2ec-2561b6709e75" contextRef="C_378538d0-b7e1-4ecd-af00-bb424f0b1747" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,216,701</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7e73daa0-bdc1-4407-a729-8b836acbabfc" contextRef="C_01d46517-67df-489d-b34d-e087cf6dadaf" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,106,900</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5da3b66c-1e23-4b04-be1f-181274cd2917" contextRef="C_378538d0-b7e1-4ecd-af00-bb424f0b1747" name="us-gaap:AccountsReceivableNetCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">274,164</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4ba4dcf8-791e-4870-a71d-2ebbd60658db" contextRef="C_01d46517-67df-489d-b34d-e087cf6dadaf" name="us-gaap:AccountsReceivableNetCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">272,313</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Patient service revenue is recognized at the time services are provided by the Company&#8217;s affiliated physicians. The Company&#8217;s performance obligations related to the delivery of services to patients are satisfied at the time of service. Accordingly, there are no performance obligations that are unsatisfied or partially unsatisfied at the end of the reporting period with respect to patient service revenue. Almost all of the Company&#8217;s patient service revenue is reimbursed by government-sponsored healthcare programs (&#8220;GHC Programs&#8221;) and third-party insurance payors. Payments for services rendered to the Company&#8217;s patients are generally less than billed charges. The Company monitors its revenue and receivables from these sources and records an estimated contractual allowance to properly account for the anticipated differences between billed and reimbursed amounts.</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Accordingly, patient service revenue is presented net of an estimated provision for contractual adjustments and uncollectibles. The Company estimates allowances for contractual adjustments and uncollectibles on accounts receivable based upon historical experience and other factors, including days sales outstanding (&#8220;DSO&#8221;) for accounts receivable, evaluation of expected adjustments and delinquency rates, past adjustments and collection experience in relation to amounts billed, an aging of accounts receivable, current contract and reimbursement terms, changes in payor mix and other relevant information. Contractual adjustments result from the difference between the physician rates for services performed and the reimbursements by GHC Programs and third-party insurance payors for such services.</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Collection of patient service revenue the Company expects to receive is normally a function of providing complete and correct billing information to the GHC Programs and third-party insurance payors within the various filing deadlines and typically occurs within 30 to 60 days of billing.</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Some of the Company&#8217;s hospital agreements require hospitals to pay the Company administrative fees. Some agreements provide for fees if the hospital does not generate sufficient patient volume in order to guarantee that the Company receives a specified minimum revenue level. The Company also receives fees from hospitals for administrative services performed by its affiliated physicians providing medical director or other services at the hospital.</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><ix:exclude><div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">8</span></p></div></div></ix:exclude><ix:exclude>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.3in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</span></p></div></ix:exclude><div style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_61d48caf-d913-45c5-9480-673d400103f2" contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf" name="us-gaap:DisaggregationOfRevenueTableTextBlock" escape="true"><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes the Company&#8217;s net revenue by category (in thousands):</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:29.984%;"/>
        <td style="width:1.111%;"/>
        <td style="width:1%;"/>
        <td style="width:13.136000000000001%;"/>
        <td style="width:1%;"/>
        <td style="width:2.223%;"/>
        <td style="width:1%;"/>
        <td style="width:13.113999999999999%;"/>
        <td style="width:1%;"/>
        <td style="width:1.623%;"/>
        <td style="width:1%;"/>
        <td style="width:14.914%;"/>
        <td style="width:1%;"/>
        <td style="width:1.623%;"/>
        <td style="width:1%;"/>
        <td style="width:14.27%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Three Months Ended<br/>June 30,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Six Months Ended<br/>June 30,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net patient service revenue</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f3989a8b-4566-4732-bdd7-c48e41e64df8" contextRef="C_8d682d9c-f4a6-4720-b0e5-6aba644d655b" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">432,847</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ace8dfad-174b-436e-914f-1d4a95be7da1" contextRef="C_dec064d9-341f-4d43-8d13-9380383f1ea2" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">430,383</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ba00957d-a054-48d5-93c4-a010714b3c0d" contextRef="C_3c816b3b-c82c-4a26-bf82-3219ef7103e7" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">854,678</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e9907055-ab12-4a65-9d58-c2220196af50" contextRef="C_12147e67-2e9c-4442-8daa-56def203d5b7" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">853,567</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Hospital contract administrative fees</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e86f210f-2251-4bde-9962-4eb689d8e70f" contextRef="C_26ef4d6b-17ee-42a8-8ef0-3a3202107d61" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">70,913</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b873e366-7f12-4821-9216-bf28b83521ad" contextRef="C_3f38e980-706e-4b34-b4a0-c3cf6a91f926" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">69,585</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d7d5af4b-ae37-47e5-9cf4-8327f4d5113c" contextRef="C_73da6023-b99b-4424-9d33-e387db8c2e30" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">142,716</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_68f15e18-a902-4e47-ad3c-0c15ad74cc3f" contextRef="C_d6aad445-12fd-4b00-8591-81e1e41d8cfd" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">135,574</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other revenue</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d6330e4b-d094-433b-9c0d-250e3a07cea7" contextRef="C_d2b8faaa-e3b4-40e7-b170-e0b31556d8c0" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">536</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_aad4e8e6-0476-4da5-bf65-7ccbd77e3ae5" contextRef="C_2bb8a119-7219-4b9c-be50-62118be95425" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">609</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_07b43b21-4249-48c7-940d-cdca2d9ce6ca" contextRef="C_b55fcf9b-75fb-43d4-8441-f6cc48e23e07" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,003</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6970d38d-be72-4075-a5c0-e07b6b6af9f0" contextRef="C_21d152cb-f002-4995-a0e6-8a4087443620" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,444</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bcc85955-37fd-4be7-909f-95f77f475fa4" contextRef="C_f8ba14c0-203a-4abe-895a-7068e0d681d9" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">504,296</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2ebb16c0-e6a9-44d7-a5b9-ab62b61b990d" contextRef="C_5a5fa8ad-967b-444b-af35-7dd7a8bf7ba3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">500,577</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_847d4200-5daf-482c-bb83-5ea6c7d8ffad" contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">999,397</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0106f810-c510-453f-9047-3a8eb9cc2906" contextRef="C_57ad6014-6b49-4fd8-b8f7-ae2932078fd6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">991,585</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d2b24257-8f45-43af-8c4d-0c3ad71b2d4e" contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf" name="us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" escape="true"><p style="margin-left:4.533%;text-indent:6.983%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">The approximate percentage of net patient service revenue by type of payor was as follows:</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:91.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:36.233%;"/>
        <td style="width:1.3%;"/>
        <td style="width:1%;"/>
        <td style="width:13.197%;"/>
        <td style="width:1%;"/>
        <td style="width:1.82%;"/>
        <td style="width:1%;"/>
        <td style="width:12.198%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:12.578%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:12.677999999999999%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Three Months Ended<br/>June 30,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Six Months Ended<br/>June 30,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Contracted managed care</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6f224522-bd88-4902-a743-ddd7b71a95fc" contextRef="C_a20b1ed9-1ed7-4cc0-9d05-984cabc1cbec" name="md:PercentageOfNetPatientServiceRevenueByTypeOfPayor" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">71</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_00494cac-86e8-488c-96a1-cf63033aaa7f" contextRef="C_85f3a02e-88e7-4e7f-b8f5-7e31732a7772" name="md:PercentageOfNetPatientServiceRevenueByTypeOfPayor" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">68</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b22f12b2-8997-4b90-a4d6-3e9eb78a5ced" contextRef="C_322f434d-d131-49bb-a0d5-c51c55aa30d0" name="md:PercentageOfNetPatientServiceRevenueByTypeOfPayor" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">71</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a9de9dad-3f93-466a-927f-b5c0d437bb89" contextRef="C_ac837f6b-5715-4c36-8c4a-be2ace21a7e2" name="md:PercentageOfNetPatientServiceRevenueByTypeOfPayor" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">67</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Government</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_13dea165-c7f0-4c76-bc2a-a2d8ec8f9cb1" contextRef="C_e3eb8c28-c7e1-4a49-b42b-e63f13e290c4" name="md:PercentageOfNetPatientServiceRevenueByTypeOfPayor" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">23</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9a821a02-e824-4c1b-b92e-2534a7a16efd" contextRef="C_9a4ff3c3-70d2-4f27-923d-76e5a8c48431" name="md:PercentageOfNetPatientServiceRevenueByTypeOfPayor" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">25</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f4b4651d-9d2e-4826-9efc-e6c5597b710b" contextRef="C_6ac5d2f3-36f9-4043-a22d-1a055bff677d" name="md:PercentageOfNetPatientServiceRevenueByTypeOfPayor" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">24</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3ace5ff3-20ec-4d78-b4d1-00f02740302e" contextRef="C_3c0663a6-a6a7-4ee3-809d-8c8aeb1fca8a" name="md:PercentageOfNetPatientServiceRevenueByTypeOfPayor" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">25</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other third-parties</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ee16b0ce-3e71-4f5d-9194-f9ca43100a5f" contextRef="C_9909352a-5fba-478d-bc57-50fb72a6c67d" name="md:PercentageOfNetPatientServiceRevenueByTypeOfPayor" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">4</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_35a3e64a-0dab-468e-88cb-1b4532ff2311" contextRef="C_156059b8-27ec-4255-9fd4-8a26b81f0b31" name="md:PercentageOfNetPatientServiceRevenueByTypeOfPayor" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">5</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_db34fbfb-4c7b-4261-90bf-2d424ab979b5" contextRef="C_1c3d0626-f775-4377-9dde-87804a3a8785" name="md:PercentageOfNetPatientServiceRevenueByTypeOfPayor" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">3</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8abd0d38-f403-4f4c-a67d-719119dca339" contextRef="C_671fe710-eb0a-40ea-9b5f-3fc84da58634" name="md:PercentageOfNetPatientServiceRevenueByTypeOfPayor" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">6</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Private-pay patients</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_aa667d95-d94f-47d7-a959-0e934ab05925" contextRef="C_e6d4fa65-6594-4957-b174-3dcd01093f75" name="md:PercentageOfNetPatientServiceRevenueByTypeOfPayor" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">2</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dc867d57-5f12-42e6-aa45-86d47bc876c0" contextRef="C_cc98a5b3-d80a-4eb1-aeee-1a0e562d5e27" name="md:PercentageOfNetPatientServiceRevenueByTypeOfPayor" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">2</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5947f32b-0040-4e0e-9db3-f680305f4059" contextRef="C_6cc6fddd-3fb2-40be-bc2f-d396ff6d56c5" name="md:PercentageOfNetPatientServiceRevenueByTypeOfPayor" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">2</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c8b768ba-31bb-4f84-a741-3e42e1c66cf1" contextRef="C_5b39fcf4-ee54-4657-b078-1fee2e008ed8" name="md:PercentageOfNetPatientServiceRevenueByTypeOfPayor" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">2</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9be8bc4d-2ff2-4fa1-bc84-e30f48bcbc9e" contextRef="C_f8ba14c0-203a-4abe-895a-7068e0d681d9" name="md:PercentageOfNetPatientServiceRevenueByTypeOfPayor" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:num-dot-decimal">100</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_313eb969-9bc4-4101-a96a-43dc7fcf3a9f" contextRef="C_5a5fa8ad-967b-444b-af35-7dd7a8bf7ba3" name="md:PercentageOfNetPatientServiceRevenueByTypeOfPayor" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:num-dot-decimal">100</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_391fb6b4-3179-4231-83e0-7a3c2eea1c0b" contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf" name="md:PercentageOfNetPatientServiceRevenueByTypeOfPayor" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:num-dot-decimal">100</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bb45aa06-296b-4589-9b59-bfced6d4dbc4" contextRef="C_57ad6014-6b49-4fd8-b8f7-ae2932078fd6" name="md:PercentageOfNetPatientServiceRevenueByTypeOfPayor" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:num-dot-decimal">100</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_097bc21a-8a2e-49df-b9ed-5e9f0edc551f" contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf" name="us-gaap:BusinessCombinationDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">5. 	Business Combinations</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">During the six months ended June 30, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">, the Company completed the acquisition of </span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fac345a2-072a-48a3-8ba9-6677a7b3cd7f" contextRef="C_4fd51aa1-699c-4d1f-a3f5-aa92a33bc175" name="md:NumberOfMaternalFetalMedicinePracticesAcquired" unitRef="U_Number" decimals="0" format="ixt-sec:numwordsen">one</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> maternal-fetal medicine practice for total consideration of $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_412db57a-834c-4e13-bc39-ff2ae74ce379" contextRef="C_4fd51aa1-699c-4d1f-a3f5-aa92a33bc175" name="us-gaap:BusinessCombinationConsiderationTransferred1" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">9.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million, of which $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9df50c0d-aedd-4baa-9097-f9cce8240db2" contextRef="C_4fd51aa1-699c-4d1f-a3f5-aa92a33bc175" name="us-gaap:PaymentsToAcquireBusinessesGross" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">6.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million was paid in cash at closing and $</span><span style="font-size:9pt;font-family:Times New Roman;white-space:pre-wrap;min-width:fit-content;color:#000000;"><ix:nonFraction id="F_e500b76c-9455-4350-ba20-5743432bada4" contextRef="C_aab2ef2b-f5d5-463b-af2e-d14d85478a3f" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">3.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million was recorded as a contingent consideration liability. The acquisition expanded the Company&#8217;s national network of physician practices across women&#8217;s and children&#8217;s services. In connection with this acquisition, the Company recorded tax deductible goodwill of $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7be6b672-81fe-4830-be59-55fec462e6fe" contextRef="C_378538d0-b7e1-4ecd-af00-bb424f0b1747" name="us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">9.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million, fixed assets of $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e9883ef2-d9fb-485c-8476-f9b3000431a5" contextRef="C_378538d0-b7e1-4ecd-af00-bb424f0b1747" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million and other intangible assets consisting primarily of physician and hospital agreements of $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a0801f57-d097-44bf-81d8-ec64730ee485" contextRef="C_378538d0-b7e1-4ecd-af00-bb424f0b1747" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million.</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">   </span></p></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:12pt;font-family:Arial;"><ix:nonNumeric id="F_a535d0f8-669b-400e-9a72-f5c7f4440f7e" contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">6.</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">  	</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Goodwill, Long-Lived Asset Impairments and Loss on Disposal of Businesses:</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">During the second quarter of 2024, the Company formalized its practice portfolio management plans, resulting in a decision to exit almost all of its affiliated office-based practices, other than maternal-fetal medicine. The practice exits are expected to be completed by December 31, 2024. Accordingly, a recoverability assessment for each individual physician practice was performed, and the estimated future cash flows related to the physician practices did not support the carrying value of the specifically identified individual long-lived assets. As a result, the Company recorded fixed asset impairments of $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_219e0b90-0cb1-4c73-a29f-9a698212c320" contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">20.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million, intangible asset impairments of $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_de80ca39-0722-4259-b8d4-8cd54a89d677" contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">7.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million and operating lease right-of-use asset impairments of $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dbbac23a-defd-41ca-aafe-f648ffc6b7a1" contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf" name="us-gaap:OperatingLeaseImpairmentLoss" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">8.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million. The operating lease right-of-use impairments are recorded within the transformational and restructuring related expenses line item.</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">During the second quarter of 2024, the Company made the decision to exit its primary and urgent care service line based on a review of the cost and time that would be required to build the platform to scale.  The Company divested one of its two previously acquired primary and urgent care practices during the second quarter and divested of the second of its two acquired primary and urgent care practices subsequent to the end of the second quarter. The total loss on disposal of these two businesses was $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c95f3af9-5ef1-4130-8259-ef1a1dfdfdad" contextRef="C_f8ba14c0-203a-4abe-895a-7068e0d681d9" name="us-gaap:GainLossOnSaleOfBusiness" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:num-dot-decimal">10.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million, resulting from the loss on sale for one practice and marking the net assets to their fair value less costs to sell for the other practice.</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">During the second quarter of 2024, the Company experienced a triggering event, due to a sustained decline in its stock price and a market capitalization below the Company's book equity value. As the Company consists of only one reporting unit, and is publicly traded, management estimates the fair value of its reporting unit utilizing the Company&#8217;s market capitalization, multiplying the number of actual shares outstanding on June 30, 2024 by its stock price on June 30, 2024 and applying an additional premium to give effect to the Company&#8217;s best estimate of a control premium. With respect to the estimated control premium used in its analysis, the Company believes that it is reasonable to expect that a market participant would pay a premium to obtain a controlling interest in the Company. The Company considered information from the public markets for premiums on acquisitions in its industry and also considered other factors, such as the value that may arise from the ability to take advantage of synergies and other benefits that flow from control over another entity.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">This assessment resulted in a non-cash impairment charge of $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_86122c08-6c66-4208-a394-9b8cdd42b5ae" contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf" name="md:GoodWillImpairmentLossExcludingDeferredTaxAssetsCharge" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">130.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million, representing the amount by which the Company's book value exceeded its implied fair value, based on its market capitalization plus an estimated control premium. </span><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">Consideration was first given to other individual and group long-lived assets, and no impairment was considered necessary on such assets.</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Recognition of this non-cash charge against goodwill resulted in a tax benefit which generated an additional deferred tax asset of $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_58143611-cfb1-41ce-b3ea-d0a4b6055b25" contextRef="C_378538d0-b7e1-4ecd-af00-bb424f0b1747" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">24.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million </span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">that increased the Company's book value. An incremental non-cash charge was required to reduce the</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">9</span></p></div></div></ix:exclude><ix:exclude>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.3in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Company's </span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">book value to its previously determined fair value. </span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Accordingly, the Company recorded the incremental non-cash charge of $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_eb4e19d7-4d4f-4b61-a931-8c9327bc50d0" contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf" name="md:IncrementalNonCashCharge" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">24.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million for a total non-cash charge of $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_488f9313-f9c0-48a8-8854-2543a5518a26" contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf" name="md:NonCashCharge" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">154.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million. A </span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f9978919-1c95-4639-9374-402445d5a5a7" contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf" name="md:ChangeInRateOfControlPremium" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">% change in the control premium used would have impacted the non-cash impairment charge by approximately $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_780b40fe-6768-43c9-b129-9e5b6efc1823" contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf" name="md:ChangeInNonCashImpairmentCharges" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">6.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million.</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">  </span></p></ix:nonNumeric></div>
  <p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_74911537-1f1b-4802-981b-570817718b71" contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">7.            Accounts Payable and Accrued Expenses:	</span></p><div style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_87997623-1279-494d-a76c-9345e2cd119e" contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf" name="us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" escape="true"><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Accounts payable and accrued expenses consist of the following (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:60.048%;"/>
        <td style="width:1.56%;"/>
        <td style="width:18.416%;"/>
        <td style="width:1.56%;"/>
        <td style="width:18.416%;"/>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">June 30, 2024</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accounts payable</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">$</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3f4c3b28-6ccd-4a26-ab76-ed9340cdd6e6" contextRef="C_378538d0-b7e1-4ecd-af00-bb424f0b1747" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">32,000</ix:nonFraction></span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">$</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1b8948e3-945f-43d8-ba05-8dfb310c8476" contextRef="C_01d46517-67df-489d-b34d-e087cf6dadaf" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">34,588</ix:nonFraction></span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued salaries and incentive compensation</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c8eb22a5-5b56-416a-a0bb-65e7a1b35f38" contextRef="C_378538d0-b7e1-4ecd-af00-bb424f0b1747" name="us-gaap:AccruedSalariesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">115,093</ix:nonFraction></span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8ad2efc0-efcf-46c3-924c-5e019667f20d" contextRef="C_01d46517-67df-489d-b34d-e087cf6dadaf" name="us-gaap:AccruedSalariesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">193,112</ix:nonFraction></span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued payroll taxes and benefits</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_24cdbe20-98cb-4faf-8b30-a24f4b2c1db7" contextRef="C_378538d0-b7e1-4ecd-af00-bb424f0b1747" name="md:AccruedPayrollTaxesAndBenefitsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">28,034</ix:nonFraction></span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_499907f5-b3c0-42f6-a2be-9a68a5792517" contextRef="C_01d46517-67df-489d-b34d-e087cf6dadaf" name="md:AccruedPayrollTaxesAndBenefitsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">36,545</ix:nonFraction></span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued professional liabilities</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_61372d17-ef8b-477e-b4db-310322945176" contextRef="C_378538d0-b7e1-4ecd-af00-bb424f0b1747" name="us-gaap:MalpracticeLossContingencyAccrualUndiscountedCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">28,966</ix:nonFraction></span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_554dc2b3-9e3c-474c-8555-bae2a37f9552" contextRef="C_01d46517-67df-489d-b34d-e087cf6dadaf" name="us-gaap:MalpracticeLossContingencyAccrualUndiscountedCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">32,039</ix:nonFraction></span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued interest</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_68886411-1bc2-43fe-b3ca-d3005cb571a7" contextRef="C_378538d0-b7e1-4ecd-af00-bb424f0b1747" name="us-gaap:InterestPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,258</ix:nonFraction></span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_504dcf7d-7b3b-4f37-8bfd-3eee28629e3f" contextRef="C_01d46517-67df-489d-b34d-e087cf6dadaf" name="us-gaap:InterestPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,262</ix:nonFraction></span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other accrued expenses</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a14d5d34-effd-43f5-8428-e13b06374aa9" contextRef="C_378538d0-b7e1-4ecd-af00-bb424f0b1747" name="us-gaap:OtherAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">54,982</ix:nonFraction></span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_295e0391-b0c1-4c45-9d41-ca5e835ba35f" contextRef="C_01d46517-67df-489d-b34d-e087cf6dadaf" name="us-gaap:OtherAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">46,252</ix:nonFraction></span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">$</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3db53c5c-d6a0-4de0-a52e-d32dfb9c3b6c" contextRef="C_378538d0-b7e1-4ecd-af00-bb424f0b1747" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">267,333</ix:nonFraction></span></p></td>
        <td style="vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">$</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8ca75e4c-571c-4581-94a3-f45672b27f59" contextRef="C_01d46517-67df-489d-b34d-e087cf6dadaf" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">350,798</ix:nonFraction></span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">The net decrease in accrued salaries and incentive compensation of $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4fbc0680-dcf0-45c4-90d9-e517928e69e4" contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf" name="md:IncreaseDecreaseInAccruedSalariesAndBonuses" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">78.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million, from December 31, 2023 to June 30, 2024, </span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">is primarily due to the payment of performance-based incentive compensation, principally to the Company&#8217;s affiliated physicians, partially offset by performance-based incentive compensation accrued during the six months ended June 30, 2024. A majority of the Company&#8217;s payments for performance-based incentive compensation is paid annually during the first quarter.</span></p></ix:nonNumeric></div>
  <p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:12pt;font-family:Arial;"><ix:nonNumeric id="F_4f046ff6-2573-41a7-91ca-aa26d423dc12" contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf" name="md:LineOfCreditAndLongTermDebtTextBlock" escape="true"><p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">8.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Arial;min-width:fit-content;">          </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Line of Credit and Long-Term Debt:</span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">On February 11, 2022, the Company issued $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_86a95aa3-4702-43d6-a656-a164556360d5" contextRef="C_51999449-03d0-412b-a0e1-24677d710d3a" name="us-gaap:SeniorNotes" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">400.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million of </span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b1f3f3bc-a244-4d1e-9f64-fd211b06a4ab" contextRef="C_51999449-03d0-412b-a0e1-24677d710d3a" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" unitRef="U_pure" scale="-2" decimals="5" format="ixt:num-dot-decimal">5.375</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">% unsecured senior notes due 2030 (the &#8220;2030 Notes&#8221;).  The Company used the net proceeds from the issuance of the </span><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c0927320-9210-47fa-9ded-084486911614" contextRef="C_e0420691-52ea-4671-94fc-b8e7b69e3142" name="md:DebtInstrumentMaturityYear"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">2030</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> Notes, together with $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_09cc41a9-2814-480c-8650-20b250422e84" contextRef="C_0b63294a-0107-49a4-a13e-bda5f278d21c" name="us-gaap:ProceedsFromIssuanceOfUnsecuredDebt" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">100.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million drawn under the Revolving Credit Line (as defined below), $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6397d8d9-97e9-4a29-bd2b-c1914e85ca55" contextRef="C_21dc151c-5f14-4067-a9f0-945b9851cd13" name="us-gaap:UnsecuredLongTermDebt" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">250.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million of Term A Loan (as defined below) and approximately $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2c32a91f-50c0-4566-9fcd-fd5c4c7e4f32" contextRef="C_21dc151c-5f14-4067-a9f0-945b9851cd13" name="us-gaap:Cash" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">308.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million of cash on hand, to redeem (the &#8220;Redemption&#8221;) the 2027 Notes, which had an outstanding principal balance of $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_51e6d9c6-a488-4403-839d-8613aa9fb524" contextRef="C_407e9c0c-05d2-4164-85d8-d7f2fdffa0b3" name="us-gaap:LongTermDebt" unitRef="U_USD" scale="9" decimals="-8" format="ixt:num-dot-decimal">1.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> billion, and to pay costs, fees and expenses associated with the Redemption and the Credit Agreement Amendment (as defined below).</span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Interest on the 2030 Notes accrues at the rate of </span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2c438d09-2dda-42a3-989e-51ebfbe30c3c" contextRef="C_378538d0-b7e1-4ecd-af00-bb424f0b1747" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" unitRef="U_pure" scale="-2" decimals="5" format="ixt:num-dot-decimal">5.375</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">% per annum, or $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1540b4fc-4e0a-45a5-9379-6478109f8ff1" contextRef="C_13c390ad-a46f-4851-8328-8c24f9da6308" name="us-gaap:DebtInstrumentPeriodicPaymentInterest" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">21.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million, and is </span><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ed7a63d7-af86-4731-9d4f-fee4585befb2" contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf" name="us-gaap:DebtInstrumentFrequencyOfPeriodicPayment"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">payable semi-annually in arrears on February 15 and August 15, beginning on August 15, 2022</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">. The Company's obligations under the 2030 </span><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a9f2d720-e082-4058-8be9-cf973f4eda1a" contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf" name="us-gaap:DebtInstrumentDescription"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Notes are guaranteed on an unsecured senior basis by the same subsidiaries and affiliated professional contractors that guarantee the Amended Credit Agreement (as defined below). The indenture under which the 2030 Notes are issued, among other things, limits the Company's ability to (1) incur liens and (2) enter into sale and lease-back transactions, and also limits the Company's ability to merge or dispose of all or substantially all of its assets, in all cases, subject to a number of customary exceptions</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">. Although the Company is not required to make mandatory redemption or sinking fund payments with respect to the 2030 Notes, upon the occurrence of a change in control, the Company may be required to repurchase the 2030 Notes at a purchase price equal to </span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d78da273-1bab-47c9-8dcc-681a2c4c4604" contextRef="C_378538d0-b7e1-4ecd-af00-bb424f0b1747" name="md:PurchasePrice" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">101</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">% of the aggregate principal amount of the 2030 Notes repurchased plus accrued and unpaid interest.</span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Also in connection with the Redemption, the Company amended its credit agreement (the &#8220;Credit Agreement&#8221;, and such amendment, the "Credit Agreement Amendment"), concurrently with the issuance of the 2030 Notes. The Credit Agreement Amendment, among other things, (i) refinanced the prior unsecured revolving credit facility with a $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_65f78bb1-1abd-4690-8cf6-5fb833cc8fe8" contextRef="C_d408367b-f06f-4217-a293-02fa802d8521" name="us-gaap:UnsecuredDebt" unitRef="U_USD" scale="6" decimals="-6" format="ixt:num-dot-decimal">450</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million unsecured revolving credit facility, including a $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f016b171-191d-445e-8a70-d365c1f46917" contextRef="C_9949ee77-7752-43b8-9d0b-21296bfbc11e" name="us-gaap:ProceedsFromLinesOfCredit" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">37.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million sub-facility for the issuance of letters of credit (the &#8220;Revolving Credit Line&#8221;), and a $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3842249f-0548-4a87-846d-72f8d14bf642" contextRef="C_ef12bbdb-7da5-4d1d-98f3-f1b0c3da31ba" name="us-gaap:UnsecuredLongTermDebt" unitRef="U_USD" scale="6" decimals="-6" format="ixt:num-dot-decimal">250</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million term A loan facility (&#8220;Term A Loan&#8221;) and (ii) removed JPMorgan Chase Bank, N.A., as the administrative agent under the Credit Agreement and appointed Bank of America, N.A. as the administrative agent for the lenders.</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">  </span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">The Credit Agreement, as amended by the Credit Agreement Amendment (the &#8220;Amended Credit Agreement&#8221;) matures on February 11, 2027 and is guaranteed on an unsecured basis by substantially all of the Company's subsidiaries and affiliated professional contractors. At the Company's option, borrowings under the Amended Credit Agreement bear interest at </span><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6ef581d0-45b5-41de-b5d0-32415546f2fa" contextRef="C_e050a756-0027-4664-943e-74db5426b7c8" name="us-gaap:DescriptionOfInterestRateRiskExposure"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">(i) the Alternate Base Rate (defined as the highest of (a) the prime rate as announced by Bank of America, N.A., (b) the Federal Funds Rate plus 0.50% and (c) Term Secured Overnight Financing Rate ("SOFR") for an interest period of one month plus 1.00% with a 1.00% floor) plus an applicable margin rate of 0.50% for the first two fiscal quarters after the date of the Credit Agreement Amendment, and thereafter at an applicable margin rate ranging from 0.125% to 0.750% based on the Company's consolidated net leverage ratio or (ii) Term SOFR rate (calculated as the Secured Overnight Financing Rate published on the applicable Reuters screen page plus a spread adjustment of 0.10%, 0.15% or 0.25% depending on if the Company selects a one-month, three-month or six-month interest period, respectively, for the applicable loan with a 0% floor), plus an applicable margin rate of 1.50% for the first two full fiscal quarters after the date of the Credit Agreement Amendment, and thereafter at an applicable margin rate ranging from 1.125% to 1.750% based on the Company's consolidated net leverage ratio. The Amended Credit Agreement also provides for other customary fees and charges, including an unused commitment fee with respect to the Revolving Credit Line ranging from 0.150% to 0.200% of the unused lending commitments under the Revolving Credit Line</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">, based on the Company's consolidated net leverage ratio.</span></p><ix:exclude><div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">10</span></p></div></div></ix:exclude><ix:exclude>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.3in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">The Amended Credit Agreement contains customary covenants and restrictions, including covenants that require the Company to maintain a minimum interest coverage ratio, a maximum consolidated total consolidated net leverage ratio and to comply with laws, and restrictions on the ability to pay dividends, incur indebtedness or liens and make certain other distributions subject to baskets and exceptions, in each case, as specified therein. Failure to comply with these covenants would constitute an event of default under the Amended Credit Agreement, notwithstanding the ability of the Company to meet its debt service obligations. The Amended Credit Agreement includes various customary remedies for the lenders following an event of default, including the acceleration of repayment of outstanding amounts under the Amended Credit Agreement. In addition, the Company may increase the principal amount of the Revolving Credit Line or incur additional term loans under the Amended Credit Agreement in an aggregate principal amount such that on a pro forma basis after giving effect to such increase or additional term loans, the Company would be in compliance with the financial covenants, subject to the satisfaction of specified conditions and additional caps in the event that the Amended Credit Agreement is secured.</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">At June 30, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">, the Company had an outstanding principal balance on the Amended Credit Agreement of $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_85534152-90e1-4704-82c1-00f2091d5142" contextRef="C_4506227b-6467-48fd-bf2a-12d647f3a96a" name="us-gaap:LongTermDebt" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">221.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million, composed of the Term A Loan.  There was no outstanding balance under the Revolving Credit Line. The Company had $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_af04071e-f98d-4278-9dfe-ff78a0d71c82" contextRef="C_4506227b-6467-48fd-bf2a-12d647f3a96a" name="us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">450.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million available on its Amended Credit Agreement at June 30, 2024.</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">At June 30, 2024, the Company had an outstanding principal balance of $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2413387c-dd28-4747-8e62-383ae7b014fa" contextRef="C_a0685afe-439a-454c-a102-de37c36a07ad" name="us-gaap:LongTermDebt" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">400.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million on the 2030 Notes.</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <div style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_571b7f60-ca82-44e7-bcf9-40c5976684d9" contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf" name="us-gaap:EarningsPerShareTextBlock" escape="true"><p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">9.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Arial;min-width:fit-content;">            </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Common and Common Equivalent Shares:</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Basic net income per common share is calculated by dividing net income by the weighted average number of common shares outstanding during the period. Diluted net income per common share is calculated by dividing net income by the weighted average number of common and potential common shares outstanding during the period. Potential common shares consist of outstanding restricted stock and stock options and is calculated using the treasury stock method.</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_80381e4f-a1c2-4b7b-9497-1ae07de4f0f2" contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf" name="us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" escape="true"><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">The calculation of shares used in the basic and diluted net income per common share calculation for the </span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">three and six months ended June 30, 2024 and 2023 is as follows (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:49.07%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:10.498%;"/>
        <td style="width:1%;"/>
        <td style="width:1.88%;"/>
        <td style="width:1%;"/>
        <td style="width:9.178%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:8.978%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:9.398%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Three Months Ended<br/>June 30,</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Six Months Ended<br/>June 30,</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted average number of common shares outstanding</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_24204417-d660-4713-bd7d-dc0d69f64459" contextRef="C_f8ba14c0-203a-4abe-895a-7068e0d681d9" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">83,332</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_506620dc-b993-4f5d-b4a7-519d111a2803" contextRef="C_5a5fa8ad-967b-444b-af35-7dd7a8bf7ba3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">82,399</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ab0f7450-5aa9-4f30-bf43-47992e4823e3" contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">83,074</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4ffc61a8-526e-46dc-9164-dd5498f886b2" contextRef="C_57ad6014-6b49-4fd8-b8f7-ae2932078fd6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">82,033</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted average number of dilutive common share<br/>&#160;&#160;&#160;equivalents (a)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_66ce8c6b-bf02-4620-aebb-b797c84e03c0" contextRef="C_f8ba14c0-203a-4abe-895a-7068e0d681d9" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" unitRef="U_shares" scale="3" decimals="INF" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_366def61-6f60-45f1-ba3d-c025beb3a2f3" contextRef="C_5a5fa8ad-967b-444b-af35-7dd7a8bf7ba3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" unitRef="U_shares" scale="3" decimals="INF" format="ixt:num-dot-decimal">265</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_76080b36-bd54-43be-8e29-8555378a28cc" contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" unitRef="U_shares" scale="3" decimals="INF" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_57572a1b-018e-4ddb-a8a8-a910ae1e8652" contextRef="C_57ad6014-6b49-4fd8-b8f7-ae2932078fd6" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" unitRef="U_shares" scale="3" decimals="INF" format="ixt:num-dot-decimal">344</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted average number of common and common<br/>&#160;&#160;&#160;equivalent shares outstanding</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_27617bf4-843f-42ab-bd4f-d87a00af5dc3" contextRef="C_f8ba14c0-203a-4abe-895a-7068e0d681d9" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">83,332</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4de0b138-dce2-485d-97c7-44272da7deca" contextRef="C_5a5fa8ad-967b-444b-af35-7dd7a8bf7ba3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">82,664</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_889191eb-a96d-4e00-a5d4-c5d53b72846d" contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">83,074</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c4d4c140-d72f-419b-988c-2aca845b915a" contextRef="C_57ad6014-6b49-4fd8-b8f7-ae2932078fd6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">82,377</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Antidilutive securities (restricted stock and stock options) not included in the diluted net income per common share calculation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a3b39698-cc60-4981-9a80-dbdfad3aa137" contextRef="C_f8ba14c0-203a-4abe-895a-7068e0d681d9" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" scale="3" decimals="INF" format="ixt:num-dot-decimal">916</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_653049d4-bed2-4fa8-a155-329545114a13" contextRef="C_5a5fa8ad-967b-444b-af35-7dd7a8bf7ba3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" scale="3" decimals="INF" format="ixt:num-dot-decimal">1,338</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0e86b410-6079-4bc8-8f4d-5716d7e8d799" contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" scale="3" decimals="INF" format="ixt:num-dot-decimal">661</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f1a5e710-1ebb-4866-998b-2a772ec0690c" contextRef="C_57ad6014-6b49-4fd8-b8f7-ae2932078fd6" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" scale="3" decimals="INF" format="ixt:num-dot-decimal">1,358</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;">(a) </span><ix:footnote id="FNT_744c8b1e-b9b8-41e6-bb9a-b20ca1c97fb6" xml:lang="en-US"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;">Due to a loss for the three and six months ended June 30, 2024, </span><span style="font-size:8.5pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_181412ae-4e8f-4c1f-92c6-af668cc6bb09" contextRef="C_f8ba14c0-203a-4abe-895a-7068e0d681d9" name="md:IncrementalSharesNotIncludedDueToAntiDilutiveEffect" unitRef="U_shares" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;"> million and </span><span style="font-size:8.5pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_19a0a234-01ed-4015-825b-870ed9d5bb52" contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf" name="md:IncrementalSharesNotIncludedDueToAntiDilutiveEffect" unitRef="U_shares" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;"> million incremental shares, respectively, are not included because the effect would be antidilutive.</span></ix:footnote></p></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:12pt;font-family:Arial;"><ix:nonNumeric id="F_004b56ee-63da-41b7-9a30-480dc24698f0" contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" escape="true"><p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">10.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Arial;min-width:fit-content;">            </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Stock Incentive Plans and Stock Purchase Plans:</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s Amended and Restated 2008 Incentive Compensation Plan (the &#8220;Amended and Restated 2008 Incentive Plan&#8221;) provides for grants of stock options, stock appreciation rights, restricted stock, deferred stock, and other stock-related awards and performance awards that may be settled in cash, stock or other property.</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Under the Amended and Restated 2008 Incentive Plan, options to purchase shares of common stock may be granted at a price not less than the fair market value of the shares on the date of grant. The options must be exercised within </span><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_48e02f9c-80b0-4dee-81c9-bae010472edd" contextRef="C_270805f0-aab2-410a-81a6-0fd72e3a746a" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">10 years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> from the date of grant and generally become exercisable on a pro rata basis over a </span><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c38c526a-9750-4ff5-8557-8b0cdcbffedf" contextRef="C_ab52b5b0-1d74-4f4b-8f22-0ab60d83e515" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">three-year</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> period from the date of grant. The Company issues new shares of its common stock upon exercise of its stock options. Restricted stock awards generally vest over periods of </span><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_594a1192-7cd8-47c5-8fcb-79ec5eabc3a8" contextRef="C_7cf5d7c6-f082-42c8-aa0e-fe1ed65ec2d0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">three years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> upon the fulfillment of specified service-based conditions and in certain instances performance-based conditions. Deferred stock awards generally vest upon the satisfaction of specified performance-based conditions and service-based conditions. The Company recognizes compensation expense related to its restricted stock and deferred stock awards ratably over the corresponding vesting periods. During the </span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">six months ended June 30, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">, the Company granted </span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4f968453-9d20-44a6-86b9-3523e1b4e653" contextRef="C_0ca0f3da-cd87-48f0-9af2-4b8a86903bc0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" unitRef="U_shares" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million shares of restricted stock to its employees and non-employee directors under the Amended and Restated 2008 Incentive Plan. At June 30, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">, the Company had </span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_38c7607e-83f7-4ea7-81ac-11970a17267e" contextRef="C_70422dcf-ff02-49e5-8b94-24099256e942" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" unitRef="U_shares" scale="6" decimals="-5" format="ixt:num-dot-decimal">6.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million shares available for future grants and awards under the Amended and Restated 2008 Incentive Plan.</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">   </span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Under the Company&#8217;s Amended and Restated 1996 Non-Qualified Employee Stock Purchase Plan, as amended (the &#8220;ESPP&#8221;), employees are permitted to purchase the Company's common stock at </span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f22ed4c3-d8a7-4326-a97d-9f456348f59e" contextRef="C_2d25298d-eb54-4bce-a6ef-521cc063eeb3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">85</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">% of market value on January 1st, April 1st, July 1st and October 1st of each year. Under the Company&#8217;s 2015 Non-Qualified Stock Purchase Plan (the &#8220;SPP&#8221;), certain eligible non-employee service providers are permitted to purchase the Company&#8217;s common stock at </span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1ac5c239-2459-496f-926c-2c87f35233b7" contextRef="C_32a74e36-4b2a-435f-abc7-46f886f94451" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">90</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">% of market value on January 1st, April 1st, July 1st and October 1st of each year.</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><ix:exclude><div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">11</span></p></div></div></ix:exclude><ix:exclude>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.3in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">The Company recognizes stock-based compensation expense for the discount received by participating employees and non-employee service providers. During the six months ended June 30, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">, approximately </span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e8a9f8c3-2877-44ad-a895-8f623d7ffa28" contextRef="C_ab52b5b0-1d74-4f4b-8f22-0ab60d83e515" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" unitRef="U_shares" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million shares were issued under the ESPP. At June 30, 2024, the Company had approximately </span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8bf964f2-0952-4ce6-9630-92021394ff61" contextRef="C_690872af-c97c-4e54-9314-3d7d7de3a6f3" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million shares reserved for issuance under the ESPP. At June 30, 2024, the Company had approximately </span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1d5a86e1-1b50-4b16-853f-1ded171d5022" contextRef="C_5dea8f8c-6ce2-4ac6-b2b8-2c6020fb27ef" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">61,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> shares in the aggregate reserved for issuance under the SPP.  </span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6fce273e-733d-4533-8a7a-1172ffb059a4" contextRef="C_dc0ea4b3-aac8-4793-b9f2-f1f63e43c02c" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" unitRef="U_shares" scale="6" decimals="-6" format="ixt-sec:numwordsen">No</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> shares have been issued under the SPP since 2020.</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">During the three and six months ended June 30, 2024 and 2023, the Company recognized stock-based compensation expense of $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f78f5d6b-c5cc-4114-9373-cbfc89493e16" contextRef="C_f8ba14c0-203a-4abe-895a-7068e0d681d9" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e547d652-a034-400b-837b-f025d05483ca" contextRef="C_5a5fa8ad-967b-444b-af35-7dd7a8bf7ba3" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">4.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_545508f3-2d60-406c-8bdb-163c74485e54" contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">3.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_57897584-9fe7-4903-b71c-5c602e446b65" contextRef="C_57ad6014-6b49-4fd8-b8f7-ae2932078fd6" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">6.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">  </span></p></ix:nonNumeric></div>
  <p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_05c93d01-3c3e-45fd-8125-f1328991bf46" contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf" name="md:CommonStockRepurchasesTextBlock" escape="true" continuedAt="F_05c93d01-3c3e-45fd-8125-f1328991bf46_1"><p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">11.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Arial;min-width:fit-content;">            </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Common Stock Repurchase Programs:</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">In July 2013, the Company&#8217;s Board of Directors authorized the repurchase of shares of the Company&#8217;s common stock up to an amount sufficient to offset the dilutive impact from the issuance of shares under the Company&#8217;s equity compensation programs. The share repurchase program allows the Company to make open market purchases from time-to-time based on general economic and market conditions and trading restrictions. The repurchase program also allows for the repurchase of shares of the Company&#8217;s common stock to offset the dilutive impact from the issuance of shares, if any, related to the Company&#8217;s acquisition program. </span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_db755eae-a413-40de-beb8-7b3a4f44d139" contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf" name="us-gaap:StockRepurchasedDuringPeriodShares" unitRef="U_shares" scale="3" decimals="INF" format="ixt-sec:numwordsen">No</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> shares were purchased under this program during the </span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">six months ended June 30, 2024.</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">In August 2018, the Company announced that its Board of Directors had authorized the repurchase of up to $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ca315e02-a0ef-4df3-b5f2-927fcdf53091" contextRef="C_c38ac2d9-9615-4715-baeb-08e4368151a9" name="srt:StockRepurchaseProgramAuthorizedAmount1" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">500.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million of the Company&#8217;s common stock in addition to its existing share repurchase program, of which $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_400d3bc6-d503-499a-b3b2-cf774d58f11a" contextRef="C_01d46517-67df-489d-b34d-e087cf6dadaf" name="us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">4.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million remained available for repurchase as of December 31, 2023. Under this share repurchase program, during the six months ended June 30, 2024, the Company purchased a nominal number of shares of its common stock for $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4944c6ac-3ceb-4db8-a510-2517baa60588" contextRef="C_0971ef72-7587-4d12-8daf-522e84254143" name="us-gaap:PaymentsForRepurchaseOfCommonStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million representing shares withheld to satisfy minimum statutory withholding obligations in connection with the vesting of restricted stock, resulting in $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_809bd645-0ac7-4981-8361-e54525932844" contextRef="C_f58ff9fd-0a96-40d3-97e1-a038b63ab720" name="us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">3.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million remaining available for repurchase under this authorization as of June 30, 2024.</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div>
  <p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span><ix:continuation id="F_05c93d01-3c3e-45fd-8125-f1328991bf46_1"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">The Company intends to utilize various methods to effect any future share repurchases, including, among others, open market purchases and accelerated share repurchase programs. The amount and timing of repurchases will depend upon several factors, including general economic and market conditions and trading restrictions.</span></ix:continuation></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_822c3995-8358-44aa-b217-3574aaff9dd7" contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" escape="true"><p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">12.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Arial;min-width:fit-content;">            </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Commitments and Contingencies:	</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">The Company expects that audits, inquiries and investigations from government authorities and agencies will occur in the ordinary course of business. Such audits, inquiries and investigations and their ultimate resolutions, individually or in the aggregate, could have a material adverse effect on the Company's business, financial condition, results of operations, cash flows and the trading price of its securities. The Company has not included an accrual for these matters as of June 30, 2024 in its Consolidated Financial Statements, as the variables affecting any potential eventual liability depend on the currently unknown facts and circumstances that arise out of, and are specific to, any particular future audit, inquiry and investigation and cannot be reasonably estimated at this time.</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">In the ordinary course of business, the Company becomes involved in pending and threatened legal actions and proceedings, most of which involve claims of medical malpractice related to medical services provided by the Company's affiliated physicians. The Company's contracts with hospitals generally require the Company to indemnify them and their affiliates for losses resulting from the negligence of the Company's affiliated physicians. The Company may also become subject to other lawsuits which could involve large claims and significant costs. The Company believes, based upon a review of pending actions and proceedings, that the outcome of such legal actions and proceedings will not have a material adverse effect on its business, financial condition, results of operations, cash flows and the trading price of its securities. The outcome of such actions and proceedings, however, cannot be predicted with certainty and an unfavorable resolution of one or more of them could have a material adverse effect on the Company's business, financial condition, results of operations, cash flows and the trading price of its securities.</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Although the Company currently maintains liability insurance coverage intended to cover professional liability and certain other claims, the Company cannot assure that its insurance coverage will be adequate to cover liabilities arising out of claims asserted against it in the future where the outcomes of such claims are unfavorable. With respect to professional liability risk, the Company generally self-insures a portion of this risk through its wholly owned captive insurance subsidiary. Liabilities in excess of the Company's insurance coverage, including coverage for professional liability and certain other claims, could have a material adverse effect on the Company's business, financial condition, results of operations, cash flows and the trading price of its securities.</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">12</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.3in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="mda"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Item 2. Management&#8217;s Discussion and Analysis</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> of Financial Condition and Results</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">of Operations</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">The following discussion highlights the principal factors that have affected our financial condition and results of operations, as well as our liquidity and capital resources, for the periods described. This discussion should be read in conjunction with the unaudited Consolidated Financial Statements and the notes thereto included in this Quarterly Report. In addition, reference is made to our audited consolidated financial statements and notes thereto and related Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023, filed with the Securities and Exchange Commission on February 20, 2024 (the &#8220;2023 Form 10-K&#8221;). As used in this Quarterly Report, the terms &#8220;Pediatrix&#8221;, the &#8220;Company&#8221;, &#8220;we&#8221;, &#8220;us&#8221; and &#8220;our&#8221; refer to the parent company, Pediatrix Medical Group, Inc., a Florida corporation, and the consolidated subsidiaries through which its businesses are actually conducted (collectively, &#8220;PMG&#8221;), together with PMG&#8217;s affiliated business corporations or professional associations, professional corporations, limited liability companies and partnerships (&#8220;affiliated professional contractors&#8221;). Certain subsidiaries of PMG have contracts with our affiliated professional contractors, which are separate legal entities that provide physician services in certain states. The following discussion contains forward-looking statements. Please see the Company&#8217;s 2023 Form 10-K, including Item 1A, Risk Factors, for a discussion of the uncertainties, risks and assumptions associated with these forward-looking statements. In addition, please see &#8220;Caution Concerning Forward-Looking Statements&#8221; below.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Overview</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Pediatrix is a leading provider of physician services including newborn, maternal-fetal, and other pediatric subspecialty care. Our national network is comprised of affiliated physicians who provide clinical care in 37 states. Our affiliated physicians provide neonatal clinical care, primarily within hospital-based neonatal intensive care units (&#8220;NICUs&#8221;), to babies born prematurely or with medical complications; and maternal-fetal and obstetrical medical care to expectant mothers experiencing complicated pregnancies, primarily in areas where our affiliated neonatal physicians practice. We also provide services across multiple other pediatric subspecialties.</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">General Economic Conditions and Other Factors</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Our operations and performance depend significantly on economic conditions. During the three months ended June 30, 2024, the percentage of our patient service revenue being reimbursed under government-sponsored healthcare programs (&#8220;GHC Programs&#8221;) decreased as compared to the three months ended June 30, 2023. However, we could experience shifts toward GHC Programs if changes occur in economic behaviors or population demographics within geographic locations in which we provide services, including an increase in unemployment and underemployment as well as losses of commercial health insurance. Payments received from GHC Programs are substantially less for equivalent services than payments received from commercial insurance payors. In addition, costs of managed care premiums and patient responsibility amounts continue to rise, and accordingly, we may experience lower net revenue resulting from increased bad debt due to patients&#8217; inability to pay for certain services.</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Practice Portfolio Management Plan and Impairment of Long-Lived Assets</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">During the second quarter of 2024, we formalized our physician practice optimization plans, resulting in a decision to exit almost all of our affiliated office-based practices, other than maternal-fetal medicine. Over the course of many years, we expanded our pediatric service lines and footprint to provide specialized care to more patients, including through our office-based portfolio of practices. This added complexity to our operations over time and, accordingly, increased costs that resulted in operating challenges primarily for our office-based portfolio of practices. Recognizing this and our need to adapt to the current healthcare climate, during the second quarter, we made the decision to return to a hospital-based and maternal-fetal medicine-focused organization. The exits of our pediatric office-based practices are expected to be completed by December 31, 2024. Accordingly, a recoverability assessment for each impacted individual physician practice was performed, and the estimated future cash flows related to the physician practices did not support the carrying value of the specifically identified individual long-lived assets. As a result, during the second quarter of 2024, we recorded fixed asset impairments of $20.1 million, intangible asset impairments of $7.7 million and operating lease right-of-use asset impairments of $8.1 million. The operating lease right-of-use impairments are recorded within the transformational and restructuring related expenses line item.</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Loss on Disposal of Businesses</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">During the second quarter of 2024, we made the decision to exit our primary and urgent care service line based on a review of the cost and time that would be required to build the platform to scale.  We divested one of our two previously acquired primary and urgent care practices during the second quarter and divested of the second of our two acquired primary and urgent care practices subsequent to the end of the second quarter. The total loss on disposal of these two businesses was $10.9 million, resulting from the loss on sale for one practice and marking the net assets to their fair value less costs to sell for the other practice.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Goodwill Impairment</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Goodwill is tested for impairment on at least an annual basis, in accordance with the subsequent measurement provisions of the accounting guidance for goodwill. During the second quarter of 2024, we experienced a triggering event resulting from a sustained decline in our stock price that resulted in our market capitalization being lower than the book value of our equity. This impairment assessment resulted in a non-cash impairment charge of $130.0 million. Recognition of this non-cash charge against goodwill resulted in a tax benefit which generated an additional deferred tax asset of $24.2 million that increased the book value of our equity. An incremental non-cash charge was required to reduce the book value of our equity to our previously determined fair value. Accordingly, we recorded the incremental non-cash charge of $24.2 million for a total non-cash charge of $154.2 million.</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">13</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.3in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">&#8220;Surprise&#8221; Billing Legislation</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">	</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">In late 2020, Congress enacted the No Surprises Act (&#8220;NSA&#8221;) legislation intended to protect patients from &#8220;surprise&#8221; medical bills when certain services are furnished by providers who are not in-network with the patient&#8217;s insurer. Effective January 1, 2022, if the patient&#8217;s insurance plan or coverage is subject to the NSA, providers are not permitted to send patients an unexpected or &#8220;surprise&#8221; medical bill that arises from out-of-network emergency care provided at certain out-of-network facilities or at certain in-network facilities by out-of-network emergency providers, as well as nonemergency care provided at certain in-network facilities by out-of-network providers without the patient&#8217;s informed consent (as defined by the NSA). Many states have legislation on this topic and will continue to modify and review their laws pertaining to surprise billing.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">For claims subject to the NSA, insurers are required to calculate the patient&#8217;s total cost-sharing amount pursuant to rules set forth in the NSA and its implementing regulations which, in some cases, can be calculated by reference to the applicable qualifying payment amount for the items or services received.  The patient&#8217;s cost-sharing amount for out-of-network services covered by the NSA must be no more than the patient&#8217;s in-network cost-sharing amounts. Patient cost-sharing amounts for items and services subject to the NSA count toward the patient&#8217;s health plan deductible and out-of-pocket cost-sharing limits. For claims subject to the NSA, providers are generally not permitted to balance bill patients beyond this cost-sharing amount. An out-of-network provider is only permitted to bill a patient more than the cost-sharing amount allowed under the NSA for certain types of services if the provider satisfies all aspects of an informed consent process set forth in the NSA&#8217;s implementing regulations. Providers that violate these surprise billing prohibitions may be subject to state enforcement action or federal civil monetary penalties.</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">For claims subject to the NSA, including many emergency care services, out-of-network providers will be paid an amount determined by the patient&#8217;s insurer; if a provider is not satisfied with the initial amount paid for the services, the provider can pursue recourse through an independent dispute resolution process. The outcome of each IDR dispute is generally binding on both the provider and payor with respect to the particular claims at issue in that dispute but may not affect an insurer&#8217;s future offers of payment. Accordingly, we cannot predict how these IDR results will compare to the rates that our affiliated physicians customarily receive for their services. These measures could limit the amount we can charge and recover for services we furnish where we have not contracted with the patient&#8217;s insurer, and therefore could have a material adverse effect on our business, financial condition, results of operations, cash flows and the trading price of our securities.</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Healthcare Reform</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">The Patient Protection and Affordable Care Act and the Health Care and Education Reconciliation Act (collectively the &#8220;ACA&#8221;) has altered how health care is delivered and reimbursed in the U.S. and contain various provisions, including the establishment of health insurance exchanges to facilitate the purchase of qualified health plans, expanded Medicaid eligibility, subsidized insurance premiums and additional requirements and incentives for businesses to provide healthcare benefits. Other provisions have expanded the scope and reach of the FCA and other healthcare fraud and abuse laws. The status of the ACA may be subject to change as a result of political, legislative, regulatory, and administrative developments, as well as judicial proceedings. As a result, we could be affected by potential changes to various aspects of the ACA, including changes to subsidies, healthcare insurance marketplaces and Medicaid expansion. We cannot say for certain whether there will be additional future challenges to the ACA or what impact, if any, such challenges may have on our business. Changes resulting from various legal proceedings, and any legislative or administrative change to the current healthcare financing system, could have a material adverse effect  on our business, financial condition, results of operations, cash flows and the trading price of our securities.</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">In addition to the ACA, there could be changes to other GHC Programs, such as a change to the Medicaid program design or Medicaid coverage and reimbursement rates set forth under federal or state law. These changes, if implemented, could eliminate the guarantee that everyone who is eligible and applies for Medicaid benefits would receive them and could potentially give states new authority to restrict eligibility, cut benefits and/or make it more difficult for people to enroll. Moreover, the expiration of the COVID-19 national emergency and public health emergency declarations in May 2023 may impact the coverage for and access to certain services for Medicaid patients. Expiration of the national emergency and public health emergency declarations will also end waivers for the provision of certain services, and returning our services to a pre-pandemic regulatory state similarly may increase our exposure to legal, regulatory, compliance and clinical risks.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Medicaid Expansion</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">The ACA also allows states to expand their Medicaid programs through federal payments that fund most of the cost of increasing the Medicaid eligibility income limit from a state&#8217;s historic eligibility levels to 133% of the federal poverty level. All of the states in which we operate, however, already cover children in the first year of life and pregnant women if their household income is at or below 133% of the federal poverty level.  Recently, Democrats in Congress have sought to expand Medicaid or Medicaid-like coverage in states that have not yet expanded Medicaid. They also have sought to reduce payments to certain hospitals in some of these states. Should any of these changes take effect, we cannot predict with any assurance the ultimate effect on reimbursements for our services.</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Non-GAAP Measures</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">In our analysis of our results of operations, we use various GAAP and certain non-GAAP financial measures. We have incurred certain expenses that we do not consider representative of our underlying operations, including transformational and restructuring related expenses. Accordingly, we report adjusted earnings before interest, taxes and depreciation and amortization (&#8220;Adjusted EBITDA&#8221;), defined as net income before interest, taxes, depreciation and amortization, and transformational and restructuring related expenses. Earnings per share has also been adjusted (&#8220;Adjusted EPS&#8221;) and consists of diluted net income per common and common equivalent share adjusted for amortization expense, stock-based compensation expense, transformational and restructuring related expenses and impacts from discrete tax events. For the</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">14</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.3in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">three and six months ended June 30, 2024, both Adjusted EBITDA and Adjusted EPS are being further adjusted to exclude loss on disposal of businesses and impairment losses.</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">We believe these measures, in addition to income from operations, net income and diluted net income per common and common equivalent share, provide investors with useful supplemental information to compare and understand our underlying business trends and performance across reporting periods on a consistent basis.  These measures should be considered a supplement to, and not a substitute for, financial performance measures determined in accordance with GAAP. In addition, since these non-GAAP measures are not determined in accordance with GAAP, they are susceptible to varying calculations and may not be comparable to other similarly titled measures of other companies. We encourage investors to review our financial statements and publicly-filed reports in their entirety and not to rely on any single financial measure.</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">For a reconciliation of each of Adjusted EBITDA and Adjusted EPS to the most directly comparable GAAP measures for the three and six months ended June 30, 2024 and 2023, refer to the tables below (in thousands, except per share data).</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:40.78%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:13%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:12.36%;"/>
    <td style="width:1%;"/>
    <td style="width:1.38%;"/>
    <td style="width:1%;"/>
    <td style="width:12.36%;"/>
    <td style="width:1%;"/>
    <td style="width:1.14%;"/>
    <td style="width:1%;"/>
    <td style="width:8.98%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Three Months Ended<br/>June 30,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Six Months Ended<br/>June 30,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net (loss) income</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(153,025</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">28,282</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(148,990</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">42,488</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Interest expense</span></p></td>
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,308</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11,230</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">20,907</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21,620</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Income tax (benefit) provision</span></p></td>
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(14,703</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,665</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(10,914</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">17,171</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Depreciation and amortization expense</span></p></td>
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,791</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,945</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">19,099</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">17,898</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Transformational and restructuring related expenses</span></p></td>
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13,579</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">22,059</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Goodwill impairment</span></p></td>
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">154,243</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">154,243</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Fixed assets impairments</span></p></td>
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">20,112</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">20,112</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Intangible assets impairments</span></p></td>
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,679</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,679</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Loss on disposal of businesses</span></p></td>
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,873</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,873</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Adjusted EBITDA</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">57,857</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">59,122</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">95,068</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">99,177</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:49.98%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:10.44%;"/>
    <td style="width:1%;"/>
    <td style="width:2.28%;"/>
    <td style="width:1%;"/>
    <td style="width:8.22%;"/>
    <td style="width:1%;"/>
    <td style="width:1.26%;"/>
    <td style="width:1%;"/>
    <td style="width:9.68%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:8.14%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Three Months Ended<br/>June 30,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted average diluted shares outstanding</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">83,332</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">82,664</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net (loss) income and diluted net (loss) income per share</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(153,025</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(1.84</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">28,282</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.34</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Adjustments </span><span style="color:#000000;top:-4.221pt;white-space:pre-wrap;font-size:6.03pt;position:relative;min-width:fit-content;">(1)</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Amortization (net of tax of $533 and $512)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,599</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.02</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,533</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.02</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock-based compensation (net of tax of $500 and $782)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,501</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.02</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,344</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.03</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Transformational and restructuring expenses (net of tax of $3,395)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,184</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.12</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Goodwill impairment (net of tax of $15,490)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">138,753</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.67</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Fixed assets impairments (net of tax of $5,028)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15,084</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.18</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Intangible assets impairments (net of tax of $1,920)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,759</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.07</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Loss on disposal of businesses (net of tax of $2,718)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,155</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.10</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net impact from discrete tax events</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">328</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">150</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Adjusted income and diluted EPS</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">28,338</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.34</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">32,309</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.39</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="transform:scale(0.67);color:#000000;white-space:pre-wrap;vertical-align:super;font-size:8pt;font-family:Times New Roman;transform-origin:top left;min-width:3.333%;display:inline-flex;justify-content:flex-start;">(1)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">A blended tax rate of 25% was used to calculate the tax effects of the adjustments for the three months ended June 30, 2024 and 2023, other than for goodwill impairment for the relevant period. Tax effects for the goodwill impairment approximate 10% due to a portion of the expense being non-deductible. </span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:49.74%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:10.620000000000001%;"/>
    <td style="width:1%;"/>
    <td style="width:2%;"/>
    <td style="width:1%;"/>
    <td style="width:8.620000000000001%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:9.78%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:8.24%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Six Months Ended<br/>June 30,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted average diluted shares outstanding</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">83,074</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">82,377</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net (loss) income and diluted net (loss) income per share</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(148,990</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(1.79</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">42,488</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.52</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Adjustments </span><span style="color:#000000;top:-4.221pt;white-space:pre-wrap;font-size:6.03pt;position:relative;min-width:fit-content;">(1)</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Amortization (net of tax of $1,396 and $1,010)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,188</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.05</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,029</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.04</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock-based compensation (net of tax of $1,215 and $1,534)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,647</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.04</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,601</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.06</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Transformational and restructuring expenses (net of tax of $5,515)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">16,544</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.20</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Goodwill impairment (net of tax of $15,490)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">138,753</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.67</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Fixed assets impairments (net of tax of $5,028)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15,084</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.18</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Intangible assets impairments (net of tax of $1,920)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,759</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.07</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Loss on disposal of businesses (net of tax of $2,718)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,155</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.10</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net impact from discrete tax events</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,004</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.02</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">870</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Adjusted income and diluted EPS</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">45,144</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.54</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">50,988</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.62</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="transform:scale(0.67);color:#000000;white-space:pre-wrap;vertical-align:super;font-size:8pt;font-family:Times New Roman;transform-origin:top left;min-width:3.333%;display:inline-flex;justify-content:flex-start;">(1)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">A blended tax rate of 25% was used to calculate the tax effects of the adjustments for the six months ended June 30, 2024 and 2023, other than for goodwill impairment for the relevant period. Tax effects for the goodwill impairment approximate 10% due to a portion of the expense being non-deductible.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">15</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.3in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Results of Operations</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Three Months Ended June 30, 2024 as Compared to Three Months Ended June 30, 2023</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Our net revenue was $504.3 million for the three months ended June 30, 2024, as compared to $500.6 million for the same period in 2023. The increase in net revenue of $3.7 million, or 0.7%, was primarily attributable to an increase in same-unit revenue, partially offset by a decrease in revenue from non-same unit activity, primarily resulting from practice dispositions. Same units are those units at which we provided services for the entire current period and the entire comparable period. Same-unit net revenue increased by $13.5 million, or 2.8%. The increase in same-unit revenue was comprised of an increase of $11.6 million, or 2.4%, from net reimbursement-related factors and $1.9 million, or 0.4%, related to patient service volumes. The net increase in revenue related to net reimbursement-related factors was primarily due to an increase in revenue resulting from a favorable shift in payor mix and an increase in administrative fees from our hospital partners. The increase in revenue from patient service volumes was related to increases in maternal-fetal medicine and certain hospital-based pediatric subspecialty services, partially offset by modest declines in primary and urgent care and neonatology services.</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Practice salaries and benefits increased $3.8 million, or 1.1%, to $357.8 million for the three months ended June 30, 2024, as compared to $354.0 million for the same period in 2023. The $3.8 million increase was primarily attributable to an increase in clinical compensation expense, including benefits and incentive compensation, and modest increases in medical malpractice insurance expense, all at our existing units, partially offset by decreases in non-same unit activity.</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Practice supplies and other operating expenses increased $1.3 million, or 4.1%, to $32.4 million for the three months ended June 30, 2024, as compared to $31.1 million for the same period in 2023. The increase was primarily attributable to practice supply, rent and other costs related to our existing units, primarily professional services and rent expense, partially offset by decreases in non-same unit activity.</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">General and administrative expenses primarily include all billing and collection functions and all other salaries, benefits, supplies and operating expenses not specifically related to the day-to-day operations of our affiliated physician practices and services. General and administrative expenses were $56.6 million for the three months ended June 30, 2024, as compared to $58.0 million for the same period in 2023.  The net decrease of $1.4 million was primarily related to decreases in overall staffing levels and timing of certain incentive compensation expenses, partially offset by increases in salary expense for enhancement of front-end revenue cycle management staffing. General and administrative expenses as a percentage of net revenue was 11.2% for the three months ended June 30, 2024, as compared to 11.6% for the same period in 2023.</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Depreciation and amortization expense was $8.8 million for the three months ended June 30, 2024, as compared to $8.9 million for the same period in 2023.</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Transformational and restructuring related expenses were $13.6 million for the three months ended June 30, 2024 and primarily related to impairment of various right-of-use lease assets resulting from our practice portfolio management activities, revenue cycle management transition activities and position eliminations across various shared services and operations departments.</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Goodwill impairment was $154.2 million for the three months ended June 30, 2024, resulting from the triggering event during the second quarter based on a sustained stock price decline.</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Fixed assets impairments were $20.1 million for the three months ended June 30, 2024, resulting from the practice portfolio management plan.</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Intangible assets impairments were $7.7 million for the three months ended June 30, 2024, resulting from the practice portfolio management plan.</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Loss on disposal from businesses was $10.9 million for the three months ended June 30, 2024, resulting from the disposals of our primary and urgent care practices.</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Loss from operations was $157.7 million for the three months ended June 30, 2024, as compared to income from operations of $48.5 million for the same period in 2023. Our operating margin was (31.3)% for the three months ended June 30, 2024, as compared to 9.7% for the same period in 2023.  The decrease in our operating margin was primarily due to the impairment activity recorded during the second quarter and  transformational and restructuring related activity, as well as net unfavorable impacts in our same-unit results driven by higher operating expenses, partially offset by same-unit revenue increases and decreases in general and administrative expenses. Excluding impairment activity and transformational and restructuring related expenses for the three months ended June 30, 2024, our income from operations was $48.8 million and our operating margin was 9.7% for such period.  We believe excluding the impacts from the impairment and transformational and restructuring related activity provides a more comparable view of our operating income and operating margin.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Total non-operating expenses were $10.0 million for the three months ended June 30, 2024, as compared to $9.6 million for the same period in 2023. The net increase in non-operating expenses was primarily related to an increase in other expense from the settlement of a litigation matter, partially offset by a decrease in interest expense.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Our effective income tax rate (&#8220;tax rate&#8221;) was 8.8% for the three months ended June 30, 2024 as compared to 27.4% for the three months ended June 30, 2023.  The decrease in our tax rate from 27.4% to 8.8% for the three months ended June 30, 2024 primarily relates to the effects of the non-cash goodwill impairment charge and the pre-tax loss generated excluding the impairment charge. Discrete tax impacts during the three months ended June 30, 2024 and 2023 were nominal.</span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">16</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.3in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Net loss was $153.0 million for the three months ended June 30, 2024, as compared to net income of $28.3 million for the same period in 2023. Adjusted EBITDA was $57.9 million for the three months ended June 30, 2024, as compared to $59.1 million for the same period in 2023.  The decrease in our Adjusted EBITDA was primarily due to net unfavorable impacts in our same-unit results, primarily from higher operating expenses.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Diluted net loss per common and common equivalent share was $1.84 on weighted average shares outstanding of 83.3 million for the three months ended June 30, 2024, as compared to diluted net income per common and common equivalent share of $0.34 on weighted average shares outstanding of 82.7 million for the same period in 2023. Adjusted EPS was $0.34 for the three months ended June 30, 2024, as compared to $0.39 for the same period in 2023.</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Six Months Ended June 30, 2024 as Compared to Six Months Ended June 30, 2023</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Our net revenue was $999.4 million for the six months ended June 30, 2024, as compared to $991.6 million for the same period in 2023. The increase in revenue of $7.8 million, or 0.8%, was primarily attributable to increases in same-unit revenue, partially offset by a decrease in revenue from non-same unit activity, primarily resulting from practice dispositions. Same units are those units at which we provided services for the entire current period and the entire comparable period. Same-unit net revenue increased by $27.9 million, or 2.9%. The increase in same-unit net revenue was comprised of an increase of $15.8 million, or 1.6%, from net reimbursement-related factors and an increase of $12.1 million, or 1.3%, related to patient service volumes. The net increase in revenue related to net reimbursement-related factors was primarily due to an increase in revenue resulting from a favorable shift in payor mix and an increase in administrative fees from our hospital partners. The increase in revenue from patient service volumes was related to increases in our neonatology, newborn nursery, maternal-fetal medicine, and certaince hospital-based pediatric subspecialty services, partially offset by declines in primary and urgent care and pediatric cardiology services.</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Practice salaries and benefits increased $10.7 million, or 1.5%, to $726.9 million for the six months ended June 30, 2024, as compared to $716.3 million for the same period in 2023. The $10.7 million increase was primarily attributable to an increase in clinical compensation expense and a modest increase in medical malpractice expense at our existing units, partially offset by decreases in benefits and incentive compensation at our existing units as well as decreases in non-same unit activity.</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Practice supplies and other operating expenses increased $1.7 million, or 2.7%, to $63.5 million for the six months ended June 30, 2024, as compared to $61.8 million for the same period in 2023. The increase was primarily attributable to practice supply, rent and other costs at our existing units, including increases in rent expense, collection fees and professional services expenses, partially offset by decreases in medical supplies and other office expenses.</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">General and administrative expenses primarily include all billing and collection functions and all other salaries, benefits, supplies and operating expenses not specifically identifiable to the day-to-day operations of our physician practices and services. General and administrative expenses were $116.8 million for the six months ended June 30, 2024, as compared to $117.1 million for the same period in 2023. The net decrease of $0.3 million is primarily related to lower information technology expenses, professional services fees, travel expenses, and decreases in expenses from net staffing reductions, partially offset by increases in salary expense for enhancement of revenue cycle management staffing. General and administrative expenses as a percentage of net revenue were 11.7% for the six months ended June 30, 2024, as compared to 11.8% for the same period in 2023.</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Depreciation and amortization expense was $19.1 million for the six months ended June 30, 2024, as compared to $17.9 million for the same period in 2023. The increase of $1.2 million was primarily related to an increase in depreciation expense for non-same unit activity.</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Transformational and restructuring related expenses were $22.1 million for the six months ended June 30, 2024 and primarily related to the impairment of various right-of-use lease assets resulting from our practice portfolio management activities, position eliminations across various shared services and operations departments and revenue cycle management transition activities.</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Goodwill impairment was $154.2 million for the six months ended June 30, 2024, resulting from the triggering event during the second quarter based on a sustained stock price decline.</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Fixed assets impairments were $20.1 million for the six months ended June 30, 2024, resulting from the practice portfolio management plan.</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Intangible assets impairments were $7.7 million for the six months ended June 30, 2024, resulting from the practice portfolio management plan.</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Loss on disposal from businesses was $10.9 million for the six months ended June 30, 2024, resulting from the disposals of the primary and urgent care practices.</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> Loss from operations was $141.8 million for the six months ended June 30, 2024, as compared to income from operations of $78.5 million for the same period in 2023. Our operating margin was (14.2)% for the six months ended June 30, 2024, as compared to 7.9% for the same period in 2023. The decrease in our operating margin was primarily due to the impairment activity recorded during the second quarter and transformational and restructuring related activity, as well as net unfavorable impacts in our same-unit results driven by higher operating expenses, partially offset by same-unit revenue increases and decreases in general and administrative expenses. Excluding impairment activity and transformational and restructuring related expenses for the six months ended June 30, 2024, our income from operations was $73.2 million</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">17</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.3in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">and our operating margin was 7.3% for such period. We believe excluding the impacts from the impairment and transformational and restructuring related activity provides a more comparable view of our operating income and operating margin.</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Total non-operating expenses were $18.1 million for the six months ended June 30, 2024, as compared to $18.9 million for the same period in 2023.</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Our tax rate was 6.8% for the six months ended June 30, 2024 compared to 28.8% for the six months ended June 30, 2023. The tax rates for the six months ended June 30, 2024 and 2023 include net discrete tax benefits of $2.0 million and $0.9 million, respectively. After excluding discrete tax impacts, during the six months ended June 30, 2024 and 2023, our tax rate was 8.1% and 27.3%, respectively. We believe excluding discrete tax impacts on our tax rate provides a more comparable view of our effective income tax rate. The decrease in our tax rate from 27.3% to 8.1% for the six months ended June 30, 2024 primarily relates to the effects of the non-cash goodwill impairment charge and the pre-tax loss generated excluding the impairment charge.</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Net loss was $149.0 million for the six months ended June 30, 2024, as compared to net income of $42.5 million for the six months ended June 30, 2023. Adjusted EBITDA was $95.1 million for the six months ended June 30, 2024, as compared to $99.2 million for the same period in 2023.  The decrease in our Adjusted EBITDA was primarily due to net unfavorable impacts in our same-unit results, primarily from higher operating expenses.</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Diluted net loss per common and common equivalent share was $1.79 on weighted average shares outstanding of 83.1 million for the six months ended June 30, 2024, as compared to diluted net income per common and common equivalent share of $0.52 on weighted average shares outstanding of 82.4 million for the same period in 2023. Adjusted EPS was $0.54 for the six months ended June 30, 2024, as compared to $0.62 for the same period in 2023.</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">   </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Liquidity and Capital Resources</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">As of June 30, 2024, we had $19.4 million of cash and cash equivalents as compared to $73.3 million at December 31, 2023. Additionally, we had working capital of $119.1 million at June 30, 2024, an increase of $24.5 million from working capital of $94.5 million at December 31, 2023.</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Cash Flows from Continuing Operations</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Cash (used in) provided from operating, investing and financing activities is summarized as follows (in thousands):</span></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:67.287%;"/>
    <td style="width:1.46%;"/>
    <td style="width:1%;"/>
    <td style="width:12.897%;"/>
    <td style="width:1%;"/>
    <td style="width:1.46%;"/>
    <td style="width:1%;"/>
    <td style="width:12.897%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Six Months Ended<br/>June 30,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating activities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(13,280</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(8,038</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Investing activities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(29,130</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(21,748</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Financing activities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(6,451</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">29,636</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Operating Activities</span></p>
  <p style="text-indent:2.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">During the six months ended June 30, 2024, our net cash used in operating activities for continuing operations was $13.3 million, compared to $8.0 million for the same period in 2023. The net increase in cash used of $5.3 million was primarily due to decreases in cash flow from accounts receivable, partially offset by increases in cash flow from income tax-related activity as well as accounts payable and accrued expenses.</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">During the six months ended June 30, 2024, cash outflow from accounts receivable was $0.9 million, as compared to a cash inflow of $28.9 million for the same period in 2023. The decrease in cash flow from accounts receivable for the six months ended June 30, 2024 as compared to the prior year period was primarily due to the prior year period reflecting a significant improvement in collections.</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">DSO is one of the key factors that we use to evaluate the condition of our accounts receivable and the related allowances for contractual adjustments and uncollectibles. DSO reflects the timeliness of cash collections on billed revenue and the level of reserves on outstanding accounts receivable. Our DSO for continuing operations was 49.5 days at June 30, 2024 as compared to 50.5 days at December 31, 2023 and 49.2 days at June 30, 2023.  The change in our DSO was primarily related to an increase in cash collections at our existing units.</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Investing Activities</span></p>
  <p style="text-indent:2.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">During the six months ended June 30, 2024, our net cash used in investing activities of $29.1 million consisted primarily of capital expenditures of $12.3 million, net purchases of investments of $8.7 million and acquisition payments of $8.2 million.</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Financing Activities</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">During the six months ended June 30, 2024, our net cash used in financing activities of $6.5 million primarily consisted of net payments on our Term A Loan (as defined below).</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">    </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Liquidity</span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">18</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.3in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">On February 11, 2022, we issued $400.0 million of 5.375% unsecured senior notes due 2030 (the &#8220;2030 Notes&#8221;).  We used the net proceeds from the issuance of the 2030 Notes, together with $100.0 million drawn under our Revolving Credit Line (as defined below), $250.0 million of Term A Loan and approximately $308.0 million of cash on hand, to redeem (the &#8220;Redemption&#8221;) the 2027 Notes, which had an outstanding principal balance of $1.0 billion, and to pay costs, fees and expenses associated with the Redemption and the Credit Agreement Amendment (as defined below).</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Also in connection with the Redemption, we amended and restated the Credit Agreement (the "Credit Agreement"), and such amendment and restatement (the &#8220;Credit Agreement Amendment&#8221;), concurrently with the issuance of the 2030 Notes. The Credit Agreement, as amended by the Credit Agreement Amendment (the &#8220;Amended Credit Agreement&#8221;), among other things, (i) refinanced the prior unsecured revolving credit facility with a $450.0 million unsecured revolving credit facility, including a $37.5 million sub-facility for the issuance of letters of credit (the &#8220;Revolving Credit Line&#8221;), and a new $250.0 million term A loan facility (&#8220;Term A Loan&#8221;) and  (ii) removed JPMorgan Chase Bank, N.A., as the administrative agent under the Credit Agreement and appointed Bank of America, N.A. as the administrative agent for the lenders under the Amended Credit Agreement.</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">The Amended Credit Agreement matures on February 11, 2027 and is guaranteed on an unsecured basis by substantially all of our subsidiaries and affiliated professional contractors. At our option, borrowings under the Amended Credit Agreement bear interest at (i) the Alternate Base Rate (defined as the highest of (a) the prime rate as announced by Bank of America, N.A., (b) the Federal Funds Rate plus 0.50% and (c) Term Secured Overnight Financing Rate ("SOFR") for an interest period of one month plus 1.00% with a 1.00% floor) plus an applicable margin rate of 0.50% for the first two fiscal quarters after the date of the Credit Agreement Amendment, and thereafter at an applicable margin rate ranging from 0.125% to 0.750% based on our consolidated net leverage ratio or (ii) Term SOFR rate (calculated as the Secured Overnight Financing Rate published on the applicable Reuters screen page plus a spread adjustment of 0.10%, 0.15% or 0.25% depending on if we select a one-month, three-month or six-month interest period, respectively, for the applicable loan with a 0% floor), plus an applicable margin rate of 1.50% for the first two full fiscal quarters after the date of the Credit Agreement Amendment, and thereafter at an applicable margin rate ranging from 1.125% to 1.750% based on our consolidated net leverage ratio. The Amended Credit Agreement also provides for other customary fees and charges, including an unused commitment fee with respect to the Revolving Credit Line ranging from 0.150% to 0.200% of the unused lending commitments under the Revolving Credit Line, based on our consolidated net leverage ratio.</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">The Amended Credit Agreement contains customary covenants and restrictions, including covenants that require us to maintain a minimum interest coverage ratio, a maximum consolidated total consolidated net leverage ratio and to comply with laws, and restrictions on the ability to pay dividends, incur indebtedness or liens and make certain other distributions subject to baskets and exceptions, in each case, as specified therein. Failure to comply with these covenants would constitute an event of default under the Amended Credit Agreement, notwithstanding the ability of the company to meet its debt service obligations. The Amended Credit Agreement includes various customary remedies for the lenders following an event of default, including the acceleration of repayment of outstanding amounts under the Amended Credit Agreement. In addition, we may increase the principal amount of the Revolving Credit Line or incur additional term loans under the Amended Credit Agreement in an aggregate principal amount such that on a pro forma basis after giving effect to such increase or additional term loans, we are in compliance with the financial covenants, subject to the satisfaction of specified conditions and additional caps in the event that the Amended Credit Agreement is secured.</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">At June 30, 2024, we had an outstanding principal balance on the Amended Credit Agreement of $221.9 million, composed of the Term A Loan. There was no balance outstanding under the Revolving Credit Line. We had $450.0 million available on our Amended Credit Agreement at June 30, 2024.</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">At June 30, 2024, we had an outstanding principal balance of $400.0 million on the 2030 Notes. Our obligations under the 2030 Notes are guaranteed on an unsecured senior basis by the same subsidiaries and affiliated professional contractors that guarantee our Amended Credit Agreement. Interest on the 2030 Notes accrues at the rate of 5.375% per annum, or $21.5 million, and is payable semi-annually in arrears on February 15 and August 15, beginning on August 15, 2022.</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">The indenture under which the 2030 Notes are issued, among other things, limits our ability to (1) incur liens and (2) enter into sale and lease-back transactions, and also limits our ability to merge or dispose of all or substantially all of our assets, in all cases, subject to a number of customary exceptions.  Although we are not required to make mandatory redemption or sinking fund payments with respect to the 2030 Notes, upon the occurrence of a change in control, we may be required to repurchase the 2030 Notes at a purchase price equal to 101% of the aggregate principal amount of the 2030 Notes repurchased plus accrued and unpaid interest.</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">At June 30, 2024, we believe we were in compliance, in all material respects, with the financial covenants and other restrictions applicable to us under the Amended Credit Agreement and the 2030 Notes. We believe we will be in compliance with these covenants throughout 2024.</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">We maintain professional liability insurance policies with third-party insurers, subject to self-insured retention, exclusions and other restrictions. We self-insure our liabilities to pay self-insured retention amounts under our professional liability insurance coverage through a wholly owned captive insurance subsidiary. We record liabilities for self-insured amounts and claims incurred but not reported based on an actuarial valuation using historical loss information, claim emergence patterns and various actuarial assumptions. Our total liability related to professional liability risks at June 30, 2024 was $283.7 million, of which $29.0 million is classified as a current liability within accounts payable and accrued expenses in the Consolidated Balance Sheet. In addition, there is a corresponding insurance receivable of $29.4 million recorded as a component of other assets for certain professional liability claims that are covered by insurance policies.</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">19</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.3in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">We anticipate that funds generated from operations, together with our current cash on hand and funds available under our Amended Credit Agreement, will be sufficient to finance our working capital requirements, fund anticipated acquisitions and capital expenditures, fund expenses related to our transformational and restructuring activities, fund our share repurchase programs and meet our contractual obligations for at least the next 12 months from the date of issuance of this Quarterly Report on Form 10-Q.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Caution Concerning Forward-Looking Statements</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Certain information included or incorporated by reference in this Quarterly Report may be deemed to be &#8220;forward-looking statements&#8221; within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;). Forward-looking statements may include, but are not limited to, statements relating to our objectives, plans and strategies, and all statements, other than statements of historical facts, that address activities, events or developments that we intend, expect, project, believe or anticipate will or may occur in the future are forward-looking statements. These statements are often characterized by terminology such as &#8220;believe,&#8221; &#8220;hope,&#8221; &#8220;may,&#8221; &#8220;anticipate,&#8221; &#8220;should,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221; &#8220;will,&#8221; &#8220;expect,&#8221; &#8220;estimate,&#8221; &#8220;project,&#8221; &#8220;positioned,&#8221; &#8220;strategy&#8221; and similar expressions, and are based on assumptions and assessments made by our management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. Any forward-looking statements in this Quarterly Report are made as of the date hereof, and we undertake no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties. Important factors that could cause actual results, developments and business decisions to differ materially from forward-looking statements are described in the 2023 Form 10-K, including the section entitled &#8220;Risk Factors.&#8221;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">20</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.3in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_3"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Item 3. Quantitative and Qual</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">itative Disclosures about Market Risk</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">We are subject to market risk primarily from exposure to changes in interest rates based on our financing, investing and cash management activities.  We intend to manage interest rate risk through the use of a combination of fixed rate and variable rate debt.  We borrow under our Amended Credit Agreement at various interest rate options based on the Alternate Base Rate or SOFR rate depending on certain financial ratios. At June 30, 2024, we had an outstanding principal balance of $221.9 million on our Amended Credit Agreement under our Term A Loan. Considering the total outstanding balance, a 1% change in interest rates would result in an impact to income before taxes of approximately $2.2 million per year.</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_4"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Item 4. Controls a</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">nd Procedures</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Evaluation of Disclosure Controls and Procedures</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">We maintain disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) that are designed to provide reasonable assurance that information required to be disclosed by the Company in reports it files or submits under the Exchange Act is (i) recorded, processed, summarized and reported within the time periods specified in SEC rules and forms and (ii) accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">We carried out an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of our disclosure controls and procedures. Based upon that evaluation, the Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of June 30, 2024.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Changes in Internal Controls Over Financial Reporting</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">No changes in our internal control over financial reporting occurred during the three months ended June 30, 2024 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">21</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.3in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="part_ii"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">PART II - OTH</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">ER INFORMATION</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_1"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Item 1.	Legal Pro</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">ceedings	</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">We expect that audits, inquiries and investigations from government authorities and agencies will occur in the ordinary course of business. Such audits, inquiries and investigations and their ultimate resolutions, individually or in the aggregate, could have a material adverse effect on our business, financial condition, results of operations, cash flows and the trading price of our securities.</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">In the ordinary course of our business, we become involved in pending and threatened legal actions and proceedings, most of which involve claims of medical malpractice related to medical services provided by our affiliated physicians. Our contracts with hospitals generally require us to indemnify them and their affiliates for losses resulting from the negligence of our affiliated physicians and other clinicians. We may also become subject to other lawsuits, including with payors or other counterparties that could involve large claims and significant defense costs. We believe, based upon a review of pending actions and proceedings, that the outcome of such legal actions and proceedings will not have a material adverse effect on our business, financial condition, results of operations, cash flows or the trading price of our securities. The outcome of such actions and proceedings, however, cannot be predicted with certainty and an unfavorable resolution of one or more of them could have a material adverse effect on our business, financial condition, results of operations, cash flows and the trading price of our securities.</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">	Although we currently maintain liability insurance coverage intended to cover professional liability and certain other claims, we cannot ensure that our insurance coverage will be adequate to cover liabilities arising out of claims asserted against us in the future where the outcomes of such claims are unfavorable to us. With respect to professional liability risk, we self-insure a significant portion of this risk through our wholly owned captive insurance subsidiary. Liabilities in excess of our insurance coverage, including coverage for professional liability and certain other claims, could have a material adverse effect on our business, financial condition, results of operations, cash flows and the trading price of our securities.</span></p>
  <p style="text-indent:0.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_1a"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Item 1A. Risk</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> Factors</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">There have been no material changes to the risk factors previously disclosed in our 2023 Form 10-K.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_2"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Item 2. Unregiste</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">red Sales of Equity Securities and Use of Proceeds</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:7pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">During the three months ended June 30, 2024, we withheld 1,564 shares of our common stock to satisfy minimum statutory withholding obligations in connection with the vesting of restricted stock.</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:40.092%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:11.018%;"/>
    <td style="width:1%;"/>
    <td style="width:1.1%;"/>
    <td style="width:1%;"/>
    <td style="width:10.278%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:13.417%;"/>
    <td style="width:1%;"/>
    <td style="width:1.26%;"/>
    <td style="width:14.837%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Period</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total Number<br/>of Shares<br/>Repurchased </span><span style="color:#000000;top:-3.752pt;white-space:pre-wrap;font-weight:bold;font-size:5.36pt;position:relative;min-width:fit-content;">(a)</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Average Price<br/>Paid per Share</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total Number of<br/>Shares Purchased<br/>as part of<br/>the Repurchase<br/>Program</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Approximate Dollar<br/>Value of Shares<br/>that May Yet<br/>Be Purchased<br/>Under the<br/>Repurchase<br/>Programs </span><span style="color:#000000;top:-3.752pt;white-space:pre-wrap;font-weight:bold;font-size:5.36pt;position:relative;min-width:fit-content;">(a)</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">April 1 &#8211;  April 30, 2024</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(a)</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">May 1 &#8211; May 31, 2024</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(a)</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">June 1 &#8211; June 30, 2024</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,564 (b)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.31</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(a)</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,564</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.31</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(a)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">(a)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">We have two active repurchase programs. Our July 2013 program allows us to repurchase shares of our common stock up to an amount sufficient to offset the dilutive impact from the issuance of shares under our equity compensation programs, which is estimated to be approximately 1.5 million shares for 2024. </span><span style="color:#231f20;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Our August 2018 repurchase program allows us to repurchase up to an additional $500.0 million of shares of our common stock, of which we repurchased $496.3</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#231f20;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">million as of June 30, 2024.  </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">(b)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Shares withheld to satisfy nominal minimum statutory withholding obligations in connection with the vesting of restricted stock.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">The amount and timing of any future repurchases will depend upon several factors, including general economic and market conditions and trading restrictions.</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_5"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Item 5. Other Information</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Rule 10b5-1 Trading Plans</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">During the three months ended June 30, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">, none of the Company&#8217;s directors or officers </span><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6fcdac8a-10fb-4404-834f-c4d1f4fea0d3" contextRef="C_f8ba14c0-203a-4abe-895a-7068e0d681d9" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-false"><ix:nonNumeric id="F_bac399c8-c17a-4d2f-87d7-9613da402582" contextRef="C_f8ba14c0-203a-4abe-895a-7068e0d681d9" name="ecd:NonRule10b51ArrAdoptedFlag" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">adopted</span></ix:nonNumeric></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> or </span><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1c553998-bee3-4ea1-a87f-96e9a93dc9f7" contextRef="C_f8ba14c0-203a-4abe-895a-7068e0d681d9" name="ecd:Rule10b51ArrTrmntdFlag" format="ixt:fixed-false"><ix:nonNumeric id="F_109f24c6-b24c-4c79-b699-6e8f793328e9" contextRef="C_f8ba14c0-203a-4abe-895a-7068e0d681d9" name="ecd:Rule10b51ArrTrmntdFlag" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">terminated</span></ix:nonNumeric></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> any Rule 10b5-1 trading arrangement or non-Rule 10b5-1 trading arrangement (as such terms are defined in Item 408 of Regulation S-K).</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">22</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.3in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="exhibit_index"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Item 6. 	Exh</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">ibits</span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="padding-bottom:1pt;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Exhibit No.		    	Description								</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:10%;"/>
    <td style="width:90%;"/>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.1+&#134;</span></p><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="md-ex10_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Master Services Agreement, dated as of April 19, 2024, by and between Guidehouse Managed Services LLC and PMG Services, Inc.</span><span style="color:#0000ff;white-space:pre-wrap;min-width:fit-content;"> </span></a></p><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">31.1+</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="md-ex31_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Certification of Chief Executive Officer pursuant to Securities Exchange Act Rule 13a-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a></p><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">31.2+</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="md-ex31_2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Certification of Chief Financial Officer pursuant to Securities Exchange Act Rule 13a-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a></p><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">32.1++</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="md-ex32_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></a></p><p style="text-indent:-54pt;padding-left:54pt;font-size:9pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">101.1+</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Interactive Data File</span></p><p style="font-size:9pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">101.INS+</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">XBRL Instance Document &#8211; the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.</span></p><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">101.SCH+</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">XBRL Schema Document.</span></p><p style="font-size:9pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">101.CAL+</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">XBRL Calculation Linkbase Document.</span></p><p style="font-size:9pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">101.DEF+</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">XBRL Definition Linkbase Document.</span></p><p style="font-size:9pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">101.LAB+</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">XBRL Label Linkbase Document.</span></p><p style="font-size:9pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">101.PRE+</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">XBRL Presentation Linkbase Document.</span></p><p style="font-size:9pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">104+</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).</span></p><p style="font-size:9pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:-11.111%;padding-left:10%;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">+  Filed herewith.</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">++  Furnished herewith.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#134; Portions of this exhibit have been redacted in accordance with Regulation S-K Item 601(b)(10). The omitted information is not material and would likely cause competitive harm to the Company if publicly disclosed. Certain of the exhibits and schedules to this exhibit have been omitted in accordance with Regulation S-K Item 601(a)(5).</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">23</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.3in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:center;" id="signatures"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">SIGNAT</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">URES</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">	</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:57.8%;"/>
    <td style="width:42.2%;"/>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;min-width:fit-content;">Pediatrix Medical Group, Inc</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">.</span></p></td>
   </tr>
   <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Date:  August 6, 2024</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">By:</span><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">&#160;/s/ James D. Swift, M.D.</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">             </span></p></td>
   </tr>
   <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;James D. Swift, M.D.</span></p></td>
   </tr>
   <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;Chief Executive Officer</span></p></td>
   </tr>
   <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;(Principal Executive Officer)</span></p></td>
   </tr>
   <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Date:  August 6, 2024</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">By:</span><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">&#160;/s/ C. Marc Richards</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">        </span></p></td>
   </tr>
   <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;C. Marc Richards</span></p></td>
   </tr>
   <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;Chief Financial Officer</span></p></td>
   </tr>
   <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;(Principal Financial Officer and</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;&#160;Principal Accounting Officer)</span></p></td>
   </tr>
   <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:-74.419%;padding-left:42.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:-74.419%;padding-left:42.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:-74.419%;padding-left:42.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">24</span></p></div></div>
  <hr style="page-break-after:always;"/>
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>md-ex10_1.htm
<DESCRIPTION>EX-10.1
<TEXT>
<html>
 <head>
  <title>EX-10.1</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 10.1</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">[***] CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN EXCLUDED PURSUANT TO REGULATION S-K, ITEM 601(B)(10). SUCH EXCLUDED INFORMATION IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">MASTER SERVICES AGREEMENT</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">This Master Services Agreement (this &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) is entered into on April 19, 2024 (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Effective Date</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) by and between </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Guidehouse Managed Services LLC</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">, a Delaware limited liability company (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">GMS</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), and </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">PMG Services, Inc</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.,</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">a Florida corporation (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Client</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), with reference to the following facts and circumstances:</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">WHEREAS</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">, GMS provides comprehensive revenue cycle business process management services to healthcare entities;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">WHEREAS</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">, entities affiliated with Client are healthcare providers that deliver health care services to patients; and</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">WHEREAS</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">, Client desires to utilize certain of the services provided by GMS and GMS desires to provide such services.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">NOW, THEREFORE</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">, for and in consideration of the foregoing, the mutual promises and covenants contained herein, and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows:</font></p>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">DEFINITIONS; CAPTIONS; REFERENCES; TERMINOLOGY.  </font></div></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">1.1</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Definitions</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Capitalized terms have the meanings set forth or referred to below and shall be equally applicable to both the singular and plural forms.  Capitalized terms that are used and not otherwise defined shall have the meaning commonly used in the medical insurance industry.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Acceptance Criteria&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> means: (i) conformance to the description or specification of the relevant Services and/or deliverables set out in, or developed and approved pursuant to, the applicable Statement of Work or Disentanglement Transition Plan (together with any additional criteria there set out) and/or set out in the Documentation (the Statement or Work or Disentanglement Transition Plan prevailing in the event of any conflict or inconsistency); or (ii) if there is no such description or specification, meeting Client&#x2019;s commercially reasonable requirements.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Acceptance Testing&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> has the meaning set forth in Section 3.6.2(b).</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Affiliate&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> means a business entity which directly or indirectly Controls, is under the Control of or under common Control with a party.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Agreement&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> has the meaning set forth in the first paragraph.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Auditor&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> means, with respect to a party, the independent third-party auditor designated by such party in writing from time to time, in its sole discretion.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Business Associate Agreement&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> means a written agreement that contains the requirements set forth in HIPAA and 45 CFR 164.504(e)(2).</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;CERT Letter&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> means a letter sent to a provider by the Centers for Medicare and Medicaid Services pursuant to its Comprehensive Error Rate Testing program requesting medical documentation for review of a claim(s).</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Change in Control</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means (i) any change in the legal, beneficial or equitable ownership, direct or indirect, of an entity such that Control of such party entity is no longer with the same party or parties as immediately prior to such change, (ii) the sale or other disposition of all or substantially all of the assets of an entity to an entity that is not an Affiliate of such entity, or (iii) the entrance into a contract or arrangement that, upon consummation thereof, would result in the occurrence of an event set forth in (i) or (ii) hereof.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Change Proposal&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> has the meaning set forth in Section 2.4.1.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Claim&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> means any pending or threatened lawsuit, claim, action, suit, proceeding, inquiry, civil investigative demand, subpoena, or investigation (including proceedings, inquiries or investigations by any Governmental Body and/or so-called &#x201c;whistleblower&#x201d; actions or investigations or qui tam complaints, even if the government has declined to intervene in such &#x201c;whistleblower&#x201d; or qui tam complaint) or any similar type of action or investigation.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Client&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> has the meaning set forth in the first paragraph and includes its permitted successors and permitted assigns.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Client Data&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> has the meaning set forth in Section 14.1.2.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Client Indemnitee&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> has the meaning set forth in Section 10.1.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Client IP&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> has the meaning set forth in Section 14.1.1.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Commencement Date&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> has the meaning set forth in Section 3.4.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Comptroller&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> means the United States Comptroller General.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Confidential Information&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> has the meaning set forth in Section 7.1.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Consultants&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> has the meaning set forth in Section 7.4.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Continued Service Period&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> has the meaning set forth in Section 2.5.1.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Control&#x201d; </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">means:  (i) the legal, beneficial, or equitable ownership, directly or indirectly, of  (a) at least thirty-five percent (35%) of the aggregate of all voting equity interest in an entity or (b) equity interest having the right to at least thirty-five percent (35%) of the profits of an entity or, in the event of dissolution, to at least thirty-five percent (35%) of the assets of an entity; (ii) the right to appoint, directly or indirectly, a majority of the board of directors of the entity; (iii) the possession, directly or indirectly, of the power to direct or cause the direction of the management or policies of an entity, whether through the ability to exercise voting power, by contract or otherwise; or (iv)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">2</font></p></div></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">in the case of a partnership, the holding by an entity (or one of its Affiliates) of the position of general partner.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Cure Period&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> means the [***]-day period immediately following a party&#x2019;s receipt of notice from the other party of any suspected material breach (other than a Payment Breach), as required in Section 3.2.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Data Privacy Requirements&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> means applicable federal, state, and local laws and regulations, including applicable binding agency guidance relating to (i) privacy, confidentiality, integrity, availability, collection, use, access, processing, protection, security, deletion or disclosure of Client Data; (ii) cybersecurity (including secure software development); or (iii) artificial intelligence, automated decision making, or machine learning technologies.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Demand&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> means a notice by a party to the other party pursuant to this Agreement describing such party&#x2019;s Claims and Losses.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Disabling Device&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> has the meaning set forth in Section 8.5.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Disclosing Party&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> has the meaning set forth in Section 7.1.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Disentanglement&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> has the meaning set forth in Section 3.6.1(b).</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Disentanglement Commencement Date&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> has the meaning set forth in Section 3.6.2(a).</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Disentanglement Period&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> has the meaning set forth in Section 3.6.2(a).</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Disentanglement Transition Plan&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> has the meaning set forth in Section 3.6.2(a).</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Dispute&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> means any dispute, Claim or controversy between the parties arising out of or related to this Agreement or any Statements of Work.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Documentation&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> means, with respect to any particular items: (a) all of the written, printed, electronic, or otherwise formatted materials that relate to such items, or any component thereof; (b) all user, operator, system administration, technical, training, support, and other manuals and all other written, printed, electronic, or other format materials that represent, demonstrate, explain or describe the functional, operational or performance capabilities of such items; and (c) all specifications, materials, flow charts, notes, outlines, manuscripts, writings, pictorial or graphical materials, schematics, and other documents that represent, demonstrate, explain or describe such items.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;EEA&#x201d; </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">has the meaning set forth in Section 8.6(a).</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Effective Date&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> has the meaning set forth in the first paragraph.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Expenses&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> means any and all out-of-pocket expenses incurred in connection with investigating, defending, asserting or enforcing any Claim or alleged Claim, including court filing fees, court costs, arbitration or mediation fees or costs, witness fees, discovery costs and reasonable fees and</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">3</font></p></div></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">disbursements of legal counsel, investigators, expert witnesses, consultants, accountants and other professionals.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">   </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Extension Term&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> has the meaning set forth in Section 3.1.2.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Federal Health Care Program&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> means any plan or program providing health care benefits, whether directly through insurance or otherwise, that is funded directly, in whole or part, by the United States Government (other than the Federal Employees Health Benefits Program), including any State health care program that receives funding from the United States Government.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Fees&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> means the fees set forth in each Statement of Work and payable by Client to GMS or a GMS Affiliate as consideration for GMS&#x2019; or its Affiliate&#x2019;s provision of Services.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Force Majeure Event&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> has the meaning set forth in Section 19.13.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Former Affiliate&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> has the meaning set forth in Section 2.5.1.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;GAAP&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> has the meaning set forth in Section 16.1.1.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;GDPR&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> has the meaning set forth in Section 8.6(b).</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;GMS&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> has the meaning set forth in the first paragraph and includes its permitted successors and permitted assigns.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;GMS Indemnitee&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> has the meaning set forth in Section 10.2.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;GMS IP&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> has the meaning set forth in Section 14.2.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Governance Procedures&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> has the meaning set forth in each Statement of Work.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Governmental Body&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> means any:  (a) United States federal, state or local, or any supra-national or non-United States federal, state/provincial or local, government or political subdivision; (b) governmental, regulatory or administrative (i) authority, (ii) instrumentality or (iii) agency body or commission; (c) self-regulatory organization; or (d) court, tribunal or judicial or arbitral body.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Healthcare Compliance Program&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> means a formalized system of policies, procedures, and processes developed and implemented to prevent, detect, and correct conduct that is inconsistent with applicable federal and state Laws governing a healthcare organization.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> &#x201c;HIPAA&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> means the Health Insurance Portability and Accountability Act of 1996 and its supporting regulations, including 45 CFR Part 160; 45 CFR Part 162 and 45 CFR Part 164, as amended from time to time.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;HITECH&#x201d; </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">means Health Information Technology for Economic and Clinical Health Act codified at 42 U.S.C. &#167; 300jj et seq., as amended from time to time.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Indemnitee&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> has the meaning set forth in Section 10.3.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Indemnitor&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> has the meaning set forth in Section 10.3.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">4</font></p></div></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Information Security Program&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> has the meaning set forth in Section 8.2.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Initial Term&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> has the meaning set forth in Section 3.1.1.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Key Performance Indicator&#x201d; </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">or</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> &#x201c;KPI&#x201d; </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">has the meaning set forth in each Statement of Work.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Law&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> means any United States federal, state or local, and any supra-national or non-United States federal, state/provincial or local, laws, statutes, regulations, rules, codes, ordinances or guidance enacted, adopted, issued or promulgated by any Governmental Body or common law.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Losses&#x201d; </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">means any and all losses, costs, obligations, liabilities, settlement payments, awards, judgments, interest, taxes, fines, penalties, damages, deficiencies and other similar types of items arising out of or in connection with a Claim.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Medical Professionals&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> has the meaning set forth in Section 13.2.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Non-Renewal Notice&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> has the meaning set forth in Section 3.1.2.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;OIG&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> means the U.S. Department of Health and Human Services Office of Inspector General.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Payment Breach&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> means Client&#x2019;s failure to timely pay its undisputed invoices due under SOW(s) when such outstanding amounts are equal to or greater than [***] for more than [***] days.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Payment Breach Cure Period&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> has the meaning set forth in Section 3.3.2(a).</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Payment Breach Notice&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> has the meaning set forth in Section 3.3.2(a).</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;PEPPER Report&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> means a Program for Evaluating Payment Patterns Electronic Report summarizing provider-specific Medicare data statistics for target areas often associated with Medicare improper payments due to billing, DRG coding and/or admission medical necessity issues.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;PHI&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> has the meaning set forth in Section 7.5.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Receiving Party&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> has the meaning set forth in Section 7.1.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Regulator</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means any: (a) governmental, regulatory (or quasi-governmental or quasi-regulatory) or other competent authority (wherever in the world located) having supervisory oversight or jurisdiction (including pursuant to an insolvency event) over any Service Recipient; or (b) any law enforcement authority.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Secretary&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> means the Secretary of the U.S. Department of Health and Human Services.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Security Event&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> means any security or data incident or outage, whether or not intentional or caused by a disaster or an attack, and whether completed or in process, that affects or may reasonably be likely to affect any of the Services or the confidentiality, integrity or availability of Client Confidential Information or Client Data.  A Security Event includes any potential or actual</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">5</font></p></div></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">loss, theft, damage or destruction of, or unauthorized access to, use or disclosure of, Client Confidential Information or Client Data.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Service Level&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> has the meaning set forth in each Statement of Work.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Service Recipient&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> has the meaning set forth in Section 2.2(c).</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Services&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> means the revenue cycle management services, including the facilities, personnel, equipment, software, technical knowledge and other resources necessary for GMS or its Affiliate(s) to provide such services as described in and in accordance with an applicable Statement of Work.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;SOW Effective Date&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> has the meaning set forth in the first paragraph of each Statement of Work.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Spin-Off Agreement&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> has the meaning set forth in Section 2.5.2(a).</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Spin-off Entity&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> has the meaning set forth in Section 2.5.2(a).</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Spin-off Event&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> has the meaning set forth in Section 2.5.2(a).</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Statement of Work&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> or </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;SOW&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> means the written statement describing the specific Services to be provided by GMS or its specified Affiliate(s) that shall include details regarding GMS&#x2019; or its specified Affiliates&#x2019; responsibilities, Client responsibilities, compensation, payment terms, and any term or termination provisions specific to such Services described.  The Statements of Work entered into under this Agreement shall be: (a) in a form substantially similar to the form set forth in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 1</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">; (b) executed by authorized individuals on behalf of each of the parties; and (c) incorporated into this Agreement by reference as sequentially numbered Statements of Work (e.g., Statement of Work #1, Statement of Work #2, etc.).</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Subcontractor&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> means any party other than GMS or its Affiliate(s) that provides Services to any Service Recipient in connection with this Agreement pursuant to an agreement such party has with GMS or any of its Affiliates.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Term&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> has the meaning set forth in Section 3.1.2.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;WARN Act&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> means the Worker Adjustment and Retraining Notification Act, 29 U.S.C. 2101 et. seq.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">   </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;WARN Notice&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> means a notice required to be provided in accordance with the WARN Act.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">   </font></p>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">1.2</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Captions; References; Terminology</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Captions, Tables of Contents (if any), Indices of Definitions and titles of transaction documents are used herein for convenience of reference only and may not be used in the construction or interpretation of this Agreement.  Any reference herein to a particular Section number (e.g., &#x201c;Section 2&#x201d;), shall be deemed a reference to all Sections of this Agreement that bear sub numbers to the number of the referenced Section (e.g., Sections 2.1, 2.1.1, 2.1.1(a) etc.).  Any reference herein to a particular Exhibit (e.g., Exhibit A) shall be deemed a reference to the Exhibit hereto that bears the same description.  The words &#x201c;including,&#x201d; &#x201c;include&#x201d; and &#x201c;includes&#x201d; shall each be deemed to be followed by the term &#x201c;without limitation.&#x201d; Unless </font></div></div>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">6</font></p></div></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:4.533%;visibility:hidden;display:inline-flex;justify-content:flex-start;"></font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">otherwise specified, all consents and approvals identified in this Agreement shall be in writing.  Any agreement, amendment, addendum, schedule, statement of work, annex, appendix, attachment or exhibit referred to herein means such agreement, amendment, addendum, schedule, statement of work, annex, appendix, attachment or exhibit as amended, restated, supplemented or modified from time to time to the extent permitted by the applicable provisions thereof and this Agreement.  Except to the extent expressly indicated otherwise, reference to any Law means such Law as amended at the time and from time to time and includes any successor Law. Unless otherwise stated, references to recitals, sections, paragraphs, amendments, addenda, annexes, schedules, statements of work, appendices, attachments, or exhibits shall be references to recitals, sections, paragraphs, amendments, addenda, annexes, schedules, statements of work, appendices, attachments or exhibits of this Agreement.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">  </font></div></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">SERVICES</font></div></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">2.1</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Services Framework</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  This Agreement is intended to serve as the framework for entering into separate Statements of Work.  Unless otherwise agreed by the parties, all Statements of Work that are entered into under this Agreement shall be governed by the terms of this Agreement and are hereby made part of and incorporated into this Agreement when executed by duly authorized individuals.  In the event of a conflict between this Agreement and a Statement of Work, the terms of the Statement of Work shall prevail solely with respect to such Statement of Work.  GMS shall provide the Services in accordance with this Agreement, including each applicable Statement of Work. GMS Affiliates are permitted to execute SOWs independent of GMS under this Agreement.  The GMS Affiliate that executes an SOW with Client shall be considered &#x201c;GMS&#x201d; for all purposes of such SOW and shall assume all obligations thereof; and the SOW shall be considered a two party agreement between Client and such GMS Affiliate.</font></div></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">2.2</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Provision of Services</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  GMS shall provide the Services to:  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(a)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> Client; </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(b)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> Client&#x2019;s Affiliates; and </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(c)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> Client Affiliates&#x2019; clinicians and clinician groups all of whom shall receive Services of the type that GMS is to provide under this Agreement (each, a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Service Recipient</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; and collectively, &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Service Recipients</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;).  Only Client may request Services and execute SOWs with GMS under this Agreement.  Client warrants it has the requisite authority to cause other Service Recipients to comply with the terms and conditions of the Agreement and shall be responsible for all acts or omissions of other Service Recipients in relation to this Agreement.  </font></div></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">2.3</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Governance Procedures</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  The parties shall comply with the Governance Procedures mutually agreed upon and set forth in writing or incorporated by reference into each Statement of Work. </font></div></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">2.4</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Change Management</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:2.57143775513484%;display:inline-flex;justify-content:flex-start;">2.4.1</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Change Management Process</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Either party may request a change by providing the other party with notice of such request in such form as the parties may agree in writing.  Regardless of which party has proposed a change, GMS shall prepare and submit to Client as soon as practicable, but in any event within ten (10) business days after GMS&#x2019; receipt of a change request, a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Change Proposal</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; outlining at a high level GMS&#x2019; recommended approach to implementing the proposed change, including acceptance test procedures and </font></div></div>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">7</font></p></div></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:2.57143775513484%;visibility:hidden;display:inline-flex;justify-content:flex-start;"></font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Acceptance criteria, if applicable, along with GMS&#x2019; analysis of the impact, if any, of the proposed change on the following Service elements:</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.333%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:5.53844023676832%;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The Services&#x2019; scope and the parties&#x2019; respective responsibilities;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.333%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:5.53844023676832%;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The Fees and other expenses;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.333%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:5.53844023676832%;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Service Levels and KPIs, as applicable;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.333%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:5.53844023676832%;display:inline-flex;justify-content:flex-start;">(d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Governance Procedures; and</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.333%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:5.53844023676832%;display:inline-flex;justify-content:flex-start;">(e)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Any other element Client reasonably requests or that is reasonably considered by either party to be relevant to or potentially impacted by the proposed change&#x2019;s implementation.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:2.57143775513484%;display:inline-flex;justify-content:flex-start;">2.4.2</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Review and Approval</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  The parties shall promptly review each Change Proposal and either approve and execute it or submit it for further investigation.  The parties shall continue to review and revise each Change Proposal until:  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(a)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> the parties approve and execute it; </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(b)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> either party finally rejects the Change Proposal;  or </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(c)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> either party escalates any issues regarding the Change Proposal in accordance with the Governance Procedures.  </font></div></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">2.5</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Former Affiliates; Divestment</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:2.57143775513484%;display:inline-flex;justify-content:flex-start;">2.5.1</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Former Affiliates</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  If Client relinquishes Control of a Service Recipient, business unit or Affiliate during the Term and wishes to provide transition services to such Service Recipient, business unit or Affiliate for a limited period of time (each such party, a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Former Affiliate</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), upon Client&#x2019;s written request, GMS shall continue to provide identified Services to such entity after the date such entity becomes a Former Affiliate for the period of time Client requests in writing, which period shall not exceed twelve (12) months (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Continued Service Period</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;); </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">however</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">, that (x) the Former Affiliate agrees in writing to abide by the terms and conditions of this Agreement; and (y) the Former Affiliate remains on Client&#x2019;s information technology systems used by GMS to perform the Services prior to such change in control event as such Client systems may change and evolve in the ordinary course during the applicable Continued Service Period.  For purposes of this Agreement, Services provided to a Former Affiliate during a Continued Service Period shall be deemed Services provided to Client.  During any Continued Service Period, Client shall:</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.333%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:5.53844023676832%;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">remain the single point-of-contact with GMS with respect to the Services provided to the Former Affiliate;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.333%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:5.53844023676832%;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">remain obligated to perform its payment obligations under this Agreement with respect to those Services; and</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.333%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:5.53844023676832%;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">be responsible for all acts or omissions of such Former Affiliate to the same extent that it would have been responsible prior to the Former Affiliate&#x2019;s divestiture.</font></div></div>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">8</font></p></div></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Upon the expiration or termination of the applicable Continued Service Period, the Fees to be paid by Client under this Agreement shall be equitably adjusted to reflect the reduction in the Services provided to Client and other Service Recipients, if applicable.  If a Former Affiliate desires to continue receiving Services from GMS following the applicable Continued Service Period, the parties may agree to extend the Continued Service Period for a period agreed in writing by the parties or GMS and such Former Affiliate may agree to enter into a direct agreement with each other if the parties can reach mutually agreeable terms.</font></p>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:2.57143775513484%;display:inline-flex;justify-content:flex-start;">2.5.2</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Divestment</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.333%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:5.53844023676832%;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">If Client or any other Service Recipient sells assets or divests entities to create a new entity that is no longer a Service Recipient or otherwise entitled to receive Services under this Agreement (any such entity, a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Spin-off Entity</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; and any such sale or divestiture, a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Spin-off Event</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), and Client desires that Services provided hereunder continue to be provided for the Spin-off Entity, upon Client&#x2019;s written request, GMS and the applicable Spin-off Entity shall execute and deliver an agreement (including applicable SOWs), to be effective as of the date such entity is no longer part of Client&#x2019;s enterprise or such other date as Client directs, containing substantially similar terms and conditions to this Agreement, including applicable SOWs (each, a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Spin-Off Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), subject to the operation of the final sentence of this Section 2.5.2(a).  GMS&#x2019; obligation to contract with any Spin-off Entity shall be subject to the applicable Spin-off Entity meeting the reasonable client and new business approval criteria of GMS in relation to the Services, generally applicable to new business. </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.333%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:5.53844023676832%;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">GMS and Client shall negotiate in good faith the equitable allocation of the Fees to be paid by Client and each Spin-off Entity under the applicable SOWs and Spin-Off Agreements.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.333%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:5.53844023676832%;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">In addition to GMS&#x2019; obligations set forth hereunder, upon Client&#x2019;s notice to GMS that Client expects to or is considering the possibility of engaging in a Spin-off Event, GMS shall provide to Client all commercially reasonable assistance, which may include preparing SOWs, meeting with representatives of Spin-off Entities and other activities as Client reasonably directs.  GMS and Client shall negotiate in good faith the Fees (if any) to be paid for such assistance.</font></div></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">2.6</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Fees and Taxes</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:2.57143775513484%;display:inline-flex;justify-content:flex-start;">2.6.1</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Fees</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  The Fees payable hereunder shall be as set forth in each applicable Statement of Work.  </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:2.57143775513484%;display:inline-flex;justify-content:flex-start;">2.6.2</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Currency</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  All Fees, prices and billing shall be in United States Dollars.  GMS shall bear all risks with respect to foreign exchange.  </font></div></div>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">9</font></p></div></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:2.57143775513484%;display:inline-flex;justify-content:flex-start;">2.6.3</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Taxes</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.333%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:5.53844023676832%;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">If any state or local taxing authority imposes a sales, use or similar tax on the compensation to be paid to GMS under this Agreement, the payment of that tax shall be the sole responsibility of Client, provided however, that no Service Recipient shall be responsible for, and the Fees shall not include, any personal property taxes on property that GMS or any of its Affiliates own or lease, corporate, franchise or privilege taxes on GMS&#x2019; or any of its Affiliates&#x2019; business, gross receipts taxes to which GMS or any of its Affiliates are subject or income taxes based on GMS&#x2019; or any of its Affiliates&#x2019; income or net worth. </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.333%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:5.53844023676832%;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The parties shall cooperate with each other in a commercially reasonable and legally permissible manner to enable each to more accurately determine its tax liability.  GMS&#x2019; invoices shall separately state the amounts of any taxes that GMS is properly collecting pursuant to the terms hereof.  GMS shall remit to the applicable taxing authority any taxes collected from any Service Recipient within the period required by Law.  To the extent that GMS is required under applicable Law to collect from any Service Recipient and remit to the applicable taxing authority any taxes in connection with this Agreement, if GMS </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(i)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> fails to collect and remit any such taxes or </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(ii)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> collects and fails to remit any such taxes, GMS shall be responsible for any penalties, fees, fines and interest directly related thereto.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:2.57143775513484%;display:inline-flex;justify-content:flex-start;">2.6.4</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Only Payments</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  The Fees identified in this Section 2.6 are the only payments to be made by any Service Recipient to GMS under this Agreement with respect to the Services.  Other than as expressly set forth in any SOW, no Service Recipient shall pay GMS any fees, assessments, reimbursements, costs or expenses, including any travel, meals or overhead expenses.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:2.57143775513484%;display:inline-flex;justify-content:flex-start;">2.6.5</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Disputed Amounts</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Client may withhold payment of any GMS invoice (or part thereof) that it in good faith disputes is due or owing pending resolution of such dispute.  In such case, Client shall, by the applicable due date, pay any undisputed amounts and at the same time provide to GMS a written explanation of the basis for the dispute.  Client&#x2019;s failure to pay a disputed invoice or the disputed part of an invoice that it disputes in good faith shall not constitute Client&#x2019;s breach or default, so long as Client complies with the provisions of this Section 2.6.5.  The parties shall make a good faith effort to resolve any dispute relating to amounts owed by a party hereunder through the applicable Governance Procedures prior to taking additional actions permissible under this Agreement or applicable Law. </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:2.57143775513484%;display:inline-flex;justify-content:flex-start;">2.6.6</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Invoices and Payment Terms</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  GMS shall submit invoices between the 1st and 15th day of the month for applicable Fees set forth in each SOW for Services performed in the previous month or on such date as may be otherwise specified in a SOW.  Invoices must reference this Agreement and shall be accompanied by information and data that support the invoiced Fees. Such information may include the separate billing of multiple entities and general Fee visibility and other billing requirements consistent with Client&#x2019;s specific financial requirements and practices.  Invoices are payable within thirty (30) days after Client&#x2019;s receipt of each invoice, correct as to the form agreed by the parties in writing.  An </font></div></div>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">10</font></p></div></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:2.57143775513484%;visibility:hidden;display:inline-flex;justify-content:flex-start;"></font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">invoice shall be deemed to have been &#x201c;received&#x201d; for purposes of this Section 2.6.6: </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(a)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> when personally delivered, or delivered by same-day courier; </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(b)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> on the third business day after mailing by registered or certified mail, postage prepaid, return receipt requested; </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(c)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> upon delivery when sent by prepaid overnight express delivery service (e.g., FedEx, UPS); or </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(d)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> upon sending when sent by email or facsimile to email addresses or facsimile numbers designated in writing by Client.  Client may, in good faith, dispute any invoice in accordance with the provisions of this Agreement.  Undisputed invoiced amounts not paid within forty-five (45) days after receipt of invoice may bear interest at GMS&#x2019; sole discretion at the lesser of </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(i)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> [***] per annum, or </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(ii)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> the maximum rate permitted by applicable Law.  Client agrees that such interest charges are reasonable and agrees to pay all such fees.</font></div></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">3.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">TERM AND TERMINATION</font></div></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">3.1</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Term and Renewal</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:2.57143775513484%;display:inline-flex;justify-content:flex-start;">3.1.1</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Initial Term</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  The term of this Agreement shall commence on the Effective Date and shall end on the eighth anniversary of the Effective Date (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Initial Term</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;).  </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:2.57143775513484%;display:inline-flex;justify-content:flex-start;">3.1.2</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Extension Term and Term</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  This Agreement shall automatically renew for successive two (2)-year terms after the expiration of the Initial Term (each an &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Extension Term</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), unless either party delivers a notice of non-renewal to the other party at least twelve (12) months prior to the expiration of the Initial Term or of any Extension Term, as the case may be (in each case, a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Non-Renewal Notice</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), or unless terminated earlier as set forth herein.  Any such Non-Renewal Notice delivered by a party shall be effective upon the expiration of the Initial Term or the then-current Extension Term, as the case may be.  The Initial Term and any Extension Term(s) shall be referred to as the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Term</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:2.57143775513484%;display:inline-flex;justify-content:flex-start;">3.1.3</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Limitation</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Notwithstanding Section 3.1.1 or 3.1.2, this Agreement shall remain in effect as long as any SOW under it is in effect.  </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:2.57143775513484%;display:inline-flex;justify-content:flex-start;">3.1.4</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Term of SOWs</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Each SOW shall become effective on the applicable SOW Effective Date and shall remain in effect for the specified term of those Services (or if no period is specified, for the Term) unless terminated earlier or extended as set forth herein or therein.  </font></div></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">3.2</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Termination of Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  This Agreement may be terminated as follows:</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:2.57143775513484%;display:inline-flex;justify-content:flex-start;">3.2.1</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Termination without Cause After Initial Term</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. This Agreement may be terminated without cause by Client at any time after the Initial Term by providing GMS no less than [***] days&#x2019; notice prior to the effective date of termination.  </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:2.57143775513484%;display:inline-flex;justify-content:flex-start;">3.2.2</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Termination for Cause by Client</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  If Client provides notice of suspected material breach of this Agreement by GMS, which notice of breach describes the material breach with reasonable specificity, and GMS fails to cure such breach within the Cure Period, Client may terminate this Agreement by providing notice of termination to GMS at the end of the Cure Period, which notice of termination shall specify the effective date of termination (which may, at Client&#x2019;s election, be immediate).  </font></div></div>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">11</font></p></div></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:2.57143775513484%;display:inline-flex;justify-content:flex-start;">3.2.3</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Additional Termination Rights of Client</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  In addition, Client may terminate this Agreement upon notice to GMS, which notice of termination shall specify the effective date of termination, if:</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.333%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:5.53844023676832%;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">a Force Majeure Event exceeds [***] days; </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.333%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:5.53844023676832%;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">regulatory requirements mandate termination; </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.333%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:5.53844023676832%;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">GMS is excluded or debarred by the federal government from performing services, including under any Federal Health Care Program;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.333%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:5.53844023676832%;display:inline-flex;justify-content:flex-start;">(d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">GMS is sanctioned by the federal government in relation to its performance of services, including under any Federal Health Care Program;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.333%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:5.53844023676832%;display:inline-flex;justify-content:flex-start;">(e)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">changes in Laws make it unlawful for any Service Recipient to receive Services from GMS; and/or </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.333%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:5.53844023676832%;display:inline-flex;justify-content:flex-start;">(f)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">if no Statements of Work are in effect.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:2.57143775513484%;display:inline-flex;justify-content:flex-start;">3.2.4</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Additional Termination Rights of GMS</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  In addition, GMS may terminate this Agreement upon notice to Client, which notice of termination shall specify the effective date of termination, if no Statements of Work are in effect.  </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:2.57143775513484%;display:inline-flex;justify-content:flex-start;">3.2.5</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Termination Upon Occurrence of Certain Events by Either Party</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  A party may terminate this Agreement upon notice to the other party to be effective as of the date set forth in any such notice, if any of the following occurs: </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.333%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:5.53844023676832%;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">the other party is convicted of an act of fraud; </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.333%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:5.53844023676832%;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">the other party is excluded or suspended from participation in Medicare or Medicaid programs; </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.333%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:5.53844023676832%;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">the other party files a general assignment for the benefit of creditors or bankruptcy; and/or </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.333%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:5.53844023676832%;display:inline-flex;justify-content:flex-start;">(d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">the other party takes any formal action toward its dissolution or liquidation.  </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:2.57143775513484%;display:inline-flex;justify-content:flex-start;">3.2.6</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Termination for Cause by GMS</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  GMS may terminate this Agreement immediately upon notice to Client if GMS terminates one or more Statements of Work for Payment Breach as provided below in Section 3.3.2. </font></div></div>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">12</font></p></div></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">3.3</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Termination of a Statement of Work</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  A Statement of Work may be terminated in accordance with the following terms or as otherwise set forth in the applicable SOW: </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:2.57143775513484%;display:inline-flex;justify-content:flex-start;">3.3.1</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">By Client</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.333%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:5.53844023676832%;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Termination for Cause</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:20%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.3337499999999998%;display:inline-flex;justify-content:flex-start;">(i)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">If Client provides notice of suspected material breach of any SOW by GMS, which notice describes the material breach with reasonable specificity, and GMS fails to cure such breach within the Cure Period, Client may terminate such SOW by providing notice of termination to GMS at the end of the Disentanglement Period.  </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:20%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.3337499999999998%;display:inline-flex;justify-content:flex-start;">(ii)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">If Client provides notice of the occurrence of a series of uncured breaches of any SOW by GMS of which Client has notified GMS and that collectively constitute a material breach and GMS fails to cure such breach within the Cure Period, Client may terminate such SOW by providing notice of termination to GMS at the end of the Disentanglement Period.  </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.333%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:5.53844023676832%;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Additional Termination Rights of Client</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  In addition, unless otherwise set forth in a SOW, Client may terminate any SOW upon notice to GMS, which notice of termination shall specify the effective date of termination, if:</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:20%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.3337499999999998%;display:inline-flex;justify-content:flex-start;">(i)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Client elects to terminate any such SOW by notifying GMS at least [***] days before the effective date of termination;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:20%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.3337499999999998%;display:inline-flex;justify-content:flex-start;">(ii)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">a Force Majeure Event exceeds [***] days; </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:20%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.3337499999999998%;display:inline-flex;justify-content:flex-start;">(iii)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">regulatory requirements mandate termination; </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:20%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.3337499999999998%;display:inline-flex;justify-content:flex-start;">(iv)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">GMS is excluded or debarred by the federal government from performing services, including under any Federal Health Care Program;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:20%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.3337499999999998%;display:inline-flex;justify-content:flex-start;">(v)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">GMS is sanctioned by the federal government in relation to its performance of services, including under any Federal Health Care Program;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:20%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.3337499999999998%;display:inline-flex;justify-content:flex-start;">(vi)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">changes in Laws make it unlawful for any Service Recipient to receive Services from GMS; </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:20%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.3337499999999998%;display:inline-flex;justify-content:flex-start;">(vii)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">in the event of a Change in Control of GMS after the applicable SOW Effective Date resulting from a single transaction or series of related transactions at least [***] days before the effective date of termination; and/or </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:20%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.3337499999999998%;display:inline-flex;justify-content:flex-start;">(viii)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">as set forth in a Statement of Work.  </font></div></div>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">13</font></p></div></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:2.57143775513484%;display:inline-flex;justify-content:flex-start;">3.3.2</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">By GMS</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.333%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:5.53844023676832%;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">If GMS provides notice to Client of a Payment Breach (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Payment Breach Notice</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) and Client fails to cure such Payment Breach within [***] days after the date of the Payment Breach Notice (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Payment Breach Cure Period</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), GMS may terminate the applicable Statement of Work immediately upon notice to Client. </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.333%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:5.53844023676832%;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">If GMS provides notice to Client of a material breach of a Statement of Work by Client as set forth in such Statement of Work, which notice describes the material breach with reasonable specificity, GMS may terminate the applicable Statement of Work if Client fails to cure such breach within the Cure Period by providing notice of termination to Client at the end of the Cure Period, which notice of termination shall specify the effective date of termination (which may, at GMS&#x2019; election, may be immediate).  For purposes of this Section 3.3.2 only, a material breach shall not include any breach of Section 5.6.</font></div></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">3.4</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Acceleration of Cure Period</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Notwithstanding anything to the contrary in this Agreement, if a party has given notice of a breach of this Agreement or any Statement of Work prior to the commencement, voluntary or involuntary, of proceedings of assignment for the benefit of creditors, in reorganization or bankruptcy for the other party, including filing under Chapter 7 or 11 of the U.S. Bankruptcy Code (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Commencement Date</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), any applicable period within which the other party has to cure the breach shall be shortened and accelerated so that such period shall be deemed to have expired on the business day immediately preceding the Commencement Date, and the party giving the notice of breach shall be deemed to have elected to terminate this Agreement effective immediately upon the expiration of such cure period.  </font></div></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">3.5</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Default</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  A party that fails to cure a material breach, including a Payment Breach, during the Cure Period or Payment Breach Cure Period, as applicable, will be in default of this Agreement and/or the applicable SOW.  </font></div></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">3.6</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Effect of Termination; Disentanglement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:2.57143775513484%;display:inline-flex;justify-content:flex-start;">3.6.1</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">General Obligations</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.333%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:5.53844023676832%;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Termination of this Agreement, any Statement of Work or any portion of either is without prejudice to any other right or remedy of the parties.  Termination of this Agreement, any Statement of Work or any portion of either for any cause does not release either party from any liability </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(i)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> which at the time of termination, has already accrued to the other party, </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(ii)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> which may accrue in respect of any act or omission prior to termination, or </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(iii)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> from any obligation which is expressly stated to survive termination.  In the event of any termination, Client shall pay GMS for all undisputed amounts due and owing under active SOWs through the effective date of termination, which shall be inclusive of any transition periods.  </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.333%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:5.53844023676832%;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">In connection with any termination of this Agreement, any Statement of Work or any portion of either, GMS shall take commercially reasonable actions to accomplish a complete, timely, and seamless transition from GMS to applicable Service Recipients, or to any third party service providers designated by Client, of </font></div></div>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">14</font></p></div></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div class="item-list-element-wrapper" style="margin-left:13.333%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:5.53844023676832%;visibility:hidden;display:inline-flex;justify-content:flex-start;"></font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">the Services being terminated without material interruption or material adverse impact on the Services, the Service Levels and KPIs, as applicable, or any other services provided to any Service Recipient by third parties (all such actions, collectively, a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Disentanglement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;).</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.333%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:5.53844023676832%;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">GMS shall promptly cooperate with Service Recipients and any designated third party service providers, and take commercially reasonable steps reasonably requested to assist Service Recipients in effecting a complete and timely Disentanglement, including </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(i)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> the provision of reasonable use of and access to GMS, its Affiliates, Subcontractor(s) and their respective personnel, that are dedicated to the provision of Services, Service Recipients&#x2019; equipment, data, documentation, and software, third parties and other resources being used by GMS or its Affiliates to provide the Services (subject to GMS&#x2019; reasonable security requirements, its contractual obligations to third parties, and its continuing obligation to perform the Services), and </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(ii)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> the provision to Service Recipients and any designated third party service providers of all relevant information (subject to the confidentiality provisions of this Agreement) necessary to effect the transition, and assume and continue the provision, of any terminated Services sufficient for reasonably skilled personnel to understand and perform those Services.  GMS shall also provide for the prompt and orderly conclusion of all work related to the Services being terminated, as Client may reasonably direct, including completion or partial completion and documentation of all work in progress, and other appropriate measures reasonably required to effect an orderly transition to Service Recipients or their respective designated third-party service providers. </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:2.57143775513484%;display:inline-flex;justify-content:flex-start;">3.6.2</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Disentanglement Process</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.333%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:5.53844023676832%;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;" id="docxtextref213"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">If requested by Client in writing, a Disentanglement Period will commence as of </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(i)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> the specified termination date in a termination notice given by a party if this Agreement or any portion thereof is earlier terminated, or </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(ii)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> [***] months prior to the expiration of any Statement of Work (a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Disentanglement Commencement Date</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), and shall continue for a period of up to [***] months therefrom (collectively, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Disentanglement Period</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;).  No later than thirty (</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">30</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">) days following a Disentanglement Commencement Date, the parties and any third party service providers shall work in good faith to reach a mutually agreeable agreement on and document a detailed written plan for the separation of equipment, software, data, and documentation owned, licensed or leased by any Service Recipient and used by GMS and all operations performed by GMS, its Affiliates or Subcontractors (a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Disentanglement Transition Plan</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) that:  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(A)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> allocates responsibilities for Disentanglement and transition of the Services between the parties and, to the extent applicable, such third party service providers; </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(B)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> defines phases, tasks, timelines and major milestones identified in transitioning Services back to applicable Service Recipients (or their designees); and </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(C)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> sets forth in reasonable detail the respective services to be provided by each of the parties and such third party service providers, including all Services with respect to Disentanglement to be performed by GMS.  GMS shall update each such Disentanglement Transition Plan from time to time, as appropriate and subject to </font></div></div>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">15</font></p></div></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div class="item-list-element-wrapper" style="margin-left:13.333%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:5.53844023676832%;visibility:hidden;display:inline-flex;justify-content:flex-start;"></font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Client&#x2019;s reasonable approval, in order to address any impact of any unexpected changes in the Services or the observed Service Level or KPI performance, or the hardware, software, or other resources used to provide the Services, as such Disentanglement progresses.  GMS shall be required to perform its Disentanglement Services on a reasonably expedited basis, as reasonably determined by Client, if Client terminates the Term or any portion of the Services pursuant to Sections 3.3.1(b)(iii), 3.3.1(b)(iv), 3.3.1(b)(v) or 3.3.1(b)(vi).  For clarity, GMS&#x2019; obligation to provide such Services with respect to any Disentanglement shall terminate on the earlier of (1) completion of Disentanglement in accordance with the terms of this Agreement, or (2) [***] months following the applicable termination date.  For the avoidance of doubt, during any Disentanglement, GMS shall continue to perform Services underlying such Disentanglement (for which Client shall continue to pay GMS the Fees for Services rendered during such Disentanglement).</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">  </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.333%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:5.53844023676832%;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Acceptance Testing Regarding Disentanglement-Related Services</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Client may perform &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Acceptance Testing</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; to determine whether the Services and associated deliverables provided in respect of a Disentanglement satisfy the relevant Acceptance Criteria set forth in the applicable Disentanglement Transition Plan.  If Client requests GMS to assist Client with Acceptance Testing, GMS shall promptly do so.  GMS shall notify Client when the relevant Services and deliverables (or portion of them) are ready for Acceptance Testing to commence.  Subject to 3.6.2(c), Client shall, by the end of the Acceptance Testing period set out in the applicable Disentanglement Transition Plan, conduct Acceptance Testing and notify GMS of its acceptance or non-acceptance of the relevant Services and/or deliverables (or portion of them).  Acceptance by Client shall not be unreasonably withheld, conditioned or delayed.  If Client determines that the relevant Services and/or deliverables (or portion of them) satisfy the relevant Acceptance Criteria or otherwise decides to accept them, Client shall notify GMS accordingly.  Notwithstanding the foregoing, acceptance of any individual Services and deliverables (or portion of them) shall not constitute Client&#x2019;s waiver of its right to assert claims based upon defects or deficiencies not reasonably discernible through conduct of the applicable Acceptance Testing and subsequently discovered in relation to subsequent Services or deliverables.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.333%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:5.53844023676832%;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Failure of Acceptance Testing</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  If Client notifies GMS that the relevant Services and/or deliverables (or portion of them) do not satisfy the relevant Acceptance Criteria, GMS shall correct all non-compliance not later than ten (10) days (unless otherwise agreed) from the date of such notification.  After such corrections have been made, Client shall have a further ten (10) days, or such additional period of time Client may reasonably require, to re-test the relevant Services and/or deliverables (or portion of them).  If, following re-testing, they still do not satisfy the relevant Acceptance Criteria, Client may, in its sole discretion: </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(i)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> grant GMS additional time to correct the outstanding non-compliance, following which Client shall re-test again; or </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(ii)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> reject the relevant Services and/or deliverables (or portion of them) that have failed Acceptance Testing, together with any other Services and/or deliverables provided pursuant to the same </font></div></div>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">16</font></p></div></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div class="item-list-element-wrapper" style="margin-left:13.333%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:5.53844023676832%;visibility:hidden;display:inline-flex;justify-content:flex-start;"></font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Disentanglement Transition Plan (even if they have already passed Acceptance Testing) that, as a result, cannot be used as intended.  Such failure shall be a material breach of the applicable Statement of Work.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">  </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.333%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:5.53844023676832%;display:inline-flex;justify-content:flex-start;">(d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Deemed Acceptance</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  If Client fails to notify GMS of its acceptance or non-acceptance of the relevant Services and/or deliverables (or portion of them) in accordance with Section 3.6.2(b) by the end of the applicable Acceptance Testing period (or such later date as prescribed for completion of re-testing in accordance with Section 3.6.2(c)), subject to the final sentence of Section 3.6.2(b), the relevant Services and/or deliverables (or portion of them) shall be deemed to have been accepted as of the expiration of such period.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:2.57143775513484%;display:inline-flex;justify-content:flex-start;">3.6.3</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Specific Disentanglement Obligations</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  During any Disentanglement, as part of the Services with respect to a Disentanglement, the parties shall perform their respective obligations specifically identified in this Section 3.6.3 with respect to the Services or, in the event of a termination of less than all of the Services, the portion of Services being terminated.  </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.333%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:5.53844023676832%;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Extension of Services</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Client may elect to delay any expiration or termination of all or a part of the Services by giving GMS at least sixty (60) days&#x2019; advance written notice to such effect, which written notice shall specify the new expiration or termination date.  In such cases, notwithstanding anything herein to the contrary, the applicable Disentanglement Period shall also be extended as specified by Client.  </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.333%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:5.53844023676832%;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">License to Proprietary Technology</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  To the extent set forth in any Statement of Work, GMS, at no charge to any Service Recipient, hereby grants to Service Recipients (or their designees) a fully-paid, perpetual, royalty-free, worldwide license to use all GMS IP that is embedded in any Client IP in order to allow Service Recipients (or their designees) to continue to use the same.  Service Recipients may only exercise the foregoing right upon any Disentanglement.  GMS shall provide Client with a full and complete copy of any such GMS IP that is embedded in Client IP in such commercially reasonable forms and media as requested by Client in writing.  </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.333%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:5.53844023676832%;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Data and Documentation</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  In addition to GMS&#x2019; obligations with regard to Documentation set forth herein, GMS shall deliver to Client or its designee, promptly upon Client&#x2019;s written request, all Documentation and data related to specified Service Recipients or the performance of the Services, including all Client Data then held by or on behalf of GMS, and GMS shall securely destroy, in accordance with Client&#x2019;s data and documentation destruction policies, all copies thereof not turned over to Client or its designee, except that GMS may retain a copy of its reports and work papers for its internal recordkeeping purposes or compliance with applicable professional standards, subject to the obligations set forth in Section 7.  </font></div></div>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">17</font></p></div></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div class="item-list-element-wrapper" style="margin-left:13.333%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:5.53844023676832%;display:inline-flex;justify-content:flex-start;">(d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">No Interruptions or Adverse Impact</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  GMS shall reasonably cooperate with Service Recipients and all of Service Recipients&#x2019; other service-providers throughout Disentanglement, in an effort to avoid </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(i)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> any interruption of the performance of the Services, </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(ii)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> any material adverse impact upon the provision of Services or upon the achievement of Service Levels or KPIs, </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(iii)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> any material adverse impact upon Service Recipients&#x2019; governmental activities and Affiliates, </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(iv)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> any material interruption of any services provided to Service Recipients by third parties, and </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(v)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> any material adverse impact upon the provision of such third party services or their quality.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.333%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:5.53844023676832%;display:inline-flex;justify-content:flex-start;">(e)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Hiring of Personnel</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  During any Disentanglement, except as set forth in any Statement of Work, GMS shall reasonably cooperate with and assist as reasonably requested, excepting the disclosure of any compensation details (and shall cause its Affiliates to cooperate with and assist as reasonably requested) with any Service Recipient or designee of any Service Recipient offering of employment or engagement to those personnel of GMS and its Affiliates who are selected by any Service Recipient or designee of any Service Recipient, in its or their sole discretion, and whose then-current job functions or positions are solely dedicated to the Services being terminated, including taking commercially reasonable steps (and shall cause its Affiliates to timely cooperate with and assist as reasonably requested) in effecting the transition of any such personnel who are hired by any Service Recipient or designee of any Service Recipient.  GMS shall waive its rights, if any, and cause its Affiliates to waive their rights, if any, under contracts with such personnel restricting the ability of such personnel to be recruited or hired by any Service Recipient or designee of any Service Recipient.  Any Service Recipient or any designee of any Service Recipient will have reasonable access to such personnel for interviews and recruitment and GMS shall not interfere, and shall cause its Affiliates to not interfere with any such hiring efforts.  For the avoidance of doubt, the performance of administrative-related tasks by any personnel of GMS or its Affiliates shall not exclude any such personnel from being &#x201c;solely dedicated&#x201d; for purposes of this Section 3.6.3(e).  </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.333%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:5.53844023676832%;display:inline-flex;justify-content:flex-start;">(f)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Continuation of &#x2018;Steady State&#x2019; Services</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  As applicable, each Service Recipient will continue to use the Services during the Disentanglement Period, and such &#x2018;steady state&#x2019; Services will be gradually reduced in accordance with the time frames outlined in the Disentanglement Transition Plan. Client will continue to pay the Fees for any Services received or consumed in accordance with this Agreement that are in effect as of the termination date. </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.333%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:5.53844023676832%;display:inline-flex;justify-content:flex-start;">(g)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Payment for Services with respect to Disentanglement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Client shall pay all Fees for the provision of Services for any Disentanglement.  For clarity, Services with respect to Disentanglement will be performed at no additional cost above the fees specified in the Agreement or applicable SOW unless such tasks require, in GMS&#x2019; reasonable discretion, the use of additional resources beyond the GMS personnel assigned to perform the &#x2018;steady state&#x2019; Services, in which case, such additional resources and rates will be set forth in the Disentanglement Transition Plan and subject to the operation of Section 2.4.  </font></div></div>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">18</font></p></div></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">3.7</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Survival</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  The following provisions shall survive the termination or cancellation of this Agreement or a Statement of Work executed under this Agreement: Sections 3.6, 3.7, 4.5, 4.9, 5.9, 6, 7, 8.1.2, 8.4, 10, 11, 12, 13, 14, 15, 16, 17 and 19.</font></div></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">4.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">GMS REPRESENTATIONS, WARRANTIES, AND CERTAIN AGREEMENTS</font></div></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">4.1</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">General</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  GMS represents and warrants as follows:  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(a)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> it shall act fairly and in good faith in performance of its obligations under this Agreement; </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(b)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> all Services shall be provided in a commercially reasonable and professional and workmanlike manner consistent with applicable Laws and shall meet the applicable specifications as set forth in each relevant SOW and performance standards required under this Agreement in all material respects; </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(c)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> its execution, delivery and performance of this Agreement </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(i)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> has been authorized by all necessary corporate action, </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(ii)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> does not violate the terms of any Law or court order to which GMS is subject, or the terms of any material agreement to which it or any of its assets may be subject, and </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(iii)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> is not subject to the consent or approval of any third party; </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(d)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> upon execution and delivery by both parties, this Agreement is a valid and binding obligation of GMS, enforceable against it in accordance with its terms; </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(e)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> as of the Effective Date, GMS is not the subject to any pending or threatened litigation or governmental action which could reasonably be expected to interfere in any material respect with its performance of its obligations hereunder; </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(f)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> GMS has disclosed to Client any restrictions that may reasonably be expected to adversely affect GMS&#x2019; ability to perform its obligations under this Agreement, which may include existing non-compete agreements, confidentiality agreements, court orders, collective bargaining agreements or pending or threatened litigation; and </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(g)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> without regard to this Agreement, GMS conducts or has conducted, or has otherwise required that background checks be conducted on its and its Affiliates&#x2019; employees and personnel as well as the employees and personnel of Subcontractors at the time of hire or engagement and annually thereafter, which background checks each included and will include </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(i)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> employment and social security verification and criminal background, as permitted by applicable Law, and </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(ii)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> screening to ensure that such employees and personnel are not otherwise excluded from providing Services to any Service Recipient, including through comprehensive pre-hire and required annual screening of exclusion databases at state, federal and international levels (including Federal, OIG, GSA, SAM, OFAC Specially Designated Nationals List, Department of Commerce Denied Persons List, State Medicaid Sanctions List and State Licensing Lists).</font></div></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">4.2</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Non-Citizen Workers</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  GMS represents and warrants that all non-U.S. citizens performing Services in the United States under this Agreement are and shall remain in compliance with U.S. immigration Laws promulgated by the U.S. Bureau of Citizenship and Immigration Services (formerly, the Immigration National Service), including, as applicable, the requirements for I-9 employment eligibility and B-1, H-1, L-1, or TN visa status.  </font></div></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">4.3</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Exclusion from State and Federal Health Care Programs</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  GMS represents and warrants that: </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(a)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(i)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> as of the Effective Date, GMS is not excluded from any State or Federal Health Care Programs or any form of state Medicaid program, </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(ii)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> after reasonable inquiry at the time of employment or engagement or if later the Effective Date, no GMS director, officer, employee or individual otherwise engaged by GMS or any Affiliate of GMS, including any independent contractor is </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(A)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> a &#x201c;sanctioned person&#x201d; under any federal or state health care program or Law, </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(B)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> listed in the current Cumulative Sanction List of the OIG for currently sanctioned or excluded individuals or entities, </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(C)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> listed on the General Services Administration&#x2019;s List of Parties Excluded </font></div></div>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">19</font></p></div></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:4.533%;visibility:hidden;display:inline-flex;justify-content:flex-start;"></font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Individuals or Entities, </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(D)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> listed on the General Services Administration&#x2019;s List of Parties Excluded from Federal Programs, or </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(E)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> convicted of a criminal offense related to health care; </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(b)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> GMS screens all its directors, officers, employees and any individual otherwise engaged by GMS or any Affiliate of GMS, including independent contractors, against the aforementioned lists at the time of hire or engagement, as applicable, and at least annually; </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(c)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> to GMS&#x2019; knowledge, as of the Effective Date, there are no pending or threatened governmental investigations that may lead to GMS being excluded from any State or Federal Health Care Programs or any form of state Medicaid program; and </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(d)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> as of the Effective Date, none of GMS&#x2019; Affiliates or Subcontractors is an &#x201c;excluded provider&#x201d; under any Federal Health Care Program.  If any director, officer, employee or person otherwise engaged by GMS or any Affiliate of GMS, including any independent contractor, any GMS Affiliate or Subcontractor is found on any of the foregoing lists or are convicted of a criminal offense related to health care, they shall immediately stop performing Services and if located at a Service Recipient location, be removed immediately.  If at any time during the Term (i) GMS, any of its Affiliates or Subcontractors is excluded from any State or Federal Health Care Program or any form of State Medicaid program, (ii) any director, officer, employee or person otherwise engaged by GMS or any Affiliate of GMS, including any independent contractor, any GMS Affiliate or Subcontractor is excluded from any State or Federal Health Care Program or any form of State Medicaid program, or (iii) any director, officer, employee or person otherwise engaged by GMS or any Affiliate of GMS, including any independent contractor, any GMS Affiliate or Subcontractor is listed on any of the aforementioned lists, GMS shall promptly, but in no event greater than three (3) business days, notify Client.  If any GMS Affiliate or Subcontractor is confirmed as an &#x201c;excluded provider&#x201d; under applicable governmental standards, GMS shall promptly terminate its use of such Affiliate or Subcontractor and promptly notify Client of the same.  In no event may GMS use any GMS Affiliate or Subcontractor located in any country that is subject to sanctions as determined by the US State Department&#x2019;s Office of Economic Sanctions Policy and Implementation or otherwise employ or engage, or permit any GMS Affiliate or Subcontractor to employ or engage, any individual from any such countries.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">  </font></div></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">4.4</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Compliance</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:2.57143775513484%;display:inline-flex;justify-content:flex-start;">4.4.1</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">GMS represents and warrants that:  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(a)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> it maintains and will continue to maintain throughout the Term a Healthcare Compliance Program that meets the requirements set forth by the OIG; and </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(b)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> GMS has trained its directors, officers, employees and individuals otherwise engaged by GMS or any Affiliate of GMS, including independent contractors, on its Healthcare Compliance Program and shall continue such training throughout the Term.  In connection with the foregoing, GMS shall provide to Client information reasonably requested by Client in writing regarding any aspects of its Healthcare Compliance Program.  </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:2.57143775513484%;display:inline-flex;justify-content:flex-start;">4.4.2</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">If any GMS director, officer, employee or person otherwise engaged by GMS or any Affiliate of GMS, including any independent contractor, identifies and reports what they believe to be a Client-related compliance issue during the performance of the Services, GMS, through its Compliance Officer, will contact the Client Chief Compliance Officer to discuss such matter.  Client, following its compliance policies and procedures, may investigate, address and respond to any Client compliance issue as identified by a GMS director, officer, employee or person otherwise engaged by GMS or any Affiliate of GMS, </font></div></div>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">20</font></p></div></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:2.57143775513484%;visibility:hidden;display:inline-flex;justify-content:flex-start;"></font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">including any independent contractor, and GMS shall reasonably cooperate with any inquiry or investigation conducted by Client&#x2019;s compliance office related to such matter.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></div></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">4.5</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Access to Books and Records</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  During the Term and for a period of six (6) years after the furnishing of the Services, upon written request by the Secretary, the Comptroller, or any of their duly authorized representatives, GMS will make available the contracts, books, documents and records necessary to verify the nature and extent of the costs of providing the Services under this Agreement.  If any of GMS&#x2019; duties set forth in this Agreement (including any SOW) are performed by a GMS Affiliate or through a subcontract with the value of Ten Thousand Dollars ($10,000) or more over a 12-month period, the party subcontracting such duties shall include in or pass through by reference to such Affiliate or in any such subcontract a clause permitting access by the Secretary, the Comptroller, and their representatives to the related Affiliate&#x2019;s or Subcontractor&#x2019;s books and records, as applicable.  This section is included pursuant to and is governed by requirements of 1102 and 1871 of the Social Security Act (42 U.S.C. 1302 and 1395hh) and the regulations in 42 CFR 420-300-420.304.</font></div></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">4.6</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Employment Matters of Client Employees</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  In the event GMS employees are onsite providing Services and a concern arises regarding a Client employee, GMS shall refer any such concerns regarding Client employees to Client&#x2019;s People Services Department.  GMS shall not provide human resources services or legal advice to Client or Client employees.  </font></div></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">4.7</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Employment Laws</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  GMS represents and warrants that, to its knowledge, it is in compliance in all materials respects as of the Effective Date and will remain in compliance in all material respects throughout the Term, with applicable employment laws, employment benefit plans and policies, regulations, rules and ordinances. </font></div></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">4.8</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">WARN Act</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. With respect to GMS personnel, GMS shall be solely and fully responsible for, and Client shall have no responsibility with respect to, GMS&#x2019; compliance with the WARN Act including all WARN Notices, if any, that may be required by the WARN Act.  </font></div></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">4.9</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">LIMITATIONS</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  EXCEPT AS SET FORTH IN SECTION 4 OF THIS AGREEMENT, INCLUDING EXPRESSLY SET FORTH ANY STATEMENT OF WORK, GMS MAKES NO WARRANTY, REPRESENTATION, OR GUARANTEE OF ANY KIND THAT THE SERVICES WILL IDENTIFY COMPLIANCE ISSUES OR FRAUD, GENERATE ANY SPECIFIC PERFORMANCE IMPROVEMENT OR FINANCIAL RESULTS, OR RESULT IN ANY SPECIFIC LEVEL OF IMPROVEMENT IN CLIENT&#x2019;S FINANCIAL PERFORMANCE.  THE FOREGOING REPRESENTATIONS AND WARRANTIES AND THOSE EXPRESSLY SET FORTH IN ANY STATEMENT OF WORK ARE EXCLUSIVE AND IN LIEU OF ALL OTHER REPRESENTATIONS OR WARRANTIES, WHETHER EXPRESS OR IMPLIED, INCLUDING THE IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE.  </font></div></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">5.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">CLIENT REPRESENTATIONS, WARRANTIES AND CERTAIN AGREEMENTS</font></div></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">5.1</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">General</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Client represents and warrants as follows:  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(a)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> it shall act fairly and in good faith in performance of its obligations under this Agreement; </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(b)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> its execution, delivery and performance of this Agreement </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(i)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> has been authorized by all necessary corporate action, </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(ii)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> does not violate </font></div></div>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">21</font></p></div></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:4.533%;visibility:hidden;display:inline-flex;justify-content:flex-start;"></font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">the terms of any Law or court order to which Client is subject, or the terms of any material agreement to which it or any of its assets may be subject; and </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(iii)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> is not subject to the consent or approval of any third party; </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(c)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> upon execution and delivery by both parties, this Agreement is a valid and binding obligation of Client, enforceable against it in accordance with its terms; </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(d)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> as of the Effective Date, Client is not the subject to any pending or threatened litigation or governmental action which could reasonably be expected to interfere in any material respect with its performance of its obligations hereunder; and </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(e)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> Client has disclosed to GMS any restrictions that may reasonably be expected to adversely affect Client&#x2019;s ability to perform its obligations under this Agreement, which may include existing non-compete agreements, confidentiality agreements, court orders, collective bargaining agreements or pending or threatened litigation.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">  </font></div></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">5.2</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Exclusion from State and Federal Health Care Programs</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Client represents and warrants to GMS that as of the Effective Date: </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(a)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(i)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> Client is not excluded from any State or Federal Health Care Programs or any form of State Medicaid program; </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(ii)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> after reasonable inquiry at the time of employment or engagement, no employee or contractor (excluding GMS and personnel engaged or provided by GMS) of Client receiving the Services under this Agreement is </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(A)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> a &#x201c;sanctioned person&#x201d; under any federal or state health care program or Law, </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(B)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> listed in the current Cumulative Sanction List of the OIG for currently sanctioned or excluded individuals or entities, </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(C)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> listed on the General Services Administration&#x2019;s List of Parties Excluded Individuals or Entities, </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(D)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> listed on the General Services Administration&#x2019;s List of Parties Excluded from Federal Programs, or </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(E)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> convicted of a criminal offense related to health care; and </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(b)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> Client screens all its employees and contractors (excluding GMS and personnel engaged or provided by GMS) against the aforementioned lists at the time of hire and at least annually.  If at any time during the Term, </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(i)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> Client is excluded from a State or Federal Health Care Program or any form of State Medicaid program, </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(ii)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> an employee or contractor of Client (excluding GMS or personnel engaged or provided by GMS) is excluded from any State or Federal Health Care Program or any form of State Medicaid program, or </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(c)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> an employee or contractor of Client (excluding GMS or personnel engaged or provided by GMS) is listed on any of the aforementioned lists, Client shall immediately notify GMS.  </font></div></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">5.3</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Accurate Information</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Client represents and warrants that during the Term, Client will use commercially reasonable efforts to provide to GMS, and cause its employees, medical staff and contractors (other than GMS and personnel engaged or provided by GMS) to use commercially reasonable efforts to provide to GMS, accurate and complete data and information, including clinical documentation and claims data that is reasonably necessary for GMS to perform the Services.  </font></div></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">5.4</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">WARN Act</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. With respect to Client employees, it shall be solely and fully responsible for, and GMS shall have no responsibility with respect to, Client&#x2019;s compliance with the WARN Act including all WARN Notices, if any, that may be required by the WARN Act.</font></div></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">5.5</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Compliance</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Client represents and warrants that:  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(a)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> it maintains, and will continue to maintain throughout the Term, a Healthcare Compliance Program that meets the requirements set forth by the OIG; and </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(b)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> Client has trained its employees and contractors (other than GMS and personnel engaged or provided by GMS) on its Healthcare Compliance Program and shall continue such training throughout the Term.  </font></div></div>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">22</font></p></div></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">5.6</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Safe Working Environment</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Client represents and warrants that during the Term it is, and will use commercially reasonable efforts to cause other Service Recipients to be, in compliance in all material respects with all applicable Laws pertaining to work site safety and health, including the Occupational Safety and Health Act (OSHA).</font></div></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">5.7</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Limitation of Authority</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Notwithstanding any other provision, Client shall not cause GMS to:  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(a)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> hire or retain physicians, employees and staff on behalf of any Service Recipient;  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(b)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> determine the financial and compensation terms of Service Recipient relationships with each such physician, employee or staff; </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(c)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> organize or acquire any Affiliate of Client; </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(d)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> adopt or amend an annual capital or operating budget of any Service Recipient; </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(e)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> execute any financial, loan or letter of credit instrument or document; </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(f)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> determine whether any Service Recipient outsources business functions or departments (other than what is contemplated as part of the Services under this Agreement); </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(g)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> adopt or amend any strategic plan for any Service Recipient, including any plan for the governance or structure of any Service Recipient; </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(h)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> involve any Service Recipient in any joint venture, affiliation or management arrangement, including with a hospital or health system; </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(i)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> enter any discussions or negotiations with a collective bargaining unit or contract with a collective bargaining unit or union; </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(j)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> fire any physician, employee or staff of any Service Recipient; </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(k)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> execute any related party agreements of any Service Recipient; or </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(l)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> execute any academic affiliations of any Service Recipient. </font></div></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">5.8</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Employment Laws</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Client represents and warrants that, to its knowledge, Client is in compliance in all material respects as of the Effective Date and will remain in compliance in all material respects throughout the Term, with applicable employment laws, employment benefit plans and policies, regulations, rules and ordinances.  </font></div></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">5.9</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">LIMITATIONS</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  EXCEPT AS SET FORTH IN THIS SECTION 5, INCLUDING EXPRESSLY SET FORTH ANY STATEMENT OF WORK, NEITHER CLIENT NOR ANY OTHER SERVICE RECIPIENT MAKES ANY WARRANTY, REPRESENTATION, OR GUARANTEE OF ANY KIND.  THE FOREGOING REPRESENTATIONS AND WARRANTIES AND THOSE EXPRESSLY SET FORTH IN ANY STATEMENT OF WORK ARE EXCLUSIVE AND IN LIEU OF ALL OTHER REPRESENTATIONS OR WARRANTIES, WHETHER EXPRESS OR IMPLIED, INCLUDING THE IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE.  </font></div></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">6.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">DISPUTE RESOLUTION</font></div></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">6.1</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Any Dispute shall be resolved through the following procedure, which can be initiated by either party delivering a Demand. </font></div></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">6.2</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Subject to Section 6.4, the parties shall first attempt to resolve any Dispute through good&#x2011;faith consultation and negotiation between the leader of the GMS business unit and the designated Client executive, each of whom must possess full authority to resolve the matter for their respective organizations.  Such representatives shall meet promptly, applying commercially reasonable efforts to meet within two weeks (2) after delivery of the Demand.  </font></div></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">6.3</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">If the parties are unable to resolve a Dispute through good-faith negotiations within such two (2) week period, either party may elect to resolve the Dispute in an appropriate federal or state </font></div></div>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">23</font></p></div></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:4.533%;visibility:hidden;display:inline-flex;justify-content:flex-start;"></font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">court in Broward County, Florida, and the parties hereby consent to the jurisdiction of such courts over themselves and the subject matter of such Dispute, and further consent to the venue of Broward County, Florida.  The fullest extent permissible under applicable Law, GMS hereby irrevocably waives any objection of forum non conveniens or any similar objection to the foregoing venue.  The parties unconditionally waive their respective rights to a jury trial in connection with any Dispute.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">  </font></div></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">6.4</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Notwithstanding Section 6.2, neither party shall be required to submit a Dispute to the procedures set forth in Section 6.2 to the extent a party solely seeks injunctive relief from irreparable harm in a state or federal court of competent jurisdiction located in Broward County, Florida. </font></div></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">7.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">CONFIDENTIALITY</font></div></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">7.1</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Confidential Information</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  In connection with this Agreement including, as part of negotiations or due diligence conducted prior to the Effective Date, one party (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Receiving Party</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) may have or will learn, discover or have disclosed to it information from or about the other party (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Disclosing Party</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) or its or its Affiliates&#x2019; (or Service Recipients&#x2019;, in the case of Client) business, finances, plans, operations, software, computer systems, know-how, data, products, technology, processes, techniques, strategies or networks.  All information identified by the Disclosing Party as proprietary or confidential, or that is of a nature that it should reasonably be considered as proprietary or confidential (including intellectual property of a confidential nature such as a trade secret), shall be &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Confidential Information</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; and shall not be disclosed by the Receiving Party to any third party without the express written consent of the Disclosing Party.  The terms of this Agreement constitute Confidential Information of each party.  Client&#x2019;s Confidential Information includes Client Data.  Confidential Information does not include </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(a)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> anything that is known to the Receiving Party prior to the time of first disclosure thereof by the Disclosing Party to the Receiving Party, as identified by Receiving Party&#x2019;s written records, </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(b)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> anything that becomes publicly known or generally known in the industry or profession of either party through no fault of the Receiving Party or its personnel, </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(c)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> anything that is lawfully disclosed by a third party (who did not receive the information directly or indirectly from the Disclosing Party) to the Receiving Party on a nonconfidential basis, or </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(d)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> anything lawfully created by or for the Receiving Party without reference to or use of any of the Disclosing Party&#x2019;s Confidential Information.  The requirements for consent in the second sentence of this Section 7.1 do not apply to disclosure by Client of GMS&#x2019; Confidential Information to Service Recipients.  </font></div></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">7.2</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Obligations</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Each party shall: </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(a)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> treat as confidential all Confidential Information of the other party, and </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(b)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> not disclose or use the other party&#x2019;s Confidential Information except as expressly set forth herein or otherwise authorized by the Disclosing Party in writing.  These restrictions do not apply to any disclosure required by Law or government regulation or by an order of a court or government agency; provided, however, that the Disclosing Party is provided with reasonable advance notice of such disclosure, to the extent practicable (unless the Receiving Party is prohibited by Law or by order of a court or government agency from giving such notice to the Disclosing Party), and thereafter the Receiving Party cooperates with any reasonable request of the Disclosing Party (at the Disclosing Party&#x2019;s expense) to obtain a protective order or to otherwise protect the Confidential Information, including seeking confidential treatment of such information, in which case the Receiving Party shall only disclose such Confidential Information </font></div></div>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">24</font></p></div></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:4.533%;visibility:hidden;display:inline-flex;justify-content:flex-start;"></font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">that it is advised by its counsel in writing that it is legally bound to disclose under such legal requirement.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">  </font></div></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">7.3</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Injunctive Relief</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Failure on the part of Receiving Party to abide by this Section 7 will cause the Disclosing Party irreparable harm for which damages, although available, will not be an adequate remedy at law.  Accordingly, the Disclosing Party has the right to seek preliminary and permanent injunctions to prevent any threatened or actual violations of this Section 7 in addition to all other available and applicable remedies.</font></div></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">7.4</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Consultants</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Notwithstanding anything in this Section 7 to the contrary, each party may disclose the other party&#x2019;s Confidential Information to its employees as well as their directors, advisors, consultants, vendors, service providers, licensors, and other contractors (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Consultants</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), in each case as reasonably needed in connection with the Services.  However, in each such case, the following will apply:</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:2.57143775513484%;display:inline-flex;justify-content:flex-start;">7.4.1</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">the disclosure of Confidential Information will be limited to that which is reasonably needed for the services or solution to be provided by such Consultant;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:2.57143775513484%;display:inline-flex;justify-content:flex-start;">7.4.2</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">each Consultant must agree in writing (which, in the case of a party, need not be specific to the other party) to keep the Confidential Information confidential and to not use the Confidential Information for any purpose other than as necessary in connection with the services or solution to be provided by such Consultant; and</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:2.57143775513484%;display:inline-flex;justify-content:flex-start;">7.4.3</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">each party shall be responsible for their respective employees&#x2019; and Consultants&#x2019; compliance with the confidentiality and use obligations set forth in this Agreement.  </font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">For purpose of this Agreement, Subcontractors are Consultants of GMS.  To the extent an Affiliate is identified as providing Services in a Statement of Work such Affiliate and its employees and personnel are deemed to be Consultants for purpose of this Section 7.4.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">7.5</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Other Agreements</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Confidential Information does not include Protected Health Information (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">PHI</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;).  The definition, management and protection of PHI is specifically set forth in any Business Associate Agreement and nothing in this Section 7 or elsewhere in this Agreement negates, limits or affects of any Business Associate Agreement contemplated by Section 9).</font></div></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">7.6</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Disposal of Confidential Information</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Upon the earliest of: </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(a)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> the Confidential Information (or the relevant portion of it) becoming no longer required for the Receiving Party&#x2019;s performance or exercise of its rights under this Agreement; </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(b)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> termination or expiration of this Agreement; or </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(c)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> the Disclosing Party&#x2019;s written request, the Receiving Party shall securely destroy the Confidential Information of the Disclosing Party (or the relevant portion of it), ensuring it is irrecoverable, unless the Disclosing Party requests in writing the return of its Confidential Information, in which case the Receiving Party shall promptly return it, and promptly certify such destruction or return (as applicable), if so requested.  Notwithstanding the foregoing, a Receiving Party may retain copies of such Confidential Information as required by applicable Laws or, to the extent such copies are electronically stored, in accordance with the Receiving Party&#x2019;s records retention or back-up policies or procedures, so long as they continue to be kept in accordance with the provisions of this Section 7. </font></div></div>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">25</font></p></div></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">8.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">DATA PRIVACY; INFORMATION SECURITY; BACKUP</font></div></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">8.1</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Data Privacy</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:2.57143775513484%;display:inline-flex;justify-content:flex-start;">8.1.1</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">GMS will process Client Data to provide the specified Services in the Agreement and in compliance with all Data Privacy Requirements.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:2.57143775513484%;display:inline-flex;justify-content:flex-start;">8.1.2</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">GMS is prohibited from and represents and acknowledges its understanding that it is prohibited from:  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(a)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> selling, sharing for cross-context behavioral advertising or otherwise disclosing personal information to third parties; </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(b)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> using, retaining, or disclosing personal information for any purpose other than the specified purpose set forth in this Agreement; however, GMS may disclose personal information to a Subcontractor, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> the Subcontractor has executed a written agreement limiting its use, retention, and disclosure of personal information in compliance with this Agreement, and GMS may disclose personal information to an Affiliate of GMS if such Affiliate is authorized to provide Services under a specific SOW and such Affiliate has executed a written agreement limiting its use, retention, and disclosure of personal information in compliance with this Agreement; </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(c)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> using, retaining, or disclosing personal information outside of the direct relationship between GMS and any Service Recipient; and </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(d)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> combining or updating personal information with personal information received from another source, including GMS&#x2019; own direct interaction with an individual, unless expressly permitted by applicable Data Privacy Requirements. </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:2.57143775513484%;display:inline-flex;justify-content:flex-start;">8.1.3</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">If GMS becomes aware or makes a determination that it can no longer meet its obligations under applicable Data Privacy Requirements or this Agreement, it shall promptly notify Client.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:2.57143775513484%;display:inline-flex;justify-content:flex-start;">8.1.4</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">GMS shall provide reasonable assistance with Service Recipients&#x2019; obligations to respond to individuals&#x2019; requests to exercise their rights under applicable Data Privacy Requirements.  </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:2.57143775513484%;display:inline-flex;justify-content:flex-start;">8.1.5</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Upon at least thirty (30) day prior written request from Client from time to time, GMS shall promptly make available to Service Recipients information reasonably necessary to comply with and demonstrate GMS&#x2019; compliance with Data Privacy Requirements, it being understood that the foregoing time period shall be inapplicable to the extent such request is in response to a Regulator.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:2.57143775513484%;display:inline-flex;justify-content:flex-start;">8.1.6</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">In the event of any changes to applicable Data Privacy Requirements, those terms will be viewed as incorporated herein.</font></div></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">8.2</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Information Security Program</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  GMS shall maintain a comprehensive, written information security program that contains administrative, technical, organizational, and physical safeguards to protect the confidentiality, security, integrity and availability of Client Data (such program, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Information Security Program</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) that complies with all Data Privacy Requirements.  For the avoidance of doubt, this includes Client Data stored on Client IT systems, as well as Client Data stored on GMS systems or its service providers.  The security safeguards shall be no less rigorous than those maintained by GMS for its own information of a similar nature.  GMS shall provide </font></div></div>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">26</font></p></div></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:4.533%;visibility:hidden;display:inline-flex;justify-content:flex-start;"></font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">evidence of this plan to Client for its review.  The Information Security Program shall contain at least the following elements:</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">    </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:2.57143775513484%;display:inline-flex;justify-content:flex-start;">8.2.1</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">the designation of one or more employees to maintain the Information Security Program;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:2.57143775513484%;display:inline-flex;justify-content:flex-start;">8.2.2</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">the identification and assessment of reasonably foreseeable internal and external risks, and development of safeguards to protect against such risks; </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:2.57143775513484%;display:inline-flex;justify-content:flex-start;">8.2.3</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">the equivalent oversight of any GMS service providers by requiring such third-party service providers by contract to implement and maintain equivalent security measures;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:2.57143775513484%;display:inline-flex;justify-content:flex-start;">8.2.4</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">continuous monitoring of software, systems, and processes used by GMS; </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:2.57143775513484%;display:inline-flex;justify-content:flex-start;">8.2.5</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">specific secure user authentication protocols;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:2.57143775513484%;display:inline-flex;justify-content:flex-start;">8.2.6</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">specific secure access control measures, including requiring multi-factor authentication and regular review of account access to Client Data to ensure proper provisioning and deprovisioning of user access;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:2.57143775513484%;display:inline-flex;justify-content:flex-start;">8.2.7</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">encryption of all personal information and PHI </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(i)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> transmitted across public networks, </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(ii)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> transmitted wirelessly, and </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(iii)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> stored on laptops or other portable devices, including backup media;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:2.57143775513484%;display:inline-flex;justify-content:flex-start;">8.2.8</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">commercially reasonable up-to-date firewall protection, operating system security patches, and system security agent software; </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:2.57143775513484%;display:inline-flex;justify-content:flex-start;">8.2.9</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">appropriate ongoing security and privacy education of GMS personnel; </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:2.57143775513484%;display:inline-flex;justify-content:flex-start;">8.2.10</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">annual reviews of the Information Security Program by GMS and Client with modifications made to ensure safeguards are in place to respond to developing external threats and regulatory requirements (including prompt remediation of any critical- or high-rated vulnerabilities); </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:2.57143775513484%;display:inline-flex;justify-content:flex-start;">8.2.11</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">at least annual penetration testing by qualified, in accordance with recognized commercial standards, independent third parties of systems used by or on behalf of GMS in the performance of the Services and discussion of the results of the same with Client (including sharing of executive summaries of such testing) as well as prompt remediation of any critical- or high-rated vulnerabilities; and</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:2.57143775513484%;display:inline-flex;justify-content:flex-start;">8.2.12</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">third-party annual certification of compliance with these requirements or an annual international information security standard certification Client deems equivalent.  </font></div></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">8.3</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Questionnaires</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Client requires its service providers to complete periodic (but not more than once per year, except in the event of a Security Event) security and compliance questionnaires (and any follow-up questions) as a part of its ongoing vendor management protocols.  GMS completed this questionnaire and provided it to Client on or prior to the Effective Date, and </font></div></div>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">27</font></p></div></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:4.533%;visibility:hidden;display:inline-flex;justify-content:flex-start;"></font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">represents and warrants that the responses contained therein are complete and correct as of the date they were provided, and that GMS will comply with the controls described in response to each questionnaire on an ongoing basis during the Term.  GMS shall promptly, fully and accurately, to the best of its knowledge at that time, respond to all such questionnaires (and follow-up questions).</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">    </font></div></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">8.4</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Security Events</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  GMS shall provide notice to Client of any reasonably suspected or actual Security Event within 24 hours after GMS becomes aware of such reasonably suspected or actual Security Event.  Upon notice, GMS shall fully cooperate with Client and other Service Recipients to respond to and remediate any such Security Event, including providing all relevant information, to the extent known, about the Security Event, as well as assisting in investigating and other reasonably requested support.  Subject to Section 11, GMS shall be responsible for the cost of remediating any such Security Event, and shall reimburse each Service Recipient to the extent caused by or attributable to GMS for the following incurred costs:  </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:2.57143775513484%;display:inline-flex;justify-content:flex-start;">8.4.1</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">the preparation and mailing or other transmission of notification to data subjects, governmental authorities, the media, or any other third party regarding the Security Event; </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:2.57143775513484%;display:inline-flex;justify-content:flex-start;">8.4.2</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">the performance of any security review in connection with the Security Event; </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:2.57143775513484%;display:inline-flex;justify-content:flex-start;">8.4.3</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">the portion of any fine or other monetary penalty imposed on any Service Recipient by a governmental authority or third party pertaining to the Security Event; </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:2.57143775513484%;display:inline-flex;justify-content:flex-start;">8.4.4</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">reasonable attorneys&#x2019; fees and expenses for addressing any Service Recipient&#x2019;s obligations related to the Security Event; </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:2.57143775513484%;display:inline-flex;justify-content:flex-start;">8.4.5</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">call center expenses needed to respond to inquiries from data subjects related to the Security Event; </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:2.57143775513484%;display:inline-flex;justify-content:flex-start;">8.4.6</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">credit monitoring and/or credit or identity repair services; and the provision of identity theft insurance for data subjects affected by the Security Event in relation to personal information and/or PHI for a period of at least two (2) years; the performance of a forensic investigation regarding the Security Event; and </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:2.57143775513484%;display:inline-flex;justify-content:flex-start;">8.4.7</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">other remediation expenses and reasonable assistance to data subjects or third parties as required to comply with applicable Law.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Additionally, GMS shall take such actions as may be reasonably requested by Client to understand and minimize the effects of any Security Event, including steps to secure Client Confidential Information and PHI and to determine the scope of the Security Event in a commercially reasonable manner, at GMS&#x2019; expense subject to Section 11.  Notwithstanding the foregoing, to the extent Client so elects, and to the extent permitted by applicable Law, GMS shall in consultation with Client, perform the activities contemplated by this Section 8.4 in its own name and at its own expense, subject to Section 11.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">8.5</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Viruses and Disabling Devices</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> GMS shall use industry leading practices to regularly identify, screen, and prevent any Disabling Device in resources used or accessed by GMS or any Service Recipient (if accessed or managed by GMS) in connection with the provision or receipt of the Services and shall not itself knowingly or intentionally install (and shall prevent its Affiliates </font></div></div>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">28</font></p></div></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:4.533%;visibility:hidden;display:inline-flex;justify-content:flex-start;"></font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">and Subcontractors from knowingly and intentionally installing) any Disabling Device in resources used by GMS, any Service Recipient, or any GMS Affiliate or Subcontractor, in connection with the provision or receipt of the Services.  For the avoidance of doubt, this includes introducing a Disabling Device on any Service Recipient IT systems.  A &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Disabling Device</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; is a virus, timer, clock, counter, time lock, time bomb, or other limiting design, instruction, or routine that would purposely and inappropriately erase data or programming or cause any resource to become inoperable or otherwise incapable of being used in the full manner for which such resource was intended to be used.  GMS shall assist each Service Recipient in reducing and mitigating the effects of any Disabling Device discovered in any resource related to the provision or receipt of the Services, especially if such Disabling Device is causing a loss of operating efficiency or data.  Timers, clocks, counters, and time locks included as part of any commercial software by the manufacturer of that software shall not be considered Disabling Devices for purposes of this Section 8.5.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">  </font></div></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">8.6</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">International Processing</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  GMS shall not process, or permit any third party to process, any Client Confidential Information or PHI outside of the United States or otherwise move such Confidential Information or PHI outside of the United States or across any national borders, except as expressly permitted by Client in this Agreement.  GMS shall ensure that the processing of personal information outside of the GMS shall not access, store, or process&#x2014;or permit any third party to access, store, or process&#x2014;any Client Data outside of the United States or otherwise move such Client Data outside of the United States or across any national borders, except as expressly permitted by Client in this Agreement.  GMS shall ensure that the processing of personal information outside of the United States, if any is permitted in this Agreement, complies with the data protection Laws applicable to the relevant jurisdictions including, where relevant, applicable European Laws relating to privacy and/or data protection which are applicable to either party, including: </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(a)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> the EU e-Privacy Directive 2002/58/EC as implemented by countries within the European Economic Area (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">EEA</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;); </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(b)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> the EU General Data Protection Regulation (EU) 2016/679 (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">GDPR</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) as implemented by countries within the EEA; and </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(c)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> other Laws that are similar, equivalent to, or successors to the Laws that are identified in (a) and (b) above.  Outside of the United States and the EEA, GMS shall provide the following enhanced security elements:  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(i)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> implementation of enhanced physical security measures including the use of electronic access controls, CCTV, and intrusion detection systems; </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(ii)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> logical separation of Client Data from the data of GMS and GMS&#x2019; other customers; </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(iii)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> prohibition on functioning drives and ports by which Client Data could be copied or saved onto portable electronic media; </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(iv)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> prohibition on any local subcontracting of the processing of Client Data; and </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(v)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> prohibition on access to personal email and personal Internet access at any workstation capable of accessing Client Data.  As used in this Section 8.6, the term &#x201c;process&#x201d; (and its corollaries) shall have the meaning set forth in applicable data protection Laws.  For avoidance of doubt, to the extent set forth in a Statement of Work, GMS may use its offshore Affiliates in India, subject to prohibitions or limitations imposed by Federal, State, hospital and payor restrictions and obligations.  </font></div></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">8.7</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Backup and Disaster Recovery</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  GMS shall commit to establish and regularly test its backup (including validation) and disaster recovery procedures; such disaster recovery procedures to contain agreed upon RPO and RTO commitments and annual testing paradigms.</font></div></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">8.8</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Access to and Use of Service Recipient Systems</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  GMS shall comply with Client&#x2019;s access and credentialing processes in relation to access and use of Client&#x2019;s systems.  </font></div></div>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">29</font></p></div></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">9.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">BUSINESS ASSOCIATE AGREEMENT</font></div></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">9.1</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Without limiting the mutual confidentiality obligations herein, contemporaneously with the execution and delivery of this Agreement, GMS and Client shall execute and deliver that certain Business Associate Agreement attached hereto as </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 2</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  </font></div></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">10.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">INDEMNIFICATION</font></div></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">10.1</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Indemnification by GMS</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  GMS shall indemnify, defend and hold harmless Client, its Affiliates, Service Recipients, and its and their respective officers, directors, employees, subcontractors and agents (each, a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Client Indemnitee</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) from and against any Losses and Expenses to the extent arising from any third-party Claims alleged or filed against any Client Indemnitee whereby such Claim arose from: </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:2.57143775513484%;display:inline-flex;justify-content:flex-start;">10.1.1</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">[***]; </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:2.57143775513484%;display:inline-flex;justify-content:flex-start;">10.1.2</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">[***]; </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:2.57143775513484%;display:inline-flex;justify-content:flex-start;">10.1.3</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">[***]; </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:2.57143775513484%;display:inline-flex;justify-content:flex-start;">10.1.4</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">[***];  </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:2.57143775513484%;display:inline-flex;justify-content:flex-start;">10.1.5</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">[***];</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:2.57143775513484%;display:inline-flex;justify-content:flex-start;">10.1.6</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">[***]; </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:2.57143775513484%;display:inline-flex;justify-content:flex-start;">10.1.7</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">[***]; and/or</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:2.57143775513484%;display:inline-flex;justify-content:flex-start;">10.1.8</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">[***].</font></div></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">10.2</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Indemnification by Client</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Client shall indemnify, defend and hold harmless GMS, its Affiliates, Subcontractors and its and their respective officers, directors, employees and agents (each, a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">GMS Indemnitee</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) from and against any Losses and Expenses to the extent arising from any third-party Claims alleged or filed against any GMS Indemnitee whereby such Claim arose from:</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:2.57143775513484%;display:inline-flex;justify-content:flex-start;">10.2.1</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">[***]; and/or</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:2.57143775513484%;display:inline-flex;justify-content:flex-start;">10.2.2</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">[***]. </font></div></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">10.3</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Indemnification Procedures</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  If any Claim governed by this Section 10 is threatened or commenced against any Client Indemnitee or GMS Indemnitee (as applicable, an &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Indemnitee</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), such Indemnitee shall give notice thereof to GMS or Client (as applicable, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Indemnitor</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) promptly after such Claim is threatened or commenced; </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">however</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">, that failure to give prompt notice shall not reduce the Indemnitor&#x2019;s obligations under this Section 10 except to the extent the Indemnitor is prejudiced thereby.  After such notice, if the Indemnitor acknowledges in writing to the Indemnitee and the other party that the right of indemnification under this Agreement applies with respect to such Claim, then the Indemnitor shall be entitled, if it so elects in a notice </font></div></div>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">30</font></p></div></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:4.533%;visibility:hidden;display:inline-flex;justify-content:flex-start;"></font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">delivered to the Indemnitee and the other party not fewer than [***] days prior to the date on which a response to such Claim is due (except to the extent the Indemnitee failed to provide the Indemnitor at least [***] days&#x2019; notice prior to the date on which a response to such Claim is due) to take control of the defense and investigation of such Claim and to employ and engage attorneys of its choice that are reasonably satisfactory to the other party to handle and defend same, at the Indemnitor&#x2019;s expense.  The applicable Indemnitee shall cooperate in all reasonable respects with the Indemnitor and its attorneys in the investigation, trial and defense of such Claim and any appeal arising therefrom; </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">however</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">, that the applicable Indemnitee and the other party may participate, at its and their own expense, on a monitoring, non-controlling basis (solely to the extent the parties&#x2019; interests are aligned), through its or their attorneys or otherwise, in the investigation, trial and defense of such Claim and any appeal arising therefrom.  No settlement of a Claim that involves a remedy other than the payment of money by the applicable Indemnitee shall be entered into by the Indemnitor without the other party&#x2019;s prior written consent, which consent may be withheld in such other party&#x2019;s sole discretion.  If an Indemnitor does not assume the defense of a Claim subject to defense as provided in this Section 10, the Indemnitor may participate in such defense, at its expense, on a monitoring, non-controlling basis, and the other party shall have the right to defend, compromise or settle the Claim in such manner as it may deem appropriate, at the Indemnitor&#x2019;s expense.</font></div></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">11.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">LIMITATION OF LIABILITY; DISCLAIMER OF DAMAGES </font></div></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">11.1</font><div style="width:100%;display:inline;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Limitation of Liability</font><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  NOTWITHSTANDING THE TERMS OF ANY OTHER PROVISION OF THIS AGREEMENT OTHER THAN SECTION 11.3, except as set forth in Section 11.3, the total liability, including Losses and Expenses, of a party arising out of or relating to this Agreement AND THE BUSINESS ASSOCIATE AGREEMENT, whether in contract, tort or otherwise shall be limited to and not exceed the greater of: </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(a)</font><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> all Fees and expenses paid by any service recipient in the applicable Statement of Work during the [***] immediately preceding the event from which LIABILITY arose; OR </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(b)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">[***]. </font></div></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">11.2</font><div style="width:100%;display:inline;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Disclaimer of Damages</font><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Except as set forth in SectionS 11.3 and 11.4, [***].  </font></div></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">11.3</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Limitation of Liability and Disclaimer of Damages Exceptions</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Notwithstanding Sections 11.1 and 11.2, the limitation of liability set forth in Section 11.1 and the disclaimer of damages set forth in Section 11.2 shall not apply to:</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:2.57143775513484%;display:inline-flex;justify-content:flex-start;">11.3.1</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> [***];</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:2.57143775513484%;display:inline-flex;justify-content:flex-start;">11.3.2</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">[***]; and/or</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:2.57143775513484%;display:inline-flex;justify-content:flex-start;">11.3.3</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">[***].</font></div></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">11.4</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Disclaimer of Damages Exceptions</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:2.57143775513484%;display:inline-flex;justify-content:flex-start;">11.4.1</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">[***].  </font></div></div>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">31</font></p></div></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:2.57143775513484%;display:inline-flex;justify-content:flex-start;">11.4.2</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">[***].  </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:2.57143775513484%;display:inline-flex;justify-content:flex-start;">11.4.3</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">[***].  </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:2.57143775513484%;display:inline-flex;justify-content:flex-start;">11.4.4</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">[***].  </font></div></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">12.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">INSURANCE REQUIREMENTS</font></div></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">12.1</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">By GMS</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  GMS shall obtain and maintain throughout the Term insurance coverage reasonably acceptable to Client.  GMS shall provide evidence of such insurance coverage at the time of the execution and delivery of this Agreement and upon reasonable written request thereafter (no more frequently than annually).  </font></div></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">12.2</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">By Client</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Client shall obtain and maintain throughout the Term insurance coverage reasonably acceptable to GMS.  Client shall provide evidence of such insurance coverage at the time of the execution and delivery of this Agreement and upon reasonable written request thereafter (no more frequently than annually).  </font></div></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">12.3</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The insurance coverage limits identified pursuant to the processes set forth in Sections 12.1 and 12.2 may be provided through a combination of primary and umbrella/excess insurance.  Any umbrella/excess form must provide terms and conditions equal to or broader than the primary insurance. </font></div></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">12.4</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">For any policy written on a claims made basis, coverage must be maintained for a period of not less than ten years, if available, beyond the termination of this Agreement. </font></div></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">12.5</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Commercial insurance must be written with a carrier licensed to do business in the State of Florida and carrying an A.M. Best rating of A- VII or higher. </font></div></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">12.6</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Upon written request, each party will promptly furnish the other party with certificates of insurance evidencing coverage requirements identified pursuant to the processes set forth in Sections 12.1 and 12.2.  </font></div></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">12.7</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Each party will notify the other as soon as practical in the event of cancellation, non-renewal or material change in any of the insurance coverages required to be maintained pursuant to the processes set forth in Sections 12.1 and 12.2.  </font></div></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">13.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">INDEPENDENT CONTRACTOR; NO CORPORATE PRACTICE OF MEDICINE; NO REFERRALS</font></div></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">13.1</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The relationship between Client, on the one hand, and GMS, on the other hand, shall be that of independent contractors, and nothing in this Agreement is intended to create, nor shall be construed to create, any partnership, joint venture, agency, employment or joint employment relationship between or among such parties and/or their respective personnel.</font></div></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">13.2</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Notwithstanding any other term herein or in any exhibits, schedules, appendices or attachments hereto, </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(a)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> Service Recipients &#x2018;affiliated physicians, clinicians and other professional staff (collectively, &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Medical Professionals</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), shall retain the sole authority and the sole obligation </font></div></div>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">32</font></p></div></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:4.533%;visibility:hidden;display:inline-flex;justify-content:flex-start;"></font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">to direct all of the medical, professional, and ethical aspects of Medical Professionals, and </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(b)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> all matters pertaining to Medical Professionals, including clinical matters, quality of care issues, and matters pertaining to the care delivered to patients shall, as between the parties hereto, remain the sole obligation of Service Recipients&#x2019; Medical Professionals and other providers.  GMS shall not exercise control over or interfere with the physician-patient relationship maintained between Service Recipients&#x2019; Medical Professionals and their patients, which relationship shall be maintained strictly between the applicable Medical Professionals and their patients.  GMS shall not interfere with, control, direct, or supervise Service Recipients&#x2019; personnel or any of their Medical Professionals in connection with the provision of medical or ancillary services by any such personnel or Medical Professionals.  To the extent that any act or Service set forth in this Agreement as required to be performed or provided by GMS is alleged by a third party, construed by a court of competent jurisdiction or by the appropriate licensure bureau or division in Florida to constitute the practice of medicine, </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(i)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> the requirement that GMS perform or provide such act or Service shall be deemed waived and unenforceable, </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(ii)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> the parties shall determine and, if applicable implement an equitable reduction of Fees payable in respect of such acts or Services, and </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(iii)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> notwithstanding any such unenforceability, subject to the foregoing, all other terms and provisions of this Agreement shall remain fully enforceable and in full force and effect.</font></div></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">13.3</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Nothing contained in this Agreement, including the benefits delivered by one party to another party hereunder, shall be construed as a solicitation, offer or payment by one party to another party (or its Affiliates) of cash or other remuneration, directly or indirectly, in exchange for, as a requirement for, or in any way contingent upon, the admission, referral or any other arrangement or recommendation of orders for the furnishing of any item or service, including any &#x201c;designated health services&#x201d; (as such term is defined 42 U.S.C. &#167; 1395nn, et seq., and the regulations promulgated thereunder) to any patients of any health care practice, provider or facility, owned, managed or operated by GMS or its Affiliates (to the extent applicable) or any other person or entity.  </font></div></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">14.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">INTELLECTUAL PROPERTY AND RIGHTS TO DELIVERABLES</font></div></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">14.1</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Client Ownership</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:2.57143775513484%;display:inline-flex;justify-content:flex-start;">14.1.1</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">All materials, policies, processes, know-how, methodologies, software, and deliverables (including reports), and all inventions and copyrightable materials contained therein which GMS, any GMS Affiliate or any Subcontractor prepares or develops for any Service Recipient in the performance of the Services (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Client IP</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) shall be the exclusive property of Client, subject to GMS rights to use the same solely to perform the Services under this Agreement.  GMS hereby assigns all right, title and interest in and to any such Client IP to Client.  GMS shall execute, and shall cause its Affiliates and Subcontractors to execute, all documents and take all steps requested by Client in writing, at Client&#x2019;s expense, which Client deems necessary or desirable to complete and perfect Client&#x2019;s ownership and property rights in any Client IP, it being understood that execution of any documents shall be undertaken by such parties at no expense to Client (travel expenses, if any, excluded).  For the avoidance of doubt, all materials, policies, processes know-how, methodologies, software and deliverables and all inventions and copyrightable materials contained therein created by any Service Recipient prior to the Effective Date or independent of this Agreement shall be owned by the applicable Service Recipient.  </font></div></div>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">33</font></p></div></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:2.57143775513484%;display:inline-flex;justify-content:flex-start;">14.1.2</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">As between the parties, all data accessed or generated or otherwise processed by GMS in the performance of the Services (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Client Data</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) shall be owned by Client.  For the avoidance of doubt, Client Data includes all Client Confidential Information and PHI.  GMS hereby assigns, and shall cause its Affiliates and Subcontractors to hereby assign, all right, title and interest in and to any such Client Data to Client.  GMS shall execute, and shall cause its Affiliates and Subcontractors to execute, all documents and take all steps requested by Client in writing, at Client&#x2019;s expense, which Client deems necessary or desirable to complete and perfect Client&#x2019;s ownership and property rights in any Client Data, it being understood that execution of any documents shall be undertaken by such parties at no expense to Client (travel expenses, if any, excluded).  GMS shall only use Client Data to provide the Services.  </font></div></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">14.2</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">GMS Ownership</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Subject to Section 14.1, all materials, policies, processes, know-how, work papers (except to the extent such work papers include Client Confidential Information or PHI), methodologies, inventions and copyrightable materials contained therein, data, software and other materials, including computer programs, software as a service, reports and specifications, provided by or used by GMS in connection with performing the Services, in each case </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(a)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> developed or acquired by GMS prior to the commencement of this Agreement, or </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(b)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> developed or acquired during the Term that is </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(i)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> of general application and does not rely upon, contain or is based upon any Client IP, Client Data or Confidential Information of Client, or </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(ii)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> independent of this Agreement, including all intellectual property rights therein is the exclusive property of GMS (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">GMS IP</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), subject to Service Recipients&#x2019; right to use GMS IP for internal use during the Term.  </font></div></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">15.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">RESPONSIBILITY TO OWN EMPLOYEES</font></div></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">15.1</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Of Client</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:2.57143775513484%;display:inline-flex;justify-content:flex-start;">15.1.1</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">As between the parties, Client has the sole and exclusive responsibility to provide its employees any salary, compensation or other benefits and to make all appropriate tax, social security, Medicare and other withholding deductions and payments for all Client employees, including the following: </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(a)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> federal income tax withholding (including Form 941 and Form W-2 filing requirements); </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(b)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> state and/or local income tax withholding; </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(c)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> Federal Insurance Contributions Act (FICA); and </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(d)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> Federal and State Unemployment Tax Acts (FUTA and SUTA) (including Form 940 and state filing requirements).  Client employees shall not be entitled to holiday, vacation or disability pay, or any other benefits offered or provided by GMS to its employees.  </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:2.57143775513484%;display:inline-flex;justify-content:flex-start;">15.1.2</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Client maintains such employee benefit plans and policies for Client employees as Client deems necessary in the sole exercise of its discretion.    </font></div></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">15.2</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Of GMS</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:2.57143775513484%;display:inline-flex;justify-content:flex-start;">15.2.1</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">As between the parties, GMS has the sole and exclusive responsibility to provide its employees any salary, compensation or other benefits and to make all appropriate tax, social security, Medicare and other withholding deductions and payments for all GMS employees, including the following: </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(a)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> federal income tax withholding (including Form 941 and Form W-2 filing requirements); </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(b)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> state and/or local income tax withholding; </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(c)</font></div></div>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">34</font></p></div></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:2.57143775513484%;visibility:hidden;display:inline-flex;justify-content:flex-start;"></font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> Federal Insurance Contributions Act (FICA); and </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(d)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> Federal and State Unemployment Tax Acts (FUTA and SUTA) (including Form 940 and state filing requirements).  GMS employees shall not be entitled to holiday, vacation or disability pay, or any other benefits offered or provided by Client to its employees.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">  </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:2.57143775513484%;display:inline-flex;justify-content:flex-start;">15.2.2</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">GMS maintains such employee benefit plans and policies for GMS employees as GMS deems necessary in its sole discretion.</font></div></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">16.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">RECORDKEEPING AND AUDITS</font></div></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">16.1</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Recordkeeping</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:2.57143775513484%;display:inline-flex;justify-content:flex-start;">16.1.1</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">General Obligations</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  GMS shall maintain true, complete, and accurate records and books of account with respect to GMS&#x2019; performance of the Services (including records or books relating to invoicing, operational activities and service performance metrics) that use generally accepted accounting principles (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">GAAP</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) and are in compliance in all material respects with all applicable Laws. Such records and books of account, and the accounting controls related thereto shall be: </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(a)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> accessible and available to Client upon at least thirty (30) days advance notice in order to conduct the audits set forth in this Agreement; and </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(b)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> maintained by GMS at a principal business location reasonably acceptable to Client.  If GMS ceases to exist as a legal entity, such records and books pertaining to this Agreement shall be forwarded to the surviving entity in a merger or acquisition, or in the event of liquidation, to Client.  GMS shall retain for a period of seven (7) years after the date of creation of records for Services rendered hereunder (including any Services with respect to Disentanglement), or such longer period as may be required by applicable Law, all records and information required to verify amounts invoiced under this Agreement and GMS&#x2019; and its Subcontractors&#x2019; compliance with applicable Law in its performance under this Agreement.  The obligations and requirements of this Section 16.1.1 shall apply to all Subcontractors. </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:2.57143775513484%;display:inline-flex;justify-content:flex-start;">16.1.2</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Access and Remedy</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Each Service Recipient, or each Service Recipient&#x2019;s Auditors, who shall not be direct competitors of GMS, shall be granted access to the aforesaid records for the purpose of verifying the accuracy of GMS&#x2019; invoicing and contractual compliance, upon at least thirty (30) days advance notice to GMS and in such a manner so as not to interfere with GMS&#x2019; operations.  All such audits and verifications, notwithstanding anything to the contrary elsewhere in this Agreement, shall not include access to GMS, any GMS Affiliate&#x2019;s or Subcontractor&#x2019;s Confidential Information except to the extent necessary to confirm the accuracy of GMS&#x2019; invoices or the extent of GMS&#x2019; legal and contractual compliance.  Subject to the foregoing, GMS shall grant each Service Recipient and its representatives commercially reasonable access to the relevant portion of GMS&#x2019; books, records, documents, data, or information, and, with the prior consent of GMS (which will not be unreasonably withheld, conditioned or delayed), access to relevant GMS personnel, as they relate to amounts invoiced, invoices submitted, or the extent of GMS&#x2019; compliance with this Agreement, or as such access to personnel, books, records, documents, data, and information may be required (excluding any internal costs or other customer information) in order for each Service Recipient to ascertain any facts relevant to </font></div></div>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">35</font></p></div></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:2.57143775513484%;visibility:hidden;display:inline-flex;justify-content:flex-start;"></font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">determining the accuracy of GMS&#x2019; invoicing hereunder, including facts with regard to verification of Fees (and components and calculations thereof).</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></div></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">16.2</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Financial Audits</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Each Service Recipient (or each Service Recipient&#x2019;s Auditors), at each Service Recipient&#x2019;s cost and expense, may conduct an examination of GMS&#x2019;, its Affiliates&#x2019; and Subcontractors&#x2019; Fees and invoices to verify the accuracy of invoices, Fees charged, and payments collected hereunder.  All such audits shall be conducted with at least thirty (30) days advance notice.  If any such Fees audit reveals an overcharge (net of any undercharges) to Service Recipients with respect to the Fees, then GMS shall review and if it agrees with the findings: </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(a)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> GMS shall promptly refund such overcharge or issue to Client or its designee a credit for such overcharge; and </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(b)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> if such overcharge represents, as to any invoice(s), more than [***] percent ([***]%) of the amounts that should have been charged under such invoice(s), then GMS shall promptly refund to Client or its designee, or issue to Client or its designee a credit for, an amount equal to the reasonable cost of the audit.  If GMS disagrees with any such findings, it shall notify Client in writing of the same within thirty (30) days after receipt of such findings identifying with specificity its disagreement and the parties shall make a good faith effort to resolve such Dispute through the applicable Governance Procedures prior to taking additional actions permissible under this Agreement or applicable Law.  </font></div></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">16.3</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Third Party Audit</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  If any Service Recipient or GMS is required to disclose any books and records to any third party related to this Agreement in connection with an audit by any such third party, the notified party shall promptly notify the other party of the nature and scope of such third party request and shall cooperate and make available, to the extent permitted by Law, all of the books and records disclosed in connection with the third party audit.</font></div></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">16.4</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Audits and Findings</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  To the extent a Service Recipient receives a PEPPER report, CERT Letter or any other commercial or government payor report or correspondence, the subject of which relates to the Services, Client shall </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(a)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> promptly notify GMS of the receipt of such reports, </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(b)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> share with GMS the results of any audits or inquiry related to the data presented in such reports, and </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(c)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> allow GMS to participate in any corrective action plans that relate to the Services.  </font></div></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">16.5</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Operational and Security Audits</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Service Recipients (or Service Recipients&#x2019; Auditors), at Service Recipients&#x2019; cost and expense, may engage such Auditors as the same shall deem appropriate to participate in operational and/or security audits (excluding penetration testing).  Any such operational and/or security audit shall be conducted in a reasonable manner upon at least thirty (30) days advance notice.  If any such audit reveals an inadequacy or insufficiency of GMS&#x2019; performance, including performance in connection with any operational or security obligations of GMS as set forth in this Agreement, GMS shall promptly develop and provide to Client a reasonable and detailed corrective action plan and promptly thereafter implement such plan in accordance with its terms. </font></div></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">16.6</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Provision of GMS Audit Reports</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  GMS shall provide Client, annually, with a copy of the report of an independent audit conducted in relation to the systems, procedures and internal controls of GMS, its Affiliates and Subcontractors, and their respective compliance with the requirements of this Agreement.  Such report shall take the forms of: </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(a)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> a Statement on Standards for Attestation Engagements (SSAE), System and Organization Controls (SOC1 or SOC2), Type II Report (covering the most recent 12-month period); </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(b)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> an International Standard on Assurance </font></div></div>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">36</font></p></div></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:4.533%;visibility:hidden;display:inline-flex;justify-content:flex-start;"></font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Engagements (ISAE) No. 3402, Assurance Report on Controls at a Service Organization, Type II Report (covering the most recent 12-month period); or </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(c)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> a current International Organization for Standardization (ISO) 27001 Certificate; and </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(d)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> a current ISO 23001 Certificate (unless submitting a SOC2 report (above) covering &#x2018;Availability&#x2019; and &#x2018;Integrity&#x2019; trust principles); and </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(e)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> a NIST 800-171 attestation; or </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(f)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> with Client&#x2019;s approval, an equivalent of any of the foregoing reports or certificates.  If requested in writing by any Regulator, GMS shall also provide a copy of the auditor&#x2019;s associated working papers except to the extent such working papers are subject to a valid privilege claim.  Additionally, Client and/or any Regulator may require GMS, its Affiliates and/or any Subcontractors to expand the scope of such report or provide other information or cooperation and GMS shall, and shall procure that each of its Affiliates and Subcontractors shall, promptly do so.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></div></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">16.7</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Client and Regulator Audit Rights</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  GMS shall, and shall procure that each of its Affiliates and Subcontractors shall throughout the Term and for 12 months thereafter: </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(a)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> allow Client to conduct (either itself or through a third party) an on-site audit of: </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(i)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> GMS&#x2019;, its Affiliates&#x2019; and/or Subcontractors&#x2019; systems, procedures and internal controls used, and records kept, in connection with its provision of any Services (including the right to take copies of such records); and </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(ii)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> GMS&#x2019;, its Affiliates&#x2019; and/or Subcontractors&#x2019; compliance with the requirements of this Agreement; and </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(b)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> provide access to GMS personnel and its external Auditors and all reasonable cooperation in connection with any such audit.  GMS shall, and shall procure that each of its Affiliates and Subcontractors shall, allow any Regulator (either itself or through a third party) to exercise the same rights to audit (and be given the same access and cooperation) as set out above.  Any audit shall be conducted during normal business hours and upon at least thirty (30) days advance notice, unless a Regulator requires shorter notice or in the case of investigations of reasonable suspicion of fraud or business irregularities of a potentially criminal nature, or relating to Client&#x2019;s or any other Service Recipient&#x2019;s data protection requirements. </font></div></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">16.8</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Corrective Actions</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  If, following any audit, Client notifies GMS that GMS or its relevant Affiliate or Subcontractor is non-compliant with any provisions of this Agreement, GMS shall, or shall procure that such Affiliate or Subcontractor (as applicable) shall, promptly make all necessary changes to ensure compliance.  Failure to promptly make all necessary changes to ensure compliance shall be a material breach of this Agreement.    </font></div></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">17.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">NON-SOLICITATION</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Unless otherwise specified in a SOW, Client and GMS agree that, during the Term and for a period of [***] following termination or expiration of the Agreement, neither party will, except with the other party&#x2019;s prior written approval, directly or indirectly through a third party, solicit or hire any employee or staff member of such other party including employees of Client or GMS, respectively.  Nothing contained herein will prohibit any party from employing an individual who responds to a general advertisement for employment (whether or not made by a professional search firm).</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">   </font></p>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">18.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">AFFILIATES; SUBCONTRACTORS</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">In connection with each Statement of Work, GMS shall obtain Client&#x2019;s prior written consent to GMS&#x2019; use of any Affiliates or Subcontractors in the performance of the Services, such consent shall not be unreasonably withheld.  Identification of any Affiliate or Subcontractor in a fully</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">37</font></p></div></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">executed SOW shall be deemed written consent, subject to prohibitions or limitations imposed by Federal, State, hospital and payor restrictions and obligations.</font></p>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">19.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">MISCELLANEOUS PROVISIONS</font></div></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">19.1</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Entire Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  This Agreement, including any schedules, appendices, exhibits and Statements of Work executed after the Effective Date, constitutes the entire agreement between the parties with respect to the subject matter hereof, and supersedes any and all other agreements, either oral or in writing, between the parties hereto with respect hereto and there.  Each party to this Agreement acknowledges that no representation, inducements, promises, or agreements, orally or otherwise, have been made by any party, or anyone acting on behalf of any party, which is not included herein, and that no other agreement, statement, or promise not contained in this Agreement or referred to herein shall be valid or binding.</font></div></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">19.2</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Notices</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  All communications and notices hereunder shall be in writing and shall be sufficient in all respects if delivered personally, by electronic mail with a &#x201c;Read Receipt&#x201d; confirmation, by certified mail with return receipt, or by commercial overnight delivery service with confirmation, delivered to the respective parties at the following addresses or to such other address as may be given by a party to the other pursuant hereto.</font></div></div>
  <p style="text-indent:-11.111%;padding-left:10%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">	GMS:		Guidehouse Managed Services LLC</font></p>
  <p style="text-indent:-11.111%;padding-left:10%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">				Attn: [***]</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">				Email: [***]</font></p>
  <p style="margin-left:20%;text-indent:8.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">1676 International Drive, Suite 800</font></p>
  <p style="margin-left:20%;text-indent:8.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">McLean, VA 22102</font></p>
  <p style="margin-left:20%;text-indent:8.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">	With a copy to:	Office of General Counsel</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">				Guidehouse Inc.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">				Same address</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">				 </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">	Client:			PMG Services, Inc.</font></p>
  <p style="margin-left:20%;text-indent:8.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Attn:  [***]</font></p>
  <p style="text-indent:-11.111%;padding-left:10%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">				1301 Concord Terrace</font></p>
  <p style="text-indent:-11.111%;padding-left:10%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">				Sunrise, FL 33323</font></p>
  <p style="margin-left:26.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Email: [***]</font></p>
  <p style="text-indent:-11.111%;padding-left:10%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:-11.111%;padding-left:10%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">            With a copy to:	General Counsel</font></p>
  <p style="text-indent:-11.111%;padding-left:10%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">				1301 Concord Terrace</font></p>
  <p style="text-indent:-11.111%;padding-left:10%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">				Sunrise, FL 33323</font></p>
  <p style="text-indent:-11.111%;padding-left:10%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">				[***]</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">19.3</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Waiver and Amendment</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  No provision of this Agreement may be waived unless in writing signed by both of the parties hereto, and waiver of any one provision hereof shall not be deemed to be a waiver of any other provision.  This Agreement or any part hereof, including each Statement of Work, may be amended or waived only by an instrument in writing properly executed by both parties hereto.  Services may be modified, adjusted or otherwise redirected as deemed appropriate </font></div></div>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">38</font></p></div></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:4.533%;visibility:hidden;display:inline-flex;justify-content:flex-start;"></font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">by the parties, provided that all such changes shall be included as amendments executed by both parties.</font></div></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">19.4</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Governing Law; Jurisdiction</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  This Agreement shall be governed by and construed in accordance with the laws of the State of Florida, without giving effect to the conflicts of laws principles thereof.  To the extent a party seeks injunctive relief, any such proceeding shall be brought in a state or federal court located in Broward County, Florida.  The parties hereby submit to the jurisdiction of such courts.</font></div></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">19.5</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Cooperation</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Each party shall cooperate fully and provide assistance to the other party in the event of any investigation, complaint, claim, action, or proceeding which may be brought by any Affiliate of a party, any third party, any party&#x2019;s or its Affiliate&#x2019;s personnel or any Subcontractor or Service Recipient subcontractor.</font></div></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">19.6</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Assignment</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Neither party may assign this Agreement or any of its rights or delegate any of its obligations under this Agreement without prior written consent of the other party (which consent may not be unreasonably withheld, conditioned or delayed), and any such attempted assignment shall be void.  Notwithstanding the foregoing, a party may assign </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(a)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> all of its rights or delegate all of its obligations under this Agreement to an Affiliate, or </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(b)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> to a surviving entity with or into which a party may merge or consolidate, or an entity to which a party transfers all, or substantially all, of its business and assets.  Subject to this Section 19.6, this Agreement, and all of the terms and provisions hereof, will inure to the benefit of and be binding upon the parties, and their permitted successors and permitted assigns.  Any assignee of this Agreement must confirm in writing to the non-assigning party that the assignee has assumed all of the assigning party&#x2019;s duties and obligations under this Agreement.    </font></div></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">19.7</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Severability</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Whenever possible, each provision of this Agreement shall be interpreted in such manner as to be effective and valid under applicable law, but if any one or more of the provisions of this Agreement are for any reason held to be invalid, illegal or unenforceable, the remaining provisions of this Agreement shall be unimpaired and shall remain in full force and effect, and the invalid, illegal or unenforceable provision shall be replaced by a valid, legal and enforceable provision that comes closest to the parties&#x2019; intent underlying the invalid, illegal or unenforceable provision.  </font></div></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">19.8</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Captions</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  The various heading and captions in this Agreement are for reference only and shall not be considered or referred to in resolving questions of interpretation of this Agreement.</font></div></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">19.9</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Counterparts</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  This Agreement may be executed in any number of counterparts, each of which shall be deemed to be an original, but all of which together shall constitute one and the same instrument.</font></div></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">19.10</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Publicity</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Client and GMS shall each submit to the other all advertising, written sales promotion, press releases and other publicity matters relating to this Agreement in which the other party&#x2019;s name or mark is mentioned or language from which the connection of such name or mark may reasonably be inferred or implied, and will not publish or use such advertising, sales promotion, press releases, or publicity matters without prior written approval of the other party in each instance, which approval may be withheld in the other party&#x2019;s sole discretion.  The parties </font></div></div>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">39</font></p></div></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:4.533%;visibility:hidden;display:inline-flex;justify-content:flex-start;"></font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">shall keep the terms of this Agreement strictly confidential, and shall not disclose to any third party, either directly or indirectly, the terms of this Agreement without the approval of the other party, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> either party may disclose the terms of this Agreement without the approval of the other party to its financial and legal advisors (who are under obligations of confidentiality).  Except as set forth in this Section 19.10, any approval required under this Section 19.10 shall not be unreasonably withheld, conditioned or delayed.  Notwithstanding any other provision in this Agreement to the contrary, either party may disclose this Agreement and the terms and conditions hereof, make filings, issue press releases and conduct earnings calls without the prior approval of the other party and use the other party&#x2019;s name or mark or language from which the connection of such name or mark may reasonably be inferred or implied whenever required by reason of legal, accounting or regulatory requirements, including the requirements of the U.S. Securities and Exchange Commission or any national securities exchange on which a party&#x2019;s securities are listed.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">  </font></div></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">19.11</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Contingency Fees/Guarantees</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Neither party can predict or warrant a particular outcome related reimbursement from federal or state funded healthcare programs and compensation for Services rendered is not dependent upon such outcomes.</font></div></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">19.12</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Third Party Beneficiaries</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Except for Service Recipients and indemnified parties, this Agreement does not and is not intended to confer any rights or remedies upon any person or entity other than the parties.  </font></div></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">19.13</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Force Majeure</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Neither party shall be deemed in default of any provision of this Agreement or be liable for any delay, failure in performance, or interruption of the Services to the extent resulting directly or indirectly from acts of God, electronic virus attack or infiltration, civil or military authority action, civil disturbance, war, epidemic, strike and other labor disputes, fires, floods, other catastrophes, and other forces beyond its reasonable control (each, a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Force Majeure Event</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) making it commercially impracticable to perform its obligations of this Agreement.  Notwithstanding the foregoing, &#x201c;Force Majeure Event&#x201d; expressly excludes any event with respect to which GMS could reasonably have prevented the event&#x2019;s detrimental consequences by using commercially reasonable efforts to prepare for the effects of events of such kind.</font></div></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">19.14</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Key Terms for Statement of Work #2</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Due to the fact that the parties will execute this Agreement along with SOW #1 earlier than they execute SOW #2, it is the parties desire to document certain key terms related to the Services to be provided under SOW #2; such key terms are set forth in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 3</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> and </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 4</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> attached hereto and incorporated herein. </font></div></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">19.15</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Execution of Certain Agreements</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Contemporaneously with the execution and delivery of this Agreement, the parties shall execute and deliver SOW #1 attached hereto as </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 5</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> and the Business Associate Agreement attached hereto as </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 2</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  </font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">[Signatures on following page]</font></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">40</font></p></div></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">IN WITNESS WHEREOF</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">, the parties have each caused this Agreement to be executed by duly authorized individuals as of the Effective Date.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Guidehouse Managed Services LLC</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">By:	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">_/s/ Ian Stewart________________________________</font></p>
  <p style="margin-left:6.667%;text-indent:-14.286%;padding-left:11.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:6.667%;text-indent:-14.286%;padding-left:11.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Print Name:	Ian Stewart</font></p>
  <p style="margin-left:6.667%;text-indent:-14.286%;padding-left:11.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Print Title:	Partner</font></p>
  <p style="margin-left:6.667%;text-indent:-14.286%;padding-left:11.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Date: 04/19/2024</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">PMG Services, Inc.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">By:	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">_/s/ C. Marc Richards____</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">_______________________</font></p>
  <p style="margin-left:6.667%;text-indent:-14.286%;padding-left:11.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:6.667%;text-indent:-14.286%;padding-left:11.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Print Name:	C. Marc Richards</font></p>
  <p style="margin-left:6.667%;text-indent:-14.286%;padding-left:11.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Print Title:	Executive Vice President &amp; Chief Financial Officer</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Date: 4/19/2024</font></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>md-ex31_1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html>
 <head>
  <title>EX-31.1</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 31.1</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">I, James D. Swift, M.D., certify that:</font><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="margin-left:3.333%;text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:3.333%;text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">1.	I have reviewed this quarterly report on Form 10-Q of Pediatrix Medical Group, Inc.;</font></p>
  <p style="margin-left:3.333%;text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:3.333%;text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></p>
  <p style="margin-left:3.333%;text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:3.333%;text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></p>
  <p style="margin-left:3.333%;text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:3.333%;text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">4.	The registrant&#x2019;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:6.667%;text-indent:-3.704%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">(a)	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></p>
  <p style="margin-left:6.667%;text-indent:-3.704%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:6.667%;text-indent:-3.704%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">(b)	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></p>
  <p style="margin-left:6.667%;text-indent:-3.704%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:6.667%;text-indent:-3.704%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">(c)	Evaluated the effectiveness of the registrant&#x2019;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></p>
  <p style="margin-left:6.667%;text-indent:-3.704%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:6.667%;text-indent:-3.704%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">(d)	Disclosed in this report any change in the registrant&#x2019;s internal control over financial reporting that occurred during the registrant&#x2019;s most recent fiscal quarter (the registrant&#x2019;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#x2019;s internal control over financial reporting; and</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:3.333%;text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">5.	The registrant&#x2019;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#x2019;s auditors and the audit committee of the registrant&#x2019;s board of directors (or persons performing the equivalent functions):</font></p>
  <p style="margin-left:3.333%;text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:6.667%;text-indent:-3.704%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">(a)	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#x2019;s ability to record, process, summarize and report financial information; and</font></p>
  <p style="margin-left:6.667%;text-indent:-3.704%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:6.667%;text-indent:-3.704%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">(b)	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#x2019;s internal control over financial reporting.</font></p>
  <p style="margin-left:6.667%;text-indent:-3.704%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Date: August 6, 2024</font></p>
  <p style="margin-left:43.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">By:	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">/s/</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">James D. Swift, M.D</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">	</font></p>
  <p style="margin-left:43.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">	James D. Swift, M.D.</font><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="margin-left:43.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">	Chief Executive Officer</font></p>
  <p style="margin-left:43.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">	(Principal Executive Officer)</font></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>4
<FILENAME>md-ex31_2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html>
 <head>
  <title>EX-31.2</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="margin-left:43.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 31.2</font></p>
  <p style="margin-left:43.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">I, C. Marc Richards, certify that:</font><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:3.333%;text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">1.	I have reviewed this quarterly report on Form 10-Q of Pediatrix Medical Group, Inc.;</font></p>
  <p style="margin-left:3.333%;text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:3.333%;text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></p>
  <p style="margin-left:3.333%;text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:3.333%;text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></p>
  <p style="margin-left:3.333%;text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:3.333%;text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">4.	The registrant&#x2019;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:6.667%;text-indent:-3.704%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">(a)	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></p>
  <p style="margin-left:6.667%;text-indent:-3.704%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:6.667%;text-indent:-3.704%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">(b)	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></p>
  <p style="margin-left:6.667%;text-indent:-3.704%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:6.667%;text-indent:-3.704%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">(c)	Evaluated the effectiveness of the registrant&#x2019;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></p>
  <p style="margin-left:6.667%;text-indent:-3.704%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:6.667%;text-indent:-3.704%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">(d)	Disclosed in this report any change in the registrant&#x2019;s internal control over financial reporting that occurred during the registrant&#x2019;s most recent fiscal quarter (the registrant&#x2019;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#x2019;s internal control over financial reporting; and</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:3.333%;text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">5.	The registrant&#x2019;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#x2019;s auditors and the audit committee of the registrant&#x2019;s board of directors (or persons performing the equivalent functions):</font></p>
  <p style="margin-left:3.333%;text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:6.667%;text-indent:-3.704%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">(a)	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#x2019;s ability to record, process, summarize and report financial information; and</font></p>
  <p style="margin-left:6.667%;text-indent:-3.704%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:6.667%;text-indent:-3.704%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">(b)	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#x2019;s internal control over financial reporting.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Date: August 6, 2024</font></p>
  <p style="margin-left:43.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">By:	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">/s/</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">C. Marc Richards	</font></p>
  <p style="margin-left:43.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">	C. Marc Richards</font></p>
  <p style="margin-left:43.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">	Chief Financial Officer</font><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="margin-left:43.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">	(Principal Financial Officer and</font><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="margin-left:43.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">          Principal Accounting Officer)</font></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>5
<FILENAME>md-ex32_1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html>
 <head>
  <title>EX-32.1</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 32.1</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Certification Pursuant to 18 U.S.C Section 1350</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">(Adopted by Section 906 of the Sarbanes-Oxley Act of 2002)</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:2.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">In connection with the Quarterly Report of Pediatrix Medical Group, Inc. on Form 10-Q for the quarter ended June 30, 2024 (the &#x201c;Report&#x201d;), each of the undersigned hereby certifies, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that (i) the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and (ii) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Pediatrix Medical Group, Inc.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:2.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">A signed original of this written statement required by Section 906 has been provided to Pediatrix Medical Group, Inc. and will be retained by Pediatrix Medical Group, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">August 6, 2024</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">By: </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">/s/ James D. Swift, M.D. 	</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">James D. Swift, M.D.</font><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Chief Executive Officer</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">(Principal Executive Officer)</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">By: /</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">s/</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">C. Marc Richards	</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">C. Marc Richards</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Chief Financial Officer</font><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">(Principal Financial Officer and</font><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> Principal Accounting Officer)</font></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>img260269913_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img260269913_0.jpg
M_]C_X1FB17AI9@  34T *@    @ !P$2  ,    !  $   $:  4    !
M8@$;  4    !    :@$H  ,    !  (   $Q  (    A    <@$R  (    4
M    DX=I  0    !    J    -0 +<;    G$  MQL   "<0061O8F4@4&AO
M=&]S:&]P(#(S+C0@*$UA8VEN=&]S:"D ,C R,CHP-SHR-R Q-3HS.#HS-
M  .@ 0 #     0 !  "@ @ $     0  !D"@ P $     0   ^D
M!@$#  ,    !  8   $:  4    !   !(@$;  4    !   !*@$H  ,    !
M  (   (!  0    !   !,@("  0    !   8:         !(     0   $@
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MR@)R@ 8R&27'*7%_C<*?NQ.,QD8B5\0,(\(C6SQ.9_C-P[.F6-HQ;J\^RLM
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M<')I;G1E<DYA;65415A4     0      #W!R:6YT4')O;V93971U<$]B:F,
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M      !%;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0
M     %)'0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6)
M;^            !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
M             $)L9"!5;G1&(U)L=                %)S;'15;G1&(U!X
M;$!RP           "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !0
M9U!S     %!G4$,     3&5F=%5N=$8C4FQT                5&]P(%5N
M=$8C4FQT                4V-L(%5N=$8C4')C0%D            08W)O
M<%=H96Y0<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P
M   ,8W)O<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M        "V-R;W!296-T5&]P;&]N9P      .$))30/M       0 2P    !
M  $!+     $  3A"24T$)@      #@             _@   .$))300-
M   $    6CA"24T$&0      !    !XX0DE- _,       D           $
M.$))32<0       *  $          3A"24T#]0      2  O9F8  0!L9F8
M!@       0 O9F8  0"AF9H !@       0 R     0!:    !@       0 U
M     0 M    !@       3A"24T#^       <   ____________________
M_________P/H     /____________________________\#Z     #_____
M________________________ ^@     ____________________________
M_P/H   X0DE-!         (  3A"24T$ @      !      X0DE-!#
M  (! 3A"24T$+0      !@ !     CA"24T$"       $     $   )    "
M0      X0DE-!$0      !     "   "0    D      .$))300>       $
M     #A"24T$&@     #20    8              ^D   9     "@!5 &X
M= !I '0 ; !E &0 +0 Q     0                         !
M      9    #Z0                     !
M !     !        ;G5L;     (    &8F]U;F1S3V)J8P    $       !2
M8W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<          $)T
M;VUL;VYG   #Z0    !29VAT;&]N9P  !D     &<VQI8V5S5FQ,<P    %/
M8FIC     0      !7-L:6-E    $@    =S;&EC94E$;&]N9P         '
M9W)O=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN
M    #6%U=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90
M  !);6<@    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P
M(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P   ^D
M4F=H=&QO;F<   9      W5R;%1%6%0    !        ;G5L;%1%6%0    !
M        37-G951%6%0    !       &86QT5&%G5$585     $       YC
M96QL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585     $       EH
M;W)Z06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT
M"79E<G1!;&EG;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0
M   +8F=#;VQO<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E     $YO
M;F4    )=&]P3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<
M    #&)O='1O;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P
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MW7/%=5;2^Q[C#6M:-SGN<?HM:U)34ZSUC$Z/A.R\DDB=M=;?I/<?S&K%H?\
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MO_0JHW#RLKHMF6ZJW)ZGC]4JS.MX): YYHVL?C8M+?T5]'H-IOQ/?9]J_?\
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M]).CUWV/R_R^5!Z;;]7ZJ27RJDFI?JI)?*J22G__V3A"24T$(0      5P
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M   ,2$QI;F\"$   ;6YT<E)'0B!865H@!\X  @ )  8 ,0  86-S<$U31E0
M    245#('-21T(               $  /;6  $     TRU(4" @
M                                                       18W!R
M=    5     S9&5S8P   80   !L=W1P=    ?     48FMP=    @0    4
M<EA96@   A@    49UA96@   BP    48EA96@   D     49&UN9    E0
M  !P9&UD9    L0   "(=G5E9    TP   "&=FEE=P   ]0    D;'5M:0
M _@    4;65A<P  ! P    D=&5C:   !#     ,<E120P  !#P   @,9U12
M0P  !#P   @,8E120P  !#P   @,=&5X=     !#;W!Y<FEG:'0@*&,I(#$Y
M.3@@2&5W;&5T="U086-K87)D($-O;7!A;GD  &1E<V,         $G-21T(@
M245#-C$Y-C8M,BXQ               2<U)'0B!)14,V,3DV-BTR+C$
M
M %A96B        #S40 !     1;,6%E:(                     !865H@
M        ;Z(  #CU   #D%A96B        !BF0  MX4  !C:6%E:(
M "2@   /A   ML]D97-C         !9)14,@:'1T<#HO+W=W=RYI96,N8V@
M             !9)14,@:'1T<#HO+W=W=RYI96,N8V@
M                                            9&5S8P         N
M245#(#8Q.38V+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@+2!S4D="
M               N245#(#8Q.38V+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@
M<W!A8V4@+2!S4D="                             &1E<V,
M+%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR+C$
M             "Q2969E<F5N8V4@5FEE=VEN9R!#;VYD:71I;VX@:6X@245#
M-C$Y-C8M,BXQ                                  !V:65W       3
MI/X %%\N !#/%  #[<P !!,+  -<G@    %865H@      !,"58 4    %<?
MYVUE87,          0                        */     G-I9R
M0U)4(&-U<G8        $      4 "@ / !0 &0 > ", *  M #( -P [ $
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M0R0T5%8)XF/"@Z/41(2D)97#Q$;PX62%)K4G_]H # ,!  (1 Q$ /P"_P
M
M
M
M
M
M                              __T+_
M
M
M
M
M
M        #__1O\
M
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M;;:%?S^V[3'S3X]SFSS+<5W*Y:<ER/IT_8]Z[/:3X?Z+5H1?Y>@]"TUIU?\
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MI2I*B4E1$I*DF1I4DRZDI)E[2/Y#&LD?&G%X/8T?Z!_
M
M
M                  #_TK_
M
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MY#6@
M
M                                   /_]._P
M
M
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MF^=PP;S"[A&4X3Z[6CY5*U2>/#*'%7P;C*O-$;HW E4
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M[6O.VN82IU*<G&<))QE&47A*,HO!QDFFFFDTU@SR1_#Y
M
M
M            !__4O\
M
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MG"KJ>%62Z*-GF%9/Q3IVLH?VMO0??M>B=Z@3B#6O7&',*))*)IW9^$FLS/\
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M!1JTY=:PE!XPJ1A4C*"SL,6<Z
M
M                                                    _]6_P
M
M
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M"
M
M                          '_UK_
M
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MWW-_G1.KE]W=O*<GGBEE]E*5.G*#Z+FMBJMTVL.)3:HN2XH4(,D<&GD60
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MK8TRRJTN[6_M:=[8U85J-:,9TZE.2G"<)+&,X2BW&49)IQDFTT\4\#PA^CT
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M46J=U03PQZ5"O3QC&O1Q;IR:DG*E.G.>Y UTX4
M
M
M '__U[_
M
M                              "J3ZR_J-/9_>W/$;2=_P!,"QN=[GN;
M*:J1\W,LGKI'<O!($ID^BJRL?07U041_[S,1Y7@S&,Y'=>76D%:4HY_F4/;9
MK&C%^HB_5M>NDO2]4=N^6RY7N(]UNGIK+J'.S7]M_P#<KN'%E=O4C_E;><=E
MY.+W5[B+]I7]U0EQ[9U<*5>8=:+.@   _1AAZ2\S&C,NR)$AUMAAAAM;KS[S
MJR;:99:;(U*4I1DE*4D9F9]"!M16+V)'XJ5*=*G*K5DHQBFVVTDDEBVV]B26
MUM[$BR=Z=_HKKMF:+=',FIDQ(+I1K;%=#.K=B393:NC\2?M-UHTN,(,NBRHF
ME)</YJ9RT='8:N-ZNYCJFY9=IV2;VJ5?>EUJET/ZM[/6I[)%4W>?[^\;*I<:
M"Y%5HSJ+BIW&<)*4(O=*&7IXQF]Z=W)."VNWC+&%=6:Z>FJ,>JJZBH*JNHZ2
MHAQZZIIZB%&K:JLKXC9,Q8-?7PTH:99:01(;:;024D1$1$0XO4J5*U1U:LG*
M4GBVVVVWO;;VMOK*EKZ^O<SO*N8YE6G<7%>4IU*M6<JE2I.3QE.<Y-RE*3>+
ME)MM[6SV0_!Y0                     (UN=?IEZ3YH5,W(2C1=<[RBPS1
M2;1I8#?6V6PSV1*K8%6QV%:1.B4MH?-12XY$GR7O*)<=W<M+ZTS+3E14<76M
M6_*I-[NMTWZE^#TKZ5CM4K>[MWM-?\AKVGECG+-=/3EC5R^K-^UIO&52SJ/'
MWO4VN3@DZ-5M\<.-JI"FAR*XV[>XL['LM8;CQA_'[Z(2I-98,FN7CN54QNFU
M&R'%;GM2B7#=Z&1*(DN-K)33[;3Z'&DR)RC.<OSRS5[ET^.#WK=*+Z8R70UY
MSWIM-,O<Y7\U=$<X=*TM7:%NU<VT_)J0>$:]O5P3E1N*6+=.K''=BXS6$Z<I
MTY1F\$#*'1@   V;XD<J=C</MRT&V]>R5/HCJ369AB<B0ZS3YQB$E]#EICEJ
M2"423422=B2>Q2H\A#;R4J[30K"Y_D5GJ#+IV%VL,=L)=,)]$EZ#72L5X3DG
M.ODYI;GAH2YT5J>'"Y>V6UQ&*=6TN8IJG7IXX8X8N-2&*56E*=-M8J2OK:'W
MAK[D;JG$-PZQMBM<3S"M1+82YY:+&GL&C\FUQZ[BMJ5Y$Z#(2N/):[C+N3W(
M4MM2%JBUFF67>3WU3+[V/#4IO#P-=$HOIC);4_/V[#_.%S&Y>ZFY6:ROM#:M
MH]C>V,W%X8N%6#VTZU*32XZ56#4Z<L$\'A)1DI167ACS2
M
M
M       /_]"_P
M
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M[7BI12[>4E=7(R41*29&DR(R,CZD9'XD9&0C>4&M-/!G^@?P
M
M
M        _]&_P
M
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M61\G^7N6Z R!)T[*FNTJ\*C*XN)^57N)[_*JU&Y)-O@APTXOAA%+ 0RITH
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MCG) X
M
M                         __2O\
M
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M6,E*C%2N;D1$1$1$1$70B+P(B+V$1".A0]OVL_T
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MH^9XP
M
M                       __]._P
M
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M:-6A/LZT7"2Z))I^<S)TZM.K'CI24EUIIKST>8/F?L
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MU/7.6T^"QU/3=:6"PC&^H<$+I>#M(RHW#;>,JE6K@L(DU8YN0&
M
M
M        #__4O\
M
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M(;K0[N^9:_LO>V:YDK"UISBZBI4^VJ5&EQ=GQ2G"-/AQC-OAJ)MQP6QE&?\
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M+F]_57RKE9Q_R[1'(/3."V3ETB#8XOGV!S[G&K##\NI'RE4N2G07:K9N4?\
MK(LQEB5%\R,^^A"D=Q$.E:+YWYCI_.J%]?VT*D$^&IV<I0QIRV2Q3[3%I>4E
ML\I)^ GEW4?^6/6O(_FSE&LM89%;7=K3J*A>NSK5K5SLJV$+CBISC=JI*$<*
MT(Q<%VU.G)+9PN!>MV?A%A)?@/W+=%:Q')K4^HR9!T4VO>@R#C/1I3\PRB&]
MW$9$RS*<7X&73J1B;^5<S=*YGPQJ596TI88*JL(O'Z>+E!+PR<3_ %Z\O>_?
MW?==JE2N[^KD=:MP<*S"FH49N2QXHW5"5>VC3714KU*&*:E@MN&0#(T]"41D
M9I2HB,C+JE:26A1=?D,C(R/Y2\1OE&O1N:2KV\XU(2VJ46I1:\#6*?F$N\KS
M;*\\L*6:Y+<TKRUK+BIUJ%2%6E4CNQA4IN4)+%-8Q;1_@^ID"4;T?-]N:/YM
M:]KIT[W7%-S-2=09$VXYT85-R5QM_"GR;4?9YI7C%?')P^AI:?>(C^<9'I',
M'*EF>FJTXK&I;>VQ\4?3^9P.3\:1$#OQ<MX\P>0&9W5O3X[S(7',J#2V\-!-
M72QW\/O2=:;6YSIP;W)J\2(SG^>\
M
M                                              /_U;_
M
M
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M#I*YT'KK.-%7;;GE5Y<6O$_5JC5E",_%4BE-/I4DS*0\)IX
M
M
M   '_]:_P
M
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M?TLN'@?U1SGFQG;R+0&8W,&E4K0["&W!XUVJ<G%[^*-.4YKZD^O'92O<
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M)3A-*491:<91:Q336QIK:FMC6U'[C^GT
M
M                                               /_]>_P
M
M
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M.:2<J56#\JG5ABN*$DG@U)8QE&3RP/>;@
M
M                                              '_T+_
M
M
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M-K27./2E/5&E:N["%Q;S:[:UK88NE5BO/A->14CY47O2V2&9.G@
M
M
M  ?_T;_
M
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M*G00
M
M             #__TK_
M
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MR6O&YM+NG"K1JP>,9TYQ4HR7C3W/!I[&DTT?1C[&3
M
M                                                 #__T[_
M
M
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MEVO(Q?!;K3^JWD.Q).#8W.V52*LLOSV*X1*^J\NM4][C6*Z%7M+\Z01SS2U
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M<RQE.UQ>Q0N-LZ2V)7'%%*4KC9:''<"UL
M
M                                         /_4O\
M
M                                                    #QY<N+ B
MR9TZ2Q#A0H[TN9,E/-QXL6+';-Z1)DR'3)"&T((U+6HR))$9F9$0_=.G.K4C
M2I1<I2:226+;>Q));6V]B2WGYG.%.#J5&HQBFVV\$DMK;;W)=+.<%ZL?.>=S
MIY891E]-82'--ZY7-U]I.M-3J(SF*UTU7U0S)<9?0BDY!+2J>M2D)<3&]TC.
M=?=4F+C>0G*^ERNT%0R^Y@EF-YPU[R6S'M91\FCCZVA%]FEBTY]I-8<;*P.<
M?,"IS!UC6O:$F[&UQHVL>CLXORJN'KJTO+>S%0X(/TB(R!VPY0   %I/T&?2
MJC[&GTG.#D-CB)."4-DN1H'!+J(3D?,,CJ91M+V?=PY)=JZVMDMJ;IV5$?O$
MQM4E1)9C,^]0;[U'/:>3TJO++2-;ANJL<+^O![:-.:Q][0:W5*D7C6:])3:@
ML93EV<M^[QR@CF=2GK[4M+&WIRQLZ4ELJ3B_L\D]\(26%->JFG-X1A'CM!\X
M<.7GW#ODWBS+1ORY^D=BRJYA*>XWK:FQF1>5#)%_I2HS*>I>SKU$ ],W'O74
M-E7>Q*M33\3DHOZ#9:%W?,]6F^>6DLXF^&%/-;*,WU4ZM>%*J_,ISDSGK"69
M_IN   "T1\/%GZ9&*<E-6O.DE=3D."9_6L&KYSZ<AK9N.W;J$_0:.LKR4?\
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MWKN_\PY:,U='*K^>&7YHXTJF+\FG5QPHU>I+B?9S>Q<$N*6/ CH"BILL>
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M&O**S*V_PU_!8+"YIQ6-11Z(5X.-:."X8N4J:;=-F[XV8[N
M
M                                                     !__U;_
M
M
M      @?]?SF:YQQXCGIG$+;W+9_)]RUPALXSQHG4^JX##:ME6Z3;/J@YK<B
M+1H)9%WMS9"VS[XY])3=T_EPM8\P/VCS"GQ6.2<-;:O)G=2;][0\/ XRK/#<
MZ<$UA,CUWC=<O2^C/R'93X;O-N*EL>V-NDNWEX.).-)=:J2:VQ*$8M6*[
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M<-63I2DVE&G7J2?I47/Q) N^
M
M                               __]:_P
M
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M':X1KI=$:L3<0;$=I
M
M                      /_U[_
M
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M;GU,M5RV'3^E:9D0FRZ%T(<!YH9*[3-89O27M=RL)>"I!8?VHX-=;4F4D?\
M(OREGI?F1:\T,MI866H::IUVELA?VT%!XX;(]O;JG./3.=*O)[<2> <N*YP
M  IZ>M7O%>SN6Z]=0)1O8YHK&(&)M-H7WQG,MR)EK)\NG->/@LDNP*YXNA=%
MPC_[1'CF5F;O=0>\X/R+6*A_3EA*;^C&+^I*7>_-KV6JN<3TU;SXK;(*$+=)
M/&+N*RC7N)+PX2I49+UU A^'/2&  'ZLLO2'FH\=IQ]]]Q#+##*%.O//.J)#
M;33:"-2E*49$E)%U,_ A_4FW@MK9^H0G4FJ=-.4I-))+%MO8DDMK;>Y%\C@E
MQQB\6N,>M]7N16F,K76IRO8K[9(-<O/\F:;FWZ'7D>#A0B)FK8<Z%W,16C,N
MO42GTMD\<CR2C8M85,.*IX:DMLO'P[(KP11_H)Y <LZ7*;E7EFE)04;MP]\7
MC6^5W72E53:],J7DT(/IITH=)M^-A.S            <Y'UC.(C7$#G!L7'<
M=K"KM8[3).X=8-,,^7!@T67SGSO,:B)078VBIN&;"%'8)1J1$3%6KIYA=;B.
M[MS!ES"Y96=Y>3X[VQ_PERV\92G2C'@J/I;JT73G*6YU'42]*5B<[M%K16OK
MJVMH<-I>?XFAAN4*C?'!="5.HIQ2WJ"@WO(L1W0Y$ ![S%\EN\,R7'<PQJP>
MJ<CQ2]J<EQ^TC'VR*V[HI[=I56$=1^Q;+[3;B#^B1#RWUE;9E95LNO8*I1KP
MG3J1>Z4)Q<91?@<6TST6EU<6-U2O;63A5HSC.$EOC.#4HM>%-)G4PXT[JJ.1
MO'[3>]:-+3,':FN\6S)R$RLW$U-G;53;UY1+69GU7 F^\0G?$_GM*\3]HHTU
MIIJXT=JW,=+W6+E87%6CQ/U<82:A/Q5(<,UX)(MQTKGM#4^F['4%OLC>4:=7
M!>IE**<X>.$N*+\*,X#6#/@ 8WW!M+%M):MS[;>:2?=<8U[BUOE%L:5(2_):
MK(JGF*V$3G@J3+>\N+%;]JWG$(+Q40]F7V-?,KZE86RQG6DHKP8O>_ EM?4D
MS:M#Z/SCF!K#+=%9!#CN\SN*=O3WX1=223J3PW4Z<>*I4EZF$92>Q'.WVMLC
M(]P[+SS:F7/^\9+L+++W+KA25+4RU,O+!R>J'$)?BEA@EDQ';+P0VA""(B21
M"7-C9T<OLJ5C;K"%&,8+Q16&+\+WOPG^H#1NE<JT-I/+='9)'AM,LMJ-M2W8
MN-*"AQ2PWSFTYS>^4Y2D]K/@!ZC90 -W?3FT4OD-S)TC@<B&<S':_*6,[S,E
M-^9%+$\"+^4]C%G>!]&ISD=FLZ]/IY*"\.O4M:U?FGY(T[<W2>$W'@AU\4_)
M37ACBY?T2/O>DYB1Y8\BM0:CI5."ZJV[M+7;A+WS>?X>$H=<J*G*O]32D]NX
MOY"*I_FR   ")CUBN-;6[^*]GL"F@>\9UH%V9GM6ZRUWR96%NM-L;#JC7[2:
M1#::ME>'7N@)273O,:#S$R59GD4KNFL:MIC-=;A_>+Q8)3_H$/N^IROAKSE+
M5U%94^+,-.N5W3:6,I6S25Y3^I5.,;A^&W27IF4VA'0I/   "PKZ">\5U>;[
M>X\6DSM@Y53Q=H8E'=7VMMWV.N-4.51XR?USTR%(@O*+V^7!4?R&.N<JLT<+
MFXRB;V5$JL/JHX1EAX7%Q?BB6/?\>^O96F>YSRWNY^UW=.-];IO8JM%QI7"C
MURJ4ITI/Z6W;+.X[:6I@
M
M                        '__0O\
M
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MB7VQ*L_T)
M
M              '_T;_
M
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M(+M;^JT!#$]OK\YV0W/</V"0/+'/??V52RBM+VVU]+UNE)[/ZDL8^!.*+O\
M_CQYQQUARWK<L,VJ\68:<>-!2?E5,OK2;IX8[7[VK.=&71"E*VCTD%PZ<6(
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MKS\%2I1A*HGX8U.*+\*,SC)&[@
M
M                            !__2O\
M
M                                       Y?'/;/%[-YL\L,X-XWX]Y
MR"VN=6X:N\_J%79G+J<?;-7R]D%B.CP\/#P\!=[RJRI9)RTR#+,,'2L+7B^K
ME1A.IY\Y294US$S%YMKS.,PQQ52\N.'ZB-648>=!11J4-_-,  EC]$+6*-G^
MI=QV9E1TR*K!9F7[.L^Y)+\A>%89.GX](2E7AU3<JK>A_)UZEXD0X)WFL[>2
M<E\XE3>%2Z5*VCX>VK0C47WGM/'N.Q\@\I6;<U,LC-8PMW4KR\'94IN#^^\!
MT613\6:@      :P\QN-6/<M./.P-*WAQHLZ\KOJEAEY(;-?\F<[IR5+Q>\(
MT$:R;2_^P3$M]%.177VB,O,,9O3V<ULAS:EF5+%J+PG'UT'LE'SMJQW22?0=
M=Y%\U\SY+<SLLU]E_%.G;SX+JC%X=O:5<(W%';LXG#RZ3ELC6A3FUY)S],TP
M[)=>9=DV"9E4R:+*\.O;3&\BIYB23)K;FFF+@6$1SMZI5V.(41+29I47123-
M)D9RNMKBC=V\+JWDI4ZD5*+72FL4S_2WD.>Y5J?)+34>15HW%E?4:=>A5CZ6
M=*K%3A)=*QBUBG@T]C2::/F1]C+@ >YQS(KW$,@I,JQ>VG4.28W:U]Y0W59(
M7%L:FXJI29M=8P9+?12'674(<0HO89$/G6HTKBE*A7BI0FG&2>U--8-/P-'@
MS3*\NSO+;C)LWHPN;6[ISHUJ51*4*E*I%PG"<7L<91;374R\OZ;G/;&^;.I&
MU6ST"HWE@<.% VABC)ML)G+4GW>)G>.Q>O4ZVQ4DS<;21G$D=\=?5!QW7XR:
MQTM6TWF'M:<K6JVZ4NKKA)^NC_:6U;<4O\\W>J[M^:\@-:M649U]/9E*<\ON
M'B^!;Y6E>717HI[)/[-2X:L?*[6%/5KUY,O.IXOZTP]EXVW\OW/739""49>?
M58OB5H]):-)>TBE2X*^OR&DOHC@/-2X[/(Z-NGMJ5D_,C"6/T7$IE_Y!,Y]Y
M\J<KR6$L)7N90DUUTZ%O7<E]\J4GYA4W'!"H$   +Q'I:8"C7W!+0<%3/E3<
MEH+7/I[AI)*Y2\WR*7D-:\OI_FP'H;23^5*$B3FAK16FEK2.&V<74?AXY.2_
MLM+S"^7NFZ>6G.0&GJ#CA.ZHU+N;]=[ZK5*T&_%2E3BO!%$@@VTD8
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M.;XIV4[NVD_J+JK."\RE4IKS"3,;J2E
M
M                                  #_T[_
M
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M3\,:5O7V?UIQ?F(D_P!U6R5;7-]>R6/8V4DO!*I6H[?ZL9+S67@A603Y
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M5J3]17EYSA3_ )<2X3_C[OW<<H,RL)/%V^;5FO!&I:V;2_K*;\TFY'3"=H
M
M
M ?_4O\
M
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M<9O25(0[)<247]6:DKZES-W+QC1IXQI0ZH];^FEOEYD<6HH_SI]Y?G[F_/\
MYA5,_J<=#*;/BHY=;2?V*AQ8NK42;C[XN&E4K-8X)0I*4H4H,WJ&KD=@
M    U/YW1$S>&'*-E:242-&;(ED1].G= QB1.0KQ^@ILC(8#5,>+3=\G]HJ/
MSHMG(.\!15?DAJR$MN&57LOZE"<E]&)0C$53_/:   %I/T!9*EZ;W[#-1&AC
M9N.R4H^5*I>+$TM1_P#:3*2+_L'<N5$O_MUW'JJ1?GQ__D6Q?\=]5O1.HJ..
MR-]1EA]50P^CPKSB?D=7+#P
M
M                          __U;_
M
M                                  #X':T,['5VR:]*36J?@.80R02>
M\UG*QZ2P223X=>O=TZ=1E<AJ=CGEE6>S@KT7YU2+,=G$.URFZI[^*C47GPDC
ME B^<IX   "T[\+Q8M-;4Y;U)K(GINOM7V+;?0NJFJO([6,\LC]OS3F(+_*(
M+]^"C*61:?N,-D:]S'S94Z37L'YQ+KNEU4LWSFCTRHT)?U9U$_9(N/BNLF\
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MBK*GI>PJ8N:QB\RKP>RO-/!JVIO_ "U*2QD_;ZBXW3A1F7'.B"0
M!J7SSFHK^%W*%]Q78ES2&PH1&?0NJ[/'GJUM/CU^F4Z2?\HP&JI*&F[YO[34
M7GQ:_E./=X.O&VY'ZKJ2>&.5WD?-G1E!>>Y8%"<15/\ />   %IGT!XIHTGO
MB;VGVR-ITL4E>/0SB8DTZI)>'R>>77Q^7Y/E[GRHC_\ ;+J7752\Z"_G+9?^
M/"DUH74%?UU_2C_5MXO_ ,1/F.K%A@
M
M                                 ?_6O\
M
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MNWTR4(K^E4BG]#$C;WNLTCE/=YU%4Q\JM"WH176ZUW0IR\Z#D_$BD&(RE$
M  6X/0CHEUW$/-K=ULTKR+?&528[AET)V!787CU8UT^CVR&Y)=1W_E;2X-/U
M:C]77EYRA37HXEQ?_'_E[MN35_>S6#N<VKM/KA"VLX+SIJ9-8.E$Y@
M
M                                                         __7
MO\
M
M       YB'J*X [K'G?RYPYQCW9B'R V;;5C';V^50Y7D\C+,=21?O"=&\?8
M?M+P,7:\G\VCG?*S3^8I\3E86T)/KG2I1I5/[<)%4',W+GE/,+.K%K!1O*\H
MKZ2I4=2']B<33(='-&  E(]%W:+6J?4KXQVDN44:LR_)[O5]@A2NQ$MS96*3
ML0H(JC_5MY5<M)?*I*2'#N\AD<L^Y,9W0IQXIV].%S'P>]JL*M1_>HU%XFSK
M?(O-ED_-/*:LWA"O4E0?A[>G.G!??)0?C1T=!3H6>@            !BG=6D
M=8<A=>W>KMNXG7Y?AUZV1OP9J5-RJ^<TE28=S263!I?A3HYJ4;$J.M+B>JD]
M30I25>_+<SO<INXWV7U'3J1Z5N:Z5);G%]*>PW+0/,#5W+'4]OJ_1-[.QOK=
M[)QVQG!X<5*K!XPJTIX+CIS3B\$\,4FJ;W/WTKMM</9]GG.((L]H<?G9*W8N
M:PX?FWV$,/.](U;L>NA)[6>WJ32+9A!1'E=O>45UQ$<2&TIKFPU#"-K<84+O
MI@WY,_#3;W]? _*7TR6)>IW:^^+HKGC;4=/9XZ>4:F44I6LI84;MI>54L9R>
M,L?3.VFW7IK'A=:$)52#S?\ #E3-=K7'90MJKR"HM9SIGT6S%\B33H["Z>/<
M]-9(_$AKO."U53)+:\Z:5;A\R<)-_1A'SSEW_)-I^G><KLBU,L74L<S[#=L5
M.[MJTYMOH\NUI+P\1HZ(\%,@   2)ZQM';C7N'SGDM-J33,U:4-K[^C6/O+Q
MYA3G@712T1$N&7^D)4<M;V-YI"VCCC*BYTY>!J;<5_4E$O\ .XYJ:EJ/NX9-
M04W.MEE2ZLJN/J94[B=6E%>!6U>AZ'0?>M.N,.-O,N+9>96AUIUI:FW&G&U=
MZ'&UHZ&E23(C(R/J1C>VDU@R6\X0J0=.HE*,DTTUBFGO372GTHW0U1ZBG-C2
MZ8\?!^16PE5D8DML4F83XVQ*-B.GP]UB56?-6349LR\.D5+9EU,TF2O$:Y?Z
M1TWF3<KJSI\3]5!.G+QMP<6_-Q."ZS[KW('7LI5=0Z7LNVGM=6VA*RJN7KI5
M+.5"4Y?='+'<TUL) ,$]?GEA0M,Q<XU[IG/V6NWS)R*G)<3O)'R*\V35V+L$
MNOR>76IZ'U]I="+5+KE5D-5N5M5K4GU8QE'SG%2_M$:M1?\ &QR8S*<JVG\S
MS3+9/=!U*%S2CXHU*$:OGUWYAM#0?$35ZTMMY3Q2F1UD22=ET&X6)B7%=/G*
M;K[''&#07T$G)5_VC"5>44]]"_3\$J6'T54?H'(<R_XOKF+<LGUG&2Z(ULL<
M</'.%]/'Q]FO$9 :^(9TV:%&_P >-FMN=#[4-93BKR#/KX$IQ:6S(NGR]I_]
M@\CY2YCCLNZ?]61K,_\ C&UVI84]46#7AM[A/SDWZ)Z*V^(AP%EM1T7&#+[%
M[YW:BVV72TK9^/S>YV'43S+KX=?F'T_5'UI\H[IOVV]@EX*;?HSB9*R_XP=2
M5)89CJZVI1ZZ=A5JOSI7-'T3 N8_$,[AG)=+ ..VM<949&3*LPRO*,Y)M73P
M-Q-,WCW?T^@1I&4M^4N7Q_S=Y4G]1&,/1[0Z/D7_ !C:&MVOVEU1?7?7[VM[
M>TQ\7:RO</HFD>S/6*Y\;);E1&MM0M=5<LE$Y7:SQ.AQUQLE>PHN0S6IEPUV
M^PC;LDG]$S/H8V6RY>Z5LVI.W=:2Z:DI2\^*:@_-B2 TGW&>[=I64*T\EGFE
M:&Z=_<5JZ?U5&$J5M+'Z:@UU8$=N:["S[95NO(-BYOEV>WRR4E=UF>27&3VJ
MDK5WJ2=A=O/N]#/QZ=_0;=;6EK9T^RLZ4*4.J$5%>=%)$G\@TQIO2EBLLTOE
M]MEMLO[JUH4K>GLV>DI1A''PX'R ]!G2/S;=FJUV/EKZV4QUQ+,J53:%)6E2
ML=C-T!O$I/@?F>[>9_\ I?*),:8M?>>G[2AT]G&3\<_+:\QRP/\ *3WA=64]
M<\\]6ZIMZG;4+O-;QT)^NMZ=:=*V?B["%/!="V&.1G3C@ &8=$Q7W]DU,AN-
M[RS70;R5,/P[8[#].]5LR5=?\V1)9(NGRF0U/7%>-#3-SB\'/@BO"W..*_JX
M^82E[E.FHZJ[T6D,OGLC0NYWC>&.#L+>M>PQ^JJ4(13ZY(E/T/Q\V[R6S^NU
MKIK#;++\EFFAV4J.CR*C'ZTW2:?O,FN7ND>#":,R[GWUEW*-+;9+=6AM49<T
MS;+\FM'>9C45."W=<GZV*WR;ZEXW@L6?Z-^8W,W1/*?3575>N[^%C:4\5'B>
M-6M4PQ5*A27EUJLL-D()X+&4G&$925R;T_/3$U;PMJ8V7W:X&QM_V,%35QL"
M1#/ZF8LW+:[)E!KN%++OBL=IFT_8.)*7*3W=WD,K]U1'?5FM;[4=1V]+&C:)
M[*>.V6&Z51K>^E17DQ\+7$Z*>\OWN-8<^[V>29>IY5IJE/&E9J7MEPXO&-:]
MG%X5)XX2A1BW1HO##M*D>VE*$-)(A@            !!YZ\.P$4/&37.OF9!
M-3]@[9B3WF.[QDX_A6/3)=B7;\I(G3:I77V%X?1(<QYIW:I9)1M$]M:JG_1A
M%M_VG$@;_P @6HHY?RLRS3D)85,RS",VO74;:C4E/SJM6@RIL."%0    7;?
M26PYS#N!6D426?)FY,WF68RBZ=/,;R#-[!^H>\?$^ZO3#/K_ .CPZ"2^@;9V
MVE;;B6#GQS?]*<L/[.!>OW/<DEDG=[R)55PU+I7-S+PJM=5G3?FT53)'QN1)
MH
M
M    /__0O\
M
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MA:#T['2&B,GTK'#_ .W65M;/#IE1HPIR?A<I1;;Z6\3*(]QM@
M
M                                                    ?__1O\
M
M
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MN9QEU*IV2I>.:6]E[L2E/] (
M
M                            !__2O\
M
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MV<A-:K1^O:%.ZGPVF8I6U7%[(RDUV-1]"X:F$6WLC"<V=#D5$EE@
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M**\$$U&/4DD6YZ=R:WT[D-GD-I]CLZ-.DGNQX(J+D_#)IR?6VV99& ,R
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ML>E)6T4UT2G''>G90'9BSX
M
M                           __]._P
M
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M4P]*R1_=HT<\]UK+45S'&WRJ'&L5L=Q43C27]&/:5-GI91AUE[@5:EA(
M          !ZN\NZC&J6WR*_L8E114%9/NKJVGO)CP:RIJXJYMC83'U^"&F6
M4+<<6?@22,Q^*M6G1IRK56HQ@FVWN22Q;?@2/)?WUGE=C6S+,:D:-O;PG5JU
M)O",*=.+E.<F]BC&*;;Z$BB'SDY/V7+;D7FFU7#E,8JVZC%];U,GN2NHP&B>
M<12I<95U\M^8M;UE+;ZF29$EU"3-"4](LZGSN>?YQ5OWBJ?I::?13CN\U[9/
MPR9_G^Y]\U;KG%S+OM72XHVB:H65.6^G:4FU2Q71*HW*O46W"I5FD\$C4,:^
M<:  \N!!FVDZ'65L61.L;&7'@P(,1I;\J9-EO%'BQ8S#9&I;CBU)0A"2,S,R
M(O$?J$93DH06+;P26]M[D?:WMZ]W7A:VT'4J59*$(Q3<I2DTHQBEM;;:22VM
MLOQ\-=!Q^,W&K5.G_*83=8_CC,[,7XYH<3,SC('%7>6O%(3XNMHFONQXZS/K
MY#;22Z$DB*5FG,J62Y+0R[U4(XS\,Y>5/Q[6TO D?Z%N27+RGRMY7Y1HS!*O
M;45*Y:P?%=5FZMP\?5)59RA!O^[C!;DD;/#-G50
M
M                                           #_]2_P
M
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MFEKOF:M89E3XLNT[P5]J\FI>2Q]ZP6._LW&5Q)KTLJ5-26%1%PL2'+H@
M
M
M  /_U;_
M
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ML>3O+BQTA;\,KE+MKRK'^^NZJ3JRQV8QAA&C2Q2?94X8^5B;9#/G7P
M
M
M/__6O\
M
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M-NU+1^E<LT5IVVTYE2]JMXX.37E5)O;.I/Z:<L6^A+"*\E)+8D:@;,
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M-)27.G5-'#T]/*Z<UUXPJWN#Z,.*C;M[\:M3#[%,LCCLI9R
M
M                                                       '_]>_
MP
M
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M*7"N;7/#-^8$YY1E*E9Y2G]CQPJ5\'LE7:>'#TQI1;BGMDYR47&$L27.#
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MC1H4(1ITZ<(J,(4X1480A%8*,8Q244MB221[(?L]0
M
M                                                 ?_0O\
M
M
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MT_"GK35E+"^FL;:A-?Y>+7V2HGNKR7I8O[%%[?;'A3LS"%9*H
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MZD'A;0:WTZ$G/>I5Y0DX$,)F:C-2C-2E&9F9F9F9F?4S,S'-R$#;;Q9_@
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ML%QU:DL93DTL6\$E%**RJ/>;<
M
M                                   ?_]&_P
M
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M\NM*\KM+T-):0MU0MJ.V4G@ZM:HTN.M7G@G4JSP6+P2BDH0C&G&,8YI&2-X
M
M
M           __]*_P
M
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ME)MO[8>DSH
M
M                       ?_]._P
M
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MED7F>7QQ?:4HOM:<?^[16,L$M\Z?'#!<4N#' A-]@DL<&
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MVD(]6ZTU'K?,GF>HKF5:2QX(>EI4HO#R:5->3!8)8O;*>"E4E.6,G[ 8PU8
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M/<XAA*/%#_!6TUM3HT9K&M.+W5JZWJ,H4:4UB3#CH9-(
M
M
M#__4O\
M
M                          BEYF^C?POYENVF47&&.ZCVU8>?(<VGJ9NO
MQ^SM;!SYY2LRQQ;2ZNX-:^TWY$B,B:M)=B)K9>)=WY<=XKF1RYC"QMKG\H9?
M#!>];IRJ1C%=%&IBJM'!>EC&3I)[73D<?USR0T+KB4[NO0]Y7LL7[XM\(2D^
MNK#!TZN+WMQ51K8IHJU<J_0 YNZ!=M+S5M76<G=?Q#=>8LM:MK@["9@HZ]BK
M75UHXJ6X^KV$Q1R;,_$C,R\2*<NA.]CRRU9&%MGE2627<L$XW/E6[E]+<Q7
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M
M
M                  ?_U;_
M
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M6HW3MJC\2ACX#57)N"_,C$%N)NN,>Z^QGKYLFGU]D.306R+VJ588TS+8)/\
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M$1%["(;,=T226"/] _H
M
M                                        '__6O\
M
M
M
M
M
M                   /_]>_P
M
M
M
M
M                                                          __
MT+_
M
M
M
M
M                                    #__1O\
M
M
M
M
M
M               /_]*_P
M
M
M
M
M                                                      __T[_
M
M
M
M
M
M                                #__4O\
M
M
M
M
M
M           /_]6_P
M
M
M
M
M                                                  __UK_
M
M
M
M
M
M                            #__7O\
M
M
M
M
M
M       /_]"_P
M
M
M
M
M                                              __T;_
M
M
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M:POLNK0KT*BQA4IRC.$EUQE%M->)GTP\1Z@
M
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M7-K.-2G42E&<&I1E%[4XR3::?0T\&>T'P/L
M                                        ?__2O\
M
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MB-:Y+K[(*>?Y++R9>34IRPXZ-1).5.:72L4T]THM26QFU(T4V\
M
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MJ=I;UUBNB4)+9*G..WAG![)+S4W%IO.0U@V
M                                       /_]._P
M
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M*HM[6'10%0)9D
M                                                           !
M0F]?3FY9\C.5]GH7%KE;FGN,MA-Q)J%$D&<#(-MD@H^PLBFMH,DN.5SQ'012
M<)7E>[2G&C(ICA':KW4N6='1^@X:JOJ>&8YW&-5MKRJ=KOMZ:ZE47M\L,.+C
M@I8]G$KN[Q>O:NI]8ST[:5,;+*FZ>">R=QNK3?6X/VF./I>&;7IV0."4Y'@
M       )Y_0-YRV7'#E-7: RVX6C37)BU@8NJ)+D**#C.W74>Y8%DD)M9FEM
M5F[V4,TD$GS?/B.NJ-,)!"*_>LY84=8Z&GJS+Z?_ -QR6,JN*7E5+1;:].77
MV:QKPQQX>&I&*QJ,D1W=>8%72^KHZ<O)_P"!S62IX-[(7.ZC-=7:/"C+##'B
M@V_(1?5%598@
M               '_]2_P
M
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MG.:SXJE6WIJI)[Y5*:[*I+S9PD_--S!S@WD
M
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M-=,V
M     !__U;_
M
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M&SXO'[RM_P"3 LM[O+F^4F5\6Y2NL/%[[K_RXDP CT=K
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ME=5XWE6FIRC"+4(TJ$E'"$8K8YR>[';O)G1' [F
M                 $??JL3),#TYN8;\0UDZO2F30U^6HTJ]VL?*KYI&9?K?
M)=<[B^4NI'[1UKD13A5YPZ=C4W*\IOS8XR7T4CF_."<Z?+'.Y0W^]:B\R6"?
MT&SFCBZ(JO            Z6_I2N2G?3EX>JF=3>+2N-MHZ]?W*RIUJ#[?\
M[!+?04N\^%"/.'42I[O?E3SW@Y?VL2T_D^YOECDCGO\ >L/.VX?0P)!1R4Z2
M
M !__UK_
M
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MM9<=*M"-2$ENE&<5*+7C33*?+FWK6=S4M+B/#4I2E"2?1*+<9+S&FCTX]!\
M         #I>^E?K"7I_T\>)6$SXYQ)YZDJ<SGQ%-FT[$G;/FR-FS(LEI7BE
MYMRX4AY)^)+)77Q%+?/3.Z>H>;N?YG2?%#WU.C%[TXVT8VR:?4U237@P+4>4
M64SR3EIDUA47#+WO&JUU.NY5VGX4ZF#\.)O^.3G1P
M                              ",GUE/T9?+7[!L?_"%3#M?=S^>O(/N
M]3\7K'*>>'S4YS]RA[M3.;R+D2KT        +UGPU7X@>=?G0["_!SAXJZ[Y
M_P Z]K^K+?\ &+LL%[K/S<W'P^M[A;%A 1())@
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M+<M&93/(M(Y9DU183M;6A3E]7"E%3\^2;-A1J)LH
M                                         '__U[_
M
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MLPA"G!4Z:48Q222V));$DNA(\@?@_0
M                   !&3ZRGZ,OEK]@V/\ X0J8=K[N?SUY!]WJ?B]8Y3SP
M^:G.?N4/=J9S>1<B5>@       !>L^&J_$#SK\Z'87X.</%77?/^=>U_5EO^
M,798+W6?FYN/A];W"V+" B023
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MMM3AAAOX..2]*SHWBG8L[
M                        #__0O\
M
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M-O;V<,7B]CJ3;D\$H1C*R.$'8
M                 (R?64_1E\M?L&Q_\(5,.U]W/YZ\@^[U/Q>L<IYX?-3G
M/W*'NU,YO(N1*O0        O6?#5?B!YU^=#L+\'.'BKKOG_ #KVOZLM_P 8
MNRP7NL_-S<?#ZWN%L6$!$@DF
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MVG(Y7;M5;JLU.YK88=I4PP2CCM5.FFXTXOPR:4IR)!1R4Z2
M                                                  '_T;_
M
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MJ*>TW.'.#>0
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M6PVB&CFV@
M             '__TK_
M
M              *VWQ.'XGFBOSE:S\%V2B9?<G^</-/U=+\9MR+O>M^1.7_#
MH^X5RD8+,2!(        =4GB_P#BT\>/N&:D^T&O%%>M_EIF_P -NO=ZA;QI
M/Y*Y9\$M_<8&<QJYL
M                           !&3ZRGZ,OEK]@V/\ X0J8=K[N?SUY!]WJ
M?B]8Y3SP^:G.?N4/=J9S>1<B5>@       !>L^&J_$#SK\Z'87X.</%77?/^
M=>U_5EO^,798+W6?FYN/A];W"V+" B023
M
M                               #_]._P
M
M                               "MM\3A^)YHK\Y6L_!=DHF7W)_G#S3
M]72_&;<B[WK?D3E_PZ/N%<I&"S$@2        '5)XO\ XM/'C[AFI/M!KQ17
MK?Y:9O\ #;KW>H6\:3^2N6?!+?W&!G,:N;
M                                             1D^LI^C+Y:_8-C_
M .$*F':^[G\]>0?=ZGXO6.4\\/FISG[E#W:F<WD7(E7H        7K/AJOQ
M\Z_.AV%^#G#Q5UWS_G7M?U9;_C%V6"]UGYN;CX?6]PMBP@(D$DP
M
M                                                 __4O\ "-GF+
MZK/$[@QLVBU+O>=L&-EV18)6;%KF\4PQ>15QXY;9!:8U#6]-3)9[7O>JB82F
MNT^B20KK\[H79N7?(C7O-#)*N?Z6C0E;T:\K>7:UNSEVD*=*H\(\+Q7#5AMQ
MWXKH.6ZWYP:.Y?YK3R;4,JRK5:4:T>SI<<>"4ZD%B^);>*G+9U8/I-3_ /$4
M>G)_Q;<_WK7?X<-]_A YQ?:[/XROK#3OXF>6/K[KXO\ ]8_Q%'IR?\6W/]ZU
MW^'!_"!SB^UV?QE?6#^)GECZ^Z^+_P#6/\11Z<G_ !;<_P!ZUW^'!_"!SB^U
MV?QE?6#^)GECZ^Z^+_\ 6/\ $4>G)_Q;<_WK7?X<'\('.+[79_&5]8/XF>6/
MK[KXO_UC_$4>G)_Q;<_WK7?X<'\('.+[79_&5]8/XF>6/K[KXO\ ]9O#PM]2
M'C-SVF[#KM!6>7R)^LHN,S<EB9AC"\9?5$RMV<Q72*M*WWO/0A<!U,@RZ>6:
MVNO7O+IS'F3R;UKRJIV=;5<*2A>NI&FZ-7M%C24')2\E<+:J)QZ\)=1O^A>:
M&E>8D[FEIR=1RM%!S52GP/"IQJ+CM>.#@\>K%=9OJ.5'1  /#L+"!4P9=I:S
MH=96U\=V7/L;"2S"@PHD=!N/RI<N2I+;;:$D:EK6HB(BZF?0?2C1JW%6-"A%
MSG-I1C%-RDWL226+;?0EM9^*E6G1IRJUI*$(IMR;222WMM[$ETMD2_(KUP?3
MSX\NSJG^EI_=.5P5.MNXSHFM:SM!.M]4=BLS>?AXYX+(TK0BY6XGH?5OV=>^
MZ/[LG-W5T8U_R>LMH3P]LOI.AL^XJ,[C=M3=%)]9QO4W/WEIIIRH^_'?UH_W
M=I'M=OW5N-#?OPJMKJ(9-P?$_P"?S')430?%_$,?80;B(=[MW,+G+GY*3/\
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M-:%.SPFDU_B5N:Q7J"/]3O+<LJ525*4[G&+:?M'2GAZ\\7_$4>G)_P 6W/\
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M:IG WWE>5J6/;W#_ /EYGC?XA_TWO^\NW/O56G^W'[_A#YR?:+3XU'ZT_/\
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MW^FMOC5,?Q*<K?M]?XO,?XA;TU_^^VT/O3Y&'\(W.;_36WQJF/XE.5OV^O\
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MY(VG1_.30NN,W_(>15ZCN."511J4I4U)0PXE%O8Y)/BX=_"I/<F25#C!U,
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M<@             __]6_P *-/Q,_X^&IOS1\#_#'GHL^[E7S67_ZUK_BEB0
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M&,H22E&2?2I)II]*951<4*UK7G:W,7"I3DXRBU@XRB\)1:Z&FFFNL]8/N?$
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ME<Y.95;F+J>56VDUEUIQ4[6#Q6*Q\JM)>OJM)X/;&"A%[4VXKQW0Y"
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M09%EFF<FM\BR>FJ5M;04(1Z>MRD^F<Y-RG+?*3;>\RL,"9@
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MX(LU$P^Y3\YN8_JNK^-V9&/O6?("Q_6%/\6NBCJ+.2 8
M  9GXX?C#Z&^[/J[[>((UO6/R0S7X'<^XS,[ICY2Y=\)H>ZP.JJ*)RWL
M \.P_<$[]YR?VE0^E'[-#QKT3\5/L<O$_0.2>+^"FH        .IOQ'=\_BE
MQC>[>WSN/6EW>WKU[?,UO6K[>OR].HHQY@1X=>9W'JO[Q?\ U%0MST9+BT?E
M,NNSM7_Z$#84:B;*?%;$V1@.H\-O=A[/S''<"P?&H:IU[E.56L2FIJZ.1]J/
M.F3%)2;CBS2VRRCJXZXI+;:5+4E)Y/)\FS;4&8TLHR2WJ7=U6?#"E2BYSD_
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M#B=G'*'EK:\N--1M:BC/,+GAG=5%MQGAY-*+^UTDVEZZ3G/9Q8*3D<3.K@
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MTL=W:32V.K-;9/:HK"$6TL91ICM!RL
M #JD\7_Q:>/'W#-2?:#7BBO6_P M,W^&W7N]0MXTG\E<L^"6_N,#.8U<V
M   Y,F7_ ,[,H^R*[^N3HOPR_P#R%#[G#V**<;W_ #E;ZN7LF?/#V'E
M  M,?"\_UM\L_N=:T^V:R$&>_!^8,@^$7/N=,ESW3/SSG/W&A[.9<D%=)-\
M     "LQZY_JR2]&UMMPXXX9*J'N#(JI#>Y,_II1HFZOQBYA$\QA^/S&#[F;
M^TC.I=D2D*)<"&M!M=)4EMV)-7NO\A*>IZU/F+K*CQ9=1EC9T)KR;FK!X.M4
M3]-0I2348O95J)\7M<'&I%3O \XYZ?I3T1I>KPWM6/\ B:T7MH4Y+%4X-;JU
M2+Q<M].#6'ER3A2J,S,^I^)GXF9^TS%DY!(
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MBS[N5?-9?_K6O^*6) #O5_.'9_JZC^,W979$OB,P
M           &8= ;UV+QHW%@.\=4W*Z3.->WT:[JG^KIPI[">K%I0W,=I2#?
M@6,5;T*='[B\QAU:>I&9&6NZLTOD^M-.W>F,^I]K:WD'"2V8Q>^,X-X\-2G)
M*<)=$HIF;TYJ#,]*YW;9_D\^SN+::E%]#6Z4)+9C"<6XS73%M'3)XB\G<#YA
M\>]<<@=>K\FHSBG2Y:4;LAN188CE=>LX&4XC:J02?V>!,0ZR3AH23S7ER$%Y
M3R#.ECF!HG->7FKKS26;K&I:S\F:6$:M*7E4JL?I9P:>&+X9<4'Y466J:,U7
MEVMM-6NI,MV0N(^5#'%TZBV5*<O#"2:QP7$L)+9)&R0TPVD     ]!E64X[@
M^,9#F>7W,#'<4Q.DM,DR6_M9"(M92T5+"78VUK/DK\$,L,-K=<4?L2DQZ["Q
MO,SO:.6Y?3E6KW$XTZ=.*QE.<Y*,8Q72Y2:276SS7EW;9?:5;Z]FJ5&C&4YS
MD\(QA%.4I-]"23;.<;ZHGJ#Y9Z@/(6QRUMZQJ=*X([88WI+"I*UM)K\<.012
M\MN(1'V%;W:FVY,P^AFRTF/#);B(J7%W%<C^4EARFTC#+VHU,RNE&I>UEMXJ
MF&RE![^RHXN,/72<ZF"<VE6'S:YDWG,?4LKU.4+"WQA:TGZF&.VI);NTJX*4
MO6KAABU!-QJ#LYRP                            +5?H">I_*QN\I."&
M]LA6_C.0RG(_'/++B7U/'<ADJ4^YJ2;+D'T]RL5FIRA[E$;4LU04=Z945N/!
M/O7\D87MK5YI:6HX5Z*QS"E!?9*:V*ZBEZNFL%7]=3PJO!TYN<ON[ES9G:W%
M/E[J&KC2JO"RJ2?I)O;[W;?J9O;1ZIXTUBIP4;B(KO)M       4I_B$/41D
M[4V6YPFU7>++6VI;9F7N:PK91E'S3:D3H['Q)];!]'86-=>C[2C[56BG2<;[
MZ]AP64=TCE!#(LE7,O/:7^-S"#5G&2VT;5['56.Z=SZE[U04<'A5FB"/>3YF
M2S?-7H/**G^%LY)W+B]E6X6ZF\-\:'2NFMCBL:<65FQ-0BJ
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M5>WEW=9A=U;Z]J2JUJTI3G.3QE*<FW*4GTMMML]"/4>8
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M6VWM;;VMO:V620A"E!4Z:48Q2226"26Q));$DMB2/)'X/T
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ML(QBEL22222V);"K"K5JUZLJ]>3G.;<I2;Q<I-XMMO:VWM;>]GA#ZGS
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M[3GYUF(_@BS43#[E/SFYC^JZOXW9D8^]9\@+']84_P 6NBCJ+.2 8
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MS#YC?9=ICZS9&*\N_%^=-._<KSV=N39[I7YOSS[I:^QKEK$00)?@
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MU&I"+PVX8$<M1Z4U'I*\]X:CLZEI4VX<<?)FEO=.:QA47AA*2\)@H;2:\
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M%K%2C)8IIK:FG@UN.!5:56A5E0KQ<)P;4HR34HM;&FGM33V-/:CP1]3Y@
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MW0YCSAU:]&<O[_-*$N&XJQ["@T\&JM;&*E'PTX\=5?4'-<]HN;*M0
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M:OQ'M.?G68C^"+-1,/N4_.;F/ZKJ_C=F1C[UGR L?UA3_%KHHZBSD@&
M             &9^.'XP^AONSZN^WB"-;UC\D,U^!W/N,S.Z8^4N7?":'NL#
MJJBB<M[     /#L/W!._><G]I4/I1^S0\:]$_%3['+Q/T#DGB_@IJ
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MLY3J3D^F4Y-R;\;)NV5C99;:0L<NI0H4*2X84Z<5"$4NB,8I)+Q(^E'B/4
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MR:N^75VLURIRKY37EA&;VSH3>U4JK6]/^[J8+BP<9)22<H5Q),X2
M  6Z?A:?W#SA_??'#]ISL5^]^7[+ICQ9AZ-B3/[H_P!CS_QV7H79;3$!29(
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M*49)IIIK%--;&FMJ:V-%6%2G.E4E2JIQE%M--8--;&FGM33V-'C#]GX
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M&Y69\F>6-MR[TW&5U!/,[R,9W,]C<>F-"+]93Q\K#T]3BEBUP*,L8X(=B
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MX:F_-'P/\,>>BS[N5?-9?_K6O^*6) #O5_.'9_JZC^,W979$OB,P
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M6RZ&TK:Z+TI9:;MDO\/32G)>KJR\JK/K\JHY-8[HX1W)&T T@VP
M  "J5\3=QNC3L0T+RPI:Y!6>/W,W2.>366B4_*I+QB3EV /RE)+JEJ%+CW3'
M>KJ1KG-HZD?:1SP[E&LITLQS705S/R*T%>T$WL4X.-*NEX9QE1EAU4I/K(?=
MZW2\*EEEVL:$?+IR=K6:WN,U*I1;\$91JK'KJ)%/@6&$*         MT_"T_
MN'G#^^^.'[3G8K][\OV73'BS#T;$F?W1_L>?^.R]"[+:8@*3)       C)]9
M3]&7RU^P;'_PA4P[7W<_GKR#[O4_%ZQRGGA\U.<_<H>[4SF\BY$J]
M "_C\/!^C>QK[KFU?KHP*HN]Y\\E?X):^QD6,]VCYKZ7PBX]DB<L1@._@
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M?(#^H;=OW(]D?:;-&P:3^5.6?"[?W:!AM1_)Z_\ @]?W*1RGQ>X5
M !<+^%R_F'S&^R[3'UFR,5Y=^+\Z:=^Y7GL[<FSW2OS?GGW2U]C7+6(@@2_
M            "/3U0N'47FYP\V3JB##8>V+1QRV'IZ6X2$N1MDXG$>>JZY#[
MG@VBWC.2Z5]:NI(1+-WH:FT].N<D.8E3EGS$LL^JR:LZK][W:Z[>JTI2PZ72
MDH5HKI=/AW-G->;6B(:]T3=9/3BG=4UVUL^JO33<8X]"J1<J3?0IX[TCFJRH
MLF#)D0IL=^',AOO19<24RY'DQ9,=PVGX\AATB6AQ"R-*T*(C(R,C(C(7/0G"
MK!5*;4HR2::>*:>U--;&FMJ:WE6<X3IS=.HG&46TTU@TUO370UTH_ ?H_(
M              &7M":,V-R4V]@FD-3TB[[.]A7D>EIXO[(B'#;-)R+*[N)3
M:5^[P*^*AZ;.DFDR:8:<7T/IT/7M5:HR?1FGKK4V?U>RM;2#G-]+Z(P@MG%.
MI)J$(^JE)(S>G=/YIJG.K?(,FI]I<7,U&*Z%TRG)]$(13E.71%-G2HX1\/\
M7/![CUAVB==M-RU537U7S?+G(J(UGGV?63#99%EMFE)J-/FJ;0Q#84XOW>(U
M'C$M9-=QTQ\S.86<<SM77&J<W?#VCX*-+'&-"A%OLZ4?$FY3E@N.I*<\%Q8*
MTO06BLKT#IJAI[+%Q<'E5:F&$JU:27'4EX\$HK%\,%&.+PQ-MAH!N0
M                 ?_6O\ "C3\3/^/AJ;\T? _PQYZ+/NY5\UE_^M:_XI8D
M .]7\X=G^KJ/XS=E=D2^(S        !U2^,NLF-+\<]$:DCQ2AEK?4.N\,?9
M(NBCG8]BD6MLGWO NKKLAMUUU1EU4M2E'XF**M:YW+4FL,US^<N+WY=W%9/Z
M6I5E**7@46DET))%O.E,JCD6F,OR:*X?>MM1I->&%.,9-^%R3;\+,XC6#/@
M          ?RM"'$*;<2E:%I4A:%I)2%H47:I*DJ\#(R\#(Q_4VGBMC1_&DU
M@SER\U]--<>^7'(S3,.-[I48#M[-JC&F.WL-.'NW+ECAJS1\AKJGX:S(O NO
M@9EXB\3EKJ.6KN7^3ZCJ2XJEW:49U'_W5!1K>=5C-%2NO,CCIK6>9Y'!80MK
MFK&"_P"WQ.5+_P!-Q9J^-W-2       RUH+(G,0WMI7+&5^4]B^VM<9$T[UZ
M>6Y2YC#LD+Z_)T-HC& U79QS#2V96$EBJ]K<4VO!.C./\IF=.7+LM0V%Y'8Z
M-Q0G_5JQE_(=6(41%OYZ?(;F-CE!>9#-_<=#3V=S+Z'T/W:KA+G/^)_Z"#'H
MM+:=Y=TK2GZ:K.,%XY-17T6?"YKPM;:I<U/2TXRD_%%-OT#DU6MG,NK2RN+!
MTWY]M/F6<Y]1F:GID^0J5)=49]3ZJ6M1GU,7WT*-.VH0MZ*PA3BHQ74HK!+S
MD4Y5JLZ]:5>H\93;DWUMO%_1/ 'U/F
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MEFLPUAE.7R6*KWEK3?\ 3KPC_*8+5-R[+3.8WD=CHVMQ/^K2G+^0Y5HO7*A
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M_F'S&^R[3'UFR,5Y=^+\Z:=^Y7GL[<FSW2OS?GGW2U]C7+6(@@2_
M       *"WKY\,/[-?+V5MW$JCW+5?)TK3/8!Q6>R!3[.BOMELZB+L+H@Y,A
M]B\;ZF1'[\ZVV7;'/I:UW4N8_P"V?+V.G[^IQ7V2<-"6+\J=LT_>T_#PQC*B
M_N47+;-%=/>*T-^RVM7G5G#AL\VXJRP6R-=-=O#^E)JJONC2V1(+!*(CZ
M            ?ZE*EJ2A"5*6I1)2E)&I2E*/HE*4EXF9G["!M)8L_J3;P1?:
M]$#TST\/=0_TZ;<H4L<D=T4<5V1 L(Y)GZJUQ,4W8U>$)0Z7>S93C2S.O2/M
M4AQ,>$:4JB.+>JI[S?.E\P]0_LOI^KCDV6S:4HOR;JX6,95MFQTX8N%#>FG.
MIBU4BHV)<@^52T3DO[09U3PS2^@L5);;>@\)1I=:G/9.KTIJ,,,8-RGA$620
MH                        !__U[_  HT_$S_CX:F_-'P/\,>>BS[N5?-9
M?_K6O^*6) #O5_.'9_JZC^,W979$OB,P      'W.L*EB_V7KRBE()R-=9SB
M53(;/P)QBQOX\-U!F?T4K,AB\[N)6F2WEU!X2I4*LT_#&G)KT#(931C<YK;6
M\]JJ5:<7XI32?HG6#%"Y<0               <^3U_<19QGU,]M6;#26DYUA
MFI<N6E)$E"GD:_A8B^ZE)>!&M=2:EG\JC4H_$S%MG=/S"5[R5R^C)X^]:UU2
M\SMYU4O,57!>#!%;?>-LHVG-6]JQ6'OBE;U/-[&--^?V?GD+PD@<+
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M:C[(^![5E)3W%VDJ9D-.RI1)^0S)@NI_+T+Z L3[C\$LDU!5Z77M5YU.L_\
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M)]93]&7RU^P;'_PA4P[7W<_GKR#[O4_%ZQRGGA\U.<_<H>[4SF\BY$J]
M    "_C\/!^C>QK[KFU?KHP*HN]Y\\E?X):^QD6,]VCYKZ7PBX]DB<L1@._@
M         #V@#DAB_P *9P        F5]";C%5<D.>^&V64US5EA6A*&PW==
M0I31.0K&\QVQB5.!U[_>1I,T7,Z)9>4HC)QN&Z@R[3,1S[TFMZ^C>55S1L9N
M%SFLXV4&GA*,*D93KR73MHPG3Q6V+J1:VG<>[YI.CJCF+0JWD>.AET'=23W2
MG"48T8O_ ,V<9X=*@UN.A.*CRR<               Q'R _J&W;]R/9'VFS1
ML&D_E3EGPNW]V@8;4?R>O_@]?W*1RGQ>X5         !<+^%R_F'S&^R[3'U
MFR,5Y=^+\Z:=^Y7GL[<FSW2OS?GGW2U]C7+6(@@2_               (Y_5
M0X;L\V^'.QM8U<%J3LO&&BV3IV0I*"?3L+%(CSD2E:=7T[4W,-R93+-1]J#E
M)>41FTGIV'D7S%ERSYBV>=UY.-E7?O>[71[WJM)S:Z71FH5ETO@<5Z9G,>;N
MB(Z]T1=951CC=4O;[9]/;4T\(_\ FQ<J3Z%QJ70<V!]A^*^]&DLNQY,=UQB1
M'?;6R^P^RLVW67FG")25I41I4E1$9&70_$7,QE&<5.#3BUBFMJ:>YI]*95O*
M,H2<)K!K8T]C370S\A^C\@            !95] STS?Z;LYA\S=U8_YVHM8W
MJDZ@Q^UB]8FQ-F4LCJK)W6'RZ/5..OI(T&1=C]DE+?<I,*4RN&'>MYU?LSE<
MN7&FJN&87L/\74B]MO;37V--;JMQ'?TPHMO!.K"2E-W=>57Y>S".N<^IXV5I
M/_#0DME:O%_9,'OIT7NZ)5<%CA3G%W9Q6D3R
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M/Q,_X^&IOS1\#_#'GHL^[E7S67_ZUK_BEB0 [U?SAV?ZNH_C-V5V1+XC,
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MV>6>82>"H5Z-1OZBI&7\ACLXM7>Y3=645BZU&I#^O"4?Y3E "^<IX
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MM9K#M+J5=>%7,8W"?_J^>6E<F<QCFG*_);B+QX+=47XZ$I4,/_3)&1QXZ<
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M56/BXZ<(^.2)0]U7,8V^M;[+9O#WS:.2\,J56F\/'PSF_$F7>Q663W
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M\+E_,/F-]EVF/K-D8KR[\7YTT[]RO/9VY-GNE?F_//NEK[&N6L1! E^
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MPG<3PG<U4MM6LUMPQV]G#TM-;,(KB:XI2;WT'*SH@
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M8P&;,2      !)KZ..MU[0]2GBK3G&-^+CF=3=D37#0:FH:-8XS.SN#)>/\
M6D<V!%:0?_M%H+Y1Q3O%9RLCY,9[<<6$JU"-O'K?OFI"A)+^A.3?@3.K<D<K
M>;<TLGH88JE5==^#L*<ZR;_I0BEX6CI#BFXM"  Y6?)O7R]3<C]^ZO6PJ.6O
M-S[.PMII23011L:S2;41%MD?M0MII"VU%X*29&74C(7JZ)S99_HW*<\3Q]^6
M=M6;\-2C";\U-M/J94/JO+7DVJ,QREK#WM=5Z6'@A5E%>8TDUX#!XV<U\
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M5*4)23\*DVGU--%0VJ\K>2:GS')VN'WK<UZ27@A4E%8>!I)KP&#QLY@
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M%1<6 D,         MT_"T_N'G#^^^.'[3G8K][\OV73'BS#T;$F?W1_L>?\
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MQ/-WWQ.KR]TW5\B+PO:L7Z:2_P#AHM>IB_LS6^7M6Y5%*J")YD/
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M$S_CX:F_-'P/\,>>BS[N5?-9?_K6O^*6) #O5_.'9_JZC^,W979$OB,P
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MI/\ H3[2FO,H5:2\PK6[PV2/)N:-[52PA>PI7,/Z<.";\VK3J/S2'$2*.(
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MBG8GI7SU1,ILI:4&9MJOUH71Q4+3T=CG8J2I*V$]9;=TSE;5U9K%:WS.G_\
M;\FDI4VUY-6\PQI177V":KR:>,9]BFFILC;WC^85/3FF'I.PJ?XW-(N,\'MI
MVN.%23ZNVP=**>^/:M;8HHI"T8KY          .J3Q?_ !:>/'W#-2?:#7BB
MO6_RTS?X;=>[U"WC2?R5RSX);^XP,YC5S8     #DR9?_.S*/LBN_KDZ+\,O
M_P A0^YP]BBG&]_SE;ZN7LF?/#V'E       M,?"\_UM\L_N=:T^V:R$&>_!
M^8,@^$7/N=,ESW3/SSG/W&A[.9<D%=)-\   .?5Z_&EG-2^HSL+(6(QQZ3=^
M(X3MNI[$=&"DRJP\*R9).EX&XY:TLR6XDS[B\])F7123.VKNHZDCG_)ZTM)2
MQJY95K6D^O!2[:GLZE2K0@NCR7U,K=[QF1/)N9US<Q6%._ITKB/5BX]E/S74
MI2D_JD0L"21PD        .@+Z'//FNY;<7ZC5>97;;N^>.]/4X=E,69(([/+
ML!A-%78-L".EP^]\_=T-UEJ[W+64QGSWC04U@E5-]YWE36T!K>IGN74L,JS>
M<ZU)I>32KM\5>@^B/E-U*2V+LY<,<>REA8]R!YBTM9Z3AE%]4QS'+(QIU$WY
M52BO)I5ETOR4H5'M?''BEAVD<9MQ&<[T          8[VWM7!=':SSC;VR[R
M/CF":\QRQRC)K>0:3\BOKF3<\B*R9D;TJ0OLCPXR.KC[[C;+9*6M)'F-/Y#F
MFI\ZM=/9+2=:ZO*D:5."Z92>]OHC%8RG)[(Q3D\$F8S.<XR_3^57&=9K45*W
MMH2J5)/HC%;DNF3>$8Q6V4FHK:T<Q_F)R8ROF!R2VKR$R]+D27G^1NR*6D6^
M;[>+X?6,HJ,.Q=A9?-/W&N8C,NN(2DG7B<?-)*=4+K^7>BK#E[HVPTCE^$HV
ME-*<\,.UK2;G6JOI\NI*32>/#'ACCA%%4FMM57FM=47FI;WR97,\8PQQ[.G%
M*-*FOJ(**;6'%+&6&+9K.-U-5        "W3\+3^X></[[XX?M.=BOWOR_9=
M,>+,/1L29_='^QY_X[+T+LMIB I,D      #1SU,:%62>GQS+KD-^:ICCIM*
M\)!%U/\ _9C%I&2FHB^BGW3N+_L'3^2MTK/FWIRLWACF%M#[[5C3_P#&:!S5
MMW=<ML\I)8X65Q/[W3<__"<R876E4P        6Z?A?]SP#@<H>/,Z8VU9HF
M8?N;&(!K_9)L)UA>$YS+2V9^!1EMX\@S(CZ^>77IVEUK][[NFZO:Y'JZE'&&
M%:SJRZFFJU!?TD[A_P!'PDS^Z;GM/L\VTU4EA/&G<TUUK!TJK_HM4?ZQ;3$!
M29(           ')#%_A3.        %K#X7+^?G,;[$=,_7G(A!'OQ?FK3OW
M6\]A;DO^Z5^<<[^YVWLJQ<,%>)-D               Q'R _J&W;]R/9'VFS
M1L&D_E3EGPNW]V@8;4?R>O\ X/7]RD<I\7N%0         7"_A<OYA\QOLNT
MQ]9LC%>7?B_.FG?N5Y[.W)L]TK\WYY]TM?8URUB(($OP           ('/6O
M]4ECAMK9S1.F+UH^3FTZ-TTV,%Y"W].X+8$N(_F<DT&9MV\TB<8HF3Z&V9.3
ME]$LL-R93]VKD;+F+G*U3J2D_P B6,UY,ELNZ\<&J*ZZ4-DJ[Z=E);92<(\\
M]^;<=#Y6]/9%4_\ NUY#TR>VVI/%.J^JI+:J2Z-M1^EBIT*WWWY3[TJ4\[)D
MR77'Y$A]Q;S[[[RS<=>>=<,U*6I1FI2E&9F9]3\1:G"$:<5""48Q6"2V));D
MET)%=\I2G)SF\6]K;VMM[VV?D/T?D               NN_#;<M2V#H?/>)>
M3VA.Y/HRT=S+7[$AWJ_+U;F]DI^VA1&U&:E)J+YQY;RS,B2BSBMI+H@5J]\K
M0#RG55IKZQAA0S2*HUVEL5S1BE"3ZG5H))+I=";>\G?W7-9?E+3USHV[GC5R
M^7:T4][MZLL9)?<ZS;;Z%5@EN++XA:2I
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M\39QW=O]6Z&Y/TL#S).O,DMM49O)8;[WOY.9NT5YB,V8OI\V/"L8,R,D^O\
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MJJ^EJ1*K>;&EY:1Y@9EE$8\-%U76H]78UO;()>"'$Z;\,&:##JQSD
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ME@E6;J74>;:LSNOG^=U.TN+B6,GNC%;HP@MO#"$<(Q70EM;>+>%QLA@@
M     #JD\7_Q:>/'W#-2?:#7BBO6_P M,W^&W7N]0MXTG\E<L^"6_N,#.8U<
MV      Y,F7_ ,[,H^R*[^N3HOPR_P#R%#[G#V**<;W_ #E;ZN7LF?/#V'E
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MO*S[5NP<+2R1=3=5E.)2Z,FR+_2\_H,YI?,EDVI<NSAO#WI<T*V/5V56$_\
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M'.<XS'4&:5\YS>JZUS<S<YS?2WT);E%+",8K!1BE%)))&.QES&
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M!))8))+8DMB6XCE4J5*U25:M)SG-MRDVVVV\6VWM;;VMO:V>(/H?@
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M;[+M,?6;(Q 'OQ?G33OW*\]G;DS>Z5^;\\^Z6OL:Y:Q$$"7X   <D,7^%,X
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MUK_BEB0 [U?SAV?ZNH_C-V5V1+XC,
M  %X[X>K@B_HG15IRKV)2JA;-Y$5D1G"(LYCRYV-Z28D(L:I\B61*;7DDI#5
MHM/B2H;%:LC2I3B16)WN.:4-4ZIAH3)ZO%991)NLXOR:EZTXR7A5O%NDNJI*
MLGBDF3][M?+V6GM/3UAF=/AN\SBE236V%JFI1?@=>251]<(TGO;18N$/B38
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MU/=:<S!-NC+VN>&"JTI;:=1='E1PQ2QX9*4'MBS5X;P:D
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MGYS&^Q'3/UYR(01[\7YJT[]UO/86Y+_NE?G'._N=M[*L7#!7B39
M      ,1\@/ZAMV_<CV1]ILT;!I/Y4Y9\+M_=H&&U'\GK_X/7]RD<I\7N%0
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M=G->MS#SOWCELG'*;.35&.U=M/:G<37A6*I)[80>Y2G-$-8D8<.
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M?_K6O^*6) #O5_.'9_JZC^,W979$OB,P
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M9)E6&MM'YKH74=?3N;1\ND\832PC5I-O@JP^EDEM6+X9*4'Y46:Q#=C4P
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M3'UFR,5Y=^+\Z:=^Y7GL[<FSW2OS?GGW2U]C7+6(@@2_   #DAB_PIG
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MXI8D .]7\X=G^KJ/XS=E=D2^(S                              &\7
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M*3LYTMIC*-'Y'0T_DE/LZ%!8?33D_35)O9Q3F]LGYB2BDEG4:N;
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M316AG.39GI_,ZV39Q1E0N;>3C.$MZ?6GN<6L'&2;C*+4HMIIF.AF#&
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M3K'U7I3.M%YW5R'/J3IUJ3V/:X5(/'AJ4Y8+BA+#8]Z>,9)2C**U_&V&M@
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M^?G,;[$=,_7G(A!'OQ?FK3OW6\]A;DO^Z5^<<[^YVWLJQ<,%>)-D
M       Q'R _J&W;]R/9'VFS1L&D_E3EGPNW]V@8;4?R>O\ X/7]RD<I\7N%
M0         7"_A<OYA\QOLNTQ]9LC%>7?B_.FG?N5Y[.W)L]TK\WYY]TM?8U
MRUB(($OP    " /UN?5,;XC:^?XZZ0R!">2FSZ-?U4NJV01RM-8#:-JCN9$I
MYH^K-Y9([VJ9LC)R.WWV"C0:892)8=V;D8^8&;K6&IJ7_P!EL9^3"2V7E>.W
ML\'OH4W@ZSW3>%)8XU.".7/OFXM&9:],Y!4_^ZW</*E%[;:C+9QX]%6:Q5);
MXK&H\,(<5$)QQQYQ;KJUNNNK4XZZXI2W''%J[EK6M74S,S,S,S/J9BTM)12C
M%8);D5ZMN3Q>UL_@?T_@        ;$\4^,>S.8.]<&T)JF![QD>86!%/MI#3
MJZ?$,9AF3V0YED3S7^KA5\?JZOQ[W5^7'9);[S3:M/UYK;)>7FEKK56?3PHV
M\?)@FN.K4>RG1II[YU);%T16,Y80C)K9M'Z4S76NH;?3N3QQJUY;9-/AITUM
MG5GANC!;7TMX1CC*23Z5W%?C-K/B%HO!="ZHKO=,9PRM)N59R&VDW&69'+Z/
MY!F&1/M$1.SK"1W/.F7S&T]C#)(89:;13#KK6N=<P=476JL^GQ5[F6R*QX*5
M-;*=&FGNA3C@ETR>,Y-SE)NTW2&E<JT7I^WT[D\<*5".V3PXJDWMG4F^F<Y;
M7T)81CA&*2V%&HFRE)?XA_@4O4FX*_F3KJE\K7>\;--3M*/ C](N,[B:B*>1
M>/(:(DMLY+$97(4KM/K/CRW'5]\MI)V7=T/FJM0:>GRYSBIC>99'CMG)[:EH
MWAP+'>[>;45_VITU%84Y,@;WE^7;R;.XZXRRGA:YA+AN$ELA<X8\;ZE7BL?N
MD9MO&:16K$SB+(        ?;:WV+FFHL^P_9^NK^;B^<X'D%9E&+7]>LDR:V
MXJ9*945[L61H<;,T]CS#J5-NMJ4VXE3:U)/&YSD^6Z@RJXR3.*4:]K=4Y4JM
M.6Z4)K!KK3Z5)8.+2DFFDSWY7F=]DN8T,VRRHZ-Q;SC4IS6^,HO%/J:Z&GBF
ML4TTVCI)^G3SIP7GUQVQ_:V/K@56>TR(F.;BP-AXSD87GC,4ERR89>4IU578
MD2IM1)4:B6RHVEK]YCR4-TT\X.5V:<J=85<ANU*I:5,:EI7:V5J#>S%K9VM/
MTE6.S"2XDN"<&[1N67,'+^8NF:><6V$+B&$+FBGMI5DMN">WLY^FIRVXQV-\
M49);YCE9T,           #_%*2A*E*424I(U*4HR)*4D74U*,_81?*8)-O!!
MO#:RF+ZV_K"-;;=R/AUQ8R@G=6Q'WJG=6U*&89M;*FQG>R5@&(6$8^B\?86D
MTV4YM1E9N%Y+1G7H6NPL>[L_=YEI^-'F)KJAA?22G9VLUMMXM;*]6+W5Y+;3
M@]M%>5+VYI4H,\^N=BSEU=$:1K8VD6XW5Q!_9VM]&G);Z*?IYK[*_)C[6FZE
M7X3>(F@ 7U_0)X/JXT\6?Z<,WJ#A[:Y-,5.5J;F1^R?C6IXC:WM?4?1TC4TN
MP0\[>2B2:>]$B(TZ@G(A=*J^]=S-6M-=?LQEE3BR_)'.EL?DU+IX*XGLWJFT
MJ,<<<'"I*+PJ%B/=TT"]*Z1_+]_#AO<U4:FU;86ZQ=&'@<TW5EUJ4$UC GE$
M5R0X '__T;_  HT_$S_CX:F_-'P/\,>>BS[N5?-9?_K6O^*6) #O5_.'9_JZ
MC^,W979$OB,P      'W6K\:@9ILS7>'6KDIFKRS.L1QJR=@N-M36H%[?QZN
M8Y#=>0XA+J6W5&VI;:B)70S2HO \7GE[5RW);S,:"3G;T*M2*EBTY0IRDL4F
MGABMN#3PZ49#*;6G?9K:V-9M0K5:<)8;\)S47ABFL<'LV/Q&[WJ*^FWN;T]]
MG.4F5QI66:@R:PE_T6[@@05MTN2PD=S[=)>H;[TUUY'9+_>J]Q?19)4]&4\Q
M\\N9<G^<NG.;>2*YL)*WS"A%>^K24O+IRW<<-SJ4)/TM1+9BHS49;#?N9O*[
M/.6V;.A>)UK*JW[WN4O)FM_#/UE6*]-!O;@Y0<H[2.<=A.8@
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M+<91:VIIM-;B$-Q;W%I7G:W=.5*K3;C*$XN,HR3P<91:333V--8H]2/0?$
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M=I#/-$9W4R+/J79U8;8R6+A5ACY-2G+!<4)8;]C3QC)1DG%:YC<#6
M     +A?PN7\P^8WV7:8^LV1BO+OQ?G33OW*\]G;DV>Z5^;\\^Z6OL:Y:Q$$
M"7X   <D,7^%,X        6L/A<OY^<QOL1TS]><B$$>_%^:M._=;SV%N2_[
MI7YQSO[G;>RK%PP5XDV0              #$?(#^H;=OW(]D?:;-&P:3^5.6
M?"[?W:!AM1_)Z_\ @]?W*1RGQ>X5         !<+^%R_F'S&^R[3'UFR,5Y=
M^+\Z:=^Y7GL[<FSW2OS?GGW2U]C7+6(@@2_   ".SU+/4$P7T^M!S\\LOJ??
M;7R],^@TOKV0^9.9+E+<<C>N;5AA274TU03K4FS>2:>[N9BH<0_*9,=?Y+\I
M<TYM:KCE5'BI6%OPU+RX2^QTL=D(M['6JX.--/'#"51IQA(YES3YD9?RWTY+
M,:N%2\KXPM:+?IZF&V4DMO94\5*H]F/DP34IQ.<CL_9F=;FV%E^U-F9'89;G
MN=WLW(LHR&S<)<JQLYSG>LR0@B0TRTDDLQHS*4M,,H0RTA#2$)*XG),ERO3F
M46^19+1C;VEK"-.E3CNC&/T6V\7*3;E*3<I-R;96+FV:YAGF95\WS6JZUQ<3
M<ZDY;Y2?T$ENC%8*,4HI))(^$&4,<        'F5U=86]A!J:F#,L[6TF1:Z
MLK:^,]-GV%A-?3&AP8,..E3CKSKBDMM--I-2E&24D9F1#YUJU*WHRN+B2A3@
MG*4I-*,8Q6+E)O8DDFVWL2VL^E*E4KU(T:,7.<VHQC%-N3;P226UMO8DMK9T
M*/1U]-NOX(:*3D>>5L1[DGN"OKK79M@9,R7<*INA3*75=3,1W))N":B>MG&5
M&F1.-7SW6(T12:C^\1SEJ\T]4^\\JFUDV72E&VCM2K3W3NIKKGNI)[84L-D9
M3J)V3\DN5U/E[I[WUF,$\TO5&5>6Q]E'?&WB^J.^HULE4QVRC"#4Q CN=M
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MS@^.4N(89CU+B>*8Y7QZF@QO'*R'345+5Q$>7%KZNJKT-L,,MI+HEMM!)+Z
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MO.36MM!3G7O+=W5E'=<T$YTTNNI'#CHO=CQI0QV1G+>1BCMAR<
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M:?W#SA_??'#]ISL5^]^7[+ICQ9AZ-B3/[H_V//\ QV7H79;3$!29(
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M56*F)W;^5/;U(<Q,_I^1!OWE3DO326QW+3Z(O&-'Z;BJ+#AIR=OL5[DU
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M/9'IJS67Y!:4K2BO4TH*.+ZY-;9R^FDW)]+,LC &9
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MPS' _P#ZL\N/^?-.?^ @_C5YI_Z#*OO%W_[X?PJ<O/\ 69C]^MO_ &@_PS'
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M\I-.<LZUU7R&O<UG=QIQG[XG2DDJ;DX\/9T:6#?&\<>+HPPZ9)1QHZB
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MS^"7'N,S-:<^4-A\(H>ZQ.K"*(RWX
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M \)ZP
M
M
M                                                 #'VUM68%N[7
M&9:FVACD'+,!SZBF8[D]!8(,V)M?,271;3J#);,AAPD2(DIE276'T-O-+0XV
MA19;(<]S73.<VV?Y'6E;W=I-5*52.^,EUK<XR6,91>,9Q;C).+:,;G&49=G^
M5U\FS:DJUM<P<*D);FGU=*DG@XR6#C)*2::3.<9ZD/I_["]/S?5CKZ\3/OM8
M90Y/O--;'=CDF-EV*(D$2J^P=8233=S5^8U&M8R23T4;<AM!1Y+!JN+Y-\V<
MHYM:5AFUKPTKZAPPO+=/;2JX>FBGM=&K@Y4I;=F,&^.$TJP^:'+C,N6^HI9;
M<8U+2MC.VKX;*E/'TLFMBJT\5&I'9MPDEPSB1[CK9S4
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MI3[K>M_MQA#7]6?);,_@EQ[C,S6G/E#8?"*'NL3JPBB,M^
M
M
M
M
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M[<80U_5GR6S/X)<>XS,UISY0V'PBA[K$ZL(HC+?@
M
M
M
M
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M*(RWX
M
M
M
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M'N,S-:<^4-A\(H>ZQ.K"*(RWX
M
M
M
M
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M!_7OI3[K>M_MQA#7]6?);,_@EQ[C,S6G/E#8?"*'NL3JPBB,M^
M
M
M
M
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M9\ELS^"7'N,S-:<^4-A\(H>ZQ.K"*(RWX
M
M
M
M
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MEQ[C,S6G/E#8?"*'NL3JPBB,M^
M
M
M
M
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MOX0A7HRE)VE=))5(MMMT\$DMK;V)'2K%,1:8
M
M
M
M
M                                                      '_U;_
M
M
M
M
M
M                                #__6O\
M
M
M
M
M
M           /_]>_P
M
M
M
M
M                                                  __T+_
M
M
M
M
M
M                            #__1O\
M
M
M
M
M
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ML>9&@<SO*>7Y?G%I6KUI*,(1KP<IR>Z,5CM;>Q);6]B-P!STW4
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M\<'AL,;?WFGI[?EE\=?OHXQ_MQF?W*<V_P#;F8?%JOUIBOWK<M?TY9??Z?\
M.9XTSR3T#R*8R"3HG<.O=MQ\4=K6,E>P')ZS)&Z)ZX0^Y5-6:JU:R95(3&D&
MT2^G<3:^GTIC5M1Z,U9H^5&&J<NN,O=PI.FJ].5/C4.'B<>)+'AXHXX;L5UF
MQ9%JG3FIHU9Z>O:-ZJ/"INC4C/@<L>'BX6\,>%X=>#,VC63/
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MVX?N4YM_[<S#XM5^M'[UN6OZ<LOO]/\ G']YIZ>WY9?'7[Z.,?[</W*<V_\
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MW<2ZS8,BU9IK4[JK3U]1O>PX>T[&I&?!Q\7#Q<+>'%PRPQWX/J,ZC5S8
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MWSYWLH_^:_$KDZ)HJ"+,@ *.GQ-7X\6G?S4L0_"]FPLZ[E/S8YC^M*OXI9D
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M.;%\[X<7]'C+^[_LOZS48JN[XOSO1^ 6WLZQ8?W8?FT?PRO[&D3W"*A(D
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M_K;E8KU[\?\ G]-_<[WV5J36[I/^3SWZNT]C<%KP0-)A
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M8YG_ (X?*_\ .5WK^%&U%Y/+CYO,A_5UE^+4BI'7/RVSCX==^[U#6H;F:J
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M---/!II[4T]C3VIDL83A5@JE-J49)--/%-/:FFMC36U-'DC\'Z
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M?5 _)0R/_G[4'_B$/XE.2'Z>I_>+O_VX_<1S9_0\_OUM^&']RCZH'Y*&1_\
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M"CZ=4MM/3,*:9-7R'WNI21^PS+Q&HT^^ERKG4X)66:1CZYT+7#QM*\;\Y-^
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M<4JLDOIHPDY1\U(U'.-+ZDT^\,]L+BSQV)UJ-2FGXG.*3\QLPN-D,$ !:9]
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M?I&^'OW9\>_:GAR3GS\SNHO@=3T4=)Y/?.=DGPJ'\ITM12\6G@
M  !1T^)J_'BT[^:EB'X7LV%G7<I^;',?UI5_%+,@'WJ_E_8_J^G^,W17.$PB
M,9:D^%V_K+Y>?8+J?Z_W0@KWX?S+I[[O=>YT27G=+_.N=?<K?V=4N,"NTFX
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MJPC6I-]-.HEQ1V[7%XPDUY<9+84,?4L]+_;?IXY[&.Q?D9]HK,;"0QK?;42
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M$1C+:7PM/[OYP?O/CC^W9T("]^7[#ICQYAZ%D3)[H_V3/_%9>C=ENH5^DSP
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M1?I&^'OW9\>_:GAR3GS\SNHO@=3T4=)Y/?.=DGPJ'\ITM12\6G@
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MI+PM4E1Q\ZDEYA8[W;+N=SRLMZ,GBJ%>XIKP)U.U]&HR;H1F.]@
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M@?,[3^&7/HP*ZN\S\Y\_@UOZ$B"D2C(^%P#X6_\ FGS/^R+1?UMRL5Z]^/\
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M6=OA@OQA^3'W&,<^WAH0E[[GR0R7X94]Q9*_NG?*;-?@L/=471A6Z3I
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MKM:TUA[XK7%1>)5'2_\ TWZ)-@(U'>              I1?$[?C3<>?N /\
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M5;BHWXWQKS$BPGNNVL*'+BK72VU[VM)OZFG1@EXEPOS6RP((F$CP
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M8+H2)I<CM4Y[K#0=/.M1U_?%S*M6@Y\%.GY,&E%<-*$(;.OAQ?2V2LCA!V
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M"(QEM+X6G]W\X/WGQQ_;LZ$!>_+]ATQX\P]"R)D]T?[)G_BLO1NRW4*_29X
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MGPNW]9?+S[!=3_7^Z$%>_#^9=/?=[KW.B2\[I?YUSK[E;^SJEQ@5VDW
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MD;MON,:M_:9PM9[H'S.T_AESZ,"NKO,_.?/X-;^A(@I$HR/A< ^%O_FGS/\
MLBT7];<K%>O?C_S^F_N=[[*U)K=TG_)Y[]7:>QN"UX(&DP@
M     U"]0.DD9'P4YD4T1*G)<OC#O)41I'BM^7%UM93(T=/ZKBVTH_RCH7*6
MZA9\T=.7-39&.966+ZD[BFF_,3Q-*YD6\KKE]GE"'II6%WAX6J$VEYK6!S !
M=T5.  =.'TU\HBYAZ?W#2XB+2XVQQOU)CCRTJ)9'.PW#8N'V7<9?KBD07247
MR'U+Y!2?SFL9Y=S9U';U%@WF-U47U-:M*M'^S-8%K?*V[A>\M\CKPVI65O!^
M.E2C3E_:@S=L<S-]   #EF<O_P ;3E%^<5NS\)=F+S.7OR!R/]7V7XM3*C=:
M_++-OAMU[O,UV&X&L@    %_'X>#]&]C7W7-J_71@51=[SYY*_P2U]C(L9[M
M'S7TOA%Q[)$Y8C =_  Y;',_\</E?^<KO7\*-J+R>7'S>9#^KK+\6I%2.N?E
MMG'PZ[]WJ&M0W,U4          WWX+>G+R,Y\9S'H]6XX_2:\KK!F/G6YLC@
MRV<#PZ*1I<ELMRR)/U3M/+41QZB$LWEJ4A3RH\<UR6^4\T><6C^5.5NZSRLJ
MMY.+="SIR3KUGT/#;V=+'TU6:X5@U%3GA!]%Y?<L=3\Q<P5OE%)T[:,DJMS-
M-4:2Z5CZNIAZ6G%\3Q3EPQQDNA'P^XC:DX3Z/QO1VH*UQJHJC59Y'DE@EE61
M9WE\UAMJYS#)I+)$2Y,GRFT-MI(FV&&VH[))::0DJD>8?,#4',O4];4^H9XU
M*GDTZ<<>SH4DVX4::>Z,<6VWMG)RG)N4FRR;1.C,FT'D%+3^21PA#RIS>''5
MJ-+BJ3:WRE@DENC%*,<$D;1#1S;0 .<?ZUE _CGJ>\JX;Z%)]^R/!K]A1]32
MZQD>J:&\;6A1^TB]X-)]/8HC3[2Z"XGNUW<+SDCD-2#]+3KTWX'3NJ\/_#CX
MMI6)SWMY6W-C.(2]5.E->*=O1G_*19CN9R(MI_"XY=$;G<R<">=2F=+B:3RZ
MN9[R[G8E<]DU-=.DV?CT;7*@$:B_SR(_DZP%[\67U'2TYFL5Y,7>4I/J<E;3
M@O-4:GG$R>Z3>P53/,ND_*DK6I%>"+KQEYSE#SRW2*_29X         !"K\0
M+E<7'?3,VG42'$H>SS.]0XI 2I1)-Z5#S^'G"VT$?TQDQ3/+Z%\B3/Y!)3NF
M6%2\YU6-Q!8JUH7=67@3H3H>RK)>:<)[R%Y"VY57E&3VW%6VIKPM5HU?0I-G
M/M%M!6Z>\QBBEY3DN/8S 2I<[([RIHH2$%W+7+MY[=?'2E/RF:W"(B'EOKJG
M8V5:]J[(T83F_%"+D_H(]%I;SN[JE:4_359Q@O')I+Z+.LZTVEEMMI!=$-(0
MV@C,S,DH3VI+J?ZA"@Z4G*3D][VEQZ22P70?V/X?TI1?$[?C3<>?N /_ (1;
M865=R7Y#9O\ #U^+TB"'>O\ E=EGP-^[5"M )I$5BSI\,&M)<BN2[9J+O5I7
M'UI3\II1G+"5J+_L-2?_ $B$W?<3_8_)7_\ UE3W"1*_NG-?M/FJ_P#Z6'NJ
M+I K<)T@      1!^O 9%Z6?)0C,B-4W2A$1GTZG_3YC!]"_R$9B0G=9^?/)
MOJ;S\1N3BW>%^:/-?':_CE YWXMX*T#97AA^.'Q0_.5T5^%&J&F<Q_F\S[]7
M7OXM5-JT-\MLG^'6GN],ZDXHV+;@ -&O4T_1[<R_S==H_:P^.G\E/G;TY^L+
M;W6)S_FM\VN>? J_N;.90+K2J< "3-'K(>IDVA#:.6F<I0VE*$)*AU]T2E)=
MJ2+K3_(0XJ^[KR5DVWD%#%_3U_PQU5<[^:J6"SFKL^DH_@S^O[Y/U-/RM<Z_
M_ &OOXG'\_ATY*_H"A_7K_AC^_OPYK?IFK_4H_@SQ9GK#>I=.94P_P N-B(0
MM)I-4.OPRN>(E>WMDU]6TXD_H&E1&7R#Z4^[QR6I2XXZ?MVUURK27G2JM?0/
MQ/G9S4J1X99U6\Q4HOSU33-0=N<E>0N_'FWMV;OVKM4F'O>(D7/,\R7)JVO=
M\2[JRJM9+D6*7B?1,=E!%U/H7B8Z#I_1FD=*1<=-99:V&*P;H4*=.4E]-*,5
M*7])LTK.=4ZEU%)2SZ_N+S!XI5JTZD5]3&4G&/\ 12,)#9C @ 7!?06]*J^P
MF?4<X^16,OT]Z]6O*X]8!>Q%,659"N(:HTK;-_72");#LB*ZMBACO))1-..3
MC01KA.)KT[U//:US.E4Y8:/KJI24E[_KP>,9.#Q5K3DMDE&24J\EL<HQI8[*
ML7-?N[\H+BPJ0U_J:DX5'%^\Z,UA**DL'<3B]J;BVJ*>W!NIAMILM;B!Q,$
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M*+G57]&O4JQ?A197W>LBGDG*^RG5CPU+V52ZDO!4?#3?]*C3IR\TF)$=SMH
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M"%:$(+PUB5?=7U/3L-27NEKB6"OZ<:E+'IJT.)RBO#*E.4GX*1=7%:Y.T
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MS\1/^D;MON,:M_:9PM9[H'S.T_AESZ,"NKO,_.?/X-;^A(@I$HR/A< ^%O\
MYI\S_LBT7];<K%>O?C_S^F_N=[[*U)K=TG_)Y[]7:>QN"UX(&DP@
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M'@_1O8U]US:OUT8%47>\^>2O\$M?8R+&>[1\U]+X1<>R1.6(P'?P .6QS/\
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ME"*WX';.[]JBGIGF1:QN9<-#,(RM)M[DZCC*D_-K0IQQZ%)G0W%1198
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MGG',KZ&$HPX<+:E);G&,MM62>Z=1**V-4U)*18,$2B2(
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M7R"XEPT\THX1\-:AQ3@NK;3E62ZY.*6UEZ 5?%@0
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M%)'T(\AZ0 .:5ZKOZ1OF%]V?(?VID70\AOF=T[\#I^BRK#G#\YV=_"I_R$?
MZV<V+YWPXOZ/&7]W_9?UFHQ5=WQ?G>C\ MO9UBP_NP_-H_AE?V-(GN$5"1(
M%6CXE[BI*R?7>H^7^,UJI$O6<E6I]GOL-&MUO"LILE66!W$I?@2(T"Z=F05&
M9F:G;5DB(B(S$YNY;KNG8YQF'+V]GA&]7OJV3>QUJ4>&O!=<IT5"?@C0EX"(
M_>HT?.[RRRUK:1QE:/WO7:6WLJDN*C)]4857*'CK1*;0L6(/F2=.[8S71.T\
M W'KFS53YOK;*JC+L<G?/4R5A42TR"B3F4*3YT62@EQID=1]KS#CC2NJ5F0P
MVHLARW5.17>G<XAVEM>TITJD>GAFL,8O;A*+PE"6^,DI+:C*Y)G-_I[-[;/,
MLGP7%K4C4@^C&+QP:Z8R6,9+=*+:>QG3'X7<N-;\V>/N%;WUO*9;:NXB*_,<
M65*;DVF YW CM_RDPZX)))5WQG5DN,\IM!28KC$I"2;>2*5^9'+_ #GEIJVY
MTMG,6W2?%1JX81KT)-]G6AO6$DL))-\$U*#>,66IZ%UGE>O--T-0Y6TE46%6
MGCC*C527'2EX8MXQ>"XH.,TL)(VL&B&X       88WOR'TKQDP1S9>^-B8_K
M7"D6E;2-W%\\]UFV]L^3$*MJZZ"AZ5+>,N]Y;<9AQ3;+;K[A)9:=<1L>EM(Z
MEUKFBR72UG4O;EQE/@@ELA!8RE*4FHQ6Y)RDDY.,%C*44\'J'4N1:4R]YKJ&
MYA:T.*,>*;>V4G@HQBDY2?2U%/"*<GA&+:RQ56M7>U=;=TEE N*6X@1+2HMZ
MN7'L*RTK+".F7 L:Z?$4MI]A]I:'&7FUJ0M"B4DS(R,8&O0KVM>=M<PE3J4Y
M.,X23C*,HO"491>#C*+3332::P9F*-:C<48W%O)3IS2E&46G&46L5*+6*::>
M*:V-;4>>/D?0 #'VV=FXGI;6&P-N9U.*NP[6N'Y!FN1RR[#=34XY6.6DIJ*V
MLR\Q]U+?E1VB/N<=4A">JE$0R^09)?ZDSNTT_E<>.XO:U.C371QU)**;ZHK'
M&3W**;>Q&-SG-K/(LIN<ZS"7#0M:<ZLW]+"+D\.MO#"*Z6TEM9RY.0.Z<LY&
M;MVCO/.'3<R?:.:7F7V#).K?8K&K.6I=;107'"(_=:Z*3$&(DR^:RRA/R"\3
M26F[#1^F;'2^6+"A8T84HO#!R<5Y4Y?35)<4Y=<I-E2FI,]O-3Y]=Z@OW[;=
MU9U)+>H\3\F"^EA'"$?I8HP^-A,(           !/9\/ARW_ *!N8RM*9)9^
MZ:_Y05L7#"1(>\N'!VE0J>L-;SS[C/YTPW9]&A"$]7'IT<U'VMD(J][;0'[5
M<NOVELH<5WD<G6V+;*VGA&XCXH80K-O=&E/#;(D3W;=9_L[K?\@W4\+;-HJE
MM>Q7$,70?]+&=));Y5(]1?0%5I8>   %!GXB?](W;?<8U;^TSA:SW0/F=I_#
M+GT8%=7>9^<^?P:W]"1!2)1D?"X!\+?_ #3YG_9%HOZVY6*]>_'_ )_3?W.]
M]E:DUNZ3_D\]^KM/8W!:\$#280                   !0-]?\ XMRM#<Y+
MK:%57*CX#R:JD;*J)331HA,YU7H9I=FTY.F7SI"IA1[I_P!I$5F@B/P,BM=[
MIVN:>JN6%/(Z\\;O))>]YIORG0EC.VGAT1X.*C'[@RN?O':1GIW7]3-J,<+;
M-8]O%]"JK"->/CXN&J_NJ(-1)\C^22^E9SEE<#N5N,[%N7ISVI,SC_R W/4P
MTN2'%X9:RVWF<EAPD=WF3*28AFQ92A!N.,HD16U)]Z48XSSUY80YJ:#KY/;*
M*S"V?;V<W@O;HIITW+HA6@W3>+PC)PJ-/@2.I<H>8$^7FL*69UVW95UV-U%;
M?:I--32Z94I)36&UQ4H+#C9T?<<R.AS#'Z/+,5N*W(<9R6IK[['[ZGELSZFZ
MI;:(B=66E;.C&IMYA]E:'6G$*,E),C(^ABG*\L[K+[NK87U.5&O1G*%2$TXR
MA.#<91E%[5*+333VIHL_M;JVO;:G>6<XU:56,9PG%IQE&2QC*+6QIIIIK>CW
M0\Q]P      .<)ZT/Z3KEE]EV(?@NHA<;W;_ )DL@^Y5?QFN5@<\_G7SG[I3
M]PI$7P[><F+^/P\'Z-[&ONN;5^NC JB[WGSR5_@EK[&18SW:/FOI?"+CV2)R
MQ& [^ !RV.9_XX?*_P#.5WK^%&U%Y/+CYO,A_5UE^+4BI'7/RVSCX==^[U#6
MH;F:J=$'T'_T67&K]^;K_#[E J&[TWSYYUXK/\1MBR_N]?-%E7CNOQRN2]B/
MAVD "E7\0%Z;']$><2>;.FZ#RM9;,NVV-V4=7&Z1L(V;;O\ ;'S1#+!=&J[(
MWCZ2EJ(DM6AGU69V#+:+)^Z;SF_:#+(\M-1U<;VRAC93D]M:V@MM'%[ZENO2
MK?*AN7M,FX)=X_E;^1<P>O,CIX6EW/"ZA%;*5>3V5<%NA7?INA5NGVV*59<3
M5(J&V7";EYL3A#R&PO?&O'7)1TSYU6:8HN4N-6Y[@-F\W_*7$;-224DB?0VA
MZ(^I"_=Y;4>22%*9))Z#S+Y?9/S-TC<Z5S=</:+BHU<,94*\4^SJQ^I;:G%-
M<=.4X8I2Q-RT'K3,] ZEH:BRQX\#X:M/'"-:C)KCIR\:6,7@^&:C/!N)TK]$
M;NUWR/U%@>[M4W;=_@>PZ&->TDPNQ$J,;AFQ84UM&0I?D3X$E#T*?&-1FT^T
MXV9F:>HI@U3IG.-&Z@NM,Y]2[*ZLYN$UT/IC.#V<4*D6IPEZJ$D^DM-T]G^6
M:HR6WS[)ZG:6]S!3@^E=#C)=$X23C./J9)KH,MC &9   "$KUZ^*$OD?P>N\
MVQBM58; XV6KFVZAN.UYLZ=A+4%5?LZI9]O1"*XT7+A)+N6JM0A/BKH<E^ZK
MKRGH[F=2RR]GP6F<Q]ZSQ>$8UG+BMIOPNIC170E6;>XX-WB='3U1H"I?VD.*
MYRN7OB.&]TDN&O%>!0PJOI?9)+><_@6RE<!^\65)@R8\V%(?AS(;[,J)+BO.
M1Y,63'<)UB1'?:,EH<0LB4A:3(R,B,C(R'YG"%6#I54I1DFFFL4T]C33V--;
M&GO/U"<Z<U4IMQE%IIIX--;4TUN:Z&=%?TCO4.H.=_'.I+(;>(WR%U56U6,[
MEQ]QQIJ;;OLL>Z5&S*Z,GM[X5VAHW7_+028\TI$?M)LF%NT_=X#E%=\K-85/
M>=-O*+^4JEG4VN,$WC.VD^B=%O".+QG2X)XX\2C9KR9YEVW,+3$/?,TLRLXQ
MA<PZ9-+"->*Z8U<,7AZ6IQ1PPX6Y7AP8["      !@ODGR*UCQ3TOG&]-N72
M*?#L(JW)CC2%-':Y#;ND;5+BN.Q'5)]XL;&0:(T5KN)/<KO<4AE#CB-HT9H_
M.]>:DM=+Z?I]I<7,L,=O#3@MLZM1K'AITXXRD]^"P2<FD]?U3J;*='Y%<:@S
MJIP4+>./TTY/TM."Z9SEA&*\.+:BFUS-.4?(G..5^_=F\@-AN_\ [1['R21;
M%7-ON2(6.4;#::_&<4K''22HXM77LQH+"E))2TM$M?5:E&=U.A](99H+2EEI
M/*%[39TU#BPP=2;QE4JR2]55J.4Y="<L%L2*JM6ZFS#6.H[O4F9OVVZFY<..
M*A!;(4X_2TX*,%TM+%[6S 0VLUPMU?#/\3)<2/M[F;E-8IIFTCN:7U,[)9Z'
M)B,S&+S9601$NEXH\]FLK(\EO]<W8,]?!9"OWOI:^IU)Y?RXL9XNF_?ETD]S
M:E"VIO#IX74J2B^ATI8;F3/[JVC9PC>ZYNX8*:]ZV^*WI-3KS7@Q5.$9+I52
M/66TA 4F2 !68^)PU+)R/C?Q^W-$BJD*U;MB\PZR<;0:E0J;:N-HE+G/J+Z5
MHIN.08YF?_UCS9%[3$U>Y/G\+/66;:<J2P]_6L*T?IIVM1KA7AX+B<O%%D5.
M];DTKK2^6YY!8^]+B=*7@C<0QQ?@XJ,%XY(I5"R<@D;C^GYR21Q(YC:&WU-<
M?1CF'YHS"S=,=#CSJ]?Y;">Q#.%M1&O%]UBLG29,9HR^<^VUTZ&1&7.N;6C'
MK_EUFNE:23K7%%RHX[%V]*2JT<6_2J52$8R?1&4C>.6^J5HS6^7:BJ-]E0JI
M5<-OM-1.G5V=+5.<I17KDCIT5ME7W-= MZF=$LZJUA1;*LLH$AJ7!L*^<PF5
M"G0Y3!J0XTZVI+C;B%&E23(R,R,4FUJ-:VK3M[B+A4IR<91DFI1E%X.+3VII
MIII[4RURE5IUZ4:U&2G":4HR3Q336*::V--;4UO1YH^1]     "G=\3/R>K;
M_,=)<2,=LFY3F!M3-P;+CL/>:W"R+(H!T6O:J2A/@W*CUB[.:XA74_)L(RRZ
M$KYUB'<JT16M,NS/7]Y#A5TU:6S:PQITY<=Q)=<95%2@FO54IKHV0E[U>K*5
MQ?6&C+:6+M\;FND]TYK@HQ?5)4W4DUZVI%])54$["(),_P"@7J*1M'U(M8WA
MQ52:?36*9_M:[ZHZM-E%Q]>$X^XM9^"5(M[NO>07M/RSZ>!&91O[UNH(9'R;
MOK7BX:F8U:%K#KVU%6J>?2HU$_&=T[NF2RS;FC:7&&,+&G6N)^9!TH>=4JP:
M\1T'14F62  :->II^CVYE_FZ[1^UA\=/Y*?.WIS]86WNL3G_ #6^;7//@5?W
M-G,H%UI5. !TS8/IF^GRN%#6OAKQV4M<6.I2CU?C!FI2FB-2C/R/:9BE:KSJ
MYMJK)+4>88)O_P")J]?U1:K3Y5<MG"+>1V6Y?W%/^8\K^[+]/;\C3CK]Z[&/
M]@/G^^OFW_N/,/C-7ZX_?[J>6OZ#LOO%/^8_:/Z:7I]1G"=;X9<;U*+V%(U+
MA\MOV]?%F5%6@_\ *D?F?.CFU-<+U'F/F759?14DS]1Y5\MH/%9'9>;;TW]!
MQ9G? >-_'C5+[<G5VAM,:WDL]OE2<"U?A&(2&^SZ4T/X_!CK(R^0^HU;-M9:
MOSZ+AGF:WE[%[U7N:U5>=4G)&PY=I?3.3R4\IRZUM6NFC0I4WY\(1,T#6S.@
M                   %*+XG;\:;CS]P!_\ "+;"RKN2_(;-_AZ_%Z1!#O7_
M "NRSX&_=JA6@$TB*Q9V^&"_&'Y,?<8QS[>&A"7ON?)#)?AE3W%DK^Z=\ILU
M^"P]U1=&%;I.D #0[U0OT>',C[@.P/K.L=4Y'_.]ISX=0]FCGG-KYM,\^!UO
M8G,T%U!54?<:P_K*UY]G.)?7^.,9G?YEN_N%7W.1D,I_.MM]UI^S1UA!0L7$
M   !I;SUX3ZXYX\?,DTOG*&*N\23E]K/.TQ4R++7^>Q(RVZJ\CI+HIV(Z2E1
M;.&2B*1%<<2E2'B9>:Z3RJYEYQRLU;1U)E>,Z7I+FACA&O0;3E!]"DL.*G/!
M\$TFTX\49:+S$T'E?,/3=7(LPPA4]/0JX8RHUDGPS77%^EJ1]5!M;)<,ES;-
MY:3V/QSVQG&E=LT#V-Y]K^[?I+VN<[EQW30DGX-M52C2DI,&='6U,@RD%VO,
M.-N)\%"Y73&I<GUCD%KJ7(*JK6EW!3A+I71*,EZF<))PG%[8SBT]Q5SJ#(<T
MTQG%QD6<TW2N;:3C./1UJ47ZJ$XM2A);)1::WF*!GC#GV&3Y_F6:5F#TV59#
M8WM=K;%58/@\>Q=)_P#DYB*LDL,N3C\!U1=_NR+"UL)#2%J5V><I".C:4(3C
MK'*<NRVO=7-A1C2G>U>VK.*P[2KV=.EVDENXG3I4XMK#'A3>+;;]UWF5]?4K
M>A>595(VM/LJ2EMX*?'.IP+IX5.I.271Q8+9@E\>,B>$MI?"T_N_G!^\^./[
M=G0@+WY?L.F/'F'H61,GNC_9,_\ %9>C=ENH5^DSP *V/Q(_%27LKCMK[D_B
M]:J5?<?[V10YO[LT:GW=8[!E1X:+-\T$:EIJ[IJ"2$D71#4Z4\HR2@Q,SN:Z
M[IY+J^[T1?3X:6;04Z.+V*YMU)\*Z%VM%SQ?3*E"*VLBWWHM'SS33-MJRTAC
M4RV;A5P6UT*S2XGU]G54?$JDY/8BDB+,"!9];@6<Y5K'-\0V-@UQ)Q_,L$R2
MERW%KN&HDR:J_P ?L&[2JG-$KJ2O+>:0HT*(TJ+JE1&DS(>#-<KL<[RRXR?-
M*:JVUU3G2JP>Z5.I%QE%^--[=ZWK:>W+LPO,IOZ.:9?-TZ]O.-2G-;XSA)2B
M_,:7@>YG2VX <UL"YW\<\3W-B;L&OR=#+-#M3!V9/FS,#V%"C).XJ'&UF;AP
MY!F4RJD+_P!=$<;-7:\EYMNEWFQRUS7E9K&XTY?J4Z#;J6M9K!5[>3?!/JXX
M^DJQ7I:D7AC%Q;M/Y<:\R[F%IBCGEFU&K@H7%)/%T:R7E1Z^%^FIR]5!K'RE
M)+=D<T-\       Q+N[>VH^-^N;O;.[LZI=>:_Q_R$6%_=+?4E<J4ORX=965
MT%#TN=,?41DQ#AL.ON=#[&S))],_IG2VH-99Q2R#3-K.\NZV/#3AAN6^4I2:
MC"$?53G*,5TO:8;/]0Y+I?+*F<Y_<1MK:GAC.6.][HQBDY2D^B,4Y/H1][B^
M48YFV.4688?>U63XKD]5!O,=R*CG1[.FNZ:SCIEU]G66$12FGF'FE)6VXA1D
M9&1D8Q5]8WF67E7+\PI2H5Z$I0J4YQ<9PG%X2C*+P:DFL&GN,C:7=K?VM.]L
MJD:M&K%3A.#4HRC)8J46MC36U-'O1Y3T        !__4O\ "H5\4G_\ 'N$_
M_P HY _^^8:+!NXW_E=2_5V'H7A"WO;_ .8R'ZF\]&V*G GL0Y+'OPR7XZ6Z
M_P U[(?PKXD(<]]?YMLM_6=/\5NR3_=3^7=_\ G^,6Q=_%9)/D   /7)J*E%
ML]?(JZY-[(KHU1(NDPHR;9^IAR79L.K>L23YRH[3S[[K;"EFA*W'%)22EJ,_
ML[BX=NK1SEV2DYJ'$^!3:2<E''!2:C%.6&+22;P2/DJ-%5G<*$>T<5%RP7$X
MIMJ+EOX4VVEC@FV^EGL1\3Z@  !1>^)=_'VUM^:G@'X5,V%H7<N^:J\_6E?\
M5LROWO4?.):_J^C^,717D$NB-):[^%O_ )V\SOL<T9]<\J$#>_'^;]-_=+WV
M-J3#[I/^<SWZBT]E<%P$5ZDU0 ($?B.OT>,3[O\ K3ZS7@E7W.OG>E\ N?9T
M2.W>>^;1?#*'L:I0Q%J)7@2#^E%^D;X>_=GQ[]J>').?/S.ZB^!U/11TGD]\
MYV2?"H?RG2U%+Q:>             %'3XFK\>+3OYJ6(?A>S86==RGYL<Q_6
ME7\4LR ?>K^7]C^KZ?XS=%<X3"(QEJ3X7;^LOEY]@NI_K_=""O?A_,NGON]U
M[G1)>=TO\ZYU]RM_9U2XP*[2;@   :A<BN>O$'BG G2=X;ZP'%+:$RXZ6%1+
M=K)-B35)^:AJ%@.-^]6RNY?1OS514LH,^KCB$D:BZ#H_E5S"UW5C#3&55Z].
M3P[9P=.W7AE7J<-)8+;@I.3Z$WL-+U-S$T5H^G*6?YC1HSBOL2EQUGXJ,.*I
MOV8\*BNEI%2OU'_7TV5R4I[_ $SQ9J[_ $IINX:DU629K9268^V]@5+R39D5
MJ%U3KC./ULA!FB1'B27Y3Z.B7)33+CT5<^^3G=2R;1EQ2U'KJ=/,LQIM2IT8
MINUH36U2\I)UZD7MC*<8TX/:J<I*,U#;FAWB\UU30J9'I&$["QGC&=632N*T
M7L<?);5&$NE1E*<EL<U%R@ZZ@F 1D/\ 4I4I1)21J4HR2E*2,U*49]"(B+VF
M8-I+%G]2QV(O>>A1Z:T_B9JF;R'W)0JK=_[MHXC-=164;RK75^K'W6[2#CLQ
MEPN]BTMW6X]A;,KZ+80W$BK2T^S)2JK3O1\YZ6OL^CI#3E7CRG+)MRG%XQN;
MI)QE43W2I4DY4Z36R3E4FG*,H-6$]WSE94T;D\M2YY3X<ROX)1A)>50MWA)0
M:Z*E1I3J)[8I0@TI1FG/^(G$C@   YI7JN_I&^87W9\A_:F1=#R&^9W3OP.G
MZ+*L.</SG9W\*G_(1\#K9S8OG?#B_H\9?W?]E_6:C%5W?%^=Z/P"V]G6+#^[
M#\VC^&5_8TB>X14)$@ 8YV]JG"=YZOSW3VQZI%U@^Q\7M\2R6O,TH=776\54
M9<F$^I*O)E1U&F1$D)+N9?0VZCHM!&,QI[/LSTOGEIJ')ZG975G5A5IRZ.*#
MQPDNF,EC&<=THMQ>QLQ>=9/8:@RFXR3-(=I;W5.5.<?I9+#%/HDO31EOC))K
M:CF;\U>)&Q.$O(;.-#;#8=?71RSLL-R@HRX]=GF V3[AXQF%5UZI[9#2%-2F
MD+7[O+:D15*-;*C%U'+77^3\R](VNJLH:2JKAK4L<94*\4NTHR^I;QBVEQTY
M0FDE)%5>N]&9GH/4MQIW,TWV;XJ53#"-:C)OLZD?JDL))-\,U*#>,6:HC?#3
MS>[@-Z@FZ_3\VO\ R]UG(1?X=D!PH6S=57,R0QB^?4L5Q2F?,6T2SA6D0ENJ
MK;5EI3C"EK0M#\9U^,]RWFMRETUS9R'\E9TNRN*.,K:Z@DZM";6W?AQTI8+M
M*3:4TDTXSC&<>A<NN9&?<M\X_*.5/M*%3!5[>3:IUHK=U\%2.+X*B3<6VFI1
M<HROJ<+/4HXK<Z,=A2=39W#JMA)A)D9#IK,9,.EV50/MM=\TV*=QPTVD-OV_
M5&J6^P2323JF734TFJOF3R9UUROO)0S^U=2TXL*=Y13G;U%CLQGA[5-_:ZJA
M/''A4HX2=B.A.:6D.8%M&637"A<X8SMJK4:\'TX1Q]LBO7TW*.[%Q>Q;]#E)
MT4   (GN=?K#\3>$U=<8^O)8>Y-X16WX\#3VO;:'.EUUF@C2E&PLHCD_#H6D
M+[?.9?)V=VJ)34%U/52>]<KN[QK[F76IW:HO+LLE@Y7=Q!Q4H_\ ]/2?#.NV
MMSCPTL5A*K%['QWF#SMT=H.E.V=57V8+%*VHR3<9?]ZHL8T4NE/&IAM5-K:4
M9.9O./?W.K9SNQ]W9,<B+ 5+CX3@-*<B%@FO:>4XE:ZS&*9Q:^CCA(;][GR%
MN2I)H1YSJDMM(;M Y<<L=*<KLD63:9H82E@ZU>>#KW$UZJK-);%B^"$4H0Q?
M#%-R;K_USK_4?,'-GFF?5<5'%4J,<52HQ?J:<<7M>"XIMN<\%Q2:22E>]&WU
MBK'BK:TW&ODG>SK7C9=3DQ,/RZ8I^?/T9;6$CJH_USKN,R'5FN9%02E0EFJ3
M'3V*?:<X-WB^[O1UW0J:ST92C3SFG'&M26$8WL8KS$KF*6$)/!5%A";Q4)+L
M/(_G;5TA6AI;5-1SRNH\*=1XMVDF_/=!MXRBOL;\N*PXD[R%99UMU6U]S36$
M&VJ+:#$LZJUK);$^MLZV>PF5!L*^=%4MIYAYI:7&G6U&E:3)23,C(Q6'7H5K
M:M.VN82IU*<G&49)QE&47A*,HO!J2::::Q3V,G[2JTJ]*->A)3A-*491:<91
M:Q336QIK:FMC6U'G#Y'T*SOQ)7+?^C_1> \2<7L_*R;>5DUFFPF8[W1^)JW"
MK-+M/ EMI,E)1;WS32VED9DI-7);4718FGW-- ?E;5%WK^^AC0RN+HV[:V.Y
MK1PG)>&E0;370Z\)+<16[T>L_P FZ?MM&VD\*N82[6LD]JMZ4O)3^Z5DFGU4
MII[RE*+*2"!*+Z/G$&)S&YN:[Q+*:1F\U5KAM_;6V(4^,F54V>,XG)9358O9
M,/%Y3S-Q;OU\"3&4?5<1<I1$HFU$.'=X;F%4Y=<L[S,+&JZ5_>86MJXO"<:E
M5/BJQ:VITJ4:E2,ENJ*"V8HZWR4T5#6^O;:RO*:J6=KC<7":QC*%-KAIR3V-
M5*CA"4>F#F^AEZG^[EX!_D6\7OO'ZZ_B\5=_OAYK_P"Y,S^.W'X0L$_=CRY_
M05A\5H_6#^[EX!_D6\7OO'ZZ_B\/WP\U_P#<F9_';C\(/W8\N?T%8?%:/U@_
MNY> ?Y%O%[[Q^NOXO#]\/-?_ ')F?QVX_"#]V/+G]!6'Q6C]8/[N7@'^1;Q>
M^\?KK^+P_?#S7_W)F?QVX_"#]V/+G]!6'Q6C]8/[N7@'^1;Q>^\?KK^+P_?#
MS7_W)F?QVX_"#]V/+G]!6'Q6C]8:U<P_2<XE;<XR[EP/3W&C1FM=LVF%V$S6
MN881K3#<0OZ_.*(TWV-0D7U1$8>9BSY49NOG]%]#C/ND9'[!NG+SGWK_ $_K
M7+LUU%G5[>V%.M%7-&M<UJM.5&>,*DNSG*2<J<9.I#9LG&)JNMN3FC<YTI?9
M=DF56EK>3I2="I2H4J<U5AY<%QQBFHSE%0GM]))G.NF1)=?+E0)\9^%.A2'X
MDR'*9<CRHDN,Z;,B-)8=(E(<;6DTK0HB,C(R,NI"WZG4IU:<:M*2E&2333Q3
M36*::V--;4RLV<)TYNG43C*+:::P::V--=#3WH\['[ZYQ6^I,HQRRE4^0XW;
MUM]16\%PV9M5<T\Q%A5V4-TOI76'VT.MJ^122,?*[M;:_M:MC>052C6A*$X2
MVQE":<91:Z5*+:?@9]+:XKV=Q3N[63A5I2C.$EL<91:E&2\*:37A.GUPAY,4
MW+_BQIKD#5*BMS,XQ.+_ "NK(BOV.BSZD6JCSJD2V9FM+;%I'DE&-PB4N.;3
MO3M<2*1^9NBKGE[KK,=)U\7&UJOLI/?.A/RZ$^IN5*4>+#8I\4=Z9;#H'55#
M6ND;'4E'!2N*:[2*]16CY%6/7@JD9<..^/"]S-K!H9N  %!GXB?](W;?<8U;
M^TSA:SW0/F=I_#+GT8%=7>9^<^?P:W]"1!2)1D?"X!\+?_-/F?\ 9%HOZVY6
M*]>_'_G]-_<[WV5J36[I/^3SWZNT]C<%KP0-)A                    $;
M?JH<&(//+BIDVNJIF$QMO#'EY[I:XEJ;CH:S6KAN-.XU-FKZ>7"NXJW:Y\U*
M\MMU4>6M*SBH2.R\B^:%7E7KNAG%=R>7W*["\@L7C1DTU4C'IG1DE4CLQE%3
MIIKC;.7<W>7]/F'I"KEE%)7M!]M:R>SVV*:X&^B-6.,'T)N,VGP(YOV08_>8
MG?76+9/4V%!DF-VUA17]%;Q'H%K3753+7 LZNR@R"2XR_'>;6TZTM)*2I)D9
M$9"X^TN[6_M:5]95(U:-:,9TYP:E&<)I2C*,EL<9)IIK8T\2K^YMKBSN*EI=
MPE3JTI2A.$DU*,HMJ49)[4TTTT]S/4#T'P)V?2G]9_-.$10=*;IB7>R>,<J>
MMRN8@NIE9II^3/D&]-G88B:XAN95/.+6],I''6R2XI4F(XVZI]F7%OGOW<,M
MYF\>I=-RA99W&/E.2PHW:BL(QK8)N%5))0K)/%)0J)Q494Y"<G^>=_H+AR'/
M8RNLI;\E+;5MFWBW2Q:4J;>+E2;6#QE!I\49W=-"\D=%<GL*C;!T+L_%-F8N
M^A@Y$C'K%*[*ED2&_-;KLFH)1-SZN7V^)Q+&,R\1>/9T,C.LW56C=4:(S*64
MZJL:ME76."J1\F:6SBIU%C3JP^GIRE'PD]=.ZHT_JRP69:=NZ=W1>&+A+RHM
M^IJ0>$Z<OI9QC+P&;QK)GP   C]YB>IQQ!X2U=BC:^RZ^XV%&84NOTY@3\+*
M-F6,DT&N.S,I8[R6JEISH9IEW,B(RHB,D+6OH@^L\N^2?,+F77@\ALI4[1OR
MKNNG2MHKI:FUC5:];1C4DMF*2VKF^MN:^BM!49+.+J,[E+9;46JE>3Z$XIX4
MT_757"/4V]ASX.9?(Y[EQR=V_P C'L6:PG^E#(HMM'Q5JT7=?46!64<3':V*
M]:K9C^\/''AM+?<2PVDW%*[4)3T(K;>7.CH\O]$Y?H^-=W/O&FXNJX\''*4Y
MU)-1QEPKBFU%<3>"6+;*V]<:GEK/5E[J>5'L/?<U)4^+BX5&$813E@L7A%-O
M!+''!)&L@W8U,OX_#P?HWL:^ZYM7ZZ,"J+O>?/)7^"6OL9%C/=H^:^E\(N/9
M(G+$8#OX '+8YG_CA\K_ ,Y7>OX4;47D\N/F\R']767XM2*D=<_+;./AUW[O
M4-:AN9JIT0?0?_19<:OWYNO\/N4"H;O3?/GG7BL_Q&V++^[U\T65>.Z_'*Y+
MV(^':0 /B=DZYPO;N YAK#8M!!RC!L\Q^SQC*:"Q0:HME3VT9464SW(,EMN)
M)7>R^TI+C3B4.MJ2XA*BR>39QF6G\VM\[R>K*A=6M2-6E4COC.+Q3ZFNAQ>*
MDFXR33:/!FF66.=9=7RG,Z:K6]Q"5.I"6Z49+!KK3Z4U@T\&FFDSFS>HGP>S
M3@1R0R;4%][];838F[D^HLWD,DEK,M?SI2T5SS[K24ME8P5)5 M6$DGMD-FX
MA/N[S"UW+\H.9V6\U=&T-0VO#3N884KNBGMHUXI<22>WLY^GI2VXP>#?'&:5
M7',S0%]R[U15R6XQG;R]LMJK7V6BV^%OHXX>DJ+9A)8I<,HMZ)#J1STG\]"O
MU*CXI[=3QRV[?^[<>]V7T9NML[.3Y==JS:4XFZZMR-3[Q]C%7;DEF!;J5T0T
MM,68I;33,DW8G]Z+DQ^W>G_VQT_2QS?+(-RC%>5=6T<92IX+;*K2VU*73).=
M-*4I0X9'=WWFG^Q^=?LQG53#+;^:X92?DV]P\(QGB]BIU-D*G0GP3;2C/&^
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M_K-1BJ[OB_.]'X!;>SK%A_=A^;1_#*_L:1/<(J$B0   CA]2GTY];>H9IO\
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M:=@7=YYI_M5E'[(YW4QS"Q@NSE)[:]O'!)XO?4I;(SZ90X9^4^-JPT(BDE@
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MW-G,H%UI5. !UL*_]P0?WG&_:4B@>M]FGXWZ)<K3^QQ\2] \P?,_8
M 4@/B;?QTM*?FO8]^%?+19MW*/FVS+]9U/Q6T(#=ZSY=V'P"'XQ<E<(3&(P$
MR'H'?I0=$_8[N7\#]V(Z=ZSYD,T^Z6?XW1.X=W7YV<O^HN?Q:J="P5'%E
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ME^.ENO\ ->R'\*^)"'/?7^;;+?UG3_%;LD_W4_EW?_ )_C%L7?Q623Y
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MY<LJTY:PMJ*VOA6,IO=Q5)O&=27TTVWAL6"P1G@:L;"   '+8YG_ (X?*_\
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M3DMO"VMJ2PC3@L$NMOIE)[Y2DW*3VR;;Q,C##F3  YG_ *I_Z17F+]W/,?\
MWI(NEY%_,_IWX%1] JMYN_.;G?PNKZ)H&.KG.2V]\+-__'5__K'_ /O"$ >_
M-_\ NO\ _P!R_P#V F9W1O\ ]X/_ )'_ /;"V\( DS#_U[_  QQGVG-1;675
MN;1U7KC9+E&F8BE7GV#XQF*Z=%B;2K!%6K(HLDXY/FPR;Q-=O?Y:.[KVIZ9G
M*=1:@R%5%D=_<62JX<?85JE'CX<>'B[.4>+AXGACCAB\-[,7F.1Y+G#@\WLZ
M%TZ>/#VU*G5X>+#'AXXRPQP6.&&."QW&//[('$O\EWCK]Y/6G\6#+_O#U_\
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MO3N:5_?69V%M<U<$N.K0I5)8+<N*<6\%T+'8?)_V0.)?Y+O'7[R>M/XL'O\
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M"#]BM&_HBR^*T/P9L21$DB2DB2E)$24D1$1$1="(B+Y!I[;;Q9L^[8C_ $
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MRF79)DV3\?Y(M*-KVF''V-*%+BX<>'BX(QXN'BEACCAB\-[,BC#F3/_0O\
M
M
M
M
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M%QH/2T[O-X<&89BXU*L7OI4XI]E2?TRXI3FNB4^!^DQ<TXC:=V
M
M/__1O\
M
M
M
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M!5HW]I2E=WL=UQ<82E!]=*"2A3\$DG42V<;39*L.$G7P
M                                                       /_]*_
MP
M
M
M
M
M                                  __T[_
M
M
M
M
M
M            #__4O\
M
M
M
M
I                                                   /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>md-20240630.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2024-08-05T14:02:54.1852+00:00 -->
<!-- Copyright (c) 2024 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://www.mednax.com/20240630" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:ecd-sub="http://xbrl.sec.gov/ecd-sub/2024" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:srt="http://fasb.org/srt/2024" xmlns:md="http://www.mednax.com/20240630" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:calc="https://xbrl.org/2023/calculation-1.1" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd" namespace="http://xbrl.sec.gov/ecd-sub/2024"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd" namespace="http://fasb.org/srt/2024"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" namespace="http://xbrl.sec.gov/dei/2024"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd" namespace="http://fasb.org/us-gaap/2024"/>
  <xsd:import schemaLocation="https://www.xbrl.org/2023/calculation-1.1.xsd" namespace="https://xbrl.org/2023/calculation-1.1"/>
  <xsd:import schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" namespace="http://www.xbrl.org/dtr/type/2022-03-31"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd" namespace="http://xbrl.sec.gov/ecd/2024"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.mednax.com/20240630/taxonomy/role/CoverPage" id="CoverPage">
        <link:definition>100000 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mednax.com/20240630/taxonomy/role/ConsolidatedBalanceSheetsUnaudited" id="ConsolidatedBalanceSheetsUnaudited">
        <link:definition>100010 - Statement - Consolidated Balance Sheets (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mednax.com/20240630/taxonomy/role/ConsolidatedBalanceSheetsUnauditedParenthetical" id="ConsolidatedBalanceSheetsUnauditedParenthetical">
        <link:definition>100020 - Statement - Consolidated Balance Sheets (Unaudited) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mednax.com/20240630/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnaudited" id="StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnaudited">
        <link:definition>100030 - Statement - Consolidated Statements of Income and Comprehensive Income (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mednax.com/20240630/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnauditedParenthetical" id="StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnauditedParenthetical">
        <link:definition>100040 - Statement - Consolidated Statements of Income and Comprehensive Income (Unaudited) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mednax.com/20240630/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquityUnaudited" id="StatementConsolidatedStatementsOfShareholdersEquityUnaudited">
        <link:definition>100050 - Statement - Consolidated Statements of Shareholders' Equity (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mednax.com/20240630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited" id="StatementConsolidatedStatementsOfCashFlowsUnaudited">
        <link:definition>100060 - Statement - Consolidated Statements of Cash Flows (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mednax.com/20240630/taxonomy/role/DisclosureBasisOfPresentation" id="DisclosureBasisOfPresentation">
        <link:definition>995455 - Disclosure - Basis of Presentation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mednax.com/20240630/taxonomy/role/DisclosureCoronavirusPandemicCovid191" id="DisclosureCoronavirusPandemicCovid191">
        <link:definition>995465 - Disclosure - Coronavirus Pandemic (COVID-19)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mednax.com/20240630/taxonomy/role/CashEquivalentsAndInvestments" id="CashEquivalentsAndInvestments">
        <link:definition>995475 - Disclosure - Cash Equivalents and Investments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mednax.com/20240630/taxonomy/role/FairValueMeasurements" id="FairValueMeasurements">
        <link:definition>995485 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mednax.com/20240630/taxonomy/role/AccountsReceivableAndNetRevenue" id="AccountsReceivableAndNetRevenue">
        <link:definition>995495 - Disclosure - Accounts Receivable and Net Revenue</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mednax.com/20240630/taxonomy/role/DisclosureBusinessCombinations" id="DisclosureBusinessCombinations">
        <link:definition>995505 - Disclosure - Business Combinations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mednax.com/20240630/taxonomy/role/DisclosureGoodwillAndLonglivedAssetImpairments" id="DisclosureGoodwillAndLonglivedAssetImpairments">
        <link:definition>995515 - Disclosure - Goodwill and Long-Lived Asset Impairments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mednax.com/20240630/taxonomy/role/AccountsPayableAndAccruedExpenses" id="AccountsPayableAndAccruedExpenses">
        <link:definition>995525 - Disclosure - Accounts Payable and Accrued Expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mednax.com/20240630/taxonomy/role/DisclosureLineOfCreditAndLongTermDebt" id="DisclosureLineOfCreditAndLongTermDebt">
        <link:definition>995535 - Disclosure - Line of Credit and Long Term Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mednax.com/20240630/taxonomy/role/CommonAndCommonEquivalentShares" id="CommonAndCommonEquivalentShares">
        <link:definition>995545 - Disclosure - Common and Common Equivalent Shares</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mednax.com/20240630/taxonomy/role/StockIncentivePlansAndStockPurchasePlans" id="StockIncentivePlansAndStockPurchasePlans">
        <link:definition>995555 - Disclosure - Stock Incentive Plans and Stock Purchase Plans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mednax.com/20240630/taxonomy/role/CommonStockRepurchasePrograms" id="CommonStockRepurchasePrograms">
        <link:definition>995565 - Disclosure - Common Stock Repurchase Programs</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mednax.com/20240630/taxonomy/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
        <link:definition>995575 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mednax.com/20240630/taxonomy/role/DisclosureBasisOfPresentationPolicies" id="DisclosureBasisOfPresentationPolicies">
        <link:definition>995585 - Disclosure - Basis of Presentation (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mednax.com/20240630/taxonomy/role/CashEquivalentsAndInvestmentsTables" id="CashEquivalentsAndInvestmentsTables">
        <link:definition>995595 - Disclosure - Cash Equivalents and Investments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mednax.com/20240630/taxonomy/role/FairValueMeasurementsTables" id="FairValueMeasurementsTables">
        <link:definition>995605 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mednax.com/20240630/taxonomy/role/AccountsReceivableAndNetRevenueTables" id="AccountsReceivableAndNetRevenueTables">
        <link:definition>995615 - Disclosure - Accounts Receivable and Net Revenue (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mednax.com/20240630/taxonomy/role/AccountsPayableAndAccruedExpensesTables" id="AccountsPayableAndAccruedExpensesTables">
        <link:definition>995625 - Disclosure - Accounts Payable and Accrued Expenses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mednax.com/20240630/taxonomy/role/CommonAndCommonEquivalentSharesTables" id="CommonAndCommonEquivalentSharesTables">
        <link:definition>995635 - Disclosure - Common and Common Equivalent Shares (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mednax.com/20240630/taxonomy/role/DisclosureBasisOfPresentationAdditionalInformationDetail" id="DisclosureBasisOfPresentationAdditionalInformationDetail">
        <link:definition>995645 - Disclosure - Basis of Presentation - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mednax.com/20240630/taxonomy/role/DisclosureCoronavirusPandemicCovid19AdditionalInformationDetail" id="DisclosureCoronavirusPandemicCovid19AdditionalInformationDetail">
        <link:definition>995655 - Disclosure - Coronavirus Pandemic (COVID-19) - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mednax.com/20240630/taxonomy/role/CashEquivalentsAndInvestmentsAdditionalInformationDetail" id="CashEquivalentsAndInvestmentsAdditionalInformationDetail">
        <link:definition>995665 - Disclosure - Cash Equivalents and Investments - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mednax.com/20240630/taxonomy/role/CashEquivalentsAndInvestmentsScheduleOfInvestmentsDetail" id="CashEquivalentsAndInvestmentsScheduleOfInvestmentsDetail">
        <link:definition>995675 - Disclosure - Cash Equivalents and Investments - Schedule of Investments (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mednax.com/20240630/taxonomy/role/FairValueMeasurementsScheduleOfFairValueOnARecurringBasisDetails" id="FairValueMeasurementsScheduleOfFairValueOnARecurringBasisDetails">
        <link:definition>995685 - Disclosure - Fair Value Measurements - Schedule of fair value on a recurring basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mednax.com/20240630/taxonomy/role/FairValueMeasurementsScheduleOfFinancialInstrumentsThatAreNotCarriedAtFairValueDetails" id="FairValueMeasurementsScheduleOfFinancialInstrumentsThatAreNotCarriedAtFairValueDetails">
        <link:definition>995695 - Disclosure - Fair Value Measurements - Schedule of financial instruments that are not carried at fair value (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mednax.com/20240630/taxonomy/role/FairValueMeasurementsAdditionalInformationDetail" id="FairValueMeasurementsAdditionalInformationDetail">
        <link:definition>995705 - Disclosure - Fair Value Measurements - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mednax.com/20240630/taxonomy/role/AccountsReceivableAndNetRevenueScheduleOfAccountsReceivableNetDetail" id="AccountsReceivableAndNetRevenueScheduleOfAccountsReceivableNetDetail">
        <link:definition>995715 - Disclosure - Accounts Receivable and Net Revenue - Schedule of Accounts Receivable, Net (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mednax.com/20240630/taxonomy/role/AccountsReceivableAndNetRevenueScheduleOfNetRevenueDetail" id="AccountsReceivableAndNetRevenueScheduleOfNetRevenueDetail">
        <link:definition>995725 - Disclosure - Accounts Receivable and Net Revenue - Schedule of Net Revenue (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mednax.com/20240630/taxonomy/role/AccountsReceivableAndNetRevenueScheduleOfNetPatientServiceRevenueByTypeOfPayorDetail" id="AccountsReceivableAndNetRevenueScheduleOfNetPatientServiceRevenueByTypeOfPayorDetail">
        <link:definition>995735 - Disclosure - Accounts Receivable and Net Revenue - Schedule of Net Patient Service Revenue by Type of Payor (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mednax.com/20240630/taxonomy/role/DisclosureBusinessCombinationsAdditionalInformationDetail" id="DisclosureBusinessCombinationsAdditionalInformationDetail">
        <link:definition>995745 - Disclosure - Business Combinations - Additional information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mednax.com/20240630/taxonomy/role/DisclosureGoodwillAndLonglivedAssetImpairmentsAdditionalInformationDetails" id="DisclosureGoodwillAndLonglivedAssetImpairmentsAdditionalInformationDetails">
        <link:definition>995755 - Disclosure - Goodwill and Long-Lived Asset Impairments (Additional Information) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mednax.com/20240630/taxonomy/role/AccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetail" id="AccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetail">
        <link:definition>995765 - Disclosure - Accounts Payable and Accrued Expenses - Schedule of Accounts Payable and Accrued Expenses (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mednax.com/20240630/taxonomy/role/AccountsPayableAndAccruedExpensesAdditionalInformationDetail" id="AccountsPayableAndAccruedExpensesAdditionalInformationDetail">
        <link:definition>995775 - Disclosure - Accounts Payable and Accrued Expenses - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mednax.com/20240630/taxonomy/role/DisclosureLineOfCreditAndLongTermDebtAdditionalInformationDetails" id="DisclosureLineOfCreditAndLongTermDebtAdditionalInformationDetails">
        <link:definition>995785 - Disclosure - Line of Credit and Long Term Debt (Additional Information) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mednax.com/20240630/taxonomy/role/CommonAndCommonEquivalentSharesScheduleOfCalculationOfSharesUsedInBasicAndDilutedNetIncomePerShareDetail" id="CommonAndCommonEquivalentSharesScheduleOfCalculationOfSharesUsedInBasicAndDilutedNetIncomePerShareDetail">
        <link:definition>995795 - Disclosure - Common and Common Equivalent Shares - Schedule of Calculation of Shares Used in Basic and Diluted Net Income Per Share (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mednax.com/20240630/taxonomy/role/DisclosureCommonAndCommonEquivalentSharesAdditionalInformationDetails" id="DisclosureCommonAndCommonEquivalentSharesAdditionalInformationDetails">
        <link:definition>995805 - Disclosure - Common and Common Equivalent Shares (Additional Information) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mednax.com/20240630/taxonomy/role/DisclosureCommonAndCommonEquivalentSharesScheduleOfCalculationOfSharesUsedInBasicAndDilutedNetIncomePerShareParentheticalDetails" id="DisclosureCommonAndCommonEquivalentSharesScheduleOfCalculationOfSharesUsedInBasicAndDilutedNetIncomePerShareParentheticalDetails">
        <link:definition>995815 - Disclosure - Common and Common Equivalent Shares - Schedule of Calculation of Shares Used in Basic and Diluted Net Income Per Share (Parenthetical) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mednax.com/20240630/taxonomy/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail" id="StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail">
        <link:definition>995825 - Disclosure - Stock Incentive Plans and Stock Purchase Plans - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mednax.com/20240630/taxonomy/role/CommonStockRepurchaseProgramsAdditionalInformationDetail" id="CommonStockRepurchaseProgramsAdditionalInformationDetail">
        <link:definition>995835 - Disclosure - Common Stock Repurchase Programs - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbase id="lnk">
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://www.esma.europa.eu/xbrl/esef/arcrole/wider-narrower" xlink:href="http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd#wider-narrower" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="https://xbrl.org/2023/arcrole/summation-item" xlink:href="https://www.xbrl.org/2023/calculation-1.1.xsd#summation-item" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.mednax.com/20240630/taxonomy/role/ConsolidatedBalanceSheetsUnaudited" xlink:href="md-20240630.xsd#ConsolidatedBalanceSheetsUnaudited" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.mednax.com/20240630/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnaudited" xlink:href="md-20240630.xsd#StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnaudited" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.mednax.com/20240630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited" xlink:href="md-20240630.xsd#StatementConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.mednax.com/20240630/taxonomy/role/AccountsReceivableAndNetRevenueScheduleOfAccountsReceivableNetDetail" xlink:href="md-20240630.xsd#AccountsReceivableAndNetRevenueScheduleOfAccountsReceivableNetDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.mednax.com/20240630/taxonomy/role/AccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetail" xlink:href="md-20240630.xsd#AccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.mednax.com/20240630/taxonomy/role/CommonAndCommonEquivalentSharesScheduleOfCalculationOfSharesUsedInBasicAndDilutedNetIncomePerShareDetail" xlink:href="md-20240630.xsd#CommonAndCommonEquivalentSharesScheduleOfCalculationOfSharesUsedInBasicAndDilutedNetIncomePerShareDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.mednax.com/20240630/taxonomy/role/CoverPage" xlink:href="md-20240630.xsd#CoverPage" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.mednax.com/20240630/taxonomy/role/ConsolidatedBalanceSheetsUnauditedParenthetical" xlink:href="md-20240630.xsd#ConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.mednax.com/20240630/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnauditedParenthetical" xlink:href="md-20240630.xsd#StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnauditedParenthetical" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.mednax.com/20240630/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquityUnaudited" xlink:href="md-20240630.xsd#StatementConsolidatedStatementsOfShareholdersEquityUnaudited" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.mednax.com/20240630/taxonomy/role/DisclosureBasisOfPresentation" xlink:href="md-20240630.xsd#DisclosureBasisOfPresentation" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.mednax.com/20240630/taxonomy/role/DisclosureCoronavirusPandemicCovid191" xlink:href="md-20240630.xsd#DisclosureCoronavirusPandemicCovid191" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.mednax.com/20240630/taxonomy/role/CashEquivalentsAndInvestments" xlink:href="md-20240630.xsd#CashEquivalentsAndInvestments" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.mednax.com/20240630/taxonomy/role/FairValueMeasurements" xlink:href="md-20240630.xsd#FairValueMeasurements" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.mednax.com/20240630/taxonomy/role/AccountsReceivableAndNetRevenue" xlink:href="md-20240630.xsd#AccountsReceivableAndNetRevenue" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.mednax.com/20240630/taxonomy/role/DisclosureBusinessCombinations" xlink:href="md-20240630.xsd#DisclosureBusinessCombinations" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.mednax.com/20240630/taxonomy/role/DisclosureGoodwillAndLonglivedAssetImpairments" xlink:href="md-20240630.xsd#DisclosureGoodwillAndLonglivedAssetImpairments" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.mednax.com/20240630/taxonomy/role/AccountsPayableAndAccruedExpenses" xlink:href="md-20240630.xsd#AccountsPayableAndAccruedExpenses" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.mednax.com/20240630/taxonomy/role/DisclosureLineOfCreditAndLongTermDebt" xlink:href="md-20240630.xsd#DisclosureLineOfCreditAndLongTermDebt" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.mednax.com/20240630/taxonomy/role/CommonAndCommonEquivalentShares" xlink:href="md-20240630.xsd#CommonAndCommonEquivalentShares" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.mednax.com/20240630/taxonomy/role/StockIncentivePlansAndStockPurchasePlans" xlink:href="md-20240630.xsd#StockIncentivePlansAndStockPurchasePlans" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.mednax.com/20240630/taxonomy/role/CommonStockRepurchasePrograms" xlink:href="md-20240630.xsd#CommonStockRepurchasePrograms" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.mednax.com/20240630/taxonomy/role/CommitmentsAndContingencies" xlink:href="md-20240630.xsd#CommitmentsAndContingencies" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.mednax.com/20240630/taxonomy/role/DisclosureBasisOfPresentationPolicies" xlink:href="md-20240630.xsd#DisclosureBasisOfPresentationPolicies" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.mednax.com/20240630/taxonomy/role/CashEquivalentsAndInvestmentsTables" xlink:href="md-20240630.xsd#CashEquivalentsAndInvestmentsTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.mednax.com/20240630/taxonomy/role/FairValueMeasurementsTables" xlink:href="md-20240630.xsd#FairValueMeasurementsTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.mednax.com/20240630/taxonomy/role/AccountsReceivableAndNetRevenueTables" xlink:href="md-20240630.xsd#AccountsReceivableAndNetRevenueTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.mednax.com/20240630/taxonomy/role/AccountsPayableAndAccruedExpensesTables" xlink:href="md-20240630.xsd#AccountsPayableAndAccruedExpensesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.mednax.com/20240630/taxonomy/role/CommonAndCommonEquivalentSharesTables" xlink:href="md-20240630.xsd#CommonAndCommonEquivalentSharesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.mednax.com/20240630/taxonomy/role/DisclosureBasisOfPresentationAdditionalInformationDetail" xlink:href="md-20240630.xsd#DisclosureBasisOfPresentationAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.mednax.com/20240630/taxonomy/role/DisclosureCoronavirusPandemicCovid19AdditionalInformationDetail" xlink:href="md-20240630.xsd#DisclosureCoronavirusPandemicCovid19AdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.mednax.com/20240630/taxonomy/role/CashEquivalentsAndInvestmentsAdditionalInformationDetail" xlink:href="md-20240630.xsd#CashEquivalentsAndInvestmentsAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.mednax.com/20240630/taxonomy/role/CashEquivalentsAndInvestmentsScheduleOfInvestmentsDetail" xlink:href="md-20240630.xsd#CashEquivalentsAndInvestmentsScheduleOfInvestmentsDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.mednax.com/20240630/taxonomy/role/FairValueMeasurementsScheduleOfFairValueOnARecurringBasisDetails" xlink:href="md-20240630.xsd#FairValueMeasurementsScheduleOfFairValueOnARecurringBasisDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.mednax.com/20240630/taxonomy/role/FairValueMeasurementsScheduleOfFinancialInstrumentsThatAreNotCarriedAtFairValueDetails" xlink:href="md-20240630.xsd#FairValueMeasurementsScheduleOfFinancialInstrumentsThatAreNotCarriedAtFairValueDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.mednax.com/20240630/taxonomy/role/FairValueMeasurementsAdditionalInformationDetail" xlink:href="md-20240630.xsd#FairValueMeasurementsAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.mednax.com/20240630/taxonomy/role/AccountsReceivableAndNetRevenueScheduleOfNetRevenueDetail" xlink:href="md-20240630.xsd#AccountsReceivableAndNetRevenueScheduleOfNetRevenueDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.mednax.com/20240630/taxonomy/role/AccountsReceivableAndNetRevenueScheduleOfNetPatientServiceRevenueByTypeOfPayorDetail" xlink:href="md-20240630.xsd#AccountsReceivableAndNetRevenueScheduleOfNetPatientServiceRevenueByTypeOfPayorDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.mednax.com/20240630/taxonomy/role/DisclosureBusinessCombinationsAdditionalInformationDetail" xlink:href="md-20240630.xsd#DisclosureBusinessCombinationsAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.mednax.com/20240630/taxonomy/role/DisclosureGoodwillAndLonglivedAssetImpairmentsAdditionalInformationDetails" xlink:href="md-20240630.xsd#DisclosureGoodwillAndLonglivedAssetImpairmentsAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.mednax.com/20240630/taxonomy/role/AccountsPayableAndAccruedExpensesAdditionalInformationDetail" xlink:href="md-20240630.xsd#AccountsPayableAndAccruedExpensesAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.mednax.com/20240630/taxonomy/role/DisclosureLineOfCreditAndLongTermDebtAdditionalInformationDetails" xlink:href="md-20240630.xsd#DisclosureLineOfCreditAndLongTermDebtAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.mednax.com/20240630/taxonomy/role/DisclosureCommonAndCommonEquivalentSharesAdditionalInformationDetails" xlink:href="md-20240630.xsd#DisclosureCommonAndCommonEquivalentSharesAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.mednax.com/20240630/taxonomy/role/DisclosureCommonAndCommonEquivalentSharesScheduleOfCalculationOfSharesUsedInBasicAndDilutedNetIncomePerShareParentheticalDetails" xlink:href="md-20240630.xsd#DisclosureCommonAndCommonEquivalentSharesScheduleOfCalculationOfSharesUsedInBasicAndDilutedNetIncomePerShareParentheticalDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.mednax.com/20240630/taxonomy/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail" xlink:href="md-20240630.xsd#StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.mednax.com/20240630/taxonomy/role/CommonStockRepurchaseProgramsAdditionalInformationDetail" xlink:href="md-20240630.xsd#CommonStockRepurchaseProgramsAdditionalInformationDetail" xlink:type="simple"/>
        <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_PaymentsToTermLoan" xlink:label="md_PaymentsToTermLoan"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_IncreaseDecreaseInAccruedSalariesAndBonuses" xlink:label="md_IncreaseDecreaseInAccruedSalariesAndBonuses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_BasisOfPresentationAndNewAccountingPronouncementsTable" xlink:label="md_BasisOfPresentationAndNewAccountingPronouncementsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_RepaymentsOfLongTermCapitalLeaseObligation" xlink:label="md_RepaymentsOfLongTermCapitalLeaseObligation"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_GoodWillImpairmentLossExcludingDeferredTaxAssetsCharge" xlink:label="md_GoodWillImpairmentLossExcludingDeferredTaxAssetsCharge"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCharges" xlink:label="us-gaap_RestructuringCharges"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_CashEquivalentsAndInvestmentsTable" xlink:label="md_CashEquivalentsAndInvestmentsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_CovidNinenteenMember" xlink:label="md_CovidNinenteenMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="us-gaap_OtherNoncashIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_PediatricGastroenterologyAndGynecologyPracticeAndMultiLocationPediatricUrgentCarePracticeMember" xlink:label="md_PediatricGastroenterologyAndGynecologyPracticeAndMultiLocationPediatricUrgentCarePracticeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesPayableFairValueDisclosure" xlink:label="us-gaap_NotesPayableFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="us-gaap_AccruedSalariesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_RadiologyServicesMedicalGroupMember" xlink:label="md_RadiologyServicesMedicalGroupMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:label="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_FivePointTwoFivePercentageSeniorNotesDueTwoThousandTwentyThreeMember" xlink:label="md_FivePointTwoFivePercentageSeniorNotesDueTwoThousandTwentyThreeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_TwoThousandFifteenNonQualifiedStockPurchasePlanMember" xlink:label="md_TwoThousandFifteenNonQualifiedStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USStatesAndPoliticalSubdivisionsMember" xlink:label="us-gaap_USStatesAndPoliticalSubdivisionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_TwoThousandTwentyThreeMember" xlink:label="md_TwoThousandTwentyThreeMember"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_CommonStockTable" xlink:label="md_CommonStockTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeniorNotes" xlink:label="us-gaap_SeniorNotes"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_UnnamedCorporateJointVentureTwoMember" xlink:label="md_UnnamedCorporateJointVentureTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_ScheduleOfFinancingReceivablesLineItems" xlink:label="md_ScheduleOfFinancingReceivablesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_FairValueDisclosuresTable" xlink:label="md_FairValueDisclosuresTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductAndServiceOtherMember" xlink:label="us-gaap_ProductAndServiceOtherMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HealthCareOrganizationRevenueSourcesDomain" xlink:label="us-gaap_HealthCareOrganizationRevenueSourcesDomain"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_IncreaseInDeferredTaxAssets" xlink:label="md_IncreaseInDeferredTaxAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeographicDistributionDomain" xlink:label="us-gaap_GeographicDistributionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:label="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_NumberOfMultiLocationPediatricUrgentCarePracticeAcquired" xlink:label="md_NumberOfMultiLocationPediatricUrgentCarePracticeAcquired"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateJointVentureMember" xlink:label="us-gaap_CorporateJointVentureMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentDescription" xlink:label="us-gaap_DebtInstrumentDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_TwoThousandTwentySevenMember" xlink:label="md_TwoThousandTwentySevenMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:label="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_ChangeInRateOfControlPremium" xlink:label="md_ChangeInRateOfControlPremium"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_LineOfCreditLongTermDebtAndFinanceLeaseObligationsDisclosureTextBlock" xlink:label="md_LineOfCreditLongTermDebtAndFinanceLeaseObligationsDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:label="us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesPayable" xlink:label="us-gaap_NotesPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TextBlockAbstract" xlink:label="us-gaap_TextBlockAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_AnesthesiologyServicesMedicalGroupMember" xlink:label="md_AnesthesiologyServicesMedicalGroupMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivablesAbstract" xlink:label="us-gaap_ReceivablesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_DeferredTaxAssetsAxis" xlink:label="md_DeferredTaxAssetsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="us-gaap_DisaggregationOfRevenueTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:label="us-gaap_ProceedsFromLinesOfCredit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeographicDistributionAxis" xlink:label="us-gaap_GeographicDistributionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnsecuredLongTermDebt" xlink:label="us-gaap_UnsecuredLongTermDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_RuralAreaMember" xlink:label="md_RuralAreaMember"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_CommonStockRepurchasesTextBlock" xlink:label="md_CommonStockRepurchasesTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_ContributionsInAidOfReimbursementOfLostRevenue" xlink:label="md_ContributionsInAidOfReimbursementOfLostRevenue"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_ExtraordinaryItemsDomain" xlink:label="md_ExtraordinaryItemsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:label="us-gaap_PaymentsToAcquireInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfLinesOfCredit" xlink:label="us-gaap_RepaymentsOfLinesOfCredit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:label="us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_FinancialInstrumentsMeasuredAtCarryingAmountTableTextBlock" xlink:label="md_FinancialInstrumentsMeasuredAtCarryingAmountTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_NumberOfPediatricOrThopedicPracticesAcquired" xlink:label="md_NumberOfPediatricOrThopedicPracticesAcquired"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember" xlink:label="md_RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfBusiness" xlink:label="us-gaap_GainLossOnSaleOfBusiness"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HealthCareOrganizationRevenueSourcesAxis" xlink:label="us-gaap_HealthCareOrganizationRevenueSourcesAxis"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_SixPointTwoFivePercentageSeniorNotesDueTwoThousandTwentySevenMember" xlink:label="md_SixPointTwoFivePercentageSeniorNotesDueTwoThousandTwentySevenMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_PediatricSubspecialtyPracticeMember" xlink:label="md_PediatricSubspecialtyPracticeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DescriptionOfInterestRateRiskExposure" xlink:label="us-gaap_DescriptionOfInterestRateRiskExposure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:label="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodAxis" xlink:label="us-gaap_TaxPeriodAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_PercentageOfNetPatientServiceRevenueByTypeOfPayor" xlink:label="md_PercentageOfNetPatientServiceRevenueByTypeOfPayor"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionDescription" xlink:label="us-gaap_DebtConversionDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ThirdPartyPayorMember" xlink:label="us-gaap_ThirdPartyPayorMember"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_CommonStockLineItems" xlink:label="md_CommonStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMember" xlink:label="us-gaap_LongTermDebtMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_PercentageIncreaseDecreaseInSalaryAndWage" xlink:label="md_PercentageIncreaseDecreaseInSalaryAndWage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_NetOfTaxUnrealizedHoldingGainLossOnInvestments" xlink:label="md_NetOfTaxUnrealizedHoldingGainLossOnInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_MaternalFetalMedicinePracticeMember" xlink:label="md_MaternalFetalMedicinePracticeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MalpracticeLossContingencyAccrualUndiscountedCurrent" xlink:label="us-gaap_MalpracticeLossContingencyAccrualUndiscountedCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_MoneyMarketFundsFairValueDisclosure" xlink:label="md_MoneyMarketFundsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueAbstract" xlink:label="us-gaap_DisaggregationOfRevenueAbstract"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_LongTermDebtAndCapitalLeaseObligationsExcludingLongTermLineOfCredit" xlink:label="md_LongTermDebtAndCapitalLeaseObligationsExcludingLongTermLineOfCredit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfUnsecuredDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfUnsecuredDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeNet" xlink:label="us-gaap_InvestmentIncomeNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsAtCarryingValue" xlink:label="us-gaap_MoneyMarketFundsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MalpracticeLossContingencyAccrualUndiscountedNoncurrent" xlink:label="us-gaap_MalpracticeLossContingencyAccrualUndiscountedNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRepurchasedDuringPeriodValue" xlink:label="us-gaap_StockRepurchasedDuringPeriodValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_MutualFundsFairValueDisclosure" xlink:label="md_MutualFundsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFrequencyOfPeriodicPayment" xlink:label="us-gaap_DebtInstrumentFrequencyOfPeriodicPayment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:label="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_AccruedPayrollTaxesAndBenefitsCurrent" xlink:label="md_AccruedPayrollTaxesAndBenefitsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_PracticeSalariesAndBenefits" xlink:label="md_PracticeSalariesAndBenefits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="us-gaap_BusinessCombinationsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="us-gaap_PaymentsToAcquireBusinessesGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnsecuredDebt" xlink:label="us-gaap_UnsecuredDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupClassificationAxis" xlink:label="us-gaap_DisposalGroupClassificationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_CoronavirusPandemicCOVIDNineteenDisclosureTextBlock" xlink:label="md_CoronavirusPandemicCOVIDNineteenDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_TwoZeroThreeZeroMember" xlink:label="md_TwoZeroThreeZeroMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:label="us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_PracticeSuppliesAndOtherOperatingExpenses" xlink:label="md_PracticeSuppliesAndOtherOperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_AmendedAndRestatedTwoThousandEightPlanMember" xlink:label="md_AmendedAndRestatedTwoThousandEightPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_NonCashCharge" xlink:label="md_NonCashCharge"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_FairValueDisclosuresLineItems" xlink:label="md_FairValueDisclosuresLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_AccountsReceivableAndNetRevenueDisclosureTextBlock" xlink:label="md_AccountsReceivableAndNetRevenueDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_UnnamedCorporateJointVentureOneMember" xlink:label="md_UnnamedCorporateJointVentureOneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanMember" xlink:label="md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_NumberOfPediatricGastroenterologyPracticeAcquired" xlink:label="md_NumberOfPediatricGastroenterologyPracticeAcquired"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_GaapSeniorNotesMember" xlink:label="md_GaapSeniorNotesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableGrossAllowanceAndNetAbstract" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivableGrossAllowanceAndNetAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_IncrementalSharesNotIncludedDueToAntiDilutiveEffect" xlink:label="md_IncrementalSharesNotIncludedDueToAntiDilutiveEffect"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_IncrementalSharesInContinuingOperation" xlink:label="md_IncrementalSharesInContinuingOperation"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_ExtraordinaryItemsAbstract" xlink:label="md_ExtraordinaryItemsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_PrimaryBeneficiaryMember" xlink:label="md_PrimaryBeneficiaryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_NumberOfMaternalFetalMedicinePracticesAcquired" xlink:label="md_NumberOfMaternalFetalMedicinePracticesAcquired"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReceivable" xlink:label="us-gaap_IncomeTaxReceivable"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_LineOfCreditAndLongTermDebtTextBlock" xlink:label="md_LineOfCreditAndLongTermDebtTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_FivePointThreeSevenFivePercentUnsecuredSeniorNotesDueTwoThousandThirtyMember" xlink:label="md_FivePointThreeSevenFivePercentUnsecuredSeniorNotesDueTwoThousandThirtyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_CashEquivalentsAndInvestmentsLineItems" xlink:label="md_CashEquivalentsAndInvestmentsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_DissolutionOfAndNetIncomeLossAttributableToNoncontrollingInterest" xlink:label="md_DissolutionOfAndNetIncomeLossAttributableToNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="us-gaap_GoodwillImpairmentLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCredit" xlink:label="us-gaap_LineOfCredit"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_PurchasePrice" xlink:label="md_PurchasePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_BasisOfPresentationLineItems" xlink:label="md_BasisOfPresentationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve" xlink:label="us-gaap_IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_ProceedsFromContributionInAidOfReimbursementOfLostRevenue" xlink:label="md_ProceedsFromContributionInAidOfReimbursementOfLostRevenue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupClassificationDomain" xlink:label="us-gaap_DisposalGroupClassificationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract" xlink:label="us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashEquivalentsMember" xlink:label="us-gaap_CashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedIncomeTaxesCurrent" xlink:label="us-gaap_AccruedIncomeTaxesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_OperatingAndFinanceLeaseRightOfUseAssets" xlink:label="md_OperatingAndFinanceLeaseRightOfUseAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GovernmentMember" xlink:label="us-gaap_GovernmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMember" xlink:label="md_SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="us-gaap_CertificatesOfDepositMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:label="us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_NorthAmericanPartnersInAnesthesiaMember" xlink:label="md_NorthAmericanPartnersInAnesthesiaMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions" xlink:label="us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LettersOfCreditOutstandingAmount" xlink:label="us-gaap_LettersOfCreditOutstandingAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" xlink:label="us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_PercentageOfRefundOfIncomeTaxAtThePriorPeriodCorporateTaxRate" xlink:label="md_PercentageOfRefundOfIncomeTaxAtThePriorPeriodCorporateTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentPeriodicPaymentInterest" xlink:label="us-gaap_DebtInstrumentPeriodicPaymentInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseImpairmentLoss" xlink:label="us-gaap_OperatingLeaseImpairmentLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_TwoThousandTwentyTaxYearMember" xlink:label="md_TwoThousandTwentyTaxYearMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationLiabilitiesArisingFromContingenciesAmountRecognized" xlink:label="us-gaap_BusinessCombinationLiabilitiesArisingFromContingenciesAmountRecognized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_ExtraordinaryItemsAxis" xlink:label="md_ExtraordinaryItemsAxis"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_DebtInstrumentMaturityYear" xlink:label="md_DebtInstrumentMaturityYear"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_AccountsPayableAndAccruedLiabilitiesExcludingAccruedIncomeTaxesCurrent" xlink:label="md_AccountsPayableAndAccruedLiabilitiesExcludingAccruedIncomeTaxesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember" xlink:label="md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_DeferredTaxAssetsDomain" xlink:label="md_DeferredTaxAssetsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StockRepurchaseProgramAuthorizedAmount1" xlink:label="srt_StockRepurchaseProgramAuthorizedAmount1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SelfPayMember" xlink:label="us-gaap_SelfPayMember"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_HospitalsContractsMember" xlink:label="md_HospitalsContractsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxAssetsNet" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="us-gaap_UnrealizedGainLossOnInvestments"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_ChangeInNonCashImpairmentCharges" xlink:label="md_ChangeInNonCashImpairmentCharges"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HealthCarePatientServiceMember" xlink:label="us-gaap_HealthCarePatientServiceMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableGrossCurrent" xlink:label="us-gaap_AccountsReceivableGrossCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:label="us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="us-gaap_DisaggregationOfRevenueLineItems"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_IncrementalNonCashCharge" xlink:label="md_IncrementalNonCashCharge"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ExecutiveOfficerMember" xlink:label="srt_ExecutiveOfficerMember"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_CreditAgreementMember" xlink:label="md_CreditAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_ContractedManagedCareMember" xlink:label="md_ContractedManagedCareMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="us-gaap_InvestmentsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevolvingCreditFacilityMember" xlink:label="us-gaap_RevolvingCreditFacilityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllOtherCorporateBondsMember" xlink:label="us-gaap_AllOtherCorporateBondsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentMaturityDateDescription" xlink:label="us-gaap_DebtInstrumentMaturityDateDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAbstract" xlink:label="us-gaap_LiabilitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnsecuredDebtMember" xlink:label="us-gaap_UnsecuredDebtMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_PaymentsToTermLoan_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Payments on term loan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_PaymentsToTermLoan_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Term Loan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_PaymentsToTermLoan_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash outflow to term loan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_IncreaseDecreaseInAccruedSalariesAndBonuses_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net decrease in accrued salaries and bonuses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_IncreaseDecreaseInAccruedSalariesAndBonuses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accrued Salaries and Bonuses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_IncreaseDecreaseInAccruedSalariesAndBonuses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase (decrease) in accrued salaries and bonuses.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_BasisOfPresentationAndNewAccountingPronouncementsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Basis of Presentation and New Accounting Pronouncements [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_BasisOfPresentationAndNewAccountingPronouncementsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Basis Of Presentation And New Accounting Pronouncements Table</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Fair Value Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accounts receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accounts Receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_RepaymentsOfLongTermCapitalLeaseObligation_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Payment on finance lease obligation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_RepaymentsOfLongTermCapitalLeaseObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Repayments Of Long Term Capital Lease Obligation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_RepaymentsOfLongTermCapitalLeaseObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Repayments Of Long Term Capital Lease Obligation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_GoodWillImpairmentLossExcludingDeferredTaxAssetsCharge_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Good will Impairment Loss excluding Deferred Tax Assets Charge</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_GoodWillImpairmentLossExcludingDeferredTaxAssetsCharge_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Good will Impairment Loss excluding Deferred Tax Assets Charge</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_GoodWillImpairmentLossExcludingDeferredTaxAssetsCharge_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Good will Impairment Loss excluding Deferred Tax Assets Charge</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, State or Country Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringCharges_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Transformational and restructuring related expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringCharges_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring Charges</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringCharges_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Restructuring Charges, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Business Combinations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_CashEquivalentsAndInvestmentsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Equivalents and Investments [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_CashEquivalentsAndInvestmentsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash Equivalents And Investments Table</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Federal Home Loan Securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">US Government-sponsored Enterprises Debt Securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_CovidNinenteenMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">COVID-19 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_CovidNinenteenMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Covid Ninenteen [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_CovidNinenteenMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Covid Ninenteen [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNoncashIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNoncashIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNoncashIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Noncash Income (Expense)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNoncashIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Noncash Income (Expense), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_PediatricGastroenterologyAndGynecologyPracticeAndMultiLocationPediatricUrgentCarePracticeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pediatric Gastroenterology And Gynecology practice And Multi Location Pediatric Urgent Care Practice [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_PediatricGastroenterologyAndGynecologyPracticeAndMultiLocationPediatricUrgentCarePracticeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Pediatric Gastroenterology And Gynecology practice And Multi Location Pediatric Urgent Care Practice [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 2 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NotesPayableFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Notes Payable Fair Value Disclosure</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NotesPayableFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Notes Payable, Fair Value Disclosure</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongtermDebtTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt, Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Consideration Transferred</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Business Combination, Consideration Transferred, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Business acquisition total consideration</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and Contingencies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedSalariesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued salaries and incentive compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedSalariesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Salaries, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductOrServiceAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Product and Service [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductOrServiceAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Product and Service [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred income tax liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Income Tax Liabilities, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Income Tax Liabilities, Net, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_EquityMethodInvesteeNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment, Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Depreciation and amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation and amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation, Depletion and Amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Depreciation, Depletion and Amortization, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_RadiologyServicesMedicalGroupMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Radiology Services Medical Group [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_RadiologyServicesMedicalGroupMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Radiology Services Medical Group [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Repurchased common stock, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Repurchased During Period, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock repurchased during period, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchases of property and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Other Property, Plant, and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title and Position [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of restricted stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Issued, Value, Share-Based Payment Arrangement, before Forfeiture</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Income taxes payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income taxes receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Income Taxes Receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Line of Credit Facility, Remaining Borrowing Capacity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Line of Credit facility, available balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_FivePointTwoFivePercentageSeniorNotesDueTwoThousandTwentyThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Five Point Two Five Percentage Senior Notes Due Two Thousand Twenty Three [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_FivePointTwoFivePercentageSeniorNotesDueTwoThousandTwentyThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Five Point Two Five Percentage Senior Notes Due Two Thousand Twenty Three [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_FivePointTwoFivePercentageSeniorNotesDueTwoThousandTwentyThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Five Point Two Five Percentage Senior Notes Due Two Thousand Twenty Three [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Available-for-sale [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_TwoThousandFifteenNonQualifiedStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2015 Non-Qualified Stock Purchase Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_TwoThousandFifteenNonQualifiedStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Fifteen Non Qualified Stock Purchase Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_TwoThousandFifteenNonQualifiedStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two Thousand Fifteen Non Qualified Stock Purchase Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in assets and liabilities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Operating Capital [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USStatesAndPoliticalSubdivisionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Municipal Debt Securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USStatesAndPoliticalSubdivisionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">US States and Political Subdivisions Debt Securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Common Stock, Shares, Issued, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Prepaid expenses and other current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Prepaid Expense and Other Assets, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses and other current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_TwoThousandTwentyThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2023 Notes [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_TwoThousandTwentyThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty Three [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_TwoThousandTwentyThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two Thousand Twenty Three Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_CommonStockTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_CommonStockTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_CommonStockTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Common Stock [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeniorNotes_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Senior Notes, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeniorNotes_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Senior Notes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeniorNotes_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Senior notes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_UnnamedCorporateJointVentureTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unnamed Corporate Joint Venture Two [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_UnnamedCorporateJointVentureTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Unnamed Corporate Joint Venture Two [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_UnnamedCorporateJointVentureTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Unnamed Corporate Joint Venture Two Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_ScheduleOfFinancingReceivablesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Financing Receivables [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_ScheduleOfFinancingReceivablesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Financing Receivables [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_ScheduleOfFinancingReceivablesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of financing receivables.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Employee Stock Purchase Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock issued under employee stock purchase plan Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">(Loss) income before income taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">(Loss) income from continuing operations before income taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_FairValueDisclosuresTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_FairValueDisclosuresTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair value disclosures.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProductAndServiceOtherMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Other revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProductAndServiceOtherMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Product and Service, Other [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_HealthCareOrganizationRevenueSourcesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Health Care Organization, Revenue Sources [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_HealthCareOrganizationRevenueSourcesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Health Care Organization, Revenue Sources [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_IncreaseInDeferredTaxAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase in deferred tax assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_IncreaseInDeferredTaxAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase In Deferred Tax assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_IncreaseInDeferredTaxAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase in deferred tax Assets.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeographicDistributionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Geographic Distribution [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Basic, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase decrease in valuation allowance deferred tax assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income taxes payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Income Taxes Payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating expenses:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investments, Debt and Equity Securities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Long-term Debt, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long term debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Retained deficit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings (Accumulated Deficit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Retained Earnings (Accumulated Deficit), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Retained Earnings (Accumulated Deficit), Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Retained Earnings (Accumulated Deficit), Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current assets:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, reserved for issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Operating Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in operating activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductsAndServicesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Product and Service [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductsAndServicesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Product and Service [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Accumulated other comprehensive loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accumulated Other Comprehensive Income (Loss), Net of Tax, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fixed assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxPeriodDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Period [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Property, Plant and Equipment, Net, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Property, Plant and Equipment, Net, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Property, Plant and Equipment, Net, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from operating activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_NumberOfMultiLocationPediatricUrgentCarePracticeAcquired_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of other multi location pediatric urgent care practice acquired</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_NumberOfMultiLocationPediatricUrgentCarePracticeAcquired_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Multi Location Pediatric Urgent Care Practice Acquired</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_NumberOfMultiLocationPediatricUrgentCarePracticeAcquired_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of multi location pediatric urgent care practice acquired.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Recurring [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CorporateJointVentureMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Corporate Joint Venture [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, par value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Par or Stated Value Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized holding gain on investments, net of tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Cash Flows [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument, Description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Deferred Tax Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Goodwill and Intangible Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Components [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Components [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_TwoThousandTwentySevenMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2027 Notes [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_TwoThousandTwentySevenMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty Seven [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_TwoThousandTwentySevenMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two Thousand Twenty Seven Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Percentage of Net Revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedules of Concentration of Risk, by Risk Factor [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total non-operating expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nonoperating Income (Expense)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Cash Equivalents and Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_ChangeInRateOfControlPremium_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in Rate of Control Premium</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_ChangeInRateOfControlPremium_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change in Rate of Control Premium</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_ChangeInRateOfControlPremium_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Change in Rate of Control Premium</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_LineOfCreditLongTermDebtAndFinanceLeaseObligationsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Line of Credit and Long Term Debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_LineOfCreditLongTermDebtAndFinanceLeaseObligationsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Line Of Credit Long Term Debt And Finance Lease Obligations Disclosure Text Block</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_LineOfCreditLongTermDebtAndFinanceLeaseObligationsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Line of credit long term debt and finance lease obligations disclosure text block.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel">Net loss attributable to noncontrolling interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss) Attributable to Noncontrolling Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net Income (Loss) Attributable to Noncontrolling Interest, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss attributable to noncontrolling interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Net loss attributable to noncontrolling interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Dissolution of and net loss attributable to noncontrolling interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current portion of debt and finance lease liabilities, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt and Lease Obligation, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Long-Term Debt and Lease Obligation, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term operating lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NotesPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Notes Payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NotesPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Notes Payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NotesPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Notes Payable, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TextBlockAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Text Block [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional paid-in capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid in Capital, Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Additional Paid in Capital, Common Stock, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Additional Paid in Capital, Common Stock, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_AnesthesiologyServicesMedicalGroupMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Anesthesiology Services Medical Group [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_AnesthesiologyServicesMedicalGroupMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Anesthesiology services medical group.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ReceivablesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Receivables [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net Income (loss) attributable to Pediatrix Medical Group, Inc.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Component [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Component [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Range [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and administrative expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General and Administrative Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">General and Administrative Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_DeferredTaxAssetsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_DeferredTaxAssetsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred Tax Assets Axis</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting period of options, maximum years</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisaggregationOfRevenueTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disaggregation of Revenue [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromLinesOfCredit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Lines of Credit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromLinesOfCredit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Borrowings on revolving credit line</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromLinesOfCredit_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Borrowings on line of credit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net (loss) income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeographicDistributionAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Geographic Distribution [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Preferred Stock, Shares Issued, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnsecuredLongTermDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unsecured Long-Term Debt, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnsecuredLongTermDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of unsecured debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payables and Accruals [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate number Shares issued under Stock Purchase Plans</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common stock issued under employee stock purchase plan shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_RuralAreaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Rural Area [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_RuralAreaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Rural Area [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_RuralAreaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Rural Area [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_CommonStockRepurchasesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock Repurchase Programs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_CommonStockRepurchasesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Repurchases [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_CommonStockRepurchasesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Entire disclosure of common stock repurchases.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_ContributionsInAidOfReimbursementOfLostRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reimbursement of Lost Revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_ContributionsInAidOfReimbursementOfLostRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contributions In Aid Of Reimbursement of Lost Revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_ContributionsInAidOfReimbursementOfLostRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Contributions In Aid Of Reimbursement of Lost Revenue.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_ExtraordinaryItemsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Extraordinary Items [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_ExtraordinaryItemsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Extraordinary Items [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total comprehensive (loss) income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total comprehensive income (loss) attributable to Pediatrix Medical Group, Inc.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Common Stock, Shares, Outstanding, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Common Stock, Shares, Outstanding, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireInvestments_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchases of investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Payments to Acquire Investments, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, par value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Par or Stated Value Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Issuance of restricted stock and conversion of restricted stock units to common stock, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of restricted stock, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Issued, Shares, Share-Based Payment Arrangement, before Forfeiture</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RepaymentsOfLinesOfCredit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Repayments of Lines of Credit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RepaymentsOfLinesOfCredit_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Payments on line of credit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Calculation of Shares Used in Basic and Diluted Net Income Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Weighted Average Number of Shares [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Cash_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Cash_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Cash_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Cash_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash on hand</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_FinancialInstrumentsMeasuredAtCarryingAmountTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Financial Instruments Measured At Carrying Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_FinancialInstrumentsMeasuredAtCarryingAmountTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instruments Measured At Carrying Amount Table Text Block</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_FinancialInstrumentsMeasuredAtCarryingAmountTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Tabular disclosure of financial instruments measured at carrying amount.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_NumberOfPediatricOrThopedicPracticesAcquired_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of other pediatric orthopedic practice acquired</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_NumberOfPediatricOrThopedicPracticesAcquired_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Pediatric Or thopedic Practices Acquired</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_NumberOfPediatricOrThopedicPracticesAcquired_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of pediatric or thopedic practices acquired.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Interactive Data Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Retained Deficit [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings And Accumulated Other Comprehensive Income [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Retained earnings and accumulated other comprehensive income [Member].</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainLossOnSaleOfBusiness_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Loss on disposal of businesses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainLossOnSaleOfBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss on disposal of businesses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainLossOnSaleOfBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gain (Loss) on Disposition of Business</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentQuarterlyReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Quarterly Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_HealthCareOrganizationRevenueSourcesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Health Care Organization, Revenue Sources [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_HealthCareOrganizationRevenueSourcesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Health Care Organization, Revenue Sources [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_SixPointTwoFivePercentageSeniorNotesDueTwoThousandTwentySevenMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Six Point Two Five Percentage Senior Notes Due Two Thousand Twenty Seven [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_SixPointTwoFivePercentageSeniorNotesDueTwoThousandTwentySevenMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Six Point Two Five Percentage Senior Notes Due Two Thousand Twenty Seven [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_SixPointTwoFivePercentageSeniorNotesDueTwoThousandTwentySevenMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Six Point Two Five Percentage Senior Notes Due Two Thousand Twenty Seven [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Range [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_PediatricSubspecialtyPracticeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Pediatric Subspecialty Practice [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_PediatricSubspecialtyPracticeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pediatric Subspecialty Practice [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_PediatricSubspecialtyPracticeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pediatric Subspecialty Practice [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related and Nonrelated Parties [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Net Revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disaggregation of Revenue [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Acquisition payments, net of cash acquired</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Businesses, Net of Cash Acquired</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Payments to Acquire Businesses, Net of Cash Acquired, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares available for future grants and awards under Stock Incentive Plans</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DescriptionOfInterestRateRiskExposure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Description of Interest Rate Risk Exposure</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DescriptionOfInterestRateRiskExposure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest Rate, description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Basis of Presentation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxPeriodAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Period [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Long-Term Debt Instruments [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_PercentageOfNetPatientServiceRevenueByTypeOfPayor_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of net patient service revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_PercentageOfNetPatientServiceRevenueByTypeOfPayor_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Net Patient Service Revenue By Type Of Payor</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_PercentageOfNetPatientServiceRevenueByTypeOfPayor_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of net patient service revenue by type payor.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">New Accounting Pronouncements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Other Comprehensive Loss [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">AOCI Attributable to Parent [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity in earnings of unconsolidated affiliate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income (Loss) from Equity Method Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Income (Loss) from Equity Method Investments, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Fair Value Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtConversionDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Conversion, Description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtConversionDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Conversion Description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ThirdPartyPayorMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other Third-Parties</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ThirdPartyPayorMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Third-Party Payor [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_CommonStockLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_CommonStockLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_CommonStockLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Common Stock [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Long-Term Debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Term A loan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Incentive Plans and Stock Purchase Plans</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_PercentageIncreaseDecreaseInSalaryAndWage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Decrease In Salary | %</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_PercentageIncreaseDecreaseInSalaryAndWage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Increase Decrease In Salary And Wage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_PercentageIncreaseDecreaseInSalaryAndWage_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage Increase Decrease In Salary And Wage.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_NetOfTaxUnrealizedHoldingGainLossOnInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized holding (loss) gain on investments, net of tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_NetOfTaxUnrealizedHoldingGainLossOnInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Of Tax, Unrealized Holding Gain (Loss) on Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_NetOfTaxUnrealizedHoldingGainLossOnInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Net Of Tax, Unrealized Holding Gain (Loss) on Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_NetOfTaxUnrealizedHoldingGainLossOnInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Unrealized holding gain (loss) on investments, net of tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current liabilities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of 12(b) Security</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash and cash equivalents at beginning of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash and cash equivalents at end of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, at Carrying Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash and Cash Equivalents, at Carrying Value, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_MaternalFetalMedicinePracticeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maternal Fetal Medicine Practice [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_MaternalFetalMedicinePracticeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Maternal Fetal Medicine Practice [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Stockholders' Equity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MalpracticeLossContingencyAccrualUndiscountedCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued professional liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MalpracticeLossContingencyAccrualUndiscountedCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Malpractice Loss Contingency, Accrual, Undiscounted, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Period Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_MoneyMarketFundsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair value of money market funds.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_MoneyMarketFundsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Money Market Funds Fair Value Disclosure</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_MoneyMarketFundsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Money market funds</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisaggregationOfRevenueAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Disaggregation of Revenue [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisaggregationOfRevenueAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disaggregation of Revenue [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_LongTermDebtAndCapitalLeaseObligationsExcludingLongTermLineOfCredit_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Long-term debt and finance lease liabilities, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_LongTermDebtAndCapitalLeaseObligationsExcludingLongTermLineOfCredit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long Term Debt and Capital Lease Obligations Excluding Long Term Line of Credit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_LongTermDebtAndCapitalLeaseObligationsExcludingLongTermLineOfCredit_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Long term debt and capital lease obligations excluding long term line of credit.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instruments [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfUnsecuredDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Unsecured Debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfUnsecuredDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of unsecured debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investment and other (loss) income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeNet_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Investment and other income (expense)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment Income, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Investment Income, Net, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangible assets impairments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Impairment of Intangible Assets, Indefinite-Lived (Excluding Goodwill)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from investing activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentTypeCategorizationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investments [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Payments for repurchase of common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amount withheld to satisfy minimum statutory tax withholding obligations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Repurchases of common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments for Repurchase of Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MoneyMarketFundsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Cash equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MoneyMarketFundsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Money Market Funds, at Carrying Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MalpracticeLossContingencyAccrualUndiscountedNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term professional liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MalpracticeLossContingencyAccrualUndiscountedNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Malpractice Loss Contingency, Accrual, Undiscounted, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockRepurchasedDuringPeriodValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Repurchased common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockRepurchasedDuringPeriodValue_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Repurchased common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockRepurchasedDuringPeriodValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Repurchased During Period, Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CreditFacilityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Credit Facility [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_MutualFundsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Mutual funds fair value disclosure.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_MutualFundsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Mutual Funds Fair Value Disclosure</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_MutualFundsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Mutual funds</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangible assets, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Assets, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Finite-Lived Intangible Assets, Net, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Finite-Lived Intangible Assets, Net, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Finite-Lived Intangible Assets, Net, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentFrequencyOfPeriodicPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Debt Instrument, Frequency of Periodic Payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentFrequencyOfPeriodicPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Frequency of Periodic Payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentFrequencyOfPeriodicPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt instrument maturity date description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other accrued expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Accrued Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from (Payments for) Other Financing Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">LIABILITIES AND EQUITY</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash (used in) provided by financing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Financing Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Incremental loss on sale, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Antidilutive securities (restricted stock and stock options) not included in the diluted net income per common share calculation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity method ownership percentage in joint venture</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Method Investment, Ownership Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_AccruedPayrollTaxesAndBenefitsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued payroll taxes and benefits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_AccruedPayrollTaxesAndBenefitsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Payroll Taxes And Benefits Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_AccruedPayrollTaxesAndBenefitsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued payroll taxes and benefits current.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel">Income tax benefit (provision)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Income Tax Expense (Benefit), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Income tax provision</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_PracticeSalariesAndBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Practice salaries and benefits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_PracticeSalariesAndBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Practice Salaries and Benefits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_PracticeSalariesAndBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Practice salaries and benefits.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combinations [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total shareholders' equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity, Attributable to Parent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Stockholders' Equity Attributable to Parent, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Stockholders' Equity Attributable to Parent, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Liabilities, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Liabilities, Noncurrent, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireBusinessesGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Businesses, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireBusinessesGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Business acquisition consideration paid in cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Goodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Goodwill</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Goodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Goodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Goodwill, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Goodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Goodwill, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Goodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Goodwill, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnsecuredDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Unsecured Debt, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnsecuredDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unsecured Debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnsecuredDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unsecured note issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Accounts Receivable, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisposalGroupClassificationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disposal Group Classification [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred income taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Income Tax Expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Income Tax Expense (Benefit), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_CoronavirusPandemicCOVIDNineteenDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Coronavirus Pandemic COVID Nineteen Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_CoronavirusPandemicCOVIDNineteenDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Coronavirus Pandemic COVID Nineteen Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_CoronavirusPandemicCOVIDNineteenDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Coronavirus Pandemic (COVID-19)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_StatementScenarioAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Scenario [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_TwoZeroThreeZeroMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two Zero Three Zero [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_TwoZeroThreeZeroMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Zero Three Zero [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_TwoZeroThreeZeroMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2030 Notes [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Proceeds from maturities or sales of investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Sale, Maturity and Collection of Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Proceeds from Sale, Maturity and Collection of Investments, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_PracticeSuppliesAndOtherOperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Practice supplies and other operating expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_PracticeSuppliesAndOtherOperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Practice Supplies And Other Operating Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_PracticeSuppliesAndOtherOperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The aggregate amount of supplies and other operating expenses directly attributable to the physician practices.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition, Acquiree [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total operating expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_AmendedAndRestatedTwoThousandEightPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amended and Restated 2008 Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_AmendedAndRestatedTwoThousandEightPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amended and Restated Two Thousand Eight Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_AmendedAndRestatedTwoThousandEightPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amended and restated two thousand eight plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_NonCashCharge_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non cash charges</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_NonCashCharge_lbl" xlink:role="http://www.xbrl.org/2003/role/label">non-cash charge</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_NonCashCharge_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">non-cash charge</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities and shareholders' equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Prepaid Expense, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_FairValueDisclosuresLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_FairValueDisclosuresLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair value disclosures.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Diluted, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_AccountsReceivableAndNetRevenueDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts Receivable and Net Revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_AccountsReceivableAndNetRevenueDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Receivable And Net Revenue Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_AccountsReceivableAndNetRevenueDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accounts receivable and net revenue disclosure.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_UnnamedCorporateJointVentureOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unnamed Corporate Joint Venture One [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_UnnamedCorporateJointVentureOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Unnamed Corporate Joint Venture [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">1996 Non-Qualified Employee Stock Purchase Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nineteen Ninety Six Non Qualified Employee Stock Purchase Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">1996 non-qualified employee stock purchase plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Investing Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in investing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_NumberOfPediatricGastroenterologyPracticeAcquired_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Pediatric Gastroenterology Practice Acquired</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_NumberOfPediatricGastroenterologyPracticeAcquired_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Pediatric Gastroenterology Practice Acquired</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_NumberOfPediatricGastroenterologyPracticeAcquired_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of Pediatric Gastroenterology Practice Acquired</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_GaapSeniorNotesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">GAAP Senior Notes [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_GaapSeniorNotesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">GAAP Senior Notes [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_GaapSeniorNotesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">GAAP Senior Notes [Member].</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award vesting period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Filer Category</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Goodwill, Long-Lived Asset Impairments and Loss on Disposal of Businesses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivableGrossAllowanceAndNetAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts, Notes, Loans and Financing Receivable, Gross, Allowance, and Net [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_IncrementalSharesNotIncludedDueToAntiDilutiveEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Incremental shares not Included due to anti dilutive effect</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_IncrementalSharesNotIncludedDueToAntiDilutiveEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Incremental Shares not Included Due to Anti dilutive Effect</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_IncrementalSharesNotIncludedDueToAntiDilutiveEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Incremental Shares Not Included Due To Anti dilutive Effect</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_IncrementalSharesInContinuingOperation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Incremental Shares In Continuing operation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_IncrementalSharesInContinuingOperation_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Incremental Shares In Continuing operation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_ExtraordinaryItemsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Extraordinary Items [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_ExtraordinaryItemsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Extraordinary Items [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Noncash Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-based Payment Arrangement, Noncash Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Business combination consideration identifiable as current and long term liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_PrimaryBeneficiaryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Primary beneficiary [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_PrimaryBeneficiaryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Primary beneficiary [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related and Nonrelated Parties [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_NumberOfMaternalFetalMedicinePracticesAcquired_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Maternal Fetal Medicine Practices Acquired</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_NumberOfMaternalFetalMedicinePracticesAcquired_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of maternal fetal medicine practices acquired.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common and Common Equivalent Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Maturity Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument Maturity Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Weighted average number of common shares outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted Average Number of Shares Outstanding, Basic, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Taxes Receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income taxes receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_LineOfCreditAndLongTermDebtTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Line Of Credit And Long Term Debt [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_LineOfCreditAndLongTermDebtTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Line Of Credit And Long Term Debt [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_LineOfCreditAndLongTermDebtTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Line of Credit and Long Term Debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_FivePointThreeSevenFivePercentUnsecuredSeniorNotesDueTwoThousandThirtyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Five point three seven five percent unsecured senior notes due two thousand thirty member.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_FivePointThreeSevenFivePercentUnsecuredSeniorNotesDueTwoThousandThirtyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Five Point Three Seven Five Percent Unsecured Senior Notes Due Two Thousand Thirty Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_FivePointThreeSevenFivePercentUnsecuredSeniorNotesDueTwoThousandThirtyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">5.375% Unsecured Senior Notes Due 2030 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common stock, shares authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, aggregate shares authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Payable, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 1 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable and accrued expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Accounts Payable and Accrued Liabilities, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instrument [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_CashEquivalentsAndInvestmentsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Equivalents And Investments [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_CashEquivalentsAndInvestmentsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash Equivalents And Investments Line Items</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fixed assets impairments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Impairment, Long-Lived Asset, Held-for-Use</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Impairment, Long-Lived Asset, Held-for-Use, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_DissolutionOfAndNetIncomeLossAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Dissolution Of And Net Income (Loss) Attributable to Noncontrolling Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_DissolutionOfAndNetIncomeLossAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Dissolution Of And Net Income (Loss) Attributable to Noncontrolling Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_DissolutionOfAndNetIncomeLossAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Dissolution of and net loss attributable to noncontrolling interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillImpairmentLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Goodwill impairment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillImpairmentLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Goodwill impairment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillImpairmentLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill, Impairment Loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt Securities, Available-for-sale, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Available-for-sale Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Policies [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCredit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Long-term Line of Credit, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCredit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Line of Credit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCredit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Line of credit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_PurchasePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Purchase price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_PurchasePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Purchase price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_PurchasePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchase price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shareholders' equity:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity, Attributable to Parent [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_BasisOfPresentationLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Basis Of Presentation [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_BasisOfPresentationLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Basis Of Presentation Line Items</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term professional liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Liability for Claims and Claims Adjustment Expense Reserve</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_ProceedsFromContributionInAidOfReimbursementOfLostRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds From Contribution In Aid Of Reimbursement of Lost Revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_ProceedsFromContributionInAidOfReimbursementOfLostRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Contribution In Aid Of Reimbursement of Lost Revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_ProceedsFromContributionInAidOfReimbursementOfLostRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds From Contribution In Aid Of Reimbursement of Lost Revenue.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisposalGroupClassificationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disposal Group Classification [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue from Contract with Customer, Including Assessed Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average common shares:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Basic, Other Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net decrease in cash and cash equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue from Contract with Customer [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net (loss) income:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashEquivalentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Equivalents [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Financial Position [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpense_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Interest expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Expense, Operating and Nonoperating</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Interest Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">(Loss) income from operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income from operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Income (Loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedIncomeTaxesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Income Taxes, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedIncomeTaxesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income taxes payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Shell Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt instrument, interest rate, effective percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Interest Rate, Effective Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Restricted Stock Award, Forfeitures</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Forfeitures of restricted stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_OperatingAndFinanceLeaseRightOfUseAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating and finance lease right-of-use assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_OperatingAndFinanceLeaseRightOfUseAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating And Finance Lease Right Of Use Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_OperatingAndFinanceLeaseRightOfUseAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating and finance lease right-of-use assets.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ASSETS</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GovernmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Government</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GovernmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Government [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Current Reporting Status</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">2027 Notes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">6.25% Senior Unsecured Notes Due 2027 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Six Point Two Five Percent Senior Unsecured Notes Due Two Thousand Twenty Seven [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Six point two five percent senior unsecured notes due two thousand twenty seven.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Forfeitures of restricted stock, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Restricted Stock Award, Forfeited</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Forfeitures of restricted stock, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Accounts Payable and Accrued Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongtermDebtTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt, Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Year Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CertificatesOfDepositMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Certificates of Deposit [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CertificatesOfDepositMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Certificates of Deposit [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock; $.01 par value; 1,000 shares authorized; none issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Value, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Preferred Stock, Value, Issued, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Preferred Stock, Value, Issued, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Preferred Stock, Value, Issued, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net cash used in operating activities - discontinued operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Provided by (Used in) Operating Activities, Discontinued Operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net cash provided by operating activities - discontinued operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash Provided by (Used in) Operating Activities, Discontinued Operations, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_NorthAmericanPartnersInAnesthesiaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">North American Partners In Anesthesia [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_NorthAmericanPartnersInAnesthesiaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">North American Partners In Anesthesia [member].</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash and cash equivalents at end of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash and cash equivalents at beginning of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax adjustments, sttlements and unusual provisions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Adjustments, Settlements, and Unusual Provisions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LettersOfCreditOutstandingAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Letters of Credit Outstanding, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LettersOfCreditOutstandingAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Letter of credit outstanding amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Operating Activities, Continuing Operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in operating activities - continuing operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Goodwill</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition, Goodwill, Expected Tax Deductible Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_PercentageOfRefundOfIncomeTaxAtThePriorPeriodCorporateTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Percentage of refund of income tax at the prior period corporate tax rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_PercentageOfRefundOfIncomeTaxAtThePriorPeriodCorporateTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Refund Of Income Tax At The Prior Period Corporate Tax Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_PercentageOfRefundOfIncomeTaxAtThePriorPeriodCorporateTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of refund of income tax at the prior period corporate tax rate.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentPeriodicPaymentInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Periodic Payment, Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentPeriodicPaymentInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest accrued periodically</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseImpairmentLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease right-of-use asset impairments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseImpairmentLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Impairment Loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Other intangible assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_TwoThousandTwentyTaxYearMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">2020 Tax Year [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_TwoThousandTwentyTaxYearMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty Tax Year [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_TwoThousandTwentyTaxYearMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand twenty tax year.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationLiabilitiesArisingFromContingenciesAmountRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Liabilities Arising from Contingencies, Amount Recognized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationLiabilitiesArisingFromContingenciesAmountRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Business combination consideration identifiable as current and long term liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_ExtraordinaryItemsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Extraordinary Items [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_ExtraordinaryItemsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Extraordinary Items [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_DebtInstrumentMaturityYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt instrument, maturity year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_DebtInstrumentMaturityYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Maturity Year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_DebtInstrumentMaturityYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Debt instrument maturity year.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_AccountsPayableAndAccruedLiabilitiesExcludingAccruedIncomeTaxesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable and accrued expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_AccountsPayableAndAccruedLiabilitiesExcludingAccruedIncomeTaxesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable and Accrued Liabilities Excluding Accrued Income Taxes Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_AccountsPayableAndAccruedLiabilitiesExcludingAccruedIncomeTaxesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accounts payable and accrued liabilities excluding accrued income taxes current.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current portion of operating lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Interest Rate, Stated Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt instrument interest rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization of premiums, discounts and issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amortization of Debt Issuance Costs and Discounts</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Amortization of Debt Issuance Costs and Discounts, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">1996 Non-Qualified Employee Stock Purchase Plan and 2015 Non-Qualified Stock Purchase Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nineteen Ninety Six Non Qualified Employee Stock Purchase Plan And Two Thousand Fifteen Non Qualified Stock Purchase Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Nineteen Ninety Six Non Qualified Employee Stock Purchase Plan And Two Thousand Fifteen Non Qualified Stock Purchase Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_DeferredTaxAssetsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_DeferredTaxAssetsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred Tax Assets Domain</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Transition Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_StockRepurchaseProgramAuthorizedAmount1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock authorized for repurchase</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_StockRepurchaseProgramAuthorizedAmount1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Repurchase Program, Authorized, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of market value of common stock at which employees are permitted to purchase</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SelfPayMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Private-Pay Patients</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SelfPayMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Self-Pay [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_HospitalsContractsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Hospital contract administrative fees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_HospitalsContractsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Hospitals Contracts [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_HospitalsContractsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Hospitals Contracts [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred income tax assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Income Tax Assets, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Income Tax Assets, Net, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Minimum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Minimum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrealizedGainLossOnInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized holding gain (loss) on investments, net of tax of $66, $126, $86 and $353</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrealizedGainLossOnInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrealized Gain (Loss) on Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_ChangeInNonCashImpairmentCharges_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangible asset impairments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_ChangeInNonCashImpairmentCharges_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change in Non Cash Impairment Charges</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_ChangeInNonCashImpairmentCharges_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Change in Non Cash Impairment Charges</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts Payable and Accrued Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment, Name [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other long-term assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Other Noncurrent Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Paid-in Capital [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid-in Capital [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_HealthCarePatientServiceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net patient service revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_HealthCarePatientServiceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Health Care, Patient Service [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Short-term investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt Securities, Available-for-sale, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustments to reconcile net income to net cash from operating activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsReceivableGrossCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross accounts receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsReceivableGrossCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Receivable, before Allowance for Credit Loss, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Other non-current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Assets, Noncurrent, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Other Operating Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Other Operating Liabilities, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Company's Common stock repurchased</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Repurchase Program, Remaining Authorized, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Common Stock, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisaggregationOfRevenueLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disaggregation of Revenue [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_IncrementalNonCashCharge_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Incremental Non Cash Charge</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_IncrementalNonCashCharge_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Incremental Non Cash Charge</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_IncrementalNonCashCharge_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Incremental Non Cash Charge</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Accounts, Notes, Loans and Financing Receivable [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts and Financing Receivables [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ScenarioUnspecifiedDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Scenario [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title and Position [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common stock; $.01 par value; 200,000 shares authorized; 85,753,258 and 84,018,023 shares issued and outstanding, respectively</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Value, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Common Stock, Value, Issued, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Common Stock, Value, Issued, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Common Stock, Value, Issued, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ExecutiveOfficerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Executive Officer [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ExecutiveOfficerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Executive Officer [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_CreditAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Credit Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_CreditAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Credit Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_CreditAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Credit Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_CreditAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amended Credit Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Schedule of Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Frequency [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and contingencies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted average number of common and common equivalent shares outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_ContractedManagedCareMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contracted Managed Care</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_ContractedManagedCareMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contracted Managed Care [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_ContractedManagedCareMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Contracted Managed Care [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accounts receivable, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts receivable, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Small Business</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USTreasurySecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S. Treasury securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USTreasurySecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">US Treasury Securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investments, Fair Value Disclosure</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Investments, Fair Value Disclosure, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-term investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CreditFacilityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Credit Facility [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevolvingCreditFacilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revolving Credit Facility [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllOtherCorporateBondsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Corporate Bonds [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllOtherCorporateBondsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Corporate securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentMaturityDateDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Maturity Date, Description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentMaturityDateDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt instrument maturity date description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from financing activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average number of dilutive common share equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Incremental Common Shares Attributable to Share-based Payment Arrangements, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnsecuredDebtMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unsecured Debt [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Frequency [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accounts Payable, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Allowance for contractual adjustments and uncollectibles</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Receivable, Allowance for Credit Loss, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accounts payable and accrued expenses, total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable and Accrued Liabilities, Current</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_PaymentsToTermLoan" xlink:to="md_PaymentsToTermLoan_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_IncreaseDecreaseInAccruedSalariesAndBonuses" xlink:to="md_IncreaseDecreaseInAccruedSalariesAndBonuses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_BasisOfPresentationAndNewAccountingPronouncementsTable" xlink:to="md_BasisOfPresentationAndNewAccountingPronouncementsTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_LiabilitiesFairValueDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_RepaymentsOfLongTermCapitalLeaseObligation" xlink:to="md_RepaymentsOfLongTermCapitalLeaseObligation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_GoodWillImpairmentLossExcludingDeferredTaxAssetsCharge" xlink:to="md_GoodWillImpairmentLossExcludingDeferredTaxAssetsCharge_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringCharges" xlink:to="us-gaap_RestructuringCharges_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="us-gaap_BusinessCombinationDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_CashEquivalentsAndInvestmentsTable" xlink:to="md_CashEquivalentsAndInvestmentsTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:to="us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_CovidNinenteenMember" xlink:to="md_CovidNinenteenMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncashIncomeExpense" xlink:to="us-gaap_OtherNoncashIncomeExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_PediatricGastroenterologyAndGynecologyPracticeAndMultiLocationPediatricUrgentCarePracticeMember" xlink:to="md_PediatricGastroenterologyAndGynecologyPracticeAndMultiLocationPediatricUrgentCarePracticeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableFairValueDisclosure" xlink:to="us-gaap_NotesPayableFairValueDisclosure_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_LongtermDebtTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedSalariesCurrent" xlink:to="us-gaap_AccruedSalariesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="us-gaap_DeferredIncomeTaxLiabilitiesNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="srt_EquityMethodInvesteeNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_RadiologyServicesMedicalGroupMember" xlink:to="md_RadiologyServicesMedicalGroupMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchasedDuringPeriodShares" xlink:to="us-gaap_StockRepurchasedDuringPeriodShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:to="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:to="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_FivePointTwoFivePercentageSeniorNotesDueTwoThousandTwentyThreeMember" xlink:to="md_FivePointTwoFivePercentageSeniorNotesDueTwoThousandTwentyThreeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_TwoThousandFifteenNonQualifiedStockPurchasePlanMember" xlink:to="md_TwoThousandFifteenNonQualifiedStockPurchasePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USStatesAndPoliticalSubdivisionsMember" xlink:to="us-gaap_USStatesAndPoliticalSubdivisionsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_TwoThousandTwentyThreeMember" xlink:to="md_TwoThousandTwentyThreeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_CommonStockTable" xlink:to="md_CommonStockTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeniorNotes" xlink:to="us-gaap_SeniorNotes_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_UnnamedCorporateJointVentureTwoMember" xlink:to="md_UnnamedCorporateJointVentureTwoMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_ScheduleOfFinancingReceivablesLineItems" xlink:to="md_ScheduleOfFinancingReceivablesLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_FairValueDisclosuresTable" xlink:to="md_FairValueDisclosuresTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductAndServiceOtherMember" xlink:to="us-gaap_ProductAndServiceOtherMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_HealthCareOrganizationRevenueSourcesDomain" xlink:to="us-gaap_HealthCareOrganizationRevenueSourcesDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_IncreaseInDeferredTaxAssets" xlink:to="md_IncreaseInDeferredTaxAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeographicDistributionDomain" xlink:to="us-gaap_GeographicDistributionDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:to="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebt_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="us-gaap_TaxPeriodDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_NumberOfMultiLocationPediatricUrgentCarePracticeAcquired" xlink:to="md_NumberOfMultiLocationPediatricUrgentCarePracticeAcquired_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CorporateJointVentureMember" xlink:to="us-gaap_CorporateJointVentureMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentDescription" xlink:to="us-gaap_DebtInstrumentDescription_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockMember" xlink:to="us-gaap_RestrictedStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_TwoThousandTwentySevenMember" xlink:to="md_TwoThousandTwentySevenMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:to="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_ChangeInRateOfControlPremium" xlink:to="md_ChangeInRateOfControlPremium_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_LineOfCreditLongTermDebtAndFinanceLeaseObligationsDisclosureTextBlock" xlink:to="md_LineOfCreditLongTermDebtAndFinanceLeaseObligationsDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:to="us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayable" xlink:to="us-gaap_NotesPayable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TextBlockAbstract" xlink:to="us-gaap_TextBlockAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_AnesthesiologyServicesMedicalGroupMember" xlink:to="md_AnesthesiologyServicesMedicalGroupMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesAbstract" xlink:to="us-gaap_ReceivablesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_DeferredTaxAssetsAxis" xlink:to="md_DeferredTaxAssetsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_DisaggregationOfRevenueTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromLinesOfCredit" xlink:to="us-gaap_ProceedsFromLinesOfCredit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeographicDistributionAxis" xlink:to="us-gaap_GeographicDistributionAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnsecuredLongTermDebt" xlink:to="us-gaap_UnsecuredLongTermDebt_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_RuralAreaMember" xlink:to="md_RuralAreaMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_CommonStockRepurchasesTextBlock" xlink:to="md_CommonStockRepurchasesTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_ContributionsInAidOfReimbursementOfLostRevenue" xlink:to="md_ContributionsInAidOfReimbursementOfLostRevenue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_ExtraordinaryItemsDomain" xlink:to="md_ExtraordinaryItemsDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireInvestments" xlink:to="us-gaap_PaymentsToAcquireInvestments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfLinesOfCredit" xlink:to="us-gaap_RepaymentsOfLinesOfCredit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:to="us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_FinancialInstrumentsMeasuredAtCarryingAmountTableTextBlock" xlink:to="md_FinancialInstrumentsMeasuredAtCarryingAmountTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_NumberOfPediatricOrThopedicPracticesAcquired" xlink:to="md_NumberOfPediatricOrThopedicPracticesAcquired_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember" xlink:to="md_RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfBusiness" xlink:to="us-gaap_GainLossOnSaleOfBusiness_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_HealthCareOrganizationRevenueSourcesAxis" xlink:to="us-gaap_HealthCareOrganizationRevenueSourcesAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_SixPointTwoFivePercentageSeniorNotesDueTwoThousandTwentySevenMember" xlink:to="md_SixPointTwoFivePercentageSeniorNotesDueTwoThousandTwentySevenMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_PediatricSubspecialtyPracticeMember" xlink:to="md_PediatricSubspecialtyPracticeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:to="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_CashAndCashEquivalentsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DescriptionOfInterestRateRiskExposure" xlink:to="us-gaap_DescriptionOfInterestRateRiskExposure_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:to="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_PercentageOfNetPatientServiceRevenueByTypeOfPayor" xlink:to="md_PercentageOfNetPatientServiceRevenueByTypeOfPayor_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromEquityMethodInvestments" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionDescription" xlink:to="us-gaap_DebtConversionDescription_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ThirdPartyPayorMember" xlink:to="us-gaap_ThirdPartyPayorMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_CommonStockLineItems" xlink:to="md_CommonStockLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMember" xlink:to="us-gaap_LongTermDebtMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_PercentageIncreaseDecreaseInSalaryAndWage" xlink:to="md_PercentageIncreaseDecreaseInSalaryAndWage_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_NetOfTaxUnrealizedHoldingGainLossOnInvestments" xlink:to="md_NetOfTaxUnrealizedHoldingGainLossOnInvestments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_MaternalFetalMedicinePracticeMember" xlink:to="md_MaternalFetalMedicinePracticeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MalpracticeLossContingencyAccrualUndiscountedCurrent" xlink:to="us-gaap_MalpracticeLossContingencyAccrualUndiscountedCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_MoneyMarketFundsFairValueDisclosure" xlink:to="md_MoneyMarketFundsFairValueDisclosure_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueAbstract" xlink:to="us-gaap_DisaggregationOfRevenueAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_LongTermDebtAndCapitalLeaseObligationsExcludingLongTermLineOfCredit" xlink:to="md_LongTermDebtAndCapitalLeaseObligationsExcludingLongTermLineOfCredit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfUnsecuredDebt" xlink:to="us-gaap_ProceedsFromIssuanceOfUnsecuredDebt_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeNet" xlink:to="us-gaap_InvestmentIncomeNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_InvestmentTypeCategorizationMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="us-gaap_PaymentsForRepurchaseOfCommonStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsAtCarryingValue" xlink:to="us-gaap_MoneyMarketFundsAtCarryingValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MalpracticeLossContingencyAccrualUndiscountedNoncurrent" xlink:to="us-gaap_MalpracticeLossContingencyAccrualUndiscountedNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchasedDuringPeriodValue" xlink:to="us-gaap_StockRepurchasedDuringPeriodValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="us-gaap_CreditFacilityDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_MutualFundsFairValueDisclosure" xlink:to="md_MutualFundsFairValueDisclosure_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFrequencyOfPeriodicPayment" xlink:to="us-gaap_DebtInstrumentFrequencyOfPeriodicPayment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:to="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_AccruedPayrollTaxesAndBenefitsCurrent" xlink:to="md_AccruedPayrollTaxesAndBenefitsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_PracticeSalariesAndBenefits" xlink:to="md_PracticeSalariesAndBenefits_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_BusinessCombinationsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireBusinessesGross" xlink:to="us-gaap_PaymentsToAcquireBusinessesGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Goodwill" xlink:to="us-gaap_Goodwill_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnsecuredDebt" xlink:to="us-gaap_UnsecuredDebt_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupClassificationAxis" xlink:to="us-gaap_DisposalGroupClassificationAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_CoronavirusPandemicCOVIDNineteenDisclosureTextBlock" xlink:to="md_CoronavirusPandemicCOVIDNineteenDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_TwoZeroThreeZeroMember" xlink:to="md_TwoZeroThreeZeroMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:to="us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_PracticeSuppliesAndOtherOperatingExpenses" xlink:to="md_PracticeSuppliesAndOtherOperatingExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_AmendedAndRestatedTwoThousandEightPlanMember" xlink:to="md_AmendedAndRestatedTwoThousandEightPlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_NonCashCharge" xlink:to="md_NonCashCharge_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_FairValueDisclosuresLineItems" xlink:to="md_FairValueDisclosuresLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_AccountsReceivableAndNetRevenueDisclosureTextBlock" xlink:to="md_AccountsReceivableAndNetRevenueDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_UnnamedCorporateJointVentureOneMember" xlink:to="md_UnnamedCorporateJointVentureOneMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanMember" xlink:to="md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_NumberOfPediatricGastroenterologyPracticeAcquired" xlink:to="md_NumberOfPediatricGastroenterologyPracticeAcquired_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_GaapSeniorNotesMember" xlink:to="md_GaapSeniorNotesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivableGrossAllowanceAndNetAbstract" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivableGrossAllowanceAndNetAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_IncrementalSharesNotIncludedDueToAntiDilutiveEffect" xlink:to="md_IncrementalSharesNotIncludedDueToAntiDilutiveEffect_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_IncrementalSharesInContinuingOperation" xlink:to="md_IncrementalSharesInContinuingOperation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_ExtraordinaryItemsAbstract" xlink:to="md_ExtraordinaryItemsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_PrimaryBeneficiaryMember" xlink:to="md_PrimaryBeneficiaryMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_NumberOfMaternalFetalMedicinePracticesAcquired" xlink:to="md_NumberOfMaternalFetalMedicinePracticesAcquired_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDate" xlink:to="us-gaap_DebtInstrumentMaturityDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReceivable" xlink:to="us-gaap_IncomeTaxReceivable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_LineOfCreditAndLongTermDebtTextBlock" xlink:to="md_LineOfCreditAndLongTermDebtTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_FivePointThreeSevenFivePercentUnsecuredSeniorNotesDueTwoThousandThirtyMember" xlink:to="md_FivePointThreeSevenFivePercentUnsecuredSeniorNotesDueTwoThousandThirtyMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPayableCurrent" xlink:to="us-gaap_InterestPayableCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_CashEquivalentsAndInvestmentsLineItems" xlink:to="md_CashEquivalentsAndInvestmentsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_DissolutionOfAndNetIncomeLossAttributableToNoncontrollingInterest" xlink:to="md_DissolutionOfAndNetIncomeLossAttributableToNoncontrollingInterest_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillImpairmentLoss" xlink:to="us-gaap_GoodwillImpairmentLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCredit" xlink:to="us-gaap_LineOfCredit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_PurchasePrice" xlink:to="md_PurchasePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_BasisOfPresentationLineItems" xlink:to="md_BasisOfPresentationLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve" xlink:to="us-gaap_IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_ProceedsFromContributionInAidOfReimbursementOfLostRevenue" xlink:to="md_ProceedsFromContributionInAidOfReimbursementOfLostRevenue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupClassificationDomain" xlink:to="us-gaap_DisposalGroupClassificationDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract" xlink:to="us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashEquivalentsMember" xlink:to="us-gaap_CashEquivalentsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedIncomeTaxesCurrent" xlink:to="us-gaap_AccruedIncomeTaxesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_OperatingAndFinanceLeaseRightOfUseAssets" xlink:to="md_OperatingAndFinanceLeaseRightOfUseAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GovernmentMember" xlink:to="us-gaap_GovernmentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMember" xlink:to="md_SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CertificatesOfDepositMember" xlink:to="us-gaap_CertificatesOfDepositMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:to="us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_NorthAmericanPartnersInAnesthesiaMember" xlink:to="md_NorthAmericanPartnersInAnesthesiaMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions" xlink:to="us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LettersOfCreditOutstandingAmount" xlink:to="us-gaap_LettersOfCreditOutstandingAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" xlink:to="us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_PercentageOfRefundOfIncomeTaxAtThePriorPeriodCorporateTaxRate" xlink:to="md_PercentageOfRefundOfIncomeTaxAtThePriorPeriodCorporateTaxRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentPeriodicPaymentInterest" xlink:to="us-gaap_DebtInstrumentPeriodicPaymentInterest_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseImpairmentLoss" xlink:to="us-gaap_OperatingLeaseImpairmentLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_TwoThousandTwentyTaxYearMember" xlink:to="md_TwoThousandTwentyTaxYearMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationLiabilitiesArisingFromContingenciesAmountRecognized" xlink:to="us-gaap_BusinessCombinationLiabilitiesArisingFromContingenciesAmountRecognized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_ExtraordinaryItemsAxis" xlink:to="md_ExtraordinaryItemsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_DebtInstrumentMaturityYear" xlink:to="md_DebtInstrumentMaturityYear_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_AccountsPayableAndAccruedLiabilitiesExcludingAccruedIncomeTaxesCurrent" xlink:to="md_AccountsPayableAndAccruedLiabilitiesExcludingAccruedIncomeTaxesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember" xlink:to="md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_DeferredTaxAssetsDomain" xlink:to="md_DeferredTaxAssetsDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StockRepurchaseProgramAuthorizedAmount1" xlink:to="srt_StockRepurchaseProgramAuthorizedAmount1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SelfPayMember" xlink:to="us-gaap_SelfPayMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_HospitalsContractsMember" xlink:to="md_HospitalsContractsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxAssetsNet" xlink:to="us-gaap_DeferredIncomeTaxAssetsNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrealizedGainLossOnInvestments" xlink:to="us-gaap_UnrealizedGainLossOnInvestments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_ChangeInNonCashImpairmentCharges" xlink:to="md_ChangeInNonCashImpairmentCharges_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_HealthCarePatientServiceMember" xlink:to="us-gaap_HealthCarePatientServiceMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableGrossCurrent" xlink:to="us-gaap_AccountsReceivableGrossCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:to="us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_DisaggregationOfRevenueLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_IncrementalNonCashCharge" xlink:to="md_IncrementalNonCashCharge_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:to="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioUnspecifiedDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ExecutiveOfficerMember" xlink:to="srt_ExecutiveOfficerMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_CreditAgreementMember" xlink:to="md_CreditAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_ContractedManagedCareMember" xlink:to="md_ContractedManagedCareMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USTreasurySecuritiesMember" xlink:to="us-gaap_USTreasurySecuritiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsFairValueDisclosure" xlink:to="us-gaap_InvestmentsFairValueDisclosure_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevolvingCreditFacilityMember" xlink:to="us-gaap_RevolvingCreditFacilityMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllOtherCorporateBondsMember" xlink:to="us-gaap_AllOtherCorporateBondsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDateDescription" xlink:to="us-gaap_DebtInstrumentMaturityDateDescription_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_LiabilitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:to="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnsecuredDebtMember" xlink:to="us-gaap_UnsecuredDebtMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl"/>
        </link:labelLink>
        <link:presentationLink xlink:role="http://www.mednax.com/20240630/taxonomy/role/CoverPage" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="49.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentQuarterlyReport" order="50.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport" order="51.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="52.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="53.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus" order="54.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus" order="55.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="56.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="57.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate" order="58.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus" order="59.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent" order="60.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="61.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="62.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="63.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="64.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="65.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="66.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="67.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="68.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="69.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="70.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="71.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="72.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory" order="73.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness" order="74.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="75.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany" order="76.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding" order="77.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.mednax.com/20240630/taxonomy/role/ConsolidatedBalanceSheetsUnaudited" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_AccountsPayableAndAccruedLiabilitiesExcludingAccruedIncomeTaxesCurrent" xlink:label="md_AccountsPayableAndAccruedLiabilitiesExcludingAccruedIncomeTaxesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:label="us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCredit" xlink:label="us-gaap_LineOfCredit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_LongTermDebtAndCapitalLeaseObligationsExcludingLongTermLineOfCredit" xlink:label="md_LongTermDebtAndCapitalLeaseObligationsExcludingLongTermLineOfCredit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedIncomeTaxesCurrent" xlink:label="us-gaap_AccruedIncomeTaxesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReceivable" xlink:label="us-gaap_IncomeTaxReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MalpracticeLossContingencyAccrualUndiscountedNoncurrent" xlink:label="us-gaap_MalpracticeLossContingencyAccrualUndiscountedNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_OperatingAndFinanceLeaseRightOfUseAssets" xlink:label="md_OperatingAndFinanceLeaseRightOfUseAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxAssetsNet" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="md_AccountsPayableAndAccruedLiabilitiesExcludingAccruedIncomeTaxesCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LineOfCredit" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="md_LongTermDebtAndCapitalLeaseObligationsExcludingLongTermLineOfCredit" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Goodwill" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedIncomeTaxesCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_IncomeTaxReceivable" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_MalpracticeLossContingencyAccrualUndiscountedNoncurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="md_OperatingAndFinanceLeaseRightOfUseAssets" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OtherAssetsCurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_DeferredIncomeTaxLiabilitiesNet" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_DeferredIncomeTaxAssetsNet" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.mednax.com/20240630/taxonomy/role/ConsolidatedBalanceSheetsUnauditedParenthetical" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesIssued" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.mednax.com/20240630/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnaudited" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_PracticeSalariesAndBenefits" xlink:label="md_PracticeSalariesAndBenefits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract" xlink:label="us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_PracticeSuppliesAndOtherOperatingExpenses" xlink:label="md_PracticeSuppliesAndOtherOperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeNet" xlink:label="us-gaap_InvestmentIncomeNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCharges" xlink:label="us-gaap_RestructuringCharges"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="us-gaap_GoodwillImpairmentLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfBusiness" xlink:label="us-gaap_GainLossOnSaleOfBusiness"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="us-gaap_UnrealizedGainLossOnInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="md_PracticeSalariesAndBenefits" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="md_PracticeSuppliesAndOtherOperatingExpenses" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_InvestmentIncomeNet" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_InterestExpense" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_RestructuringCharges" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GoodwillImpairmentLoss" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GainLossOnSaleOfBusiness" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ProfitLoss" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_UnrealizedGainLossOnInvestments" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareAbstract" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.mednax.com/20240630/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnauditedParenthetical" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_NetOfTaxUnrealizedHoldingGainLossOnInvestments" xlink:label="md_NetOfTaxUnrealizedHoldingGainLossOnInvestments"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="md_NetOfTaxUnrealizedHoldingGainLossOnInvestments" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.mednax.com/20240630/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquityUnaudited" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember" xlink:label="md_RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_DissolutionOfAndNetIncomeLossAttributableToNoncontrollingInterest" xlink:label="md_DissolutionOfAndNetIncomeLossAttributableToNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRepurchasedDuringPeriodValue" xlink:label="us-gaap_StockRepurchasedDuringPeriodValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_16"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued_17"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesIssued" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="md_RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="md_DissolutionOfAndNetIncomeLossAttributableToNoncontrollingInterest" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockRepurchasedDuringPeriodValue" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockRepurchasedDuringPeriodShares" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_16" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesIssued_17" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.mednax.com/20240630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:label="us-gaap_ProceedsFromLinesOfCredit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:label="us-gaap_PaymentsToAcquireInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfLinesOfCredit" xlink:label="us-gaap_RepaymentsOfLinesOfCredit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:label="us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="us-gaap_GoodwillImpairmentLoss"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_PaymentsToTermLoan" xlink:label="md_PaymentsToTermLoan"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_RepaymentsOfLongTermCapitalLeaseObligation" xlink:label="md_RepaymentsOfLongTermCapitalLeaseObligation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:label="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:label="us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve" xlink:label="us-gaap_IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_5"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfBusiness" xlink:label="us-gaap_GainLossOnSaleOfBusiness"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:label="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="us-gaap_OtherNoncashIncomeExpense"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromLinesOfCredit" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireInvestments" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfLinesOfCredit" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GoodwillImpairmentLoss" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="md_PaymentsToTermLoan" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="md_RepaymentsOfLongTermCapitalLeaseObligation" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_5" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainLossOnSaleOfBusiness" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsForRepurchaseOfCommonStock" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OtherNoncashIncomeExpense" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.mednax.com/20240630/taxonomy/role/DisclosureBasisOfPresentation" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:label="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.mednax.com/20240630/taxonomy/role/DisclosureCoronavirusPandemicCovid191" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_ExtraordinaryItemsAbstract" xlink:label="md_ExtraordinaryItemsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_CoronavirusPandemicCOVIDNineteenDisclosureTextBlock" xlink:label="md_CoronavirusPandemicCOVIDNineteenDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="md_ExtraordinaryItemsAbstract" xlink:to="md_CoronavirusPandemicCOVIDNineteenDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.mednax.com/20240630/taxonomy/role/CashEquivalentsAndInvestments" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.mednax.com/20240630/taxonomy/role/FairValueMeasurements" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.mednax.com/20240630/taxonomy/role/AccountsReceivableAndNetRevenue" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TextBlockAbstract" xlink:label="us-gaap_TextBlockAbstract"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_AccountsReceivableAndNetRevenueDisclosureTextBlock" xlink:label="md_AccountsReceivableAndNetRevenueDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TextBlockAbstract" xlink:to="md_AccountsReceivableAndNetRevenueDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.mednax.com/20240630/taxonomy/role/DisclosureBusinessCombinations" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="us-gaap_BusinessCombinationsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_BusinessCombinationDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.mednax.com/20240630/taxonomy/role/DisclosureGoodwillAndLonglivedAssetImpairments" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.mednax.com/20240630/taxonomy/role/AccountsPayableAndAccruedExpenses" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.mednax.com/20240630/taxonomy/role/DisclosureLineOfCreditAndLongTermDebt" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_LineOfCreditLongTermDebtAndFinanceLeaseObligationsDisclosureTextBlock" xlink:label="md_LineOfCreditLongTermDebtAndFinanceLeaseObligationsDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_LineOfCreditAndLongTermDebtTextBlock" xlink:label="md_LineOfCreditAndLongTermDebtTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="md_LineOfCreditLongTermDebtAndFinanceLeaseObligationsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="md_LineOfCreditAndLongTermDebtTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.mednax.com/20240630/taxonomy/role/CommonAndCommonEquivalentShares" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.mednax.com/20240630/taxonomy/role/StockIncentivePlansAndStockPurchasePlans" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.mednax.com/20240630/taxonomy/role/CommonStockRepurchasePrograms" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_CommonStockRepurchasesTextBlock" xlink:label="md_CommonStockRepurchasesTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="md_CommonStockRepurchasesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.mednax.com/20240630/taxonomy/role/CommitmentsAndContingencies" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.mednax.com/20240630/taxonomy/role/DisclosureBasisOfPresentationPolicies" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.mednax.com/20240630/taxonomy/role/CashEquivalentsAndInvestmentsTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.mednax.com/20240630/taxonomy/role/FairValueMeasurementsTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_FinancialInstrumentsMeasuredAtCarryingAmountTableTextBlock" xlink:label="md_FinancialInstrumentsMeasuredAtCarryingAmountTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="md_FinancialInstrumentsMeasuredAtCarryingAmountTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.mednax.com/20240630/taxonomy/role/AccountsReceivableAndNetRevenueTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TextBlockAbstract" xlink:label="us-gaap_TextBlockAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:label="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TextBlockAbstract" xlink:to="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TextBlockAbstract" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TextBlockAbstract" xlink:to="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.mednax.com/20240630/taxonomy/role/AccountsPayableAndAccruedExpensesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.mednax.com/20240630/taxonomy/role/CommonAndCommonEquivalentSharesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:label="us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.mednax.com/20240630/taxonomy/role/DisclosureBasisOfPresentationAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_BasisOfPresentationAndNewAccountingPronouncementsTable" xlink:label="md_BasisOfPresentationAndNewAccountingPronouncementsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_UnnamedCorporateJointVentureOneMember" xlink:label="md_UnnamedCorporateJointVentureOneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateJointVentureMember" xlink:label="us-gaap_CorporateJointVentureMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_BasisOfPresentationLineItems" xlink:label="md_BasisOfPresentationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_UnnamedCorporateJointVentureTwoMember" xlink:label="md_UnnamedCorporateJointVentureTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_PrimaryBeneficiaryMember" xlink:label="md_PrimaryBeneficiaryMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="md_BasisOfPresentationAndNewAccountingPronouncementsTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="md_UnnamedCorporateJointVentureOneMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_CorporateJointVentureMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="md_BasisOfPresentationAndNewAccountingPronouncementsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="md_BasisOfPresentationLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="md_BasisOfPresentationAndNewAccountingPronouncementsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="md_UnnamedCorporateJointVentureTwoMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="md_BasisOfPresentationAndNewAccountingPronouncementsTable" xlink:to="md_BasisOfPresentationLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="md_PrimaryBeneficiaryMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.mednax.com/20240630/taxonomy/role/DisclosureCoronavirusPandemicCovid19AdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_PercentageIncreaseDecreaseInSalaryAndWage" xlink:label="md_PercentageIncreaseDecreaseInSalaryAndWage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeographicDistributionDomain" xlink:label="us-gaap_GeographicDistributionDomain"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_RuralAreaMember" xlink:label="md_RuralAreaMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_TwoThousandTwentyTaxYearMember" xlink:label="md_TwoThousandTwentyTaxYearMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeographicDistributionAxis" xlink:label="us-gaap_GeographicDistributionAxis"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_ExtraordinaryItemsDomain" xlink:label="md_ExtraordinaryItemsDomain"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_CovidNinenteenMember" xlink:label="md_CovidNinenteenMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodAxis" xlink:label="us-gaap_TaxPeriodAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_ExtraordinaryItemsAbstract" xlink:label="md_ExtraordinaryItemsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_ExtraordinaryItemsAxis" xlink:label="md_ExtraordinaryItemsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ExecutiveOfficerMember" xlink:label="srt_ExecutiveOfficerMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_ContributionsInAidOfReimbursementOfLostRevenue" xlink:label="md_ContributionsInAidOfReimbursementOfLostRevenue"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_ProceedsFromContributionInAidOfReimbursementOfLostRevenue" xlink:label="md_ProceedsFromContributionInAidOfReimbursementOfLostRevenue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_PercentageOfRefundOfIncomeTaxAtThePriorPeriodCorporateTaxRate" xlink:label="md_PercentageOfRefundOfIncomeTaxAtThePriorPeriodCorporateTaxRate"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="md_PercentageIncreaseDecreaseInSalaryAndWage" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GeographicDistributionDomain" xlink:to="md_RuralAreaMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="md_TwoThousandTwentyTaxYearMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GeographicDistributionAxis" xlink:to="us-gaap_GeographicDistributionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="md_ExtraordinaryItemsDomain" xlink:to="md_CovidNinenteenMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="md_ExtraordinaryItemsAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="md_ExtraordinaryItemsAxis" xlink:to="md_ExtraordinaryItemsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_ExecutiveOfficerMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="md_ContributionsInAidOfReimbursementOfLostRevenue" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="md_ExtraordinaryItemsAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="md_ProceedsFromContributionInAidOfReimbursementOfLostRevenue" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_TitleOfIndividualAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="md_PercentageOfRefundOfIncomeTaxAtThePriorPeriodCorporateTaxRate" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_StatementScenarioAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CreditFacilityAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_GeographicDistributionAxis" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TaxPeriodAxis" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.mednax.com/20240630/taxonomy/role/CashEquivalentsAndInvestmentsAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_CashEquivalentsAndInvestmentsTable" xlink:label="md_CashEquivalentsAndInvestmentsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashEquivalentsMember" xlink:label="us-gaap_CashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_CashEquivalentsAndInvestmentsLineItems" xlink:label="md_CashEquivalentsAndInvestmentsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsAtCarryingValue" xlink:label="us-gaap_MoneyMarketFundsAtCarryingValue"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="md_CashEquivalentsAndInvestmentsTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_CashEquivalentsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="md_CashEquivalentsAndInvestmentsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="md_CashEquivalentsAndInvestmentsLineItems" xlink:to="us-gaap_MoneyMarketFundsAtCarryingValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="md_CashEquivalentsAndInvestmentsTable" xlink:to="srt_RangeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="md_CashEquivalentsAndInvestmentsTable" xlink:to="md_CashEquivalentsAndInvestmentsLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.mednax.com/20240630/taxonomy/role/CashEquivalentsAndInvestmentsScheduleOfInvestmentsDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllOtherCorporateBondsMember" xlink:label="us-gaap_AllOtherCorporateBondsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USStatesAndPoliticalSubdivisionsMember" xlink:label="us-gaap_USStatesAndPoliticalSubdivisionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="us-gaap_CertificatesOfDepositMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_AllOtherCorporateBondsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_InvestmentTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USStatesAndPoliticalSubdivisionsMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CertificatesOfDepositMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.mednax.com/20240630/taxonomy/role/FairValueMeasurementsScheduleOfFairValueOnARecurringBasisDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_MoneyMarketFundsFairValueDisclosure" xlink:label="md_MoneyMarketFundsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="us-gaap_InvestmentsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_MutualFundsFairValueDisclosure" xlink:label="md_MutualFundsFairValueDisclosure"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="md_MoneyMarketFundsFairValueDisclosure" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_InvestmentsFairValueDisclosure" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="md_MutualFundsFairValueDisclosure" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.mednax.com/20240630/taxonomy/role/FairValueMeasurementsScheduleOfFinancialInstrumentsThatAreNotCarriedAtFairValueDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAbstract" xlink:label="us-gaap_LiabilitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesPayableFairValueDisclosure" xlink:label="us-gaap_NotesPayableFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_TwoThousandTwentyThreeMember" xlink:label="md_TwoThousandTwentyThreeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesPayable" xlink:label="us-gaap_NotesPayable"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_TwoThousandTwentySevenMember" xlink:label="md_TwoThousandTwentySevenMember"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_TwoZeroThreeZeroMember" xlink:label="md_TwoZeroThreeZeroMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_NotesPayableFairValueDisclosure" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="md_TwoThousandTwentyThreeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_NotesPayable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesFairValueDisclosureAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="md_TwoThousandTwentySevenMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="md_TwoZeroThreeZeroMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.mednax.com/20240630/taxonomy/role/FairValueMeasurementsAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_GaapSeniorNotesMember" xlink:label="md_GaapSeniorNotesMember"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_FairValueDisclosuresTable" xlink:label="md_FairValueDisclosuresTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_FivePointTwoFivePercentageSeniorNotesDueTwoThousandTwentyThreeMember" xlink:label="md_FivePointTwoFivePercentageSeniorNotesDueTwoThousandTwentyThreeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_FairValueDisclosuresLineItems" xlink:label="md_FairValueDisclosuresLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_SixPointTwoFivePercentageSeniorNotesDueTwoThousandTwentySevenMember" xlink:label="md_SixPointTwoFivePercentageSeniorNotesDueTwoThousandTwentySevenMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="md_GaapSeniorNotesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="md_FairValueDisclosuresTable" xlink:to="us-gaap_DebtInstrumentAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="md_FivePointTwoFivePercentageSeniorNotesDueTwoThousandTwentyThreeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="md_FairValueDisclosuresTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="md_FairValueDisclosuresLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="md_FairValueDisclosuresTable" xlink:to="us-gaap_LongtermDebtTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="md_SixPointTwoFivePercentageSeniorNotesDueTwoThousandTwentySevenMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="md_FairValueDisclosuresTable" xlink:to="md_FairValueDisclosuresLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.mednax.com/20240630/taxonomy/role/AccountsReceivableAndNetRevenueScheduleOfAccountsReceivableNetDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivablesAbstract" xlink:label="us-gaap_ReceivablesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableGrossCurrent" xlink:label="us-gaap_AccountsReceivableGrossCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReceivablesAbstract" xlink:to="us-gaap_AccountsReceivableGrossCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReceivablesAbstract" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReceivablesAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.mednax.com/20240630/taxonomy/role/AccountsReceivableAndNetRevenueScheduleOfNetRevenueDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_ScheduleOfFinancingReceivablesLineItems" xlink:label="md_ScheduleOfFinancingReceivablesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueAbstract" xlink:label="us-gaap_DisaggregationOfRevenueAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HealthCarePatientServiceMember" xlink:label="us-gaap_HealthCarePatientServiceMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableGrossAllowanceAndNetAbstract" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivableGrossAllowanceAndNetAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_HospitalsContractsMember" xlink:label="md_HospitalsContractsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductAndServiceOtherMember" xlink:label="us-gaap_ProductAndServiceOtherMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="md_ScheduleOfFinancingReceivablesLineItems" xlink:to="us-gaap_DisaggregationOfRevenueAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_HealthCarePatientServiceMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivableGrossAllowanceAndNetAbstract" xlink:to="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:to="srt_ProductOrServiceAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="md_HospitalsContractsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:to="md_ScheduleOfFinancingReceivablesLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ProductAndServiceOtherMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.mednax.com/20240630/taxonomy/role/AccountsReceivableAndNetRevenueScheduleOfNetPatientServiceRevenueByTypeOfPayorDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HealthCareOrganizationRevenueSourcesDomain" xlink:label="us-gaap_HealthCareOrganizationRevenueSourcesDomain"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_ContractedManagedCareMember" xlink:label="md_ContractedManagedCareMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="us-gaap_DisaggregationOfRevenueTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HealthCareOrganizationRevenueSourcesAxis" xlink:label="us-gaap_HealthCareOrganizationRevenueSourcesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="us-gaap_DisaggregationOfRevenueLineItems"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_PercentageOfNetPatientServiceRevenueByTypeOfPayor" xlink:label="md_PercentageOfNetPatientServiceRevenueByTypeOfPayor"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GovernmentMember" xlink:label="us-gaap_GovernmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ThirdPartyPayorMember" xlink:label="us-gaap_ThirdPartyPayorMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SelfPayMember" xlink:label="us-gaap_SelfPayMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_HealthCareOrganizationRevenueSourcesDomain" xlink:to="md_ContractedManagedCareMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_HealthCareOrganizationRevenueSourcesAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_HealthCareOrganizationRevenueSourcesAxis" xlink:to="us-gaap_HealthCareOrganizationRevenueSourcesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_DisaggregationOfRevenueTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="md_PercentageOfNetPatientServiceRevenueByTypeOfPayor" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_HealthCareOrganizationRevenueSourcesDomain" xlink:to="us-gaap_GovernmentMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_DisaggregationOfRevenueLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_HealthCareOrganizationRevenueSourcesDomain" xlink:to="us-gaap_ThirdPartyPayorMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_HealthCareOrganizationRevenueSourcesDomain" xlink:to="us-gaap_SelfPayMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.mednax.com/20240630/taxonomy/role/DisclosureBusinessCombinationsAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_NumberOfPediatricOrThopedicPracticesAcquired" xlink:label="md_NumberOfPediatricOrThopedicPracticesAcquired"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_DeferredTaxAssetsAxis" xlink:label="md_DeferredTaxAssetsAxis"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_DeferredTaxAssetsDomain" xlink:label="md_DeferredTaxAssetsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodAxis" xlink:label="us-gaap_TaxPeriodAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="us-gaap_BusinessCombinationsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupClassificationAxis" xlink:label="us-gaap_DisposalGroupClassificationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupClassificationDomain" xlink:label="us-gaap_DisposalGroupClassificationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_PediatricGastroenterologyAndGynecologyPracticeAndMultiLocationPediatricUrgentCarePracticeMember" xlink:label="md_PediatricGastroenterologyAndGynecologyPracticeAndMultiLocationPediatricUrgentCarePracticeMember"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_NorthAmericanPartnersInAnesthesiaMember" xlink:label="md_NorthAmericanPartnersInAnesthesiaMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_NumberOfMultiLocationPediatricUrgentCarePracticeAcquired" xlink:label="md_NumberOfMultiLocationPediatricUrgentCarePracticeAcquired"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_PediatricSubspecialtyPracticeMember" xlink:label="md_PediatricSubspecialtyPracticeMember"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_AnesthesiologyServicesMedicalGroupMember" xlink:label="md_AnesthesiologyServicesMedicalGroupMember"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_NumberOfMaternalFetalMedicinePracticesAcquired" xlink:label="md_NumberOfMaternalFetalMedicinePracticesAcquired"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_MaternalFetalMedicinePracticeMember" xlink:label="md_MaternalFetalMedicinePracticeMember"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_RadiologyServicesMedicalGroupMember" xlink:label="md_RadiologyServicesMedicalGroupMember"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_NumberOfPediatricGastroenterologyPracticeAcquired" xlink:label="md_NumberOfPediatricGastroenterologyPracticeAcquired"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="us-gaap_PaymentsToAcquireBusinessesGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationLiabilitiesArisingFromContingenciesAmountRecognized" xlink:label="us-gaap_BusinessCombinationLiabilitiesArisingFromContingenciesAmountRecognized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" xlink:label="us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:label="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions" xlink:label="us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_IncreaseInDeferredTaxAssets" xlink:label="md_IncreaseInDeferredTaxAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="md_NumberOfPediatricOrThopedicPracticesAcquired" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="md_DeferredTaxAssetsAxis" xlink:to="md_DeferredTaxAssetsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisposalGroupClassificationAxis" xlink:to="us-gaap_DisposalGroupClassificationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="md_PediatricGastroenterologyAndGynecologyPracticeAndMultiLocationPediatricUrgentCarePracticeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="md_DeferredTaxAssetsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisposalGroupClassificationDomain" xlink:to="md_NorthAmericanPartnersInAnesthesiaMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="md_NumberOfMultiLocationPediatricUrgentCarePracticeAcquired" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="md_PediatricSubspecialtyPracticeMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DisposalGroupClassificationAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisposalGroupClassificationDomain" xlink:to="md_AnesthesiologyServicesMedicalGroupMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="md_NumberOfMaternalFetalMedicinePracticesAcquired" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="md_MaternalFetalMedicinePracticeMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisposalGroupClassificationDomain" xlink:to="md_RadiologyServicesMedicalGroupMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="md_NumberOfPediatricGastroenterologyPracticeAcquired" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TaxPeriodAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PaymentsToAcquireBusinessesGross" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_BusinessCombinationLiabilitiesArisingFromContingenciesAmountRecognized" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="md_IncreaseInDeferredTaxAssets" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.mednax.com/20240630/taxonomy/role/DisclosureGoodwillAndLonglivedAssetImpairmentsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseImpairmentLoss" xlink:label="us-gaap_OperatingLeaseImpairmentLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfBusiness" xlink:label="us-gaap_GainLossOnSaleOfBusiness"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_NonCashCharge" xlink:label="md_NonCashCharge"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_IncrementalNonCashCharge" xlink:label="md_IncrementalNonCashCharge"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="us-gaap_GoodwillImpairmentLoss"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_ChangeInRateOfControlPremium" xlink:label="md_ChangeInRateOfControlPremium"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_ChangeInNonCashImpairmentCharges" xlink:label="md_ChangeInNonCashImpairmentCharges"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_GoodWillImpairmentLossExcludingDeferredTaxAssetsCharge" xlink:label="md_GoodWillImpairmentLossExcludingDeferredTaxAssetsCharge"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseImpairmentLoss" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_GainLossOnSaleOfBusiness" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="md_NonCashCharge" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="md_IncrementalNonCashCharge" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_GoodwillImpairmentLoss" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="md_ChangeInRateOfControlPremium" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="md_ChangeInNonCashImpairmentCharges" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="md_GoodWillImpairmentLossExcludingDeferredTaxAssetsCharge" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.mednax.com/20240630/taxonomy/role/AccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="us-gaap_AccruedSalariesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_AccruedPayrollTaxesAndBenefitsCurrent" xlink:label="md_AccruedPayrollTaxesAndBenefitsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MalpracticeLossContingencyAccrualUndiscountedCurrent" xlink:label="us-gaap_MalpracticeLossContingencyAccrualUndiscountedCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedSalariesCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="md_AccruedPayrollTaxesAndBenefitsCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_MalpracticeLossContingencyAccrualUndiscountedCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_InterestPayableCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.mednax.com/20240630/taxonomy/role/AccountsPayableAndAccruedExpensesAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_IncreaseDecreaseInAccruedSalariesAndBonuses" xlink:label="md_IncreaseDecreaseInAccruedSalariesAndBonuses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="md_IncreaseDecreaseInAccruedSalariesAndBonuses" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.mednax.com/20240630/taxonomy/role/DisclosureLineOfCreditAndLongTermDebtAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnsecuredDebtMember" xlink:label="us-gaap_UnsecuredDebtMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeniorNotes" xlink:label="us-gaap_SeniorNotes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMember" xlink:label="us-gaap_LongTermDebtMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevolvingCreditFacilityMember" xlink:label="us-gaap_RevolvingCreditFacilityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnsecuredDebt" xlink:label="us-gaap_UnsecuredDebt"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_CreditAgreementMember" xlink:label="md_CreditAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_FivePointThreeSevenFivePercentUnsecuredSeniorNotesDueTwoThousandThirtyMember" xlink:label="md_FivePointThreeSevenFivePercentUnsecuredSeniorNotesDueTwoThousandThirtyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMember" xlink:label="md_SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMember"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_DebtInstrumentMaturityYear" xlink:label="md_DebtInstrumentMaturityYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFrequencyOfPeriodicPayment" xlink:label="us-gaap_DebtInstrumentFrequencyOfPeriodicPayment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentMaturityDateDescription" xlink:label="us-gaap_DebtInstrumentMaturityDateDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnsecuredLongTermDebt" xlink:label="us-gaap_UnsecuredLongTermDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfUnsecuredDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfUnsecuredDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentPeriodicPaymentInterest" xlink:label="us-gaap_DebtInstrumentPeriodicPaymentInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LettersOfCreditOutstandingAmount" xlink:label="us-gaap_LettersOfCreditOutstandingAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentDescription" xlink:label="us-gaap_DebtInstrumentDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionDescription" xlink:label="us-gaap_DebtConversionDescription"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_PurchasePrice" xlink:label="md_PurchasePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:label="us-gaap_ProceedsFromLinesOfCredit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCredit" xlink:label="us-gaap_LineOfCredit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DescriptionOfInterestRateRiskExposure" xlink:label="us-gaap_DescriptionOfInterestRateRiskExposure"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_UnsecuredDebtMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_SeniorNotes" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_CreditFacilityAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_LongTermDebtMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="us-gaap_RevolvingCreditFacilityMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_UnsecuredDebt" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="md_CreditAgreementMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="md_FivePointThreeSevenFivePercentUnsecuredSeniorNotesDueTwoThousandThirtyMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_LongtermDebtTypeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="md_SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="md_DebtInstrumentMaturityYear" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentFrequencyOfPeriodicPayment" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDateDescription" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_UnsecuredLongTermDebt" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfUnsecuredDebt" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_Cash" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentPeriodicPaymentInterest" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LettersOfCreditOutstandingAmount" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebt" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentDescription" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtConversionDescription" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="md_PurchasePrice" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ProceedsFromLinesOfCredit" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LineOfCredit" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DescriptionOfInterestRateRiskExposure" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.mednax.com/20240630/taxonomy/role/CommonAndCommonEquivalentSharesScheduleOfCalculationOfSharesUsedInBasicAndDilutedNetIncomePerShareDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.mednax.com/20240630/taxonomy/role/DisclosureCommonAndCommonEquivalentSharesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_IncrementalSharesInContinuingOperation" xlink:label="md_IncrementalSharesInContinuingOperation"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="md_IncrementalSharesInContinuingOperation" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.mednax.com/20240630/taxonomy/role/DisclosureCommonAndCommonEquivalentSharesScheduleOfCalculationOfSharesUsedInBasicAndDilutedNetIncomePerShareParentheticalDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_IncrementalSharesNotIncludedDueToAntiDilutiveEffect" xlink:label="md_IncrementalSharesNotIncludedDueToAntiDilutiveEffect"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="md_IncrementalSharesNotIncludedDueToAntiDilutiveEffect" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.mednax.com/20240630/taxonomy/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanMember" xlink:label="md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_TwoThousandFifteenNonQualifiedStockPurchasePlanMember" xlink:label="md_TwoThousandFifteenNonQualifiedStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_AmendedAndRestatedTwoThousandEightPlanMember" xlink:label="md_AmendedAndRestatedTwoThousandEightPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember" xlink:label="md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="md_TwoThousandFifteenNonQualifiedStockPurchasePlanMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="md_AmendedAndRestatedTwoThousandEightPlanMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="3.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="4.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.mednax.com/20240630/taxonomy/role/CommonStockRepurchaseProgramsAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_CommonStockTable" xlink:label="md_CommonStockTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_CommonStockLineItems" xlink:label="md_CommonStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StockRepurchaseProgramAuthorizedAmount1" xlink:label="srt_StockRepurchaseProgramAuthorizedAmount1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:label="us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="md_CommonStockTable" xlink:to="us-gaap_AwardTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="md_CommonStockTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="md_CommonStockLineItems" xlink:to="us-gaap_StockRepurchasedDuringPeriodShares" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="md_CommonStockTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="md_CommonStockLineItems" xlink:to="srt_StockRepurchaseProgramAuthorizedAmount1" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="md_CommonStockTable" xlink:to="md_CommonStockLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="md_CommonStockLineItems" xlink:to="us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="3.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="md_CommonStockLineItems" xlink:to="us-gaap_PaymentsForRepurchaseOfCommonStock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.mednax.com/20240630/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquityUnaudited">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember" xlink:label="md_RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_DissolutionOfAndNetIncomeLossAttributableToNoncontrollingInterest" xlink:label="md_DissolutionOfAndNetIncomeLossAttributableToNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRepurchasedDuringPeriodValue" xlink:label="us-gaap_StockRepurchasedDuringPeriodValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="md_RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="md_DissolutionOfAndNetIncomeLossAttributableToNoncontrollingInterest" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockRepurchasedDuringPeriodValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockRepurchasedDuringPeriodShares" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.mednax.com/20240630/taxonomy/role/DisclosureBasisOfPresentationAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_BasisOfPresentationLineItems" xlink:label="md_BasisOfPresentationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_BasisOfPresentationAndNewAccountingPronouncementsTable" xlink:label="md_BasisOfPresentationAndNewAccountingPronouncementsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_UnnamedCorporateJointVentureOneMember" xlink:label="md_UnnamedCorporateJointVentureOneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateJointVentureMember" xlink:label="us-gaap_CorporateJointVentureMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_UnnamedCorporateJointVentureTwoMember" xlink:label="md_UnnamedCorporateJointVentureTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_PrimaryBeneficiaryMember" xlink:label="md_PrimaryBeneficiaryMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="md_BasisOfPresentationLineItems" xlink:to="md_BasisOfPresentationAndNewAccountingPronouncementsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="md_BasisOfPresentationAndNewAccountingPronouncementsTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="md_UnnamedCorporateJointVentureOneMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_CorporateJointVentureMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="md_BasisOfPresentationLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="md_BasisOfPresentationAndNewAccountingPronouncementsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="md_UnnamedCorporateJointVentureTwoMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="md_PrimaryBeneficiaryMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.mednax.com/20240630/taxonomy/role/DisclosureCoronavirusPandemicCovid19AdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_PercentageIncreaseDecreaseInSalaryAndWage" xlink:label="md_PercentageIncreaseDecreaseInSalaryAndWage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeographicDistributionDomain" xlink:label="us-gaap_GeographicDistributionDomain"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_RuralAreaMember" xlink:label="md_RuralAreaMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_TwoThousandTwentyTaxYearMember" xlink:label="md_TwoThousandTwentyTaxYearMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeographicDistributionAxis" xlink:label="us-gaap_GeographicDistributionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeographicDistributionDomain" xlink:label="us-gaap_GeographicDistributionDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_ExtraordinaryItemsDomain" xlink:label="md_ExtraordinaryItemsDomain"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_CovidNinenteenMember" xlink:label="md_CovidNinenteenMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodAxis" xlink:label="us-gaap_TaxPeriodAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_ExtraordinaryItemsAxis" xlink:label="md_ExtraordinaryItemsAxis"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_ExtraordinaryItemsDomain" xlink:label="md_ExtraordinaryItemsDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ExecutiveOfficerMember" xlink:label="srt_ExecutiveOfficerMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_ContributionsInAidOfReimbursementOfLostRevenue" xlink:label="md_ContributionsInAidOfReimbursementOfLostRevenue"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_ProceedsFromContributionInAidOfReimbursementOfLostRevenue" xlink:label="md_ProceedsFromContributionInAidOfReimbursementOfLostRevenue"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_PercentageOfRefundOfIncomeTaxAtThePriorPeriodCorporateTaxRate" xlink:label="md_PercentageOfRefundOfIncomeTaxAtThePriorPeriodCorporateTaxRate"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="md_PercentageIncreaseDecreaseInSalaryAndWage" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GeographicDistributionDomain" xlink:to="md_RuralAreaMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="md_TwoThousandTwentyTaxYearMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_GeographicDistributionAxis" xlink:to="us-gaap_GeographicDistributionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_GeographicDistributionAxis" xlink:to="us-gaap_GeographicDistributionDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="md_ExtraordinaryItemsDomain" xlink:to="md_CovidNinenteenMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="md_ExtraordinaryItemsAxis" xlink:to="md_ExtraordinaryItemsDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="md_ExtraordinaryItemsAxis" xlink:to="md_ExtraordinaryItemsDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_ExecutiveOfficerMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="md_ContributionsInAidOfReimbursementOfLostRevenue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="md_ExtraordinaryItemsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="md_ProceedsFromContributionInAidOfReimbursementOfLostRevenue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_TitleOfIndividualAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="md_PercentageOfRefundOfIncomeTaxAtThePriorPeriodCorporateTaxRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_StatementScenarioAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CreditFacilityAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_GeographicDistributionAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TaxPeriodAxis" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.mednax.com/20240630/taxonomy/role/CashEquivalentsAndInvestmentsAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_CashEquivalentsAndInvestmentsLineItems" xlink:label="md_CashEquivalentsAndInvestmentsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_CashEquivalentsAndInvestmentsTable" xlink:label="md_CashEquivalentsAndInvestmentsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashEquivalentsMember" xlink:label="us-gaap_CashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsAtCarryingValue" xlink:label="us-gaap_MoneyMarketFundsAtCarryingValue"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="md_CashEquivalentsAndInvestmentsLineItems" xlink:to="md_CashEquivalentsAndInvestmentsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="md_CashEquivalentsAndInvestmentsTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_CashEquivalentsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="md_CashEquivalentsAndInvestmentsLineItems" xlink:to="us-gaap_MoneyMarketFundsAtCarryingValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="md_CashEquivalentsAndInvestmentsTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.mednax.com/20240630/taxonomy/role/CashEquivalentsAndInvestmentsScheduleOfInvestmentsDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllOtherCorporateBondsMember" xlink:label="us-gaap_AllOtherCorporateBondsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USStatesAndPoliticalSubdivisionsMember" xlink:label="us-gaap_USStatesAndPoliticalSubdivisionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="us-gaap_CertificatesOfDepositMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_AllOtherCorporateBondsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_InvestmentTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_FinancialInstrumentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USStatesAndPoliticalSubdivisionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CertificatesOfDepositMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.mednax.com/20240630/taxonomy/role/FairValueMeasurementsScheduleOfFairValueOnARecurringBasisDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_MoneyMarketFundsFairValueDisclosure" xlink:label="md_MoneyMarketFundsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="us-gaap_InvestmentsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_MutualFundsFairValueDisclosure" xlink:label="md_MutualFundsFairValueDisclosure"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="md_MoneyMarketFundsFairValueDisclosure" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_InvestmentsFairValueDisclosure" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="md_MutualFundsFairValueDisclosure" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.mednax.com/20240630/taxonomy/role/FairValueMeasurementsScheduleOfFinancialInstrumentsThatAreNotCarriedAtFairValueDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAbstract" xlink:label="us-gaap_LiabilitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesPayableFairValueDisclosure" xlink:label="us-gaap_NotesPayableFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_TwoThousandTwentyThreeMember" xlink:label="md_TwoThousandTwentyThreeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesPayable" xlink:label="us-gaap_NotesPayable"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_TwoThousandTwentySevenMember" xlink:label="md_TwoThousandTwentySevenMember"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_TwoZeroThreeZeroMember" xlink:label="md_TwoZeroThreeZeroMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_NotesPayableFairValueDisclosure" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="md_TwoThousandTwentyThreeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_NotesPayable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesFairValueDisclosureAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="md_TwoThousandTwentySevenMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="md_TwoZeroThreeZeroMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.mednax.com/20240630/taxonomy/role/FairValueMeasurementsAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_FairValueDisclosuresLineItems" xlink:label="md_FairValueDisclosuresLineItems"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_FairValueDisclosuresTable" xlink:label="md_FairValueDisclosuresTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_GaapSeniorNotesMember" xlink:label="md_GaapSeniorNotesMember"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_FivePointTwoFivePercentageSeniorNotesDueTwoThousandTwentyThreeMember" xlink:label="md_FivePointTwoFivePercentageSeniorNotesDueTwoThousandTwentyThreeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_SixPointTwoFivePercentageSeniorNotesDueTwoThousandTwentySevenMember" xlink:label="md_SixPointTwoFivePercentageSeniorNotesDueTwoThousandTwentySevenMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="md_FairValueDisclosuresLineItems" xlink:to="md_FairValueDisclosuresTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="md_GaapSeniorNotesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="md_FairValueDisclosuresTable" xlink:to="us-gaap_DebtInstrumentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="md_FivePointTwoFivePercentageSeniorNotesDueTwoThousandTwentyThreeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="md_FairValueDisclosuresLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="md_FairValueDisclosuresTable" xlink:to="us-gaap_LongtermDebtTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="md_SixPointTwoFivePercentageSeniorNotesDueTwoThousandTwentySevenMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.mednax.com/20240630/taxonomy/role/AccountsReceivableAndNetRevenueScheduleOfNetRevenueDetail">
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_ScheduleOfFinancingReceivablesLineItems" xlink:label="md_ScheduleOfFinancingReceivablesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueAbstract" xlink:label="us-gaap_DisaggregationOfRevenueAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HealthCarePatientServiceMember" xlink:label="us-gaap_HealthCarePatientServiceMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_HospitalsContractsMember" xlink:label="md_HospitalsContractsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductAndServiceOtherMember" xlink:label="us-gaap_ProductAndServiceOtherMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="md_ScheduleOfFinancingReceivablesLineItems" xlink:to="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="md_ScheduleOfFinancingReceivablesLineItems" xlink:to="us-gaap_DisaggregationOfRevenueAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_HealthCarePatientServiceMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="md_HospitalsContractsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ProductAndServiceOtherMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.mednax.com/20240630/taxonomy/role/AccountsReceivableAndNetRevenueScheduleOfNetPatientServiceRevenueByTypeOfPayorDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="us-gaap_DisaggregationOfRevenueLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="us-gaap_DisaggregationOfRevenueTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HealthCareOrganizationRevenueSourcesDomain" xlink:label="us-gaap_HealthCareOrganizationRevenueSourcesDomain"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_ContractedManagedCareMember" xlink:label="md_ContractedManagedCareMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HealthCareOrganizationRevenueSourcesAxis" xlink:label="us-gaap_HealthCareOrganizationRevenueSourcesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HealthCareOrganizationRevenueSourcesDomain" xlink:label="us-gaap_HealthCareOrganizationRevenueSourcesDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_PercentageOfNetPatientServiceRevenueByTypeOfPayor" xlink:label="md_PercentageOfNetPatientServiceRevenueByTypeOfPayor"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GovernmentMember" xlink:label="us-gaap_GovernmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ThirdPartyPayorMember" xlink:label="us-gaap_ThirdPartyPayorMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SelfPayMember" xlink:label="us-gaap_SelfPayMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_DisaggregationOfRevenueTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_HealthCareOrganizationRevenueSourcesDomain" xlink:to="md_ContractedManagedCareMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_HealthCareOrganizationRevenueSourcesAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_HealthCareOrganizationRevenueSourcesAxis" xlink:to="us-gaap_HealthCareOrganizationRevenueSourcesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_HealthCareOrganizationRevenueSourcesAxis" xlink:to="us-gaap_HealthCareOrganizationRevenueSourcesDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="md_PercentageOfNetPatientServiceRevenueByTypeOfPayor" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_HealthCareOrganizationRevenueSourcesDomain" xlink:to="us-gaap_GovernmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_HealthCareOrganizationRevenueSourcesDomain" xlink:to="us-gaap_ThirdPartyPayorMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_HealthCareOrganizationRevenueSourcesDomain" xlink:to="us-gaap_SelfPayMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.mednax.com/20240630/taxonomy/role/DisclosureBusinessCombinationsAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_NumberOfPediatricOrThopedicPracticesAcquired" xlink:label="md_NumberOfPediatricOrThopedicPracticesAcquired"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_DeferredTaxAssetsAxis" xlink:label="md_DeferredTaxAssetsAxis"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_DeferredTaxAssetsDomain" xlink:label="md_DeferredTaxAssetsDomain"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_DeferredTaxAssetsDomain" xlink:label="md_DeferredTaxAssetsDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodAxis" xlink:label="us-gaap_TaxPeriodAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupClassificationAxis" xlink:label="us-gaap_DisposalGroupClassificationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupClassificationDomain" xlink:label="us-gaap_DisposalGroupClassificationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupClassificationDomain" xlink:label="us-gaap_DisposalGroupClassificationDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_PediatricGastroenterologyAndGynecologyPracticeAndMultiLocationPediatricUrgentCarePracticeMember" xlink:label="md_PediatricGastroenterologyAndGynecologyPracticeAndMultiLocationPediatricUrgentCarePracticeMember"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_NorthAmericanPartnersInAnesthesiaMember" xlink:label="md_NorthAmericanPartnersInAnesthesiaMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_NumberOfMultiLocationPediatricUrgentCarePracticeAcquired" xlink:label="md_NumberOfMultiLocationPediatricUrgentCarePracticeAcquired"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_PediatricSubspecialtyPracticeMember" xlink:label="md_PediatricSubspecialtyPracticeMember"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_AnesthesiologyServicesMedicalGroupMember" xlink:label="md_AnesthesiologyServicesMedicalGroupMember"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_NumberOfMaternalFetalMedicinePracticesAcquired" xlink:label="md_NumberOfMaternalFetalMedicinePracticesAcquired"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_MaternalFetalMedicinePracticeMember" xlink:label="md_MaternalFetalMedicinePracticeMember"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_RadiologyServicesMedicalGroupMember" xlink:label="md_RadiologyServicesMedicalGroupMember"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_NumberOfPediatricGastroenterologyPracticeAcquired" xlink:label="md_NumberOfPediatricGastroenterologyPracticeAcquired"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="us-gaap_PaymentsToAcquireBusinessesGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationLiabilitiesArisingFromContingenciesAmountRecognized" xlink:label="us-gaap_BusinessCombinationLiabilitiesArisingFromContingenciesAmountRecognized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" xlink:label="us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:label="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions" xlink:label="us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_IncreaseInDeferredTaxAssets" xlink:label="md_IncreaseInDeferredTaxAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="md_NumberOfPediatricOrThopedicPracticesAcquired" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="md_DeferredTaxAssetsAxis" xlink:to="md_DeferredTaxAssetsDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="md_DeferredTaxAssetsAxis" xlink:to="md_DeferredTaxAssetsDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DisposalGroupClassificationAxis" xlink:to="us-gaap_DisposalGroupClassificationDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DisposalGroupClassificationAxis" xlink:to="us-gaap_DisposalGroupClassificationDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="md_PediatricGastroenterologyAndGynecologyPracticeAndMultiLocationPediatricUrgentCarePracticeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="md_DeferredTaxAssetsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisposalGroupClassificationDomain" xlink:to="md_NorthAmericanPartnersInAnesthesiaMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="md_NumberOfMultiLocationPediatricUrgentCarePracticeAcquired" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="md_PediatricSubspecialtyPracticeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DisposalGroupClassificationAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisposalGroupClassificationDomain" xlink:to="md_AnesthesiologyServicesMedicalGroupMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="md_NumberOfMaternalFetalMedicinePracticesAcquired" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="md_MaternalFetalMedicinePracticeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisposalGroupClassificationDomain" xlink:to="md_RadiologyServicesMedicalGroupMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="md_NumberOfPediatricGastroenterologyPracticeAcquired" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TaxPeriodAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BusinessAcquisitionAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PaymentsToAcquireBusinessesGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_BusinessCombinationLiabilitiesArisingFromContingenciesAmountRecognized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="md_IncreaseInDeferredTaxAssets" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.mednax.com/20240630/taxonomy/role/AccountsPayableAndAccruedExpensesAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_IncreaseDecreaseInAccruedSalariesAndBonuses" xlink:label="md_IncreaseDecreaseInAccruedSalariesAndBonuses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="md_IncreaseDecreaseInAccruedSalariesAndBonuses" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.mednax.com/20240630/taxonomy/role/DisclosureLineOfCreditAndLongTermDebtAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnsecuredDebtMember" xlink:label="us-gaap_UnsecuredDebtMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeniorNotes" xlink:label="us-gaap_SeniorNotes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMember" xlink:label="us-gaap_LongTermDebtMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevolvingCreditFacilityMember" xlink:label="us-gaap_RevolvingCreditFacilityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnsecuredDebt" xlink:label="us-gaap_UnsecuredDebt"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_CreditAgreementMember" xlink:label="md_CreditAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_FivePointThreeSevenFivePercentUnsecuredSeniorNotesDueTwoThousandThirtyMember" xlink:label="md_FivePointThreeSevenFivePercentUnsecuredSeniorNotesDueTwoThousandThirtyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMember" xlink:label="md_SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMember"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_DebtInstrumentMaturityYear" xlink:label="md_DebtInstrumentMaturityYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFrequencyOfPeriodicPayment" xlink:label="us-gaap_DebtInstrumentFrequencyOfPeriodicPayment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentMaturityDateDescription" xlink:label="us-gaap_DebtInstrumentMaturityDateDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnsecuredLongTermDebt" xlink:label="us-gaap_UnsecuredLongTermDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfUnsecuredDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfUnsecuredDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentPeriodicPaymentInterest" xlink:label="us-gaap_DebtInstrumentPeriodicPaymentInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LettersOfCreditOutstandingAmount" xlink:label="us-gaap_LettersOfCreditOutstandingAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentDescription" xlink:label="us-gaap_DebtInstrumentDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionDescription" xlink:label="us-gaap_DebtConversionDescription"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_PurchasePrice" xlink:label="md_PurchasePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:label="us-gaap_ProceedsFromLinesOfCredit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCredit" xlink:label="us-gaap_LineOfCredit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DescriptionOfInterestRateRiskExposure" xlink:label="us-gaap_DescriptionOfInterestRateRiskExposure"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_UnsecuredDebtMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_SeniorNotes" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_CreditFacilityAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_LongTermDebtMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="us-gaap_RevolvingCreditFacilityMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_UnsecuredDebt" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_FinancialInstrumentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="md_CreditAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="md_FivePointThreeSevenFivePercentUnsecuredSeniorNotesDueTwoThousandThirtyMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_LongtermDebtTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="md_SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="md_DebtInstrumentMaturityYear" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentFrequencyOfPeriodicPayment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDateDescription" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_UnsecuredLongTermDebt" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfUnsecuredDebt" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_Cash" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentPeriodicPaymentInterest" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LettersOfCreditOutstandingAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebt" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentDescription" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtConversionDescription" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="md_PurchasePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ProceedsFromLinesOfCredit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LineOfCredit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DescriptionOfInterestRateRiskExposure" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.mednax.com/20240630/taxonomy/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanMember" xlink:label="md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_TwoThousandFifteenNonQualifiedStockPurchasePlanMember" xlink:label="md_TwoThousandFifteenNonQualifiedStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_AmendedAndRestatedTwoThousandEightPlanMember" xlink:label="md_AmendedAndRestatedTwoThousandEightPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember" xlink:label="md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="md_TwoThousandFifteenNonQualifiedStockPurchasePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="md_AmendedAndRestatedTwoThousandEightPlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.mednax.com/20240630/taxonomy/role/CommonStockRepurchaseProgramsAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_CommonStockLineItems" xlink:label="md_CommonStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_CommonStockTable" xlink:label="md_CommonStockTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StockRepurchaseProgramAuthorizedAmount1" xlink:label="srt_StockRepurchaseProgramAuthorizedAmount1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:label="us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="md_CommonStockLineItems" xlink:to="md_CommonStockTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="md_CommonStockTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="md_CommonStockLineItems" xlink:to="us-gaap_StockRepurchasedDuringPeriodShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="md_CommonStockTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="md_CommonStockLineItems" xlink:to="srt_StockRepurchaseProgramAuthorizedAmount1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="md_CommonStockLineItems" xlink:to="us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="md_CommonStockLineItems" xlink:to="us-gaap_PaymentsForRepurchaseOfCommonStock" priority="2" use="optional"/>
        </link:definitionLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.mednax.com/20240630/taxonomy/role/ConsolidatedBalanceSheetsUnaudited">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="md_AccountsPayableAndAccruedLiabilitiesExcludingAccruedIncomeTaxesCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LineOfCredit" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Goodwill" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="md_LongTermDebtAndCapitalLeaseObligationsExcludingLongTermLineOfCredit" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="md_OperatingAndFinanceLeaseRightOfUseAssets" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_MalpracticeLossContingencyAccrualUndiscountedNoncurrent" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_IncomeTaxReceivable" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedIncomeTaxesCurrent" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_DeferredIncomeTaxAssetsNet" order="5" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilitiesNet" order="5" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent" order="5" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent" order="6" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="6" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_AccountsPayableAndAccruedLiabilitiesExcludingAccruedIncomeTaxesCurrent" xlink:label="md_AccountsPayableAndAccruedLiabilitiesExcludingAccruedIncomeTaxesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCredit" xlink:label="us-gaap_LineOfCredit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:label="us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_LongTermDebtAndCapitalLeaseObligationsExcludingLongTermLineOfCredit" xlink:label="md_LongTermDebtAndCapitalLeaseObligationsExcludingLongTermLineOfCredit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_OperatingAndFinanceLeaseRightOfUseAssets" xlink:label="md_OperatingAndFinanceLeaseRightOfUseAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MalpracticeLossContingencyAccrualUndiscountedNoncurrent" xlink:label="us-gaap_MalpracticeLossContingencyAccrualUndiscountedNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReceivable" xlink:label="us-gaap_IncomeTaxReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedIncomeTaxesCurrent" xlink:label="us-gaap_AccruedIncomeTaxesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxAssetsNet" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.mednax.com/20240630/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnaudited">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_OperatingIncomeLoss" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InvestmentIncomeNet" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="0" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_UnrealizedGainLossOnInvestments" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="md_PracticeSalariesAndBenefits" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_NonoperatingIncomeExpense" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InterestExpense" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ProfitLoss" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="md_PracticeSuppliesAndOtherOperatingExpenses" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_RestructuringCharges" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GoodwillImpairmentLoss" order="5" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" order="6" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" order="9" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GainLossOnSaleOfBusiness" order="10" weight="-1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeNet" xlink:label="us-gaap_InvestmentIncomeNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="us-gaap_UnrealizedGainLossOnInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_PracticeSalariesAndBenefits" xlink:label="md_PracticeSalariesAndBenefits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_PracticeSuppliesAndOtherOperatingExpenses" xlink:label="md_PracticeSuppliesAndOtherOperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCharges" xlink:label="us-gaap_RestructuringCharges"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="us-gaap_GoodwillImpairmentLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfBusiness" xlink:label="us-gaap_GainLossOnSaleOfBusiness"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.mednax.com/20240630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromLinesOfCredit" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" order="0" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_NetIncomeLoss" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_RepaymentsOfLinesOfCredit" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireInvestments" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="md_PaymentsToTermLoan" order="2" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment" order="3" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_GoodwillImpairmentLoss" order="5" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="md_RepaymentsOfLongTermCapitalLeaseObligation" order="6" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="7" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" order="7" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_PaymentsForRepurchaseOfCommonStock" order="8" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_GainLossOnSaleOfBusiness" order="8" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" order="9" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_ShareBasedCompensation" order="9" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_OtherNoncashIncomeExpense" order="10" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" order="11" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="12" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="13" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" order="14" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" order="15" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve" order="16" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" order="18" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts" order="19" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="21" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:label="us-gaap_ProceedsFromLinesOfCredit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:label="us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfLinesOfCredit" xlink:label="us-gaap_RepaymentsOfLinesOfCredit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:label="us-gaap_PaymentsToAcquireInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_PaymentsToTermLoan" xlink:label="md_PaymentsToTermLoan"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:label="us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="us-gaap_GoodwillImpairmentLoss"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_RepaymentsOfLongTermCapitalLeaseObligation" xlink:label="md_RepaymentsOfLongTermCapitalLeaseObligation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfBusiness" xlink:label="us-gaap_GainLossOnSaleOfBusiness"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:label="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="us-gaap_OtherNoncashIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:label="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve" xlink:label="us-gaap_IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.mednax.com/20240630/taxonomy/role/AccountsReceivableAndNetRevenueScheduleOfAccountsReceivableNetDetail">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableGrossCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" order="1" weight="-1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableGrossCurrent" xlink:label="us-gaap_AccountsReceivableGrossCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.mednax.com/20240630/taxonomy/role/AccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetail">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedSalariesCurrent" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="md_AccruedPayrollTaxesAndBenefitsCurrent" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_MalpracticeLossContingencyAccrualUndiscountedCurrent" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_InterestPayableCurrent" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="7" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="us-gaap_AccruedSalariesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="md-20240630.xsd#md_AccruedPayrollTaxesAndBenefitsCurrent" xlink:label="md_AccruedPayrollTaxesAndBenefitsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MalpracticeLossContingencyAccrualUndiscountedCurrent" xlink:label="us-gaap_MalpracticeLossContingencyAccrualUndiscountedCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.mednax.com/20240630/taxonomy/role/CommonAndCommonEquivalentSharesScheduleOfCalculationOfSharesUsedInBasicAndDilutedNetIncomePerShareDetail">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" order="1" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
        </link:calculationLink>
      </link:linkbase>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="md_TwoThousandFifteenNonQualifiedStockPurchasePlanMember" name="TwoThousandFifteenNonQualifiedStockPurchasePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="md_TwoThousandTwentySevenMember" name="TwoThousandTwentySevenMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="md_FinancialInstrumentsMeasuredAtCarryingAmountTableTextBlock" name="FinancialInstrumentsMeasuredAtCarryingAmountTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="md_NonCashCharge" name="NonCashCharge" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="md_RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember" name="RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="md_CovidNinenteenMember" name="CovidNinenteenMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="md_NorthAmericanPartnersInAnesthesiaMember" name="NorthAmericanPartnersInAnesthesiaMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="md_NumberOfPediatricGastroenterologyPracticeAcquired" name="NumberOfPediatricGastroenterologyPracticeAcquired" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="md_PediatricGastroenterologyAndGynecologyPracticeAndMultiLocationPediatricUrgentCarePracticeMember" name="PediatricGastroenterologyAndGynecologyPracticeAndMultiLocationPediatricUrgentCarePracticeMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="md_CommonStockRepurchasesTextBlock" name="CommonStockRepurchasesTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="md_GaapSeniorNotesMember" name="GaapSeniorNotesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="md_DebtInstrumentMaturityYear" name="DebtInstrumentMaturityYear" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="md_BasisOfPresentationAndNewAccountingPronouncementsTable" name="BasisOfPresentationAndNewAccountingPronouncementsTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="md_PercentageIncreaseDecreaseInSalaryAndWage" name="PercentageIncreaseDecreaseInSalaryAndWage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="md_DeferredTaxAssetsDomain" name="DeferredTaxAssetsDomain" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="md_PercentageOfNetPatientServiceRevenueByTypeOfPayor" name="PercentageOfNetPatientServiceRevenueByTypeOfPayor" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="md_FairValueDisclosuresLineItems" name="FairValueDisclosuresLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="md_RadiologyServicesMedicalGroupMember" name="RadiologyServicesMedicalGroupMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="md_MutualFundsFairValueDisclosure" name="MutualFundsFairValueDisclosure" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="md_IncreaseInDeferredTaxAssets" name="IncreaseInDeferredTaxAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="md_NumberOfPediatricOrThopedicPracticesAcquired" name="NumberOfPediatricOrThopedicPracticesAcquired" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="md_ExtraordinaryItemsAbstract" name="ExtraordinaryItemsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="md_CoronavirusPandemicCOVIDNineteenDisclosureTextBlock" name="CoronavirusPandemicCOVIDNineteenDisclosureTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="md_ExtraordinaryItemsAxis" name="ExtraordinaryItemsAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="md_ChangeInRateOfControlPremium" name="ChangeInRateOfControlPremium" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="md_TwoZeroThreeZeroMember" name="TwoZeroThreeZeroMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="md_HospitalsContractsMember" name="HospitalsContractsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="md_MaternalFetalMedicinePracticeMember" name="MaternalFetalMedicinePracticeMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="md_SixPointTwoFivePercentageSeniorNotesDueTwoThousandTwentySevenMember" name="SixPointTwoFivePercentageSeniorNotesDueTwoThousandTwentySevenMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="md_PurchasePrice" name="PurchasePrice" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="md_RuralAreaMember" name="RuralAreaMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="md_AccountsPayableAndAccruedLiabilitiesExcludingAccruedIncomeTaxesCurrent" name="AccountsPayableAndAccruedLiabilitiesExcludingAccruedIncomeTaxesCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="md_PracticeSalariesAndBenefits" name="PracticeSalariesAndBenefits" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="md_AmendedAndRestatedTwoThousandEightPlanMember" name="AmendedAndRestatedTwoThousandEightPlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="md_FivePointThreeSevenFivePercentUnsecuredSeniorNotesDueTwoThousandThirtyMember" name="FivePointThreeSevenFivePercentUnsecuredSeniorNotesDueTwoThousandThirtyMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="md_ChangeInNonCashImpairmentCharges" name="ChangeInNonCashImpairmentCharges" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="md_GoodWillImpairmentLossExcludingDeferredTaxAssetsCharge" name="GoodWillImpairmentLossExcludingDeferredTaxAssetsCharge" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="md_IncrementalSharesNotIncludedDueToAntiDilutiveEffect" name="IncrementalSharesNotIncludedDueToAntiDilutiveEffect" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="md_LineOfCreditAndLongTermDebtTextBlock" name="LineOfCreditAndLongTermDebtTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="md_LineOfCreditLongTermDebtAndFinanceLeaseObligationsDisclosureTextBlock" name="LineOfCreditLongTermDebtAndFinanceLeaseObligationsDisclosureTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="md_AccountsReceivableAndNetRevenueDisclosureTextBlock" name="AccountsReceivableAndNetRevenueDisclosureTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="md_CommonStockTable" name="CommonStockTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="md_UnnamedCorporateJointVentureOneMember" name="UnnamedCorporateJointVentureOneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="md_FairValueDisclosuresTable" name="FairValueDisclosuresTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="md_LongTermDebtAndCapitalLeaseObligationsExcludingLongTermLineOfCredit" name="LongTermDebtAndCapitalLeaseObligationsExcludingLongTermLineOfCredit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="md_IncrementalNonCashCharge" name="IncrementalNonCashCharge" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="md_DissolutionOfAndNetIncomeLossAttributableToNoncontrollingInterest" name="DissolutionOfAndNetIncomeLossAttributableToNoncontrollingInterest" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="md_TwoThousandTwentyThreeMember" name="TwoThousandTwentyThreeMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="md_OperatingAndFinanceLeaseRightOfUseAssets" name="OperatingAndFinanceLeaseRightOfUseAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="md_MoneyMarketFundsFairValueDisclosure" name="MoneyMarketFundsFairValueDisclosure" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="md_TwoThousandTwentyTaxYearMember" name="TwoThousandTwentyTaxYearMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="md_IncrementalSharesInContinuingOperation" name="IncrementalSharesInContinuingOperation" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="md_DeferredTaxAssetsAxis" name="DeferredTaxAssetsAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="md_PercentageOfRefundOfIncomeTaxAtThePriorPeriodCorporateTaxRate" name="PercentageOfRefundOfIncomeTaxAtThePriorPeriodCorporateTaxRate" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="md_ProceedsFromContributionInAidOfReimbursementOfLostRevenue" name="ProceedsFromContributionInAidOfReimbursementOfLostRevenue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="md_CashEquivalentsAndInvestmentsLineItems" name="CashEquivalentsAndInvestmentsLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="md_UnnamedCorporateJointVentureTwoMember" name="UnnamedCorporateJointVentureTwoMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="md_RepaymentsOfLongTermCapitalLeaseObligation" name="RepaymentsOfLongTermCapitalLeaseObligation" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="md_AccruedPayrollTaxesAndBenefitsCurrent" name="AccruedPayrollTaxesAndBenefitsCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="md_ScheduleOfFinancingReceivablesLineItems" name="ScheduleOfFinancingReceivablesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="md_FivePointTwoFivePercentageSeniorNotesDueTwoThousandTwentyThreeMember" name="FivePointTwoFivePercentageSeniorNotesDueTwoThousandTwentyThreeMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="md_IncreaseDecreaseInAccruedSalariesAndBonuses" name="IncreaseDecreaseInAccruedSalariesAndBonuses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="md_PracticeSuppliesAndOtherOperatingExpenses" name="PracticeSuppliesAndOtherOperatingExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="md_PrimaryBeneficiaryMember" name="PrimaryBeneficiaryMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="md_PaymentsToTermLoan" name="PaymentsToTermLoan" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="md_ContractedManagedCareMember" name="ContractedManagedCareMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="md_NumberOfMaternalFetalMedicinePracticesAcquired" name="NumberOfMaternalFetalMedicinePracticesAcquired" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="md_BasisOfPresentationLineItems" name="BasisOfPresentationLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="md_CashEquivalentsAndInvestmentsTable" name="CashEquivalentsAndInvestmentsTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="md_SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMember" name="SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="md_NetOfTaxUnrealizedHoldingGainLossOnInvestments" name="NetOfTaxUnrealizedHoldingGainLossOnInvestments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="md_NumberOfMultiLocationPediatricUrgentCarePracticeAcquired" name="NumberOfMultiLocationPediatricUrgentCarePracticeAcquired" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="md_ExtraordinaryItemsDomain" name="ExtraordinaryItemsDomain" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="md_PediatricSubspecialtyPracticeMember" name="PediatricSubspecialtyPracticeMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="md_AnesthesiologyServicesMedicalGroupMember" name="AnesthesiologyServicesMedicalGroupMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanMember" name="NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="md_CommonStockLineItems" name="CommonStockLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="md_CreditAgreementMember" name="CreditAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember" name="NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="md_ContributionsInAidOfReimbursementOfLostRevenue" name="ContributionsInAidOfReimbursementOfLostRevenue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140198476235024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Aug. 02, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Pediatrix Medical Group, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000893949<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $.01 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MD<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-12111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">FL<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">26-3667538<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1301 Concord Terrace<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Sunrise<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">FL<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">33323<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">954<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">384-0175<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85,865,841<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140198568276672">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 19,402<span></span>
</td>
<td class="nump">$ 73,258<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">113,795<span></span>
</td>
<td class="nump">104,485<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">274,164<span></span>
</td>
<td class="nump">272,313<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">11,910<span></span>
</td>
<td class="nump">13,525<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReceivable', window );">Income taxes receivable</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">7,565<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">9,941<span></span>
</td>
<td class="nump">12,308<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">429,212<span></span>
</td>
<td class="nump">483,454<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">47,893<span></span>
</td>
<td class="nump">75,639<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">1,239,007<span></span>
</td>
<td class="nump">1,384,166<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, net</a></td>
<td class="nump">10,193<span></span>
</td>
<td class="nump">21,240<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_md_OperatingAndFinanceLeaseRightOfUseAssets', window );">Operating and finance lease right-of-use assets</a></td>
<td class="nump">65,392<span></span>
</td>
<td class="nump">70,294<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxAssetsNet', window );">Deferred income tax assets</a></td>
<td class="nump">124,115<span></span>
</td>
<td class="nump">102,852<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">79,539<span></span>
</td>
<td class="nump">82,165<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">1,995,351<span></span>
</td>
<td class="nump">2,219,810<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_md_AccountsPayableAndAccruedLiabilitiesExcludingAccruedIncomeTaxesCurrent', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">267,333<span></span>
</td>
<td class="nump">350,798<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent', window );">Current portion of debt and finance lease liabilities, net</a></td>
<td class="nump">17,730<span></span>
</td>
<td class="nump">14,913<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of operating lease liabilities</a></td>
<td class="nump">18,764<span></span>
</td>
<td class="nump">21,076<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesCurrent', window );">Income taxes payable</a></td>
<td class="nump">6,329<span></span>
</td>
<td class="nump">2,159<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">310,156<span></span>
</td>
<td class="nump">388,946<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_md_LongTermDebtAndCapitalLeaseObligationsExcludingLongTermLineOfCredit', window );">Long-term debt and finance lease liabilities, net</a></td>
<td class="nump">612,640<span></span>
</td>
<td class="nump">618,421<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term operating lease liabilities</a></td>
<td class="nump">49,176<span></span>
</td>
<td class="nump">47,238<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MalpracticeLossContingencyAccrualUndiscountedNoncurrent', window );">Long-term professional liabilities</a></td>
<td class="nump">254,770<span></span>
</td>
<td class="nump">251,284<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred income tax liabilities</a></td>
<td class="nump">30,627<span></span>
</td>
<td class="nump">34,308<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other liabilities</a></td>
<td class="nump">31,521<span></span>
</td>
<td class="nump">30,552<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">1,288,890<span></span>
</td>
<td class="nump">1,370,749<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Shareholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock; $.01 par value; 1,000 shares authorized; none issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock; $.01 par value; 200,000 shares authorized; 85,753,258 and 84,018,023 shares issued and outstanding, respectively</a></td>
<td class="nump">858<span></span>
</td>
<td class="nump">840<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">1,006,018<span></span>
</td>
<td class="nump">999,906<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(1,954)<span></span>
</td>
<td class="num">(2,214)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained deficit</a></td>
<td class="num">(298,461)<span></span>
</td>
<td class="num">(149,471)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total shareholders' equity</a></td>
<td class="nump">706,461<span></span>
</td>
<td class="nump">849,061<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and shareholders' equity</a></td>
<td class="nump">$ 1,995,351<span></span>
</td>
<td class="nump">$ 2,219,810<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_AccountsPayableAndAccruedLiabilitiesExcludingAccruedIncomeTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accounts payable and accrued liabilities excluding accrued income taxes current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_AccountsPayableAndAccruedLiabilitiesExcludingAccruedIncomeTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_LongTermDebtAndCapitalLeaseObligationsExcludingLongTermLineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long term debt and capital lease obligations excluding long term line of credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_LongTermDebtAndCapitalLeaseObligationsExcludingLongTermLineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_OperatingAndFinanceLeaseRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating and finance lease right-of-use assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_OperatingAndFinanceLeaseRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482598/350-20-45-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of income taxes previously overpaid to tax authorities (such as U.S. Federal, state and local tax authorities) representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes. Also called income tax refund receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt and lease obligation, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MalpracticeLossContingencyAccrualUndiscountedNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the noncurrent portion of the accrued liability on an undiscounted basis for malpractice claims (including general and professional liability).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MalpracticeLossContingencyAccrualUndiscountedNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482955/340-10-05-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140198476232736">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">85,753,258<span></span>
</td>
<td class="nump">84,018,023<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">85,753,258<span></span>
</td>
<td class="nump">84,018,023<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140198474027984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Income and Comprehensive Income (Unaudited) - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Net revenue</a></td>
<td class="nump">$ 504,296<span></span>
</td>
<td class="nump">$ 500,577<span></span>
</td>
<td class="nump">$ 999,397<span></span>
</td>
<td class="nump">$ 991,585<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_md_PracticeSalariesAndBenefits', window );">Practice salaries and benefits</a></td>
<td class="nump">357,808<span></span>
</td>
<td class="nump">354,032<span></span>
</td>
<td class="nump">726,946<span></span>
</td>
<td class="nump">716,267<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_md_PracticeSuppliesAndOtherOperatingExpenses', window );">Practice supplies and other operating expenses</a></td>
<td class="nump">32,369<span></span>
</td>
<td class="nump">31,089<span></span>
</td>
<td class="nump">63,454<span></span>
</td>
<td class="nump">61,809<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">56,565<span></span>
</td>
<td class="nump">58,013<span></span>
</td>
<td class="nump">116,763<span></span>
</td>
<td class="nump">117,072<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">8,791<span></span>
</td>
<td class="nump">8,945<span></span>
</td>
<td class="nump">19,099<span></span>
</td>
<td class="nump">17,898<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Transformational and restructuring related expenses</a></td>
<td class="nump">13,579<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">22,059<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment</a></td>
<td class="nump">154,243<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">154,243<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Fixed assets impairments</a></td>
<td class="nump">20,112<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">20,112<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">Intangible assets impairments</a></td>
<td class="nump">7,679<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">7,679<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfBusiness', window );">Loss on disposal of businesses</a></td>
<td class="nump">10,873<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">10,873<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">662,019<span></span>
</td>
<td class="nump">452,079<span></span>
</td>
<td class="nump">1,141,228<span></span>
</td>
<td class="nump">913,046<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">(Loss) income from operations</a></td>
<td class="num">(157,723)<span></span>
</td>
<td class="nump">48,498<span></span>
</td>
<td class="num">(141,831)<span></span>
</td>
<td class="nump">78,539<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNet', window );">Investment and other (loss) income</a></td>
<td class="num">(161)<span></span>
</td>
<td class="nump">1,189<span></span>
</td>
<td class="nump">1,852<span></span>
</td>
<td class="nump">1,823<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(10,308)<span></span>
</td>
<td class="num">(11,230)<span></span>
</td>
<td class="num">(20,907)<span></span>
</td>
<td class="num">(21,620)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Equity in earnings of unconsolidated affiliate</a></td>
<td class="nump">464<span></span>
</td>
<td class="nump">490<span></span>
</td>
<td class="nump">982<span></span>
</td>
<td class="nump">917<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total non-operating expenses</a></td>
<td class="num">(10,005)<span></span>
</td>
<td class="num">(9,551)<span></span>
</td>
<td class="num">(18,073)<span></span>
</td>
<td class="num">(18,880)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">(Loss) income before income taxes</a></td>
<td class="num">(167,728)<span></span>
</td>
<td class="nump">38,947<span></span>
</td>
<td class="num">(159,904)<span></span>
</td>
<td class="nump">59,659<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit (provision)</a></td>
<td class="nump">14,703<span></span>
</td>
<td class="num">(10,665)<span></span>
</td>
<td class="nump">10,914<span></span>
</td>
<td class="num">(17,171)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net (loss) income</a></td>
<td class="num">(153,025)<span></span>
</td>
<td class="nump">28,282<span></span>
</td>
<td class="num">(148,990)<span></span>
</td>
<td class="nump">42,488<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Unrealized holding gain (loss) on investments, net of tax of $66, $126, $86 and $353</a></td>
<td class="nump">200<span></span>
</td>
<td class="num">(387)<span></span>
</td>
<td class="nump">260<span></span>
</td>
<td class="nump">217<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Total comprehensive (loss) income</a></td>
<td class="num">$ (152,825)<span></span>
</td>
<td class="nump">$ 27,895<span></span>
</td>
<td class="num">$ (148,730)<span></span>
</td>
<td class="nump">$ 42,705<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net (loss) income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic</a></td>
<td class="num">$ (1.84)<span></span>
</td>
<td class="nump">$ 0.34<span></span>
</td>
<td class="num">$ (1.79)<span></span>
</td>
<td class="nump">$ 0.52<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted</a></td>
<td class="num">$ (1.84)<span></span>
</td>
<td class="nump">$ 0.34<span></span>
</td>
<td class="num">$ (1.79)<span></span>
</td>
<td class="nump">$ 0.52<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract', window );"><strong>Weighted average common shares:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic</a></td>
<td class="nump">83,332<span></span>
</td>
<td class="nump">82,399<span></span>
</td>
<td class="nump">83,074<span></span>
</td>
<td class="nump">82,033<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted</a></td>
<td class="nump">83,332<span></span>
</td>
<td class="nump">82,664<span></span>
</td>
<td class="nump">83,074<span></span>
</td>
<td class="nump">82,377<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_PracticeSalariesAndBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Practice salaries and benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_PracticeSalariesAndBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_PracticeSuppliesAndOtherOperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of supplies and other operating expenses directly attributable to the physician practices.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_PracticeSuppliesAndOtherOperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from sale and disposal of integrated set of activities and assets capable of being conducted and managed for purpose of providing return in form of dividend, lower cost, or other economic benefit to investor, owner, member and participant.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss from asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482598/350-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-2<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481664/323-10-45-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-24<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483013/835-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482047/420-10-45-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140198478437168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Income and Comprehensive Income (Unaudited) (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_md_NetOfTaxUnrealizedHoldingGainLossOnInvestments', window );">Unrealized holding gain (loss) on investments, net of tax</a></td>
<td class="nump">$ 66<span></span>
</td>
<td class="nump">$ 126<span></span>
</td>
<td class="nump">$ 86<span></span>
</td>
<td class="nump">$ 353<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_NetOfTaxUnrealizedHoldingGainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net Of Tax, Unrealized Holding Gain (Loss) on Investments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_NetOfTaxUnrealizedHoldingGainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140198474114192">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Shareholders' Equity (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Accumulated Other Comprehensive Loss [Member]</div></th>
<th class="th"><div>Retained Deficit [Member]</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Dec. 31, 2022</a></td>
<td class="nump">$ 891,632<span></span>
</td>
<td class="nump">$ 829<span></span>
</td>
<td class="nump">$ 983,601<span></span>
</td>
<td class="num">$ (3,735)<span></span>
</td>
<td class="num">$ (89,063)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, Shares at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">82,947,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="nump">14,206<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,206<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized holding gain on investments, net of tax</a></td>
<td class="nump">604<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">604<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Common stock issued under employee stock purchase plan Value</a></td>
<td class="nump">1,095<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,095<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Common stock issued under employee stock purchase plan shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">86,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross', window );">Issuance of restricted stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="num">(9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross', window );">Issuance of restricted stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">871,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures', window );">Forfeitures of restricted stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2)<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited', window );">Forfeitures of restricted stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(221,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">3,009<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,009<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchased common stock</a></td>
<td class="num">(775)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(775)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchased common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(49,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Mar. 31, 2023</a></td>
<td class="nump">909,771<span></span>
</td>
<td class="nump">$ 836<span></span>
</td>
<td class="nump">986,923<span></span>
</td>
<td class="num">(3,131)<span></span>
</td>
<td class="num">(74,857)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, Shares at Mar. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">83,634,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Dec. 31, 2022</a></td>
<td class="nump">891,632<span></span>
</td>
<td class="nump">$ 829<span></span>
</td>
<td class="nump">983,601<span></span>
</td>
<td class="num">(3,735)<span></span>
</td>
<td class="num">(89,063)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, Shares at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">82,947,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="nump">42,488<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Jun. 30, 2023</a></td>
<td class="nump">942,375<span></span>
</td>
<td class="nump">$ 838<span></span>
</td>
<td class="nump">991,630<span></span>
</td>
<td class="num">(3,518)<span></span>
</td>
<td class="num">(46,575)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, Shares at Jun. 30, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">83,841,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Mar. 31, 2023</a></td>
<td class="nump">909,771<span></span>
</td>
<td class="nump">$ 836<span></span>
</td>
<td class="nump">986,923<span></span>
</td>
<td class="num">(3,131)<span></span>
</td>
<td class="num">(74,857)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, Shares at Mar. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">83,634,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="nump">28,282<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,282<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized holding gain on investments, net of tax</a></td>
<td class="num">(387)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(387)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Common stock issued under employee stock purchase plan Value</a></td>
<td class="nump">1,594<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">1,593<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Common stock issued under employee stock purchase plan shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">126,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross', window );">Issuance of restricted stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross', window );">Issuance of restricted stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">93,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited', window );">Forfeitures of restricted stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">3,126<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,126<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchased common stock</a></td>
<td class="num">(11)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchased common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Jun. 30, 2023</a></td>
<td class="nump">942,375<span></span>
</td>
<td class="nump">$ 838<span></span>
</td>
<td class="nump">991,630<span></span>
</td>
<td class="num">(3,518)<span></span>
</td>
<td class="num">(46,575)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, Shares at Jun. 30, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">83,841,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Dec. 31, 2023</a></td>
<td class="nump">849,061<span></span>
</td>
<td class="nump">$ 840<span></span>
</td>
<td class="nump">999,906<span></span>
</td>
<td class="num">(2,214)<span></span>
</td>
<td class="num">(149,471)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, Shares at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">84,018,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="nump">4,035<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,035<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized holding gain on investments, net of tax</a></td>
<td class="nump">60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Common stock issued under employee stock purchase plan Value</a></td>
<td class="nump">860<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">859<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Common stock issued under employee stock purchase plan shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">108,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited', window );">Forfeitures of restricted stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(21,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">3,067<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,067<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchased common stock</a></td>
<td class="num">(887)<span></span>
</td>
<td class="num">$ (1)<span></span>
</td>
<td class="num">(886)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchased common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(97,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Mar. 31, 2024</a></td>
<td class="nump">856,196<span></span>
</td>
<td class="nump">$ 840<span></span>
</td>
<td class="nump">1,002,946<span></span>
</td>
<td class="num">(2,154)<span></span>
</td>
<td class="num">(145,436)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, Shares at Mar. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">84,008,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Dec. 31, 2023</a></td>
<td class="nump">849,061<span></span>
</td>
<td class="nump">$ 840<span></span>
</td>
<td class="nump">999,906<span></span>
</td>
<td class="num">(2,214)<span></span>
</td>
<td class="num">(149,471)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, Shares at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">84,018,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (148,990)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchased common stock, shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Jun. 30, 2024</a></td>
<td class="nump">$ 706,461<span></span>
</td>
<td class="nump">$ 858<span></span>
</td>
<td class="nump">1,006,018<span></span>
</td>
<td class="num">(1,954)<span></span>
</td>
<td class="num">(298,461)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, Shares at Jun. 30, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85,753,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Mar. 31, 2024</a></td>
<td class="nump">856,196<span></span>
</td>
<td class="nump">$ 840<span></span>
</td>
<td class="nump">1,002,946<span></span>
</td>
<td class="num">(2,154)<span></span>
</td>
<td class="num">(145,436)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, Shares at Mar. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">84,008,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">(153,025)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(153,025)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized holding gain on investments, net of tax</a></td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Common stock issued under employee stock purchase plan Value</a></td>
<td class="nump">1,149<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">1,147<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Common stock issued under employee stock purchase plan shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">139,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross', window );">Issuance of restricted stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16<span></span>
</td>
<td class="num">(16)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross', window );">Issuance of restricted stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,630,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited', window );">Forfeitures of restricted stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(22,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">1,952<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,952<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchased common stock</a></td>
<td class="num">(11)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchased common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Jun. 30, 2024</a></td>
<td class="nump">$ 706,461<span></span>
</td>
<td class="nump">$ 858<span></span>
</td>
<td class="nump">$ 1,006,018<span></span>
</td>
<td class="num">$ (1,954)<span></span>
</td>
<td class="num">$ (298,461)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, Shares at Jun. 30, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85,753,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares related to Restricted Stock Award forfeited during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number, before forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock related to Restricted Stock Awards forfeited during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, before forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-24<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-23<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-5<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-3<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 39: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 43: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 44: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 45: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 46: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-15<br><br>Reference 47: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-16<br><br>Reference 48: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4I<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140198476650688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="num">$ (148,990)<span></span>
</td>
<td class="nump">$ 42,488<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income to net cash from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">19,099<span></span>
</td>
<td class="nump">17,898<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of premiums, discounts and issuance costs</a></td>
<td class="nump">440<span></span>
</td>
<td class="nump">733<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment</a></td>
<td class="nump">154,243<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Fixed assets impairments</a></td>
<td class="nump">20,112<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">Intangible assets impairments</a></td>
<td class="nump">7,679<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfBusiness', window );">Loss on disposal of businesses</a></td>
<td class="nump">10,873<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">5,019<span></span>
</td>
<td class="nump">6,135<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income taxes</a></td>
<td class="num">(25,028)<span></span>
</td>
<td class="nump">8,376<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other</a></td>
<td class="num">(1,678)<span></span>
</td>
<td class="num">(900)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(934)<span></span>
</td>
<td class="nump">28,900<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">3,703<span></span>
</td>
<td class="nump">2,141<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Other long-term assets</a></td>
<td class="nump">16,955<span></span>
</td>
<td class="nump">5,052<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued expenses</a></td>
<td class="num">(82,917)<span></span>
</td>
<td class="num">(97,315)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable', window );">Income taxes payable</a></td>
<td class="nump">11,735<span></span>
</td>
<td class="num">(12,028)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve', window );">Long-term professional liabilities</a></td>
<td class="nump">8,039<span></span>
</td>
<td class="nump">838<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities', window );">Other liabilities</a></td>
<td class="num">(11,630)<span></span>
</td>
<td class="num">(10,356)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations', window );">Net cash used in operating activities - continuing operations</a></td>
<td class="num">(13,280)<span></span>
</td>
<td class="num">(8,038)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations', window );">Net cash used in operating activities - discontinued operations</a></td>
<td class="num">(4,995)<span></span>
</td>
<td class="num">(3,825)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(18,275)<span></span>
</td>
<td class="num">(11,863)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Acquisition payments, net of cash acquired</a></td>
<td class="num">(8,167)<span></span>
</td>
<td class="num">(1,667)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInvestments', window );">Purchases of investments</a></td>
<td class="num">(39,915)<span></span>
</td>
<td class="num">(17,761)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments', window );">Proceeds from maturities or sales of investments</a></td>
<td class="nump">31,244<span></span>
</td>
<td class="nump">12,810<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(12,292)<span></span>
</td>
<td class="num">(15,130)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(29,130)<span></span>
</td>
<td class="num">(21,748)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromLinesOfCredit', window );">Borrowings on line of credit</a></td>
<td class="nump">235,500<span></span>
</td>
<td class="nump">421,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLinesOfCredit', window );">Payments on line of credit</a></td>
<td class="num">(235,500)<span></span>
</td>
<td class="num">(384,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_md_PaymentsToTermLoan', window );">Payments on term loan</a></td>
<td class="num">(6,250)<span></span>
</td>
<td class="num">(6,250)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_md_RepaymentsOfLongTermCapitalLeaseObligation', window );">Payment on finance lease obligation</a></td>
<td class="num">(1,391)<span></span>
</td>
<td class="num">(1,404)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="nump">2,009<span></span>
</td>
<td class="nump">2,689<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Repurchases of common stock</a></td>
<td class="num">(898)<span></span>
</td>
<td class="num">(786)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities', window );">Other</a></td>
<td class="nump">79<span></span>
</td>
<td class="num">(1,613)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash (used in) provided by financing activities</a></td>
<td class="num">(6,451)<span></span>
</td>
<td class="nump">29,636<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net decrease in cash and cash equivalents</a></td>
<td class="num">(53,856)<span></span>
</td>
<td class="num">(3,975)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">73,258<span></span>
</td>
<td class="nump">9,824<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">$ 19,402<span></span>
</td>
<td class="nump">$ 5,849<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_PaymentsToTermLoan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash outflow to term loan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_PaymentsToTermLoan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_RepaymentsOfLongTermCapitalLeaseObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Repayments Of Long Term Capital Lease Obligation</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_RepaymentsOfLongTermCapitalLeaseObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of operating activities of discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from sale and disposal of integrated set of activities and assets capable of being conducted and managed for purpose of providing return in form of dividend, lower cost, or other economic benefit to investor, owner, member and participant.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss from asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482598/350-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-2<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in liability to reflect the estimated ultimate cost of settling claims relating to insured events that have occurred on or before the balance sheet date, whether or not reported to the insurer at that date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of all investments (debt, security, other) during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from the acquisition of or improvements to long-lived, physical assets used to produce goods and services and not intended for resale, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromPaymentsForOtherFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140198479839328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (153,025)<span></span>
</td>
<td class="nump">$ 4,035<span></span>
</td>
<td class="nump">$ 28,282<span></span>
</td>
<td class="nump">$ 14,206<span></span>
</td>
<td class="num">$ (148,990)<span></span>
</td>
<td class="nump">$ 42,488<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140198478406048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140198478176304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">1.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">            Basis of Presentation:</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">The accompanying unaudited Consolidated Financial Statements of the Company and the notes thereto presented in this Form 10-Q have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission ("SEC") applicable to interim financial statements, and do not include all disclosures required by accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) for complete financial statements. In the opinion of management, these financial statements include all adjustments, consisting only of normal recurring adjustments, necessary for a fair statement of the results of interim periods. The financial statements include all the accounts of Pediatrix Medical Group, Inc. and its consolidated subsidiaries (collectively, &#8220;PMG&#8221;) together with the accounts of PMG&#8217;s affiliated business corporations or professional associations, professional corporations, limited liability companies and partnerships (the &#8220;affiliated professional contractors&#8221;). Certain subsidiaries of PMG have contractual management arrangements with its affiliated professional contractors, which are separate legal entities that provide physician services in certain states. The terms &#8220;Pediatrix&#8221; and the &#8220;Company&#8221; refer collectively to Pediatrix Medical Group Inc., its subsidiaries and the affiliated professional contractors.</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">The Compan</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">y is a party to a joint venture in which it owns a </span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">37.5</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">% economic interest.  The Company accounts for this joint venture under the equity method of accounting because the Company exercises significant influence over, but does not control, this entity.</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">  </span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">The consolidated results of operations for the interim periods presented are not necessarily indicative of the results to be experienced for the entire fiscal year. In addition, the accompanying unaudited Consolidated Financial Statements and the notes thereto should be read in conjunction with the Consolidated Financial Statements and the notes thereto included in the Company&#8217;s most recent Annual Report on Form 10-K (the &#8220;Form 10-K&#8221;).</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 275<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/275/tableOfContent<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/810/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 250<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/250/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140198478480032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash Equivalents and Investments<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">Cash Equivalents and Investments</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">2.            Cash Equivalents and Investments:</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">As of June 30, 2024 and December 31, 2023, the Company's cash equivalents consisted entirely of money market funds totaling $</span><span style="font-size:9pt;font-family:Times New Roman;white-space:pre-wrap;min-width:fit-content;color:#000000;">0.4</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:9pt;font-family:Times New Roman;white-space:pre-wrap;min-width:fit-content;color:#000000;">2.8</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">  </span></p><div style="font-size:9pt;font-family:Times New Roman;"><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Investments held are all classified as current and at </span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">June 30, 2024 and December 31, 2023 are summarized as follows (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:72.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:56.529%;"></td>
        <td style="width:1.42%;"></td>
        <td style="width:1%;"></td>
        <td style="width:18.316%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.42%;"></td>
        <td style="width:1%;"></td>
        <td style="width:18.316%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">June 30, 2024</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Corporate securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">55,777</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">57,878</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. Treasury securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">31,456</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">22,674</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Municipal debt securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">17,377</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">14,649</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Federal home loan securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">6,503</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">5,670</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Certificates of deposit</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">2,682</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">3,614</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">113,795</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">104,485</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 940<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/940-320/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1403<br> -Paragraph b<br> -Publisher SEC<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/320/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6B<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/942-320/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140198480068976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">3.            Fair Value Measurements:</span></p><p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">The accounting guidance establishes a fair value hierarchy that prioritizes valuation inputs into three levels based on the extent to which inputs used in measuring fair value are observable in the market. Each fair value measurement is reported in one of three levels:</span></p><p style="margin-left:6.667%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Level 1 &#8211; inputs are based upon unadjusted quoted prices for identical instruments traded in active markets.</span></p><p style="margin-left:6.667%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Level 2 &#8211; inputs are based upon quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, and model-based valuation techniques for which all significant assumptions are observable in the market or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span></p><p style="margin-left:6.667%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Level 3 &#8211; inputs are generally unobservable and typically reflect management&#8217;s estimates of assumptions that market participants would use in pricing the asset or liability. The fair values are therefore determined using model-based techniques that include option pricing models, discounted cash flow models, and similar techniques.</span></p><div style="font-size:12pt;font-family:Arial;"><p style="text-indent:6.667%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">The following table presents information about the Company&#8217;s financial instruments that are accounted for at fair value on a recurring basis at </span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">June 30, 2024 and December 31, 2023 (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.54%;"></td>
        <td style="width:1.32%;"></td>
        <td style="width:13%;"></td>
        <td style="width:1.26%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.54%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.26%;"></td>
        <td style="width:1%;"></td>
        <td style="width:15.08%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair Value<br/>Category</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">June 30, 2024</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Assets:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Money market funds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Level 1</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">397</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">2,814</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Short-term investments</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Level 2</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">113,795</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">104,485</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Mutual Funds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Level 1</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">19,002</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">17,687</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:9pt;font-family:Times New Roman;"><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">The following table presents information about the Company&#8217;s financial instruments that are not carried at fair value at </span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">June 30, 2024 and December 31, 2023 (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.72%;"></td>
        <td style="width:1.08%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.24%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.08%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.24%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.08%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.24%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.08%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.24%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">June 30, 2024</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Carrying<br/>Amount</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair<br/>Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Carrying<br/>Amount</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair<br/>Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Liabilities:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2030 Notes</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">400,000</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">353,760</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">400,000</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">357,000</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">The carrying amounts of cash equivalents, accounts receivable and accounts payable and accrued expenses approximate fair value due to the short maturities of the respective instruments. The carrying value of the line of credit approximates fair value.  If the Company&#8217;s line of credit was measured at fair value, it would be categorized as Level 2 in the fair value hierarchy.</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">  </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 107<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 940<br> -SubTopic 820<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140198478437664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Receivable and Net Revenue<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TextBlockAbstract', window );"><strong>Text Block [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_md_AccountsReceivableAndNetRevenueDisclosureTextBlock', window );">Accounts Receivable and Net Revenue</a></td>
<td class="text"><p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">4. </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Arial;min-width:fit-content;">            </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Accounts Receivable and Net Revenue:</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:9pt;font-family:Times New Roman;"><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Accounts receivable, net consists of the following (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:93.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:63.441%;"></td>
        <td style="width:2.151%;"></td>
        <td style="width:1%;"></td>
        <td style="width:14.128%;"></td>
        <td style="width:1%;"></td>
        <td style="width:2.151%;"></td>
        <td style="width:1%;"></td>
        <td style="width:14.128%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">June 30, 2024</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Gross accounts receivable</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,490,865</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,379,213</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Allowance for contractual adjustments and uncollectibles</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,216,701</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,106,900</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">274,164</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">272,313</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Patient service revenue is recognized at the time services are provided by the Company&#8217;s affiliated physicians. The Company&#8217;s performance obligations related to the delivery of services to patients are satisfied at the time of service. Accordingly, there are no performance obligations that are unsatisfied or partially unsatisfied at the end of the reporting period with respect to patient service revenue. Almost all of the Company&#8217;s patient service revenue is reimbursed by government-sponsored healthcare programs (&#8220;GHC Programs&#8221;) and third-party insurance payors. Payments for services rendered to the Company&#8217;s patients are generally less than billed charges. The Company monitors its revenue and receivables from these sources and records an estimated contractual allowance to properly account for the anticipated differences between billed and reimbursed amounts.</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Accordingly, patient service revenue is presented net of an estimated provision for contractual adjustments and uncollectibles. The Company estimates allowances for contractual adjustments and uncollectibles on accounts receivable based upon historical experience and other factors, including days sales outstanding (&#8220;DSO&#8221;) for accounts receivable, evaluation of expected adjustments and delinquency rates, past adjustments and collection experience in relation to amounts billed, an aging of accounts receivable, current contract and reimbursement terms, changes in payor mix and other relevant information. Contractual adjustments result from the difference between the physician rates for services performed and the reimbursements by GHC Programs and third-party insurance payors for such services.</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Collection of patient service revenue the Company expects to receive is normally a function of providing complete and correct billing information to the GHC Programs and third-party insurance payors within the various filing deadlines and typically occurs within 30 to 60 days of billing.</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Some of the Company&#8217;s hospital agreements require hospitals to pay the Company administrative fees. Some agreements provide for fees if the hospital does not generate sufficient patient volume in order to guarantee that the Company receives a specified minimum revenue level. The Company also receives fees from hospitals for administrative services performed by its affiliated physicians providing medical director or other services at the hospital.</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:9pt;font-family:Times New Roman;"><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes the Company&#8217;s net revenue by category (in thousands):</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:29.984%;"></td>
        <td style="width:1.111%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.136000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:2.223%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.113999999999999%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.623%;"></td>
        <td style="width:1%;"></td>
        <td style="width:14.914%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.623%;"></td>
        <td style="width:1%;"></td>
        <td style="width:14.27%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Three Months Ended<br/>June 30,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Six Months Ended<br/>June 30,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net patient service revenue</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">432,847</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">430,383</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">854,678</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">853,567</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Hospital contract administrative fees</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">70,913</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">69,585</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">142,716</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">135,574</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other revenue</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">536</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">609</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">2,003</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">2,444</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">504,296</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">500,577</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">999,397</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">991,585</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:9pt;font-family:Times New Roman;"><p style="margin-left:4.533%;text-indent:6.983%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">The approximate percentage of net patient service revenue by type of payor was as follows:</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:91.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:36.233%;"></td>
        <td style="width:1.3%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.197%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.82%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.198%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.578%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.677999999999999%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Three Months Ended<br/>June 30,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Six Months Ended<br/>June 30,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Contracted managed care</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">71</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">68</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">71</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">67</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Government</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">23</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">25</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">24</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">25</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other third-parties</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">4</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">5</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">3</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">6</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Private-pay patients</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">2</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">2</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">2</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">2</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">100</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">100</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">100</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">100</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_AccountsReceivableAndNetRevenueDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accounts receivable and net revenue disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_AccountsReceivableAndNetRevenueDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140198479996336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Combinations<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">Business Combinations</a></td>
<td class="text"><p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">5. 	Business Combinations</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">During the six months ended June 30, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">, the Company completed the acquisition of </span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">one</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> maternal-fetal medicine practice for total consideration of $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">9.7</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million, of which $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">6.5</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million was paid in cash at closing and $</span><span style="font-size:9pt;font-family:Times New Roman;white-space:pre-wrap;min-width:fit-content;color:#000000;">3.2</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million was recorded as a contingent consideration liability. The acquisition expanded the Company&#8217;s national network of physician practices across women&#8217;s and children&#8217;s services. In connection with this acquisition, the Company recorded tax deductible goodwill of $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">9.1</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million, fixed assets of $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.4</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million and other intangible assets consisting primarily of physician and hospital agreements of $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.2</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million.</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">   </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-5<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/805/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140198478449920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Long-Lived Asset Impairments<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">Goodwill, Long-Lived Asset Impairments and Loss on Disposal of Businesses</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">6.</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">  	</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Goodwill, Long-Lived Asset Impairments and Loss on Disposal of Businesses:</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">During the second quarter of 2024, the Company formalized its practice portfolio management plans, resulting in a decision to exit almost all of its affiliated office-based practices, other than maternal-fetal medicine. The practice exits are expected to be completed by December 31, 2024. Accordingly, a recoverability assessment for each individual physician practice was performed, and the estimated future cash flows related to the physician practices did not support the carrying value of the specifically identified individual long-lived assets. As a result, the Company recorded fixed asset impairments of $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">20.1</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million, intangible asset impairments of $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">7.7</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million and operating lease right-of-use asset impairments of $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">8.1</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million. The operating lease right-of-use impairments are recorded within the transformational and restructuring related expenses line item.</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">During the second quarter of 2024, the Company made the decision to exit its primary and urgent care service line based on a review of the cost and time that would be required to build the platform to scale.  The Company divested one of its two previously acquired primary and urgent care practices during the second quarter and divested of the second of its two acquired primary and urgent care practices subsequent to the end of the second quarter. The total loss on disposal of these two businesses was $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">10.9</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million, resulting from the loss on sale for one practice and marking the net assets to their fair value less costs to sell for the other practice.</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">During the second quarter of 2024, the Company experienced a triggering event, due to a sustained decline in its stock price and a market capitalization below the Company's book equity value. As the Company consists of only one reporting unit, and is publicly traded, management estimates the fair value of its reporting unit utilizing the Company&#8217;s market capitalization, multiplying the number of actual shares outstanding on June 30, 2024 by its stock price on June 30, 2024 and applying an additional premium to give effect to the Company&#8217;s best estimate of a control premium. With respect to the estimated control premium used in its analysis, the Company believes that it is reasonable to expect that a market participant would pay a premium to obtain a controlling interest in the Company. The Company considered information from the public markets for premiums on acquisitions in its industry and also considered other factors, such as the value that may arise from the ability to take advantage of synergies and other benefits that flow from control over another entity.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">This assessment resulted in a non-cash impairment charge of $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">130.0</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million, representing the amount by which the Company's book value exceeded its implied fair value, based on its market capitalization plus an estimated control premium. </span><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">Consideration was first given to other individual and group long-lived assets, and no impairment was considered necessary on such assets.</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Recognition of this non-cash charge against goodwill resulted in a tax benefit which generated an additional deferred tax asset of $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">24.2</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million </span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">that increased the Company's book value. An incremental non-cash charge was required to reduce the</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Company's </span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">book value to its previously determined fair value. </span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Accordingly, the Company recorded the incremental non-cash charge of $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">24.2</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million for a total non-cash charge of $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">154.2</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million. A </span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">% change in the control premium used would have impacted the non-cash impairment charge by approximately $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">6.5</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million.</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">  </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140198480154032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Payable and Accrued Expenses<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accounts Payable and Accrued Expenses</a></td>
<td class="text"><p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">7.            Accounts Payable and Accrued Expenses:	</span></p><div style="font-size:9pt;font-family:Times New Roman;"><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Accounts payable and accrued expenses consist of the following (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:60.048%;"></td>
        <td style="width:1.56%;"></td>
        <td style="width:18.416%;"></td>
        <td style="width:1.56%;"></td>
        <td style="width:18.416%;"></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">June 30, 2024</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accounts payable</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">$</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">32,000</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">$</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">34,588</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued salaries and incentive compensation</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">115,093</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">193,112</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued payroll taxes and benefits</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">28,034</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">36,545</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued professional liabilities</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">28,966</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">32,039</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued interest</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">8,258</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">8,262</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other accrued expenses</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">54,982</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">46,252</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">$</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">267,333</span></p></td>
        <td style="vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">$</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">350,798</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">The net decrease in accrued salaries and incentive compensation of $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">78.0</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million, from December 31, 2023 to June 30, 2024, </span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">is primarily due to the payment of performance-based incentive compensation, principally to the Company&#8217;s affiliated physicians, partially offset by performance-based incentive compensation accrued during the six months ended June 30, 2024. A majority of the Company&#8217;s payments for performance-based incentive compensation is paid annually during the first quarter.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 720<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483384/720-30-45-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140198476125440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Line of Credit and Long Term Debt<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_md_LineOfCreditAndLongTermDebtTextBlock', window );">Line of Credit and Long Term Debt</a></td>
<td class="text"><p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">8.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Arial;min-width:fit-content;">          </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Line of Credit and Long-Term Debt:</span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">On February 11, 2022, the Company issued $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">400.0</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million of </span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">5.375</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">% unsecured senior notes due 2030 (the &#8220;2030 Notes&#8221;).  The Company used the net proceeds from the issuance of the </span><span style="font-size:9pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">2030</span></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> Notes, together with $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">100.0</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million drawn under the Revolving Credit Line (as defined below), $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">250.0</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million of Term A Loan (as defined below) and approximately $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">308.0</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million of cash on hand, to redeem (the &#8220;Redemption&#8221;) the 2027 Notes, which had an outstanding principal balance of $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.0</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> billion, and to pay costs, fees and expenses associated with the Redemption and the Credit Agreement Amendment (as defined below).</span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Interest on the 2030 Notes accrues at the rate of </span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">5.375</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">% per annum, or $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">21.5</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million, and is </span><span style="font-size:9pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">payable semi-annually in arrears on February 15 and August 15, beginning on August 15, 2022</span></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">. The Company's obligations under the 2030 </span><span style="font-size:9pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Notes are guaranteed on an unsecured senior basis by the same subsidiaries and affiliated professional contractors that guarantee the Amended Credit Agreement (as defined below). The indenture under which the 2030 Notes are issued, among other things, limits the Company's ability to (1) incur liens and (2) enter into sale and lease-back transactions, and also limits the Company's ability to merge or dispose of all or substantially all of its assets, in all cases, subject to a number of customary exceptions</span></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">. Although the Company is not required to make mandatory redemption or sinking fund payments with respect to the 2030 Notes, upon the occurrence of a change in control, the Company may be required to repurchase the 2030 Notes at a purchase price equal to </span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">101</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">% of the aggregate principal amount of the 2030 Notes repurchased plus accrued and unpaid interest.</span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Also in connection with the Redemption, the Company amended its credit agreement (the &#8220;Credit Agreement&#8221;, and such amendment, the "Credit Agreement Amendment"), concurrently with the issuance of the 2030 Notes. The Credit Agreement Amendment, among other things, (i) refinanced the prior unsecured revolving credit facility with a $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">450</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million unsecured revolving credit facility, including a $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">37.5</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million sub-facility for the issuance of letters of credit (the &#8220;Revolving Credit Line&#8221;), and a $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">250</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million term A loan facility (&#8220;Term A Loan&#8221;) and (ii) removed JPMorgan Chase Bank, N.A., as the administrative agent under the Credit Agreement and appointed Bank of America, N.A. as the administrative agent for the lenders.</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">  </span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">The Credit Agreement, as amended by the Credit Agreement Amendment (the &#8220;Amended Credit Agreement&#8221;) matures on February 11, 2027 and is guaranteed on an unsecured basis by substantially all of the Company's subsidiaries and affiliated professional contractors. At the Company's option, borrowings under the Amended Credit Agreement bear interest at </span><span style="font-size:9pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">(i) the Alternate Base Rate (defined as the highest of (a) the prime rate as announced by Bank of America, N.A., (b) the Federal Funds Rate plus 0.50% and (c) Term Secured Overnight Financing Rate ("SOFR") for an interest period of one month plus 1.00% with a 1.00% floor) plus an applicable margin rate of 0.50% for the first two fiscal quarters after the date of the Credit Agreement Amendment, and thereafter at an applicable margin rate ranging from 0.125% to 0.750% based on the Company's consolidated net leverage ratio or (ii) Term SOFR rate (calculated as the Secured Overnight Financing Rate published on the applicable Reuters screen page plus a spread adjustment of 0.10%, 0.15% or 0.25% depending on if the Company selects a one-month, three-month or six-month interest period, respectively, for the applicable loan with a 0% floor), plus an applicable margin rate of 1.50% for the first two full fiscal quarters after the date of the Credit Agreement Amendment, and thereafter at an applicable margin rate ranging from 1.125% to 1.750% based on the Company's consolidated net leverage ratio. The Amended Credit Agreement also provides for other customary fees and charges, including an unused commitment fee with respect to the Revolving Credit Line ranging from 0.150% to 0.200% of the unused lending commitments under the Revolving Credit Line</span></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">, based on the Company's consolidated net leverage ratio.</span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">The Amended Credit Agreement contains customary covenants and restrictions, including covenants that require the Company to maintain a minimum interest coverage ratio, a maximum consolidated total consolidated net leverage ratio and to comply with laws, and restrictions on the ability to pay dividends, incur indebtedness or liens and make certain other distributions subject to baskets and exceptions, in each case, as specified therein. Failure to comply with these covenants would constitute an event of default under the Amended Credit Agreement, notwithstanding the ability of the Company to meet its debt service obligations. The Amended Credit Agreement includes various customary remedies for the lenders following an event of default, including the acceleration of repayment of outstanding amounts under the Amended Credit Agreement. In addition, the Company may increase the principal amount of the Revolving Credit Line or incur additional term loans under the Amended Credit Agreement in an aggregate principal amount such that on a pro forma basis after giving effect to such increase or additional term loans, the Company would be in compliance with the financial covenants, subject to the satisfaction of specified conditions and additional caps in the event that the Amended Credit Agreement is secured.</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">At June 30, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">, the Company had an outstanding principal balance on the Amended Credit Agreement of $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">221.9</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million, composed of the Term A Loan.  There was no outstanding balance under the Revolving Credit Line. The Company had $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">450.0</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million available on its Amended Credit Agreement at June 30, 2024.</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">At June 30, 2024, the Company had an outstanding principal balance of $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">400.0</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million on the 2030 Notes.</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_LineOfCreditAndLongTermDebtTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line Of Credit And Long Term Debt [Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_LineOfCreditAndLongTermDebtTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140198480116832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common and Common Equivalent Shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Common and Common Equivalent Shares</a></td>
<td class="text"><p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">9.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Arial;min-width:fit-content;">            </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Common and Common Equivalent Shares:</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Basic net income per common share is calculated by dividing net income by the weighted average number of common shares outstanding during the period. Diluted net income per common share is calculated by dividing net income by the weighted average number of common and potential common shares outstanding during the period. Potential common shares consist of outstanding restricted stock and stock options and is calculated using the treasury stock method.</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:9pt;font-family:Times New Roman;"><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">The calculation of shares used in the basic and diluted net income per common share calculation for the </span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">three and six months ended June 30, 2024 and 2023 is as follows (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:49.07%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.498%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.88%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.178%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:8.978%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.398%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Three Months Ended<br/>June 30,</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Six Months Ended<br/>June 30,</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted average number of common shares outstanding</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">83,332</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">82,399</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">83,074</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">82,033</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted average number of dilutive common share<br/>&#160;&#160;&#160;equivalents (a)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">265</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">344</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted average number of common and common<br/>&#160;&#160;&#160;equivalent shares outstanding</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">83,332</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">82,664</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">83,074</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">82,377</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Antidilutive securities (restricted stock and stock options) not included in the diluted net income per common share calculation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">916</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,338</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">661</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,358</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;">(a) </span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;">Due to a loss for the three and six months ended June 30, 2024, </span><span style="font-size:8.5pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.1</span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;"> million and </span><span style="font-size:8.5pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.3</span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;"> million incremental shares, respectively, are not included because the effect would be antidilutive.</span></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140198480154032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Incentive Plans and Stock Purchase Plans<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock Incentive Plans and Stock Purchase Plans</a></td>
<td class="text"><p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">10.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Arial;min-width:fit-content;">            </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Stock Incentive Plans and Stock Purchase Plans:</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s Amended and Restated 2008 Incentive Compensation Plan (the &#8220;Amended and Restated 2008 Incentive Plan&#8221;) provides for grants of stock options, stock appreciation rights, restricted stock, deferred stock, and other stock-related awards and performance awards that may be settled in cash, stock or other property.</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Under the Amended and Restated 2008 Incentive Plan, options to purchase shares of common stock may be granted at a price not less than the fair market value of the shares on the date of grant. The options must be exercised within </span><span style="font-size:9pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">10 years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> from the date of grant and generally become exercisable on a pro rata basis over a </span><span style="font-size:9pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">three-year</span></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> period from the date of grant. The Company issues new shares of its common stock upon exercise of its stock options. Restricted stock awards generally vest over periods of </span><span style="font-size:9pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">three years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> upon the fulfillment of specified service-based conditions and in certain instances performance-based conditions. Deferred stock awards generally vest upon the satisfaction of specified performance-based conditions and service-based conditions. The Company recognizes compensation expense related to its restricted stock and deferred stock awards ratably over the corresponding vesting periods. During the </span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">six months ended June 30, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">, the Company granted </span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.4</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million shares of restricted stock to its employees and non-employee directors under the Amended and Restated 2008 Incentive Plan. At June 30, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">, the Company had </span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">6.3</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million shares available for future grants and awards under the Amended and Restated 2008 Incentive Plan.</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">   </span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Under the Company&#8217;s Amended and Restated 1996 Non-Qualified Employee Stock Purchase Plan, as amended (the &#8220;ESPP&#8221;), employees are permitted to purchase the Company's common stock at </span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">85</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">% of market value on January 1st, April 1st, July 1st and October 1st of each year. Under the Company&#8217;s 2015 Non-Qualified Stock Purchase Plan (the &#8220;SPP&#8221;), certain eligible non-employee service providers are permitted to purchase the Company&#8217;s common stock at </span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">90</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">% of market value on January 1st, April 1st, July 1st and October 1st of each year.</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">The Company recognizes stock-based compensation expense for the discount received by participating employees and non-employee service providers. During the six months ended June 30, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">, approximately </span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.2</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million shares were issued under the ESPP. At June 30, 2024, the Company had approximately </span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.8</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million shares reserved for issuance under the ESPP. At June 30, 2024, the Company had approximately </span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">61,000</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> shares in the aggregate reserved for issuance under the SPP.  </span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">No</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> shares have been issued under the SPP since 2020.</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">During the three and six months ended June 30, 2024 and 2023, the Company recognized stock-based compensation expense of $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.0</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">4.9</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">3.1</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">6.1</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">  </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140198480125200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock Repurchase Programs<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_md_CommonStockRepurchasesTextBlock', window );">Common Stock Repurchase Programs</a></td>
<td class="text"><p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">11.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Arial;min-width:fit-content;">            </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Common Stock Repurchase Programs:</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">In July 2013, the Company&#8217;s Board of Directors authorized the repurchase of shares of the Company&#8217;s common stock up to an amount sufficient to offset the dilutive impact from the issuance of shares under the Company&#8217;s equity compensation programs. The share repurchase program allows the Company to make open market purchases from time-to-time based on general economic and market conditions and trading restrictions. The repurchase program also allows for the repurchase of shares of the Company&#8217;s common stock to offset the dilutive impact from the issuance of shares, if any, related to the Company&#8217;s acquisition program. </span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">No</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> shares were purchased under this program during the </span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">six months ended June 30, 2024.</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">In August 2018, the Company announced that its Board of Directors had authorized the repurchase of up to $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">500.0</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million of the Company&#8217;s common stock in addition to its existing share repurchase program, of which $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">4.6</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million remained available for repurchase as of December 31, 2023. Under this share repurchase program, during the six months ended June 30, 2024, the Company purchased a nominal number of shares of its common stock for $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.9</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million representing shares withheld to satisfy minimum statutory withholding obligations in connection with the vesting of restricted stock, resulting in $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">3.7</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million remaining available for repurchase under this authorization as of June 30, 2024.</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">The Company intends to utilize various methods to effect any future share repurchases, including, among others, open market purchases and accelerated share repurchase programs. The amount and timing of repurchases will depend upon several factors, including general economic and market conditions and trading restrictions.</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_CommonStockRepurchasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Entire disclosure of common stock repurchases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_CommonStockRepurchasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140198480010128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">12.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Arial;min-width:fit-content;">            </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Commitments and Contingencies:	</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">The Company expects that audits, inquiries and investigations from government authorities and agencies will occur in the ordinary course of business. Such audits, inquiries and investigations and their ultimate resolutions, individually or in the aggregate, could have a material adverse effect on the Company's business, financial condition, results of operations, cash flows and the trading price of its securities. The Company has not included an accrual for these matters as of June 30, 2024 in its Consolidated Financial Statements, as the variables affecting any potential eventual liability depend on the currently unknown facts and circumstances that arise out of, and are specific to, any particular future audit, inquiry and investigation and cannot be reasonably estimated at this time.</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">In the ordinary course of business, the Company becomes involved in pending and threatened legal actions and proceedings, most of which involve claims of medical malpractice related to medical services provided by the Company's affiliated physicians. The Company's contracts with hospitals generally require the Company to indemnify them and their affiliates for losses resulting from the negligence of the Company's affiliated physicians. The Company may also become subject to other lawsuits which could involve large claims and significant costs. The Company believes, based upon a review of pending actions and proceedings, that the outcome of such legal actions and proceedings will not have a material adverse effect on its business, financial condition, results of operations, cash flows and the trading price of its securities. The outcome of such actions and proceedings, however, cannot be predicted with certainty and an unfavorable resolution of one or more of them could have a material adverse effect on the Company's business, financial condition, results of operations, cash flows and the trading price of its securities.</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Although the Company currently maintains liability insurance coverage intended to cover professional liability and certain other claims, the Company cannot assure that its insurance coverage will be adequate to cover liabilities arising out of claims asserted against it in the future where the outcomes of such claims are unfavorable. With respect to professional liability risk, the Company generally self-insures a portion of this risk through its wholly owned captive insurance subsidiary. Liabilities in excess of the Company's insurance coverage, including coverage for professional liability and certain other claims, could have a material adverse effect on the Company's business, financial condition, results of operations, cash flows and the trading price of its securities.</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140198568905520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash Equivalents and Investments (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Schedule of Investments</a></td>
<td class="text"><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Investments held are all classified as current and at </span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">June 30, 2024 and December 31, 2023 are summarized as follows (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:72.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:56.529%;"></td>
        <td style="width:1.42%;"></td>
        <td style="width:1%;"></td>
        <td style="width:18.316%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.42%;"></td>
        <td style="width:1%;"></td>
        <td style="width:18.316%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">June 30, 2024</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Corporate securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">55,777</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">57,878</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. Treasury securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">31,456</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">22,674</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Municipal debt securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">17,377</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">14,649</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Federal home loan securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">6,503</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">5,670</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Certificates of deposit</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">2,682</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">3,614</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">113,795</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">104,485</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140198480103680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis</a></td>
<td class="text"><p style="text-indent:6.667%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">The following table presents information about the Company&#8217;s financial instruments that are accounted for at fair value on a recurring basis at </span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">June 30, 2024 and December 31, 2023 (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.54%;"></td>
        <td style="width:1.32%;"></td>
        <td style="width:13%;"></td>
        <td style="width:1.26%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.54%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.26%;"></td>
        <td style="width:1%;"></td>
        <td style="width:15.08%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair Value<br/>Category</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">June 30, 2024</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Assets:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Money market funds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Level 1</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">397</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">2,814</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Short-term investments</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Level 2</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">113,795</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">104,485</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Mutual Funds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Level 1</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">19,002</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">17,687</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_md_FinancialInstrumentsMeasuredAtCarryingAmountTableTextBlock', window );">Financial Instruments Measured At Carrying Amount</a></td>
<td class="text"><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">The following table presents information about the Company&#8217;s financial instruments that are not carried at fair value at </span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">June 30, 2024 and December 31, 2023 (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.72%;"></td>
        <td style="width:1.08%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.24%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.08%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.24%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.08%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.24%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.08%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.24%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">June 30, 2024</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Carrying<br/>Amount</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair<br/>Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Carrying<br/>Amount</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair<br/>Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Liabilities:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2030 Notes</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">400,000</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">353,760</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">400,000</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">357,000</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_FinancialInstrumentsMeasuredAtCarryingAmountTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of financial instruments measured at carrying amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_FinancialInstrumentsMeasuredAtCarryingAmountTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140198480091984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Receivable and Net Revenue (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TextBlockAbstract', window );"><strong>Text Block [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock', window );">Schedule of Accounts Receivable, Net</a></td>
<td class="text"><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Accounts receivable, net consists of the following (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:93.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:63.441%;"></td>
        <td style="width:2.151%;"></td>
        <td style="width:1%;"></td>
        <td style="width:14.128%;"></td>
        <td style="width:1%;"></td>
        <td style="width:2.151%;"></td>
        <td style="width:1%;"></td>
        <td style="width:14.128%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">June 30, 2024</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Gross accounts receivable</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,490,865</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,379,213</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Allowance for contractual adjustments and uncollectibles</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,216,701</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,106,900</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">274,164</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">272,313</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Schedule of Net Revenue</a></td>
<td class="text"><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes the Company&#8217;s net revenue by category (in thousands):</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:29.984%;"></td>
        <td style="width:1.111%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.136000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:2.223%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.113999999999999%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.623%;"></td>
        <td style="width:1%;"></td>
        <td style="width:14.914%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.623%;"></td>
        <td style="width:1%;"></td>
        <td style="width:14.27%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Three Months Ended<br/>June 30,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Six Months Ended<br/>June 30,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net patient service revenue</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">432,847</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">430,383</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">854,678</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">853,567</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Hospital contract administrative fees</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">70,913</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">69,585</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">142,716</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">135,574</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other revenue</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">536</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">609</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">2,003</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">2,444</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">504,296</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">500,577</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">999,397</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">991,585</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock', window );">Schedule of Percentage of Net Revenue</a></td>
<td class="text"><p style="margin-left:4.533%;text-indent:6.983%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">The approximate percentage of net patient service revenue by type of payor was as follows:</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:91.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:36.233%;"></td>
        <td style="width:1.3%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.197%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.82%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.198%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.578%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.677999999999999%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Three Months Ended<br/>June 30,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Six Months Ended<br/>June 30,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Contracted managed care</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">71</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">68</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">71</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">67</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Government</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">23</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">25</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">24</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">25</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other third-parties</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">4</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">5</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">3</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">6</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Private-pay patients</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">2</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">2</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">2</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">2</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">100</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">100</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">100</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">100</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-16<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-21<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140198474658816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Payable and Accrued Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Schedule of Accounts Payable and Accrued Expenses</a></td>
<td class="text"><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Accounts payable and accrued expenses consist of the following (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:60.048%;"></td>
        <td style="width:1.56%;"></td>
        <td style="width:18.416%;"></td>
        <td style="width:1.56%;"></td>
        <td style="width:18.416%;"></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">June 30, 2024</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accounts payable</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">$</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">32,000</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">$</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">34,588</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued salaries and incentive compensation</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">115,093</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">193,112</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued payroll taxes and benefits</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">28,034</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">36,545</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued professional liabilities</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">28,966</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">32,039</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued interest</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">8,258</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">8,262</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other accrued expenses</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">54,982</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">46,252</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">$</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">267,333</span></p></td>
        <td style="vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">$</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">350,798</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140198478256240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common and Common Equivalent Shares (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock', window );">Schedule of Calculation of Shares Used in Basic and Diluted Net Income Per Share</a></td>
<td class="text"><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">The calculation of shares used in the basic and diluted net income per common share calculation for the </span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">three and six months ended June 30, 2024 and 2023 is as follows (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:49.07%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.498%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.88%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.178%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:8.978%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.398%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Three Months Ended<br/>June 30,</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Six Months Ended<br/>June 30,</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted average number of common shares outstanding</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">83,332</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">82,399</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">83,074</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">82,033</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted average number of dilutive common share<br/>&#160;&#160;&#160;equivalents (a)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">265</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">344</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted average number of common and common<br/>&#160;&#160;&#160;equivalent shares outstanding</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">83,332</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">82,664</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">83,074</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">82,377</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Antidilutive securities (restricted stock and stock options) not included in the diluted net income per common share calculation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">916</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,338</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">661</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,358</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;">(a) </span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;">Due to a loss for the three and six months ended June 30, 2024, </span><span style="font-size:8.5pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.1</span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;"> million and </span><span style="font-size:8.5pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.3</span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;"> million incremental shares, respectively, are not included because the effect would be antidilutive.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140198480128912">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Basis of Presentation - Additional Information (Detail)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=md_UnnamedCorporateJointVentureOneMember', window );">Unnamed Corporate Joint Venture One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_md_BasisOfPresentationLineItems', window );"><strong>Basis Of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity method ownership percentage in joint venture</a></td>
<td class="nump">37.50%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_BasisOfPresentationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Basis Of Presentation Line Items</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_BasisOfPresentationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=md_UnnamedCorporateJointVentureOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=md_UnnamedCorporateJointVentureOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140198480002336">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash Equivalents and Investments - Additional Information (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashEquivalentsMember', window );">Cash Equivalents [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_md_CashEquivalentsAndInvestmentsLineItems', window );"><strong>Cash Equivalents And Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MoneyMarketFundsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">$ 0.4<span></span>
</td>
<td class="nump">$ 2.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_CashEquivalentsAndInvestmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash Equivalents And Investments Line Items</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_CashEquivalentsAndInvestmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MoneyMarketFundsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Investment in short-term money-market instruments (such as commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and so forth) which are highly liquid (that is, readily convertible to known amounts of cash) and so near their maturity that they present an insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify as cash equivalents by definition. Original maturity means an original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MoneyMarketFundsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140198475259920">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash Equivalents and Investments - Schedule of Investments (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale Securities</a></td>
<td class="nump">$ 113,795<span></span>
</td>
<td class="nump">$ 104,485<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_AllOtherCorporateBondsMember', window );">Corporate securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale Securities</a></td>
<td class="nump">55,777<span></span>
</td>
<td class="nump">57,878<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. Treasury securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale Securities</a></td>
<td class="nump">31,456<span></span>
</td>
<td class="nump">22,674<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USStatesAndPoliticalSubdivisionsMember', window );">Municipal Debt Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale Securities</a></td>
<td class="nump">17,377<span></span>
</td>
<td class="nump">14,649<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember', window );">Federal Home Loan Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale Securities</a></td>
<td class="nump">6,503<span></span>
</td>
<td class="nump">5,670<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of Deposit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale Securities</a></td>
<td class="nump">$ 2,682<span></span>
</td>
<td class="nump">$ 3,614<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_AllOtherCorporateBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_AllOtherCorporateBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USStatesAndPoliticalSubdivisionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USStatesAndPoliticalSubdivisionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140198584405120">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Schedule of fair value on a recurring basis (Details) - Fair Value, Recurring [Member] - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_md_MoneyMarketFundsFairValueDisclosure', window );">Money market funds</a></td>
<td class="nump">$ 397<span></span>
</td>
<td class="nump">$ 2,814<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_md_MutualFundsFairValueDisclosure', window );">Mutual funds</a></td>
<td class="nump">19,002<span></span>
</td>
<td class="nump">17,687<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Short-term investments</a></td>
<td class="nump">$ 113,795<span></span>
</td>
<td class="nump">$ 104,485<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_MoneyMarketFundsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of money market funds.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_MoneyMarketFundsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_MutualFundsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Mutual funds fair value disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_MutualFundsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140198480028080">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Schedule of financial instruments that are not carried at fair value (Details) - 2030 Notes [Member] - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes Payable</a></td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Notes Payable Fair Value Disclosure</a></td>
<td class="nump">$ 353,760<span></span>
</td>
<td class="nump">$ 357,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of notes payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=md_TwoZeroThreeZeroMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=md_TwoZeroThreeZeroMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140198480052288">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accounts Receivable and Net Revenue - Schedule of Accounts Receivable, Net (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesAbstract', window );"><strong>Receivables [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableGrossCurrent', window );">Gross accounts receivable</a></td>
<td class="nump">$ 1,490,865<span></span>
</td>
<td class="nump">$ 1,379,213<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Allowance for contractual adjustments and uncollectibles</a></td>
<td class="num">(1,216,701)<span></span>
</td>
<td class="num">(1,106,900)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">$ 274,164<span></span>
</td>
<td class="nump">$ 272,313<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableGrossCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableGrossCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479344/326-20-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140198476241616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Receivable and Net Revenue - Schedule of Net Revenue (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueAbstract', window );"><strong>Disaggregation of Revenue [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Net revenue</a></td>
<td class="nump">$ 504,296<span></span>
</td>
<td class="nump">$ 500,577<span></span>
</td>
<td class="nump">$ 999,397<span></span>
</td>
<td class="nump">$ 991,585<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_HealthCarePatientServiceMember', window );">Net patient service revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueAbstract', window );"><strong>Disaggregation of Revenue [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Net revenue</a></td>
<td class="nump">432,847<span></span>
</td>
<td class="nump">430,383<span></span>
</td>
<td class="nump">854,678<span></span>
</td>
<td class="nump">853,567<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=md_HospitalsContractsMember', window );">Hospital contract administrative fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueAbstract', window );"><strong>Disaggregation of Revenue [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Net revenue</a></td>
<td class="nump">70,913<span></span>
</td>
<td class="nump">69,585<span></span>
</td>
<td class="nump">142,716<span></span>
</td>
<td class="nump">135,574<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember', window );">Other revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueAbstract', window );"><strong>Disaggregation of Revenue [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Net revenue</a></td>
<td class="nump">$ 536<span></span>
</td>
<td class="nump">$ 609<span></span>
</td>
<td class="nump">$ 2,003<span></span>
</td>
<td class="nump">$ 2,444<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_HealthCarePatientServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_HealthCarePatientServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=md_HospitalsContractsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=md_HospitalsContractsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140198477311296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Receivable and Net Revenue - Schedule of Net Patient Service Revenue by Type of Payor (Detail)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_md_PercentageOfNetPatientServiceRevenueByTypeOfPayor', window );">Percentage of net patient service revenue</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationRevenueSourcesAxis=md_ContractedManagedCareMember', window );">Contracted Managed Care</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_md_PercentageOfNetPatientServiceRevenueByTypeOfPayor', window );">Percentage of net patient service revenue</a></td>
<td class="nump">71.00%<span></span>
</td>
<td class="nump">68.00%<span></span>
</td>
<td class="nump">71.00%<span></span>
</td>
<td class="nump">67.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationRevenueSourcesAxis=us-gaap_GovernmentMember', window );">Government</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_md_PercentageOfNetPatientServiceRevenueByTypeOfPayor', window );">Percentage of net patient service revenue</a></td>
<td class="nump">23.00%<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="nump">24.00%<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationRevenueSourcesAxis=us-gaap_ThirdPartyPayorMember', window );">Other Third-Parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_md_PercentageOfNetPatientServiceRevenueByTypeOfPayor', window );">Percentage of net patient service revenue</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationRevenueSourcesAxis=us-gaap_SelfPayMember', window );">Private-Pay Patients</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_md_PercentageOfNetPatientServiceRevenueByTypeOfPayor', window );">Percentage of net patient service revenue</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_PercentageOfNetPatientServiceRevenueByTypeOfPayor">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of net patient service revenue by type payor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_PercentageOfNetPatientServiceRevenueByTypeOfPayor</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HealthCareOrganizationRevenueSourcesAxis=md_ContractedManagedCareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HealthCareOrganizationRevenueSourcesAxis=md_ContractedManagedCareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HealthCareOrganizationRevenueSourcesAxis=us-gaap_GovernmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HealthCareOrganizationRevenueSourcesAxis=us-gaap_GovernmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HealthCareOrganizationRevenueSourcesAxis=us-gaap_ThirdPartyPayorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HealthCareOrganizationRevenueSourcesAxis=us-gaap_ThirdPartyPayorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HealthCareOrganizationRevenueSourcesAxis=us-gaap_SelfPayMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HealthCareOrganizationRevenueSourcesAxis=us-gaap_SelfPayMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140198478305936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Combinations - Additional information (Detail)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($) </div>
<div>Number</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount', window );">Goodwill</a></td>
<td class="nump">$ 9.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Other intangible assets</a></td>
<td class="nump">0.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment', window );">Fixed assets</a></td>
<td class="nump">$ 0.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=md_MaternalFetalMedicinePracticeMember', window );">Maternal Fetal Medicine Practice [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_md_NumberOfMaternalFetalMedicinePracticesAcquired', window );">Number of Maternal Fetal Medicine Practices Acquired | Number</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Business acquisition total consideration</a></td>
<td class="nump">$ 9.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Business acquisition consideration paid in cash</a></td>
<td class="nump">6.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets', window );">Business combination consideration identifiable as current and long term liabilities</a></td>
<td class="nump">$ 3.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_NumberOfMaternalFetalMedicinePracticesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of maternal fetal medicine practices acquired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_NumberOfMaternalFetalMedicinePracticesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of goodwill arising from a business combination that is expected to be deductible for tax purposes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 8<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479637/805-30-30-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 7<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479637/805-30-30-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable intangible assets recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-37<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of property, plant, and equipment recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-37<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=md_MaternalFetalMedicinePracticeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=md_MaternalFetalMedicinePracticeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140198477559712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Long-Lived Asset Impairments (Additional Information) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Fixed assets impairments</a></td>
<td class="nump">$ 20,112<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 20,112<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">Intangible assets impairments</a></td>
<td class="nump">7,679<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">7,679<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseImpairmentLoss', window );">Operating lease right-of-use asset impairments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets', window );">Additional Deferred Tax Assets</a></td>
<td class="nump">24,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfBusiness', window );">Loss on disposal of businesses</a></td>
<td class="nump">10,873<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">10,873<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_md_NonCashCharge', window );">Non cash charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">154,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_md_IncrementalNonCashCharge', window );">Incremental Non Cash Charge</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment</a></td>
<td class="nump">$ 154,243<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 154,243<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_md_ChangeInRateOfControlPremium', window );">Change in Rate of Control Premium</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_md_ChangeInNonCashImpairmentCharges', window );">Intangible asset impairments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_md_GoodWillImpairmentLossExcludingDeferredTaxAssetsCharge', window );">Good will Impairment Loss excluding Deferred Tax Assets Charge</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 130,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_ChangeInNonCashImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in Non Cash Impairment Charges</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_ChangeInNonCashImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_ChangeInRateOfControlPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in Rate of Control Premium</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_ChangeInRateOfControlPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_GoodWillImpairmentLossExcludingDeferredTaxAssetsCharge">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Good will Impairment Loss excluding Deferred Tax Assets Charge</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_GoodWillImpairmentLossExcludingDeferredTaxAssetsCharge</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_IncrementalNonCashCharge">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Incremental Non Cash Charge</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_IncrementalNonCashCharge</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_NonCashCharge">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>non-cash charge</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_NonCashCharge</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from sale and disposal of integrated set of activities and assets capable of being conducted and managed for purpose of providing return in form of dividend, lower cost, or other economic benefit to investor, owner, member and participant.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss from asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482598/350-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-2<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from impairment of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479365/842-20-25-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140198475360000">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accounts Payable and Accrued Expenses - Schedule of Accounts Payable and Accrued Expenses (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">$ 32,000<span></span>
</td>
<td class="nump">$ 34,588<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedSalariesCurrent', window );">Accrued salaries and incentive compensation</a></td>
<td class="nump">115,093<span></span>
</td>
<td class="nump">193,112<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_md_AccruedPayrollTaxesAndBenefitsCurrent', window );">Accrued payroll taxes and benefits</a></td>
<td class="nump">28,034<span></span>
</td>
<td class="nump">36,545<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MalpracticeLossContingencyAccrualUndiscountedCurrent', window );">Accrued professional liabilities</a></td>
<td class="nump">28,966<span></span>
</td>
<td class="nump">32,039<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Accrued interest</a></td>
<td class="nump">8,258<span></span>
</td>
<td class="nump">8,262<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other accrued expenses</a></td>
<td class="nump">54,982<span></span>
</td>
<td class="nump">46,252<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued expenses, total</a></td>
<td class="nump">$ 267,333<span></span>
</td>
<td class="nump">$ 350,798<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_AccruedPayrollTaxesAndBenefitsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued payroll taxes and benefits current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_AccruedPayrollTaxesAndBenefitsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedSalariesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedSalariesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MalpracticeLossContingencyAccrualUndiscountedCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the current portion of the accrued liability on an undiscounted basis for malpractice claims (including general and professional liability).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MalpracticeLossContingencyAccrualUndiscountedCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140198478491792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Payable and Accrued Expenses - Additional Information (Detail)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_md_IncreaseDecreaseInAccruedSalariesAndBonuses', window );">Net decrease in accrued salaries and bonuses</a></td>
<td class="nump">$ 78.0<span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_IncreaseDecreaseInAccruedSalariesAndBonuses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) in accrued salaries and bonuses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_IncreaseDecreaseInAccruedSalariesAndBonuses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140198476823616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Line of Credit and Long Term Debt (Additional Information) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 11, 2022</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.375%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFrequencyOfPeriodicPayment', window );">Debt Instrument, Frequency of Periodic Payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">payable semi-annually in arrears on February 15 and August 15, beginning on August 15, 2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentDescription', window );">Debt Instrument, Description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Notes are guaranteed on an unsecured senior basis by the same subsidiaries and affiliated professional contractors that guarantee the Amended Credit Agreement (as defined below). The indenture under which the 2030 Notes are issued, among other things, limits the Company's ability to (1) incur liens and (2) enter into sale and lease-back transactions, and also limits the Company's ability to merge or dispose of all or substantially all of its assets, in all cases, subject to a number of customary exceptions<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_md_PurchasePrice', window );">Purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">101.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromLinesOfCredit', window );">Borrowings on revolving credit line</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 235,500<span></span>
</td>
<td class="nump">$ 421,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_LongTermDebtMember', window );">Long-Term Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnsecuredLongTermDebt', window );">Proceeds from issuance of unsecured debt</a></td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash on hand</a></td>
<td class="nump">308,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=md_CreditAgreementMember', window );">Credit Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity', window );">Line of Credit facility, available balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">450,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">221,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfUnsecuredDebt', window );">Proceeds from issuance of unsecured debt</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromLinesOfCredit', window );">Borrowings on revolving credit line</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility [Member] | Long-Term Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnsecuredLongTermDebt', window );">Proceeds from issuance of unsecured debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility [Member] | Credit Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnsecuredDebt', window );">Unsecured note issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 450,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DescriptionOfInterestRateRiskExposure', window );">Interest Rate, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">(i) the Alternate Base Rate (defined as the highest of (a) the prime rate as announced by Bank of America, N.A., (b) the Federal Funds Rate plus 0.50% and (c) Term Secured Overnight Financing Rate ("SOFR") for an interest period of one month plus 1.00% with a 1.00% floor) plus an applicable margin rate of 0.50% for the first two fiscal quarters after the date of the Credit Agreement Amendment, and thereafter at an applicable margin rate ranging from 0.125% to 0.750% based on the Company's consolidated net leverage ratio or (ii) Term SOFR rate (calculated as the Secured Overnight Financing Rate published on the applicable Reuters screen page plus a spread adjustment of 0.10%, 0.15% or 0.25% depending on if the Company selects a one-month, three-month or six-month interest period, respectively, for the applicable loan with a 0% floor), plus an applicable margin rate of 1.50% for the first two full fiscal quarters after the date of the Credit Agreement Amendment, and thereafter at an applicable margin rate ranging from 1.125% to 1.750% based on the Company's consolidated net leverage ratio. The Amended Credit Agreement also provides for other customary fees and charges, including an unused commitment fee with respect to the Revolving Credit Line ranging from 0.150% to 0.200% of the unused lending commitments under the Revolving Credit Line<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=md_FivePointThreeSevenFivePercentUnsecuredSeniorNotesDueTwoThousandThirtyMember', window );">5.375% Unsecured Senior Notes Due 2030 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeniorNotes', window );">Senior notes</a></td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument interest rate</a></td>
<td class="nump">5.375%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_md_DebtInstrumentMaturityYear', window );">Debt instrument, maturity year</a></td>
<td class="text">2030<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentInterest', window );">Interest accrued periodically</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=md_SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMember', window );">2027 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long term debt</a></td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_DebtInstrumentMaturityYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt instrument maturity year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_DebtInstrumentMaturityYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_PurchasePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_PurchasePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477796/946-210-45-21<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 210<br> -Topic 946<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477796/946-210-45-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Identification of the lender and information about a contractual promise to repay a short-term or long-term obligation, which includes borrowings under lines of credit, notes payable, commercial paper, bonds payable, debentures, and other contractual obligations for payment. This may include rationale for entering into the arrangement, significant terms of the arrangement, which may include amount, repayment terms, priority, collateral required, debt covenants, borrowing capacity, call features, participation rights, conversion provisions, sinking-fund requirements, voting rights, basis for conversion if convertible and remarketing provisions. The description may be provided for individual debt instruments, rational groupings of debt instruments, or by debt in total.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477734/942-470-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFrequencyOfPeriodicPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the frequency of periodic payments (monthly, quarterly, annual).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477734/942-470-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFrequencyOfPeriodicPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentPeriodicPaymentInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the required periodic payments applied to interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentPeriodicPaymentInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DescriptionOfInterestRateRiskExposure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the sources of interest rate risk exposure faced by the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 815<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-1A<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-1B<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DescriptionOfInterestRateRiskExposure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfUnsecuredDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of long-term debt that is not secured by collateral. Excludes proceeds from tax exempt unsecured debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfUnsecuredDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeniorNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying value as of the balance sheet date of Notes with the highest claim on the assets of the issuer in case of bankruptcy or liquidation (with maturities initially due after one year or beyond the operating cycle if longer). Senior note holders are paid off in full before any payments are made to junior note holders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeniorNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnsecuredDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying value as of the balance sheet date of uncollateralized debt obligations (with maturities initially due after one year or beyond the operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnsecuredDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnsecuredLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of uncollateralized debt obligation (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnsecuredLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_LongTermDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_LongTermDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=md_CreditAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=md_CreditAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=md_FivePointThreeSevenFivePercentUnsecuredSeniorNotesDueTwoThousandThirtyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=md_FivePointThreeSevenFivePercentUnsecuredSeniorNotesDueTwoThousandThirtyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=md_SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=md_SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140198571578576">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Common and Common Equivalent Shares - Schedule of Calculation of Shares Used in Basic and Diluted Net Income Per Share (Detail) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of common shares outstanding</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">83,332,000<span></span>
</td>
<td class="nump">82,399,000<span></span>
</td>
<td class="nump">83,074,000<span></span>
</td>
<td class="nump">82,033,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Weighted average number of dilutive common share equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">265,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">344,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average number of common and common equivalent shares outstanding</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">83,332,000<span></span>
</td>
<td class="nump">82,664,000<span></span>
</td>
<td class="nump">83,074,000<span></span>
</td>
<td class="nump">82,377,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities (restricted stock and stock options) not included in the diluted net income per common share calculation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">916,000<span></span>
</td>
<td class="nump">1,338,000<span></span>
</td>
<td class="nump">661,000<span></span>
</td>
<td class="nump">1,358,000<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;">Due to a loss for the three and six months ended June 30, 2024, </span><span style="font-size:8.5pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.1</span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;"> million and </span><span style="font-size:8.5pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.3</span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;"> million incremental shares, respectively, are not included because the effect would be antidilutive.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480454/718-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-22<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-28A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140198480116080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common and Common Equivalent Shares - Schedule of Calculation of Shares Used in Basic and Diluted Net Income Per Share (Parenthetical) (Details) - shares<br> shares in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_md_IncrementalSharesNotIncludedDueToAntiDilutiveEffect', window );">Incremental shares not Included due to anti dilutive effect</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_IncrementalSharesNotIncludedDueToAntiDilutiveEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Incremental Shares Not Included Due To Anti dilutive Effect</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_IncrementalSharesNotIncludedDueToAntiDilutiveEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140198476824816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Incentive Plans and Stock Purchase Plans - Additional Information (Detail) - USD ($)<br> shares in Thousands, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 2.0<span></span>
</td>
<td class="nump">$ 4.9<span></span>
</td>
<td class="nump">$ 3.1<span></span>
</td>
<td class="nump">$ 6.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Aggregate number Shares issued under Stock Purchase Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Vesting period of options, maximum years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanMember', window );">1996 Non-Qualified Employee Stock Purchase Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Aggregate number Shares issued under Stock Purchase Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock, reserved for issuance</a></td>
<td class="nump">61,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=md_TwoThousandFifteenNonQualifiedStockPurchasePlanMember', window );">2015 Non-Qualified Stock Purchase Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Percentage of market value of common stock at which employees are permitted to purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=md_AmendedAndRestatedTwoThousandEightPlanMember', window );">Amended and Restated 2008 Plan [Member] | Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for future grants and awards under Stock Incentive Plans</a></td>
<td class="nump">6,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=md_AmendedAndRestatedTwoThousandEightPlanMember', window );">Amended and Restated 2008 Plan [Member] | Restricted Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember', window );">1996 Non-Qualified Employee Stock Purchase Plan and 2015 Non-Qualified Stock Purchase Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Percentage of market value of common stock at which employees are permitted to purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock, reserved for issuance</a></td>
<td class="nump">1,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=md_TwoThousandFifteenNonQualifiedStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=md_TwoThousandFifteenNonQualifiedStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=md_AmendedAndRestatedTwoThousandEightPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=md_AmendedAndRestatedTwoThousandEightPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140198472678160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock Repurchase Programs - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Aug. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_md_CommonStockLineItems', window );"><strong>Common Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchased common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StockRepurchaseProgramAuthorizedAmount1', window );">Common stock authorized for repurchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1', window );">Company's Common stock repurchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Payments for repurchase of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 898<span></span>
</td>
<td class="nump">$ 786<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_md_CommonStockLineItems', window );"><strong>Common Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchased common stock, shares</a></td>
<td class="num">(2,000)<span></span>
</td>
<td class="num">(97,000)<span></span>
</td>
<td class="num">(1,000)<span></span>
</td>
<td class="num">(49,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Payments for repurchase of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_md_CommonStockLineItems', window );"><strong>Common Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1', window );">Company's Common stock repurchased</a></td>
<td class="nump">$ 3,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_CommonStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common Stock [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_CommonStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StockRepurchaseProgramAuthorizedAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount authorized for purchase of share under share repurchase plan. Includes, but is not limited to, repurchase of stock and unit of ownership.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481520/505-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StockRepurchaseProgramAuthorizedAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount remaining authorized for purchase of share under share repurchase plan. Includes, but is not limited to, repurchase of stock and unit of ownership.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>52
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M2L:R,IP)F"FBJZ*@ZL\U<+F>>*'W/'#'EKFQ WXR+ND2YF#NRYG"GM^X9*P
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MQ7OLPJJ<0>7&R(UKLDMIL&6[989C&Y15P/.5E&:_L0;J/P+Q'U!+ P04
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M0!.AZ0.M# *&&P1/<<%P2.>%#"CV9\"MM*19.2F:H$+3253V !ML#QS?A,5
M\@![($Z"S'KSC2'V   FMZ P8]:<@?R!(#;] 2@L8#&+3KP;!E/^ '/V!\X/
M%:D_P$!_ #Q^D?H#I&B""DVG4?D#;-"]_X/L'0;<I0\98<PN[@-7N@T&&F%
M'&2$06&8$<:4:F>X:G^*$89#.E_HP-/SL!%&FI>3H@DJ-/W=>Y2FCW%-/\@(
MBX''W .6RLO2?(\>2I$](T7CI&B""DVG31D ,6X /.4X%=NJW.*/M/I.BL9)
MT005FLZ?DO?QX/O^C^MDX/$@MN_GG_@)L_87("Z-S8)B;,MY>9)*?+-4R('
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M"2HTG4OE0B3TM?O$]@V"+#8?8\<3NYX8!^7DI#D%%9I.C7(6$KK:?0*)=]-
MP_,Y,S(@)2=-*:C0=$*4CY'0U_AQ2.<%#ZCQ0^L=J8E!BB:HT'0.CSXJ8'")
M_ZS;FMBE>]"8!N)L8QH(@HUI(! RIJ$PS)A.E*N0.)?XSP\5:8D_ 4K\L#%-
MFI>3H@DJM$<:QT<?G-5]D-K[O+XK-XVW*FXEO/]Z(D>K?OQLLL<?VFK;?Y;6
MYZIMJW7_[;+(I<KM N3?;ZNJ_?Y#]_%<AT^(N_X_4$L#!!0    (  DX!EFP
M071!R0<  %PB   8    >&PO=V]R:W-H965T<R]S:&5E=#<N>&ULK9IM;]LX
M$L>_BN!;'%J@KD52C]G$0.)>]W:Q#T%SO7U-2[3-JR1Z13E)[]/O4)(E6WQP
M N1-8LE#ZC\<<GX<6M=/HOXF=XPUWG-95/)FMFN:_=5B(;,=*ZG\*/:L@F\V
MHBYI Y?U=B'W-:-YVZ@L%MCWHT5)>35;7K?W[NOEM3@T!:_8?>W)0UG2^OL=
M*\33S0S-CC>^\.VN43<6R^L]W;('UGS=W]=PM1AZR7G)*LE%Y=5L<S.[15>K
M@*@&K<5_.7N2)Y\]Y<I:B&_JXN?\9N8K1:Q@6:.ZH/#OD:U84:B>0,=??:>S
MX9FJX>GG8^^?6^?!F365;"6*/WG>[&YFR<S+V88>BN:+>/HWZQT*57^9*&3[
MUWOJ;.-PYF4'V8BR;PP*2EYU_^ES/Q G#9"M >X;X&F#P-* ] W:D5MTREJW
M/M&&+J]K\>35RAIZ4Q_:L6E;@S>\4F%\:&KXED.[9KD2E10%SVG#<N^A@7\0
MHT9Z8N.MJ-QYGR'.TGOWM:*'G(/->V_N?7WXY+W[X;WW@\<K[S\[<9"TRN7U
MH@$]JM=%UC_[KGLVMCP[\GX35;.3WK^JG.7G[1?@Q^ ,/CISAYT=_G*H/GK$
M_^!A'P<&/:N7-R<..6086]+V1VQCJP9PTP[@IA:E!VNOI@VOMMWDY0UG\LHT
M;%VW@;E;M;"OY)YF[&8&*U>R^I'-EO_\!XK\'TT^OU%G9R,0#",0N'I?_@YY
MB%>9*)G)S:YMU+95Z>9Q.4=!DJ;^]>+QU /=+L!!D@Q69]+"05KH#,YM_C]8
M7=UD;P1DI$Q4&2^85PV:U7UUE;5Q?%4$P[>,X!MU=C9,T3!,D3."GQATFG':
MY=PJ]V@IZH;_O[UA\KSK+CP)%DK]-)V$U& 5)ZDEI/&@-79JO3V1IA(8*"_Y
MH90?O)S+3!Q4J)4+7,H#K3+F94(VQKP5:_*"8#HK=9N8$+,#R>! XG3@)R'R
M)UX4'B_WE-=J<IK4)?K@A; BR$2@;N:;Y:6#O-0I[S-_!DA0*1D,Y"C1.(*I
M]G#L(X0G$G4KBT3DCSSSG2)_KAI:;?D:5O++E/;]G04RBJ<3UF!EDWJ"7N24
M^JN0 -I*S<Z]D+10<W9]D& %PLU:D1YZ/XFGD3>8V<3B42QVBGUH1/9MKG9,
M.:R;$K:1LEMH[%E]-B;XOLM3':&/M*'5K2)$0HO@$;[(23;(7!M6UZ#VF,SI
MLV50B?;\.0Y]G$QUZG8)B2.+SA&1R,W(/YH=JXVZ ET7BF)-EL$L]6WQ'O&(
MW'Q<[6 9,:FV>/TZ4JFSX'3-"SOWT)N"[ZUZ.Q^"$7W(S;[;K(<&$)#Q1PHY
MQ>BS#K-Y2H)IF'0KG-CC-#(/N:%W7S-(;_EQ&79A$FI.0?D \[]J^O@9I>L0
M([&OI1/="J, 692/L$-NVK43WRM$M9TWK"Y=,@W$B](PG.K4S4(_Q!:=(_60
M&WO#--C3[[3EBMH&95E]8..P&V7K>)LG.$7Q5+?!+HT)LJ1 /+(07V+AF/F.
MZDU"L0XWA&(R'5^#V1SATT1YKG,$(;X$PN,<V-=B _0#K@ .3Y*-4;5.N<0G
M4[J8K(A-\4A#[*9A/W<O"-3!-D<H(M.=I-'.)Z$%+7A$('8C\/=C\7*0+0>-
M]0L4]%#ZP,V#NM];B,KLD0&5B.!$\\A@![&Q#?O(2GRYGGR)0^U^O_4)S"ZX
M9,!GD*;:W#>8D03;ENB(6>QDV,L\,NH.#:%(<*P)-]FA)+*4*GBD(XY>=;K!
MJT<F7U(;8R=U7[M'>*O>SD=AQ"^^4'-F?QVXY.U.&#)L6V5\:$\-8#/?!I8J
MBWIZOM4/A4[6>0)[O&D,#68H.C$[%S\2&+L)?'^HLQU5FP80V\7/6B9A':YS
MDJ9(FV\&.Q3'D66[@$<,8S>&[VN1,9;WLZVDS:'NEKNH/2B>7N:$3EJ"<##=
MJQG,$$Z09:]&1AX3-X_/QAM0!TN]^=YN)QC,D;VMWB=&[N)T6DT;[4)$;+I'
M/A,WG[4D95KK1N4Z?.>P =((:+1#<6 !!ADY3?"KDM2&5[3*7G($Z^3_J\]@
MWZBW\U$X.8=V[P/N1 UMP.OVN$%]VV8G2$K</.%T?&,2AKX6-MTNP,BW%35D
MY#QQ<_Z^SZ0OE&M@LUFO$>*!7?"(<>+&^*G@=B-;"&H\'B4&'$<XU)1>,CO7
M.4*;N$O:7J>2V2T%YA4,,I(GU@7?6@]UB:'$121%4]4FL\ /+*I'R))+->YI
MZA^.;]6D$&4)ODAU.&44;BA=?7]:(YBLHB2UR![Q2MQX_<+VIPG_HE8#.4_/
MQ'NM!JLXL90*9*0K<=/5>@I%=!9JAZ,&&]B?(,L6,QAY&;AY.7#G70^>]XJ:
MCSR'B_5W8S(W_LYDX&(4A-/9:S##:40L0QN,] PNTS-GD+[4.@-X=KM"@'[[
M09'_$;8OEAU+8"!C2)*3VK 7;[ C:6RI3X(1H(&[T%W9Q'JT\=9LRZNJ+1MA
M/\-J+HR[W$"O;V."P^G,-IBE";8DCV"$7^"&G],#I@[+G-J)]N,C2@-_NO4R
MF(5),,T@BY/?Z4M6;]O7%Z37'B]UOW(/=X=7)&[;%P,F]^_0U:I[T6'LIGOO
MXC=:0TPD9/4-=.E_5"\JU-VK#-U%(_;MVP!KT32B;#_N&,U9K0S@^XT0S?%"
M/6!XH63Y-U!+ P04    "  ). 99'ZA[2[T"  "("0  &    'AL+W=O<FMS
M:&5E=',O<VAE970X+GAM;*U6;4_;,!#^*U:&)B8-\AY*ET:B]&5,8ZI@;)]-
M<FTB$CNSG1;^_6PGS5I(JXI5E1K;>9[G[GP7G\,594\\!1#HN<@)'QBI$&7?
M-'F<0H'Y.2V!R#=SR@HLY)0M3%XRP(DF%;GI6%9@%C@C1A3JM1F+0EJ)/",P
M8XA718'9RQ!RNAH8MK%>N,L6J5 +9A26> 'W(![*&9,SLU5)L@((SRA!#.8#
MX\KN3SV%UX!?&:SXQABI2!XI?5*3FV1@6,HAR"$62@'+QQ*N(<^5D'3C3Z-I
MM"85<7.\5I_HV&4LCYC#-<U_9XE(!T;/0 G,<96+.[KZ"DT\OM*+:<[U/UK5
M6-\W4%QQ08N&+#TH,E(_\7.S#QL$>Q?!:0C.:X*W@^ V!/=0@M<0O$,)?D/P
M#XTA: C!H18N&L*%3E:]NSHU(RQP%#*Z0DRAI9H:Z/QJMLQ(1E0EW@LFWV:2
M)Z(9?D%+CF; =%63&- HXW%.><4 G:&'^Q$Z/?F$3E!&T,^45AR3A(>FD+:5
M@ADW=H:U'6>''1?=4B)2CL8D@:2#/]G/#_;P31ES&[BS#GSH[!7\5I%SY%J?
MD6,Y7H<_U_OIMYA)NKV3/CK<NMM!'Q]NO8L^^;_8I^]V?BL5;EN#KM9SWU.#
M7:56RWG=<NKL[O,2QS PY.',@2W!B#Y^L /K2U>>CRDV.J;8^)ABDV.*38\D
MME4M7ELMWC[UZ(=LSS<DI@6@T^^4\T]=%5)+!%I"->-E=&;[KN7XH;G<3/Y;
MG&>YKT"CMR"G)W_;J/%;E.TY5K"-FG0YYO4N+ZUMW+3#,<?K]5I4O77FQL%?
M %OHGLY13"LBZN^O76VO#5>Z6[Y:']K]L=VQ/I'7C/I6\$^^OJ/((VB1$8YR
MF$M3UOF%;'"L[OOU1-!2MYU'*F03T\-47I6 *8!\/Z=4K"?*0'OYBOX"4$L#
M!!0    (  DX!EEB@4-5-@(  .H%   8    >&PO=V]R:W-H965T<R]S:&5E
M=#DN>&ULG91O;YLP$,:_BL6DO6H#@81-&2 EW:9E4J<H[;;7#C[ JK&9;4+[
M[6<;PK(I85+?!/^YY^?G+KI+.B&?5 6@T7/-N$J]2NMFY?LJKZ#&:B8:X.:F
M$++&VFQEZ:M& B9.5#,_#(+8KS'E7I:XLYW,$M%J1CGL)%)M76/YL@$FNM2;
M>Z>#/2TK;0_\+&EP"0^@OS<[:7;^2"&T!JZHX$A"D7KK^6H3VW@7\(-"I\[6
MR&9R$.+);K8D]0)K"!CDVA*P^1SA#ABS(&/CU\#TQB>M\'Q]HG]VN9M<#EC!
MG6 _*=%5ZKWW$($"MTSO1?<%AGR6EI<+IMPOZOK8*/90WBHMZD%L'-24]U_\
M/-3A3& XEP7A( B=[_XAY_(CUCA+I.B0M-&&9A<N5:<VYBBW?\J#EN:6&IW.
MMJ:\!"1ZE)A07J*UE)B78,JN5>)K\X*-\_.!MNEIX15:A.X%UY5"GS@!\K?>
M-\Y&>^')WB:<!'YM^0Q%P0T*@W QP8O&="/'BZ[P+J5Y@PXO:,L)/5+28G8I
MZQZZN RU?;-2#<XA]4QC*)!'\+*W;^9Q\&'"\F*TO)BB9_N6 9H'A^7M_-PV
M6A/1Z'^+W-N=!A:8*9@PMAR-+2<YWP2_?86Y:>C_S,6CN?A557L$:;H(7_$V
MS;SJS3_KOQIDZ::,0KEHN>Y;<3P=!]FZ[]\_X?T4O,>RI%PA!H61!K-WIERR
MGRS]1HO&=?-!:#,;W+(RPQBD#3#WA1#ZM+$/C.,]^PU02P,$%     @ "3@&
M6<FIC,QM!0  (@T  !D   !X;"]W;W)K<VAE971S+W-H965T,3 N>&ULG5=M
M;]LV$/XKA(H5+>#9CI.^("\&G*S-NB& UZS;AV$?:.ELL:5(E:3L^-_O.5*2
M[<+)BGY))/'NN>>.=P_IRXUU7WQ)%,1#I8V_RLH0ZO/1R.<E5=(/;4T&*TOK
M*AGPZE8C7SN2172J]&@R'K\>55*9;'H9O\W=]-(V02M#<R=\4U72;:])V\U5
M=I)U'SZJ51GXPVAZ6<L5W5/X5,\=WD8]2J$J,EY9(QPMK[+9R?GU&=M'@[\4
M;?S>L^!,%M9^X9</Q54V9D*D*0^,(/%O33>D-0.!QM<6,^M#LN/^<X?^/N:.
M7!;2TXW5?ZLBE%?9VTP4M)2-#A_MYE=J\WG%>+G5/OX5FV1[BHAYXX.M6F>\
M5\JD__*AK<.>P]OQ(PZ3UF$2>:= D>4O,LCII;,;X=@::/P04XW>(*<,;\I]
M<%A5\ O3:^F5%W8IYHX\F2"Y5I>C &@V&.4MS'6"F3P"\UK<61-*+]Z9@HI#
M_Q$H];PF':_KR9. OS5F*$[' S$93\Z>P#OM\SR->*>/X,WRW#8F*+,2<ZM5
MKLB+?V8+'QSZXM]C"2>\L^-X/"OGOI8Y764U5\ZM*9L^?W;R>GSQ!-NSGNW9
M4^C?ORM/PAPG>3(41^'/Q9\E84IR6]72;+E2C9%-H0(5XL8:C[(5DE_>*R--
MKJ06]W EC&B(: '^-\E;2%/$=V,#*HTG1\&*.L4#AC+X"!(\6N)D_/,?HI1K
M$@LBPU:U=,F(^;@"X0B#$<J(Z1H-3([@:-7HR+XG<$]YXU10K<6[A[R49A6)
M5<I'+7F1W;^[R5X*6=?H!+G0),!-@9=3E5CVV?D^NT'$*BRG \-<-P5*I;4H
ME,^U]0WR IFOC6+:BVVDW;9;[>"@:J:\(D,.;G&=ZKX.)#Z96.98SYC*K *9
M7(H7SY^]G4S&%[>SV3P^GER\%-!BP=ND*=!1OD/Q(>':6AE.&8B5-%!97A[P
MDC_N>9"=+#Y#@=H*Y"BR\C$E:Y "( WKHD;B*+GCA0,'0SEY#Z6/?*582N5V
MD;K]0N4@H#'G;@=J_+4%DN"&_%^2H>W:INW".15*!J<>Q!V><CC>.MO4 Y0D
M'\9]5##,]QO:-PNOX.6X:UY 4N.9L2:]'8BV_O.[V[[\P:Z(.WK7D0?QD^7)
MFPMTX'*IM(HQ%HW'='J.[&KKNJ9UZ ^[I-B8H"J]MT@V+@X.E_;]!D*K*G8,
MT!<($;8BS6W7]QB@@&;SI:J1$G-L$]FC] V\B5IHG>\2'8H;<@$'^V&!4HYI
M7CNO!@B[!A/2.1ZZM%FQ2ESS[P@]$)M2Y24 2'A6 5@+32M8 2N-=2AE8("U
M0@?4Y=9#S24X0MX4.HY'*N]XQWE*C83>JGR_G5V3M+GV>M6NMS+6K>*F0#QR
MN\9@Q7BDTV*C#6+&!W7K0GQ'&1+C1$)L!712QAV-8:7X;#$J8HV*0'@XWU0T
MA:':&+8]?3-\)7X2!$A;J3Q-%OFPC[O==2W/9U3C0^ &9[F+E%G9$+Q"V]N"
M&V!/WQ:4RP9JLJ_^]$ N5QY)>[4R:HGB&!;.I6Z(I=RNR0TP$@&:"B-6U9B]
MU8-$)&[V-M$]&-4]N<#%M!NCE !]JR![YPTW%(?I1$EA"Y7A7>/]_%:,4.4%
MLGY@'"9<]!&8F&-5\KS?6Y(N:JTL<$Z"RJ"7@Q\Z1(^?FKZTC2Z8$5^[8W];
M\[DQZ5[;B]"/PK=BVI]%>[T?1:RR/K#&\V#/C.%1_TB0(G2;Z<_OWP]$IO^Z
MDY)CMZ+1WKT5Y]TJWLY9(=%:Z0K;?^U_ ,S2O7=GGGX]W$FW4N@$34NXCH=O
M7F7"I1MY>@FVCK?@A0VX4\?'$M4DQP987UH4I7WA /W/HNE_4$L#!!0    (
M  DX!EFXN9.T/@,  " '   9    >&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM
M;)V5VV[;.!"&[_T4 VVP!T"PSK;KM0TD3HMV@0!!L]U>%'M!2V.+"$6J)!77
M^_0[I&Q7Q2;>HC<2AYKY9H:'7XN]TH^F1K3PI1'2+(/:VG8>1::LL6%FK%J4
M]&6K=,,LF7H7F58CJWQ0(Z(TCB=1P[@,5@L_=Z]7"]59P27>:S!=TS!]N$&A
M]LL@"4X3[_FNMFXB6BU:ML,'M!_:>TU6=*94O$%IN)*@<;L,KI/Y3>[\O<-?
M'/=F, ;7R4:I1V>\JY9![ I"@:5U!$:O)URC$ Y$97P^,H-S2A<X')_H;WSO
MU,N&&5PK\9%7MEX&LP JW+).V/=J_Q:/_12.5RIA_!/VO6]!&<O.6-4<@\EN
MN.S?[,MQ'08!L_B%@/08D/JZ^T2^REMFV6JAU1ZT\R::&_A6?305QZ7;E >K
MZ2NG.+M:,U/#Z\\=?V("I37 9 7OY!,:VSA[$5G*XGRC\DB\Z8GI"\0)W"EI
M:P.O9875M_$157<N,3V5>)->!/[1R3%D<0AIG.87>-FYY<SSLA=X@^Y"N,6-
M]3V[-; '>,"RT]QR-/#I>F.LIF/S]W.+T.?(G\_AKM+<M*S$94!WQ:!^PF#U
M\T_))/[]0@?YN8/\$OV'-NTB\?EZTS'\7Z8Y7!M06Z ]PO,>>:=;++'9H(8L
M\;-9"+9&6*NF9?+PBX'2H7& +A5==6.Q C*Y1G%PY$9)/-")UX^D4-M.5@:L
MLHP:V,$5Q..<;H40_H)3UBM(Q[/33$BJ85KT]UX<QL.ZH491 =,(3 @H!3.&
M;SFE9E1'IS7Y>!ZSW].:!_6RQO_I(5LE2.\,_,HE]:TZ0X'FM_GH6]I_2*.U
MTJW2S!+OZTF\@J((I].I&TS#V70V^C!^&,.?I,*FTX>A*X'R8@)I&DZF^>BN
MD[SD+1,D5'3.!W[)-,P(F.3A)'\U>H,5:O*J58,@%)-#UTE8Q!D4!(Q':]26
M%JJD OV^5]@JPRU0NED*63A)\M$5)$D63E\55&X2YV$^*^"Y0Q\-5*M!O?/:
M[(Y!)VTO8.?9L_Q?]ZKWU;W_=]PQO>/2@, MA<;C:1& [O6X-ZQJO09NE"5%
M]<.:?F&HG0-]WRIE3X9+</XIKOX%4$L#!!0    (  DX!ED'%?+U6@4  &$-
M   9    >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;+U7VV[;1A!]]U<LE*!H
M 46B+KY$L0783H*FB(L@:=.'H@\K<B1N0^[2>[&L?'W/+"F*<F0'[4,?))++
MF3-GKKL\7QO[Q>5$7MR7A787O=S[:C8<NC2G4KJ!J4CCS=+84GH\VM70599D
M%I7*8CA.DI-A*97NS<_CV@<[/S?!%TK3!RM<*$MI-U=4F/5%;]3;+GQ4J]SS
MPG!^7LD5?2+_>_7!XFG8HF2J).V4T<+2\J)W.9I=35D^"GQ6M':=>\&>+(SY
MP@_OLHM>PH2HH-0S@L3ECJZI*!@(-&X;S%YKDA6[]UOTM]%W^+*0CJY-\8?*
M?'[1.^N)C)8R%/ZC6?],C3_'C)>:PL5_L:YE)].>2(/SIFR4P:!4NK[*^R8.
M'86SY!&%<:,PCKQK0Y'E:^GE_-R:M; L#32^B:Y&;9!3FI/RR5N\5=#S\[=2
M6?%9%H'$#4D7+"'BWIT//<!99)@V0%<UT/@1H!-Q8[3/G7BC,\KV]8<@U3(;
M;YE=C9\$_"7H@9@D?3%.QM,G\":MIY.(-_F^IZ^52PO#SCKQY^7">8OB^.N0
MSS7D]# D-\S,53*EBQXZPI&]H][\AV>CD^35$X2G+>'I4^C_)C5/ AVF.1F(
M1PS,Q&\YH5U2$[17>B560652IR3(>;DH%*K-"2F6K'X7U7-%5MHTWPB?2R\J
MJXQ57GV%' O(V(!*5\$[7+R!F"42!=U1X6)790(2'G;IWH.$@,PZ5VF^U0HL
MHK0H(U%FU3$O+0FS8,= CUB,D3!DOI ?B#<2,!WI<N>K4 Z3I3+6U^A& VBY
MQVXFWO-5C,0/S\[&H]&K+2,V6C,/%;@'+;._T:]XO@V&+XA"B@!@< J5P9A*
M90%E5%N(<18HNZRV6\^FAK$;-";'WS'YK1VG2E5(NV?E&_C^DP0?1VG4ZQ0S
M%6U\ ]T74F>B-!D5+VJ"N[1[2G.M;D-CJ<ZJ+ J866FUA%'D03KL"A7+NR>S
MR?2@(!8D4F.M61@KV97%IJO2R&88B'58 GH<9A3,;B+:,H" )UO6Z28FP+Y!
MN%!RH0I4+[6)F!Q*Q(HTBIX!@^[8YD#X3<6QQ"ML,;S_@)'&%L>AC$BGKQPW
MD\*N@K" 0M?_&-_&A4I:I$55DG.P-J'(N!,X)IP\;H.6?)?[9A![>%?T-67(
M@I#!74;L/.8$XS%,-W>=C$4N2J=%R)"42+"U'%5031FF*8\*:*;2H=6PT;<O
M.1S;>MKA-O1, ='H1 Q='$YUL=6GC;AM+W"4B%Y>FQ)QV+0!7"J-J:0>-M6V
M.IL!!E9< ECLC #&16[28.,H@=L8!!#!GD/MGA.YOZ:4R@59,1G%U8GX,1:D
M"0ZOW4^SH]T4[=P^0/H&Y>@RUMOL")LF;;;97@9 MO/FN9B\/,7_N'\VFAY]
MRC&E7L225?H.Q5.[NYT4H]&D?_KR6(R2:7]Z=GQT$WQ 9-[N(8Y>]I,$LJ?]
MD[/3_R$%/"!2B1@C"?L)^(^Q_EY4KV%LP][$3.P]';W?]?7L:)Q,$O&KX>Y[
M+J9)@K@D'/!C1/$D>;!V&N\X7.D6499<6[%U8\W3;5#PC-WO;RN/MY:4U&XL
MM.N5W'07;4!\Z![G;,>-6E76W,?1T(U8AE_<.$DX+@74C \VNK.=8<A=1?6H
M[Z1CL,^\:8!:@T\*T0=+F?)=TZYC>R#>+0^F_X'Z6KKMYOH@WWW!K^/XXLD-
M_!4."%]9;%?"S: _=*P8B$/GJ6'GV%N27<7#O1,QR/4)N%UMOQ\NZV/S3KS^
M^+B1=H688<]?0C49G![WA*T/]/6#-U4\1"^,QY$\WN;X!B++ GB_-"BFYH$-
MM%]5\W\ 4$L#!!0    (  DX!EGLC5LN0 <  /X1   9    >&PO=V]R:W-H
M965T<R]S:&5E=#$S+GAM;)U8:W/;N!7]KE^!T28[FQG&XDLOQ_:,DVR3=F:[
MGCAM/W3Z 2(A$0T), !H6_WU/1>@*,F6W68G&1D"+^[KG'MQJ8M[;;[92@C'
M'II:V<MQY5Q[/IG8HA(-MV>Z%0I/UMHTW.&KV4QL:P0O_:&FGJ1Q/)LT7*KQ
MU87?NS%7%[ISM53BQC#;-0TWV_>BUO>7XV2\V_@B-Y6CC<G51<LWXE:XO[4W
M!M\F@Y92-D)9J14S8GTYOD[.W^<D[P7^+L6]/5@SBF2E]3?Z\N?R<AR30Z(6
MA2,-''_NQ =1UZ0(;GSO=8X'DW3P<+W3_B<?.V)9<2L^Z/H?LG35Y7@Q9J58
M\ZYV7_3]9]'',R5]A:ZM_V3W03:;C5G16:>;_C \:*0*?_E#GX># XOXF0-I
M?R#U?@=#WLN/W/&K"Z/OF2%I:*.%#]6?AG-2$2BWSN"IQ#EW=5T4NE/.LB^B
M$/*.KVK!N"K97\&'+^).J$Y<3!P,D?BDZ)6^#TK39Y3.V&]:N<JR7U4IRN/S
M$S@X>)GNO'R?OJCP+YTZ8UD<L31.\Q?T94/4F=>7/:/OJWAP['VMBV_LG]<K
MZPS(\:]3<08U^6DU5##GMN6%N!RC(JPP=V)\]?-/R2Q^]X*3^>!D_I+V/PK-
MRTKS,_9_Z#W?"YE!*&(*$H5&05H\T&OF*L'6ND9A2[5AOTB%'=U9*+-OSD<
M30R@L8_0TZR$85GB=[+1)Z.M15D^,<1>L23*EW&TF$W].ILOHS3)1M=DBJN"
MK!KRQ /7\9KQ\M^H%30+**)8.H7"\)4/?9;] B5I,HOF<<+>^&])/(N6<<S>
MC%ZQ=)Y'R2QGM$JC+,G8#7<2NAA!*F'.A+0PZ=W4&R7_(TK&G<^ 0Y/:2<*Z
M$:PU^DZ"^6RU]1(?=--RM?WYIT6:S-]!9KV6M>0.$FVUM;*07-DS]O6$:"N,
M[[P4M%[5<L.IF9$;M3_OM+=0BAK-S6P)E<$5/&M#(,$MBR]V+1]YOC\1J&%*
M@%EO(Y+ (3JH]+-^N JZ2*93>_4 I^7&25[7VZ,'O5T!A'KZ&-%J2((^L"!U
MB?;G*NS:%N =1/ 8"OA:-]K"=EWO=#W)W4LHRF;5&1LPVFCD3A%[WMH646F#
M_4KPVE5%C^?&\ 8\(MUI_.[3YP_LIM_T6\F[-YYWKI*F?$O!;YE4MC,^82W?
M:@. ;_@V4)3H.\!DD YA]E@^$T; <".4,#ZOX+5/OV(K":J7K*BXV8AC'K%&
M*^E@G$E?8B$!Y.F^W.".T0V9MN"([HRG<1 !&VC-A 57/.&.JFZH1P+*8%(P
M<*RO:!\DQ<.5 \-;?[J4ZS5B561B)=R]$(/[P>( "V]\6WC$R1<@]1U8D1%J
M4Z#$D=N^)/TD\6.MXSB;.WUV'[K]T5[D1Y&G/8]&"\B"?JQ"?]5&%M E'J@L
M*%]>E:::9&L8 J01&%;4':6&E7QK4=]>?^>L@[!OR3U?/][^/M"4W#WA0,3$
M':\[7]:4/;)<4.8>AT.M1GWOX-.6&<H%H4*%^$AN%S34'40A56A=M W2]"CW
M'(@(,[XASPF_4TX6G3%$@%W"CVE#UID3IH%3* >%<B"+OOXP/3T<)!%>(&"(
M2Q5&6WAT!J!/XPAN8<P;"N6 QP.-:7OHYB$SQW7>M]">ZJ'Y'?AMJ1,=-I;_
MV5""^JZH!AL4P)!UI/"Y<G&'G/9 ^]LB)-I7DZ*<4)OA; T"#PK]S48 %3A>
M"R=ZK($*P" 8Z>%!3G==[<<BHUM AIS><=P+'8*57G6)-P\::GHEVY;J!'[J
M M08#F8QV9W%H3#@>._9&;O5X<X[U6DK;5OI"/J-$6*'_/=.HO'NGO77ZM'%
M#JI@-)<T1]([!EL+@L);.M#43P4>-9)@,G@Q6"VUH,2[OLDCM[;#I%!X"'=0
MWNFZ:WP=H2N"Q_!FTW$DSPD1;N-#QWI$D2Q&-ZKTMS#YVG3-P 84@JB/&QWB
MU/O#WEO/_7T6?!LY#OL$TT%INGA.#CP'9(*H;W>E)!I!,_WW9;J?J]Q1LH*[
M^^'3^28:7BTQG-F3^-+%L L:GA5P:*,Q-#V>7+]6 .WH'8;=HGD<;HS\4$MS
M+!M6(YJ@GRNY5RS/TFB1S_TJCK)%AM5BFD>S^<*OLF@ZFX\^[]BP[W!/R<7F
M<;3$G#I;1M/%E"5Y&LV3&4NR:32=YZ/?^PX7+$^S&2IAR=(HCN%ME.<YAMYI
MG$?I<L9H%>,4^;5<+J-L&5:)UTQ)YBV >O#W'B%;(#J\KE,-J1?BI=%WVXK0
MA:C]WG. :'O([!]/\JY%$Y&Y@B=H/S09S1/VFLT6^ BK.7L]^C0,=HQT3!DI
MF?;YV3<@B8SF;,J0T-&-P57CQ%LJ\6'R2L._48(WAM?LR>>IE[W)P3MY(S"8
MT2\/EODK+;R>#[O#CQO7X9U^+QY^&?D-<QTZ).ITC:/QV7PZ9B;\VA"^.-WZ
M-_R5=DXW?HGI%=V!!/!\K;7;?2$#PT\^5_\%4$L#!!0    (  DX!EGD6^6.
M-@,  %@'   9    >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;)55VX[;-A#]
ME8$2Y&DKR;+WDHUM8+UIT10(L$AZ>2CZ0%-CB0A%*B05V7_?&4K6>@/':%\D
M<CASYIP9<;3LK?OB:\0 ^T8;OTKJ$-K[+/.RQD;XU+9HZ&1G72,";5V5^=:A
M*&-0H[,BSV^R1BB3K)?1]N362]L%K0P^.?!=TPAWV*"V_2J9)4?#)U75@0W9
M>MF*"C]C^*-]<K3+)I12-6B\L@8<[E;)P^Q^LV#_Z/"GPMZ?K(&5;*W]PIL/
MY2K)F1!JE($1!+V^X2-JS4!$X^N(F4PI.?!T?43_)6HG+5OA\='JOU09ZE5R
MET").]'I\,GVO^*HYYKQI-4^/J$??.?S!&3G@VW&8&+0*#.\Q7ZLPTG 7?Z#
M@&(,*"+O(5%D^5X$L5XZVX-C;T+C190:HXF<,MR4S\'1J:*XL-YTGBS>PZ-M
MMLH(+I5?9H&@V2&3(\QF@"E^ ',#'ZT)M8>?38GER_B,*$V\BB.O37$1\+?.
MI##/KZ#(B\4%O/FD<Q[QYO]')_S]L/7!T9?QSSG) ^+B/"+?EGO?"HFKA*Z#
M1_<-D_6;5[.;_-T%OHN)[^(2^G_ORT68\R2O4SA?CO>=4Z:"4"-XM8=F:"ER
M2X$:@E-#X"HZ47 KS $DO34&\F*KD%\[Y56\='8'EN+H]J S0O^TPR T-%@J
M2?FAY=HKB4#3!8+E,TE$5(E.'.-?P]OTECY]K<EPQ9:^5K(F^TUZ?;1#+SRT
M0I6@#$CA:Q !I+:>]0A3DO<\+5YX.Y36L3):"TX;R!=-^(Z!5F*KM J'%'[_
M3ASN27TYJAYK\>;573&[?>=AJ"D),AAX,#'QMCYX$B[,))Q22V>I#[VE23<%
M,V-9*UVZ$R-WCT-2^&"8I!D'6Z]"3124/R7WLD&3UB#V-+/*CB*W&J&RMNRI
M)L<ZSY[KO%/[6!N/P0_'>;J8"L@$+65P5.\@3!711N=8/\_5))F*1KW2AY?J
M.;JVOE7<<%$Y1!+_G&;J4PKG;E)V,NT:=%6<Z9RV,V$8?)-U^FT\#-/RV7WX
MYWP4KE+TX6O<46B>WEXGX(8Y/FR";>/LW-I DS@N:_KUH6,'.M]9&XX;3C#]
M3-?_ E!+ P04    "  ). 99*;-X-Y('  !&$P  &0   'AL+W=O<FMS:&5E
M=',O<VAE970Q-2YX;6RM6-MNXT82_96&,IM]L259]MB3B6W GMG++!)@,-DD
M#XM]:)%%J>%F-Z>[*5GY^CU535*T+1D98%]L7JKK>NI4B==;'Q[BFBBIQ]JZ
M>#-9I]2\G\UBL:9:QZEOR.%-Y4.M$V[#:A:;0+J40[6=+>;SRUFMC9O<7LNS
MS^'VVK?)&D>?@XIM7>NPNR?KMS>3LTG_X(M9K1,_F-U>-WI%OU#ZM?D<<#<;
MM)2F)A>-=RI0=3.Y.WM_?\'R(O";H6T<72N.9.G] ]]\*F\F<W:(+!6)-6C\
MV] 'LI85P8VOG<[)8)(/CJ][[7^7V!'+4D?ZX.WOIDSKF\F[B2JITJU-7_SV
MG]3%\Y;U%=Y&^:NV6?;J8J**-B9?=X?A06U<_J\?NSR,#KR;'SFPZ XLQ.]L
M2+S\J).^O0Y^JP)+0QM?2*AR&LX9QT7Y)06\-3B7;O_A?;DUUBKM2O63=ZO3
MGY"E4MW%"$1\JAMM FJ0XO4LP1P?FA6=ZONL>G%$]:7ZV;NTCNIOKJ3RZ?D9
MW!Q\7?2^WB]>5?BOUDW5^?Q$+>:+BU?TG0^QGXN^\S\3^R>7M%N9I:4<>U0?
M32RLCVT@]9^[94P!"/KOH31D*Q>'K7!7O8^-+NAF@K:)%#8TN?W^N[/+^8^O
MQ' QQ'#QFO8AAI-7B]=5-T:%1D!<C8_:*E^I^S9"(<0/UO=5TX<#NYRJ_YM+
M[]7'-ABW4FE-*E+A<>)KJT.BP(*,@A-Y]\%#K]LIX2AK_H ] PL-5\P4I!H?
M4N6M\>@<!ZIA!U1CM8LG():(!F8K!AR!ABZ,$$[RBAY-4MK6/O(_<8[5ZJHR
MUN@$*QZ7!9TR+92#.2CU\"K ->U@$>XZ;4\K2@BPIM(4B&^J_@W'!P_9%#0'
MOFI 6% '!Y:D"H1FB>^7._61"JJ7T'Q^EIM@JNZ*PH<2[MO="=P/R-*&@E["
MP[13FM,8)5SD1I$NU@BS-!M3MG"F6>\BO(&7@R-;C;Q1X$Q2>2)%X@Q33*:6
MD*LV<4<4.JY5!4J/L&EUYS"+OE0:56E*Y7P"]3=<"Y$K= @[SOM&VY8XN5)F
M1&^05.1[ITP)SW'']=Q[;1E55E"EI5.1A2BQ<R6?(H+S$4IVVSSV\LJ,4 BS
M;Y#*Z1G(U0(A[@2F!B8X(G\UO>K%)4,8D4$+ABP!"BKP*#CUU6D;C^IXMS>9
ML?"JDO%Q1LD0U]:D-8#+,8.@7,QC&DIUIC4D)86V2+F1^E(QR!R@H;BG 6JJ
MI]_::[4N21Z\Z)C<>H9GO+C0AA4#L&"_F2489F(WMPWG$(YM>()W("BDXQAZ
MF/_<1@FSO;4E-T2@KZT)77^TQF9\HID3A\Y/(\#3]5?O++"#/(@QZMLX;3W<
MA%W?1F!-%YW>8ZZ/T'PT4WQF;ZL:BXRL?H.IV"XC N8W77N1>ZZY,YXC3CY)
MBV1>+4>\BA, $MM?#@PK[?Y&G<VG/^SQOV?$*OA:+/7ZH(J$23B/ V>P^XCC
MH4^* ]YS9W9.FZ JP+?K= O34F)YC07-BDH^F7FS5_S-F&18!T.NX%9'/YC5
MBD0!;9#!$Q2.$X17$8L5%E:( ;VY!YR4!_M6\<!UZ<+2$AAQ71J3>+9(<P&(
MH+ZQ[;]&Q:NG8G2">"52X:6Q?X@@FI@9P#N CM,8B"F1O6R=29ER#3JH75I3
M0 9M73(5CT97S\99^RBU'<B>JE1MPC3XHT]DY\SWW[U;G%W]& \'"'.,@<;N
MAJ*V,GE@ <5A&HYK0!6AM FY=#R"&"'8T6C8T7AF/<_J"QE)<]-9PM3096DZ
M D-[UJ:5IEZAJQ15%69CWPG/ UDB+4-JQ%%.> I^4#15OX,N&>#-2,]^MCT3
M5VV4R9.G/AS"8(M/$0<<&( K9I)B\N/LZPCW>7X()69;_'Y 4P,08T9"1<]L
MC08-C /V2T;H/@:;5Q1@G\/L*+]SXRG9"<I*"N+[, _VS9R1U;D2I?<ZN]+C
MPDY12A#[X#%]T3$=4VD;_=A(;MH*L/ !Z8DME@R=H9E1*;'7'& PH*#!D7Y+
MX3KH!]R7&R0$(.?BQ9VCL#*4%\5L8TF.*F%1ULC;1U;6UXU7'XAG85X=DJ0&
M-1DM0IG><F$UMA)W*KO,?L*J LC.3H :S^?3^9@;9=5UJ6\+7?L61P#T[=H@
M\ .4D)- CP51V6VF,&9YJ]FW[LE^&K+ 8=9I;,OI.([8*6SGNN0#3.^5"0 ,
M]X^,Z)R<T3K%Z5T%WS8O%ZM,1LZ/D\,J1\5W6$ECY"'&XR&7/N]D7T#8*R<X
MRN,'91BRW:58KX!Q]J[_)?:T.$D_]C7OTHL9R;&QAT^8 K_#*<A6@"-YX\J;
MW<5T,:QJN4==P0U*Y=%2@;9=%N. H?RYUYR"\1J"?VU!QTL/D;P3#<M&B8T^
MU#* ]A!XMLP?7&/YX6NNO0R:VUMW:\%!Z;.W(W'XH,[47UC K:BGF8.\F'EK
MK3=Y.\V_67A0'.\H= F8/OA'02_R\$9=3M_N;1_Z/3P;?=NHP0CR!8<AB+;+
MGSF&I\-'HKO\;60OGK\P_0PG #<L(!6.SJ=7;R=YR^YODF_D2\G2I^1KN5P3
MIF]@ ;ROO$_]#1L8/IW=_@]02P,$%     @ "3@&6:^6%!69 P  6P@  !D
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MU.J.A(L?L^)-L#5_0%K8 );BRQ7:2>7H!?Q>6.B9;FB#[HOBQ7\!4$L#!!0
M   (  DX!EEJ!DBGM ,  ,4)   9    >&PO=V]R:W-H965T<R]S:&5E=#$X
M+GAM;+U6WV_;. Q^[U]!>,#0 D'LV*F;9DF _CKL#A@0K+OMX7 /BLW$0F7)
MD^2D_>^/DAW7 =JLW<.]V)1$?OQ(B91F.Z4?3(%HX;$4TLR#PMIJ&H8F*[!D
M9J@JE+2R5KIDEH9Z$YI*(\N]42G".(K2L&1<!HN9GUOJQ4S55G")2PVF+DNF
MGZY1J-T\& 7[B:]\4U@W$2YF%=O@/=J_JZ6F4=BAY+Q$:;B2H'$]#ZY&T^NQ
MT_<*WSGN3$\&%\E*J0<W^#.?!Y$CA (SZQ 8_;9X@T(X(*+QL\4,.I?.L"_O
MT?_PL5,L*V;P1HD?/+?%/)@$D..:U<)^5;O/V,9S[O R)8S_PJ[13=( LMI8
M5;;&Q*#DLOFSQS8//8-)](I!W!K$GG?CR+.\998M9EKM0#MM0G."#]5;$SDN
MW:;<6TVKG.SLXD:5I4N.S*$5[W[6?,L$2@OW!=-H9J$E1TX]S%K0ZP8T?@4T
MA2]*VL+ G<PQ/[0/B6#',MZSO(Z/ OY5RR$DT0#B*!X?P4NZJ!./E[R"=\>T
MY')C8(FZB1+^N5H9J^F0_/M2O W<^&4X5SA34[$,YP%5AD&]Q6#Q\<,HC3X=
M(3ONR(Z/H?_N%AT'O1S"&W"G<,T,ST!2=^ R4R5"11G+&G7C$\<-9$QDM6 6
M<U@]0<ZW/*?L]JUHVA8(.U\DI,:VJ*GF0=;EB@#5^@#3 +4/8XF9@\EK[7[.
MGIQSE0_AEHO:P?Q_O%R6*F4I-9R)]Y%=OF*6*6IMQCHG?01:LIIGC@U5?_;@
M73>2JEPG,W[F,+S:[+U::LVFUD^M28FV<"2^T=)>WW5#<MK2J W9<^F-5WZW
M'7S^A@SW\>AZ:-P7&K&AS!^A;-H NC8 5,38%;%7(2%Q@3!#]H+N!P.GGHFJ
M#:V;L^G)-X_7;R=P3\#]B1./Y[$ZZ>3'[YRT23)(DA@F\2"YO'2CZ&+L1E%R
M%-#GBNZ6P^Q\_#")1_$GB-/S3D[&XS<P<ZEIQ6=&:3KN,4HN+DZNZ%!UK@UF
M=/(LIXA.?WV"SD JOZ^BSI]W_[U[?CE*843\)I"F(R>=3^"4G<%M3>=  0.A
MC'GWR1A -!S152<$;W,1#9-N3+PTTJ/ 4CDU.SAP%5.AO]W%TP <RX/H5I@Q
M.N2>!*[7I$DOA5JX!8)_SN'PI5X=]J[6$O7&/R!<[=;2-K=L-]N]4:Z:J_E9
MO7G@?&%ZPZEZ!:[)-!I>G >@FT=#,["J\A?U2EFZ]KU8T#L+M5.@];6B3M(.
MG(/NY;;X#U!+ P04    "  ). 99"L&^),,%  !P$   &0   'AL+W=O<FMS
M:&5E=',O<VAE970Q.2YX;6RU6%ESVS80_BL8)4W;&9FB#BL^-2,G[C292:K&
M3?O0Z0-$KD2,08 %0,GJK^\N0%*WXO1XL0 0N_OMAST WRRU>;09@&-/N53V
MMI4Y5UQU.C;)(.<VT@4H_#+3)N<.IV;>L84!GGJA7'9Z<3SLY%RHUNC&KTW,
MZ$:73@H%$\-LF>?<K.Y ZN5MJ]NJ%SZ)>>9HH3.Z*?@<'L!]+B8&9YU&2RIR
M4%9HQ0S,;EOC[M7=@/;[#;\*6-J-,2-/IEH_TN1=>MN*"1!(2!QIX/BS@#<@
M)2E"&']6.EN-21+<'-?:?_"^HR]3;N&-EK^)U&6WK8L62V'&2^D^Z>6/4/ES
M3OH2+:W_RY9A[^!UBR6E=3JOA!%!+E3XY4\5#QL"%_$1@5XET/.X@R&/\BUW
M?'1C])(9VHW::.!=]=((3B@ZE =G\*M .3=Z<#IY9.]4 HKH81/)E65<I2Q\
MF90FR=#K\.&FX] F27:22O]=T-\[HG_(/FCE,LON50KIMGP'L3: >S7@N]Y)
MA>]+%;%^W&:]N#<XH:_?$-#W^OK'",BX@;,[=#%E$[[">'-L; Q7<_#CW\=3
MZPP&SQ^'G ^Z!X=U4T)=V8(G<-O"C+%@%M :O7K1'<;7)Y /&N2#4]K_@Z,[
MJ?\P^FX<L:\S?,5^R8"]T7G!U>K5BXM>]_6U96,D%P/"2WT"Z[C#"5:2BPV]
M)(/ISWWZDB[VG4-5I*,77S]' PGY[=WK[UEA]$*D8!F6,C;'$W:6Z1FS'K,N
MR(IM5U->H,N)"*8-939^0A*<$0G9\;O:E/Y@S'I.6#1B-&'AS(#TL/B2FS10
M5(#QI10QULLNXPYS>L6FP"PX)U%"*)9PF]5X$''0BTZ@!K>*V&?TWC BY+E,
MM&LOF=.LJ _)4@)X)A*=Y^ANL%CA\3R1;L<X&A>(6FG')%B/6WD ,RX,"IA'
M;"(++DL@;?2AUAVVI0B,OGB=D0^+&E".E8[,P1.81% N+H7+D(1NS%; #1Z:
MT?F^%N_S'!08+B4!1A\:+7PJ@6P3<,T,ED<JX +Q+) YCMH,P!FIIU,1.CUB
M)-J,8":L+=$GA0UG39W 6-JBKRQP6'M3[]@*M<B?U68\U?&P]F>!.P+: - &
M8A%VQ8HWXX^@E#,AI2]9%-0%1N],D&;,6SRULZFO<(E6J0B4$W,491A-V+MQ
MB(&#X6(W(W1/*F)OMT+^".0&%B6OG?'0@;=PG;+BL1T#OGT:F*5ZKL1?X/E?
MEPMXHC&P.@,QXND$=E/86TH/ND3Q,D6'//WD2Z)QDRT(B)I[/^FW.A@DIC0T
M]UZ+)Y:'MA<R$YL6-$V+M?VFVH,ZP[K1 !N\E(1^'5A[@"M'("^D7@$$KI16
M9_4*2P62XC1%QU>7B(B-W4FT&4_9,.KO(N4++J3/-RJNL]*5!NH:2S8K3O\)
MH'6=>U8/Z5Y>#ME'Y./GDLL0:O<U,P?:$]9L1%@IVFPO]P^32=TZVIMTHV-X
MYKEP55@UA70#XK<[U0"KY\4Y^X8.=+M,*O:>JQ)OPZQK79N-L<+*,'Q?2K_H
MO?L)SW.*+- <=0!/,E\ 3K'3B[OG.T0<\'_+YRV7Z\( 4LP%G>Q6D%7963=5
M\TQB&G2[]%S&_PL]1TI%Z,YU93E0-BB*?1\0-M$EUE04!HS)E$U7K.#&B404
MW!> $YFX1]+750FZA.@G@4\/0&?CJ+>;=4M SGT_2C=2BR)W/X_WTWA;?3>Z
MV%5?7?I2SP:9\9>6?VMHV&W'<5S;$*%/\/G<P)R:[I>,>IL?=2V?<2P44P"U
MSP/N1(Y)&F'%6]2'%NJ[S.E#H"TXZ&\[U412^N5(PGA\R7I1W)!+*E^R072Y
ML]*/NCLKP_6*OWP6X)^P$B]_AYX/G8U78 YF[M^ZE&D8O^%!V*PVS^EQ>$6N
MMX>W^ =NYG@AP&O>#$7CZ/5Y*]R"ZXG3A7]33K7#%ZH?9L"1>=J WV=:NWI"
M!II_,HS^!E!+ P04    "  ). 99!K73OH$$  "K"P  &0   'AL+W=O<FMS
M:&5E=',O<VAE970R,"YX;6RE5MMNVT80_94%8^1)H:A+;->1!/B2H@F0PK"3
M]J'HPXH<B@OOA=F+9/7K.[.D*#J5U"!YD<C=G;-G9LX,9[8Q]LE5 )X]*ZG=
M/*F\KZ^&0Y=7H+A+30T:=TIC%??X:E=#5UO@1312<CC.LO.AXD(GBUE<N[>+
MF0E>"@WWEKF@%+?;&Y!F,T]&R6[A0:PJ3PO#Q:SF*W@$_Z6^M_@V[% *H4 [
M832S4,Z3Z]'5S93.QP-_"-BXWC,C3Y;&/-'+AV*>9$0().2>$#C^K>$6I"0@
MI/&UQ4RZ*\FP_[Q#_S7ZCKXLN8-;(_\4A:_FR67""BAYD/[!;'Z#UI^WA)<;
MZ>(OVS1G)Y.$Y<%YHUIC9*"$;O[Y<QN'GL%E=L1@W!J,(^_FHLCRCGN^F%FS
M899.(QH]1%>C-9(3FI+RZ"WN"K3SBUNC% ;GT9O\B3U '6Q>H9/LWIJ5Y<K-
MAAYOH;/#O$6\:1#'1Q#/V2>C?>78>UU \=)^B.PZBN,=Q9OQ2<"/0:=LD@W8
M.!M/3^!-.I<G$6]R!._]UR#\EOUUO73>HBK^/N1C S$]#$&5<N5JGL,\P5)P
M8->0+%Z_&IUG[TX0G'8$IZ?0?R@GIQ%'HY3]'^H5^Z#9QR"W&.?19,!\!613
M<[U]_>IR/+IXY]B-X;9@IF1WPF)9&>L8#[XR5OP#1;2P>V \YBJ.X:&G0VAY
MP\A%1J%FWC".=:I,T!Z[1%F*7  ^XKHI2X<=BE *(0-5,A.(EGM66J/BAG N
M<)WW+PXH07OP;FA$@!2PO3D>.T3=1B)EG]$B0O3]:;<9E]C)7!^5&"K^A#<C
M&#[9)^2ZLW,M0VQE;[QY0_^QCV <-5N!!LLE@]QHHT2. 2AV +A4""+FXBIJ
MM1!ZA8Q0MB+VM);I08[.[(ABY_ZYU/QP_ =,E,A].\"[)?<D$7/P.IYC.ISH
M9R%EOYL=R0U@)G;DBRZKPG7^%L%2; C;B6>FF@X$U(%0TQJZ_I&2RJ_#"CLK
MZ?SRA<Z1JT;QY5'+W#/A#TJ^XL5IV3=:/F-OLRS-L&M+28Y]3Z@%ZK]HLDX0
M1 ">A?/DW#%!#@AY4XF\PBNGZ7EWH07Z*B-#ON9"\J6$J(4> H\"N(,<U!)#
M.AG%($U2]F4?XN/7?G?07P9YGTC.2/0:]:]#)/!"E^3\B^ 0^3.6I;_T/(SM
M5^_C@V(1OJI 1JU18;MR2Q].H8)"'.X#YG#;G#(R5I192K'B3:5A K#N=#LS
MT*G(?0U-#I#6KOZ0?Z1%XG8X ] V6I^Q27KQ30IHZV@.>FK>B:II1TUROE'O
MYUX@A?88;$>.8D5*%"-;<RM,<$P!(C5;4);H#94A*X,/]K^=C>I4YS)0, ;4
M?\E1]-KBQN&.1OV(YSG.5C:6]3&-M VJ;>FQBPG5Q7&/M\%PX2R%=V%UUY1P
M6,>^6/)8<CV"/]TR#WV@A[T!2H%=Q3&1U(>TFUFJ6^TFT>MF -L?;\;83]RN
M!-XOH433++UXFS#;C(;-BS=U',>6QN-P%Q\KG*;!T@'<+XWQNQ>ZH)O/%_\"
M4$L#!!0    (  DX!ED&])"AQ 4  )0/   9    >&PO=V]R:W-H965T<R]S
M:&5E=#(Q+GAM;,U736\;-Q#]*X0*M!=5DF7'#5Q;@.TT:(H&".*V.10]4-S9
M7=9<<L,/R?KW?</]B)382M-#D8NMW>7,O)EY\TA>;IV_#S51% ^-L>%J4L?8
M7LSG0=74R#!S+5E\*9UO9,2CK^:A]22+;-28^7*Q.)\W4MO)ZC*_>^-7ERY%
MHRV]\2*DII%^=T/&;:\F)Y/AQ5M=U9%?S%>7K:SHCN+O[1N/I_GHI= -V:"=
M%9[*J\GUR<7-&:_/"_[0M U[OP5GLG;NGA]>%5>3!0,B0RJR!XE_&[HE8]@1
M8+SO?4[&D&RX_WOP_C+GCES6,M"M,^]T$>NKR?.)**B4R<2W;OLS]?D\8W_*
MF9#_BFVW]MER(E0*T36],1 TVG;_Y4-?ASV#YXLG#):]P3+C[@)EE"]DE*M+
M[[;"\VIXXQ\YU6P-<-IR4^ZBQU<-N[BZ=4VC(ZH<@Y"V$+?.1FTKLDI3N)Q'
MA."%<]6[N^G<+9]P=RY>PT$=Q$^VH.+0?@YH([[E@.]F>=3A+\G.Q.EB*I:+
MY=D1?Z=COJ?9W^E_R5>\T$$9%Y(G\>?U.D0/TOSU6!6Z(&>/!^%!N@BM5'0U
MP:0$\AN:K+[]YN1\\>.1%,[&%,Z.>?_REAUU]SC8D^5,'(US(7ZKB9>TTNX$
M/;28LB!B+:.0J= Q3(6V[Y/V7%:VUG9#(>I*\C &47K7B,IMR%N. *-8.Z_C
ML%P.+=EJ8X13*GFX0  2SA?:0D"$<LD'/)=BG0*R"F$F[I*J_QT"?@5WV@L,
ML,9\$T0F.)/R9S8N]$8721JS0\PANJPJ3_!!4XYO"E'+#=X*=N"U-$(62 JP
MJ"Q1$^$ZL[Y2WX41ZU242 -)PD8Y!..X4\8 /(&S@O)ZV:-1,M2BA(2.P 78
MB4)4HO5:Y2H@9Q$(E<IEG!UTJ)9!6!>1A3()HPDO4$3ED9Z M+-#8$82R (A
M<GS,'HVSQ_ES +  1=(%TBW$RS&#NX@7F2M3MF9\&XEZK U7/Y>"L3*4UD6L
M8R/:X <C,%BHC8X[""JVFV*H&G+Q6((&)'MOW=:*4JJ>CDI[E9H0 8 &YGG-
M?$BH>CGM:(1)#N"F+K42T4T[ -)'K9*17I0I\K!GP@Q\V7W*EBZ@M%S!-?-$
M!F>1&Y@?.NX@5 0(#238LV;BU6>Y.MWG!;PJUR /A'5F0QQ?<"6ZHG'#$11U
MPQ<#^IF\G0TT;KU31+P67AL7.'^QK35&H?<GE)&ZR5UML%#!02--R_K&Y/%D
M<@[1C9]9"#17%LXQ!OBXWGW$9+053<N&;;T+&D2PA[3#(E [RRA/<JQ%[4*K
MHS1!8,!!;QXN3UQV.J@'D&  J;&ZS&&;O7D=XX9,70AVP,]N<+A>65O8F:7*
M:!:27/@O!8\*@0HFN+XY.+BL_^:1!C8'9X@LMR'Q4'2U[O1@J#CH58UU9_!!
M5Y9Y*"%W"DWZ*-J:C,9 H(-\RBA$:IEW2&O#9QO@'^GP5.?S#&36I9@!PRBP
M'AYE3*>PS.S/*QGG^O_JU\>I/)E\[;:HGI_NC2FV,W"9.YRII\A'G%)C-]_0
MOV1+N7&>-6I/^C-RRZ.+4?(#<YJO7NVO#7;05-4'8_1!0/F SNF'/;'%4_*L
MGX"$-+#GXA5$INBD(+_D*I=( , .A#HK8E?1?AHZJA_*6M\,&?*9*A.4<3\2
M.+,039,%U( WXQ' $#/OXU!XKD*G\>-T00!\UN"*,^08PW;="_P6 &E_-L+(
MJ,$'ON\18B;>,6?0G[8?^2?J $#WASE_$#9</LKO<ZX,'1N?'PB6=PHV96'/
M7>MDQ.7#QI9E7LF6+RQ[M8+^!%UH;"<S\>M>49 J/4"JPZ<J]VFAI_T1@*LX
M%I]E](O[_+4/Q&-'[?G>3:DA"#3?!WF32C9VEZ;Q[7CEO.YN6A^6=_?5U]#W
M/$Y4PG0Q^^'9!!W-=\#N(;HVW[O6+N(6EW_6N#:3YP7X7CH<A/H'#C!>Q%?_
M %!+ P04    "  ). 991&3DS_4"  !0!@  &0   'AL+W=O<FMS:&5E=',O
M<VAE970R,BYX;6Q]55N/TSH0?N^O& 6$0(J:>UN6MM)N%P1(*ZTHG/-PQ(.;
M3!L+QPZVLV7/KS]CIQN"3K<OC6<\WS<WSW1Y5/J'J1$M_&J$-*N@MK:]BB)3
MUM@P,U4M2KK9*]TP2Z(^1*;5R"H/:D24QO$L:AB7P7KI=?=ZO52=%5SBO0;3
M-0W3CS<HU'$5),&3X@L_U-8IHO6R90?<HOW6WFN2HH&EX@U*PY4$C?M5<)U<
MW>3.WAO\Q?%H1F=PF>R4^N&$3]4JB%U *+"TCH'1YP$W*(0CHC!^GCB#P:4#
MCL]/[!]\[I3+CAG<*/$WKVR]"A8!5+AGG;!?U/$CGO(I'%^IA/&_<.QM"_)8
M=L:JY@0FN>&R_[)?ISJ, (OX&4!Z J0^[MZ1C_*66;9>:G4$[:R)S1U\JAY-
MP7'IFK*UFFXYX>QZPTP-[W]V_($)E-8 DQ5\D@]H;./EUU_93J!YLXPLN7.@
MJ#Q1W_34Z3/4,[A3TM8&WLL*JS_Q$84YQ)H^Q7J37B3\W,DI9'$(:9SF%_BR
M(??,\V7/\(W2#.$6=]8G[XIA'V&+9:>YY6C@G^N=L9K>S_=S1>A]Y.=]N)FZ
M,BTK<170T!C4#QBL7[U(9O&["QGD0P;Y)?;UEF:TZ@2"VH^;=B[,BT3GPQP_
M@QI%!4PC,"&@%,P8ON=(*D.O5&NR\<5C%JA+.'3)*V^QQ&:'&K+$:S-/U*\!
M_F]/LE>"]@,]-R[!UJHS!#1OKB9_LOV/:;)1NE6:6>+[W;"74!3A?#YWAWFX
MF"\FWZ;;*7REK64Z_3@V):*\F$&:AK-Y/KGK)"]YRP0--CV'D5TR#S,B3/)P
MEK^=?, *-5G5JD$0BLFQZ2PLX@P*(HPG&]26"E52@,8UJ<)6&6Z!W"U2R,)9
MDD]>0I)DX?QM0>$F<1[FBP+.O8UH-.4-ZH/?951^U4G;#_R@'=;E=;\E?IOW
MN_:.Z0.7!@3N"1I/YT4 NM]?O6!5ZW?&3EG:0/Y8T\I'[0SH?J^4?1*<@^%/
M9/T?4$L#!!0    (  DX!EEJ%E7&9@,  %L(   9    >&PO=V]R:W-H965T
M<R]S:&5E=#(S+GAM;,56VV[;.!!]]U<,U*)H 6]T\RVN;<!.-M@631$DO3PL
M]H&21A81BO22E-W\_0XI1W&ZK@OTI2\6+S.'<X9G.)[ME+XW%:*%;[609AY4
MUFZF86CR"FMFSM0&)>V42M?,TE2O0[/1R KO5(LPB:)16#,N@\7,K]WHQ4PU
M5G")-QI,4]=,/ZQ0J-T\B(/'A5N^KJQ;"!>S#5OC'=K/FQM-L[!#*7B-TG E
M06,Y#Y;Q=#5T]M[@"\>=.1B#8Y(I=>\F[XIY$+F 4&!N'0*CSQ8O4 @'1&'\
MN\<,NB.=X^'X$?W*<R<N&3-XH<177MAJ'DP"*+!DC;"W:O<7[OGX ',EC/^%
M76L['@:0-\:J>N],$=1<ME_V;9^' X=)] .'9.^0^+C;@WR4E\RRQ4RK'6AG
M36ANX*EZ;PJ.2W<I=U;3+B<_N[AB7,,7)AJ$:V2FT4@9MP9>?V*90/-F%EHZ
MQ=F&^1YQU2(F/T <P;62MC+PIRRP>.X?4G1=B,ECB*OD).#[1IY!&O4AB9+!
M";RTHYQZO/3GE"^YR85RK W\O<R,U:22?XYQ;B$'QR%=Y4S-AN4X#Z@T#.HM
M!HM7+^)1]/9$P(,NX,$I],4=56+1" 15PE/P?5@:@W153!;P@;.,"VXY$=G?
M8P$D^EO,&ZVY7,.*&6Z.,3MY]G%FGRJ$4@DJ:(=LG5+ [SKE<-D^%;[F,GH'
MP)+YA:HW3#Z\>C%)XO%; R673.:<";*GM#>MZFS%+#"-5*RY:J0E$@0&M%@Z
MWEM_:0Z7WH-'8IDCYDQ()]CIQ&?E$G.L,]20QGXUA==<TB&J,;1MWDQ[3^D\
M&'Z']#^47IOX:8^$C@]4C?J>7L^R(4CX@%L4$,-+2,_'])OT)_&@=U<I;?^P
MJ&NBNT5C6[JM<0)QG/;'YT.(HT%_,!GVKAO;4&:NGB'&Y_TH(MMQ?S09PPE9
M#3M9#4_*ZJJ[@G<'5]"I9VGA@FG]X'*\K-UM'%//R2-^EWJDLI!3[)QH/-?.
M+\KD9X+H$N5%]&S6.RC-:2^)T@@^*DME^A(&4417&CFM#$D H^B[M;$?';OI
M\.#!KU&O?5LSX&NF??N[U:YS+MN&\63>MMUKIM>41!!8DFMTYAJ5;EM9.[%J
MX]M'IBPU(S^LJ/NC=@:T7RJBLY^X [K_$XO_ %!+ P04    "  ). 99CGJE
MZ D$  ","0  &0   'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6R=5MMNXS80
M?==7#+3)(@'46'=96=M DFUW6V#;($G;AZ(/M#2VU4BD2E)QW*_OD+)5!W&,
MH# @#RG.F3,Z,R0G:R$?U0I1PW-3<S5U5UJWEZ.1*E;8,'4A6N3T9B%DPS0-
MY7*D6HFLM$Y-/0I]/QTUK.+N;&+G;N5L(CI=5QQO):BN:9C<7&,MUE,W<'<3
M=]5RI<W$:#9IV1+O4?_:WDH:C0:4LFJ0JTIPD+B8NE?!Y75JUML%OU6X5GLV
MF$SF0CR:P8_EU/4-(:RQT :!T=\3WF!=&R"B\?<6TQU"&L=]>X?^@\V=<IDS
MA3>B_KTJ]6KJCETH<<&Z6M^)]5?<YI,8O$+4RCYAW:^-$Q>*3FG1;)V)05/Q
M_I\];[_#GL/8?\,AW#J$EG<?R++\S#2;3:18@S2K"<T8-E7K3>0J;D2YUY+>
M5N2G9U=%(3JN%=QA@=43F]<(C)?P,]7#'3XA[Q#.'LRT.I^,-$4T?J-BBW[=
MHX=OH*?P37"]4O ]+[%\Z3\BI@/=<$?W.CP*^%/'+R#R/0C],#Z"%PWI1Q8O
M>@/O 9\U7->B>(0_KN9*2ZJ2/P_EV</$AV%,YURJEA4X=:DU%,HG=&<?/P2I
M_^D(R7@@&1]#G]U3)Y8="2,6<$ OSXAUB/-1U,.<!WBY!\^I%@I!?:CH!7'0
M*X2%J*F?*[Z$LXK3C.@4E8TZOW1((APD@L^$T\Q10A38F<CY(H52U(VO L$)
M!%Z<^]XX3:P=9;D7!I%S94(Q7IBHTC"Q,G6L!E;^12U">P0!F:KM./6#;7A3
ML'!&(&&0>ID?P+D=!7[JY;X/Y\X)A%GL!6D,Q@J]*(C@B%;)H%7R;JWV>NB0
M/$>!#LOS\.++:_O5^NVT^H?R-<+<B*9E?//QPS@,LD_*BB>WC3S?0,$T+H7<
MO)+M82417[0KW%?/+R8<JZ@1$0;+,4FV3%>D 1B6%<FTBW<"<11ZXSBSEN]%
MXXBL<1)[:3:V5N0E:>9\%:JM-.FYTY:$I;VN,OUH-FU8(&67^5Y.(J6YEXP3
M".+0RX(4@BCQDBQV?J'DY1 YB5)(_1Q"S_>)K1?',2F>^+$7YBD8RR<OPRO/
M<R_*>RNPR$>J(!VJ('UW%=RB+.CCT GWCIHX#FOD9VTKQ7-%YQ%"^P*:'U&"
ME->;UBYKV8:Z:,VH8]2VF-3_E_]FJQBM;Q@G)B65F$3( CB%=$R/WLK@U/DB
MGE!RTZU@,!(P(,E6.;VJ9/E=RR0EH""&!$AJYU;2WJ"1YC>[W!2$_<\)J)%/
MX=7SD'ZCO1.R0;FT]P %=@_J#\MA=KAJ7/4G['_+^WO*-R:7%5=0XX)<_8N,
M^ECV9W\_T**UY^U<:#J]K;FBZQ)*LX#>+X30NX$),%S 9O\"4$L#!!0    (
M  DX!EE[6WR:XP(  % &   9    >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM
M;(U5VX[3,!!][U>, D(@19M[-BUMI;V   FQ8KD\(![<9-):.':QG>WNWS-.
MTFP1W8J7Q![/.7/&DYG,=TK_,AM$"_>-D&;A;:S=SH+ E!MLF#E36Y1T4BO=
M,$M;O0[,5B.K.E C@C@,\Z!A7'K+>6>[T<NY:JW@$F\TF+9IF'ZX1*%V"R_R
M]H;/?+VQSA LYUNVQENT7[<WFG;!R%+Q!J7A2H+&>N%=1+/+U/EW#M\X[LS!
M&EPF*Z5^N<W[:N&%3A *+*UC8/2ZPRL4PA&1C-\#IS>&=,##]9[];9<[Y;)B
M!J^4^,XKNUEXA0<5UJP5]K/:O<,AG\SQE4J8[@F[WC<+/2A;8U4S@$E!PV7_
M9O?#/1P BJ< \0"(.]U]H$[E-;-L.==J!]IY$YM;=*EV:!+'I2O*K=5TR@EG
MEQ=EJ5II#=RP![82"$Q60$;=8@5O[JGV!@V\_.+.S*MY8"FF0P;EP'_9\\=/
M\.?P44F[,?!&5EC]C0](ZR@XW@N^C$\2?FCE&22A#W$8IR?XDO$"DHXO>8)O
MR-L\)LZ$@1\7*V,U?3(_CZ7<,Z;'&5T;S<R6E;CPJ$\,ZCOTEB^>17GX^H3>
M=-2;GF)?WE);5BT52M7P7\4[EL#I$"/M]H"6#;2X_R9*19UIK--A-PBU$M3@
M7*[A)9=D4:TAF'DUFU#%<*P87&.)S0HU)%%G22;_A'L.2>R'8>@6J9\5Q62?
MDV&":3X4B\L2I>MIDM(X4:SK\RC*_'":0#1-_"B*1RRQ:]((EMT/!"N46',*
M'!=^F*20Y'Z69H\ K6HT;OHP 8*S%1?<NN#D/LWS3F0R'=VYM$CEME#X<5:X
M9QY//M'5Z'_O+DO]:1%#FI-K/'D.<7[N)TGB$LY"_WQ:'/M0@H,N;U"ONUGF
MZD"7US?\:!W'Y44_)1[=^UG[D>DUEP8$U@0-S\XS#W0_O_J-5=MN9JR4I0G4
M+3<T\E$[!SJOE;+[C0LP_D26?P!02P,$%     @ "3@&61R@LL1T P  "P@
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ME$;;0VW1P>_L7X9KJC=,&N"X=KBX=S8BH-MI:QVKJO"'KY1U\Q+,TCU0J'V
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M7!<3Y\(A.:QIP_1"[-Y#Y\<*S 13]DMV7:SGD*Q16E0=&!54)6__]+[+PQ[
MCUX !!T@^%= V %":[159FW-J:9I(L6.2!.-;*9A<V/1Z*;D9A>76N)LB3B=
M3K-,-%PKLH ,RBU=,2"4Y^0S'J %;($W0,[($@]/WN"46),!Q*D-/YZ#IB4[
MP?C;Y9P<'YV0(U)R\J40C4).E;@:%9MUW:Q3=]VJ"UY0]['AYR3T3DG@!=$
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MG;&Z^7(OW[35/F*ZSBN&"EB)J:R+4%0OVG2JFA=.MG4K9DDX)V7]N &< 94
M\7U%"#^^R FZ?N'\/U!+ P04    "  ). 999EM>7A<$  #8&   &0   'AL
M+W=O<FMS:&5E=',O<VAE970S-"YX;6RUF6USXC80Q[^*QIWIM#.]^ E,D@(S
M"7;;ZURN3')M7W3Z0M@+>,ZV.$G \>TKR<9@GS"D$6^"'W9_TNY*?]!FN"7T
M,UL"</0USPHVLI:<K^YMF\5+R#&[(2LHQ)LYH3GFXI8N;+:B@!/EE&>VYSB!
MG>.TL,9#]6Q*QT.RYEE:P)0BMLYS3'>/D)'MR'*M_8/G=+'D\H$]'J[P EZ
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MT[*-7MYPLE)]XAGAG.3J<@DX 2H-Q/LY(7Q_(P>H_YDQ_@]02P,$%     @
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MYWH$FXS([]3RAN))=FFTXDKQ.'O<$AP2H3O ]S7GZK6A'90WF[-O4$L#!!0
M   (  DX!EEPZC@)(0,  %\)   9    >&PO=V]R:W-H965T<R]S:&5E=#,W
M+GAM;*V6:V_3,!2&_XH5)C2DL=S39+25=@$!$F+:&'Q ?'#3T]6:8Q?;:;=_
MSW&295WKCB+QI?7EO"?/>^)+ABNI[O0<P)#[B@L]\N;&+$Y\7Y=SJ*@^E@L0
M.#.3JJ(&N^K6UPL%=-J(*NY'09#Y%67"&P^;L4LU'LK:<";@4A%=5Q55#V?
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MXP>LR!@\GK,:YP8[F"*W:D,ZLA6Q'%1DH!ZZUN40K2@:OE;"L"TCK>EJK:T
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MF7B'=!C%4LLEM@#IHR.N',F=+;WZ/1'28,5->9&5I==LH4Q6G IPWVS1W6$
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M8=ZIF[7JXA?4);!0M(N!&UE@,8"?G\9?G,"'5.F^W/&AW+/X).&71HX@B=Y
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MCVG.D4*NU"P>-8?20$3;8T.P6BP^0"X99K>]9!:G<Z17B%S7G:4]VR]/06^
MKSI,<4)I2$LS#O#-TG\R]_,,-47E2B.56QIXT^7^=N!)T:$B6!::1<G3HAVE
M?QW']I#3Z:]C(K1Z6^CY<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @
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MT:YQK<KFZ,^Z/T?S3U!+ 0(4 Q0    (  DX!ED'04UB@0   +$    0
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M965T,RYX;6Q02P$"% ,4    "  ). 99Q!S\H+8'  !%)   &
M    @($T&   >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%     @
M"3@&6=MAZ*#* @  % @  !@              ("!("   'AL+W=O<FMS:&5E
M=',O<VAE970U+GAM;%!+ 0(4 Q0    (  DX!EE*Q-SQMPL  "UN   8
M          " @2 C  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q02P$"% ,4
M    "  ). 99L$%T0<D'  !<(@  &               @($-+P  >&PO=V]R
M:W-H965T<R]S:&5E=#<N>&UL4$L! A0#%     @ "3@&61^H>TN] @  B D
M !@              ("!##<  'AL+W=O<FMS:&5E=',O<VAE970X+GAM;%!+
M 0(4 Q0    (  DX!EEB@4-5-@(  .H%   8              " @?\Y  !X
M;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"% ,4    "  ). 99R:F,S&T%
M   B#0  &0              @(%K/   >&PO=V]R:W-H965T<R]S:&5E=#$P
M+GAM;%!+ 0(4 Q0    (  DX!EFXN9.T/@,  " '   9              "
M@0]"  !X;"]W;W)K<VAE971S+W-H965T,3$N>&UL4$L! A0#%     @ "3@&
M60<5\O5:!0  80T  !D              ("!A$4  'AL+W=O<FMS:&5E=',O
M<VAE970Q,BYX;6Q02P$"% ,4    "  ). 99[(U;+D '  #^$0  &0
M        @($52P  >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0
M   (  DX!EGD6^6.-@,  %@'   9              " @8Q2  !X;"]W;W)K
M<VAE971S+W-H965T,30N>&UL4$L! A0#%     @ "3@&62FS>#>2!P  1A,
M !D              ("!^54  'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q0
M2P$"% ,4    "  ). 99KY84%9D#  !;"   &0              @('"70
M>&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    (  DX!EFQ49Z%
M'PH  %T<   9              " @9)A  !X;"]W;W)K<VAE971S+W-H965T
M,3<N>&UL4$L! A0#%     @ "3@&66H&2*>T P  Q0D  !D
M ("!Z&L  'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q02P$"% ,4    "  )
M. 99"L&^),,%  !P$   &0              @('3;P  >&PO=V]R:W-H965T
M<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    (  DX!ED&M=.^@00  *L+   9
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M970R-"YX;6Q02P$"% ,4    "  ). 99>UM\FN,"  !0!@  &0
M    @(&)BP  >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    (
M  DX!ED<H++$= ,   L(   9              " @:..  !X;"]W;W)K<VAE
M971S+W-H965T,C8N>&UL4$L! A0#%     @ "3@&69GL2J0^ @  _@0  !D
M             ("!3I(  'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q02P$"
M% ,4    "  ). 99_O:S*T@"   B!@  &0              @('#E   >&PO
M=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4 Q0    (  DX!EG$#T[PK@,
M (D2   9              " @4*7  !X;"]W;W)K<VAE971S+W-H965T,CDN
M>&UL4$L! A0#%     @ "3@&65@D,5K; @  8 D  !D              ("!
M)YL  'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6Q02P$"% ,4    "  ). 99
MW$1*48<"  #H!@  &0              @($YG@  >&PO=V]R:W-H965T<R]S
M:&5E=#,Q+GAM;%!+ 0(4 Q0    (  DX!ED(]3QSHP(  *X&   9
M      " @?>@  !X;"]W;W)K<VAE971S+W-H965T,S(N>&UL4$L! A0#%
M  @ "3@&6==,!%KD P  .Q0  !D              ("!T:,  'AL+W=O<FMS
M:&5E=',O<VAE970S,RYX;6Q02P$"% ,4    "  ). 999EM>7A<$  #8&
M&0              @('LIP  >&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+
M 0(4 Q0    (  DX!EGBNU4L$@,  $P(   9              " @3JL  !X
M;"]W;W)K<VAE971S+W-H965T,S4N>&UL4$L! A0#%     @ "3@&6<3)9HYM
M!   Y10  !D              ("!@Z\  'AL+W=O<FMS:&5E=',O<VAE970S
M-BYX;6Q02P$"% ,4    "  ). 99<.HX"2$#  !?"0  &0
M@($GM   >&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+ 0(4 Q0    (  DX
M!EG2O^9>&0(  #@$   9              " @7^W  !X;"]W;W)K<VAE971S
M+W-H965T,S@N>&UL4$L! A0#%     @ "3@&6<9,][[("0  GC8  !D
M         ("!S[D  'AL+W=O<FMS:&5E=',O<VAE970S.2YX;6Q02P$"% ,4
M    "  ). 99SN;EN!<$  ")#0  &0              @('.PP  >&PO=V]R
M:W-H965T<R]S:&5E=#0P+GAM;%!+ 0(4 Q0    (  DX!EEX'7@5HP(  &<&
M   9              " @1S(  !X;"]W;W)K<VAE971S+W-H965T-#$N>&UL
M4$L! A0#%     @ "3@&6>X?XWFP!@  Y30  !D              ("!]LH
M 'AL+W=O<FMS:&5E=',O<VAE970T,BYX;6Q02P$"% ,4    "  ). 99.;5!
M<L $  #N)@  &0              @('=T0  >&PO=V]R:W-H965T<R]S:&5E
M=#0S+GAM;%!+ 0(4 Q0    (  DX!EF3:S,D00,   @4   -
M  "  =36  !X;"]S='EL97,N>&UL4$L! A0#%     @ "3@&69>*NQS
M$P(   L              ( !0-H  %]R96QS+RYR96QS4$L! A0#%     @
M"3@&68Y(IC/T P  6AT   \              ( !*=L  'AL+W=O<FMB;V]K
M+GAM;%!+ 0(4 Q0    (  DX!EGN2=W_G@$   @:   :              "
M 4K?  !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    (  DX
M!EFHRH?9JP$  $$:   3              "  2#A  !;0V]N=&5N=%]4>7!E
<<UTN>&UL4$L%!@     S #, W T  /SB      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.2.u1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>127</ContextCount>
  <ElementCount>219</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>35</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="md-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/20240630/taxonomy/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="md-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>100010 - Statement - Consolidated Balance Sheets (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/20240630/taxonomy/role/ConsolidatedBalanceSheetsUnaudited</Role>
      <ShortName>Consolidated Balance Sheets (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="md-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>100020 - Statement - Consolidated Balance Sheets (Unaudited) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/20240630/taxonomy/role/ConsolidatedBalanceSheetsUnauditedParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Unaudited) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="md-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>100030 - Statement - Consolidated Statements of Income and Comprehensive Income (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/20240630/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnaudited</Role>
      <ShortName>Consolidated Statements of Income and Comprehensive Income (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="md-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>100040 - Statement - Consolidated Statements of Income and Comprehensive Income (Unaudited) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/20240630/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnauditedParenthetical</Role>
      <ShortName>Consolidated Statements of Income and Comprehensive Income (Unaudited) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="md-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>100050 - Statement - Consolidated Statements of Shareholders' Equity (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/20240630/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquityUnaudited</Role>
      <ShortName>Consolidated Statements of Shareholders' Equity (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="md-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>100060 - Statement - Consolidated Statements of Cash Flows (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/20240630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited</Role>
      <ShortName>Consolidated Statements of Cash Flows (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="md-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="md-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="md-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>995455 - Disclosure - Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/20240630/taxonomy/role/DisclosureBasisOfPresentation</Role>
      <ShortName>Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="md-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>995475 - Disclosure - Cash Equivalents and Investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/20240630/taxonomy/role/CashEquivalentsAndInvestments</Role>
      <ShortName>Cash Equivalents and Investments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="md-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>995485 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/20240630/taxonomy/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="md-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>995495 - Disclosure - Accounts Receivable and Net Revenue</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/20240630/taxonomy/role/AccountsReceivableAndNetRevenue</Role>
      <ShortName>Accounts Receivable and Net Revenue</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="md-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>995505 - Disclosure - Business Combinations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/20240630/taxonomy/role/DisclosureBusinessCombinations</Role>
      <ShortName>Business Combinations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="md-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>995515 - Disclosure - Goodwill and Long-Lived Asset Impairments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/20240630/taxonomy/role/DisclosureGoodwillAndLonglivedAssetImpairments</Role>
      <ShortName>Goodwill and Long-Lived Asset Impairments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="md-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>995525 - Disclosure - Accounts Payable and Accrued Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/20240630/taxonomy/role/AccountsPayableAndAccruedExpenses</Role>
      <ShortName>Accounts Payable and Accrued Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="md-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>995535 - Disclosure - Line of Credit and Long Term Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/20240630/taxonomy/role/DisclosureLineOfCreditAndLongTermDebt</Role>
      <ShortName>Line of Credit and Long Term Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="md-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>995545 - Disclosure - Common and Common Equivalent Shares</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/20240630/taxonomy/role/CommonAndCommonEquivalentShares</Role>
      <ShortName>Common and Common Equivalent Shares</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="md-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>995555 - Disclosure - Stock Incentive Plans and Stock Purchase Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/20240630/taxonomy/role/StockIncentivePlansAndStockPurchasePlans</Role>
      <ShortName>Stock Incentive Plans and Stock Purchase Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="md-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>995565 - Disclosure - Common Stock Repurchase Programs</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/20240630/taxonomy/role/CommonStockRepurchasePrograms</Role>
      <ShortName>Common Stock Repurchase Programs</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="md-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>995575 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/20240630/taxonomy/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="md-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>995595 - Disclosure - Cash Equivalents and Investments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/20240630/taxonomy/role/CashEquivalentsAndInvestmentsTables</Role>
      <ShortName>Cash Equivalents and Investments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.mednax.com/20240630/taxonomy/role/CashEquivalentsAndInvestments</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="md-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>995605 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/20240630/taxonomy/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.mednax.com/20240630/taxonomy/role/FairValueMeasurements</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="md-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>995615 - Disclosure - Accounts Receivable and Net Revenue (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/20240630/taxonomy/role/AccountsReceivableAndNetRevenueTables</Role>
      <ShortName>Accounts Receivable and Net Revenue (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.mednax.com/20240630/taxonomy/role/AccountsReceivableAndNetRevenue</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="md-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>995625 - Disclosure - Accounts Payable and Accrued Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/20240630/taxonomy/role/AccountsPayableAndAccruedExpensesTables</Role>
      <ShortName>Accounts Payable and Accrued Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.mednax.com/20240630/taxonomy/role/AccountsPayableAndAccruedExpenses</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="md-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>995635 - Disclosure - Common and Common Equivalent Shares (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/20240630/taxonomy/role/CommonAndCommonEquivalentSharesTables</Role>
      <ShortName>Common and Common Equivalent Shares (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.mednax.com/20240630/taxonomy/role/CommonAndCommonEquivalentShares</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="md-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>995645 - Disclosure - Basis of Presentation - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/20240630/taxonomy/role/DisclosureBasisOfPresentationAdditionalInformationDetail</Role>
      <ShortName>Basis of Presentation - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="md-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>995665 - Disclosure - Cash Equivalents and Investments - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/20240630/taxonomy/role/CashEquivalentsAndInvestmentsAdditionalInformationDetail</Role>
      <ShortName>Cash Equivalents and Investments - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="md-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>995675 - Disclosure - Cash Equivalents and Investments - Schedule of Investments (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/20240630/taxonomy/role/CashEquivalentsAndInvestmentsScheduleOfInvestmentsDetail</Role>
      <ShortName>Cash Equivalents and Investments - Schedule of Investments (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="md-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>995685 - Disclosure - Fair Value Measurements - Schedule of fair value on a recurring basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/20240630/taxonomy/role/FairValueMeasurementsScheduleOfFairValueOnARecurringBasisDetails</Role>
      <ShortName>Fair Value Measurements - Schedule of fair value on a recurring basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="md-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>995695 - Disclosure - Fair Value Measurements - Schedule of financial instruments that are not carried at fair value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/20240630/taxonomy/role/FairValueMeasurementsScheduleOfFinancialInstrumentsThatAreNotCarriedAtFairValueDetails</Role>
      <ShortName>Fair Value Measurements - Schedule of financial instruments that are not carried at fair value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="md-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>995715 - Disclosure - Accounts Receivable and Net Revenue - Schedule of Accounts Receivable, Net (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/20240630/taxonomy/role/AccountsReceivableAndNetRevenueScheduleOfAccountsReceivableNetDetail</Role>
      <ShortName>Accounts Receivable and Net Revenue - Schedule of Accounts Receivable, Net (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="md-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>995725 - Disclosure - Accounts Receivable and Net Revenue - Schedule of Net Revenue (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/20240630/taxonomy/role/AccountsReceivableAndNetRevenueScheduleOfNetRevenueDetail</Role>
      <ShortName>Accounts Receivable and Net Revenue - Schedule of Net Revenue (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="md-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>995735 - Disclosure - Accounts Receivable and Net Revenue - Schedule of Net Patient Service Revenue by Type of Payor (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/20240630/taxonomy/role/AccountsReceivableAndNetRevenueScheduleOfNetPatientServiceRevenueByTypeOfPayorDetail</Role>
      <ShortName>Accounts Receivable and Net Revenue - Schedule of Net Patient Service Revenue by Type of Payor (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="md-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>995745 - Disclosure - Business Combinations - Additional information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/20240630/taxonomy/role/DisclosureBusinessCombinationsAdditionalInformationDetail</Role>
      <ShortName>Business Combinations - Additional information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="md-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>995755 - Disclosure - Goodwill and Long-Lived Asset Impairments (Additional Information) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/20240630/taxonomy/role/DisclosureGoodwillAndLonglivedAssetImpairmentsAdditionalInformationDetails</Role>
      <ShortName>Goodwill and Long-Lived Asset Impairments (Additional Information) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.mednax.com/20240630/taxonomy/role/DisclosureGoodwillAndLonglivedAssetImpairments</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="md-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>995765 - Disclosure - Accounts Payable and Accrued Expenses - Schedule of Accounts Payable and Accrued Expenses (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/20240630/taxonomy/role/AccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetail</Role>
      <ShortName>Accounts Payable and Accrued Expenses - Schedule of Accounts Payable and Accrued Expenses (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="md-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>995775 - Disclosure - Accounts Payable and Accrued Expenses - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/20240630/taxonomy/role/AccountsPayableAndAccruedExpensesAdditionalInformationDetail</Role>
      <ShortName>Accounts Payable and Accrued Expenses - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="md-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>995785 - Disclosure - Line of Credit and Long Term Debt (Additional Information) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/20240630/taxonomy/role/DisclosureLineOfCreditAndLongTermDebtAdditionalInformationDetails</Role>
      <ShortName>Line of Credit and Long Term Debt (Additional Information) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.mednax.com/20240630/taxonomy/role/DisclosureLineOfCreditAndLongTermDebt</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="md-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>995795 - Disclosure - Common and Common Equivalent Shares - Schedule of Calculation of Shares Used in Basic and Diluted Net Income Per Share (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/20240630/taxonomy/role/CommonAndCommonEquivalentSharesScheduleOfCalculationOfSharesUsedInBasicAndDilutedNetIncomePerShareDetail</Role>
      <ShortName>Common and Common Equivalent Shares - Schedule of Calculation of Shares Used in Basic and Diluted Net Income Per Share (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="md-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>995815 - Disclosure - Common and Common Equivalent Shares - Schedule of Calculation of Shares Used in Basic and Diluted Net Income Per Share (Parenthetical) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/20240630/taxonomy/role/DisclosureCommonAndCommonEquivalentSharesScheduleOfCalculationOfSharesUsedInBasicAndDilutedNetIncomePerShareParentheticalDetails</Role>
      <ShortName>Common and Common Equivalent Shares - Schedule of Calculation of Shares Used in Basic and Diluted Net Income Per Share (Parenthetical) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="md-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>995825 - Disclosure - Stock Incentive Plans and Stock Purchase Plans - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/20240630/taxonomy/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail</Role>
      <ShortName>Stock Incentive Plans and Stock Purchase Plans - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="md-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>995835 - Disclosure - Common Stock Repurchase Programs - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/20240630/taxonomy/role/CommonStockRepurchaseProgramsAdditionalInformationDetail</Role>
      <ShortName>Common Stock Repurchase Programs - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" isDefinitelyFs="true" isUsgaap="true" original="md-20240630.htm">md-20240630.htm</File>
    <File>md-20240630.xsd</File>
  </InputFiles>
  <SupplementalFiles>
    <File>img260269913_0.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="1">http://fasb.org/srt/2024</BaseTaxonomy>
    <BaseTaxonomy items="471">http://fasb.org/us-gaap/2024</BaseTaxonomy>
    <BaseTaxonomy items="29">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
    <BaseTaxonomy items="4">http://xbrl.sec.gov/ecd/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>false</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>59
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "md-20240630.htm": {
   "nsprefix": "md",
   "nsuri": "http://www.mednax.com/20240630",
   "dts": {
    "inline": {
     "local": [
      "md-20240630.htm"
     ]
    },
    "schema": {
     "local": [
      "md-20240630.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/2023/calculation-1.1.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    }
   },
   "keyStandard": 193,
   "keyCustom": 26,
   "axisStandard": 14,
   "axisCustom": 0,
   "memberStandard": 22,
   "memberCustom": 13,
   "hidden": {
    "total": 10,
    "http://xbrl.sec.gov/dei/2024": 4,
    "http://fasb.org/us-gaap/2024": 6
   },
   "contextCount": 127,
   "entityCount": 1,
   "segmentCount": 35,
   "elementCount": 508,
   "unitCount": 5,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2024": 471,
    "http://xbrl.sec.gov/dei/2024": 29,
    "http://xbrl.sec.gov/ecd/2024": 4,
    "http://fasb.org/srt/2024": 1
   },
   "report": {
    "R1": {
     "role": "http://www.mednax.com/20240630/taxonomy/role/CoverPage",
     "longName": "100000 - Document - Cover Page",
     "shortName": "Cover Page",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "C_0037f299-00cc-441c-a3a7-d37288934aaf",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0037f299-00cc-441c-a3a7-d37288934aaf",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.mednax.com/20240630/taxonomy/role/ConsolidatedBalanceSheetsUnaudited",
     "longName": "100010 - Statement - Consolidated Balance Sheets (Unaudited)",
     "shortName": "Consolidated Balance Sheets (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "C_378538d0-b7e1-4ecd-af00-bb424f0b1747",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_378538d0-b7e1-4ecd-af00-bb424f0b1747",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.mednax.com/20240630/taxonomy/role/ConsolidatedBalanceSheetsUnauditedParenthetical",
     "longName": "100020 - Statement - Consolidated Balance Sheets (Unaudited) (Parenthetical)",
     "shortName": "Consolidated Balance Sheets (Unaudited) (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "C_378538d0-b7e1-4ecd-af00-bb424f0b1747",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_378538d0-b7e1-4ecd-af00-bb424f0b1747",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.mednax.com/20240630/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnaudited",
     "longName": "100030 - Statement - Consolidated Statements of Income and Comprehensive Income (Unaudited)",
     "shortName": "Consolidated Statements of Income and Comprehensive Income (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "C_f8ba14c0-203a-4abe-895a-7068e0d681d9",
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20240630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f8ba14c0-203a-4abe-895a-7068e0d681d9",
      "name": "md:PracticeSalariesAndBenefits",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20240630.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.mednax.com/20240630/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnauditedParenthetical",
     "longName": "100040 - Statement - Consolidated Statements of Income and Comprehensive Income (Unaudited) (Parenthetical)",
     "shortName": "Consolidated Statements of Income and Comprehensive Income (Unaudited) (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "C_f8ba14c0-203a-4abe-895a-7068e0d681d9",
      "name": "md:NetOfTaxUnrealizedHoldingGainLossOnInvestments",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f8ba14c0-203a-4abe-895a-7068e0d681d9",
      "name": "md:NetOfTaxUnrealizedHoldingGainLossOnInvestments",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.mednax.com/20240630/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquityUnaudited",
     "longName": "100050 - Statement - Consolidated Statements of Shareholders' Equity (Unaudited)",
     "shortName": "Consolidated Statements of Shareholders' Equity (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "C_097f26a0-c77e-4f84-b663-38d6391e01e6",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20240630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_1e093f6f-db74-422e-95ac-c5b0a5e76558",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20240630.htm",
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.mednax.com/20240630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited",
     "longName": "100060 - Statement - Consolidated Statements of Cash Flows (Unaudited)",
     "shortName": "Consolidated Statements of Cash Flows (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "C_0037f299-00cc-441c-a3a7-d37288934aaf",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20240630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0037f299-00cc-441c-a3a7-d37288934aaf",
      "name": "us-gaap:AmortizationOfFinancingCostsAndDiscounts",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20240630.htm",
      "unique": true
     }
    },
    "R8": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "C_f8ba14c0-203a-4abe-895a-7068e0d681d9",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20240630.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R9": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "C_f8ba14c0-203a-4abe-895a-7068e0d681d9",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f8ba14c0-203a-4abe-895a-7068e0d681d9",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.mednax.com/20240630/taxonomy/role/DisclosureBasisOfPresentation",
     "longName": "995455 - Disclosure - Basis of Presentation",
     "shortName": "Basis of Presentation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "C_0037f299-00cc-441c-a3a7-d37288934aaf",
      "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0037f299-00cc-441c-a3a7-d37288934aaf",
      "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.mednax.com/20240630/taxonomy/role/CashEquivalentsAndInvestments",
     "longName": "995475 - Disclosure - Cash Equivalents and Investments",
     "shortName": "Cash Equivalents and Investments",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "C_0037f299-00cc-441c-a3a7-d37288934aaf",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0037f299-00cc-441c-a3a7-d37288934aaf",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.mednax.com/20240630/taxonomy/role/FairValueMeasurements",
     "longName": "995485 - Disclosure - Fair Value Measurements",
     "shortName": "Fair Value Measurements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "C_0037f299-00cc-441c-a3a7-d37288934aaf",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0037f299-00cc-441c-a3a7-d37288934aaf",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.mednax.com/20240630/taxonomy/role/AccountsReceivableAndNetRevenue",
     "longName": "995495 - Disclosure - Accounts Receivable and Net Revenue",
     "shortName": "Accounts Receivable and Net Revenue",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "C_0037f299-00cc-441c-a3a7-d37288934aaf",
      "name": "md:AccountsReceivableAndNetRevenueDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0037f299-00cc-441c-a3a7-d37288934aaf",
      "name": "md:AccountsReceivableAndNetRevenueDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.mednax.com/20240630/taxonomy/role/DisclosureBusinessCombinations",
     "longName": "995505 - Disclosure - Business Combinations",
     "shortName": "Business Combinations",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "C_0037f299-00cc-441c-a3a7-d37288934aaf",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0037f299-00cc-441c-a3a7-d37288934aaf",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.mednax.com/20240630/taxonomy/role/DisclosureGoodwillAndLonglivedAssetImpairments",
     "longName": "995515 - Disclosure - Goodwill and Long-Lived Asset Impairments",
     "shortName": "Goodwill and Long-Lived Asset Impairments",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "C_0037f299-00cc-441c-a3a7-d37288934aaf",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0037f299-00cc-441c-a3a7-d37288934aaf",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.mednax.com/20240630/taxonomy/role/AccountsPayableAndAccruedExpenses",
     "longName": "995525 - Disclosure - Accounts Payable and Accrued Expenses",
     "shortName": "Accounts Payable and Accrued Expenses",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "C_0037f299-00cc-441c-a3a7-d37288934aaf",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0037f299-00cc-441c-a3a7-d37288934aaf",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.mednax.com/20240630/taxonomy/role/DisclosureLineOfCreditAndLongTermDebt",
     "longName": "995535 - Disclosure - Line of Credit and Long Term Debt",
     "shortName": "Line of Credit and Long Term Debt",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "C_0037f299-00cc-441c-a3a7-d37288934aaf",
      "name": "md:LineOfCreditAndLongTermDebtTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0037f299-00cc-441c-a3a7-d37288934aaf",
      "name": "md:LineOfCreditAndLongTermDebtTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.mednax.com/20240630/taxonomy/role/CommonAndCommonEquivalentShares",
     "longName": "995545 - Disclosure - Common and Common Equivalent Shares",
     "shortName": "Common and Common Equivalent Shares",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "C_0037f299-00cc-441c-a3a7-d37288934aaf",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0037f299-00cc-441c-a3a7-d37288934aaf",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.mednax.com/20240630/taxonomy/role/StockIncentivePlansAndStockPurchasePlans",
     "longName": "995555 - Disclosure - Stock Incentive Plans and Stock Purchase Plans",
     "shortName": "Stock Incentive Plans and Stock Purchase Plans",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "C_0037f299-00cc-441c-a3a7-d37288934aaf",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0037f299-00cc-441c-a3a7-d37288934aaf",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.mednax.com/20240630/taxonomy/role/CommonStockRepurchasePrograms",
     "longName": "995565 - Disclosure - Common Stock Repurchase Programs",
     "shortName": "Common Stock Repurchase Programs",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "C_0037f299-00cc-441c-a3a7-d37288934aaf",
      "name": "md:CommonStockRepurchasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0037f299-00cc-441c-a3a7-d37288934aaf",
      "name": "md:CommonStockRepurchasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.mednax.com/20240630/taxonomy/role/CommitmentsAndContingencies",
     "longName": "995575 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "C_0037f299-00cc-441c-a3a7-d37288934aaf",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0037f299-00cc-441c-a3a7-d37288934aaf",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.mednax.com/20240630/taxonomy/role/CashEquivalentsAndInvestmentsTables",
     "longName": "995595 - Disclosure - Cash Equivalents and Investments (Tables)",
     "shortName": "Cash Equivalents and Investments (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "22",
     "firstAnchor": {
      "contextRef": "C_0037f299-00cc-441c-a3a7-d37288934aaf",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0037f299-00cc-441c-a3a7-d37288934aaf",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.mednax.com/20240630/taxonomy/role/FairValueMeasurementsTables",
     "longName": "995605 - Disclosure - Fair Value Measurements (Tables)",
     "shortName": "Fair Value Measurements (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "23",
     "firstAnchor": {
      "contextRef": "C_0037f299-00cc-441c-a3a7-d37288934aaf",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0037f299-00cc-441c-a3a7-d37288934aaf",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.mednax.com/20240630/taxonomy/role/AccountsReceivableAndNetRevenueTables",
     "longName": "995615 - Disclosure - Accounts Receivable and Net Revenue (Tables)",
     "shortName": "Accounts Receivable and Net Revenue (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "24",
     "firstAnchor": {
      "contextRef": "C_0037f299-00cc-441c-a3a7-d37288934aaf",
      "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "md:AccountsReceivableAndNetRevenueDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0037f299-00cc-441c-a3a7-d37288934aaf",
      "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "md:AccountsReceivableAndNetRevenueDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.mednax.com/20240630/taxonomy/role/AccountsPayableAndAccruedExpensesTables",
     "longName": "995625 - Disclosure - Accounts Payable and Accrued Expenses (Tables)",
     "shortName": "Accounts Payable and Accrued Expenses (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "25",
     "firstAnchor": {
      "contextRef": "C_0037f299-00cc-441c-a3a7-d37288934aaf",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0037f299-00cc-441c-a3a7-d37288934aaf",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.mednax.com/20240630/taxonomy/role/CommonAndCommonEquivalentSharesTables",
     "longName": "995635 - Disclosure - Common and Common Equivalent Shares (Tables)",
     "shortName": "Common and Common Equivalent Shares (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "C_0037f299-00cc-441c-a3a7-d37288934aaf",
      "name": "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0037f299-00cc-441c-a3a7-d37288934aaf",
      "name": "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.mednax.com/20240630/taxonomy/role/DisclosureBasisOfPresentationAdditionalInformationDetail",
     "longName": "995645 - Disclosure - Basis of Presentation - Additional Information (Detail)",
     "shortName": "Basis of Presentation - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "27",
     "firstAnchor": {
      "contextRef": "C_82895573-2795-4732-b42c-4cd5883caf98",
      "name": "us-gaap:EquityMethodInvestmentOwnershipPercentage",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "span",
       "p",
       "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_82895573-2795-4732-b42c-4cd5883caf98",
      "name": "us-gaap:EquityMethodInvestmentOwnershipPercentage",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "span",
       "p",
       "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.mednax.com/20240630/taxonomy/role/CashEquivalentsAndInvestmentsAdditionalInformationDetail",
     "longName": "995665 - Disclosure - Cash Equivalents and Investments - Additional Information (Detail)",
     "shortName": "Cash Equivalents and Investments - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "28",
     "firstAnchor": {
      "contextRef": "C_e1d34d08-f45e-4aed-a85a-ba2eecf7da87",
      "name": "us-gaap:MoneyMarketFundsAtCarryingValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e1d34d08-f45e-4aed-a85a-ba2eecf7da87",
      "name": "us-gaap:MoneyMarketFundsAtCarryingValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.mednax.com/20240630/taxonomy/role/CashEquivalentsAndInvestmentsScheduleOfInvestmentsDetail",
     "longName": "995675 - Disclosure - Cash Equivalents and Investments - Schedule of Investments (Detail)",
     "shortName": "Cash Equivalents and Investments - Schedule of Investments (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "29",
     "firstAnchor": {
      "contextRef": "C_378538d0-b7e1-4ecd-af00-bb424f0b1747",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "div",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_378538d0-b7e1-4ecd-af00-bb424f0b1747",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "div",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.mednax.com/20240630/taxonomy/role/FairValueMeasurementsScheduleOfFairValueOnARecurringBasisDetails",
     "longName": "995685 - Disclosure - Fair Value Measurements - Schedule of fair value on a recurring basis (Details)",
     "shortName": "Fair Value Measurements - Schedule of fair value on a recurring basis (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "30",
     "firstAnchor": {
      "contextRef": "C_c97ff8ba-a0bb-4c2f-9d12-7e68bbd283c7",
      "name": "md:MoneyMarketFundsFairValueDisclosure",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_c97ff8ba-a0bb-4c2f-9d12-7e68bbd283c7",
      "name": "md:MoneyMarketFundsFairValueDisclosure",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.mednax.com/20240630/taxonomy/role/FairValueMeasurementsScheduleOfFinancialInstrumentsThatAreNotCarriedAtFairValueDetails",
     "longName": "995695 - Disclosure - Fair Value Measurements - Schedule of financial instruments that are not carried at fair value (Details)",
     "shortName": "Fair Value Measurements - Schedule of financial instruments that are not carried at fair value (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "31",
     "firstAnchor": {
      "contextRef": "C_74e636e1-15c7-4b53-87ca-8d27ceeed147",
      "name": "us-gaap:NotesPayable",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "md:FinancialInstrumentsMeasuredAtCarryingAmountTableTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_74e636e1-15c7-4b53-87ca-8d27ceeed147",
      "name": "us-gaap:NotesPayable",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "md:FinancialInstrumentsMeasuredAtCarryingAmountTableTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.mednax.com/20240630/taxonomy/role/AccountsReceivableAndNetRevenueScheduleOfAccountsReceivableNetDetail",
     "longName": "995715 - Disclosure - Accounts Receivable and Net Revenue - Schedule of Accounts Receivable, Net (Detail)",
     "shortName": "Accounts Receivable and Net Revenue - Schedule of Accounts Receivable, Net (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "32",
     "firstAnchor": {
      "contextRef": "C_378538d0-b7e1-4ecd-af00-bb424f0b1747",
      "name": "us-gaap:AccountsReceivableGrossCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
       "div",
       "md:AccountsReceivableAndNetRevenueDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_378538d0-b7e1-4ecd-af00-bb424f0b1747",
      "name": "us-gaap:AccountsReceivableGrossCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
       "div",
       "md:AccountsReceivableAndNetRevenueDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.mednax.com/20240630/taxonomy/role/AccountsReceivableAndNetRevenueScheduleOfNetRevenueDetail",
     "longName": "995725 - Disclosure - Accounts Receivable and Net Revenue - Schedule of Net Revenue (Detail)",
     "shortName": "Accounts Receivable and Net Revenue - Schedule of Net Revenue (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "C_f8ba14c0-203a-4abe-895a-7068e0d681d9",
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20240630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_8d682d9c-f4a6-4720-b0e5-6aba644d655b",
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "div",
       "md:AccountsReceivableAndNetRevenueDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20240630.htm",
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.mednax.com/20240630/taxonomy/role/AccountsReceivableAndNetRevenueScheduleOfNetPatientServiceRevenueByTypeOfPayorDetail",
     "longName": "995735 - Disclosure - Accounts Receivable and Net Revenue - Schedule of Net Patient Service Revenue by Type of Payor (Detail)",
     "shortName": "Accounts Receivable and Net Revenue - Schedule of Net Patient Service Revenue by Type of Payor (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "C_f8ba14c0-203a-4abe-895a-7068e0d681d9",
      "name": "md:PercentageOfNetPatientServiceRevenueByTypeOfPayor",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
       "div",
       "md:AccountsReceivableAndNetRevenueDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f8ba14c0-203a-4abe-895a-7068e0d681d9",
      "name": "md:PercentageOfNetPatientServiceRevenueByTypeOfPayor",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
       "div",
       "md:AccountsReceivableAndNetRevenueDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.mednax.com/20240630/taxonomy/role/DisclosureBusinessCombinationsAdditionalInformationDetail",
     "longName": "995745 - Disclosure - Business Combinations - Additional information (Detail)",
     "shortName": "Business Combinations - Additional information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "C_378538d0-b7e1-4ecd-af00-bb424f0b1747",
      "name": "us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:BusinessCombinationDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_378538d0-b7e1-4ecd-af00-bb424f0b1747",
      "name": "us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:BusinessCombinationDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.mednax.com/20240630/taxonomy/role/DisclosureGoodwillAndLonglivedAssetImpairmentsAdditionalInformationDetails",
     "longName": "995755 - Disclosure - Goodwill and Long-Lived Asset Impairments (Additional Information) (Details)",
     "shortName": "Goodwill and Long-Lived Asset Impairments (Additional Information) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "C_f8ba14c0-203a-4abe-895a-7068e0d681d9",
      "name": "us-gaap:ImpairmentOfLongLivedAssetsHeldForUse",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20240630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0037f299-00cc-441c-a3a7-d37288934aaf",
      "name": "us-gaap:OperatingLeaseImpairmentLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20240630.htm",
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.mednax.com/20240630/taxonomy/role/AccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetail",
     "longName": "995765 - Disclosure - Accounts Payable and Accrued Expenses - Schedule of Accounts Payable and Accrued Expenses (Detail)",
     "shortName": "Accounts Payable and Accrued Expenses - Schedule of Accounts Payable and Accrued Expenses (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "C_378538d0-b7e1-4ecd-af00-bb424f0b1747",
      "name": "us-gaap:AccountsPayableCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "div",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_378538d0-b7e1-4ecd-af00-bb424f0b1747",
      "name": "us-gaap:AccountsPayableCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "div",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.mednax.com/20240630/taxonomy/role/AccountsPayableAndAccruedExpensesAdditionalInformationDetail",
     "longName": "995775 - Disclosure - Accounts Payable and Accrued Expenses - Additional Information (Detail)",
     "shortName": "Accounts Payable and Accrued Expenses - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "C_0037f299-00cc-441c-a3a7-d37288934aaf",
      "name": "md:IncreaseDecreaseInAccruedSalariesAndBonuses",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0037f299-00cc-441c-a3a7-d37288934aaf",
      "name": "md:IncreaseDecreaseInAccruedSalariesAndBonuses",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.mednax.com/20240630/taxonomy/role/DisclosureLineOfCreditAndLongTermDebtAdditionalInformationDetails",
     "longName": "995785 - Disclosure - Line of Credit and Long Term Debt (Additional Information) (Details)",
     "shortName": "Line of Credit and Long Term Debt (Additional Information) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "C_378538d0-b7e1-4ecd-af00-bb424f0b1747",
      "name": "us-gaap:DebtInstrumentInterestRateStatedPercentage",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "5",
      "ancestors": [
       "span",
       "p",
       "md:LineOfCreditAndLongTermDebtTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_378538d0-b7e1-4ecd-af00-bb424f0b1747",
      "name": "us-gaap:DebtInstrumentInterestRateStatedPercentage",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "5",
      "ancestors": [
       "span",
       "p",
       "md:LineOfCreditAndLongTermDebtTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.mednax.com/20240630/taxonomy/role/CommonAndCommonEquivalentSharesScheduleOfCalculationOfSharesUsedInBasicAndDilutedNetIncomePerShareDetail",
     "longName": "995795 - Disclosure - Common and Common Equivalent Shares - Schedule of Calculation of Shares Used in Basic and Diluted Net Income Per Share (Detail)",
     "shortName": "Common and Common Equivalent Shares - Schedule of Calculation of Shares Used in Basic and Diluted Net Income Per Share (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "C_f8ba14c0-203a-4abe-895a-7068e0d681d9",
      "name": "us-gaap:WeightedAverageNumberOfSharesOutstandingBasic",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20240630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f8ba14c0-203a-4abe-895a-7068e0d681d9",
      "name": "us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20240630.htm",
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.mednax.com/20240630/taxonomy/role/DisclosureCommonAndCommonEquivalentSharesScheduleOfCalculationOfSharesUsedInBasicAndDilutedNetIncomePerShareParentheticalDetails",
     "longName": "995815 - Disclosure - Common and Common Equivalent Shares - Schedule of Calculation of Shares Used in Basic and Diluted Net Income Per Share (Parenthetical) (Details)",
     "shortName": "Common and Common Equivalent Shares - Schedule of Calculation of Shares Used in Basic and Diluted Net Income Per Share (Parenthetical) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "parenthetical",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "C_f8ba14c0-203a-4abe-895a-7068e0d681d9",
      "name": "md:IncrementalSharesNotIncludedDueToAntiDilutiveEffect",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "link:footnote",
       "p",
       "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f8ba14c0-203a-4abe-895a-7068e0d681d9",
      "name": "md:IncrementalSharesNotIncludedDueToAntiDilutiveEffect",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "link:footnote",
       "p",
       "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.mednax.com/20240630/taxonomy/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail",
     "longName": "995825 - Disclosure - Stock Incentive Plans and Stock Purchase Plans - Additional Information (Detail)",
     "shortName": "Stock Incentive Plans and Stock Purchase Plans - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "C_f8ba14c0-203a-4abe-895a-7068e0d681d9",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f8ba14c0-203a-4abe-895a-7068e0d681d9",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.mednax.com/20240630/taxonomy/role/CommonStockRepurchaseProgramsAdditionalInformationDetail",
     "longName": "995835 - Disclosure - Common Stock Repurchase Programs - Additional Information (Detail)",
     "shortName": "Common Stock Repurchase Programs - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "C_0037f299-00cc-441c-a3a7-d37288934aaf",
      "name": "us-gaap:StockRepurchasedDuringPeriodShares",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "md:CommonStockRepurchasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20240630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_c38ac2d9-9615-4715-baeb-08e4368151a9",
      "name": "srt:StockRepurchaseProgramAuthorizedAmount1",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "md:CommonStockRepurchasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20240630.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsNotesLoansAndFinancingReceivableGrossAllowanceAndNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsNotesLoansAndFinancingReceivableGrossAllowanceAndNetAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts, Notes, Loans and Financing Receivable, Gross, Allowance, and Net [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/AccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Accounts payable and accrued expenses, total",
        "label": "Accounts Payable and Accrued Liabilities, Current",
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r65"
     ]
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/AccountsPayableAndAccruedExpenses"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts Payable and Accrued Expenses",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r65",
      "r71",
      "r937"
     ]
    },
    "md_AccountsPayableAndAccruedLiabilitiesExcludingAccruedIncomeTaxesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mednax.com/20240630",
     "localname": "AccountsPayableAndAccruedLiabilitiesExcludingAccruedIncomeTaxesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable and accrued expenses",
        "label": "Accounts Payable and Accrued Liabilities Excluding Accrued Income Taxes Current",
        "documentation": "Accounts payable and accrued liabilities excluding accrued income taxes current."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/AccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Accounts Payable, Current",
        "totalLabel": "Accounts Payable, Current, Total",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r722"
     ]
    },
    "md_AccountsReceivableAndNetRevenueDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.mednax.com/20240630",
     "localname": "AccountsReceivableAndNetRevenueDisclosureTextBlock",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/AccountsReceivableAndNetRevenue"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts Receivable and Net Revenue",
        "label": "Accounts Receivable And Net Revenue Disclosure [Text Block]",
        "documentation": "Accounts receivable and net revenue disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsReceivableGrossCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsReceivableGrossCurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/AccountsReceivableAndNetRevenueScheduleOfAccountsReceivableNetDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross accounts receivable",
        "label": "Accounts Receivable, before Allowance for Credit Loss, Current",
        "documentation": "Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current."
       }
      }
     },
     "auth_ref": [
      "r180",
      "r252",
      "r673"
     ]
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsReceivableNetCurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/AccountsReceivableAndNetRevenueScheduleOfAccountsReceivableNetDetail",
      "http://www.mednax.com/20240630/taxonomy/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Accounts receivable, net",
        "terseLabel": "Accounts receivable, net",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current."
       }
      }
     },
     "auth_ref": [
      "r866"
     ]
    },
    "us-gaap_AccruedIncomeTaxesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedIncomeTaxesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Income Taxes, Current",
        "terseLabel": "Income taxes payable",
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r115"
     ]
    },
    "md_AccruedPayrollTaxesAndBenefitsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mednax.com/20240630",
     "localname": "AccruedPayrollTaxesAndBenefitsCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/AccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued payroll taxes and benefits",
        "label": "Accrued Payroll Taxes And Benefits Current",
        "documentation": "Accrued payroll taxes and benefits current."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedSalariesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedSalariesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/AccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued salaries and incentive compensation",
        "label": "Accrued Salaries, Current",
        "documentation": "Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r675"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accumulated other comprehensive loss",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "totalLabel": "Accumulated Other Comprehensive Income (Loss), Net of Tax, Total",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r15",
      "r83",
      "r181",
      "r535",
      "r564",
      "r565"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Other Comprehensive Loss [Member]",
        "label": "AOCI Attributable to Parent [Member]",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r10",
      "r15",
      "r440",
      "r443",
      "r483",
      "r560",
      "r561",
      "r844",
      "r845",
      "r846",
      "r854",
      "r855",
      "r856",
      "r858"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional 402(v) Disclosure [Text Block]",
        "terseLabel": "Additional 402(v) Disclosure"
       }
      }
     },
     "auth_ref": [
      "r777"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalCommonStock",
     "crdr": "credit",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional paid-in capital",
        "label": "Additional Paid in Capital, Common Stock",
        "periodStartLabel": "Additional Paid in Capital, Common Stock, Beginning Balance",
        "periodEndLabel": "Additional Paid in Capital, Common Stock, Ending Balance",
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital."
       }
      }
     },
     "auth_ref": [
      "r77"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional Paid-in Capital [Member]",
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r575",
      "r854",
      "r855",
      "r856",
      "r858",
      "r945",
      "r1004"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation Amount",
        "terseLabel": "Adjustment to Compensation, Amount"
       }
      }
     },
     "auth_ref": [
      "r790"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation [Axis]",
        "terseLabel": "Adjustment to Compensation:"
       }
      }
     },
     "auth_ref": [
      "r790"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]",
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote"
       }
      }
     },
     "auth_ref": [
      "r790"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]",
        "terseLabel": "Adjustment To PEO Compensation, Footnote"
       }
      }
     },
     "auth_ref": [
      "r790"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation expense",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "totalLabel": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r34",
      "r376"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net income to net cash from operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r823"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Amount",
        "terseLabel": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r749",
      "r759",
      "r769",
      "r801"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]",
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined"
       }
      }
     },
     "auth_ref": [
      "r752",
      "r762",
      "r772",
      "r804"
     ]
    },
    "ecd_AggtPnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtPnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Pension Adjustments Service Cost [Member]",
        "terseLabel": "Aggregate Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r824"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Adjustments to Compensation [Member]",
        "terseLabel": "All Adjustments to Compensation"
       }
      }
     },
     "auth_ref": [
      "r790"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Executive Categories [Member]",
        "terseLabel": "All Executive Categories"
       }
      }
     },
     "auth_ref": [
      "r797"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Individuals [Member]",
        "terseLabel": "All Individuals"
       }
      }
     },
     "auth_ref": [
      "r753",
      "r763",
      "r773",
      "r797",
      "r805",
      "r809",
      "r817"
     ]
    },
    "us-gaap_AllOtherCorporateBondsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllOtherCorporateBondsMember",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/CashEquivalentsAndInvestmentsScheduleOfInvestmentsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Corporate Bonds [Member]",
        "terseLabel": "Corporate securities",
        "documentation": "Investments in corporate fixed maturity debt securities classified as other."
       }
      }
     },
     "auth_ref": [
      "r1006"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Trading Arrangements [Member]",
        "terseLabel": "All Trading Arrangements"
       }
      }
     },
     "auth_ref": [
      "r815"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation expense",
        "label": "Share-Based Payment Arrangement, Expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r406",
      "r410"
     ]
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllowanceForDoubtfulAccountsReceivableCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/AccountsReceivableAndNetRevenueScheduleOfAccountsReceivableNetDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Allowance for contractual adjustments and uncollectibles",
        "label": "Accounts Receivable, Allowance for Credit Loss, Current",
        "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current."
       }
      }
     },
     "auth_ref": [
      "r182",
      "r253",
      "r295"
     ]
    },
    "md_AmendedAndRestatedTwoThousandEightPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mednax.com/20240630",
     "localname": "AmendedAndRestatedTwoThousandEightPlanMember",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amended and Restated 2008 Plan [Member]",
        "label": "Amended and Restated Two Thousand Eight Plan [Member]",
        "documentation": "Amended and restated two thousand eight plan."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfFinancingCostsAndDiscounts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AmortizationOfFinancingCostsAndDiscounts",
     "crdr": "debit",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of premiums, discounts and issuance costs",
        "label": "Amortization of Debt Issuance Costs and Discounts",
        "totalLabel": "Amortization of Debt Issuance Costs and Discounts, Total",
        "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r351",
      "r689",
      "r690",
      "r849",
      "r956"
     ]
    },
    "md_AnesthesiologyServicesMedicalGroupMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mednax.com/20240630",
     "localname": "AnesthesiologyServicesMedicalGroupMember",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/DisclosureBusinessCombinationsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Anesthesiology Services Medical Group [Member]",
        "documentation": "Anesthesiology services medical group."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/CommonAndCommonEquivalentSharesScheduleOfCalculationOfSharesUsedInBasicAndDilutedNetIncomePerShareDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Antidilutive securities (restricted stock and stock options) not included in the diluted net income per common share calculation",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r229"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Assets",
     "crdr": "debit",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r113",
      "r126",
      "r175",
      "r200",
      "r233",
      "r237",
      "r246",
      "r247",
      "r292",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r432",
      "r437",
      "r468",
      "r528",
      "r616",
      "r680",
      "r681",
      "r722",
      "r740",
      "r904",
      "r905",
      "r961"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ASSETS",
        "label": "Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r170",
      "r185",
      "r200",
      "r292",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r432",
      "r437",
      "r468",
      "r722",
      "r904",
      "r905",
      "r961"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current assets:",
        "label": "Assets, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsFairValueDisclosureAbstract",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/FairValueMeasurementsScheduleOfFairValueOnARecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets:",
        "label": "Assets, Fair Value Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "crdr": "debit",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/CashEquivalentsAndInvestmentsScheduleOfInvestmentsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Debt Securities, Available-for-sale, Total",
        "label": "Debt Securities, Available-for-Sale",
        "terseLabel": "Available-for-sale Securities",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r259",
      "r301",
      "r450",
      "r522",
      "r710",
      "r714",
      "r868",
      "r949",
      "r950",
      "r951"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Short-term investments",
        "label": "Debt Securities, Available-for-Sale, Current",
        "totalLabel": "Debt Securities, Available-for-sale, Current, Total",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current."
       }
      }
     },
     "auth_ref": [
      "r255",
      "r301"
     ]
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Exercise Price",
        "terseLabel": "Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r812"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Grant Date Fair Value",
        "terseLabel": "Fair Value as of Grant Date"
       }
      }
     },
     "auth_ref": [
      "r813"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]",
        "terseLabel": "Award Timing Disclosures"
       }
      }
     },
     "auth_ref": [
      "r808"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing, How MNPI Considered [Text Block]",
        "terseLabel": "Award Timing, How MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r808"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Method [Text Block]",
        "terseLabel": "Award Timing Method"
       }
      }
     },
     "auth_ref": [
      "r808"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Considered [Flag]",
        "terseLabel": "Award Timing MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r808"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Disclosure [Text Block]",
        "terseLabel": "Award Timing MNPI Disclosure"
       }
      }
     },
     "auth_ref": [
      "r808"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Predetermined [Flag]",
        "terseLabel": "Award Timing Predetermined"
       }
      }
     },
     "auth_ref": [
      "r808"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/CommonStockRepurchaseProgramsAdditionalInformationDetail",
      "http://www.mednax.com/20240630/taxonomy/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Underlying Securities Amount",
        "terseLabel": "Underlying Securities"
       }
      }
     },
     "auth_ref": [
      "r811"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r810"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures"
       }
      }
     },
     "auth_ref": [
      "r809"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table"
       }
      }
     },
     "auth_ref": [
      "r809"
     ]
    },
    "md_BasisOfPresentationAndNewAccountingPronouncementsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.mednax.com/20240630",
     "localname": "BasisOfPresentationAndNewAccountingPronouncementsTable",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/DisclosureBasisOfPresentationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of Presentation and New Accounting Pronouncements [Table]",
        "documentation": "Basis Of Presentation And New Accounting Pronouncements Table"
       }
      }
     },
     "auth_ref": []
    },
    "md_BasisOfPresentationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.mednax.com/20240630",
     "localname": "BasisOfPresentationLineItems",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/DisclosureBasisOfPresentationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis Of Presentation [Line Items]",
        "documentation": "Basis Of Presentation Line Items"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionAcquireeDomain",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/DisclosureBusinessCombinationsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Acquisition, Acquiree [Domain]",
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree."
       }
      }
     },
     "auth_ref": [
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r426",
      "r702",
      "r703"
     ]
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionAxis",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/DisclosureBusinessCombinationsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Acquisition [Axis]",
        "documentation": "Information by business combination or series of individually immaterial business combinations."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r36",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r426",
      "r702",
      "r703"
     ]
    },
    "us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/DisclosureBusinessCombinationsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill",
        "label": "Business Acquisition, Goodwill, Expected Tax Deductible Amount",
        "documentation": "The amount of goodwill arising from a business combination that is expected to be deductible for tax purposes."
       }
      }
     },
     "auth_ref": [
      "r40"
     ]
    },
    "us-gaap_BusinessCombinationConsiderationTransferred1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationConsiderationTransferred1",
     "crdr": "credit",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/DisclosureBusinessCombinationsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Consideration Transferred",
        "totalLabel": "Business Combination, Consideration Transferred, Total",
        "terseLabel": "Business acquisition total consideration",
        "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r1",
      "r9"
     ]
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationDisclosureTextBlock",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/DisclosureBusinessCombinations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination Disclosure [Text Block]",
        "terseLabel": "Business Combinations",
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable)."
       }
      }
     },
     "auth_ref": [
      "r108",
      "r427"
     ]
    },
    "us-gaap_BusinessCombinationLiabilitiesArisingFromContingenciesAmountRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationLiabilitiesArisingFromContingenciesAmountRecognized",
     "crdr": "credit",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/DisclosureBusinessCombinationsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Liabilities Arising from Contingencies, Amount Recognized",
        "terseLabel": "Business combination consideration identifiable as current and long term liabilities",
        "documentation": "The amount, measured at acquisition-date fair value, of all liabilities assumed that arise from contingencies and were recognized by the entity."
       }
      }
     },
     "auth_ref": [
      "r39"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/DisclosureBusinessCombinationsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets",
        "totalLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Total",
        "terseLabel": "Business combination consideration identifiable as current and long term liabilities",
        "documentation": "Amount of assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r38"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles",
     "crdr": "debit",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/DisclosureBusinessCombinationsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other intangible assets",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles",
        "documentation": "The amount of identifiable intangible assets recognized as of the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r38"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment",
     "crdr": "debit",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/DisclosureBusinessCombinationsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fixed assets",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment",
        "totalLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment, Total",
        "documentation": "The amount of property, plant, and equipment recognized as of the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r38"
     ]
    },
    "us-gaap_BusinessCombinationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combinations [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Cash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Cash",
     "crdr": "debit",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/DisclosureLineOfCreditAndLongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash, Beginning Balance",
        "periodEndLabel": "Cash, Ending Balance",
        "label": "Cash",
        "terseLabel": "Cash on hand",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r128",
      "r532",
      "r586",
      "r611",
      "r722",
      "r740",
      "r842"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash and cash equivalents at beginning of period",
        "terseLabel": "Cash and cash equivalents",
        "periodEndLabel": "Cash and cash equivalents at end of period",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "totalLabel": "Cash and Cash Equivalents, at Carrying Value, Total",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r172",
      "r672"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAxis",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/CashEquivalentsAndInvestmentsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Axis]",
        "documentation": "Information by type of cash and cash equivalent balance."
       }
      }
     },
     "auth_ref": [
      "r172"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "crdr": "debit",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Cash and cash equivalents at end of period",
        "periodStartLabel": "Cash and cash equivalents at beginning of period",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations",
        "totalLabel": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r96",
      "r199"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net decrease in cash and cash equivalents",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r96"
     ]
    },
    "md_CashEquivalentsAndInvestmentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.mednax.com/20240630",
     "localname": "CashEquivalentsAndInvestmentsLineItems",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/CashEquivalentsAndInvestmentsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Equivalents And Investments [Line Items]",
        "documentation": "Cash Equivalents And Investments Line Items"
       }
      }
     },
     "auth_ref": []
    },
    "md_CashEquivalentsAndInvestmentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.mednax.com/20240630",
     "localname": "CashEquivalentsAndInvestmentsTable",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/CashEquivalentsAndInvestmentsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Equivalents and Investments [Table]",
        "documentation": "Cash Equivalents And Investments Table"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashEquivalentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashEquivalentsMember",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/CashEquivalentsAndInvestmentsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Equivalents [Member]",
        "documentation": "Short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r172"
     ]
    },
    "us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations",
     "crdr": "debit",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net cash used in operating activities - discontinued operations",
        "label": "Cash Provided by (Used in) Operating Activities, Discontinued Operations",
        "verboseLabel": "Net cash provided by operating activities - discontinued operations",
        "totalLabel": "Cash Provided by (Used in) Operating Activities, Discontinued Operations, Total",
        "documentation": "Amount of cash inflow (outflow) of operating activities of discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r96"
     ]
    },
    "us-gaap_CertificatesOfDepositMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CertificatesOfDepositMember",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/CashEquivalentsAndInvestmentsScheduleOfInvestmentsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Certificates of Deposit [Member]",
        "label": "Certificates of Deposit [Member]",
        "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r734",
      "r735",
      "r736",
      "r737"
     ]
    },
    "md_ChangeInNonCashImpairmentCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mednax.com/20240630",
     "localname": "ChangeInNonCashImpairmentCharges",
     "crdr": "debit",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/DisclosureGoodwillAndLonglivedAssetImpairmentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible asset impairments",
        "label": "Change in Non Cash Impairment Charges",
        "documentation": "Change in Non Cash Impairment Charges"
       }
      }
     },
     "auth_ref": []
    },
    "md_ChangeInRateOfControlPremium": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.mednax.com/20240630",
     "localname": "ChangeInRateOfControlPremium",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/DisclosureGoodwillAndLonglivedAssetImpairmentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in Rate of Control Premium",
        "label": "Change in Rate of Control Premium",
        "documentation": "Change in Rate of Control Premium"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changed Peer Group, Footnote [Text Block]",
        "terseLabel": "Changed Peer Group, Footnote"
       }
      }
     },
     "auth_ref": [
      "r788"
     ]
    },
    "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]",
        "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r785"
     ]
    },
    "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]",
        "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r783"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/AccountsPayableAndAccruedExpensesAdditionalInformationDetail",
      "http://www.mednax.com/20240630/taxonomy/role/DisclosureCoronavirusPandemicCovid19AdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Domain]",
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r131",
      "r177",
      "r178",
      "r179",
      "r200",
      "r220",
      "r224",
      "r226",
      "r228",
      "r235",
      "r236",
      "r292",
      "r327",
      "r329",
      "r330",
      "r331",
      "r334",
      "r335",
      "r355",
      "r356",
      "r357",
      "r358",
      "r360",
      "r468",
      "r568",
      "r569",
      "r570",
      "r571",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r587",
      "r603",
      "r625",
      "r642",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r827",
      "r850",
      "r859"
     ]
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Amount",
        "terseLabel": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r789"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Name",
        "terseLabel": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r789"
     ]
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and contingencies",
        "label": "Commitments and Contingencies",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r117",
      "r531",
      "r602"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/CommitmentsAndContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r104",
      "r320",
      "r321",
      "r668",
      "r892",
      "r898"
     ]
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, reserved for issuance",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r75"
     ]
    },
    "md_CommonStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.mednax.com/20240630",
     "localname": "CommonStockLineItems",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/CommonStockRepurchaseProgramsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock [Line Items]",
        "label": "Common Stock [Line Items]",
        "documentation": "Common Stock [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/CommonStockRepurchaseProgramsAdditionalInformationDetail",
      "http://www.mednax.com/20240630/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock [Member]",
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r730",
      "r731",
      "r732",
      "r734",
      "r735",
      "r736",
      "r737",
      "r854",
      "r855",
      "r858",
      "r945",
      "r1003",
      "r1004"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/ConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, par value",
        "label": "Common Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r75"
     ]
    },
    "md_CommonStockRepurchasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.mednax.com/20240630",
     "localname": "CommonStockRepurchasesTextBlock",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/CommonStockRepurchasePrograms"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock Repurchase Programs",
        "label": "Common Stock Repurchases [Text Block]",
        "documentation": "Entire disclosure of common stock repurchases."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/ConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Common stock, shares authorized",
        "terseLabel": "Common stock, aggregate shares authorized",
        "label": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r603"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/ConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares issued",
        "label": "Common Stock, Shares, Issued",
        "totalLabel": "Common Stock, Shares, Issued, Total",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r75"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/ConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares outstanding",
        "label": "Common Stock, Shares, Outstanding",
        "periodStartLabel": "Common Stock, Shares, Outstanding, Beginning Balance",
        "periodEndLabel": "Common Stock, Shares, Outstanding, Ending Balance",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r75",
      "r603",
      "r622",
      "r1004",
      "r1005"
     ]
    },
    "md_CommonStockTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.mednax.com/20240630",
     "localname": "CommonStockTable",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/CommonStockRepurchaseProgramsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock [Table]",
        "label": "Common Stock [Table]",
        "documentation": "Common Stock [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Common stock; $.01 par value; 200,000 shares authorized; 85,753,258 and 84,018,023 shares issued and outstanding, respectively",
        "label": "Common Stock, Value, Issued",
        "totalLabel": "Common Stock, Value, Issued, Total",
        "periodStartLabel": "Common Stock, Value, Issued, Beginning Balance",
        "periodEndLabel": "Common Stock, Value, Issued, Ending Balance",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r534",
      "r722"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure"
       }
      }
     },
     "auth_ref": [
      "r794"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Net Income [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Net Income"
       }
      }
     },
     "auth_ref": [
      "r793"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Other Measure"
       }
      }
     },
     "auth_ref": [
      "r795"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return"
       }
      }
     },
     "auth_ref": [
      "r792"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total comprehensive (loss) income",
        "terseLabel": "Total comprehensive income (loss) attributable to Pediatrix Medical Group, Inc.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r189",
      "r191",
      "r195",
      "r523",
      "r547",
      "r548"
     ]
    },
    "md_ContractedManagedCareMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mednax.com/20240630",
     "localname": "ContractedManagedCareMember",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/AccountsReceivableAndNetRevenueScheduleOfNetPatientServiceRevenueByTypeOfPayorDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contracted Managed Care",
        "label": "Contracted Managed Care [Member]",
        "documentation": "Contracted Managed Care [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "md_ContributionsInAidOfReimbursementOfLostRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mednax.com/20240630",
     "localname": "ContributionsInAidOfReimbursementOfLostRevenue",
     "crdr": "credit",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/DisclosureCoronavirusPandemicCovid19AdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reimbursement of Lost Revenue",
        "label": "Contributions In Aid Of Reimbursement of Lost Revenue",
        "documentation": "Contributions In Aid Of Reimbursement of Lost Revenue."
       }
      }
     },
     "auth_ref": []
    },
    "md_CoronavirusPandemicCOVIDNineteenDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.mednax.com/20240630",
     "localname": "CoronavirusPandemicCOVIDNineteenDisclosureTextBlock",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/DisclosureCoronavirusPandemicCovid191"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Coronavirus Pandemic COVID Nineteen Disclosure [Text Block]",
        "documentation": "Coronavirus Pandemic COVID Nineteen Disclosure [Text Block]",
        "terseLabel": "Coronavirus Pandemic (COVID-19)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CorporateJointVentureMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CorporateJointVentureMember",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/DisclosureBasisOfPresentationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Corporate Joint Venture [Member]",
        "documentation": "Corporation owned and operated by a small group of ventures to accomplish a mutually beneficial venture or project."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "md_CovidNinenteenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mednax.com/20240630",
     "localname": "CovidNinenteenMember",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/DisclosureCoronavirusPandemicCovid19AdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "COVID-19 [Member]",
        "label": "Covid Ninenteen [Member]",
        "documentation": "Covid Ninenteen [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "md_CreditAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mednax.com/20240630",
     "localname": "CreditAgreementMember",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/DisclosureLineOfCreditAndLongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Credit Agreement [Member]",
        "label": "Credit Agreement [Member]",
        "documentation": "Credit Agreement [Member]",
        "terseLabel": "Amended Credit Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CreditFacilityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CreditFacilityAxis",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/DisclosureCoronavirusPandemicCovid19AdditionalInformationDetail",
      "http://www.mednax.com/20240630/taxonomy/role/DisclosureLineOfCreditAndLongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Credit Facility [Axis]",
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing."
       }
      }
     },
     "auth_ref": [
      "r326",
      "r902"
     ]
    },
    "us-gaap_CreditFacilityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CreditFacilityDomain",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/DisclosureCoronavirusPandemicCovid19AdditionalInformationDetail",
      "http://www.mednax.com/20240630/taxonomy/role/DisclosureLineOfCreditAndLongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Credit Facility [Domain]",
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing."
       }
      }
     },
     "auth_ref": [
      "r326",
      "r902",
      "r903"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtConversionDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtConversionDescription",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/DisclosureLineOfCreditAndLongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Conversion, Description",
        "terseLabel": "Debt Conversion Description",
        "documentation": "Description of conversion of original debt instrument in noncash or part noncash transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/DisclosureCoronavirusPandemicCovid19AdditionalInformationDetail",
      "http://www.mednax.com/20240630/taxonomy/role/FairValueMeasurementsAdditionalInformationDetail",
      "http://www.mednax.com/20240630/taxonomy/role/FairValueMeasurementsScheduleOfFinancialInstrumentsThatAreNotCarriedAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument [Axis]",
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r64",
      "r65",
      "r114",
      "r116",
      "r201",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r721",
      "r851",
      "r893",
      "r894",
      "r895",
      "r955",
      "r957"
     ]
    },
    "us-gaap_DebtInstrumentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentDescription",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/DisclosureLineOfCreditAndLongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument, Description",
        "label": "Debt Instrument, Description",
        "documentation": "Identification of the lender and information about a contractual promise to repay a short-term or long-term obligation, which includes borrowings under lines of credit, notes payable, commercial paper, bonds payable, debentures, and other contractual obligations for payment. This may include rationale for entering into the arrangement, significant terms of the arrangement, which may include amount, repayment terms, priority, collateral required, debt covenants, borrowing capacity, call features, participation rights, conversion provisions, sinking-fund requirements, voting rights, basis for conversion if convertible and remarketing provisions. The description may be provided for individual debt instruments, rational groupings of debt instruments, or by debt in total."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r29",
      "r52",
      "r64",
      "r114",
      "r116",
      "r476"
     ]
    },
    "us-gaap_DebtInstrumentFrequencyOfPeriodicPayment": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentFrequencyOfPeriodicPayment",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/DisclosureLineOfCreditAndLongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Debt Instrument, Frequency of Periodic Payment",
        "label": "Debt Instrument, Frequency of Periodic Payment",
        "terseLabel": "Debt instrument maturity date description",
        "documentation": "Description of the frequency of periodic payments (monthly, quarterly, annual)."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r53"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/FairValueMeasurementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt instrument, interest rate, effective percentage",
        "label": "Debt Instrument, Interest Rate, Effective Percentage",
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r354",
      "r476",
      "r477",
      "r721"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/DisclosureLineOfCreditAndLongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Debt instrument interest rate",
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r337"
     ]
    },
    "us-gaap_DebtInstrumentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentLineItems",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/DisclosureLineOfCreditAndLongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r201",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r721",
      "r851",
      "r955",
      "r957"
     ]
    },
    "us-gaap_DebtInstrumentMaturityDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentMaturityDate",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/DisclosureLineOfCreditAndLongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Maturity Date",
        "terseLabel": "Debt Instrument Maturity Date",
        "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r176",
      "r686",
      "r950",
      "r951"
     ]
    },
    "us-gaap_DebtInstrumentMaturityDateDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentMaturityDateDescription",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/DisclosureLineOfCreditAndLongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Maturity Date, Description",
        "terseLabel": "Debt instrument maturity date description",
        "documentation": "Description of the maturity date of the debt instrument including whether the debt matures serially and, if so, a brief description of the serial maturities."
       }
      }
     },
     "auth_ref": [
      "r68"
     ]
    },
    "md_DebtInstrumentMaturityYear": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://www.mednax.com/20240630",
     "localname": "DebtInstrumentMaturityYear",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/DisclosureLineOfCreditAndLongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt instrument, maturity year",
        "label": "Debt Instrument Maturity Year",
        "documentation": "Debt instrument maturity year."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentNameDomain",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/DisclosureCoronavirusPandemicCovid19AdditionalInformationDetail",
      "http://www.mednax.com/20240630/taxonomy/role/FairValueMeasurementsAdditionalInformationDetail",
      "http://www.mednax.com/20240630/taxonomy/role/FairValueMeasurementsScheduleOfFinancialInstrumentsThatAreNotCarriedAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Name [Domain]",
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r201",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r721",
      "r851",
      "r893",
      "r894",
      "r895",
      "r955",
      "r957"
     ]
    },
    "us-gaap_DebtInstrumentPeriodicPaymentInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentPeriodicPaymentInterest",
     "crdr": "debit",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/DisclosureLineOfCreditAndLongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Periodic Payment, Interest",
        "terseLabel": "Interest accrued periodically",
        "documentation": "Amount of the required periodic payments applied to interest."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "us-gaap_DebtInstrumentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentTable",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/DisclosureLineOfCreditAndLongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "documentation": "Disclosure of information about long-term debt instrument or arrangement."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r29",
      "r30",
      "r51",
      "r105",
      "r106",
      "r201",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r721",
      "r851",
      "r955",
      "r957"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/CashEquivalentsAndInvestmentsScheduleOfInvestmentsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale [Table]",
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesAvailableForSaleTableTextBlock",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/CashEquivalentsAndInvestmentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Schedule of Investments",
        "label": "Debt Securities, Available-for-Sale [Table Text Block]",
        "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r869",
      "r870",
      "r871",
      "r872",
      "r873",
      "r874",
      "r875",
      "r876",
      "r877",
      "r878",
      "r879",
      "r880"
     ]
    },
    "us-gaap_DeferredIncomeTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredIncomeTaxAssetsNet",
     "crdr": "debit",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred income tax assets",
        "label": "Deferred Income Tax Assets, Net",
        "totalLabel": "Deferred Income Tax Assets, Net, Total",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r412",
      "r413"
     ]
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred income taxes",
        "label": "Deferred Income Tax Expense (Benefit)",
        "totalLabel": "Deferred Income Tax Expense (Benefit), Total",
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r129",
      "r853"
     ]
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "crdr": "credit",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred income tax liabilities",
        "label": "Deferred Income Tax Liabilities, Net",
        "totalLabel": "Deferred Income Tax Liabilities, Net, Total",
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r412",
      "r413",
      "r529"
     ]
    },
    "md_DeferredTaxAssetsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.mednax.com/20240630",
     "localname": "DeferredTaxAssetsAxis",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/DisclosureBusinessCombinationsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets [Axis]",
        "documentation": "Deferred Tax Assets Axis"
       }
      }
     },
     "auth_ref": []
    },
    "md_DeferredTaxAssetsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mednax.com/20240630",
     "localname": "DeferredTaxAssetsDomain",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/DisclosureBusinessCombinationsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets [Domain]",
        "documentation": "Deferred Tax Assets Domain"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsGoodwillAndIntangibleAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/DisclosureGoodwillAndLonglivedAssetImpairmentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional Deferred Tax Assets",
        "label": "Deferred Tax Assets, Goodwill and Intangible Assets",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill."
       }
      }
     },
     "auth_ref": [
      "r939"
     ]
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DepreciationDepletionAndAmortization",
     "crdr": "debit",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited",
      "http://www.mednax.com/20240630/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Depreciation and amortization",
        "terseLabel": "Depreciation and amortization",
        "label": "Depreciation, Depletion and Amortization",
        "totalLabel": "Depreciation, Depletion and Amortization, Total",
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r233",
      "r241",
      "r247",
      "r680",
      "r681"
     ]
    },
    "us-gaap_DescriptionOfInterestRateRiskExposure": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DescriptionOfInterestRateRiskExposure",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/DisclosureLineOfCreditAndLongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description of Interest Rate Risk Exposure",
        "terseLabel": "Interest Rate, description",
        "documentation": "Description of the sources of interest rate risk exposure faced by the entity."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r45",
      "r46",
      "r47",
      "r48",
      "r49"
     ]
    },
    "us-gaap_DisaggregationOfRevenueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisaggregationOfRevenueAbstract",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/AccountsReceivableAndNetRevenueScheduleOfNetRevenueDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disaggregation of Revenue [Abstract]",
        "label": "Disaggregation of Revenue [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisaggregationOfRevenueLineItems",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/AccountsReceivableAndNetRevenueScheduleOfNetPatientServiceRevenueByTypeOfPayorDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disaggregation of Revenue [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r363",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698"
     ]
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisaggregationOfRevenueTable",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/AccountsReceivableAndNetRevenueScheduleOfNetPatientServiceRevenueByTypeOfPayorDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disaggregation of Revenue [Table]",
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor."
       }
      }
     },
     "auth_ref": [
      "r363",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698"
     ]
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/AccountsReceivableAndNetRevenueTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Net Revenue",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor."
       }
      }
     },
     "auth_ref": [
      "r908"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/StockIncentivePlansAndStockPurchasePlans"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Incentive Plans and Stock Purchase Plans",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r374",
      "r379",
      "r407",
      "r408",
      "r409",
      "r705"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisposalGroupClassificationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisposalGroupClassificationAxis",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/DisclosureBusinessCombinationsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposal Group Classification [Axis]",
        "documentation": "Information by disposal group classification."
       }
      }
     },
     "auth_ref": [
      "r168"
     ]
    },
    "us-gaap_DisposalGroupClassificationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisposalGroupClassificationDomain",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/DisclosureBusinessCombinationsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposal Group Classification [Domain]",
        "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations."
       }
      }
     },
     "auth_ref": []
    },
    "md_DissolutionOfAndNetIncomeLossAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mednax.com/20240630",
     "localname": "DissolutionOfAndNetIncomeLossAttributableToNoncontrollingInterest",
     "crdr": "debit",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Dissolution Of And Net Income (Loss) Attributable to Noncontrolling Interest",
        "label": "Dissolution Of And Net Income (Loss) Attributable to Noncontrolling Interest",
        "terseLabel": "Dissolution of and net loss attributable to noncontrolling interest"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r744"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r776"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]",
        "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year"
       }
      }
     },
     "auth_ref": [
      "r787"
     ]
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareAbstract",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Net (loss) income:",
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Basic",
        "label": "Earnings Per Share, Basic",
        "totalLabel": "Earnings Per Share, Basic, Total",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r196",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r218",
      "r220",
      "r226",
      "r227",
      "r228",
      "r232",
      "r424",
      "r430",
      "r447",
      "r448",
      "r524",
      "r549",
      "r677"
     ]
    },
    "us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareBasicOtherDisclosuresAbstract",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average common shares:",
        "label": "Earnings Per Share, Basic, Other Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Diluted",
        "label": "Earnings Per Share, Diluted",
        "totalLabel": "Earnings Per Share, Diluted, Total",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r196",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r220",
      "r226",
      "r227",
      "r228",
      "r232",
      "r424",
      "r430",
      "r447",
      "r448",
      "r524",
      "r549",
      "r677"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/CommonAndCommonEquivalentShares"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common and Common Equivalent Shares",
        "label": "Earnings Per Share [Text Block]",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r217",
      "r229",
      "r230",
      "r231"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Employee Stock Option",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r742"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r742"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r742"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r826"
     ]
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r742"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r742"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r742"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r742"
     ]
    },
    "ecd_EqtyAwrdsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Footnote [Text Block]",
        "terseLabel": "Equity Awards Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r781"
     ]
    },
    "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]",
        "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r822"
     ]
    },
    "ecd_EqtyAwrdsAdjsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments [Member]",
        "terseLabel": "Equity Awards Adjustments"
       }
      }
     },
     "auth_ref": [
      "r822"
     ]
    },
    "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r822"
     ]
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/CommonStockRepurchaseProgramsAdditionalInformationDetail",
      "http://www.mednax.com/20240630/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Component [Domain]",
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r166",
      "r192",
      "r193",
      "r194",
      "r202",
      "r203",
      "r204",
      "r206",
      "r211",
      "r213",
      "r215",
      "r234",
      "r293",
      "r294",
      "r317",
      "r361",
      "r417",
      "r418",
      "r421",
      "r422",
      "r423",
      "r425",
      "r429",
      "r430",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r446",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r478",
      "r480",
      "r483",
      "r545",
      "r560",
      "r561",
      "r562",
      "r575",
      "r642"
     ]
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "EquityMethodInvesteeNameDomain",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/DisclosureBasisOfPresentationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Domain]",
        "documentation": "Name of investment including named security. Excludes entity that is consolidated."
       }
      }
     },
     "auth_ref": [
      "r289",
      "r290",
      "r291",
      "r420",
      "r829",
      "r830",
      "r831",
      "r941",
      "r942",
      "r943",
      "r944"
     ]
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/DisclosureBasisOfPresentationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity method ownership percentage in joint venture",
        "label": "Equity Method Investment, Ownership Percentage",
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting."
       }
      }
     },
     "auth_ref": [
      "r289"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]",
        "terseLabel": "Equity Valuation Assumption Difference, Footnote"
       }
      }
     },
     "auth_ref": [
      "r791"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneous Compensation Analysis [Text Block]",
        "terseLabel": "Erroneous Compensation Analysis"
       }
      }
     },
     "auth_ref": [
      "r749",
      "r759",
      "r769",
      "r801"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneously Awarded Compensation Recovery [Table]",
        "terseLabel": "Erroneously Awarded Compensation Recovery"
       }
      }
     },
     "auth_ref": [
      "r746",
      "r756",
      "r766",
      "r798"
     ]
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Category [Axis]",
        "terseLabel": "Executive Category:"
       }
      }
     },
     "auth_ref": [
      "r797"
     ]
    },
    "srt_ExecutiveOfficerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ExecutiveOfficerMember",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/DisclosureCoronavirusPandemicCovid19AdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Executive Officer [Member]",
        "label": "Executive Officer [Member]",
        "documentation": "Person with designation of executive officer."
       }
      }
     },
     "auth_ref": [
      "r865"
     ]
    },
    "md_ExtraordinaryItemsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.mednax.com/20240630",
     "localname": "ExtraordinaryItemsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Extraordinary Items [Abstract]",
        "documentation": "Extraordinary Items [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "md_ExtraordinaryItemsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.mednax.com/20240630",
     "localname": "ExtraordinaryItemsAxis",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/DisclosureCoronavirusPandemicCovid19AdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extraordinary Items [Axis]",
        "documentation": "Extraordinary Items [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "md_ExtraordinaryItemsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mednax.com/20240630",
     "localname": "ExtraordinaryItemsDomain",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/DisclosureCoronavirusPandemicCovid19AdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extraordinary Items [Domain]",
        "documentation": "Extraordinary Items [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/FairValueMeasurementsScheduleOfFairValueOnARecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r344",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r449",
      "r451",
      "r452",
      "r453",
      "r454",
      "r458",
      "r459",
      "r460",
      "r489",
      "r490",
      "r491",
      "r687",
      "r688",
      "r699",
      "r700",
      "r701",
      "r710",
      "r714"
     ]
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByMeasurementFrequencyAxis",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/FairValueMeasurementsScheduleOfFairValueOnARecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Axis]",
        "documentation": "Information by measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r450",
      "r451",
      "r452",
      "r454",
      "r710",
      "r950",
      "r953"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "md_FairValueDisclosuresLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.mednax.com/20240630",
     "localname": "FairValueDisclosuresLineItems",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/FairValueMeasurementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Line Items]",
        "documentation": "Fair value disclosures."
       }
      }
     },
     "auth_ref": []
    },
    "md_FairValueDisclosuresTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.mednax.com/20240630",
     "localname": "FairValueDisclosuresTable",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/FairValueMeasurementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Table]",
        "documentation": "Fair value disclosures."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/FairValueMeasurements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r455",
      "r456",
      "r457",
      "r458",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r520",
      "r710",
      "r715"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/FairValueMeasurementsScheduleOfFairValueOnARecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r344",
      "r365",
      "r370",
      "r451",
      "r459",
      "r489",
      "r699",
      "r700",
      "r701",
      "r710"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/FairValueMeasurementsScheduleOfFairValueOnARecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r344",
      "r365",
      "r370",
      "r451",
      "r452",
      "r459",
      "r490",
      "r687",
      "r688",
      "r699",
      "r700",
      "r701",
      "r710"
     ]
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementFrequencyDomain",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/FairValueMeasurementsScheduleOfFairValueOnARecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Domain]",
        "documentation": "Measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r450",
      "r451",
      "r452",
      "r454",
      "r710",
      "r950",
      "r953"
     ]
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/FairValueMeasurementsScheduleOfFairValueOnARecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r344",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r449",
      "r451",
      "r452",
      "r453",
      "r454",
      "r458",
      "r459",
      "r460",
      "r489",
      "r490",
      "r491",
      "r687",
      "r688",
      "r699",
      "r700",
      "r701",
      "r710",
      "r714"
     ]
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementsRecurringMember",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/FairValueMeasurementsScheduleOfFairValueOnARecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Recurring [Member]",
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value."
       }
      }
     },
     "auth_ref": [
      "r710",
      "r947",
      "r948",
      "r949",
      "r950",
      "r951",
      "r953"
     ]
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/CashEquivalentsAndInvestmentsScheduleOfInvestmentsDetail",
      "http://www.mednax.com/20240630/taxonomy/role/DisclosureLineOfCreditAndLongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instrument [Axis]",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r302",
      "r303",
      "r304",
      "r352",
      "r359",
      "r445",
      "r465",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r546",
      "r684",
      "r710",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720",
      "r723",
      "r834",
      "r835",
      "r836",
      "r837",
      "r838",
      "r839",
      "r840",
      "r880",
      "r881",
      "r882",
      "r883",
      "r946",
      "r949",
      "r950",
      "r951",
      "r952",
      "r953"
     ]
    },
    "md_FinancialInstrumentsMeasuredAtCarryingAmountTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.mednax.com/20240630",
     "localname": "FinancialInstrumentsMeasuredAtCarryingAmountTableTextBlock",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/FairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Financial Instruments Measured At Carrying Amount",
        "label": "Financial Instruments Measured At Carrying Amount Table Text Block",
        "documentation": "Tabular disclosure of financial instruments measured at carrying amount."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsNet",
     "crdr": "debit",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible assets, net",
        "label": "Finite-Lived Intangible Assets, Net",
        "totalLabel": "Finite-Lived Intangible Assets, Net, Total",
        "periodStartLabel": "Finite-Lived Intangible Assets, Net, Beginning Balance",
        "periodEndLabel": "Finite-Lived Intangible Assets, Net, Ending Balance",
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r519",
      "r889"
     ]
    },
    "md_FivePointThreeSevenFivePercentUnsecuredSeniorNotesDueTwoThousandThirtyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mednax.com/20240630",
     "localname": "FivePointThreeSevenFivePercentUnsecuredSeniorNotesDueTwoThousandThirtyMember",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/DisclosureLineOfCreditAndLongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Five point three seven five percent unsecured senior notes due two thousand thirty member.",
        "label": "Five Point Three Seven Five Percent Unsecured Senior Notes Due Two Thousand Thirty Member",
        "terseLabel": "5.375% Unsecured Senior Notes Due 2030 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "md_FivePointTwoFivePercentageSeniorNotesDueTwoThousandTwentyThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mednax.com/20240630",
     "localname": "FivePointTwoFivePercentageSeniorNotesDueTwoThousandTwentyThreeMember",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/FairValueMeasurementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Five Point Two Five Percentage Senior Notes Due Two Thousand Twenty Three [Member]",
        "label": "Five Point Two Five Percentage Senior Notes Due Two Thousand Twenty Three [Member]",
        "documentation": "Five Point Two Five Percentage Senior Notes Due Two Thousand Twenty Three [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r753",
      "r763",
      "r773",
      "r805"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Expense of Enforcement, Amount",
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r753",
      "r763",
      "r773",
      "r805"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r753",
      "r763",
      "r773",
      "r805"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]",
        "terseLabel": "Forgone Recovery, Explanation of Impracticability"
       }
      }
     },
     "auth_ref": [
      "r753",
      "r763",
      "r773",
      "r805"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r753",
      "r763",
      "r773",
      "r805"
     ]
    },
    "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]",
        "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year"
       }
      }
     },
     "auth_ref": [
      "r786"
     ]
    },
    "md_GaapSeniorNotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mednax.com/20240630",
     "localname": "GaapSeniorNotesMember",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/FairValueMeasurementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "GAAP Senior Notes [Member]",
        "label": "GAAP Senior Notes [Member]",
        "documentation": "GAAP Senior Notes [Member]."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainLossOnSaleOfBusiness": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GainLossOnSaleOfBusiness",
     "crdr": "credit",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/DisclosureGoodwillAndLonglivedAssetImpairmentsAdditionalInformationDetails",
      "http://www.mednax.com/20240630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited",
      "http://www.mednax.com/20240630/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Loss on disposal of businesses",
        "terseLabel": "Loss on disposal of businesses",
        "label": "Gain (Loss) on Disposition of Business",
        "documentation": "Amount of gain (loss) from sale and disposal of integrated set of activities and assets capable of being conducted and managed for purpose of providing return in form of dividend, lower cost, or other economic benefit to investor, owner, member and participant."
       }
      }
     },
     "auth_ref": [
      "r436",
      "r849"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative expenses",
        "label": "General and Administrative Expense",
        "totalLabel": "General and Administrative Expense, Total",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r87",
      "r627"
     ]
    },
    "us-gaap_GeographicDistributionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeographicDistributionAxis",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/DisclosureCoronavirusPandemicCovid19AdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographic Distribution [Axis]",
        "documentation": "Information by geographic distribution of business activity identified as either domestic or foreign. Excludes names of countries, states and provinces, and cities."
       }
      }
     },
     "auth_ref": [
      "r132",
      "r133",
      "r134",
      "r135",
      "r136",
      "r137",
      "r138",
      "r139",
      "r140",
      "r141",
      "r142",
      "r143",
      "r145",
      "r146",
      "r147",
      "r148",
      "r149",
      "r150",
      "r525",
      "r526",
      "r683"
     ]
    },
    "us-gaap_GeographicDistributionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeographicDistributionDomain",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/DisclosureCoronavirusPandemicCovid19AdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographic Distribution [Domain]",
        "documentation": "Allocation of business activity identified as domestic or foreign. Excludes names of countries, states and provinces, and cities."
       }
      }
     },
     "auth_ref": [
      "r132",
      "r133",
      "r134",
      "r135",
      "r136",
      "r137",
      "r138",
      "r139",
      "r140",
      "r141",
      "r142",
      "r143",
      "r145",
      "r146",
      "r147",
      "r148",
      "r149",
      "r150",
      "r525",
      "r526"
     ]
    },
    "md_GoodWillImpairmentLossExcludingDeferredTaxAssetsCharge": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mednax.com/20240630",
     "localname": "GoodWillImpairmentLossExcludingDeferredTaxAssetsCharge",
     "crdr": "debit",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/DisclosureGoodwillAndLonglivedAssetImpairmentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Good will Impairment Loss excluding Deferred Tax Assets Charge",
        "label": "Good will Impairment Loss excluding Deferred Tax Assets Charge",
        "documentation": "Good will Impairment Loss excluding Deferred Tax Assets Charge"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Goodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Goodwill",
     "crdr": "debit",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill",
        "label": "Goodwill",
        "totalLabel": "Goodwill, Total",
        "periodStartLabel": "Goodwill, Beginning Balance",
        "periodEndLabel": "Goodwill, Ending Balance",
        "documentation": "Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r173",
      "r307",
      "r521",
      "r681",
      "r685",
      "r712",
      "r722",
      "r886",
      "r887"
     ]
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/DisclosureGoodwillAndLonglivedAssetImpairments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill, Long-Lived Asset Impairments and Loss on Disposal of Businesses",
        "label": "Goodwill and Intangible Assets Disclosure [Text Block]",
        "documentation": "The entire disclosure for goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r885",
      "r888"
     ]
    },
    "us-gaap_GoodwillImpairmentLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillImpairmentLoss",
     "crdr": "debit",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/DisclosureGoodwillAndLonglivedAssetImpairmentsAdditionalInformationDetails",
      "http://www.mednax.com/20240630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited",
      "http://www.mednax.com/20240630/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill impairment",
        "verboseLabel": "Goodwill impairment",
        "label": "Goodwill, Impairment Loss",
        "documentation": "Amount of impairment loss from asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r308",
      "r309",
      "r310",
      "r685",
      "r712"
     ]
    },
    "us-gaap_GovernmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GovernmentMember",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/AccountsReceivableAndNetRevenueScheduleOfNetPatientServiceRevenueByTypeOfPayorDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Government",
        "label": "Government [Member]",
        "documentation": "Organization that is the governing authority of a community."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_HealthCareOrganizationRevenueSourcesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "HealthCareOrganizationRevenueSourcesAxis",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/AccountsReceivableAndNetRevenueScheduleOfNetPatientServiceRevenueByTypeOfPayorDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Health Care Organization, Revenue Sources [Axis]",
        "label": "Health Care Organization, Revenue Sources [Axis]",
        "documentation": "Information by major payor source of revenue for health care organizations."
       }
      }
     },
     "auth_ref": [
      "r908"
     ]
    },
    "us-gaap_HealthCareOrganizationRevenueSourcesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "HealthCareOrganizationRevenueSourcesDomain",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/AccountsReceivableAndNetRevenueScheduleOfNetPatientServiceRevenueByTypeOfPayorDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Health Care Organization, Revenue Sources [Domain]",
        "label": "Health Care Organization, Revenue Sources [Domain]",
        "documentation": "Major payor source of revenue for health care organizations."
       }
      }
     },
     "auth_ref": [
      "r908"
     ]
    },
    "us-gaap_HealthCarePatientServiceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "HealthCarePatientServiceMember",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/AccountsReceivableAndNetRevenueScheduleOfNetRevenueDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net patient service revenue",
        "label": "Health Care, Patient Service [Member]",
        "documentation": "Service provided to patient for maintenance, diagnosis and treatment of physical and mental health. Excludes service to resident in health care facility."
       }
      }
     },
     "auth_ref": [
      "r909"
     ]
    },
    "md_HospitalsContractsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mednax.com/20240630",
     "localname": "HospitalsContractsMember",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/AccountsReceivableAndNetRevenueScheduleOfNetRevenueDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Hospital contract administrative fees",
        "label": "Hospitals Contracts [Member]",
        "documentation": "Hospitals Contracts [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill",
     "crdr": "debit",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/DisclosureGoodwillAndLonglivedAssetImpairmentsAdditionalInformationDetails",
      "http://www.mednax.com/20240630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited",
      "http://www.mednax.com/20240630/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible assets impairments",
        "label": "Impairment of Intangible Assets, Indefinite-Lived (Excluding Goodwill)",
        "documentation": "Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value."
       }
      }
     },
     "auth_ref": [
      "r311",
      "r849",
      "r890",
      "r891"
     ]
    },
    "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ImpairmentOfLongLivedAssetsHeldForUse",
     "crdr": "debit",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/DisclosureGoodwillAndLonglivedAssetImpairmentsAdditionalInformationDetails",
      "http://www.mednax.com/20240630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited",
      "http://www.mednax.com/20240630/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fixed assets impairments",
        "label": "Impairment, Long-Lived Asset, Held-for-Use",
        "totalLabel": "Impairment, Long-Lived Asset, Held-for-Use, Total",
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale)."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r27",
      "r103",
      "r711"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "(Loss) income before income taxes",
        "terseLabel": "(Loss) income from continuing operations before income taxes",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r120",
      "r125",
      "r526",
      "r541",
      "r679",
      "r680",
      "r860",
      "r861",
      "r862",
      "r863",
      "r864"
     ]
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity",
     "crdr": "credit",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/DisclosureBusinessCombinationsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Incremental loss on sale, net",
        "label": "Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent",
        "totalLabel": "Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent, Total",
        "documentation": "Amount after tax of income (loss) from a discontinued operation attributable to the parent. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r55",
      "r56",
      "r57",
      "r58",
      "r59",
      "r61",
      "r110"
     ]
    },
    "us-gaap_IncomeLossFromEquityMethodInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromEquityMethodInvestments",
     "crdr": "credit",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity in earnings of unconsolidated affiliate",
        "label": "Income (Loss) from Equity Method Investments",
        "totalLabel": "Income (Loss) from Equity Method Investments, Total",
        "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss)."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r85",
      "r119",
      "r233",
      "r242",
      "r247",
      "r288",
      "r540"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Income tax benefit (provision)",
        "label": "Income Tax Expense (Benefit)",
        "totalLabel": "Income Tax Expense (Benefit), Total",
        "negatedLabel": "Income tax provision",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r127",
      "r130",
      "r214",
      "r215",
      "r233",
      "r243",
      "r247",
      "r414",
      "r415",
      "r419",
      "r550",
      "r707"
     ]
    },
    "us-gaap_IncomeTaxReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReceivable",
     "crdr": "debit",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes Receivable",
        "terseLabel": "Income taxes receivable",
        "documentation": "Carrying amount as of the balance sheet date of income taxes previously overpaid to tax authorities (such as U.S. Federal, state and local tax authorities) representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes. Also called income tax refund receivable."
       }
      }
     },
     "auth_ref": [
      "r843"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "crdr": "debit",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable and accrued expenses",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "totalLabel": "Increase (Decrease) in Accounts Payable and Accrued Liabilities, Total",
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "crdr": "credit",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accounts receivable",
        "label": "Increase (Decrease) in Accounts Receivable",
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccruedIncomeTaxesPayable",
     "crdr": "debit",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income taxes payable",
        "label": "Increase (Decrease) in Income Taxes Payable",
        "documentation": "The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "md_IncreaseDecreaseInAccruedSalariesAndBonuses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mednax.com/20240630",
     "localname": "IncreaseDecreaseInAccruedSalariesAndBonuses",
     "crdr": "credit",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/AccountsPayableAndAccruedExpensesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Net decrease in accrued salaries and bonuses",
        "label": "Increase (Decrease) in Accrued Salaries and Bonuses",
        "documentation": "Increase (decrease) in accrued salaries and bonuses."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInIncomeTaxesReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInIncomeTaxesReceivable",
     "crdr": "credit",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/DisclosureBusinessCombinationsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Income taxes payable",
        "terseLabel": "Income taxes receivable",
        "label": "Increase (Decrease) in Income Taxes Receivable",
        "documentation": "The increase (decrease) during the reporting period in income taxes receivable, which represents the amount due from tax authorities for refunds of overpayments or recoveries of income taxes paid."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve",
     "crdr": "debit",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term professional liabilities",
        "label": "Increase (Decrease) in Liability for Claims and Claims Adjustment Expense Reserve",
        "documentation": "Amount of increase (decrease) in liability to reflect the estimated ultimate cost of settling claims relating to insured events that have occurred on or before the balance sheet date, whether or not reported to the insurer at that date."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in assets and liabilities:",
        "label": "Increase (Decrease) in Operating Capital [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOtherNoncurrentAssets",
     "crdr": "credit",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other long-term assets",
        "label": "Increase (Decrease) in Other Noncurrent Assets",
        "documentation": "Amount of increase (decrease) in noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r848"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOtherOperatingLiabilities",
     "crdr": "debit",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other liabilities",
        "label": "Increase (Decrease) in Other Operating Liabilities",
        "totalLabel": "Increase (Decrease) in Other Operating Liabilities, Total",
        "documentation": "Amount of increase (decrease) in operating liabilities classified as other."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaid expenses and other current assets",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "totalLabel": "Increase (Decrease) in Prepaid Expense and Other Assets, Total",
        "terseLabel": "Prepaid expenses and other current assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "md_IncreaseInDeferredTaxAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mednax.com/20240630",
     "localname": "IncreaseInDeferredTaxAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/DisclosureBusinessCombinationsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase in deferred tax assets",
        "label": "Increase In Deferred Tax assets",
        "documentation": "Increase in deferred tax Assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/CommonAndCommonEquivalentSharesScheduleOfCalculationOfSharesUsedInBasicAndDilutedNetIncomePerShareDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average number of dilutive common share equivalents",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements",
        "totalLabel": "Incremental Common Shares Attributable to Share-based Payment Arrangements, Total",
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method."
       }
      }
     },
     "auth_ref": [
      "r221",
      "r222",
      "r223",
      "r228",
      "r378"
     ]
    },
    "md_IncrementalNonCashCharge": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mednax.com/20240630",
     "localname": "IncrementalNonCashCharge",
     "crdr": "debit",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/DisclosureGoodwillAndLonglivedAssetImpairmentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Incremental Non Cash Charge",
        "label": "Incremental Non Cash Charge",
        "documentation": "Incremental Non Cash Charge"
       }
      }
     },
     "auth_ref": []
    },
    "md_IncrementalSharesInContinuingOperation": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.mednax.com/20240630",
     "localname": "IncrementalSharesInContinuingOperation",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/DisclosureCommonAndCommonEquivalentSharesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Incremental Shares In Continuing operation",
        "documentation": "Incremental Shares In Continuing operation"
       }
      }
     },
     "auth_ref": []
    },
    "md_IncrementalSharesNotIncludedDueToAntiDilutiveEffect": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.mednax.com/20240630",
     "localname": "IncrementalSharesNotIncludedDueToAntiDilutiveEffect",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/DisclosureCommonAndCommonEquivalentSharesScheduleOfCalculationOfSharesUsedInBasicAndDilutedNetIncomePerShareParentheticalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Incremental shares not Included due to anti dilutive effect",
        "label": "Incremental Shares not Included Due to Anti dilutive Effect",
        "documentation": "Incremental Shares Not Included Due To Anti dilutive Effect"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Individual [Axis]",
        "terseLabel": "Individual:"
       }
      }
     },
     "auth_ref": [
      "r753",
      "r763",
      "r773",
      "r797",
      "r805",
      "r809",
      "r817"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]",
        "terseLabel": "Insider Trading Arrangements:"
       }
      }
     },
     "auth_ref": [
      "r815"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]",
        "terseLabel": "Insider Trading Policies and Procedures:"
       }
      }
     },
     "auth_ref": [
      "r745",
      "r821"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Adopted [Flag]",
        "terseLabel": "Insider Trading Policies and Procedures Adopted"
       }
      }
     },
     "auth_ref": [
      "r745",
      "r821"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]",
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted"
       }
      }
     },
     "auth_ref": [
      "r745",
      "r821"
     ]
    },
    "us-gaap_InterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Interest expense",
        "label": "Interest Expense, Operating and Nonoperating",
        "totalLabel": "Interest Expense, Total",
        "documentation": "Amount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense."
       }
      }
     },
     "auth_ref": [
      "r233",
      "r237",
      "r240",
      "r244",
      "r247",
      "r475",
      "r680",
      "r681"
     ]
    },
    "us-gaap_InterestPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestPayableCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/AccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued interest",
        "label": "Interest Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r65"
     ]
    },
    "us-gaap_InvestmentIncomeNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentIncomeNet",
     "crdr": "credit",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment and other (loss) income",
        "verboseLabel": "Investment and other income (expense)",
        "label": "Investment Income, Net",
        "totalLabel": "Investment Income, Net, Total",
        "documentation": "Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r89",
      "r91"
     ]
    },
    "us-gaap_InvestmentTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentTypeAxis",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/CashEquivalentsAndInvestmentsScheduleOfInvestmentsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Type [Axis]",
        "documentation": "Information by type of investments."
       }
      }
     },
     "auth_ref": [
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r646",
      "r648",
      "r650",
      "r653",
      "r654",
      "r655",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r732"
     ]
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentTypeCategorizationMember",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/CashEquivalentsAndInvestmentsScheduleOfInvestmentsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments [Domain]",
        "documentation": "Asset obtained to generate income or appreciate in value."
       }
      }
     },
     "auth_ref": [
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r646",
      "r648",
      "r650",
      "r653",
      "r654",
      "r655",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r732"
     ]
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/FairValueMeasurementsScheduleOfFairValueOnARecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, Fair Value Disclosure",
        "totalLabel": "Investments, Fair Value Disclosure, Total",
        "terseLabel": "Short-term investments",
        "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method."
       }
      }
     },
     "auth_ref": [
      "r947",
      "r948",
      "r952"
     ]
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/CashEquivalentsAndInvestments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Cash Equivalents and Investments",
        "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]",
        "documentation": "The entire disclosure for investments in certain debt and equity securities."
       }
      }
     },
     "auth_ref": [
      "r122",
      "r144",
      "r254",
      "r256",
      "r466",
      "r467",
      "r969"
     ]
    },
    "us-gaap_LettersOfCreditOutstandingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LettersOfCreditOutstandingAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/DisclosureLineOfCreditAndLongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Letters of Credit Outstanding, Amount",
        "terseLabel": "Letter of credit outstanding amount",
        "documentation": "The total amount of the contingent obligation under letters of credit outstanding as of the reporting date."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Liabilities",
     "crdr": "credit",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r64",
      "r65",
      "r66",
      "r70",
      "r71",
      "r72",
      "r73",
      "r200",
      "r292",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r433",
      "r437",
      "r438",
      "r468",
      "r601",
      "r678",
      "r740",
      "r904",
      "r961",
      "r962"
     ]
    },
    "us-gaap_LiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAbstract",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/FairValueMeasurementsScheduleOfFinancialInstrumentsThatAreNotCarriedAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liabilities:",
        "label": "Liabilities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities and shareholders' equity",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r118",
      "r537",
      "r722",
      "r852",
      "r884",
      "r954"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "LIABILITIES AND EQUITY",
        "label": "Liabilities and Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r171",
      "r200",
      "r292",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r433",
      "r437",
      "r438",
      "r468",
      "r722",
      "r904",
      "r961",
      "r962"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current liabilities:",
        "label": "Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesFairValueDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesFairValueDisclosureAbstract",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/FairValueMeasurementsScheduleOfFinancialInstrumentsThatAreNotCarriedAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Fair Value Disclosure [Abstract]",
        "terseLabel": "Liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LineOfCredit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LineOfCredit",
     "crdr": "credit",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/ConsolidatedBalanceSheetsUnaudited",
      "http://www.mednax.com/20240630/taxonomy/role/DisclosureLineOfCreditAndLongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Long-term Line of Credit, Total",
        "label": "Long-Term Line of Credit",
        "terseLabel": "Line of credit",
        "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r116",
      "r971"
     ]
    },
    "md_LineOfCreditAndLongTermDebtTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.mednax.com/20240630",
     "localname": "LineOfCreditAndLongTermDebtTextBlock",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/DisclosureLineOfCreditAndLongTermDebt"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line Of Credit And Long Term Debt [Text Block]",
        "label": "Line Of Credit And Long Term Debt [Text Block]",
        "terseLabel": "Line of Credit and Long Term Debt"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LineOfCreditFacilityRemainingBorrowingCapacity",
     "crdr": "credit",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/DisclosureLineOfCreditAndLongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Line of Credit Facility, Remaining Borrowing Capacity",
        "terseLabel": "Line of Credit facility, available balance",
        "documentation": "Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding)."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r69",
      "r326"
     ]
    },
    "md_LineOfCreditLongTermDebtAndFinanceLeaseObligationsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.mednax.com/20240630",
     "localname": "LineOfCreditLongTermDebtAndFinanceLeaseObligationsDisclosureTextBlock",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/DisclosureLineOfCreditAndLongTermDebt"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Line of Credit and Long Term Debt",
        "label": "Line Of Credit Long Term Debt And Finance Lease Obligations Disclosure Text Block",
        "documentation": "Line of credit long term debt and finance lease obligations disclosure text block."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebt",
     "crdr": "credit",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/DisclosureLineOfCreditAndLongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Long-term Debt, Total",
        "label": "Long-Term Debt",
        "terseLabel": "Long term debt",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r116",
      "r343",
      "r353",
      "r687",
      "r688",
      "r721",
      "r971"
     ]
    },
    "us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebtAndCapitalLeaseObligationsCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current portion of debt and finance lease liabilities, net",
        "label": "Long-Term Debt and Lease Obligation, Current",
        "totalLabel": "Long-Term Debt and Lease Obligation, Current, Total",
        "documentation": "Amount of long-term debt and lease obligation, classified as current."
       }
      }
     },
     "auth_ref": [
      "r65"
     ]
    },
    "md_LongTermDebtAndCapitalLeaseObligationsExcludingLongTermLineOfCredit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mednax.com/20240630",
     "localname": "LongTermDebtAndCapitalLeaseObligationsExcludingLongTermLineOfCredit",
     "crdr": "credit",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Long-term debt and finance lease liabilities, net",
        "label": "Long Term Debt and Capital Lease Obligations Excluding Long Term Line of Credit",
        "documentation": "Long term debt and capital lease obligations excluding long term line of credit."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebtMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebtMember",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/DisclosureLineOfCreditAndLongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Long-Term Debt",
        "label": "Long-Term Debt [Member]",
        "terseLabel": "Term A loan",
        "documentation": "Debt arrangement having an initial term longer than one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongtermDebtTypeAxis",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/DisclosureLineOfCreditAndLongTermDebtAdditionalInformationDetails",
      "http://www.mednax.com/20240630/taxonomy/role/FairValueMeasurementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt, Type [Axis]",
        "documentation": "Information by type of long-term debt."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r893",
      "r894",
      "r895"
     ]
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongtermDebtTypeDomain",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/DisclosureLineOfCreditAndLongTermDebtAdditionalInformationDetails",
      "http://www.mednax.com/20240630/taxonomy/role/FairValueMeasurementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt, Type [Domain]",
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r28",
      "r893",
      "r894",
      "r895"
     ]
    },
    "us-gaap_MalpracticeLossContingencyAccrualUndiscountedCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MalpracticeLossContingencyAccrualUndiscountedCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/AccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued professional liabilities",
        "label": "Malpractice Loss Contingency, Accrual, Undiscounted, Current",
        "documentation": "Amount of the current portion of the accrued liability on an undiscounted basis for malpractice claims (including general and professional liability)."
       }
      }
     },
     "auth_ref": [
      "r899"
     ]
    },
    "us-gaap_MalpracticeLossContingencyAccrualUndiscountedNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MalpracticeLossContingencyAccrualUndiscountedNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term professional liabilities",
        "label": "Malpractice Loss Contingency, Accrual, Undiscounted, Noncurrent",
        "documentation": "Amount of the noncurrent portion of the accrued liability on an undiscounted basis for malpractice claims (including general and professional liability)."
       }
      }
     },
     "auth_ref": [
      "r899"
     ]
    },
    "md_MaternalFetalMedicinePracticeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mednax.com/20240630",
     "localname": "MaternalFetalMedicinePracticeMember",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/DisclosureBusinessCombinationsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maternal Fetal Medicine Practice [Member]",
        "documentation": "Maternal Fetal Medicine Practice [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum [Member]",
        "label": "Maximum [Member]",
        "documentation": "Upper limit of the provided range."
       }
      }
     },
     "auth_ref": [
      "r151",
      "r152",
      "r153",
      "r154",
      "r155",
      "r164",
      "r165",
      "r322",
      "r323",
      "r324",
      "r325",
      "r372",
      "r411",
      "r454",
      "r517",
      "r558",
      "r559",
      "r566",
      "r593",
      "r594",
      "r647",
      "r649",
      "r651",
      "r652",
      "r656",
      "r669",
      "r670",
      "r682",
      "r691",
      "r704",
      "r714",
      "r715",
      "r719",
      "r720",
      "r725",
      "r906",
      "r963",
      "r964",
      "r965",
      "r966",
      "r967",
      "r968"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure [Axis]",
        "terseLabel": "Measure:"
       }
      }
     },
     "auth_ref": [
      "r789"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r789"
     ]
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "verboseLabel": "Minimum [Member]",
        "documentation": "Lower limit of the provided range."
       }
      }
     },
     "auth_ref": [
      "r151",
      "r152",
      "r153",
      "r154",
      "r155",
      "r164",
      "r165",
      "r322",
      "r323",
      "r324",
      "r325",
      "r372",
      "r411",
      "r454",
      "r517",
      "r558",
      "r559",
      "r566",
      "r593",
      "r594",
      "r647",
      "r649",
      "r651",
      "r652",
      "r656",
      "r669",
      "r670",
      "r682",
      "r691",
      "r704",
      "r714",
      "r715",
      "r719",
      "r725",
      "r906",
      "r963",
      "r964",
      "r965",
      "r966",
      "r967",
      "r968"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]",
        "terseLabel": "MNPI Disclosure Timed for Compensation Value"
       }
      }
     },
     "auth_ref": [
      "r808"
     ]
    },
    "us-gaap_MoneyMarketFundsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MoneyMarketFundsAtCarryingValue",
     "crdr": "debit",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/CashEquivalentsAndInvestmentsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Cash equivalents",
        "label": "Money Market Funds, at Carrying Value",
        "documentation": "Investment in short-term money-market instruments (such as commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and so forth) which are highly liquid (that is, readily convertible to known amounts of cash) and so near their maturity that they present an insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify as cash equivalents by definition. Original maturity means an original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months."
       }
      }
     },
     "auth_ref": []
    },
    "md_MoneyMarketFundsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mednax.com/20240630",
     "localname": "MoneyMarketFundsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/FairValueMeasurementsScheduleOfFairValueOnARecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of money market funds.",
        "label": "Money Market Funds Fair Value Disclosure",
        "terseLabel": "Money market funds"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement [Text Block]",
        "terseLabel": "Material Terms of Trading Arrangement"
       }
      }
     },
     "auth_ref": [
      "r816"
     ]
    },
    "md_MutualFundsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mednax.com/20240630",
     "localname": "MutualFundsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/FairValueMeasurementsScheduleOfFairValueOnARecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Mutual funds fair value disclosure.",
        "label": "Mutual Funds Fair Value Disclosure",
        "terseLabel": "Mutual funds"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Named Executive Officers, Footnote [Text Block]",
        "terseLabel": "Named Executive Officers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r790"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash (used in) provided by financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r198"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from financing activities:",
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r198"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from investing activities:",
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r97",
      "r98"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from operating activities:",
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations",
        "totalLabel": "Net cash used in operating activities - continuing operations",
        "documentation": "Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r97",
      "r98"
     ]
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited",
      "http://www.mednax.com/20240630/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquityUnaudited",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss)",
        "terseLabel": "Net Income (Loss)",
        "totalLabel": "Net Income (loss) attributable to Pediatrix Medical Group, Inc.",
        "verboseLabel": "Net income",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r98",
      "r121",
      "r169",
      "r188",
      "r190",
      "r194",
      "r200",
      "r205",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r214",
      "r215",
      "r225",
      "r292",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r424",
      "r430",
      "r448",
      "r468",
      "r544",
      "r624",
      "r640",
      "r641",
      "r738",
      "r904"
     ]
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "crdr": "debit",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Net loss attributable to noncontrolling interest",
        "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
        "totalLabel": "Net Income (Loss) Attributable to Noncontrolling Interest, Total",
        "terseLabel": "Net loss attributable to noncontrolling interest",
        "negatedLabel": "Net loss attributable to noncontrolling interest",
        "verboseLabel": "Dissolution of and net loss attributable to noncontrolling interest",
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r111",
      "r188",
      "r190",
      "r211",
      "r214",
      "r215",
      "r543",
      "r846"
     ]
    },
    "md_NetOfTaxUnrealizedHoldingGainLossOnInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mednax.com/20240630",
     "localname": "NetOfTaxUnrealizedHoldingGainLossOnInvestments",
     "crdr": "credit",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnauditedParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized holding (loss) gain on investments, net of tax",
        "label": "Net Of Tax, Unrealized Holding Gain (Loss) on Investments",
        "documentation": "Net Of Tax, Unrealized Holding Gain (Loss) on Investments",
        "verboseLabel": "Unrealized holding gain (loss) on investments, net of tax"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/DisclosureBasisOfPresentationPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "New Accounting Pronouncements",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mednax.com/20240630",
     "localname": "NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "1996 Non-Qualified Employee Stock Purchase Plan and 2015 Non-Qualified Stock Purchase Plan [Member]",
        "label": "Nineteen Ninety Six Non Qualified Employee Stock Purchase Plan And Two Thousand Fifteen Non Qualified Stock Purchase Plan [Member]",
        "documentation": "Nineteen Ninety Six Non Qualified Employee Stock Purchase Plan And Two Thousand Fifteen Non Qualified Stock Purchase Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mednax.com/20240630",
     "localname": "NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanMember",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "1996 Non-Qualified Employee Stock Purchase Plan [Member]",
        "label": "Nineteen Ninety Six Non Qualified Employee Stock Purchase Plan [Member]",
        "documentation": "1996 non-qualified employee stock purchase plan."
       }
      }
     },
     "auth_ref": []
    },
    "md_NonCashCharge": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mednax.com/20240630",
     "localname": "NonCashCharge",
     "crdr": "debit",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/DisclosureGoodwillAndLonglivedAssetImpairmentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non cash charges",
        "label": "non-cash charge",
        "documentation": "non-cash charge"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-GAAP Measure Description [Text Block]",
        "terseLabel": "Non-GAAP Measure Description"
       }
      }
     },
     "auth_ref": [
      "r789"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-NEOs [Member]",
        "terseLabel": "Non-NEOs"
       }
      }
     },
     "auth_ref": [
      "r753",
      "r763",
      "r773",
      "r797",
      "r805"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r780"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Total Compensation Amount",
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r779"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO [Member]",
        "terseLabel": "Non-PEO NEO"
       }
      }
     },
     "auth_ref": [
      "r797"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r816"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r816"
     ]
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total non-operating expenses",
        "label": "Nonoperating Income (Expense)",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r90"
     ]
    },
    "md_NorthAmericanPartnersInAnesthesiaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mednax.com/20240630",
     "localname": "NorthAmericanPartnersInAnesthesiaMember",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/DisclosureBusinessCombinationsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "North American Partners In Anesthesia [Member]",
        "documentation": "North American Partners In Anesthesia [member]."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NotesPayable",
     "crdr": "credit",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/FairValueMeasurementsScheduleOfFinancialInstrumentsThatAreNotCarriedAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Notes Payable",
        "label": "Notes Payable",
        "totalLabel": "Notes Payable, Total",
        "documentation": "Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r116",
      "r971",
      "r972"
     ]
    },
    "us-gaap_NotesPayableFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NotesPayableFairValueDisclosure",
     "crdr": "credit",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/FairValueMeasurementsScheduleOfFinancialInstrumentsThatAreNotCarriedAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Notes Payable Fair Value Disclosure",
        "label": "Notes Payable, Fair Value Disclosure",
        "documentation": "Fair value portion of notes payable."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r64",
      "r65",
      "r948",
      "r952"
     ]
    },
    "md_NumberOfMaternalFetalMedicinePracticesAcquired": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.mednax.com/20240630",
     "localname": "NumberOfMaternalFetalMedicinePracticesAcquired",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/DisclosureBusinessCombinationsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Maternal Fetal Medicine Practices Acquired",
        "documentation": "Number of maternal fetal medicine practices acquired."
       }
      }
     },
     "auth_ref": []
    },
    "md_NumberOfMultiLocationPediatricUrgentCarePracticeAcquired": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.mednax.com/20240630",
     "localname": "NumberOfMultiLocationPediatricUrgentCarePracticeAcquired",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/DisclosureBusinessCombinationsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of other multi location pediatric urgent care practice acquired",
        "label": "Number Of Multi Location Pediatric Urgent Care Practice Acquired",
        "documentation": "Number of multi location pediatric urgent care practice acquired."
       }
      }
     },
     "auth_ref": []
    },
    "md_NumberOfPediatricGastroenterologyPracticeAcquired": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.mednax.com/20240630",
     "localname": "NumberOfPediatricGastroenterologyPracticeAcquired",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/DisclosureBusinessCombinationsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Pediatric Gastroenterology Practice Acquired",
        "label": "Number of Pediatric Gastroenterology Practice Acquired",
        "documentation": "Number of Pediatric Gastroenterology Practice Acquired"
       }
      }
     },
     "auth_ref": []
    },
    "md_NumberOfPediatricOrThopedicPracticesAcquired": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.mednax.com/20240630",
     "localname": "NumberOfPediatricOrThopedicPracticesAcquired",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/DisclosureBusinessCombinationsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of other pediatric orthopedic practice acquired",
        "label": "Number Of Pediatric Or thopedic Practices Acquired",
        "documentation": "Number of pediatric or thopedic practices acquired."
       }
      }
     },
     "auth_ref": []
    },
    "md_OperatingAndFinanceLeaseRightOfUseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mednax.com/20240630",
     "localname": "OperatingAndFinanceLeaseRightOfUseAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating and finance lease right-of-use assets",
        "label": "Operating And Finance Lease Right Of Use Assets",
        "documentation": "Operating and finance lease right-of-use assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating expenses",
        "label": "Operating Expenses",
        "terseLabel": "Total operating expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating expenses:",
        "label": "Operating Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "(Loss) income from operations",
        "terseLabel": "Income from operations",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r125",
      "r679",
      "r860",
      "r861",
      "r862",
      "r863",
      "r864"
     ]
    },
    "us-gaap_OperatingLeaseImpairmentLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseImpairmentLoss",
     "crdr": "debit",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/DisclosureGoodwillAndLonglivedAssetImpairmentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease right-of-use asset impairments",
        "label": "Operating Lease, Impairment Loss",
        "documentation": "Amount of loss from impairment of right-of-use asset from operating lease."
       }
      }
     },
     "auth_ref": [
      "r958"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current portion of operating lease liabilities",
        "label": "Operating Lease, Liability, Current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r481"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term operating lease liabilities",
        "label": "Operating Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r481"
     ]
    },
    "us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/DisclosureBasisOfPresentation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Basis of Presentation",
        "label": "Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles."
       }
      }
     },
     "auth_ref": [
      "r99",
      "r100",
      "r101",
      "r109"
     ]
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/AccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other accrued expenses",
        "label": "Other Accrued Liabilities, Current",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r65"
     ]
    },
    "us-gaap_OtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAssetsCurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other current assets",
        "label": "Other Assets, Current",
        "documentation": "Amount of current assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r184",
      "r722"
     ]
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other non-current assets",
        "terseLabel": "Other assets",
        "label": "Other Assets, Noncurrent",
        "totalLabel": "Other Assets, Noncurrent, Total",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r174"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "crdr": "credit",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "terseLabel": "Unrealized holding gain on investments, net of tax",
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale."
       }
      }
     },
     "auth_ref": [
      "r186",
      "r187",
      "r287"
     ]
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherLiabilitiesNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other liabilities",
        "label": "Other Liabilities, Noncurrent",
        "totalLabel": "Other Liabilities, Noncurrent, Total",
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r71"
     ]
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNoncashIncomeExpense",
     "crdr": "credit",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other",
        "terseLabel": "Other",
        "label": "Other Noncash Income (Expense)",
        "totalLabel": "Other Noncash Income (Expense), Total",
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other."
       }
      }
     },
     "auth_ref": [
      "r98"
     ]
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Performance Measure, Amount",
        "terseLabel": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r789"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Aggregate Erroneous Compensation Amount",
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r751",
      "r761",
      "r771",
      "r803"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery Compensation Amount",
        "terseLabel": "Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r754",
      "r764",
      "r774",
      "r806"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r754",
      "r764",
      "r774",
      "r806"
     ]
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r778"
     ]
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PayablesAndAccrualsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "crdr": "credit",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/CommonStockRepurchaseProgramsAdditionalInformationDetail",
      "http://www.mednax.com/20240630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Payments for repurchase of common stock",
        "terseLabel": "Amount withheld to satisfy minimum statutory tax withholding obligations",
        "negatedLabel": "Repurchases of common stock",
        "label": "Payments for Repurchase of Common Stock",
        "documentation": "The cash outflow to reacquire common stock during the period."
       }
      }
     },
     "auth_ref": [
      "r94"
     ]
    },
    "us-gaap_PaymentsToAcquireBusinessesGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquireBusinessesGross",
     "crdr": "credit",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/DisclosureBusinessCombinationsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments to Acquire Businesses, Gross",
        "terseLabel": "Business acquisition consideration paid in cash",
        "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r428"
     ]
    },
    "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired",
     "crdr": "credit",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Acquisition payments, net of cash acquired",
        "label": "Payments to Acquire Businesses, Net of Cash Acquired",
        "totalLabel": "Payments to Acquire Businesses, Net of Cash Acquired, Total",
        "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "us-gaap_PaymentsToAcquireInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquireInvestments",
     "crdr": "credit",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchases of investments",
        "label": "Payments to Acquire Investments",
        "totalLabel": "Payments to Acquire Investments, Total",
        "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period."
       }
      }
     },
     "auth_ref": [
      "r92"
     ]
    },
    "us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquireOtherPropertyPlantAndEquipment",
     "crdr": "credit",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchases of property and equipment",
        "label": "Payments to Acquire Other Property, Plant, and Equipment",
        "documentation": "Amount of cash outflow from the acquisition of or improvements to long-lived, physical assets used to produce goods and services and not intended for resale, classified as other."
       }
      }
     },
     "auth_ref": [
      "r93"
     ]
    },
    "md_PaymentsToTermLoan": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mednax.com/20240630",
     "localname": "PaymentsToTermLoan",
     "crdr": "credit",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payments on term loan",
        "label": "Payments to Term Loan",
        "documentation": "Cash outflow to term loan."
       }
      }
     },
     "auth_ref": []
    },
    "md_PediatricGastroenterologyAndGynecologyPracticeAndMultiLocationPediatricUrgentCarePracticeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mednax.com/20240630",
     "localname": "PediatricGastroenterologyAndGynecologyPracticeAndMultiLocationPediatricUrgentCarePracticeMember",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/DisclosureBusinessCombinationsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pediatric Gastroenterology And Gynecology practice And Multi Location Pediatric Urgent Care Practice [Member]",
        "documentation": "Pediatric Gastroenterology And Gynecology practice And Multi Location Pediatric Urgent Care Practice [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "md_PediatricSubspecialtyPracticeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mednax.com/20240630",
     "localname": "PediatricSubspecialtyPracticeMember",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/DisclosureBusinessCombinationsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pediatric Subspecialty Practice [Member]",
        "label": "Pediatric Subspecialty Practice [Member]",
        "terseLabel": "Pediatric Subspecialty Practice [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Issuers, Footnote [Text Block]",
        "terseLabel": "Peer Group Issuers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r788"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Total Shareholder Return Amount",
        "terseLabel": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r788"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Actually Paid Compensation Amount",
        "terseLabel": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r780"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO [Member]",
        "terseLabel": "PEO"
       }
      }
     },
     "auth_ref": [
      "r797"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Name",
        "terseLabel": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r790"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Total Compensation Amount",
        "terseLabel": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r779"
     ]
    },
    "md_PercentageIncreaseDecreaseInSalaryAndWage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.mednax.com/20240630",
     "localname": "PercentageIncreaseDecreaseInSalaryAndWage",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/DisclosureCoronavirusPandemicCovid19AdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Decrease In Salary | %",
        "label": "Percentage Increase Decrease In Salary And Wage",
        "documentation": "Percentage Increase Decrease In Salary And Wage."
       }
      }
     },
     "auth_ref": []
    },
    "md_PercentageOfNetPatientServiceRevenueByTypeOfPayor": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.mednax.com/20240630",
     "localname": "PercentageOfNetPatientServiceRevenueByTypeOfPayor",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/AccountsReceivableAndNetRevenueScheduleOfNetPatientServiceRevenueByTypeOfPayorDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of net patient service revenue",
        "label": "Percentage Of Net Patient Service Revenue By Type Of Payor",
        "documentation": "Percentage of net patient service revenue by type payor."
       }
      }
     },
     "auth_ref": []
    },
    "md_PercentageOfRefundOfIncomeTaxAtThePriorPeriodCorporateTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.mednax.com/20240630",
     "localname": "PercentageOfRefundOfIncomeTaxAtThePriorPeriodCorporateTaxRate",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/DisclosureCoronavirusPandemicCovid19AdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Percentage of refund of income tax at the prior period corporate tax rate",
        "label": "Percentage Of Refund Of Income Tax At The Prior Period Corporate Tax Rate",
        "documentation": "Percentage of refund of income tax at the prior period corporate tax rate."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name [Axis]",
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r911",
      "r912",
      "r913",
      "r914",
      "r915",
      "r916",
      "r917",
      "r918",
      "r919",
      "r920",
      "r921",
      "r922",
      "r923",
      "r924",
      "r925",
      "r926",
      "r927",
      "r928",
      "r929",
      "r930",
      "r931",
      "r932",
      "r933",
      "r934",
      "r935",
      "r936"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name [Domain]",
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r911",
      "r912",
      "r913",
      "r914",
      "r915",
      "r916",
      "r917",
      "r918",
      "r919",
      "r920",
      "r921",
      "r922",
      "r923",
      "r924",
      "r925",
      "r926",
      "r927",
      "r928",
      "r929",
      "r930",
      "r931",
      "r932",
      "r933",
      "r934",
      "r935",
      "r936"
     ]
    },
    "ecd_PnsnAdjsPrrSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsPrrSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Prior Service Cost [Member]",
        "terseLabel": "Pension Adjustments Prior Service Cost"
       }
      }
     },
     "auth_ref": [
      "r781"
     ]
    },
    "ecd_PnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Service Cost [Member]",
        "terseLabel": "Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r825"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Benefits Adjustments, Footnote [Text Block]",
        "terseLabel": "Pension Benefits Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r780"
     ]
    },
    "md_PracticeSalariesAndBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mednax.com/20240630",
     "localname": "PracticeSalariesAndBenefits",
     "crdr": "debit",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Practice salaries and benefits",
        "label": "Practice Salaries and Benefits",
        "documentation": "Practice salaries and benefits."
       }
      }
     },
     "auth_ref": []
    },
    "md_PracticeSuppliesAndOtherOperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mednax.com/20240630",
     "localname": "PracticeSuppliesAndOtherOperatingExpenses",
     "crdr": "debit",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Practice supplies and other operating expenses",
        "label": "Practice Supplies And Other Operating Expenses",
        "documentation": "The aggregate amount of supplies and other operating expenses directly attributable to the physician practices."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/ConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, par value",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r355"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/ConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares authorized",
        "label": "Preferred Stock, Shares Authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r603"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/ConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, issued",
        "label": "Preferred Stock, Shares Issued",
        "totalLabel": "Preferred Stock, Shares Issued, Total",
        "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r355"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock; $.01 par value; 1,000 shares authorized; none issued",
        "label": "Preferred Stock, Value, Issued",
        "totalLabel": "Preferred Stock, Value, Issued, Total",
        "periodStartLabel": "Preferred Stock, Value, Issued, Beginning Balance",
        "periodEndLabel": "Preferred Stock, Value, Issued, Ending Balance",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r533",
      "r722"
     ]
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseCurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expenses",
        "label": "Prepaid Expense, Current",
        "totalLabel": "Prepaid Expense, Current, Total",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r183",
      "r305",
      "r306",
      "r674"
     ]
    },
    "md_PrimaryBeneficiaryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mednax.com/20240630",
     "localname": "PrimaryBeneficiaryMember",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/DisclosureBasisOfPresentationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary beneficiary [Member]",
        "label": "Primary beneficiary [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "md_ProceedsFromContributionInAidOfReimbursementOfLostRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mednax.com/20240630",
     "localname": "ProceedsFromContributionInAidOfReimbursementOfLostRevenue",
     "crdr": "credit",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/DisclosureCoronavirusPandemicCovid19AdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds From Contribution In Aid Of Reimbursement of Lost Revenue",
        "label": "Proceeds From Contribution In Aid Of Reimbursement of Lost Revenue",
        "documentation": "Proceeds From Contribution In Aid Of Reimbursement of Lost Revenue."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issuance of common stock",
        "label": "Proceeds from Issuance of Common Stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfUnsecuredDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfUnsecuredDebt",
     "crdr": "debit",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/DisclosureLineOfCreditAndLongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance of Unsecured Debt",
        "terseLabel": "Proceeds from issuance of unsecured debt",
        "documentation": "The cash inflow from the issuance of long-term debt that is not secured by collateral. Excludes proceeds from tax exempt unsecured debt."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "us-gaap_ProceedsFromLinesOfCredit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromLinesOfCredit",
     "crdr": "debit",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/DisclosureLineOfCreditAndLongTermDebtAdditionalInformationDetails",
      "http://www.mednax.com/20240630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Lines of Credit",
        "terseLabel": "Borrowings on revolving credit line",
        "verboseLabel": "Borrowings on line of credit",
        "documentation": "Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r851"
     ]
    },
    "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromPaymentsForOtherFinancingActivities",
     "crdr": "debit",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from (Payments for) Other Financing Activities",
        "terseLabel": "Other",
        "documentation": "Amount of cash inflow (outflow) from financing activities classified as other."
       }
      }
     },
     "auth_ref": [
      "r833",
      "r847"
     ]
    },
    "us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromSaleMaturityAndCollectionsOfInvestments",
     "crdr": "debit",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Proceeds from maturities or sales of investments",
        "label": "Proceeds from Sale, Maturity and Collection of Investments",
        "totalLabel": "Proceeds from Sale, Maturity and Collection of Investments, Total",
        "documentation": "The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "us-gaap_ProductAndServiceOtherMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProductAndServiceOtherMember",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/AccountsReceivableAndNetRevenueScheduleOfNetRevenueDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other revenue",
        "label": "Product and Service, Other [Member]",
        "documentation": "Article or substance produced by nature, labor or machinery and act of providing assistance, classified as other."
       }
      }
     },
     "auth_ref": [
      "r909"
     ]
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/AccountsReceivableAndNetRevenueScheduleOfNetRevenueDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service [Axis]",
        "label": "Product and Service [Axis]",
        "documentation": "Information by product and service, or group of similar products and similar services."
       }
      }
     },
     "auth_ref": [
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r248",
      "r518",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r671",
      "r692",
      "r724",
      "r725",
      "r726",
      "r727",
      "r729",
      "r841",
      "r900",
      "r901",
      "r908",
      "r973",
      "r974",
      "r975",
      "r976",
      "r977",
      "r978",
      "r979",
      "r980",
      "r981",
      "r982",
      "r983",
      "r984",
      "r985",
      "r986",
      "r987",
      "r988",
      "r989",
      "r990",
      "r991",
      "r992",
      "r993",
      "r994",
      "r995",
      "r996",
      "r997",
      "r998",
      "r999",
      "r1001",
      "r1002"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/AccountsReceivableAndNetRevenueScheduleOfNetRevenueDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service [Domain]",
        "label": "Product and Service [Domain]",
        "documentation": "Product or service, or a group of similar products or similar services."
       }
      }
     },
     "auth_ref": [
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r248",
      "r518",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r671",
      "r692",
      "r724",
      "r725",
      "r726",
      "r727",
      "r729",
      "r841",
      "r900",
      "r901",
      "r908",
      "r973",
      "r974",
      "r975",
      "r976",
      "r977",
      "r978",
      "r979",
      "r980",
      "r981",
      "r982",
      "r983",
      "r984",
      "r985",
      "r986",
      "r987",
      "r988",
      "r989",
      "r990",
      "r991",
      "r992",
      "r993",
      "r994",
      "r995",
      "r996",
      "r997",
      "r998",
      "r999",
      "r1001",
      "r1002"
     ]
    },
    "us-gaap_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net (loss) income",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r169",
      "r188",
      "r190",
      "r197",
      "r200",
      "r205",
      "r211",
      "r214",
      "r215",
      "r292",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r424",
      "r430",
      "r431",
      "r434",
      "r435",
      "r448",
      "r468",
      "r526",
      "r542",
      "r574",
      "r624",
      "r640",
      "r641",
      "r708",
      "r709",
      "r739",
      "r846",
      "r904"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment, net",
        "label": "Property, Plant and Equipment, Net",
        "totalLabel": "Property, Plant and Equipment, Net, Total",
        "periodStartLabel": "Property, Plant and Equipment, Net, Beginning Balance",
        "periodEndLabel": "Property, Plant and Equipment, Net, Ending Balance",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r482",
      "r527",
      "r539",
      "r722"
     ]
    },
    "md_PurchasePrice": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.mednax.com/20240630",
     "localname": "PurchasePrice",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/DisclosureLineOfCreditAndLongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase price",
        "label": "Purchase price",
        "terseLabel": "Purchase price"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Table]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r778"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance [Table Text Block]",
        "terseLabel": "Pay vs Performance Disclosure, Table"
       }
      }
     },
     "auth_ref": [
      "r778"
     ]
    },
    "md_RadiologyServicesMedicalGroupMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mednax.com/20240630",
     "localname": "RadiologyServicesMedicalGroupMember",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/DisclosureBusinessCombinationsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Radiology Services Medical Group [Member]",
        "label": "Radiology Services Medical Group [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/CashEquivalentsAndInvestmentsAdditionalInformationDetail",
      "http://www.mednax.com/20240630/taxonomy/role/DisclosureBusinessCombinationsAdditionalInformationDetail",
      "http://www.mednax.com/20240630/taxonomy/role/DisclosureCoronavirusPandemicCovid19AdditionalInformationDetail",
      "http://www.mednax.com/20240630/taxonomy/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Range [Axis]",
        "label": "Statistical Measurement [Axis]",
        "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median."
       }
      }
     },
     "auth_ref": [
      "r151",
      "r152",
      "r153",
      "r154",
      "r155",
      "r164",
      "r165",
      "r322",
      "r323",
      "r324",
      "r325",
      "r364",
      "r372",
      "r402",
      "r403",
      "r404",
      "r411",
      "r454",
      "r492",
      "r501",
      "r517",
      "r558",
      "r559",
      "r566",
      "r593",
      "r594",
      "r647",
      "r649",
      "r651",
      "r652",
      "r656",
      "r669",
      "r670",
      "r682",
      "r691",
      "r704",
      "r714",
      "r715",
      "r719",
      "r720",
      "r725",
      "r732",
      "r896",
      "r906",
      "r950",
      "r964",
      "r965",
      "r966",
      "r967",
      "r968"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeMember",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/CashEquivalentsAndInvestmentsAdditionalInformationDetail",
      "http://www.mednax.com/20240630/taxonomy/role/DisclosureBusinessCombinationsAdditionalInformationDetail",
      "http://www.mednax.com/20240630/taxonomy/role/DisclosureCoronavirusPandemicCovid19AdditionalInformationDetail",
      "http://www.mednax.com/20240630/taxonomy/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Range [Domain]",
        "label": "Statistical Measurement [Domain]",
        "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median."
       }
      }
     },
     "auth_ref": [
      "r151",
      "r152",
      "r153",
      "r154",
      "r155",
      "r164",
      "r165",
      "r322",
      "r323",
      "r324",
      "r325",
      "r364",
      "r372",
      "r402",
      "r403",
      "r404",
      "r411",
      "r454",
      "r492",
      "r501",
      "r517",
      "r558",
      "r559",
      "r566",
      "r593",
      "r594",
      "r647",
      "r649",
      "r651",
      "r652",
      "r656",
      "r669",
      "r670",
      "r682",
      "r691",
      "r704",
      "r714",
      "r715",
      "r719",
      "r720",
      "r725",
      "r732",
      "r896",
      "r906",
      "r950",
      "r964",
      "r965",
      "r966",
      "r967",
      "r968"
     ]
    },
    "us-gaap_ReceivablesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ReceivablesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Receivables [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]",
        "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure"
       }
      }
     },
     "auth_ref": [
      "r746",
      "r756",
      "r766",
      "r798"
     ]
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/DisclosureBasisOfPresentationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related and Nonrelated Parties [Domain]",
        "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r251",
      "r371",
      "r484",
      "r485",
      "r530",
      "r538",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r621",
      "r623",
      "r645"
     ]
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/DisclosureBasisOfPresentationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related and Nonrelated Parties [Axis]",
        "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r251",
      "r371",
      "r484",
      "r485",
      "r530",
      "r538",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r621",
      "r623",
      "r645",
      "r960"
     ]
    },
    "us-gaap_RepaymentsOfLinesOfCredit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RepaymentsOfLinesOfCredit",
     "crdr": "credit",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Repayments of Lines of Credit",
        "negatedLabel": "Payments on line of credit",
        "documentation": "Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements."
       }
      }
     },
     "auth_ref": [
      "r95",
      "r851"
     ]
    },
    "md_RepaymentsOfLongTermCapitalLeaseObligation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mednax.com/20240630",
     "localname": "RepaymentsOfLongTermCapitalLeaseObligation",
     "crdr": "credit",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payment on finance lease obligation",
        "documentation": "Repayments Of Long Term Capital Lease Obligation",
        "label": "Repayments Of Long Term Capital Lease Obligation"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date [Axis]",
        "terseLabel": "Restatement Determination Date:"
       }
      }
     },
     "auth_ref": [
      "r747",
      "r757",
      "r767",
      "r799"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date",
        "terseLabel": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r748",
      "r758",
      "r768",
      "r800"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Does Not Require Recovery [Text Block]",
        "terseLabel": "Restatement does not require Recovery"
       }
      }
     },
     "auth_ref": [
      "r755",
      "r765",
      "r775",
      "r807"
     ]
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/CashEquivalentsAndInvestmentsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Domain]",
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r172"
     ]
    },
    "us-gaap_RestrictedStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedStockMember",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/CommonStockRepurchaseProgramsAdditionalInformationDetail",
      "http://www.mednax.com/20240630/taxonomy/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted Stock [Member]",
        "label": "Restricted Stock [Member]",
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "us-gaap_RestructuringCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringCharges",
     "crdr": "debit",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Transformational and restructuring related expenses",
        "label": "Restructuring Charges",
        "totalLabel": "Restructuring Charges, Total",
        "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r318",
      "r319",
      "r897"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Retained deficit",
        "label": "Retained Earnings (Accumulated Deficit)",
        "totalLabel": "Retained Earnings (Accumulated Deficit), Total",
        "periodStartLabel": "Retained Earnings (Accumulated Deficit), Beginning Balance",
        "periodEndLabel": "Retained Earnings (Accumulated Deficit), Ending Balance",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r107",
      "r536",
      "r563",
      "r565",
      "r572",
      "r604",
      "r722"
     ]
    },
    "md_RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mednax.com/20240630",
     "localname": "RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Retained Deficit [Member]",
        "label": "Retained Earnings And Accumulated Other Comprehensive Income [Member]",
        "documentation": "Retained earnings and accumulated other comprehensive income [Member]."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerIncludingAssessedTax",
     "crdr": "credit",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/AccountsReceivableAndNetRevenueScheduleOfNetRevenueDetail",
      "http://www.mednax.com/20240630/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net revenue",
        "label": "Revenue from Contract with Customer, Including Assessed Tax",
        "totalLabel": "Net revenue",
        "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise."
       }
      }
     },
     "auth_ref": [
      "r123",
      "r124",
      "r233",
      "r238",
      "r239",
      "r245",
      "r247",
      "r248",
      "r249",
      "r250",
      "r362",
      "r363",
      "r518"
     ]
    },
    "us-gaap_RevolvingCreditFacilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevolvingCreditFacilityMember",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/DisclosureLineOfCreditAndLongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revolving Credit Facility [Member]",
        "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r816"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r816"
     ]
    },
    "md_RuralAreaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mednax.com/20240630",
     "localname": "RuralAreaMember",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/DisclosureCoronavirusPandemicCovid19AdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rural Area [Member]",
        "label": "Rural Area [Member]",
        "documentation": "Rural Area [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_ScenarioUnspecifiedDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ScenarioUnspecifiedDomain",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/DisclosureCoronavirusPandemicCovid19AdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]",
        "documentation": "Scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts."
       }
      }
     },
     "auth_ref": [
      "r163",
      "r216",
      "r373",
      "r828",
      "r857"
     ]
    },
    "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTable",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/AccountsReceivableAndNetRevenueScheduleOfNetRevenueDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table]",
        "label": "Accounts and Financing Receivables [Table]",
        "documentation": "Disclosure of information about accounts and financing receivables. Includes, but is not limited to, amount of receivable and allowance for credit loss."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r82",
      "r252",
      "r867"
     ]
    },
    "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/AccountsReceivableAndNetRevenueTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Accounts Receivable, Net",
        "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]",
        "documentation": "Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r82"
     ]
    },
    "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/AccountsPayableAndAccruedExpensesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Accounts Payable and Accrued Expenses",
        "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/CashEquivalentsAndInvestmentsScheduleOfInvestmentsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Available-for-sale [Line Items]",
        "label": "Debt Securities, Available-for-Sale [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268"
     ]
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/DisclosureBasisOfPresentationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Axis]",
        "documentation": "Information by name of investment including named security. Excludes entity that is consolidated."
       }
      }
     },
     "auth_ref": [
      "r289",
      "r290",
      "r291",
      "r420",
      "r829",
      "r830",
      "r831",
      "r941",
      "r942",
      "r943",
      "r944"
     ]
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/FairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r947",
      "r948"
     ]
    },
    "md_ScheduleOfFinancingReceivablesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.mednax.com/20240630",
     "localname": "ScheduleOfFinancingReceivablesLineItems",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/AccountsReceivableAndNetRevenueScheduleOfNetRevenueDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Financing Receivables [Line Items]",
        "label": "Schedule Of Financing Receivables [Line Items]",
        "documentation": "Schedule of financing receivables."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r375",
      "r377",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405"
     ]
    },
    "us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfWeightedAverageNumberOfSharesTableTextBlock",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/CommonAndCommonEquivalentSharesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Calculation of Shares Used in Basic and Diluted Net Income Per Share",
        "label": "Schedule of Weighted Average Number of Shares [Table Text Block]",
        "documentation": "Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit)."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/AccountsReceivableAndNetRevenueTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Percentage of Net Revenue",
        "label": "Schedules of Concentration of Risk, by Risk Factor [Table Text Block]",
        "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r24",
      "r25",
      "r26",
      "r50",
      "r112"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r741"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r743"
     ]
    },
    "us-gaap_SelfPayMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SelfPayMember",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/AccountsReceivableAndNetRevenueScheduleOfNetPatientServiceRevenueByTypeOfPayorDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Private-Pay Patients",
        "label": "Self-Pay [Member]",
        "documentation": "Patients who pay out of pocket for a health-related service in absence of insurance to cover the medical or surgical procedure performed."
       }
      }
     },
     "auth_ref": [
      "r908"
     ]
    },
    "us-gaap_SeniorNotes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SeniorNotes",
     "crdr": "credit",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/DisclosureLineOfCreditAndLongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Senior Notes, Total",
        "label": "Senior Notes",
        "terseLabel": "Senior notes",
        "documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of Notes with the highest claim on the assets of the issuer in case of bankruptcy or liquidation (with maturities initially due after one year or beyond the operating cycle if longer). Senior note holders are paid off in full before any payments are made to junior note holders."
       }
      }
     },
     "auth_ref": [
      "r116",
      "r971"
     ]
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation expense",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "totalLabel": "Share-based Payment Arrangement, Noncash Expense, Total",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award vesting period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r705"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r394"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r375",
      "r377",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares available for future grants and awards under Stock Incentive Plans",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r31"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/CommonStockRepurchaseProgramsAdditionalInformationDetail",
      "http://www.mednax.com/20240630/taxonomy/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Award Types",
        "terseLabel": "All Award Types",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting period of options, maximum years",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r706"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of market value of common stock at which employees are permitted to purchase",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent",
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesIssued",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance, Shares",
        "periodEndLabel": "Balance, Shares",
        "label": "Shares, Issued",
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "md_SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mednax.com/20240630",
     "localname": "SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMember",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/DisclosureLineOfCreditAndLongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2027 Notes",
        "terseLabel": "6.25% Senior Unsecured Notes Due 2027 [Member]",
        "label": "Six Point Two Five Percent Senior Unsecured Notes Due Two Thousand Twenty Seven [Member]",
        "documentation": "Six point two five percent senior unsecured notes due two thousand twenty seven."
       }
      }
     },
     "auth_ref": []
    },
    "md_SixPointTwoFivePercentageSeniorNotesDueTwoThousandTwentySevenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mednax.com/20240630",
     "localname": "SixPointTwoFivePercentageSeniorNotesDueTwoThousandTwentySevenMember",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/FairValueMeasurementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Six Point Two Five Percentage Senior Notes Due Two Thousand Twenty Seven [Member]",
        "label": "Six Point Two Five Percentage Senior Notes Due Two Thousand Twenty Seven [Member]",
        "terseLabel": "Six Point Two Five Percentage Senior Notes Due Two Thousand Twenty Seven [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/AccountsPayableAndAccruedExpensesAdditionalInformationDetail",
      "http://www.mednax.com/20240630/taxonomy/role/DisclosureCoronavirusPandemicCovid19AdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r131",
      "r177",
      "r178",
      "r179",
      "r200",
      "r220",
      "r224",
      "r226",
      "r228",
      "r235",
      "r236",
      "r292",
      "r327",
      "r329",
      "r330",
      "r331",
      "r334",
      "r335",
      "r355",
      "r356",
      "r357",
      "r358",
      "r360",
      "r468",
      "r568",
      "r569",
      "r570",
      "r571",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r587",
      "r603",
      "r625",
      "r642",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r827",
      "r850",
      "r859"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/CommonStockRepurchaseProgramsAdditionalInformationDetail",
      "http://www.mednax.com/20240630/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Components [Axis]",
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r75",
      "r79",
      "r80",
      "r166",
      "r192",
      "r193",
      "r194",
      "r202",
      "r203",
      "r204",
      "r206",
      "r211",
      "r213",
      "r215",
      "r234",
      "r293",
      "r294",
      "r317",
      "r361",
      "r417",
      "r418",
      "r421",
      "r422",
      "r423",
      "r425",
      "r429",
      "r430",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r446",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r478",
      "r480",
      "r483",
      "r545",
      "r560",
      "r561",
      "r562",
      "r575",
      "r642"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/AccountsPayableAndAccruedExpensesAdditionalInformationDetail",
      "http://www.mednax.com/20240630/taxonomy/role/DisclosureBusinessCombinationsAdditionalInformationDetail",
      "http://www.mednax.com/20240630/taxonomy/role/DisclosureCoronavirusPandemicCovid19AdditionalInformationDetail",
      "http://www.mednax.com/20240630/taxonomy/role/FairValueMeasurementsScheduleOfFairValueOnARecurringBasisDetails",
      "http://www.mednax.com/20240630/taxonomy/role/FairValueMeasurementsScheduleOfFinancialInstrumentsThatAreNotCarriedAtFairValueDetails",
      "http://www.mednax.com/20240630/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Line Items]",
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r202",
      "r203",
      "r204",
      "r234",
      "r480",
      "r518",
      "r567",
      "r587",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r603",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r612",
      "r613",
      "r614",
      "r615",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r623",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r642",
      "r733"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_StatementScenarioAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "StatementScenarioAxis",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/DisclosureCoronavirusPandemicCovid19AdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]",
        "documentation": "Information by scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts."
       }
      }
     },
     "auth_ref": [
      "r163",
      "r216",
      "r373",
      "r828",
      "r832",
      "r857"
     ]
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementTable",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/AccountsPayableAndAccruedExpensesAdditionalInformationDetail",
      "http://www.mednax.com/20240630/taxonomy/role/DisclosureBusinessCombinationsAdditionalInformationDetail",
      "http://www.mednax.com/20240630/taxonomy/role/DisclosureCoronavirusPandemicCovid19AdditionalInformationDetail",
      "http://www.mednax.com/20240630/taxonomy/role/FairValueMeasurementsScheduleOfFairValueOnARecurringBasisDetails",
      "http://www.mednax.com/20240630/taxonomy/role/FairValueMeasurementsScheduleOfFinancialInstrumentsThatAreNotCarriedAtFairValueDetails",
      "http://www.mednax.com/20240630/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Table]",
        "label": "Statement [Table]",
        "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r202",
      "r203",
      "r204",
      "r234",
      "r251",
      "r480",
      "r518",
      "r567",
      "r587",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r603",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r612",
      "r613",
      "r614",
      "r615",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r623",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r642",
      "r733"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Price or TSR Estimation Method [Text Block]",
        "terseLabel": "Stock Price or TSR Estimation Method"
       }
      }
     },
     "auth_ref": [
      "r750",
      "r760",
      "r770",
      "r802"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquityUnaudited",
      "http://www.mednax.com/20240630/taxonomy/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate number Shares issued under Stock Purchase Plans",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "verboseLabel": "Common stock issued under employee stock purchase plan shares",
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r74",
      "r75",
      "r107"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forfeitures of restricted stock, shares",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Forfeited",
        "negatedLabel": "Forfeitures of restricted stock, shares",
        "documentation": "Number of shares related to Restricted Stock Award forfeited during the period."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r74",
      "r75",
      "r107"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensationGross",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Issuance of restricted stock and conversion of restricted stock units to common stock, shares",
        "terseLabel": "Issuance of restricted stock, shares",
        "label": "Shares Issued, Shares, Share-Based Payment Arrangement, before Forfeiture",
        "documentation": "Number, before forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "crdr": "credit",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "terseLabel": "Common stock issued under employee stock purchase plan Value",
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r74",
      "r75",
      "r107"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures",
     "crdr": "debit",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Forfeitures",
        "terseLabel": "Forfeitures of restricted stock",
        "documentation": "Value of stock related to Restricted Stock Awards forfeited during the period."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r74",
      "r75",
      "r107"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "crdr": "credit",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture, Total",
        "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture",
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r74",
      "r75",
      "r107"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensationGross",
     "crdr": "credit",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of restricted stock",
        "label": "Shares Issued, Value, Share-Based Payment Arrangement, before Forfeiture",
        "documentation": "Value, before forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": []
    },
    "srt_StockRepurchaseProgramAuthorizedAmount1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "StockRepurchaseProgramAuthorizedAmount1",
     "crdr": "credit",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/CommonStockRepurchaseProgramsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock authorized for repurchase",
        "label": "Share Repurchase Program, Authorized, Amount",
        "documentation": "Amount authorized for purchase of share under share repurchase plan. Includes, but is not limited to, repurchase of stock and unit of ownership."
       }
      }
     },
     "auth_ref": [
      "r907"
     ]
    },
    "us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1",
     "crdr": "credit",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/CommonStockRepurchaseProgramsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company's Common stock repurchased",
        "label": "Share Repurchase Program, Remaining Authorized, Amount",
        "documentation": "Amount remaining authorized for purchase of share under share repurchase plan. Includes, but is not limited to, repurchase of stock and unit of ownership."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockRepurchasedDuringPeriodShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockRepurchasedDuringPeriodShares",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/CommonStockRepurchaseProgramsAdditionalInformationDetail",
      "http://www.mednax.com/20240630/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Repurchased common stock, shares",
        "label": "Stock Repurchased During Period, Shares",
        "terseLabel": "Stock repurchased during period, shares",
        "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r74",
      "r75",
      "r107",
      "r571",
      "r642",
      "r665"
     ]
    },
    "us-gaap_StockRepurchasedDuringPeriodValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockRepurchasedDuringPeriodValue",
     "crdr": "debit",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Repurchased common stock",
        "negatedLabel": "Repurchased common stock",
        "label": "Stock Repurchased During Period, Value",
        "documentation": "Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r74",
      "r75",
      "r107",
      "r575",
      "r642",
      "r665",
      "r739"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total shareholders' equity",
        "label": "Equity, Attributable to Parent",
        "periodStartLabel": "Stockholders' Equity Attributable to Parent, Beginning Balance",
        "periodEndLabel": "Stockholders' Equity Attributable to Parent, Ending Balance",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r79",
      "r80",
      "r102",
      "r605",
      "r622",
      "r643",
      "r644",
      "r722",
      "r740",
      "r852",
      "r884",
      "r954",
      "r1004"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shareholders' equity:",
        "label": "Equity, Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "crdr": "credit",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total equity",
        "periodStartLabel": "Balance",
        "periodEndLabel": "Balance",
        "label": "Equity, Including Portion Attributable to Noncontrolling Interest",
        "documentation": "Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r42",
      "r43",
      "r166",
      "r167",
      "r193",
      "r202",
      "r203",
      "r204",
      "r206",
      "r211",
      "r213",
      "r293",
      "r294",
      "r317",
      "r361",
      "r417",
      "r418",
      "r421",
      "r422",
      "r423",
      "r425",
      "r429",
      "r430",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r446",
      "r469",
      "r470",
      "r474",
      "r479",
      "r483",
      "r561",
      "r562",
      "r573",
      "r605",
      "r622",
      "r643",
      "r644",
      "r667",
      "r739",
      "r852",
      "r884",
      "r954",
      "r1004"
     ]
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tabular List [Table Text Block]",
        "terseLabel": "Tabular List, Table"
       }
      }
     },
     "auth_ref": [
      "r796"
     ]
    },
    "us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxAdjustmentsSettlementsAndUnusualProvisions",
     "crdr": "debit",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/DisclosureBusinessCombinationsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax adjustments, sttlements and unusual provisions",
        "label": "Tax Adjustments, Settlements, and Unusual Provisions",
        "documentation": "Amount of increase (decrease) to previously recorded tax expense. Includes, but is not limited to, significant settlements of income tax disputes, and unusual tax positions or infrequent actions taken by the entity, including tax assessment reversal, and IRS tax settlement."
       }
      }
     },
     "auth_ref": [
      "r940"
     ]
    },
    "us-gaap_TaxPeriodAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxPeriodAxis",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/DisclosureBusinessCombinationsAdditionalInformationDetail",
      "http://www.mednax.com/20240630/taxonomy/role/DisclosureCoronavirusPandemicCovid19AdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Period [Axis]",
        "documentation": "Information by period subject to enacted tax law."
       }
      }
     },
     "auth_ref": [
      "r938"
     ]
    },
    "us-gaap_TaxPeriodDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxPeriodDomain",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/DisclosureBusinessCombinationsAdditionalInformationDetail",
      "http://www.mednax.com/20240630/taxonomy/role/DisclosureCoronavirusPandemicCovid19AdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Period [Domain]",
        "documentation": "Identified tax period."
       }
      }
     },
     "auth_ref": [
      "r938"
     ]
    },
    "us-gaap_TextBlockAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TextBlockAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Text Block [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ThirdPartyPayorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ThirdPartyPayorMember",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/AccountsReceivableAndNetRevenueScheduleOfNetPatientServiceRevenueByTypeOfPayorDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Third-Parties",
        "label": "Third-Party Payor [Member]",
        "documentation": "Organization other than the patient (first party) or health care provider (second party) involved in the financing of personal health services."
       }
      }
     },
     "auth_ref": [
      "r908"
     ]
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/DisclosureCoronavirusPandemicCovid19AdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title and Position [Axis]",
        "documentation": "Information by title and position of individual or group within organization."
       }
      }
     },
     "auth_ref": [
      "r865",
      "r959"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/DisclosureCoronavirusPandemicCovid19AdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title and Position [Domain]",
        "documentation": "Title and position of individual or group within organization."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Amount",
        "terseLabel": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r788"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Vs Peer Group [Text Block]",
        "terseLabel": "Total Shareholder Return Vs Peer Group"
       }
      }
     },
     "auth_ref": [
      "r795"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement [Axis]",
        "terseLabel": "Trading Arrangement:"
       }
      }
     },
     "auth_ref": [
      "r815"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangements, by Individual [Table]",
        "terseLabel": "Trading Arrangements, by Individual"
       }
      }
     },
     "auth_ref": [
      "r817"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/CashEquivalentsAndInvestmentsScheduleOfInvestmentsDetail",
      "http://www.mednax.com/20240630/taxonomy/role/DisclosureLineOfCreditAndLongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments [Domain]",
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r352",
      "r359",
      "r445",
      "r465",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r546",
      "r710",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720",
      "r723",
      "r834",
      "r835",
      "r836",
      "r837",
      "r838",
      "r839",
      "r840",
      "r880",
      "r881",
      "r882",
      "r883",
      "r946",
      "r949",
      "r950",
      "r951",
      "r952",
      "r953"
     ]
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Adoption Date",
        "terseLabel": "Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r818"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Duration",
        "terseLabel": "Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r819"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Expiration Date",
        "terseLabel": "Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r819"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r817"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Title",
        "terseLabel": "Title"
       }
      }
     },
     "auth_ref": [
      "r817"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Securities Aggregate Available Amount",
        "terseLabel": "Aggregate Available"
       }
      }
     },
     "auth_ref": [
      "r820"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Termination Date",
        "terseLabel": "Termination Date"
       }
      }
     },
     "auth_ref": [
      "r818"
     ]
    },
    "md_TwoThousandFifteenNonQualifiedStockPurchasePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mednax.com/20240630",
     "localname": "TwoThousandFifteenNonQualifiedStockPurchasePlanMember",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2015 Non-Qualified Stock Purchase Plan [Member]",
        "label": "Two Thousand Fifteen Non Qualified Stock Purchase Plan [Member]",
        "documentation": "Two Thousand Fifteen Non Qualified Stock Purchase Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "md_TwoThousandTwentySevenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mednax.com/20240630",
     "localname": "TwoThousandTwentySevenMember",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/FairValueMeasurementsScheduleOfFinancialInstrumentsThatAreNotCarriedAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027 Notes [Member]",
        "label": "Two Thousand Twenty Seven [Member]",
        "documentation": "Two Thousand Twenty Seven Member"
       }
      }
     },
     "auth_ref": []
    },
    "md_TwoThousandTwentyTaxYearMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mednax.com/20240630",
     "localname": "TwoThousandTwentyTaxYearMember",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/DisclosureCoronavirusPandemicCovid19AdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2020 Tax Year [Member]",
        "label": "Two Thousand Twenty Tax Year [Member]",
        "documentation": "Two thousand twenty tax year."
       }
      }
     },
     "auth_ref": []
    },
    "md_TwoThousandTwentyThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mednax.com/20240630",
     "localname": "TwoThousandTwentyThreeMember",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/FairValueMeasurementsScheduleOfFinancialInstrumentsThatAreNotCarriedAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2023 Notes [Member]",
        "label": "Two Thousand Twenty Three [Member]",
        "documentation": "Two Thousand Twenty Three Member"
       }
      }
     },
     "auth_ref": []
    },
    "md_TwoZeroThreeZeroMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mednax.com/20240630",
     "localname": "TwoZeroThreeZeroMember",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/FairValueMeasurementsScheduleOfFinancialInstrumentsThatAreNotCarriedAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Zero Three Zero [Member]",
        "label": "Two Zero Three Zero [Member]",
        "terseLabel": "2030 Notes [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "USGovernmentSponsoredEnterprisesDebtSecuritiesMember",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/CashEquivalentsAndInvestmentsScheduleOfInvestmentsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Federal Home Loan Securities [Member]",
        "label": "US Government-sponsored Enterprises Debt Securities [Member]",
        "documentation": "Debentures, bonds and other debt securities issued by US government sponsored entities (GSEs), for example, but not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB). Excludes debt issued by the Government National Mortgage Association (GNMA or Ginnie Mae)."
       }
      }
     },
     "auth_ref": [
      "r910",
      "r970"
     ]
    },
    "us-gaap_USStatesAndPoliticalSubdivisionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "USStatesAndPoliticalSubdivisionsMember",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/CashEquivalentsAndInvestmentsScheduleOfInvestmentsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Municipal Debt Securities [Member]",
        "label": "US States and Political Subdivisions Debt Securities [Member]",
        "documentation": "Bonds or similar securities issued by state, city, or local US governments or the agencies operated by state, city, or local governments. Debt securities issued by state governments may include bond issuances of US state authorities including, for example, but not limited to, housing authorities, dormitory authorities, and general obligations while debt securities issued by political subdivisions of US states would include, for example, debt issuances by county, borough, city, or municipal governments."
       }
      }
     },
     "auth_ref": [
      "r699",
      "r723",
      "r728",
      "r1000"
     ]
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "USTreasurySecuritiesMember",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/CashEquivalentsAndInvestmentsScheduleOfInvestmentsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S. Treasury securities [Member]",
        "label": "US Treasury Securities [Member]",
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years)."
       }
      }
     },
     "auth_ref": [
      "r676",
      "r699",
      "r701",
      "r710",
      "r970"
     ]
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Security Market Price Change, Percent",
        "terseLabel": "Underlying Security Market Price Change"
       }
      }
     },
     "auth_ref": [
      "r814"
     ]
    },
    "md_UnnamedCorporateJointVentureOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mednax.com/20240630",
     "localname": "UnnamedCorporateJointVentureOneMember",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/DisclosureBasisOfPresentationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unnamed Corporate Joint Venture One [Member]",
        "documentation": "Unnamed Corporate Joint Venture [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "md_UnnamedCorporateJointVentureTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mednax.com/20240630",
     "localname": "UnnamedCorporateJointVentureTwoMember",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/DisclosureBasisOfPresentationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unnamed Corporate Joint Venture Two [Member]",
        "verboseLabel": "Unnamed Corporate Joint Venture Two [Member]",
        "documentation": "Unnamed Corporate Joint Venture Two Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UnrealizedGainLossOnInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrealizedGainLossOnInvestments",
     "crdr": "credit",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized holding gain (loss) on investments, net of tax of $66, $126, $86 and $353",
        "label": "Unrealized Gain (Loss) on Investments",
        "documentation": "Amount of unrealized gain (loss) on investment."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_UnsecuredDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnsecuredDebt",
     "crdr": "credit",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/DisclosureLineOfCreditAndLongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Unsecured Debt, Total",
        "label": "Unsecured Debt",
        "terseLabel": "Unsecured note issued",
        "documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of uncollateralized debt obligations (with maturities initially due after one year or beyond the operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r116",
      "r971"
     ]
    },
    "us-gaap_UnsecuredDebtMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnsecuredDebtMember",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/DisclosureLineOfCreditAndLongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unsecured Debt [Member]",
        "documentation": "Debt obligation not collateralized by pledge of, mortgage of or other lien on the entity's assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UnsecuredLongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnsecuredLongTermDebt",
     "crdr": "credit",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/DisclosureLineOfCreditAndLongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unsecured Long-Term Debt, Noncurrent",
        "terseLabel": "Proceeds from issuance of unsecured debt",
        "documentation": "Carrying value as of the balance sheet date of uncollateralized debt obligation (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/DisclosureBusinessCombinationsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase decrease in valuation allowance deferred tax assets",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset."
       }
      }
     },
     "auth_ref": [
      "r416"
     ]
    },
    "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]",
        "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r784"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/CommonAndCommonEquivalentSharesScheduleOfCalculationOfSharesUsedInBasicAndDilutedNetIncomePerShareDetail",
      "http://www.mednax.com/20240630/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Weighted average number of common and common equivalent shares outstanding",
        "terseLabel": "Diluted",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r219",
      "r228"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://www.mednax.com/20240630/taxonomy/role/CommonAndCommonEquivalentSharesScheduleOfCalculationOfSharesUsedInBasicAndDilutedNetIncomePerShareDetail",
      "http://www.mednax.com/20240630/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Weighted average number of common shares outstanding",
        "terseLabel": "Basic",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "totalLabel": "Weighted Average Number of Shares Outstanding, Basic, Total",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r218",
      "r228"
     ]
    },
    "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]",
        "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r782"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "7",
   "SubTopic": "30",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479637/805-30-30-7"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "8",
   "SubTopic": "30",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479637/805-30-30-8"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "405",
   "Topic": "942",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478353/942-405-50-1"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "30",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "815",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-2"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-16"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-21"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-4"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-5"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "37",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-37"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-15"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-16"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4I"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1A"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1B"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-5"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-20"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-3"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-3A"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-3B"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-4"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5B"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5B"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5C",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5C"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "250",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/250/tableOfContent"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "275",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/275/tableOfContent"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-2"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/805/tableOfContent"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/810/tableOfContent"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r112": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r113": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r114": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r115": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r116": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r117": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r118": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r119": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(13)(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r120": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r121": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r122": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/942-320/tableOfContent"
  },
  "r123": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r124": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r125": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r126": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "SubTopic": "210",
   "Topic": "946",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-20"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Subparagraph": "(Instruction 5)",
   "Publisher": "SEC"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(1)(Instruction 5)",
   "Publisher": "SEC"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(2)(Instruction 5)",
   "Publisher": "SEC"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(3)(Instruction 5)",
   "Publisher": "SEC"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(4)(Instruction 5)",
   "Publisher": "SEC"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(5)(Instruction 5)",
   "Publisher": "SEC"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(1)(i)(Instruction 5)",
   "Publisher": "SEC"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(1)(ii)(Instruction 5)",
   "Publisher": "SEC"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(i)(Instruction 5)",
   "Publisher": "SEC"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(ii)(Instruction 5)",
   "Publisher": "SEC"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(iii)(Instruction 5)",
   "Publisher": "SEC"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Subparagraph": "(Instruction 5)",
   "Publisher": "SEC"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1403",
   "Paragraph": "b",
   "Publisher": "SEC"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1406",
   "Paragraph": "a",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1406",
   "Paragraph": "a",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1406",
   "Paragraph": "a",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1406",
   "Paragraph": "a",
   "Subparagraph": "(4)",
   "Publisher": "SEC"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1406",
   "Paragraph": "a",
   "Subparagraph": "(5)",
   "Publisher": "SEC"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1406",
   "Paragraph": "c",
   "Publisher": "SEC"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12",
   "Paragraph": "Column A",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12A",
   "Paragraph": "Column A",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12B",
   "Paragraph": "Column A",
   "Subparagraph": "(a)",
   "Footnote": "4",
   "Publisher": "SEC"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12B",
   "Paragraph": "Column A",
   "Subparagraph": "(b)",
   "Footnote": "4",
   "Publisher": "SEC"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "14",
   "Paragraph": "Column A",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column A",
   "Publisher": "SEC"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column B",
   "Publisher": "SEC"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column C",
   "Publisher": "SEC"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column D",
   "Publisher": "SEC"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column E",
   "Publisher": "SEC"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column F",
   "Publisher": "SEC"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 11",
   "Section": "L",
   "Publisher": "SEC"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 11",
   "Section": "M",
   "Paragraph": "Question 2",
   "Publisher": "SEC"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 5",
   "Section": "Y",
   "Paragraph": "Question 2",
   "Publisher": "SEC"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 5",
   "Section": "Y",
   "Paragraph": "Question 4",
   "Publisher": "SEC"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5C",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5C"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-2"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/260/tableOfContent"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-22"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-23"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-28A"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-24"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-4"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/320/tableOfContent"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-2"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-10"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481664/323-10-45-1"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479344/326-20-45-1"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479130/326-30-45-1"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482598/350-20-45-1"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482598/350-20-45-2"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-2"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-2"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-1"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.b.1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-6"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480454/718-10-45-1"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-4"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-6"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478758/740-323-25-1"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1B"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483013/835-20-50-1"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481444/860-30-45-1"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483154/926-20-50-5"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "940",
   "SubTopic": "820",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(15)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-21"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5D",
   "Subparagraph": "(SX 210.12-13D(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5D"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-3"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "8",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-8"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479294/326-20-55-12"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-6"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "101",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-17"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "i"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iii"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iv"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "v"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "vi"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r813": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r814": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r815": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r816": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r817": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r818": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r819": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r820": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r821": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r822": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Number": "229",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1"
  },
  "r823": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "A",
   "Number": "229"
  },
  "r824": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Number": "229"
  },
  "r825": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "i",
   "Number": "229"
  },
  "r826": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r827": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r828": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-10"
  },
  "r829": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2"
  },
  "r830": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2"
  },
  "r831": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2"
  },
  "r832": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-3"
  },
  "r833": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r834": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r835": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r836": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r837": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r838": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r839": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r840": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r841": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 5",
   "Section": "Y",
   "Paragraph": "Question 2",
   "Publisher": "SEC"
  },
  "r842": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r843": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r844": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r845": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r846": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r847": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r848": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r849": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r850": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r851": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r852": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r853": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r854": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r855": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r856": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r857": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r858": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r859": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55"
  },
  "r860": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r861": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r862": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r863": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r864": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r865": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r866": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2"
  },
  "r867": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "40",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481628/310-20-40-7"
  },
  "r868": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-1"
  },
  "r869": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r870": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r871": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r872": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r873": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r874": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r875": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r876": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r877": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r878": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r879": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r880": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9"
  },
  "r881": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r882": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r883": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r884": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r885": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-20/tableOfContent"
  },
  "r886": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r887": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r888": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-30/tableOfContent"
  },
  "r889": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r890": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r891": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r892": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r893": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r894": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r895": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r896": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r897": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482047/420-10-45-3"
  },
  "r898": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r899": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1"
  },
  "r900": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r901": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r902": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r903": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r904": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r905": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r906": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r907": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481520/505-30-50-4"
  },
  "r908": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r909": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r910": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r911": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r912": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r913": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r914": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r915": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r916": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r917": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r918": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r919": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r920": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r921": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r922": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r923": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r924": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r925": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r926": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r927": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r928": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r929": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r930": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r931": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r932": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r933": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r934": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r935": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r936": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r937": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "720",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483384/720-30-45-1"
  },
  "r938": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r939": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-6"
  },
  "r940": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r941": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r942": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r943": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r944": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r945": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r946": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r947": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r948": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r949": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r950": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r951": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r952": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r953": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r954": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r955": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r956": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-3"
  },
  "r957": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r958": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479365/842-20-25-6"
  },
  "r959": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r960": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r961": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r962": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r963": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r964": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r965": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r966": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r967": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r968": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r969": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "940",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/940-320/tableOfContent"
  },
  "r970": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2"
  },
  "r971": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r972": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r973": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r974": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r975": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r976": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C"
  },
  "r977": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r978": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r979": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r980": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r981": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r982": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r983": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r984": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r985": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r986": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r987": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r988": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r989": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r990": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r991": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r992": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r993": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r994": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r995": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r996": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r997": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r998": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r999": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1000": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-1"
  },
  "r1001": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1002": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1003": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r1004": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1005": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1006": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>60
<FILENAME>0000950170-24-091193-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000950170-24-091193-xbrl.zip
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M-AWB@TP$W=)(:"]-N()GK8T!B@:,1X]BMIL61X+ZCXJW[:(_*J-FQ5-8V,?
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M:"J>_RRG G,R,84@-#B-/!' +Z#BZ<3^=W0CN"?BA'[%W_,B[,4/,HDO&(2
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M>6<HS,L!ZR\W+P<7L(B[-]B%@_UG,\B?;&=B:\86(_$K75M5]0H,ZNSFB67
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MQ(!F9&=49_1@?,18Q3C)A,\DP&3(Y,>4QM3*M,I,PZS #&*^QUS&/,:"RR+
M8L02Q)+%\H9EYRSK6<VSWF>3SK:<766E8[W(ZLX:R]K(NL1&S:;$YL86R];$
MMLQ.RWZ)W9,]D?T5^^8YEG-:YY#G,L[UG-OGX.4PY;C!4<(QR4G"*<OIS!G+
MV<RYR<7&I<=UC:N :XR;F%N6VY4[@;N=>X^'E\><YS9/%<\B+P.O-F\@;P'O
M!!\YGS*?#U\FWR _(;\LOP?_8_ZW K@"4@*N BD"O8*X@M*";H*/!?O.$YR7
M.P\YGWE^1(A,Z)*0KU"!T(PPG?!EX1O"5<+K(EPB5B*/1-I%CD2E1#U%LT7'
MQ:C$=,1NB-6*?187$ >)IX@/2I!+:$B$2E1+?)(4E 1+IDF^DZ*6TI.Z+=4L
M=2@M(PV3+I9>DN&2N2J3*C,B2R-[1392]K4<@9R*7*A<O=Q7>6EYA'R9_(:"
MD(*'0K["X@7>"^ +V1?F%#D4'10S%-\KL2M=57JB]%[YG+*#<J;R[$7.BTX7
M<R]^O,1_R?U2X:5U%5$5F$J%RIZJO&JPZ@LU/#5-M7MJ/>I4ZJ;JR>I3&AP:
M+AH%&IN:4II!FB^T"+1TM1YIC6B?U09IYVEOZLCH!.N\TB73-=9-UIV]+' 9
M=KE6#U=/1R]&;T*?6Q^B7V4 &&@;Q!A,7N&]XG.ESI#0\(IABN&"D9C1-:-V
M8VIC>^-\XUT3%9,HDW%3/E.D:;,9A9F-69[9GKF:>;3Y>PL1BV"++DLF2S?+
M:BLB*S.K7*L=:W7K..MY&RF;<)MA6UY;?]L..R8[3[L&>PI[!_ORJP17S:_F
M7SUP,'#(=-AQU'9,==P$J8(20"M.%YUBG9; BN!H\$=G1>=HYT4719<8ER57
M9==XUU4W5;=DMT_N6N[I[GL>!AXH#XRGN6>)URFOJUXU$"J(!^05E!7J#^WS
M%O0.]W[O(^\3Y[,)TX7EPG'@MO!J! UV,?4&R8>\A9SQ5?)-\?WB9^97[D_I
M#_%_$R 0<#?@8Z!&8$X0?A HJ/G:N6O7K\T$7PK.",$)<0QI#N4,#0N=_T/S
MCZ?72:Y[7.^^(7HC^L;V3?.;M6%GP_X(F[NE>:L@_'0X+'SDML+M]#OX=]SN
M]-R5N)MT]^B>T[W."-&(^(B#2%!DYWVQ^XGW,0^<'_1$24>E/21\"'DX_$CY
MT=-HRNC Z+D8O9C*6/;8>[';<?9Q'?&2\>D)) G(A/>)EQ.KD[B2'B8=)+LF
M#Z6HI)2DLJ3>3=U[[/2X/^UB6G'ZV?2(=/03MR?O,C0S*C-Y,N.S"+-\LQ:R
MS;+;<V1S\G*9<B-R#U$0U/NG1D]?Y<GDY>6SY$<5X!8@"Y8*;0K?%JD551<+
M%6>4T)5$/ .>(9\MEUXM'2[3+6LNERTO?L[]/+6"NN)>)4YE0.5FE6O5^VK+
MZKX:G9KF6H7:BCKA.E3]N?J4!MJ&J$:2QK!&3%-@T\X+[Q>K+UU>SC7;-X^W
M6+0,OC)\U=.JV_JZ3:.MI?U2>]-KQ=?U'?(=-9VRG55=TEV5;Z3>5'1+=5?T
M2/=4]LKT5K^5>UO;=Z&OL5^Y_^6 VD#;H/9@UY#^4-^PZ?"[$9N1]^^<WBV.
M>HY^&O,=VQ__8X)@XM[DF<GX*9:IS&G^Z9+WTN\;9M1FWLP:SX[/@>96/L _
M',R'+9 OQ']D^YBW*+Y8OZ2Q]';9>GE^Q7ME?S5\C7(M=9UO_?G&Q8TWFQ:;
M\Y]@GS"?([<8MU#;DMO-.U=VIG:]=O?W[GUA_/+TJ^S7=K0Y^N.^WP'10>(A
M_V'MD>[1!,8+@_GES-1%X,>9*9S_!'"_/_X">'^%/T6Q+^Q_XOX+<')F"F^)
M\"(>#N6O9Z9>8U[A$)P<@P+P_CP6!1"3$)TBQ2<@Q#M6#LO\]<P4<(J8@) (
M'\LBP7XJ$>)B5<+#):<@QB?$HP1POI^GHJ0Z1TTL1D-RB<-0G+;"M](OH4K6
MPE_.086S7!(Q.$0G32_#P,ATW<A18H#+--[<QVPX\5&_\7,I)$P5!.>.0V64
MWE#C:=<J:W:Z?:<:J_%QN?AXIRE)<?$)<(A/JJ$D(#PG1D5TR9#ZE(,/Q_5'
MI>(J1F6<Y32(6&F9#$=8OX0Q/&;@.:V4*9*.GN%EWXWH3%4N21,SXEE0\\VL
M0;6P;.ZXEE<:FS-.MW@J>/]Z\JGIQ7^\IOS_.5!@WOX_;7W?_Y#U+>.@AU8*
MZN9Q\3/C#'0U#FTF!V;BA?%E9?VMSY'KZ$<Z*VE?Q>R(MCB>S=93M+QH4VGA
M?[.EO0G>YK7<WFQ]7@^%;5G)W&?L4G* 4WV<JF7FKN_F2J/RW18P01%A %B^
M;1SW3)YL"3'MOLM(Z.U$E?GF$5,%0;C%<X_+;K&QY+,,!2N:MS6]RF4X+<[Q
MA.KD+DUP"J-6ET8"GLW[9M0TFT>C/&N-$UCJ%T%L:YF.KDU?%C_&/XD4EE+W
M8 F/?39[WZIG8887.S>;9$Y;Q;UAT[2C'']V=.[L1_>JE*%:7O,9PV%W7<A"
M@IQ2<]H8Q8M4+Z1@NP7W0<Y4<[]="S=Y[4#L*%BQ:L14H"G;,+<QRO7H'O?I
M1 P066QG^;3+POU\BVCT5)&;]>BEQMQ\P=&9V53[6TQ^\>@N]$WP:87UE'L%
MI^_L&<DRQ->,?!J_Q/8L.=W/5MX]\%IXDFVHB:?T06T_@CX.LBPU(!^G2,#7
MOGBVBWN=<S*%+RSHVKV<[;GE=6B)T_0#FH*^[(,Q9_SJ'>J/0K/Q>?6HB3=,
M;[KM#;<8ORSKEGR]V][#SWOTZA%9D2)G+G^@-9-(.X$(^&[?:E#)7D!7M!E:
M03">S:OR5JARY9K8ED$4/.5"EX]MYSR*^S4:<1@5N+H;,W,4819F/[^H2*KG
M-H0!7E@?SJ8/)[W[C/=(S$*(]E% C?K-;:_1-8^:C]V!5<3O)HH_D.9S<BZ!
M*K84? ^4(LSZIR]A@#C.CXI"N0O/XFY1B,?2/WDT6[L^]UKP]:9I7Y*XO7:"
M57](L+QWJ%I7]4@^!G@J+."Z=UKK0SQY=E=-80+3"UBSC[( W;JN,7__RK;1
MC. B(\.FV=MD_294^3UTDKY2FS:3OM=$5YT2++T1442BM_VV),#K]BT!>IJY
MC[FU?16R(B7FXF*MSX;M'[@UW"7GB8Y=BQ>$/YBHC][]2NT3P?>)V? @-W\G
MX:TV&>V(H.2:IVW]BF$P@[9V0']$Z)CFV4'[3RVO"X?%T[212?-(MIPKU3EV
MT9^:&X@'HS^916RF+!4TGE,T=?W@7Q=UR87!H: 4Y55QI*V;]DHJ_7H'K/A3
M+6^29U2KEM<2*<>N7_H?0R4U>L'X\PFVS:@;V39L$0R?<@]>:9+;8P!&^;8>
M\:(,)'?.T6[>U)4"E_.*[GDZYCZQM2GW9:N:;GEQ$UT.?+A9$)2JE:B/;BG8
MR&7VJHIP@3:5P&B[X*.$+!=:S_1);;"!@\I.'03RH=GT>,7ZQF($V\RERWWL
M\EE'6>3'PV5%\K7N)&_55BG+P5#6R@-^4EX9$7YT;G9]AG;%1A5(6[XO'AHI
M*[HT4!*3N!P!G;O:AE31V4E,)C'"V=E)05I'JDP=;$P^_HKWV1;9_D>F'DS_
M_\"4IQS'SZ<37\'-IZ.G8Q09'9O#/:1C%/7B3L280Y.C<IZ<%$.A-4=5;%K)
M@>[<S7B&->ZM\2['EBU+,\'"G)<IVK92Y9+[C=IIU>[%]_O<C*$R%--<S\L6
M/SCM:VP]^KROU$-59,2ZDWEHJC:8C+8(='G?'BZ2J=;Z 0/X'"&VC"3++S>/
MNJT6YU),TW]*%>BAR+V5W%S_24]'O."=4:J=:'[G[F?!86CB_DLS6HL'VJ0J
M#M'WAY-10T?7/#->YZ_,TSYH29ET,LB.?#U9('O*_+99/9%5IQP2!7LC8'-I
MTL162E%8B<2CH^6EL#*C\T3Q.MOK1GL!\Z3)P@KN U%(T1%5E='2^[)P&EDV
M-8CB%O?*Z[R:VIK7:SR3'Z2'_:JD103T;C6\^6H6'_-!\*5!=[J<!W(HW8!6
MR#DT7R89L=1W(T='0,PZ6IM[5M>11_'6K7!S-P.1+C[CR@QM[^;'?!J/937S
M16\8WMOD>K1"M+K[B]L)QUU9D;#RR TUC=R))%,PONJE4 X1;CKS&[*=!KL:
ME'<_J'-P03Y_S0^D8O2/0'GDB7.>/^V1*WY^2284RJB'KBYFQ !6LC*S_B4X
MK7(QD],Q-J,H.8_+]Z8JWGS" /0Z2GMU!AEUR2RTO#?'LDP'40^^2$Y)C+;9
MVU]C8S?UE>M\[+]+X+B<[# 95924'GP[>3"87GB./+ZJZ.KS:.%\$WXZ0</T
MFWSGNB2*36WZVRHUK2OL/?+"7&:-+30,VC+F!&^FV'^J> IK-9?\L.!:+J!+
M5PA-Y9N867&S5=>8*DQ7*2 UB?_:$3->)%U9,5']_,*XJ8MLVXM6ET?4]/X5
M];JN=X*>Q5?#2<3O^WRHU%!;M216+4KOMJ+*%&<IVVW;$BY>*\G3B5/OXQKX
M5.A7G%MJD!'75" )*7B;U*JG7%BV$EGV.0UM3C.OKP>Z$>L?3WVSI2./B$_;
M*S)YS GG@]23?_LXHL ,_/M';U^: SKLTUPX+0GTZ@>2UY7G7X=L7<K[Q.O8
M\Z;0:)EBTGFLLB+&] I=Z%&-G-:&MLADRL/GS""7@3$#F4&DV//;!#2;<9:S
M3VK[EV+K*;>LK+7)7T^MUO=^[%Z.3ZK<*S8G]AY^ S')\"!3E.1_7ETLR'TX
M1"M,-S?6&>N4;3*7R/KT('F^I3+Q8&5GA5Q;3/]Y3^%+7IV[A-=HV=3*DS[P
M\RS8\FNO;5F%=H6[<UA[CYG?V6 *57.JP;UOT5)5;3_5S3. UEJ[LND06?NA
M*_U#*.*TT6<C&KA@$#CEH_?+^N9URM@9I3HK)5-!D[0+XK=IKS%'%G13ULK@
MFOZ3)W 2$;D88"(5V974(UG9_/H9V2U6([""P?D'M;,2@C*4>!R9\0E7W[6M
M2YC7]3Q8"0[QX8I5 T>]*2NLDZG:JP1K2#GTW1NK%XMN-@QA>-[-; \;48%K
M<L6GC=2 R3J'YIKSV[MR>)[!,ZR$I5Q-6ES.\C=;>+:3WWKL;[IRM]@7'HO>
MB_-VWY'V87]WD\+9+.7IT-YG@RROXL,\ 1\T4:J$ ;RX>INU85WHRYTU3Q];
M[2Z%+F[!^KMU]W0]<H^Z:+>K/9,WSW._C4WKSY;;QP"L:)166V/NAWF=I&%[
M%A=!XO=;)&)30_0T&0&T5:=:C:M;PL50=A:OTT_!.2Q>12@UFKB]Y=5T=N)_
M-NU^6?L15Z6!9AR=+D^V[/@=0R%2E<A8#0T-)U!<IWA8*L\S#Y !2 \A:;86
M2+OFT3.V0(4R2DUU(>9EU##TUQ&/>-FFG9OL)CE,]EES\^N_N4,380;_S:.(
MHE,MG./9=IZ!%).D<^HC#K7;9[K(1#O)V],"/I)%AYWC<C>*=5)3'SP@VN'E
MR:*-<%E_+!^7KW&?H:;'BZ^59]SK?;2NA]>JMI=G,=M3S2+$!9^5!L46#P9Z
M>J'];F?=AONYGOSN4P9F3JK#AES<EWL">(=X86A:1D6R61GVV(GX?<*8^?H"
MO@6F>\)BTTS,*9N#0;.-CP+L:HI*?1]/)E1S7^NG0W],>XY2N3F3I\K7VERD
MWBC>%.UNXKBW/TQNZK^/6'(0,"K4N/1P&IS@FR1LB/1X],$\QKZLIJ'^69R'
MCY<#?XA3TK"T<7Q5&M)=J<"G-3GR,%?!5,#DJ=%])LHK868D8MI<\1^BWSV"
M,$(L$YQ&@UE0?%4H#P\H 8F)FXKDDG&8&678.?PLAIQ2ONQ'RT1O]TX<Q[9L
ME,,7'2W%KZ&M8Z3A;A2)IJ2D?][[@5WY?G9I$)4T&\&L"+^O(V,HWESC0D>&
M4FQ>@=4:/.XL1W03#>.4,NV9@0D[[HFO2!&JS7-W:GL_*P@EF".NCJCFL8HL
MST6]E0O/_ CE?9Z:8V"X'%G<G^TW\'BGR:,\]'G^@X(6U"E/:=^;_9R#,N=4
M6*/:[^X4GK]S,'ZP9VXHA%]"M7'+Q7<BK4GM;EK.YVT&JUH,H&WHK_!\NK^Y
ML/%>.)O:AZ2$X,952Z=4@65_T^C%+)=$,X-6>=^RV[N5VVPA(YE^3ZGO2)78
M.+SAB];A>3SZ1;OP#0:PT'A3@2HYS%]"9[W^&I-#O2\Y?62# 1*'4=-[=6K@
M&]T0I]JA6U.LBL\'T Q?*#0]%KN6V:QN"2O%%M3JD%9W%K@M-QX]ED_W\/43
MB\T2>1(MH?PP,MAMBUZK%U3C\ZF_X."ALTIO4Z@O<PW?4._RE?:UI!"'V^GZ
MPYEVD)YR/&?6Q]<^O'RX4C5A-UXB^9(IS8^QC;6'R8L8[4*S3E6 O_O(/\\V
MD-(_:9M1-]@^%Y)&4Y)W/AA1K9A.W%>FM*TX54&3159G/E\:6R6P1])7-72K
M/_-3,&F0E Q'ZV=/E=;.R/*S#6U"R<+%0Q],Z6@JA1+L'MO<<AK73XBZ?4\C
M\'Z@S)DU/GV)*!LKCUZ+K.?S26W&C\<*5I.7[T\R0O(TL@5>?D'I&T5L]:HI
MY7[[3V0 U\<;(4^#RL/+WSO&3,65/]<MBUB.KZQ):PILMPR>^FHFOSZK&3!R
M0</=YTJL3CCZ?G"W]%;:Y_LB)JZI58:71FZ8"#\;-12*7C:ES[=E0(.'^U^^
M>O#)]NTVD6)1OHMTWP/#IUEL'HTY!"VV.1^:=V.]U[)J!?*;&R2SPCZ>VC6J
M(6*5XT75Z):P>S9(Q:MW\&4'^*RQBU3RJ-\;3U%;V6:TY8A%.71!2_H+"B"H
MK$+9%4'5_"C&1KU$)S](EUCN#'?-1F1"<<22O3K$[8*A>FKOO'[-AR-47O;.
M9&P1A#,RKSO 1)A_[D81U)R Z?G\\+-85M$\!I/()^7/6E,7_ZUS&( 9^O?.
MFHJL>C&@=\Z*R'AP%3)Q2N+!<%=U0V-M<BO25-V&4%^M8VNAP\C:+?=MC%%L
M#B5%$9-4L8?&K7J;C]*QCO%"535<5>7G8N?ETH*3WG; K ,3S/V,[PM(NJGW
MY.C$^&N<"3.&Q::\Y+IW#1V/?C9_(27%+Q>A=RN7L_WI>AWNU! !1PGW^$)_
M]VFM*LZUP+-,D4V3^;T54-2N9>N05@33)==N8E7N2#A+GT "U-UZ3K?U[<<1
MH2Y$,+Q>?_GL&UB(T?CX2J-C/RHH[T/LTH"_24;\;*DAJE$*,E)0;=&6\EEH
MBGBX@$0UFWKUV%8U9R<U#6>7MW?J+[\Y#%,CVO(=UC9G.N2MB>C@65F?>7]W
MR)]K0VC0>1QL+.;Z.5,DLU-=6.I#G8^4L,Q65OT$31N\Y7">*[@U]Z/\AH'3
MVD"<W53^#LVS>(J6\R;TMWQ\A#/YX=:-?IQRIO(UP=?:/[>!#&C6Q->9[VKH
MNI!;'1A69L_NZI\N+SK;.#CV(G6-?I&_S?-LM:]"E4BW#'+<Z99._OUSW<B;
M_*&7<^\U7O\H-#(6*IF*?G[#D-[833&07NS-5]1CFRJRRE2AK+?3E0:]T>^/
M6C[%S;TQ^,JVT),1IVN+ _) K4U=D.**6YLZ>PV9Q0Q^<,06V($JU9N)B!<R
M;V-5<"/,RC)VT_.XH?4@+$-Z4#9.@9'T53I^/N3RBNZSAYD80$DMIV!'XV[P
MXX6O*9"CA1P3-+=,RX(F*^T"!\,**P2NFB@16Y$;&IS8!F7MJ>@VOQ2L3L"M
M0?J2Q,<.3S[2LN>/8T=3)'<^>Z,LG^\;(=,J5MCVZ+.AHD&<H>D'*0.JB JU
MM> Z _'BG/?!5Y0&A2%"+F/C)G%RPHD=K5^7<L&P:_L7!JHBQ ;V*E8AG+5%
M#>ZQ[B(T2YWB=B#." 1:T=O>.],F,;E-(ZLI6E=R:IG47,PLR7)'DMH_-ELW
M0X?8CD=O*$/##K]L<ZD:7/]R\&N085SHM4N!R041^[K$&, U%DW:Q.8?3,YG
M5)12N#[&$*3OHF<C,W+_C:U"Y>;.")7VVDR0SZU&530)=(*2ND06 R3/C9<]
M2A=;^!2!:']1B<N$1I322E/4&$J^C18WONU ZZ&49A."&K-EXUM(,T4,G1].
M+<H^-/J\]+5:&)O;S )1%OBYY4BSQNOIO('(@IV]M<&$+OXZ_R<[RZHZ1F\5
M&<G2H*QWPY%F%TR]+:IU>G<:7PS)G9^0 <\$*!'$F:?O3Q):ZCJHNXX[9ZG"
M*.E:*P<K;=8DW';W4[P;833920Q+9@GQ"8.FK7%:0[E[.D+: 2NH(J@:!ABP
M*M#S.)^;%I2]L;8E*-\87U%A898[?=G_R9B1Q=<K_CHB3M%!%!&L-Y6P3893
MR@*>YYF9M>NX62YYI%9;AQ\@5D9"W.A9:"V1K=KH\5Q.3\4L[+6#K8E7==RY
M!;H03S\KQ%WPG9ZRRTU*Y;Z68;+Q7SH\8]F*(Q9#+ZV[925L><0RL3V6-\J-
M&:'+K^"-?#K\@+*Z(G^8I*+A,G/8< _7 ,I(\$8A+^&L[4#8Q.S@P?CP4N?F
M[<X(Z4QG3F9J*XLNMY55I7Z5R]%;NAR:C6;:1F;>GM9>_#Y<KCYDKU4+99AV
MA).:!LP?W^J<S3D?)'\W0,*^@WLYJZ_!,1EZ<+B% >JFRM<Q0'X3I_NI_3F1
M:IBO^6:$"<2M/:.H(>X5M6T%L?3L6"RWO-$M;4CB<,^I?^>LBX,9_K=.\SN[
MNSLFM&9^5?%7W);</!:LQL<M.QW)O6S!UY"ZZ0X.TCK1X^?%^^GFBJLSL4O
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MV'WQ0'M?;_B^L.A-X0@!GM@$BH5<6%_?._>Y_\7+>X6UF37=@G2W$[8Q;6S
M8#!-1N2<0QL;L"2B$%$$8Y(E(3 YR$"W#9@@P :)(%(3A!!"9$02T.0,)F<P
M.>=DHD]__\R<.3//?^YFNB[VS7NU=U6M=U4]JRJ@-FDC)<&:Z) R2; -L$8D
MOCBO+!LEEFH9^V;L[CX53F2_]\4D6SDJ,JWM71R6YQ3$%N#7YA;@ZZ%_#UF)
M*0GU=JH)0& "\FLB/^37Q,1E<01LX /"C<@(LLB"O&[K1UM;!B%X@N5SIJ?P
M<B;(RW],L0Z$$X%Z(SJ[('[4*51E'?6$>MZ54%]?U[,KO**$@T];F6&)$(I%
MUS_E17R;<>K2- &@$(5-06V[G+S8\__]_^7#G^6JQ]83<\XRC16XA0:\^PZB
M[@\ R^&O%48G7&0FF,BO34K&3;\H\XME'AJ!8UYF\.\*)7+.=(,W=;OUH5!W
M;PKL@*102QD*(GQ7$UDWWX94UE:B]8([D)/^]JEEUFI*]F829(5M.,T1TI?=
M/GLL7ZW(MS:"VF^.SO^<^XFG:JJRJJQDJR)LL8VK?3>+*6?47!J9&+,,;5NO
M>,K=ZHJ&1+R;67, \8"C"[!#V^7G''!I0:$^C\N#7IOEH<6/LY4@B5QI:P;_
M_@"4;/?T<K"<EXZB%T7,.M-UI+?\$O_93[NNSNH1[FFD>:5^@?M,%&;T$1$P
MA'7:^[V+\PD='4/*@HZPCP)CI=BMJ;%2Z#DO22XY3)#G1<'0ZI.0Q*_+N4J(
M5_Q,>B_C?/C26X550^0/((5#FL75UUK.>=+KX]8%4E/T7DV!3#8?K468YY4$
ME<^4"-7SF>)>IL1/]Q*I,"MMP$AY=20B+<!O/N9)U7 8P(0 &$*]R2FB9)Z&
MU2^YDEH4'I101:P,)"DOJ4RK"5'LZ%NQG17MA0M4@O^COSI BYW(JNYJM0[(
M%(0EKP+OF.BO=JQ;?Z(J!Z"I,GC]Y_8PX\.3+8T^5JEJ-*G:HJ"H7)Z2/3X[
MWMLZ'Q5JKE:^"8D'Q^#,Y90]&E6?,1G%84UMGAR^^O=0XM_5=OS\6YUU]6P]
M8'VE(K>F4A>U644F:A+B'UY/C#][X)3'FMSH[SP[3#29N96F,W6AD<9_5R8D
M1^2OMPSB9=/-<Y5?VD9G<H=FE'8QJH  ^'=)&S*3VRG_SNHS#V1B_K'6 S65
M+_J/R&P2/ >[#FN3J EA=W/3:EA@41F!#]<41_# $DA@RW\.;0) &P'!9F\0
M #H+3L[;4KRG+EJG.5G8-\6O?M#17?]Q&_?SC4V+K_D;\^#2TM+$9S>]O>[L
MZJ:I>[5'JKXRS-+A5]PLK,K)I/ZGJ^" _9+\A7&)\$2K#R5$B')[ W1#'?&]
M%W=%;6UO6,\,1PM#LP%]GG$8[CM$  @2#Y**U.O2RXE#T>[YGUL'0(;V3VZR
M7"Z)R8K4;<N%B>ZK:B/84TR(XX%%4I_272[P7[[XD,FEZA[<7%ON/3.@#&CP
MZ/E&+@K@:*&;BC+MU'/Q#L89;\"6Z[;&(1KHG3.SZ9[JZN4&47+7G+ZQ:UIO
M#RQ:MY?X$;B%%2VQT94'S?N;O/L('5Y_\,;,[[]QT4\4#M)"6-;R=7$&1;X.
MH(Z-/]C7+?V9#2G46#3MW.UTR%ELJ3L81 ]XF+K1$\*:</#X9;R^,V]_&8-&
M0)$+_Z>765>BBYL.=;?KU$AI]O&I*Z/3GT>&CYTP5?-N=Z9A>I5NOEJJUL)[
M!HBY1B,["#:#64DP1M9U>?6A3P:##^W*L=0.F^=!O\G!JU 4<^&WXQM-F!,C
M(Q(Y-Y=I<]!*Y;NCKMI>%U D2D]U"S]T=A6356Q&=;M%U6<<TK0V:-QTK $W
M1]JNF<6I;@],GPQ@CUVQI$:(HN;.H(=^7=I[*:\-_O5L48Z\$:!V@3R!#=#$
M7BSSZ<T_H6E]Q7OV[919@3=@2*-2WDM]GAIJ&U0=BW_]+3FE!7^NNE\D><$6
MTS ^;T7.?[7H[\&"..7CMKQ5/[BIUEUW >=PI0RY-[^?KS?<JT_R<P</23\\
M'=M9-4C%,V_T*KR(,EKR6E46%NFF59CW45*:77)I^50R<MN/I"4^"S$SX^5_
M"!#0CN>1EE;/<0CB<W#@]7].D=US/K^]]Z]EY[\I=&+\<Q(M\7 H8%5N,GDY
MPN3-$Q85YWA;W34<S9!LGS*[S8!C?S\AS3KU3(1>?=7&\JF!B5!X0(%+H<S3
M+A]Y<B3!0JC5SQ:\ 48'TLN[X#6 JP&;T/&WVTI@:GT/>2A36R61$VC7*OAQ
MGG@3LZ&W%<(+4(M(/3_3Z-!MQZ:TJ\TDDZ-<@V N%<-#V-"&1ZRM\\$UBWYU
M_GGAM#PCR!3"$I(A-R=UG)BTT;,<!L1.+?D[BE*GO.4JCKH,7'(NQ<ZZ;U;S
M7DD>1"58< F>H1/6[O\IJ-^%WQ;>R^M:6 @R04?L'N0/NP+EOW,WZTN$/03_
M=)\T^ <=745E-C&WF?T<_RDA9?!/D7'6O932H23O\B!BB/WA^":7<D7XF1_,
MP#%P9#NOI@63Y?6#;M:&KW7>JGE4?R?G@*,P:.1V*+S(C'_CT?&7H)0QL#/!
MQD3.=W77PMC8UNH ENBKZ)@PY'6H@O?X0:=@R=A53N3_0==L%-=4GCBQ0;RY
M#9VBV'WI!+7^]U[YQ?0,W3*#[$&I>.93[SNT)@Y,J?)*1[-5%A9;E5 ?3]^;
M;#;*&1TX/LAMD2,PF<O).X6>N5:F#IT=KZ3W\ :^W8<1;]>XKT?M';4>J=7!
M3QZ\.LPV.9"P^CJJ[/3^W83^SB@$@9LI@_=%ZTHUV>3C=#E(4! 0I&J(8ZA<
MB1Q_CYH\\TF;.+:%'!2 _-O=V]ZWBXB3N224B3Q9"0M&JXWXQLSO.SYQX9BO
M"X8;'"CI6.%>,9F4N_[1V"K2L TB4"IN#6O3OEI@>O\'G3:-NB*0M%*(*1U3
MUJY$.:,?\*7?)0A'.8*8LU*^D4%^3>ZM!6:/K3*%.N<'/BO\14<G[KC6VG-\
M\/2EA.XJ2WXB55;V[@:V,VF_6D5DU#6X>J$RWWUHQ__\T."?\F7-Z652K'*%
MDE"+SXI\JH4V_$Q[4M&P!K4UPYZRS/5S8F[L4=P$4SCZ^P&[:LF*\!@^(/86
M.&]5.57*7'/VRM_L\3L8[]WQBX6X\1+O^3MY1B_[8CQ^__9O9=\O_Z; YV[?
M^>E!:QNL6?%CN"4["/Q.7GU.J/!*!> U\L<;8X;;6W*9W1&BHC67DZO@YJF)
M,XO/N1N(>^$[;6FBP<=\]2&/SLMA@I=N'F\>X7[0J1S6*.XIC2^G@CV;+QU[
MW/<4IS21A1OW"SYOWZSX@^XGZ>O8U/O(^%KKF?;2];I=G?7-MZZ%-T95NZ[^
M+)X$B2)*=)Z^JWWV\>9=1& I8[XI3AM3#JC69U>:D_0&=[IH"%J [Z6$G%".
MUG<\]D P^V>4TCEFS,/=UEGE]SD#49KKRI?LGU2)?,3;(5L%Z9*D=_@I]@H\
M[JE3L3N"8MX)PD +75_^EVE]#:?=":\+><F;^6+JI.SJ?_<Z/SU*+U!EC.X.
ME-QQ^S#,W7M*$A&TF-^([ *YNF$J9^1WK3LMP>1"I0&/?'IK-/^7\G@4TYSY
MG.PSDO\M^UTD*3BT"F[ ^35AV<C;VZ!0Q:<JR_E4:I?-+*YF'WZE94U12!L.
M54D77+(T\]/$;9FNY6T1/<,XH)(I"[B[[@#A<C$"I?+7W&D4Z$4T12 T\ZWZ
M"#?<+(*-Z\\O$0)XY&/;(T>V5GW&QR>YU-P,D,9GC=]_*I^66*+,/?)_6E@I
M!XM+)>65:^E[&[/IC/TV=NHJ\,P,@O+FHS397VVP2>0; 1(XI-6;GJCIQ$/Z
M2P,FO/86XMH81X=A;RZO8M=AUH+/5ON%I:^]/"IEOR9&"E<$N!((P&!/?Z 2
M;+@]():K8J39)6^8Q CU>IQ%R^M<6R^U"FJ2JWCPPL3:'XADZ)?G3-,J?VE
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MM&,MC!AOZY72XI/ !TH2]XW4&Q:;$_9'IM?(!47P_<GU6F<+^9+8^AV_/)A
MI0MQ%U^"7E0V1+J.Z#5R=X_0,;Y 8Q?]NAC\;\YX ^/=YX0.;'?2E^#B_GK
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M-USU*C*$VRQ[^DGXI1[+T4"#]I:V0\W)V=$,1Z2^[$(-+S/S*M^7O-$BFX5
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MZL8>3_<"A]D>N2H-A.IU6J$N 0<HG8D5W"+S?F?S&AQ^&AZ[RO;L2P\'R2D
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MDH4!U;P!;9I2$8THLYV?WN@RF-US__-MQZ"]7O0S!Z7[X BQL)Q6'-OH7+2
MS'9\P:N8"VVX)4L\/S?\O\K\-1DIK".S$,UX$C\]4 TA@^J$QC+Y%?4 VD;P
M-B/DXZ%_N"8":0\SNHA=/_I7P)WQ7](Q,^[UQ&G_1Q[,*R,CS</#L^'D9-?P
MYBFUM/A9WG7=< !E*^KY7LQ@MMCX/DXX6W*._J4*3>8V-KT 1!ES4=;7JBE'
M60.[62'+[SW%1P?D6D47]69U?*$U_?8Z)H?2J=M;LX\(]E1FLMB&&8.=L&R&
MEEPH?-<5#XX1.'2CZ=4;"==X/M>7*TR0(OF60DEJ?;*FXR-Y-4[[1,Y.J-_>
MT."F0H\,Q^#0FQ4%7XM1>_4V&[LO-DNC<3NN!_05:R:M(=U(&'/589_8?7*U
MJVA_IM?)PU\SQJC^0>!<Q/(92M%R:C!;&)JI+_PKL:7JM\PG.5E5.<6-/()P
M9G3>\8FUR%G7"J5UF6T$!U0"P:&8#260.?7[XY26,>ZN>VS_U,,\"SUB>+;2
MU,BNE)+*-ZK -@>WTAISI$<3C_$0B;LI@\TI\+W>S?EO"@RLVC(-1>Y1;6ER
M',KL)%'W_<)N1MEHSJ4R)>.NTIXT5XHIQ7DT[8F03O_V\I7Q5,SGEQ]WO4_R
M)RX0RXHKY#&EV:X.%E0<7)(#](-.DGJ%O8#)%+4O=GB%]\1FXI7]GK0ZG>T
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ML]GAZ '.^<N*,V":<#2-6.,P_MYG).C%_^9-R?EC6DWUU4' 6DXW*+EK=P$
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M#P1*KVK79:8\$&(NHT!J K65BE(.=RU&"0PZ!7]&J2AS%NYQSPV%]%>@-L?
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MAV6$Z/?O+MD3:>X3RXV>'L,NXU)[]/&S$H6N.44<X5/;EB'U+">C^$5MM._
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MXGU%P@Z;+I.U>%@E"#&0D[IV/0TJ6^#E+3SJ99!$Y'C9&8V&2/#G*0(%32U
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MM?BPXWKJGDEG6U:Q%L\Q:FV*C-?'M,,]Y1<P#F4?ZQB7H!'B8\V*YMFKJ9=
M:<8T*F[T[7JW?UL)EV\U[MB0S2#Q!WRE_-EK&U8V$P%W<I/RVC=LE4I577OD
M/XOM?A:;^1B)^PH[BY31J.OV'X-DC10'(D5K<!1MV5['_<XHJO>&*+K#EY7'
MA:6N_W=]?X0<;8:.L*$I)KIIXQX=%2UNGT/&*F?B*04,>=>=<CO$3_) %]/^
M_*]2K*?)6L>D67.[-E9+36"/F(33LOTCB5^$6XM:'JW:V2+.3CW&4HEU;A/?
MQO$8A=8^<\?5B^ %;,F/V97A[$-HNBE5H8*T[7RO'+[Z-1)K*S @E.BO.%8K
M-N'),J<4N1!U=T&K9*1JWSBZ1#-E[J5W[.2Q?::^I(2J&TOI7WCZRLU$[\JN
M2)7][^3JD"[]4:$NHZ!AZBS6W711_'#J<9>[A8Y4PX 1E_Q25M5>!@&>(B\-
M6DR[*^:\P+-F:N3DS%O5B=YV2S?A92DVRP1+"S:!-;PWWOR1-_G-N5.%^JA]
M;@QB=P5P>IG_.T'/Y[D;Y&Q# A J-1ZUJQA5+&[FA"]38,^/I_!(FQ_/,!>U
M,1?8PU)!:UY)F]G[ ?A"L(3#Y87)5PXWJ9Q!%GT1_%S[V\%R$;X7,/"KR)CF
M2#=Y#<F(R'C!==BF4Z.1LB^]:([N^"(-03?+W(&*5Z!3PA@D$=$"$I%)@F63
M)-\=M/'IC_?HMC[#J4_&EWZCT='21W%KF1LTZX$E1*\ 8QF/3\^;D]G]IE1L
M<WQ\U!8ZM[CAZ&F1P<"O%\\/'@2V17KQ_OW5@NUHDSUN::^ 4"4-]$%-5N*5
MJC.1Y7G\"ZJ^0^,;;P^W!V,Q92[BGXAXQNBI?Q5_@M%$4'>4"+_I "6P.%,)
M=WT^??VKG"C)IX .IC7$\)Q! ^@U-&<UY-DWHA8M+":L(!C!PC!A):;"D%16
MEA:5$(/"_('J/#4'::G#XN*"!$OPC&XY&VNT*/!= HZ@JROVL4 >A-UNI76"
M#?*5.GD:$ ^%<^*[C\7YRDM%@T@+3Q/Z,\2^O\T0%[/FE1,L1*>EOL\R,]VI
M(N'=;X43F#I4K\<Z#2C].E7Y^9_:^D.C(2RZI4IIA?*0U<IG>,?J#O^@A:KM
M5TDG>]>DN]6HM04ZT.'9W>#4(^&,7YUKIZ5C;8G#3<T%SB.9,=A_<1P8T)]\
M<@ I>KN=&A]/M9#WGPH5J!@$<*&3O=B@)$K_BHW@#=O)T"%R@:X/#/R$V<=)
M*XY@UB&I5C>E4U2;%0++0XC$X1*L+?&%;>-S9;8MO@%K;SD>W,3.\7[(=0S4
M7!71%+!<RC5!)?\X03;.9K1Y"'8-\B7@<^.9"!H,7+833F,C-P<Y94;#V(:1
M>;.T$Z'LN@)#<UFA],2"%K][2_$5]WC07IY/J/14JFNJZ@LW71:79 =/&:'@
M,8:?6C8[KLPRD_5D7RON01_?+@D@=93RKM\2V+(Z:P8C[WVH[B.N'Z[E,_KJ
MO6_W#E.61< 2__<8<EM;+Q%6G\JA*M!JU?>QM?:4T',R8#^1 $;M4=-S$WNS
MN&K'>+0>AN//[@$>2)!(C;.M-]1?4,7'D^*X1@P-C=1]$<%102-D%GJFIW.\
MNDI[O8(BY628M*"&EA9SXL/SWG?X6__^4@E!5'S40B#J@ZI-EJJKB25$@I\?
M6,IQ(!(/SII/OZU&U0G!9@W9,K7\;T\KTK:HR8K>2AY=.%.98HRK87-R>V0G
MOLOE3E8S"24J^V9 <-*E:I_E2QY,0$((5L <>^>B)YCUQ5EI9GWU,+C/Z5*W
M:YZ"DVWP<N)=31LL>IU&4:X4&!#S3SV@5/5@M=66PTOQN'6@S6))1'?>C_4B
MJ6WX>/(50 2DS:SJFE,Y):>?B.S]_/_^,KF)V^N%"QU;=#).&MF8#[)2TS#O
MB^:5M:46(%24 Q-U8]]W/F7)!;&XG#24#UGZFUY"8KP^%;&Z:*Y6QWK;8J8U
M>U*8G_EL&M/STT"O ,J_$];4H9]#,%-K*ZP./\$-&VSA]=Z7# N36HVUY.1/
MM? /M(I;V/3/^4W[G:L3+*"URV)+(@F72H+2Z:@;[RW>@U0I%1%7@&:];ZLM
M(?\D5OWQ3^M%SZ?M"/<4FMJU(^O'QU!$1F@E.4Q*+IBQ7T*2FW.T\W4LUO(>
MPE+J/0\Z+I*4[>;0Y<@SFVBI$_$*-"#&TNZ2P_ND<;E<"U_J5K6?7Q\F6,;-
M^"MAJO&R,?A N:1 EX$Q' FV>H:>\T,(*7:2XO:'\ *J;&]G+ZXMM>7O 6Z$
M7[*P_:"?G!B7BPRENF>/=>\PHE'VMR"U[DWZ-BJ^2$NX&.CHDCP\GZ&(/SA;
ML>M=BO>4#WHD.O$4'_.10<!<O6$M1TPJSH*R97#/S\M.A+*.#Z6H$1\UE"Z>
M-^YR%7><_T\<"\]3YV[F+!3FD2B*]LDS3C@OG>\-03J27W\ETCD3<N3YI-_,
M&BR\=*H<+!= DS>2$@/N2Q%Y=D_XO-Y_F=$X;326+M4/C$>N1":  GW](#KL
MJFC_J6%_S+ 4*CZB:(P2&F<:6>(AFB.#73;ZZ!1.VT0_3(>7RH6@'>@I'/*8
MQH*ZQKHOFXPECX%]3$1/R/']]OS/9]Z]KJ\[NPY?=ID433D48Q[CAQ5^53=&
M1@%1P:5GI;:ZJZ\:P"9GBP/;O7)(LFOGI^V#EM-$D9B_R=H7MW;YTZJYTY(,
MY0^_$4:G!O2-XJ5Y4OQ 42ZQQIYH>_*Z4XL 5"L[_=^XJM?ZMQ>=B8_P4()0
M<5M88?&OGG86Y.PAGT[R0W07Z JPPL<=8G7(](MMX7LFTMJMHE/:Y@J0L4)<
M'P.K[L(P:O'N69*5I_!]=VK:;2!=.8%3>5*O5_HI4J(0<&U-_-624./;0D-)
ME&A%CP3T&T%*U4JX@RB%T2Z,U;9NX14RD2$^'HK.=@0;S"H9C:&B'32GC_8S
M#=G!9D8A8OY6(2*J5/@U2ZOE>EN[!US#)XB[G6-S0? F9DB<N:@'O"VD@/J;
MLX% +P/M:)9%S6>5!JEUFV\N8ATB9N+5E<<7] IU47E7@&E."R=4C[@%-_>/
MK1E0;1_/EWG":V>]*HO6(:[MEYO0*ENAVECRTPZA[-77.%G=(K,@,WVLD64S
MCI,M0B[S"L!..6 $[F^6+MQW9]8] A97ID2_.10<*L<I?,GT 3WPF B"#6<D
M-5$GW)OM6!\X;YECY,Y4=]?=C.06*4&/R1DW4%X,VN<SNKK5K5$U")!RN';$
MGLYZ,G\])+RPT(A)7%E?XX\SB2I?P:T6SX8FRLUQ9H;=\_G4WHO8+<V?*RQE
MK0&^]O:;*]M 6!G=HS""IRJ&<I'"GEG.Q4UL_T\S^B"V1W*=T6Q0-79=J8_A
MA_CH5,#LT=-V.#(WY%7<),RM=6'1A'O9XF7-:8PZL8"R8* QB,WM.?VFWG'2
M(6-?RBZ;0S2T9LM[96QN+PN9TAB/ AU8A=-G"EK_^OMSX O?N9WG4%EK?8)Q
MP_Q-"S8L+*[-U(OI;Y/XF"3'Y,3ILL7JZ+I[HH:&73"[H;"A,XTK -JM2[D!
MCCN+PLFNU1)^_0RRO',*CK!X,;D0>N[GGFS2B=DLQ[!+VPJS;HQ7UB(#GA(S
M19GJ*T>*-) ',4AM,<A]1V<5*S>0/;DS8^ZXY8>U\:5 ;OZSL$C-G+R\.&N^
MZI+D.XQ9VIM0V&(57+M=>Q6ED3TX8^N8JI3:T6"_SZ 4/YVUX*I @?_BB\5F
MS3V:SXB-'W<*UN9@>\2*=&$XRI]/_;0@YNW?]VK^=<J">6YPL%C U+O>LA0S
M!2/W=_J1L &0$3C20([PSIJY%R$O-\;^=/;-'X=)/R=U_VYDAV'J<T[L545T
M'E?GC(?"A_!]^'[00YS I1JW>'B?/6$^(<[UK@#ED+9I.84.S<R_(2;C49_2
M]N#]XABJ7LS-H$B C#BFC1?[^V5.Q-(I19EXX\:B@1<DRE;JT.?F\P#K1[GQ
MT4EWDX6<G.3[Z+U1!Y3MP0I+'TK.EY )+8)&P.W0V0)3J""("!-0$ZS@V]82
MV:@HX?%V%^X2ZR@]'2,A+%.(!>6\X +3LB@%CY4?2) [-BG2EC[9#<$3\?[4
M\M3 8"=>Q')OYJ%0D<\?*LRJ,7.+V<*P_7.M?!9SN&2[-)'OI'4(T8D=(U0V
MPVV :(WYT,Q-THAD+TZX3,A%)NP$/+E*'!E,I[!O^5?39MT_2MG9/"&:5HC)
MNX,]3^'8X@(S9^"B6\3H?"HMWCZI-470&E@ Q,3NPB#)Z3V@B_\!F.@K@$%M
M(E/%'Q7[T;O\&VOB;/9"]@'W%N9-+@S,L_@/(,QMDQ*G5.(Y3IT7(>B: (G7
MX9>8E_A]<6Y7O_Q!>3VO%'4()[!<9%D=53WR>USK_12WP_7%1@+]+P#@1J7R
M[>4$BV:E\:GA'J'VBE8#/L40"ZI1AE%+9>,1O<R))U6\0UZ7AH,_R0=P52-+
M2[=@Z>59<ZOS]PN;$W%&1V7&BMCQ&KW"AZ2RCWO9V3IO5EXL_I-@^\]K0^4_
M^X;_O+_&X;6[=!\9XVG#^5@&0;1EKZLWN&\4U]XE/O0U<#N%M6TT<'!;W+,V
MK2<S9;=,;U%P1][83$VOT(.@@=';:%1_[2XKZJ/WM"SO4;%^;9% 419!?RCT
MD)_N5:BFU!L .D9]*F.8<" TQYY5I<Y2)M:Q>1#PD;ZP6=O=SB:NA/IV[N_I
M"&->GM"9E15Z?^O)URZ5^58O-:PWWE6747S;;SP?./3>-TI]UGG-/Z(G7J]'
M*3M_^F$1&,H96H%7>&?EC^:,8F>_H?#(]S_[LDFA9*%"GZ VI@LG*E,"K4(M
M21KGS 2(6]Z2%(:/O8<W[F;"+]UHN'X)4&%PUI>@K$,--MCJ<E><S-Z4'0O0
MU,WR-5RLAL8O,0ZF-KGU*_U-F2P9.CQM>#'=VWHZM8[U;'WGC03GW8H$#J;>
MB<:2(WXHB6OENKH?#=8@WAT&I+I_YNIS1)Z,"7F*.MWG3 X(>KI7QVVX[KNL
MM>%009"*L'^HSV'DZJ..:M:D904Y)=][?GM\TEIM*_O>B>0VV?6]U;7=!#)O
MF&_*^-GL<J'WA#YY; Z/AMO1XYP$K34V< O0$FRJ1!M9$59AF=06/!S$"_W4
M<P6X#^WQ)+;9W8$7/<XA8E?2U,L8V^-THQM7YB;WAU^>OW2J_4DTD-!VZDTR
MJ/3O:-2Y8-+LD_<ZCX.=>F$+VXD2+4,EW6?W)A@4:^#D9-?,+F)6K9)&].=M
MR&, @)8_'\%>.5+IOQ1+ANM(2L.>.VTM#ZOL[BS2+WWP  _0B#*_S^+5%'&U
M]<D2R8R6R%C2M;R9/6ETP$M[!5",AL--8VI"=)[I])),P*N=A2K9T$U^0[31
M!S.C]&4/3E]RX=,Y5XG9,1],^G *#(YHQ2(LEI'$S'2<E@0W-_>JABPISEC"
MK/<AX99N!C@R3D<Z'+:EXX$?C.JG<&1@1P=78CAOS1LV&KRUT78&V]/-.8-D
MN/%-4S8&#CTFTLQE8O>_@L<2(%*)0LU.":>:.HLZG:N]:70'KW6QM8@?+0VR
M=!_75-8F/XR48BR>X]9K8!LH1+H0L-"RVD!X00V2,,56,DDVHP+\4 [TL58C
MB[M'^66['YIN[/%SX7F;MWC\P_?>4D9KKE>?IUK ?3FM8!Y<%-$J@R\4%T.*
M$SC N%5_#PMM*-<H4+\"L+)]Z\8#Q]]+]DB,*?>C!,P'8\*E!32*TBQ.0OK[
M_5]0UK01"TK@1/:W6OQV_2Z/^'A;/$XZ7>K;V-[T6SWCY[4ZC.2UU-<+N+-_
M3HL+'3#@_.[&UG4I5F@S61K@P"SZ>;B+[=U.+^-OJCA61/.%Y3C$8RS]-P)S
MR#BY>*@,2:-GBQ[W%7T0;,&5<:WL'J9=?&H_T?XV5[J9=O#62?(*$(GPQ 4K
MZ[\9"9G^I2HONYP:/C'[Y&\3A*9ZZ]WZEJV4\0A$@C9H[/A\>LEZ2$]B[=?(
M(J<>A=/4/[/:=<+U3<+'Y,#(V;?Y#7.WP-!XYNA"$HZCVI,!WJ!@)!5 ]^>B
MZL/>7]@$;< <B=@*??NVL^QND4"O%M%C6Y;NU;3R#'F9)LM.Y$0[H>U\:D'K
MXH7M \UR!97?46,:9YDJ&K?0#_ :V7+R\WOE;Y%?].Z4[^MZGW&AOW/\P@LG
MA-J(@5O'BP7/LN9EY @KKQ^UZ'-I0L(]S[/;$Z5:%W22R[9VI0N;F#*X[M1P
M[ I!4+LO'/Z@)^RQ5!HR=6/<\'6!4KP/SM$EY:(%OG)AP 3"E)><PN^AWFBZ
M.!67;6!<:C_9+)YX^OF7@HU0B?,)S,JYL40O K^UY][FON3.RDP_8G@XGN1Q
M)J3P&G<_1UW=9T"+]OUC,HLKR#B_3'OA< Q1>KDZ'"SDZR?C"](/0F[_]/]K
MGWE0568JJ<!3Q?1T[!6JN0QH(!/,"P.7C/;TLS9G'7,F;DX[7 %PNV'BV2(!
M2_@- 8]#9-Q.7Y=3M]O?5P!!Y5\H.V7W/F6S7,2JYY#HGEF;6F#U= ILD!0H
MVDB_;7''.EK#8^ZO/[YYO#*:&9.68(W:$AYY5HMY>JYH6WRA2''N,++:>ZOU
M-@+?^59:&6DI)=73*W9+Y7;1'?=HH=/*DR#<)B0[,[=F ':WWH];;=,KZE?T
M_<9IXKKX:2[Z"?WI?)A>_[G_1&U\WQJQ,*G)N?0\'I8^!HJ.X<KD+)#5PF])
M."54:WZBRI38##A(<(L2(6FC'!'Z"5(]I>=) ]/VT@QR(E-N@20A_^152]F/
M+6G+,]\F>P:4\&0#E&5-0W 43@GJG2KM!&UB  7S+@SG"<NH4?TL06.MF;7,
MD\E[9#K#;5*VC)5G)2OK^]$?$"/6/U](GB9&R(H4=J!9-NE+M\+;8,EZHW*Q
M"8+*4]//A8Z@F@$F!:Y$=DU7;1:9L'5\])AUM0'+]"G4*([SCKENN%_74>4P
MVUE=JE8"8<$4CM[!V>,V$NZ+,0W782T9^*-I@YDJ-"*:[@]F^<% #P=?_A>C
M?[94=/]O]0?,TKWU]L^D5=]L?(N;MJUIU54-MB7SCB:X=KY,D2%8! 3_VG_I
MS@&;RC7A97UQ.)R;MF_]:.80^Y+U"O#8-%S^O9!$CSR5-42BFUNF#L4*E^95
M52@PO4LH_AG\K]_<U'-&RUF^6_&#J3JMR:[]?,^B263&"KG;]7'/.F>.7UOS
M61[Y[ND58'E[F:?^ \ESW' B[,U2F^R%8->#]9^6#>Z3L2;\7K5A!N;2HIB>
M[EH@D>*@<U)N(*'9.J_U_9^<-E3_<6FM@.P.S:H1ZB@'17*9#.R\F,D]V/2=
M6-9THB[[_M=B<5FXAB4'7/\YR_,L*^X5_>,<TSX/X4OY"@'"0M2<4NGJ; B[
MDC1/H<VY\0C::(C8;V3E$YFX4-N5<FJI<U'',KJ/?*9 :ZDDT-*0JY?U$2G0
M?@C@-/JP:&2Z)-\D\TAF1[.]^%41>W>.E<HLGVA)1(C+ZK3DLZ_[VNLR1=>X
MM[?%?_:XK3G/_?L0Y4=2+@1HIO0(=?&[V#U;/C^)M=43>^OG$D1O@PH"=7$
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M\SBU?>1H6P+++?<]OV/'.:2DR8V!*-(,[?XD$J=/&VL?3"-208LA98 ?H0N
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M?4:09 Y!#SAR\Q[D>H>+O?C .,Z*8A0SXTYGRY:%$O$5UB4@[MHZWG>1:9Y
M\ A6]1V(I2)79ZS,U5?[</MOWDY!"?Q)D]8X9K-XCK"'^0@PPOD&"@!Z*=K7
M5]RZ\NI5HK<(=&'II&4%@H;8()@_$#,@I,IMZXQII"K4&W9\O*'KC1SQ[=7+
M%N^5BFY]% 8+X\59W^O@;Q;VP]R[<H49M-[P\7Z)[?93$SL/1V.GXI^\0&G,
MIRUR\J/K -G>J-(U0FYV>AUIC>1655+.FU*/A)1H01J28H='O;G_O,)M-TIF
MRP#YKS;!8S:3(4=24TU='(HS\0V7)TI'R-K^>1&_:Q8*O?N%G:K%%+"<5U[9
M<6\1"J1Y#A5<H:63 #-FJ9E%W 5%[[-+PO6TM2WH<S+SZY7U13=%-FT%N>B_
M2=WC?:)3,7QG"O7^#1;+R[NF 883=6,5AO-PMBQ8B U(C!F2+5#;V" JJD(9
M3+)('H[E9'GXPRQ;11Z%*VAJW0DSHI?"P/1__),_X.&YZF__XNC[CW^YD/.?
MB-!MAJQ]N]0IKDE--^Z(I9E"4A)VM^'QK4!E* "I:#2%N%T<G97!0 6VA-#E
M'<4UGVXGE)'4MJVY)Y7;-!8R6L2K1P-%M.E]Y T?]) _5Y.%-L:Z/Z<%F[4F
M[N,4YJW4%85$9,@EA^%<SHV.?NY7URU/S6'11Y)!3J7@KP6-R6J<671K3\I^
MM(1A=#ZKX+J@ N#= ^W<2D>.KN)\&2'),8Z'SVK'3@O-^"F.WO%^Y%-8 _,S
MM]Z?RU?DL%N0[Z;D:D]+V_TT34]MB9/,'^ZHZJY!B?/\S6B%L]YW*K9QX[I(
MKRG:8GLB8C9B1:UP^>BDN8+^&RQ1ET"W*,(:7'BO6""B0T%A0#S:Q"9C2$%F
M,[*]V4)&_\TJVY#O9OWR>:.F]7WZ%5'?3&V;U:?,+RW>G-FV8=W$AB.R37BY
M.LB6"+%G_*>1B.G/.UVE=2$B*1&FT%4..X^@ZD8>%UWUDVTJ;C&4M@H=R<=V
MPB)41+S0?U[)JI<W[60S#1LS#1%CMS>#5*:W;!OY:IDT1<M\27._T8GHR>'C
MX_TKZ=G0LN2W"V[C8ZK=(?Y7O5H&Q^5(-F"7Q)$ I61"ZG)R$6AJ?>KU;%O9
M.VR903I_WM(P+2+SD(.C6EHD"??,'NPZ0+_E<<_\G+=RA".PV&V,,5"P259@
M2& -.$SQ!O;YM?1:R Q"N1&@#86]/NJ4N::0T5@]5*M8JHUU PE'B>"F8ISW
M>F5?+[WB.G9GE\.OD&B&]'^XFU4FPMVY)4IBQ+MFO*'C=A/3X\Q9:F*AH.2R
M)&H4@E&@)LV##I/2J1>0, =N/5, *Z<>5L8_S3F#'U [5#B=<FX[H*D&^UE&
MQL-*%?&.9LEXW3P/KQ)ARHCH4"(D.GTO"!:&(PUH>>",KM^KS,H:AA&$L=B_
M*NB!85I(&.:,B8F]JC_$ED,7+&524R[0U)P7O XCF>4Y#<6DKXS8WLN?3O/E
MQ]*F I@1""DCVQJI0(.,&(ZEN>G<0C7BN-KK6(Y6V+/>U@%^RI0TGY51FA"7
MP/O/"_<W(!+A;_=/I/NY7%;>T8;F7EM."7R).<Q0=JQ6?S[$Y\7X2AQ4P"7#
M8+:,GVSD<1@^F=&LM'G=\;S#0\Q%""8-H0FP1Q6:2@0D+AN)39A,U']L\W8;
M:RM%E,T;DER )QHH$2#S9=3!M-F,+ $ C^8G$IU[*C:AZKIW>ODF%( ""A1B
M%WMT6E;^@A[2]U2-^$N";%4GEDI3%C/5S:#$-G'OM[EN0-SQ1NA.0X'J8KLY
M^GV;W%]RFO0R+!SL8#V%*87J'$,3^H:-1'ZFU!7C=E"A.M*@$MB& JV%/92*
MTJIYNKHL&2AVH->:I-U?JR=3%<<4._WH9%DVZ68UM%,>\*(\$2?J[PSV)H1!
M0]0^L[T:F%YF0(P&F#]0Q66JWK-9/]R*]IC 8GPJ/R9;23/)UMTZ='C,T84=
MGDI@UK9AKH$_L/.$Z]X/6A>"A:=D:],JP&^ZBX5 +BBADOV.M/7[9\8C<AY*
MZ/WUFCBF(ETP$ ":CXXUT8"BVAB(@OWHQC8 ><*!A0#6\U$FS&.2I+ FVQ[N
MU\NW5:2JWAV<HVH>>%!,46[U&\-34#F\>!>76</S*2<].) CY8=!P*4N4)J*
MH"])QR$P-%+*A&*A-R0Z=#G P?8Z.?U]9VS3)\<;Q U5>[^[N?69A0'<3,GV
M=^R(A=*F.L6]8IH)W+8B,EY-EVU/.2=V)6=9D=%XOZ <4=NDCWLSTQ^WZG%6
M$R20>TV,I4'RY%)C%M)D-*,Q8BF7ND<D ^W%)//+*=G [Y;B0=B<@*(>?Y.6
M<LWMXZYP99D;1N#W_SEZ;_W<XO<DI[8G[H%VW3&KH&#D.^^-5 $5S_W^**BW
M7F*\S5Y@#[:^-(=E@W,?(</GUTD=U8P:J.POY<^=<C#,U>,>FE,,TC$:7VR[
M.CPT>!HY$/2/WO[*_<R:?I(I27!]N"MN@<+-XO2$$R^WA=;_$N,2IX\ =WLJ
MCRF[[3J0'ZDR=Y3@1O>COJ&W)U/#MF]1;F8\SS,Q-RZ8(L8M^#,O&"D1]58%
M>DJJJF7-X3!/]D<#+&3IJNT"U=C%[4I+MB;>/<W%<<',JR8'#<V4BO&](N+A
M+T@[4YVOF$* 9(CYXZW]C<?SJ&LUU&PAU0W#93J%.ZT.2!D89H3 D?)/CF1D
MI :Z?YMR9POY_4=W3$NP[XW;><HX:[=^9<L@M@/2(Y5M7>F8#(YTN9\>Y&O2
MM)QU8CB>1MXO^1V/S3 %N,A-.*^F37C-IC>.O.JES?40N;C![US#0I+T1KJ(
MP>UI%KD)%]B1BYW1A.Y]N[7)YQX9VXMQLMLD^17 &.FU@;,0AH9VDYU7[-RI
MAT,V9]4V=6SAF_1::U_%S)BT,9.IW%F.P$^38NYN*P2 XMU\Y>G#Y!'-4>TA
MP!-GC;N"Z'X*5;@B/!SCZ_S1CWS8JY</W78_E6.OR?922U\>3*X>YH2%9CLZ
M<_'6#*(#'(V*R\R]D1 .7:@8XJ, 2TY%P4G:RW]Y1.?YEXMK_XEZAX H&)N'
MQ>;(DD1X94F"%@PB?,<)%WET55\?%_M(YSPHG8V$6;?@T(EA$]B\\4;T+B6+
M1VK"@72'6T91SM0GKS ZL^11:?I6OQ_NI"JHKQ2<)OUF(/15P*XR?4)V=EVR
M1]C8G>J6@F.06ZPH275X.OOE,<2F>*2IXGE#AOD?Z0+&1FM*"AV+RC$*XD7Y
MAN(+-24I^@BC,U I+U#V/Q94WU8)_\\+JA>W,'IA5),<KBKJQZPO/']U$YWB
M@F11E[ROUPSJ-GLE>UDU 6UJ33:LT9>7;<]N=<EA8N1^M[A%HU+"3OQ<#2?*
M>6K/TZW;]KCTWG'/^=GW:RL7]_;-)E=V-!3I<@(104#VFP33YA1#(F"^',1M
MI7F0:[D6?C/@?FD@K>OJ;D ZD@KR>KQ0"(=DP]-_I"=LIJ*Q(<QZK')\AB,7
MF(^>;FI+<8DHG6Y1DQ!'%ZM']7)UU^7"(W9M_:)/E[I&M(=I_MB\TIJZYU33
M$^"XWU.B1^Y.P<JAT:@N%&'^K18)^IQTO[;!2>[DL6THSA_1Q/:V?\0)&>!?
MAS)N]M!M8GSP"%SL,1=ISU]O=U+W@:J2MQC_<)[7)WZ6L\V).?4@XX\W#K))
M-6_UI^:&I[B<A\LB*B3347T8VIM&G?H;/06'<N7#K,KB>DGF$]L?P62.3N:S
MZ%@?3\M[/;G-=OX-D UD4/[C=\\;UI$9)KTN&]GQ7%:A^CJ?^ SE?OT/HXG1
M@Q7%Z[EV&4]\F:Z:/6LP61J!]I6U[N@]+"JG?;-OPR1(H!XP/B>QRRPTT&A"
MX[R<:6]#M>&HI4<'ID7!8.1W)*U()U&HKKYKRWL>U)FAJ)9L&2@+"Y+"/\U+
M?@(JV)UE!*-?OU,R\KLN);EF:JZ_D$'V%N[=H159IF8(+QH1%%_@S514@+S)
MA'3G01;WB?LA-SJ*MW*L#V8G@;<F=:(@^+'6\LXUR1==?IV(S(@*P?L5T1M1
MXHTO">-R\P_M''+ 6 (:!9^I,4=O*IEJ/UH_[X69>YVKB&A5J7HK]=2;%,.P
M,05?+E+X>UN'@VC6J=,&=0.>J89BZZ,XV]UG>E5%-WI!8-T%ELM=0!Z15<2P
M,;E:T(5-O^J BU1CTYN9NC&>,+%MH<05SK0$J*)L""@0R"=O*T'B4)7]*0%O
MV6RUCXF]LK-Z6$UE3H!>?EXCJ;D%L--%T(Y0^TEO_3;":881&OQ;19BH=5C1
MIRG1/A9<$\6D%F"-R=8+30OP98K3\IK]_<J5@VR3_E+8H.A,@1=-?K%^"F8-
M%C0_,-7IEH91+,$&3_,(8R-/@QB),([ ^.>.J8Y2$2ABR::I>=OP:"[,8"5Q
MCLN&ZI&TKKG((8Z%\H@<'TJ0E-@?Q3Z#!-KA<O9FHIW)&=QZ2%6,@?&4^@-.
M%V)GV=M-_<7\6**XZC8U3J><N]#/[6YA\)-+!HB;E;.W; W/A(;5FMM9?8U@
M&,K[*$-L&&,T%:TK-TYG&X-;R-G>L.:.E@IO,2<VKI[62%9$E^$[8HV=6].0
M>G&IH" 96-Q,16(ZUF2>N3\X:MKQ2S-=\F^S7&DS9V,AOP+$Z68<"RNOVR^^
M<VM.:CW3Z+-?4@STQ1L;;UC%NNCSU_??Y6^.5[)YAQ8L&@P^FV24*B;D*89X
MJ#1W%ONZ(<U?#I5:<1^^6%2DQCZ(JC7 %?E;X+X:2L_,5<YJ# ^NAA0<<>,.
M$,B*<'H@08EMS\-7Y'.I)[V!FPBHV&E/%ZPLQ JH53!O;>YLIK&XB-1]WBK*
METU>T"O%]G?#4JR&FS@-O $W01?18$S8B[!YF(@7#1N0ZDM<L(^>FIZ:?1X[
M0'@V2@1B'.D 6I 2Z1CG4GK'=^K:$_\<3D?L=5=O2YH*;@HV%'0Y9Q.;+:JW
M<2+1W07KX\TZYU<IPS>S>:*3GJP:58O<\1;MT1 -2 1) K=47IW&6>'->L]E
M2W5I87*]!-/.=-[F5$^DZ("=CUNI41R+,V59.[XBWM6.Z7PXFN$)@R*2VS1P
M)&N?Y*:=R__*5Y0R .'=L*,UWCB\Z+-R+JZ3+0I8<!D9-@^A=3PYM[3F//H4
M^$#+Z=U@A@IUOZ/?HS7)@B=0\/N=Y9OF4G/AK\3D"BK8%)DV([NYHZ?/N._'
M#J]=^#Q6:'5/1YC&M?F]OL1,(P<_)FV^/WVSX9 D.NV7*RVW? 02/J5X]&_1
MOBJ9FK,6\Q0>'JD<U]K&AXJ71-UQ3U&]J(LAV<(E/QM55=QWMFDP&AU81)3#
MTPTYS2$YLO8*ZA $:]2M4P?K),?D8PXC]T0K^U-@97-0YN-$Q*?&NLQ=W; Z
M'R-=A8,(S2^9RUD:>Q)AB@,='1VCQI8;:)*B.RXM,5CNJYW H$SQW','H$S@
MV09Y>]01LVE,4JIV.%M6K -]DPI@:P_\\NW=7V&%879>_:I/BZQG*+G3MBG6
MQ4P1PZ<R>7QG&IT:]9J_<=GPB8,3X'BPRL[UL;,]#0S!LO5I0533H,XNER#O
MCX]?ZL?L;U17J%W=S!];*[WOC%)NX3W]N:AN/BM@7#2FNG=[J>DD2*%&%SLQ
MH^3BZ.(AW&@+%K>.QH,T&*-FV'_[^N<5$X]<,QBR25]C1D+Y>:*_ 3&V9F=?
M.?(M[E-W!8*?0(^7>YS7,"V+?8Y](I9-N8_* W$1 >4]KKG6UK?O:0<<P8*D
M$]<3_[QRRH]]UBAAL;\)WF^ ?!XVTYAY3LFEP'R5J@ME:S>-,^E&BE38)'_)
MP8;Q<7I@;%.UGLW^ZY./*^K_<GGT_\M/S0\*,B/J_[R"C[.[WX99SQX-?).P
M*U=W6V&!R;3DU2_+WOY/CIVB7T,U-U='K0PY7"=PZUDMLKI*=0-];MHGF0-5
MO(1\8"GW]^=EL4J9J0O#RM@XR2DG[6WHUU9UFR0F \)]O^KN6S4F2BG?\5\J
M^V>ETU7%[R<WU;UH*BDZMS&7";$SJ=&'V;HBQ=-R*ONVK6OV,)&6J[4CB;&>
MF*4RXVN!GC(R-N;>OM6"HNN2TF+=@PIMVZGF]AV4O(*MAH<C'((%O21'?_^-
MC&6"/48$GLQB918DA7L%9@9[^':"9(=^]L0D ZFGL3I$I9J,Z@ZAL&S@:PNH
M%U@RT)YM48 B3LY7Y'C-]L^^"/YJ#PH7B'J;I\YL;OS\PEG?$JWR;K>JY#C3
M^AB#"\_KCA4!)21\>WLQ>*?HGQ4DDQC^64%2-9:G0-=KB0BM[4%!53B#G _O
M$XN#0(KKQ 16S,TD1/VM&T_#6O.;!HHK X/O.YT9Y2S6]4P^1O&L\2KR?X=Q
MC2LOC8L<W<55FH?VPI-.6S%.(\'LL$A'N0L)D[19^, #&[LH;8E!M]Q[.YB-
MWF+V:%;?+\E_B#%,M ?_V@*;=LZ?JIDX.U"3]4EH2$::RXF6, <J*?@JR^8%
M!<-Y^2[U!SQOKYLG-R7Z'+]B>W<(JR\>_UY9[)YDL>1'0F+)WEJK.TF'R74B
M6LC77R4.AD7N/\UPZ4"H#8/$)TW8J/8G2CR&PH/7D'UVN9*,U\Z"WX\5GD@L
M&VI-2WH^\V4-,&JI=I@;DJDZ'_%DI@/0E@_VZN7I+F_F-?]Q.G$!"3Q)'4Z+
M*:DM?YZ[2;NX];-CXQEDZ<\K"RGI2?U]?UZI^_/*V^""'Z># CP,&OLW? 4L
M)R6W)CLN[YX:-ZE+(<4>NE@STN=:M&Q;@()^_F7%LJ4YWQ3B#C2F/&J\6E./
M;4FH3_O)H_VA)?T3:9E[/CM\;4?KIF)->3GJ3%7V,]1349N1H@FC!I?M<</O
MT;E*H&]E;1]<QF<6_8I\TIUF812];:/#X-=%G+&^7[M:G0:'5W?E7D'0MJ[-
M<+>+N IG@/0:4YGDVE?G7UKRA3QTO-?PQ/DO%C;?V/_PO9V=@,Y*2D5U^DEH
MVFMYS,#+B$I%'48Y&7K;G-?<^U%^F42N<?GZ(CKW2)0"/.3TI4?D,?0I#%<-
M<($E51>,$(0'P#!<D %!^$*G_\?7BP5KP@=!U<2H=,-G0Q=B <['W+PZ!3 8
MH?W=4(#96QJ#R*E>=3M XM?O 2X:/2+BRN9KXI+]YA'Y&:,^O0MAQYV(PB%2
M!%.15OX]*HGK5;&M $:(@XI[OZ]HA I*M!!MH-OK<==S=:BW%1C.RLR<J.9/
MW;<H=8! \,^)ED_L]I?&&_,D.N_JO)^#_WFEG"#P,-051U ;9G;:,JV? NV/
M+!L<I#5TDI<UVP]$1$PCP+0O#6$^PPN^PA:/;2<A;#F%J%S]VKU>F43"@U5B
MM6%$$!0>LU7"IC#L[O+19OK!(#!"O!3*]4 T'*"NRS=9^?N5?QR^ZQ3R2YX0
MK,=R9NESWC:HN47[P[*W/JM1%V=G%W8(C@5(%)DFNSB;]6.#Q=JD*GJW,V8N
M-753UX,D20(4Z"%_VJ/)[]D]7LVF*HOJ=>'D1CE%Z*ZO7.Z-8GO%JK3GH;A,
MQE_V')9?F,VF78^+3%NW#MQT 20SRH%@=".I[,S5N9M+%2 9<'SMV*XAY^B$
MDW,S:R&0/.L_0\B7106Y%Y+FTRRXGT.+7]7)IOX1.+H:YUXRO>^:HMLGTK%X
MZV61Q\AF+06G9'BOYK9X)5[K_7S"M;B7G@]?I+DC-R:UY<U<B\^MP+">CI9P
M^]-K$HM%>WSR<4E/N)?L+&XECV :&4F,%B76(;82HB*CPBUYZ;E;9G*JZL7>
M/HE%4^N!P[OB:;XU* ^SU\%JO1Y=;7$*.PZK\[-%YD>MGZE,-:/X"SDL2*$N
M3C+<'N*5N"6/$M],SW0\U"$D9/6-N":='1@B7&.G4C?2K25S%CL.=>>P)_6[
MUQ,ZX(0"1X^K&VY.9M/RBR183-&?5T@U>1/T(>;-SD8/Z=(,\RKX'K-[)M^3
M^ZUU9GV_N/R\%O CV&KR2X^<9I$>KN=J!2M _KQR:\$+(?']XFLUR#@7/SU/
MA8U5='5-S, LT=K#I>-9R='NU4J+<<(OSZ-TV00J;S4&XSZ'V\]>LRITL"I0
MFVN"/HF<0/VX,GPO7__/*]V2BN8O31UTLJR:=IM#+[(O5KLLSKX<V(Q*L+ =
M[LBZ\/&7)/Y4%@3U/D6(Q0U_B">>/;7]9)Q"2R(2MJR/'H5\(_#=#)KKRTQV
M+O).HBU2P</NC.PHRYJA]G%SZBACIB+5K:MR24U?GV-P :)@H0L(5>AE/>LL
M]KAQA_ M,-H\7/3R863=.&?ANK5RCV80;Y@:AC=K2+'$;[:A\78(N^XFS#B7
M?0BE.SM:RK*]1B6MU-7,RU*E)DR/V\O.2LMD,&U*U1NY9\1W2S6FJI&&EXKG
MVU.[=8O[%_,EYC,SLWI5#45*%9OIZ5E9@H-\&4C5)R2WH-."TAW)3?_SU".7
M3^Y40QSA4"_^@>>M_XC)=T4_M(#$8[HCG2EN^PZ+)LY"##$W6 <K"CAV.M^4
MQ%48E"V_'ZRO7KI8K,3.!13(IFN90S+WQK6&ZW\Z4/!HZO^:C6H2IQ8TX]4A
M[)NIM"81WX7\3Z\&5_V34V2R"[VWD/:F=UM?OC9G?U4^VR#<8ZL5EC0[Z\+1
M4=+)#-M^Z,KM7?+( A0QM+F-BAF9GW"39WJTON:<F\C$)S_>-)X.B]55.>\#
M*O-"-A&E"@2%C;%J@/9L\=8V^MR)9OH83KP:&CW=DM&TW8@(0+C6- 'ST0S<
M6,3Z@)2S;F_OF(KL.LQ$2S3 /0"W]!6W*@08A/:B<6GNVY%Y@[__#0D/S[]>
M-OZ?4'=>[,%C&Q=;U1.F5J_&.ZO]XL>P$' -,T&<F)#95T-G=4JC41V$7"MM
M[C\ -?,J.> LS#SA6F9DWZ#3IIK)2@C.BTPETE73/F?*U)0D:X)-"''W6186
M88!JCF)+)=WJY>.D\>,'7T>,-M#101E.UIPC:>M$^+6]+I<P7+90)(OE#4*-
MBBI#G5Z[H?DJYP9+B:;3&C+8=/F=ILKK00_P2$K=N-+XU]A3813NU7V*832>
M5?AQTZ_S)W<U[0*+=U6S_7XG+:>T)^FE0JY.&J5NB?1][WC5QC8UHTN\JC5W
M2UE'X8UXO]IOR&VVU9 DS16_0(\@@G#S6'K(SI!)WR\U@UE<C\QA7[I^NAL4
M"N&Z][]TSB6'W\1.U?GMVKZMVL@4/SRIQLR[FGG*FWC'SAFF\V8X1RTOF%_-
MNV"H+E<YX(T602G! V>'RQ7NL1;NE619H#KGE[G8JC]/7Q\PR)^V9_NK= X"
M#D5!5?N/.WBO)B.%", #)5F:ZZ+4]XU=9T#SYK-;[#!UM@$TGU!##@OAT7D)
M9R^SYZNZ'?U,<$E0'T>;9'V2-!XW953]X&0")+B==SQ_C?"$_5['\U#7]93K
MCY!#^M6?[I)80PUM&JN'EDN-:FP%PO:@U3"=K^D%Y4_*$6XRV,O+)>U2-!U7
M)[';0YPLE:/(T]"T()0J4&95\1#,+TYG-<"Z62B;1!@RS=NW,+8WZERY=PJT
M#<5"2Y0\35K)<M16@B*8N<TN910EB9)<$RT222B"GA4T&BWM!4DY S%VN&2P
MEGN;K&%L)%Y=TIOF"];S%[%-<T2? O+(+?YF/=!VO4^GW3"CKYQLM"FG_B3S
M /7Q4P<3@GNRM:?5A\L2R3:!]<;G>T3ARC#/ZXUL2</EF5;$=$_(4?2^P'?.
M]+*)#:/X2<Z.  MVL9<X(1@NH8K5$.CU,HV<_P<GY6<1V%0,ZS6<7PP8 1^L
MK83->( TF(D99NGZ JJ]:F$*S2[I#AP#?77](HK-X?52%OIQ2S6^EL=3- U5
M!!GXH*8_T[&@Q-X,\N"&OYE!SMZ^,]Q2AXW.YKC7%V" 6\9DE=UK,_I?K$3N
M;GRZZ6QZ=@\5XYQ./RX@9^E<E!XU$J3;]C5_>BTWA+=G&6O3M?9:_DZ7?Y;7
MFYX("^,!E6;]!(>4Y> V\;S5B%.WL.!"/9NO[D%T&3S)7/GCT^,#(0).F&;"
M^$TPP:%6?$V(:M981F1(,Y#R%DS<FI<OJV*\V?2K[-P#\\)/\G?Q#:6H=CF'
MISH3U_P7&3,G$]]X\KS/S-RD$RN]M C'JMQZNRAEJY2YN'WFGESG\WS1^]V\
MYTM*L7'UQTLQJWR7<<B'$9L^DZ403^Z[?7[Z(YRC;:J##\-R.QCWC'[8:ZZ6
M"R<U9L:L?C976)\ C'JTF)WX[,K? N._7BK\W]P@K+CGAMP\3=K.U_>(4"XX
M'HW,>CA )*65=FUMNW*=+HM*=[$-;^PPN&S++SW#1!6!?'A=[!<LYI*Y%^H2
M^MZU=M)6]R.L;K$WN:47:DE9L"!M"H<^^IMTZF(#+!2Y0LSWGVAL1NGN-#'Z
M6?:Q[\8$/@2HU9=]I!;%S$X;:E$ .63SHL,K*SM_^ P?&(V.H5]9M<M;VO29
M46J5Z=X);TX465@X+1!JSYK".KC29+[RR4@R _JRE2?V^XRTV":707;)Z(\*
MTZ=&.U803]8/N8>CN;^].6MKB&NBQKWB>,J7AM!&XAGPV#,D<R#T&P!,HO.[
MK?AVP5CNWHKQDQ_36*!DH3B![8FQ4M(*!::6"0RWP-X/2KZY_.0-G^1[_B;"
M<KXUZF8??5FI5DZG#%%XD-G" X>(L6099/!T\;2W-*K!+8.+'S#_5;&RF<C!
M3]V3];=>5_L?^O<?1]_DFC_Y!&M?9QR;,#(MD^X3\!E?5#!21>&L!M060.?5
MFGR2S15\TAO.KMWUWS#!SFG+I@+IE5PK*WA"HRH0//H0G/IUT$W*TF^[;W^Z
M2ZX^-LE8@S#@?&;FE2V2&"S<(7>QX*N0M;>%7D0K(M[NWZ;%8[XIK_1'NKA>
M3LG2$A?$>EIUS,%)&M:_R=_1"N<FI,'NZ2<4WLU@X!7;G#VY:*%&^Z2"TP^*
M"-&P.%F4S0FJ2.'KI^LU-%(O,Z)0'/.6IMP@5_F)2\*;?QZ/:+R/*2MZ.1Z:
M;G5+:F8;SY)S0@V(D?<8']K\(]#S(^KE1I,\HH(L#6XMZO6\K,A'3]/F$]<(
MW(&'\@]4)369.'6C98'>_*E)U7E)OZH#ZVJ*%;MX_%TXW^(Q=LLWP<^_9%\;
MN[?K+23V@-Y;! QA;UW(_"6WYY2A3ZST86VW!'IM#MY(G!S/Z-L6,8P#S$?/
M&Y0Y R<*4;*9*B 9+47 FN83N[I3'C8?ND4LZTIS+*J2)]D6-+-0$:N9KH&:
M+/_\U")6QIH-ALO=6*KB#X,-UB' J+'NHI?JU2,=71T<Q7:-]&!+#EZN@R??
MU??/20;]I]"4 )H>^Z[H*F#X+-58'U9T=>C>&-&4<E$X]/3NK@3?OG+L ;>M
M!]*\E.7WR,8D-#HB+5T:.=(\EGA3*M<@>I0<?$WGO$<)*[V+$OJBZ.9,/$A/
M-7&0V\]O\KGW\1N1RW;%-O[WW\U.$M/[E_&.>F9V)VQ>U(_&\]OBA-$V3]!@
MC/O8UZ_%1E)ZUB5\MST?_8]C5V[WMST]W 4>S1]K32J=Z20 KOG-ZHSOZUU'
MA?,,ONU\\FI9_E'"2"S*6/!)NY86-$N_S%X)H3J8ZB.W_R6XQ%)'G2PF]56;
M_8NRD,3I/P9*G,"LLB5ZIK1/C%^]QYNV89N&A7N%[[PZHXO4"4*YF.\12J4W
M#7U />;-6N,M=K2WC>QWT<&*I7QJF=$& 3=M]\GD.V!>6=)UR]<2)(_DN]L;
M=9*B6Z@R<H;!2?NEG50L<#% 2'++%R[&@V_Z>)BDM;X2^+G)KZG]I=O8S&!L
MNI7!AI\\ZY@RW/)$SRN;7_<!3_@"YSEW2?M+'9O(VQT;'(*B4A<.^0SB*FPQ
M-/VBS<]3("!/] AH(W<#*2,CPRTW2YL=CJZI#G-N5<YER4F.$@_;[T&KI.G:
M5U4$A@[C\036<"590"=>09(0QAS=%>!K,SL>H_8NJ/_]W^1LK__K);K_$Q\#
M:C"!_DNQBOJ[0<!2N73!2<2=V;[RU"G1:)SB>).!(EVVS.98D-ZQB;295=1?
M5?2T4L9H#5K3 9L0!V,V:7<VD@'.6KV(&.^H[RO$(?F/TE4:'(J,?G R(B?K
MMI!$-T+D *OKJRA\N7B$M1/;58]8#4^[BBZ67;&JJF+([:R,1]P>)2>':>U^
MY5-R[;$R8G-6RU"R TAD<BL=2F/-K)KUI-%X3J7HV7&YT#DA=I3IGU=TXZLE
M8VKB0:W5U[UGZ%+DC?E+/9(&=J*3W4$A6J64D$VFQ]7?.6;-;6]WA\#<N$6K
M"VF[^Z:-GH)C?D]+(L]YDN&\XM5(_V3JJQGV)^M4DK?TKBECD)K5G.83];Y2
M,1'5'>Z, 8%+H(BARH80]Z!RD8LR2-%NG%+S%H$[![/R')HCGWPJU%[Q6^O:
ML"Y-?VL4:-RWFUOAX)3RQ]R+TW-TFJ1M^8*-7*( NU7";6V-[]'/O-.+&D,$
M*KT:;AWC!<]$J>0GC#][.VNH(1,M[Z:MJ,2NY)O-N> ,"I*A',/D^"@X"> 7
M!_C&8-A=:]4OIJF;!.]0TUYL_UB0CEY\ME5_?"-QV\P.5 Q!ZO5"P+&"EOP.
M3P(J5[0E97YI6LRR'RU?"]^NRDHOM%UQ!]XDWR07IYW,Z@5 &"U<+"15VWYF
MZQVYCZ1+T1V=8N-(.)3&ARV5]V/.#OF$<MD_JU_^K*CW?(DUN"/(79(5Z?XY
MX4TF*)UZ+D!P^K8.]9=2GS +09DJ+HTCMV-4A]?/6<2$!'"K\94K4JS:?UY9
MHD^-_#6GML@*\=&[?F0\]^&M1,7";\XTH\0]6-HAKWVQ8UA@7W\23<I2"*UU
M*7&X'5P)<DUY-(P/8#M<,CH5)UX":S7/<O\1T#]HODQJN/CSB@0A\FDIBGK
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M[N@[00 $4PETS1N.DD,6VA-Z ]H']'I@T_HIJ3@'!T<NF6V]@B/H7$NUP%'
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MYW%3BQ[QY XS2;/AJ!*[6W/*APB#=VD0=1Z.4*C:BM5Q3MDZZ<:,K$$2;I*
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MO7P45PN?@FB!JLHM91Y+1.:ZQ]8+-Y6?:C_\=WA0F2ULZQ*4E:S]=*YH)-4
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MFYX(#J07DCQ5 V96/8[O,O-[R;<W+(TJ\*[/(KMET<@>2 GY#D=56CJF^6N
M-;P$^502C=1W-8VM1FGI[C5L,6#<I3;UB $TJV_.)=(O)24'_SG31F89:0TF
M=YM_=0S<_J@N;>XIGXD+WCR0IRMVS?3R(RS)NX;6ZTCB(N*X]_]R@8#1]DC
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M\-*W)KG,J7TFV;=.T6K7<%#.0?EAWP^&+*B^H%!,P>+++C&QU_OJ,>_7Q18
MR<)394)1218&C]HTJ[3U/Y8 3=WWA4$9L97($ZV# F97F#F0/%.4!'/+>"IU
M>[BRNI,9GR11S2LF564,+N(8RKTV]9RZI]:\&U&?1'25-*O7<RH"2J>-6Q!U
M6Z_E1H]HICF)SI\+VX%<V6E<=?(^_#EB_>'?UAGU;Z9L"@J+J*W.*)XNW(V
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MB_\Z*3$W5KE,I$ME<$A)+'&PZ]3K&&D!2H/\GMH#).:J%E8@LLJ;T3;.7_Z
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MCH]NW W\<SU,L\"<JM"GM'T EXNN?M20U5MT#BS&8TXYJ*$R]* =(0;L,^M
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MYV5,K7,?KZ^OZW'F%V:*61R\OC[TKX<6]>$.\?R[NUP-"#O#F1DP-%;^<A
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M#SG^_A[.?J-@Z%&13V5[  9-W:Y "HD8[?/00S7SW\V?I:\$:W28G:7(TCO
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M@;B>1Y+[.E.D^,T0N@E&:T!\UG.H<]6*[EQT\8?17&%AMF?N58Z0FCSR2!_
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MB6@52H#*QXSZE!#'Q2^\N&+$')MY-.09W:>P1?(%+?#MA%:A3@CPN'1E@Y&
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M)P8:+U!&IU5!W%6#'?M[;!&<+4<%J!NQZ2(..L\O:?K9$*8!1Y]TA)/DN()
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M'!S1A3"#"4P4 *C;I3R$P&1WCQ6?%&D<'.CN9Y\_B4DJ=H;V3L(!_!Z/??3
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M=KY0.[KEZCS=S;6GS)2MO<725T4AT+GUY;D'>'3&J(Q\KUR$];J>2AW:><.
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M[Q<W3^8!4G(;]K9G(IK:]X3J0^<>8NHRB\6.$QT&BVI0Y8H8I6O-=P5><^O
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M_!>3:X+\!A.'*ST@,_L44V F;.PA0.7%<#X[A^A1OCJF_Y795.OPGTFW175
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MP:29FPC]A'O1'<?'7[\;E>_X_O!12E$N.:^CA"V/<$*061&^Y%%YA<^#O3K
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M'\NQPC0LK0K^?BS_+ZA82'3L0;LVR7?/'!?3,RSRF+L*)89K_#HT#@^/6WG
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M] Z83 J;&G(U!BB..!#U'9YN5;R*,,>MCB+'W+/!O[;PV%=VR+U,A/&77XZ
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MQQJ_K&GZ=KC!QY]="V4U!I.]NAH9-6VN;\,Z^TL>C4GFY(O36JW6#1A-^^M
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M[P*+2_DHG]"\85?/$T<WME]52_<>60_^Z&OO$.'\&%/;GTB6N\PDLR/R4N5
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MYJ?,%P =-)'E]B\1E3*'*LU$B!L%+S=O.#Z8W+JBJ 8ME"J.35; <QU2#9>
M)$4W-/\[%Y):"E]8#!!0D*QZ;.44C%J6D7:MR,M#N"L,$F0;I&+H:@4T+O\?
MN4)F7 EPXKU'N+@RPE/^E910>M$8^2(J;7G^PZA_KQ9[EO3M5-$TAR6A(:/1
M)&&X1@K76]?"<?.ORRIH>9#*[)(OK#/3QN1!+9@(@W!A4L;'S,.0DBY.+GH#
M1O'=O-6H6=R=*C<SKU\EEL73"3BH#7.4#3-6: MO)E8M0*W,+B"(5;?9!1F@
MH,N*9A\__&/M/J$+"0+1>!8P2E8(*,6+Y[4$ :4/;P85,,E]>EHG5Y'60/GV
M+@Y.]53C0=@)"OBX:D\3IZ#@")L,J+"K$Y+O-XXWX7:K=<%O\AD.BF1.LVHK
M'2V?5?--463M$[]TV)?^97Y:SIM]5&9FR?"$/[FBWK1^:)'"")O0#  ?+J<(
M2O>5^HHN#?5S:5'DDMSD36Z$.KD$<WE"5PEKRPV=9VFGYFYXZ_#IAR_/65M_
M% A;7]!C"R5<F?YC;JL4) E)(=8DG0HLF&<]<D%:&^Q[QX'$&Z\K!PBB8#L:
M47%*KST?>!<U'$SVF#,L0[H=4A0JSI)Z,6V+@S1_D;>;T\2JPC9N#P^B8)TP
MVZ,IQM_J1?)#)6::(XYD#8AD^!L:O3_R58^\L:6S/LCNYP -$UZ%'UW!_T;+
MZZ<C\_=<K["N/7Z1YC5"V+I*I19$L<!OU1,0\U?(T+NE=HE3 =<>B..IAG B
MO/"MY96!W$\J5@%($[$.=VDN)L6)C\5@8=.JI<N>*#I_%@>I6N;3FM8S(3(A
M&#L^.@Q7)YM[8.Y\P@U:<124-VZ.GFGM!$:?P+?=]8)Q2_PF7,9FA5(N3*']
M;K.O+L('%M\E39YZIQ:ZU\N.)(U)'!4=L??;IZARZDGN=:5[AN)H7AD!#VO>
MH:C=@IK(]0'P[EJ7'[>\$IKWJY@&Q39/EM-5?MMQMU9EB>*Z:B5@WED<<E2C
MTX&=:7YB9BS">%I?K?BT4_GY"D_X\OU_+M6 (X()/N+DX.>N1[T%;P6L5IV1
MO-H]5-"25V<Q0&H.N?SD=:/WQ$FE^\1@' :3]IF&PC=TD##3\RJS*P4I2[)A
M>"\^/^Q@O(SK'!^=Z@/<-3V4J1-3[',F<-H(W*WL$C=P%K>W$D8_W*I8U;E,
MA<3,C37<QO0.$UZI<;CC\F(-R[;HTZ*PD+OK0%7)/(1C>;<QH:26<^#VVP!^
MRT2U3J[RSMU3E#J[7).>+7)2!D_YB);DH=A5,02+KB)*R0*/#RY: HI$:$/K
MKK'&G=[$@DD8.$),'8?P%R-1EA2!GNC,V#6Q1TDO<=@L;<+JH:$-Y<]$6%5=
M9(CI%>JZ6F8+$*1K"6FZ_FWP:MH_G/*S1#!05;SJJ-#JRL0A<]SO[C@P^<O)
MCEO3[Y'9.KS.B=./<!I.9%^94AI>3'!;8*X:K\JJH9/8DC73$>_O+&ZP'"^#
MJ.TLY<VDY^-?M]ENO:169-I3["*O:J"=Q1+1BO(R-3HH+Q$),/$-Q4Y+S*!&
MASWB6V\1U GP?NTI55"U(G;U0<>VD+ONW<T-'KV&=V]'X[7O]"09_*9!3&NP
M>Q$9AY%2D;X/YVWY(OXEZ/!$88!6^8!B_Z UR87VR H68K.8V%=%&G03[+JH
ML%VLY6^[-DQHP(U QOB6U,%A8)^^8IF0/_H5JRJ"-=U6AZ!V8OOKVMRWU_2\
M9T^&!\_2!3MDR!_=?GEW[C_9/:<RV=X 2J5*J.6&J-;W<TJ]GL2M8;LO%&DH
M__#\@%VXLTPYB["A?<1'H,^*23\E XA#/(<+&]AY!2T(MTN-C[7Z(72'A\/]
MBXR(?!R:_M U=UL=UPP _[CV>]$NZ2O+)UEF*0:9=+I3\V7O^26A)S];,B.1
M*! %Y5H[DK^2&R+=\L; _1M04@?GJ=?A'"(96U$@]FZ+?Z'G@.]OB9;=8XN"
MP%K+2@"W?_1Z%,]R=K!OQ?'1M/F1=1%-3TMQ?'&T>K#P<YQ+2W81=&VB(3HD
M*W?"Y,*I8%^(KN==AI9O8()AX:1CFITN,Q.8W$;<)D)+"?BP,3UN98"IB@8*
M\.]^,)H92OB8*SZ8BMK5?F/H,SAQUWQY>A/$SFE0M%K9X<;9D9FT$69M[\\N
M7ESC631<,-]MD!$K]-:RIQO'';ZC#7E(T-;:$RXI,FN[!)VN<U!B]H9-NJ<
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M*'_=>?^F-VH-PG%PE^&GNL'""NS^^ZO[X0L[/\TV=UOP4V8>Y#="V6J]'I3
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M4&9Y-P]0?+7WG"W+P\V"WVY-O6HPTPQ$ B4IPD5GHIKJ)!A^J,D'Z?LZ$G@
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M T3'283S3PYH1YF!+POM2^V[!Y*LZ*M,L*&V=<42._:RG[IMHU8R/#W'F1U
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M/?5O='/]%1;7$_XHME:!2R;5LP<%&G^-)B#G7B454#)+/PLD)3KVXD&=I1Q
MEX=C#(-J51->K0<7V>HZ6DM1V ]VYGW^/ZC.%[N+WV:E$J8U-WP)*Y(5J_DV
MVQ*CE(C\<90+E&'ZJ\[XP+T526([AJ90,X#RD3.,M7Y5,7EEU:Q,?'-N6N*2
M_]<6_4+"EF5X"]\>9N8-R?++D&OKJE-IEK@,4&R<[4]G&6;D2*7!)16:Q10E
M+&QI:U:U_K['W0?QMNN,)A["8E/^Z16,=F+;0ZN^O^,</>N3S,24(=<P%MY?
M]>#;+#R%1TWLEHS@,(-OLPP$XY 28Z(8CU]M3<[>C\L278@]A0V%78N)<EX
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MP!%*#9GGP29JC3R5FJX;/6-Z@8?9(G>, $1A741C&-._JGZX6X]EZBU9-)O
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MFE5(NN[-I\.Y>6-K8E53+U)Y+A@0N:F'L7A06@O65A-HF5+/&1O:O5F43)+
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M>\A973WW'3TVV*[R%?M0)Y]H03.-7(B%P9#;8,$BS*J_P<T?#G6KW8AP.U7
MYZ'+5D@.1_8&3:Y!)'=&'>=HT]\I%/Y2ZLWN\6 Q*'5U)CNG%14N6-"3LDM6
M"^92HDBHJ?OH7708">M)8=9J8WBO,?8>TFEAI_,,7!0+UI4 @:)-$WWRW?/
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MBC63W@5Y.UK%*XPJT_)!/1AA$=JAD>_<*.)4U"<@XZCPRXN"(N_4Q/H=34\
M%.J JF0.KJ(=PHVT%SI-D" ]V0DY*9/!X;9IQIO&OY@7B=^41RJ5XDR\5!KU
MQJ42>4*DM3G:(&]4:2MGR@8@"V1D%+^LI><DT%P,RXLT5GQ4S)WX$N2\(2%$
MUR<E$_/N"'DJKU9@/:WE43I]ZJ]1;2</ .=-<AN+NLM8H&<VQC$E^/ NH535
MU\XX&X.ZZ7Z+F@?+D8#F:JA3G)>SLS)#DW/QA5[6Q0='+LQTGK%9D!"<B_S
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M7!"*\<0XV.6;.B<5-31Y??QX@$T?,*\A1ZCM.=PUFVR;%ES=4T6CQU5R:3;
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MBKH)"MS9LN$6/^^Y011FF#Z?=//(:1S&Y[1IK^[D5P,7=3CWER),$R W@N]
M6@E&EL,?B1<4Q7F$\62?$Z&!W?C-ZM/]ZH8O)8]YVB3/S:,,&%])(S];>M_C
M":1][^@<7F_D0:*^UGLRA?9%58MH!RK6)!M2WK9XC^FA+X)3F:_ SM"2!\1/
M6T%+6/JUG"3-!-W1PN)\@QDAIG@L+]A=1;!#M0^>]M5' S0D/W3?"3S5A/&B
MY0K"JI6/3(YYYZW(DJ[2)=_GBF&6MP7PY]PRR.-WD5Y4WO;9#6H1 ]BK"?B&
MI=$2O@[+RF"MS6N<7>,LB:=EB]+A57=LXS:@]&39]>X4$-S0]H.6%AA.-F&>
MZOS9G$5>%K:O^%2?PV#V?R->SK)T8W.Z'=E&4NY6_2T^E[0OD'8O,SMZ?F[6
MS]]&O4/$G3:+Y/_0D\*@6],OW%UQ08B_/B ])'5E3%4Y].$L 34S7^PIAM*7
M6,K<;/=B#VM;3W,7V$L&%:DY!S<J(N\2\Q2U8H_L +T=DW3+=2P1E>EM7)VU
M!D\(\PU)^(^A@T86;C[U][U/OWP'^J9)[73 K!Y:FY9UA9N:TO$XLVG9M1"O
M:,PISL9'1Y&B KF*,%7* .W4?LNT\_<J-)F7RWPH+@$9=X:FC[ S*,%MU]6O
M4T<O2O8DB!?J.#[6H<.)QS+(B5PF1[HE &@'U'__'P&]!P4G<:O-I\H+<]UU
M615G% G5*;K)8]:]<T8;U1<1]"E=+I+Y]M<=HSIJLT$=G-007K3F^RP.=P[\
MF=L06\,3FTF8L7Q43]NUU0 _0ZUF[/9F4^C4F-LB[Y[;E5(C/XCR-3!]V_HO
M?(FC+'/!X#[QI:]V?FXG<*1>2L5%PR7]5]_A 2,CD'[.[/Z;"%V_UM6HQ*'W
MT_$ZC!XZK";.LL(^]!K%92M\5U+E:D'GXINZG?YY808Q?*H1KY1G*F..=N%;
M=BP-0P;H@KQQN",X7R2@>"FW:BCJ&7]EO-'^[%V @]HLR#N;M(6TL,A]GG[7
M[LLH@C@<FJ"K?RS[H(K%L[_=T4:#*2RYASR_AT]?Q&X3AUC4)H[)65$MZNGJ
M*:E)_F[^<EXA(\=0CAGY4"@HEEWXS^R"\+ S]W5W5PDIE.4Z"+RT"GBURGT)
M0U9?&B".;4=JLA[Y4+T/ELSK /R9Q5!(K9K!6?KN"QNLB2O0SN&QC:LM0N;*
M<D-'&O_2PBSMXNC%\E<6=?^H4EL.9RO1&.B<G9BE]7'M$&&H+X[0[&D]_H.L
M=&:H"NLNRRPP_DCJO)E+*M8X6'FHEM\IEV<3/I"U)3DN>^RXXRF\RP=K"]L2
MZB"AF:<^^E?2JRYAOQ/U<C!_NK;0[>M^J6"17/'_04;M#<P%W8^^ZNT=]PYB
M/*N*T7WG\8/L<9D<KL+/+5()O)NJQ6YI36S*#J4+E7)_2\&?B)<BF&X4=H*-
M%QHOE#2#TDCN64$;Q*U#O@YJ+T=P<1QBF"ES78E4_PR,##^K4EBG)6VJ=A=0
M;A+B,\MFIOSOOS?2XOTV(.+G*-YNOVQL?N%_5U8S<J9-LYBKBN+&UZ/RU%G7
M7ZKZVA/F?I\PD4D3&FCAB3;5[75<V-2KP4GI/#]K=5M9EFQ^;)D<0 /C2IVM
MNL'R;X'RXQ%RP!=<^/<8[2RN!7A.=,#KT.R?7_.OG]Y0O=EDKKZ*L)N?LGED
ML/OA2%IC,4$V@IRT)W:4_N83[)+Z>;:*J"P]V3_JY62_P2OVX4"82YE)X_D/
MLL'-YKJY*WXHPA/\@XPG[<8XMZQ6T.LY_.5?_V/*R+!J?!TSEQR31\U*[QZ?
MMS^KEK?_01:Z#8PO92E/VQL0%4XFJ+YY*OSGB8&A;I^P[01,P$X/ VAQ[W'1
M##OZ)]XG7EAD-Z?G)1?/!9+-:P=)K'/$-PT,%I]6=T](RW,YS755RR)1-IX#
MR<1U_PZ8U\U-[!>[ ]&C;.&,]"YA7\X>9#E+,H&C7%^S(DLEB'X$&@3OW%"D
M^4&68BW!V %W33%^;3>K@],-U($ZN%P*IC\1#7G=.-Z6WOE9JCE(Z\RH2S"+
M?\7#T]W#E3B>(% *\33CN==NE[I[L WY)!&7HO<!0#UBJ:2@Y(Z8?Z0W.@A*
MH@"J0X:Z\^18)+=W=CF83BP;A%(R[A,WFQ^:R4R*][_.?:LJB_&O%R\ 6! F
M-5VPZK)"0%U$$83N5RKQF(7_/G8N$VN!RZ$]/\@&]'QN:9"**X?+:T<O;HRM
MSJO8L]T'>^V7%\<#]MZ/9=0EXX;O#P4>&S@7G*UM7<NN_II13_"[6#?A?_,=
M&2Z\>W*DB/+:;68I5IV(#H7_\^A(2KTH)8L9AP7ZYPZ%VQP=7:<FM)Y8)_)5
MJ7CUJI[J8-7SWBC=;WWU"<9&VU>>CZ\?UN:?)F'Y=F3FW?SGRM>:M)!R3[3M
M"^0.&TH/+52FG'&K7GS:[[,;@/3!Q7H#D1I([(5KDEX!9_XL%%7$<-R#]:KU
MEF5X.Y"U__:<JK_+*$G/)LG85&JNE0)BJ;=N8-#W$[[OB5EO)\7E-"4.LW?"
M9?E@40!>.=4I:P59]P)H39;4R4K& QX >%L%8#[M#Q8P.,:J_R,A (-4D)SH
MT^D6KD5'L]$2C875PBKNHK%N+82@;W%I! MZ\!)%QQ/1GL$%O/URU:Q]^RWC
M1C[I%C:X5Y'P@ZQ]1K>H)K":&/^34>G7LL2V'>I"X*@?9#E9*NC^N?$';1>/
MPUZNJ66]^9Y1RVGM-_RWNQAU/-Y8.)>/9IO#U,7"ZHII^#IJ5PZJ/"SK#A-_
M*+HY?BJ;8VW<*'!5ATX+,>Y%--PZM^98>;YF,^;WZL#0)^F,'UU;DNV!4WNN
MC&&6PP'C%LAGJ3K\W0.._3EY%^T>WYLX1"1,_F+Q#JYO_$.D 7_ZR-6Y26;Q
MK#YX++M272&0/Y)=EO]CN0UAK9FIM5N"*KHM<\%]:W%H6<+WF;&>VF%RM2E"
MB&FRT=:0.XT":J>#:,:AI/PC&FC5SV8[(5J#%]$JITNOM<NG7.NFZXCJXIO"
M+#:R([),-G^\T J.^G\G[R_0_X>[]XQJ<NO:A>.V@X@B19"B%"%4Z1T4!21(
M"SV4B#3I! B];!%0ND @TJ6$$*I "!":TCL"H??>6PB]'?=^W_.=YWG_/>,;
M^SMC?.OOG;%R9V7-M:YKSFO.21DZ$/7=T"G:N!#]Y\ #BTYLG^%$R]BFSORA
M(7U=E5%.(*LH-L3EZ=#<"49%3%-Y;/2^QM;"6$-!FM.WK:<3[[)\7IBONK=$
MMC#?F*Q6L=<(W;80WC;)L6FV3&H(<HYSP>:='( **44Y#,4.9ALJ6+,5 NYU
M35X"U/RJV93V.L.2:1*5[[*KM8;.BY?>]@MUHAD!7P*R-LKMUG]%Q!G9 $W0
M,WZRJ$U^RQX'>0J-CII33H0GB@=4_AB_-E[L^_NS!-0#_T5'.)]\ETRZ</BL
M5A5:W>EBTGJ$<-&LPB2NR$6+_4<TOG^CA*#]F7-:X_CS8Y0\967E%[\A?U\B
ME&9Y3IR3=IM\3S'I:#. \9MK'2U1[T-IS;,SYZ.,XXZ5XH9(S0')Z#VO=/^B
MVC,(IOR]4\*H?&.A[%0B(46KQ.''E2S3G/2L\<2 Y**^4P-?MPN0[^9J[Q#M
MU/J#]#VCI6&9(YH 5VNA#W"4]I\WC<@N 1/W KQ:SE&L'];]DOS%5Y \&ANP
M78'G>S>[SO\$7)D9,QP&ZQE,C'>'&VEKW3!)144,QS S^;G=6HL7LZ^ZF\B!
M2[(A@S7G_I6Q(_\'"X2:QW@HN+S&>$TG-L*<)AR1O1,!-AIW8,<;[A7JQ9.!
MBTU!]P)=$,D_N5#A#B1V',ZE=J&H*QPO25=W>(VZ\O,C#5?[\U#3\5QM1V%H
MXE*9"]>=PO(8!K4[;0K2;_!(]1 !5<6%L@%O>>Z!0?>>EIZQ*36WCLB'VG%[
MQD;<G#I+WWOA<N:I Z./.I/VD1]T\X&H)2#;[4C$C]2K<BR^2E;"JZC"30XL
M+BYU@ZD8^9+S5C_JI?4SG[LOL^-VV3%P<K"OS.MVQ1D+:VVF36$RCYJ5F@RU
M^6T(+38]LD_W^QZ-;G2*X4WW4^ 8L6@(.\1\5 C3\HQ75KT$#/B'BOTARO0O
M1_/_W9Y%<O,& 8:0O8UEJI-+ *.Y<'U718!S_I:+$+W&LI$3?N#@_4KJ6OSJ
M=)AWX'MZ@P6]=1N/J'K;EDL :*F_7XV5;Z  I??0DH2]7[RFV"<R0/4&?UK=
M'LT'=!X12\UE5MKSO@0@\*7B<2Z8^,G*@9I,W/RULZ1?1M40B2KEX>:>9+OH
M,#'+[A[#T3TV=6D#YX$NODJTG2Y)E0*;<W@ =P:9XD#"*CL[=6[T173QZRGU
M3W^XYCWB-1)J+.8MJ<EBK(C*Q;E5Q%,-DK7@[3B',\?@9"J)]-GG&&&5F-0&
MRZKX$!BRK]L%7U+LX'J+@ )3/NQY -**]5.39S'M+Q78<!*J'JMR-U/7L?N5
MD@&F,@ )AS=HV16*GK5V4=HL\$-7Z-="SUFUM'><?!=,CI> >CC/W_Q[O&/M
MP/RS3HMXZI#V0IM<?@DZ*E@2G"6\-_-$ZX3#.69;M'.J+.82$+.5YRH/ZKL$
MD)L:3/<'CBH53)$M 1W1$ VR.ER^]EB>W.W6R8%D*&)S]ILH#727VOSB;G;:
M&&*N9..1S[(:K\W)FDVK>4YE(</C5;[G_U&[9QRR8>"T/H6EYFC^U-WML8 _
M]/MJ-+/9BN$#3KS\J/ E@ :9Y6Z4J[\J_.-J6G&QTF1,N:R*^Z A2"?)03YZ
M)BGA4]X)*B$/MD0L" Y\ 6<_,)F /#[Q\8;+A?B13?CDVQQ9&"=UKN_L$+IL
M]?'IP3U9*+5CK W8TN[P4P\J>4_I($&BH8.Z<'9F-A CNJ2+T0SI8^UA-N2<
M1<]/,![&G1I]$=<T0E*^F+F'*8FO&8:Z]N Z^]>^8C_/A6<4AD'6*SM!OJ]1
MV5V=C04BV^GYMHL0UD:5<946PT(/J:^R)#X=B[EAG?S?(/10?):#!9XJJB$X
MB$R*K8%%F2@JI<G2.#)F9M=P([B;SR'\2SP2:=_^AY[BRN6O?\PU:NP3\+[;
MJ]U!,GUE$J.9G/+HW2^5K HS.8C5"SCH35+UV*<)4&CB?O_X.S>Z4XU.OYSA
M7VT147AL6FXWR3032SBF4>]9Z\E,87F5L*I@9_4,<Y-+76(S(FE$;5,93>S6
MCC5>/9MB0M42&-GQ^F^LZ?HD5( _22I/7646+P&T.#H*K^OI*TQ?&I VGT<?
M(3PVE5QD'6T^&="W->]QOS/,C0SMJ];!M=N*L:CVI<A+?KI5E(S$+W,MB<5B
M!Q.%&U*;?/$.\]RB6:6%].<B'"4R=-3&5C6)K/GPHI@NK%QVU4!B)G&ELRWM
MH5(AT &M]WL39]$U\G/)<_,.P?!)&?R"YR;B$0%JRT=4H#1W<ARO2B1J_P54
M!S+?&'/W5:3NZ'#/GM\RRMO2(]E2':5_;*$":@I(]]@4E'/AMSV6893-Q\T2
M3=^FD:WGWV6QAS6R^**,PNV4K:,E]XZ(M<1M)SHZJR)!8NUR"/]T,;, 6SBC
M],W1V:H81O8K+13-,Y_NEJ6YNKR\W2?A4:,_U.NY[?[4="+ ,S)P/0\Y?@&V
M*$8ICCBYP2KC-PK:!=[X2W.#J<KY9+:3?)LZCLVR'.'JYD'+UW\ZJ3(R^82B
M1P=,).Q=<X=&!B(6XFPXJXF'KZP8?PQ2B^Q'"0:E,]E^?8?1"C=V]7NXJ17H
MG^02X<X9MFJ'V;>BR!8MNI^[CV+T=;HZ7+GI*!"AW<*/8L"5!]KPMWM>N/9#
MH;ZA+L9K\]M\K2G@% C"K39]N2HGIZ<(?@.N.X2OQG"7/SVQY(RZ[:;$<ZN%
MQ^(= JS"#O'70%@>W]!UBK/4&>3Q>:^4*E'TN=FM+E&6&#<.%.<,MT?=;*H^
M.K5SZM8 G'%;-73\BUOTZBG!=PYR49QUU-QG^H+_<_\_(JK]W]9UR-!XTC&<
M;BV!'#Z:IT^]L*P^#8:ZQGSI") :]QM*+U,V>*'0W/0/2VH!C)WG&H+O*SUR
M]05M,L076CS\[>]\H*"ZC14KJ%OTLFNSN3[SFJ-'ZW'XC[@!])_X(A6H3I>7
M,MK15@92DJ'!4O4";'#D'#)]6U=F!!N,%"K#4P_=GM)+8W&+PRR;RX:$1F6[
M]B^SD)\OA#+\QHS]*<+AVKCOXRV0K9U7$9_NNEQ#WI9_@A%UN)_>.7X26%F]
M#6E@0+/5JG9@[" 41\ AL*G'^S.BRZ%:)0)[X&0[U68,3MKMB=.8Z'O_XM9M
MJW^B"\NB4P?/,#'J#9'S*:+,15VQUGUQ TGQJ@QVZGO1\',QJ?/'":91#K5)
MA\G8-#?/+/7ALH]\Q/-:@)I+.XQ$]GFP@JIZT#"5<("O\!#VE]1+]@\-;/EE
MU[PE]\C>ED\<X&*7,[[*(["@_@,72XQ]55YA$CH_LF$%KK?)8%XJ9Z]3Y MX
MU6SDT5&;VBO&922^,+Y(>HP<U*W,G8[<+19D;? I&FOXQ,\]K.K@,];OM&;3
M%VC*T7 VU/G'K:^O=_[M_":C\7V14G&1+AGK;?ZH[+#6KWEMU5-!L['.0K):
M:=-^Q+[ZCTVAXUW:+@;Q>]C]E[]81-+M @FGJ/>4H^HF_OVF+T.V96(+RQTB
ML8*16%]M=?B T;R>Q*:BQV'L4  6,D^D*3@J+/V*-V)NA<DP><R':V8/O\)T
M%GSXP/UZR_CC+&K.FN@!=5"WL*1)34@F,QI#ZLD_*8IB(V]9KI"7K0XI8^,0
M-7,F0(A:]$">?#_./3V>_+J0NL,E![/.?/IY\E=%1;$^TK8QL(R;LVB5#K2V
M[MQAII.'05_=0:>3:.V$3'7"YN8X=/(%&J+Z4RKLV8Z4D D'^MI#CKXSJ0$G
ML7D!L4^&<'*;OV+.#BT3&K;C,+(U$.AS5T0$GIYRPV*.D+EC9VOW[4(D.\6B
MY,U2Y)I/TZ&$73=3;>[,<V->*G@QZ4,>S4AVJP=DJ:?*6I&,-7X..U@#QC Z
MMU6G!LTB/\2$9RU$U48+5CDAU\C*YO 1/N1%Y3!%KNZZHD'G(=5,43!W?3*#
MY(H?W"=V()JB!C5NM.].8X2@6M^8IGEZ8B*F?+1^4T+ 9F>;.'WB,*>6\&=[
MP?FR]#Q'&75\>^RA;S6%1GSE>1K-X\A&#M[\[ ISK;&@),.H)O;<D\I8&J>I
MO>?^7>M'MIU<SF/+SJX)Y!:.&*Z6TAWW&+>UN8,.E_Q/*,L@C_=# 4BL!6EQ
M8K>RPR*#T734B-"BD_XI$.1V8!]AKE'P_7FHQ=^%B/_Y1A@4"OM7:^,BG?6_
M'FH2<$LOYVEWN1QQ?K1-59"I%D9#H/"Q$:RIZN+%+R\U._*I]ZOCMLGFO!V=
M-$/QS6+#20DWD%WAH1#BJ4PQ16QD\!3SC14USB7QT"Z R:CVVRL#Z(%/#\,_
M.U.&(/H8B. ZT=7Q48J#6#4Q0U-*2B!N3>5876<XHG=1_KY*RGQMFEFWG[*K
MUGR(N<?U?9'\'H1\V37(-L_F$\O.E*@@6I89AYR+/!07 7F0W3W .#+UXZ_U
M83NWK7VSP_]R.X7NP4(%H4"??.)4^4%+WB4@H_:*])JC?)3U \SJ-Y_]!&X2
MLN9K%VXZ^<EB95UJ)P1AE56>^FBR++:JZ$M'F>H9$EOL:NV@EUU[',#,'<_5
MX(J\XXC0$W*8I<ZL8$]HP)<KRU;E(VV-6P7*NCVY?N&+U>\?EB?/!G'W"!IT
M3+;/4B?PX0YQHR'R]4:#&D34)6"7K57^[+&8QJQK#/1;_<E$XR7 _6W]9SDG
M?^0E8-6^_J#Q=+]6YQ+ #;T$4,FX7@(:KISQN_"0Z"X!1E\#MEIW;W9O]U\"
MSOF0%R,!_A5YZ8N_F=B<<E3 T7/YX!Y%_\!+P+HKY?G(Q>/CVI/?<Z!*+P'C
ME-M#^]IGF("SU[N]EX!;-W>JVHI_0<\=S2X!U2Q-+.+UO^<@X:"G[Z;2(AGC
M)HV+9D69)Z>KT,1#LZZ1ZC]"U%^>I33M.@GEQ?KP#C:?Q 7_* HT!>MD;K]Y
M!\&?[7,U^QY&]B79O=CC+TKO3Y@BE476WL[S0T'J=.8FTIEL"&E#%;"W>*JG
M2+9R=9\"$2:9=:WAP^:N?+V/Z=>E_-\P:!F+9-RR7Y]M)N% ;;,WW_XGXE2!
MUI6X-MG;@2?6N]-TW17^&8VEMJ,^GS=@$VA+LZ_[&W\DUY0:[O0X*&*'+$34
MOZ\[B4Z->HAA"V7!F<)Y_GL,JKI+*:O=VZ5=I5MS$8-H"I#>8)Z"@:%1\ZS$
MB^99]H&?&S;H<EJ>-A,5M,N%KF4"\O" P/US8E<!Y:V9U+)5;= "5GN79$=3
M+G(HI%=?_HDV &ARY7!A&-K"]O'BIUWZKXI+P(/*,_H1>7NWZ%4C^8B^D]WS
M HFR8] *9?U3_(4@Y0B?Z\EO0YWS8/G(@I-2)A6FM[P_]UK?J(IL GFN(YTZ
MHB0&FVV>5K"/.%%8W@YZ')V!<6S'@E[7;PH>9'46O9U0TZYH*[O=3E+J6*R7
MU);3A=>%9S!+C=8BJ%;C!Z_512K(5[&L%ZX>9MC:JS*,=B[<>-^H'N_^)"=3
MVN>&3MK4R%IR>I>JR)L641*G\3LWY)>HO%?6&IFZ0R(>\!X'V_S//@>=1+4R
MN[#"><U8$QD16M&)[Q.H6XJU4;"Q88E!IIEC)_3[SJF* $1^L:KZ*"SG1+!@
M)SLKZ@ %Y"A7W +&]$YK=H^O46+-ET[Y8"4UP@_?C$ &=+5 7RY$/^JJP;@1
MJVV^7ZH.8MMQ40U]2[_0D;=>.BA'C0N.ETQI$\/?$./8O*Q J79)9_Q+:S;<
M\8N,S@:\NE*:S0=N<;82%4!U1VT$PY*X4-F6Q5+';S[3$$]FD$>[X]" ,#TO
MOBD5^Q-&L)%\&ZL5I@6AEL+TM&>2A&>#BX&2R##K0]V[LKF>X^9:6&%INA%1
M_1'+0:(NC^'<;0@^P[&]S$R,LC0;0Q9*!J+[->&$%_=(7U*DH.A,.E8K?R-\
M9TD8ET5]EML?V[!4#-%"\_<(F.MRORCLO;L^>0E0&!K$ST59FCX<M72)]"ZU
M:X<_: F6)T<,/S)* ;;+KC-_5$"1LP'NPM+*]4N%6+1[]+J^E'/-+E2J/6#/
MDHML;175I7CP6D%CQ(3MD$7#)C$=V]7<[&%?'HQF+V5P-DU*M:EG4LW;\V\K
MD/,Q!BTGTS<MKEF#R)O)O9^9?J!MK&*,J&!IF(Y4)$JF?I48Y79*SA+,=4RD
M<Q7T$<I7I>WWGXHJGGQS"3A-#(BM/]V=(LP->'G[J].5,ZP'S)JS2,*\%GJV
MXNSN,A[L%_.<L=-]"/B,J#EL7*8=O7<G\?E_7Q,*O4W7PQ7;9(5PS=B0=L>9
MT;IO'6]S^Y47.I ECV=YG"/.4PTJO9A4S[;2&JE4\0ZD3<EA,Z>;@?@L#Y I
M=>&RT:B61I>$ON>IA#$QAXA-&/?&#=)]P/]"K>A:R\4X*#HR]R0,Z5)TJRW0
M)+MB"F8@C8;TV7W<>/!394.NVA#5%RQ:NU49ZFM3J$*3$@R]XE%V4L"+=%L:
MM),I'?4!B IL*E&CWZ<,T3-1W< 27[<+B(UC.-RVV"MC#:GP\-W?@YJ.JU*E
MF21#'A,^%Q:[*O_B6![U_^L& D,-]8?76*9@]3:OOWE/6Z5'GG!T#)PR^JK^
MDOFY)__VRBKQ3LC'!ZC2=J'D#E\[IIS/&Z?A9X$]-*)\.K2J^0.\A;QZXW=$
M G>UHRH1R [S/AL;CP!7<AX&[4)(EE:P%,PU9>&0JP78H49B3Y:C$Q<;<N.$
M>X%%,-H&':ZQ$>\2#H$JV;'K3G]DR97ZEQ_IM?XD%K'O[+'J*;^(%V;]"-L:
M&_"6Y</)E!$+=IA<3MKOJD9*9WXMKV!'>&1YM'YV88BMZ'LK.RE=;F4H9_T2
MNG<WVESOHRX?+^IC"K=3I$]PN8(FB8#Q]NR]39A!4#,*+G^2XQ66J<-%]HGZ
M0.!QP=T$F!9"'!1)5Z>5MA8ORYL18=:4O9 7R)E(28EJV-F(,UMZ6'0UA-!>
MUUEF'X9\T )\PEEG@GOQ9:1"6\N$GG-VBO3)R$%6 ZV]*_1DKJOLD4P6?W'2
MDB@-CX^M:[Z>DQMP(#QEX8P,6#9L9@Y/G.KK+'B[IE?\5\/#.NT4A#G-K$,V
M_/'\C9C\>2<F4MVG7#A&L-P4W[Q[6^S.XW''J25<R>TV)Q4R5I&4X[4X4<5?
M>.# CL#;K%0G3/ZZ+#31-CEHGN<TK%P'FAN4?2H1H)!^ARZ0 V<C$QB5," F
MY1VN9MB'5BM?0STLDKP$J/N"]]YLB9J;_1]D!U3<E?87F? Z_5/^2!%'JSN!
M7!!SVMD_JF6]Y5%\;)+@2W%:KH#]P^:^05E%X_6C1J+YEF"47XW($P&_WEAZ
M@49NGW". +=MQ&CQ3[.M7/RSPGZW/V]\\L[PC[YKX??#_>80/ K3=@E(W93<
M66/N9MQ+AHHE+O]8]WF0^ T?F!==.<0RI%=S*ME45]_ZL&M[CV]Z@OLT)2)$
M^WAH? M[GB350$;+_[A0O%@<-4V:_CSJ*OQJOLY]=I@4JC?;G,>ZCRP3W6<W
M)5@^FW]F L5G1$1%<694\5<Q0W309BV6HQF3T#26,LD@25B>G1G2I/>,P[ V
M87#IHFF<A+5KWUA!&\[U1ZIT")K7R ,#!$8UC%?7#*;&7YZI2126KS3[Q7#4
M%3XLK!7._CY]2['?V=#L:C0\T@)YY*ZHF#"'I)4XT(@P&H;.5PQ237VT4_70
MXGNPMFEGU2I2B)ZO&6.R::)GT(D5.J 4W4S-,;?6%ZA',Q!X&G36%&Q PD$#
M$5GL!Q+M8DD^ [*T%?IBXB+;]LO<NG\]FAM#6-*F6-+B<I+4Y$+<%$E?]Q]_
M6[X(?4]4$1WT_3QTGP=S>./93V$:VC4CJV;3]E8SM@P_=1R1X(0=>YW1Q6F>
M^$"9IG6-+CTEN7I1#N._%Y%G<=BCC<W;]642JLB]&%5EX:@OU9Y-SYF/L*^/
M\_V%6Y)+,SV!A5B_SWJ49'>]N8]AQ[0TYQ&8%-<B7<F(<G,V_XYP.TJJ9^:3
M/L:\8PG>&#$<=DE/9FS=1T&;>=MN3A4OGD>OG01$3-+T/+@588FMHTV?/)LY
M7VYE&2_+N.)#//_TQG./4J$M4;;OHCW]J*#V4>FD0KU*&H#QA]\+)W8+W\TE
M-6PPQM8G[K1?^&G96O;/PE$]W?AN%N@>6VF_?!O_.@+WO6S1,:4BI$MH_.E%
MGAYAD7.I':>S+,3/ >_B)6+Q3EO]NTHU\RR2[)$OF&[UAU?X"HX0#&I>3M,'
M/F)-]FD[KISXY$VGS_HNJ9.Y+"2J;BK4I.LC?QV+Q(EO9MGIAFD/^IE+057]
MTP3C/([9?%<8W7*>X%[HZJ32T+T^K\@U4UW5X9MS:(4(9%]>)^<M*]!SP/\8
MEWW_F,_5Y$Q/1>ZUVCZ6M*XAXGE2&%.X^H G!O(4U[-.Z?C@FKOTU=NLDL=*
M.$.LR;9<)@C=_[A=29NJ<C.6S*<3R#>9E4*9<%)!%'/5_\39S?%0S\5?C6PJ
M(;YE,DS:DT<V;8@P)8O0^EFUU\E1A)U>?%.4)ID&I0<ED'<4JOJ!F!Q.\*I.
M"2EZ3-F)O:,J8.IL/FZ%7UF@V$P1#+<*":P3M\O&MB,D:-^>4Z+HC!WXF3[#
MTM@>3&:):(L?[.,P,#  O:.^=>^O!E1E'%)O%$.I>*ZA*M?#P9KC[U4PH+_2
M]UG"RFWZT-R#V7_%K4%J'']QI /VA*&IINA)*==\B7X4W5^WA %NJBG6R,CI
MG:I7'UO?Z4 _W36)Z?M==3CQ@X\3=W07??Q_M*,MS%=5R3P>#3G_IGDU87KI
MKE.$8"!_K[MV*&24:R$L:)N\NR-E8 ALZ#N]$%'5$9_MCM)VI.&'[ ^FZ-\
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M;5JNW$CF-@_L42,I":J#_:\EBXF?WMK[1!1=M+XP%=O>E1BX!'@;_^:4L,4
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MRHYZMDO %_C-"V;*V>)8EF\VYQ?;EP!G>?^ST7-!^9IQ_VL!?AYY-Q>A,9>
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MW?PF5HP5A+B.=7-P/TZXO&!X%#B_:C'4TY_&+4K;7:G"0=\4#1N^:ZNJGQV
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M%.)(3?^H+04#Q-!\"51H),E?DKP4GU_4R,\8D;@TGQ#WR9YOV34ZPZ_ZKZ9
M,0*! ?$R3.5)B=15@"N1_,U+3!I/VB/,:]M<H .20+,5E79Y>^:@6#Y<1D!$
MPX24KU5! [80D^# )"-@+43_(]71Q:!4_L?\:4L41FZ9$&6ZR,NL[?-=\89"
M=87D5>V?XM-EJE7+;#TU'NRS.R@ZB'!%[W\^>9>1)[RQZS'&']6\D5MF]^L
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M7R8*;Y:(O&TMPCMN_MZOPPX[-M=)1Q8^UOFGOX&;^RGL4'BD(8\Z'=Z%44P
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MT)=X5C>+$76LY!LU,8KL444I864?"4YP:68Y*(D>?XV2> U6$H0(AALG6):
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MD!NXI<N5FEB&WFG=KQ>F*8Q1C;04$3EM VE0<KS#B(C0; _KZ+6^/%J;I)Y
MYM"96ZK *"^/1NS\C(4:4XEF"ZY$F+,O ::N';_7":U:Y,OH'9AI'L!$I=%(
MZ%@PO@Z?II?C%@S?8XM3;F26_\];B@^B-J=;J;;I/FUNOWEIO)M*'CF8@_36
M+>M+%E*_KZ5]&S[TS(]BH$,/5T=0B<C#& RH7&@4).\0BP.LOJ>K NHR*?%H
M&@<ILU9C9A[#TW,U^R*<F=I<^H*;Q[;,&V*RL7SX*K?3@CA?42*]B7+KIV#]
MD74VUPO:-GWJ#Z='M0>-XKN4A@VO0Z$,_$4] *$UWB==%JE*/+C8B:]05!G0
MIS(2*/NS%C5:U,S0%VLZ/(%H,5B/V!9(+H8W8B5@GI8+2_4IL6<(U_D?%@Y(
M[@%FFL%]K_HT#621%?GWPIQ@6OXZ+ .]XLWFJAQHQF%)@<=3$UUDDP:\"V4M
M)/5G,2O54WT?U$%:L2-B<,J'QB_SN_PJ:J%?[/MJJA[F\&3'67/MRG0X?UM!
M>[RW?3]7798/BU+L;U=7%[A?32J-F!J$.MI46G\OS/#"&-N!?*O73+6##61Q
M:3J)TE"K0%-*D6/L;AM;QV.&T[!K,I7IJBDKO:M!<:,^-ZKDB0"*FF^O]/6]
M,M.^7S#.?HV]^5PK]K\NVZ>X;*5J2XH*\-@&G2H4,>+KOU.F^][:W?<.:<=>
MZ=N84Y!.[)]J!-/1;OPU,:[0GLN)764$+82-)X30$4[&6SD6MB]$RW@Z&U$A
M81]BCY7X'2Q22>_C(-2LO3&@.ZK(;+OW,6SGJP"?%@=U/?'EKP$)+@7N$WKQ
M)O3UQE7Y03C%J@A4LULJLM97X]VB[Y<E/&:%$?,MJ;Z<2=1D(-S7D_=AL<;C
MO!P2P(HQC"WA5/^NAIF!-^@0&S:PM<6/U@T9&]5,.(QTG!9F]G=6T'PBL^O3
M@ WI,-&)>P _G"HI=I+0L4U<DE*<<G_ZL>[S09/98/ 3A],Q,U4*9#&3?5]$
MWB/GTOR(;WGIRJ*D:F74W:,8-J] +$$"LS6]7(%J;BA#6X2:S"7!-6XV]-X3
MWX(E'O E!I,J20N/)Z.(*JC*G($*/LZ)'#[N?5;6/2'!*6V802$Q+1:?0>5U
M$;-^\8/4!>$STKLR<N:<# .,\:^0DIE ?(YR,\K'8>RH$7[17E1@49'[U7!_
M@[ B-0@7H.%]YU ;H0_W8W78G=;XH%E*"(2/Y-\!6?3?J6H5^U8"BU]3<F4;
M- J$3?F,_EI6Z"6#@:3AL3%J.4D4="%0]A&#B%!S2OQP5\ZP37UO[P*BWJ$F
M66.C$&5A&+]EN!T;E_3S[HN7*CG$S8,\JF%%@+3V^<^U7-ET@I++2R!?;IN+
MZDJ/81(.C6* 5<4,RB7%&Q6'^[W5<$X@/317\##I%; AGW9]7;#NZ#03& 7I
M^\2="M>^"D7,[+)O\[UICQ:RSP#,":+Q;T=.K^I:#44S4J:U[TL[OS<0&8T_
MLN+^8@<8'W&EE!6;L5-!P344?AV8@+U]X]UDC$CW2E65&/; "/#4PQ8\Y=*,
MV]]BQ.?OO3XS4 (T%--.<G"D#*3X*"]W<0\FEI"R28TTD?@3E$YJ&YK]VR!R
MOO15B9(G8VG);V0_=5DE7Y-%L_!<DX%,-T^U*NGBNV)2NT./T$D+0^&QH[)\
MY3&AIN<-\D8A*PB" LO+:[)^F[;BV=3BO?.$>R&[T,/5=,\?U$U-XFVJ&^VA
MU5VLO7"I$;"4>9KSQ\!,7N:# 'S[07:*N91;ZVUWQ:A_A9+'>E[J.*TZE;[C
M>TXI,X*0O#E%I$&R5^M#GNL;*'S&>=D'L[=SVKE%N_JTK4CE#V'\\!5I96=Q
M/L]@T$[WPB9MW44)R8:J<'(ZV%T%Y@/?PI/IV]U2X9FD ;!9,X\CL3"V^I/;
MH(%2\64CPY;.TK1D\+L'"1T3YBA'9EFD&ITKHFNTM/O<S/SSE]))I;K$<7"D
M[=0[6NHO [!GW19.G]-I[,8N/$QMK.V-WED .=([T;:*:(+P!*02MRRFGF.N
M/<W5I"T.!C2K.MK1=R!5NJP-9VSPASZ^AURYZR:34/6'I@[>_WZ$ .7#3KMP
M+(S3OPF*+?[>WVXBZS6W8=G8;!6@><S\9!<<+_GSF&[LI-[+R"[]MPG]3Z(Z
MB]_GY,R&'%(Q:N*(%=IT(E[H5)<F Q.X;Q]#LXQI@^.+*!\OL?$A4PVK*)4"
M3X02JC4GM:+7W"&RZ@.C9<C'KKU(W)(>+IH_RA[7#CT5);[<6@C"\CY"\GUF
MVIK^$9RV3L9#$!ER#IL]^K4OU (L7X$>*4QG2+[_?!(BM<36"8QRPT<]? :-
M1@!;TRE'<EXT90SF:J$9>D!$UVW65%B?V_2PJF2M0 <1.K>W'AG?)AQ4!7D$
M"TKL4,129UB#9'!="!N&[7I^9-Z9/=2R="W!K)V!;S_-*,%L:) ;U-,4>MO6
M\A'?8?3#I>VM*2T'?POXU,Y ;;R%MBA6S*^+H0O/Y%T7HK4 Q7O/?8'<Y=K]
ML)[2^SO(;I:%O1LPV 5*EI_1'2&?=6,%3/9APW'LK7KQ?OSW"IZTSJM+WK$I
M]BE>(6EG6'S,]]F)'MU%E$7R*']2QS:G*]2*3X/8W[8YPTWX"'C1F>@.\Y8J
MYHI>8(AZ<QHKKA>5ZHMPV*XH&HR_2ULH"J/7AXFHO!J9&+#.X0,+"7\8I\T9
M/,OHL)5P/XXZNKVQIA.L4N#-WCQ+4;O(RY;1%L]ZRSG6#G1SL+2/#S&A:X8O
M!+ULNK>@&H8&AOL,"G[LH?](1B83\ZBE;.OX[#Y?H.4X,SQ^ K2L9_4A_6F&
MLI_E;GEGH);ZX "S?ICOR*0PL^1%NT!GH8U?BCX!*??$!E:PJ$YMZI(V$7YH
MN%%>VM#MQ&J7U)_N73Y.KQU$ 'EB'T\>4DM=B)QZ>VG7VPS;2,5X,=F-./&%
M"7%O&T>@JP6>,<0-M3H]>]IBF3.B@!\ZFMQN;([B.<M\)BNR4"58-[5F*JB.
MBXXV3RS6 T#$FP<>;F+TJO/FF^X)HN):W4M\P%19YY4;ER_%33="OW/WSTW9
M!!79UF*A4H#%.L9"B("S'9N)6#B3\&+?O:,-X,B;3\\67RPEV+F89"#BX6EV
MM%JI(L]'!3N9(6:)\XQIVFILJ1$L#?813T.&QWC:S0Y9]%TYQ;S:"FK12Z4Z
MZ^T=6"6!H?Z<#&IC6B'/7D].4,<V1V_TUPD'.9NF>)'E6AQ=8+KRLFX^^T;>
MD(_UR1Q)3KSR3JNC:()]V]2_)==?B+4]Z>EIW)BMCJ%:';,:G/+9V@%K?2!R
MA<6F6:20')RB@Z&.C4UF<&/)57=;R=-V$HJ BNS!"XGX*N#7OFXL0VLS7&2$
M4II(:  .).NS:,F&QH5:3,PB=RB[LWXO,Z:SGC!=DSRYPLVYEV=H-;%/._LJ
MY,#X6M%;Q,3 WR#Z2M;Z)4$5G'1<DM/3-H\!\"N[-MPP/3N]N;:)[B)-*4^X
MSR;[H!Y5Y2<OS7R.)84B6P]X5?>F3F_%C2QG/8-.]WA?D9R9T3&-<_P9H&MB
MWU^-V,JF^\1S/]]_/Y_-]=$L8XS$\"C ;X25DSLKZ7[1V+@P)TM[&6T'^MC1
MDP5,<Y!A?\:BF"G_J$O-01I0L#5\A>GF,M?^)#8.!<DSAR<<ZQ $<$3ZKM_E
MIZ[)5!'2?&Y;1Y088_#BV^U?AVQ"U3A)C\SH(:K-%C^5T_^ 4R;B4<O!U/'9
M+9X_+-<N?J)637?Q0SI[AJ*?]?[IHQ> ]0EO^<YK,D52=WOT-9E@UT&^X:PM
M9GU2$U^*@91'B2NB.UT1 ,_QC?*R_VF[,CAZ N?*\V8F^E.OFE]J>.'E_L:R
M C&UY=V6#M7:_"]3:PYRT\'^*RD+APM6/=6F8&?#[W&30ML2.^&<CQYZ9<UL
M@N&=0*$>LD1GOTKNOC## 3]?,[4=QK4H*4##):F;*6[YFLR]$)RA&WQ5YLQ7
M,7;.'EB;6UOMWA;NQX\7-D=,AM=$O^]/P49+C#(-&1G?R_V]A,(,5&ZHK#EP
M5GL>I"PT,N$;S*\P/J!C9ETS,(TZ23I,,XK4Y\ /,QR7]N8C*,&NDOFUNPSJ
MSBYKD<]+(I_1E+UXJQ4^%L?)_))PX">(@76X<%-7D;)+(EE'!_\8/ 8Y)RQ-
MY1R3NLM>W+(F(Z-D/!*Y9)[JNIAVCYEH620<:*\ZJ_N7D$X,TJ[)4F9%:U9_
MSS]/!260%W*GD4F,Z5_-!9[WBFT#'E,9;PWN-RG4& 58Q81YW_X@8[?U9\0)
M^&E?]$K"2/O0K+WIWG?[<J=E%M'QI$V)S/")!T\:[+KJJ'Z3WX^(JY:SHOXM
M6>!?0[F7FB):<6H=]"O+L,AWW7'Q0W3@':VDDMID.NWO:D%NNP8#2R'P$U79
MMK7TEKJ\:[*K\J1+Q;Z%8?5@.6P$U_^!@[%D5/I>8&@\;'(QF<;4;T4VP% F
M\2!QXH]I^O7MYT64&-,$!H"VL^ S3"$A!<6!R5+ZP1?)5 V%/3V8'LDNB3B<
M7@)67)VR3?.'L-DP\#(F&$&!E<!P&7W:;_RYZB,K]W 2L:@TZ_A(+'L0ENU8
M9!!.*"T,E=K5CX$Z9/SB=&0\_]Z1<[_<P<# $%$W2OD]L\/X9^%DAWSG5=!4
ML7<Q) K=)X75J98N\J@^?W0WWW7GO-?'R0$>X[,"BQ1.O=,FICE69[ 3U2.^
M,T^LS38&#+>^RN+VU27V9NB-+H\$3!JT=O'4.^D=3IR+->H=^M<^F9L9'_RT
ML,PP3_WS2R:3_\4URS_  N8GI"E^E>H8%0)&7_T^9_.-*+;T=?+C%6&YVJ:\
M)SY _\54(LCG,P/[1,R+][9=ZV @.V$<*.J##UFY5;#<^[J\@1/-XYWZ>'Z=
MJ/?6/ZY2;*E7<J^],\)7,\$F$(@TS?ZV4MW%K)N[/8SP,6&OQ0%D]2$.G4&U
MEVJ)'43EQ]J$%%DJ92XWMR['XBB!3/;*0 =O[<=?J1]B732;68$)/A1:K<^!
M'22EQ($CUKSW9W5)1Z"@4W+JY2:?="KB^F#)2,0!W^$G4!?#>,]16]&X5KN/
M;ER0'CDI]1ES[<YHOLO=WD-(4R<I@C:[)*J;3H>X%64B9@6N 6]O9;^CZBQE
M*K[9D!EA>]HF'VH]K,'DH^;*C2MK+W8PUWB;G*GE-"C$8.A+1)7)#CTL:W]1
MTL-GX9>H3W"5RVX# M2!S]A'&3Y55RY8H^O+ZKMVV.$!$#?N3_-<.I%9XHT$
M!K;!?>QJ:,$A&=E/L94A'R?JBCEB0C8H4:F.4WE@;%?6I])4WY0.RNK&/J]X
MYBP"-/'1@I/,B8/]<R ?&,R0R"(Y!+J?4N85G56/M9&3*6I0T8X) U5&UF:7
M(K? Y8"$I>0V/[<"%V.C*G1F+DY=EWT1 9BKG?S$MYVH/#?;$E%:-E[Q?5=<
MZ,9F)+2*/B6=+\CX7Z2^W0?QG-I4O%V;"9=H*722'"KOA -B1*ER^&NM0EE(
M?=]N1/R8-A'CTAG3Q,_,,XO)XM(,51(AJH;@#/E#M;3?>DIQMUMP5=QV9^H]
M>-V-/M+P[C>0]1Z(P\!/N76B7^ S(8%I$ZU6ZL:J;AM^B@45>C=C?@0705\=
MMF[3A6L!4&DN#RT^1<9_[^OTLT6XJQ%&A\>UV:H7=ZL1Z%7:A01L\0_9TK3S
MQ@+S,Q!/4I(\T#/"1)A!QQ%[/WVK8^3S!,N22!CXN=W2.+\NX6##2UW5F=P!
MH7IG\.TG?M*9#6<C+-XE?I)C\O.7EOO6O__R(_?)"UBG61&8[A.\)IN)XT^*
M#1 ^\YC3\?LYWZON,#7]@K\XVYY^8Q7$U[!7'G"!#K@JO28[;WYPNTGLFJSV
MFNR:S.6:[/AG6P^E:[*3P&NRV!^?FB>;R>)?7(\V_?X+D]V$JQ;29KBF FU6
M/<ZOA;<$Z&>^.FVSK'4S2(64*!J5<96I@V0<A9P?F39<&4G6'A/P=H AH\!G
MNK3* 2CKO/GV,3VB<DPH,S-_K];"_(*G531]O5@YW8<E+_[7<X<^$G3J&5+2
ME=QH3\^2]M!HH18F6G&+:/*G;5)77YA4+Y(\-T_B1S); P7.6T:OR0C"5-%3
M5P_:_%OM9_MIS6FR3H6W2TQI<M#HG/P&.P+0K+8V_2>T-G+/U.?=@F@\]]3[
MJ2H>&XWV^7;TEPUTHJDVC^''D2"NKCR8360/4 G?QZ4T*=GM5 QH,]$*]@FO
MM,0%FD" G&RX0(?'I9\J:\J?):UO!7(5[ CE/_$QBC/AU\D=)' R:<\[44,+
M8)YB(0"90&X*ZJ3_R,@OC^TDGBAMG;L+46+P0*66Q@BS'C6'^E532P9DO7?N
MP=,DYM((GE,79@4WB?.=K(2"]YCJ2FKJ0B6OK6)=1&3<](1U#68X'0#N:0YN
M-=)T@7-R,KJ&NR $H?,18%YW5JH/\&G95#U]4&%40X\B#8U$!7PH+AR92U3G
MR\5/JC()(K^5+\J6W7YX3<8^(W&Y=$38?]7AOW=T3;;>W;)8)1LDQ5)J)/9-
M,:G5WI_BB\']U"$)8I=8I7O>R-GT9H4"8GGJ]JVV%R=\D[\1:&[6 1?[K=*"
MRIPED(_PV2\+_1HD8XI8@4/>H3*:T5X!*&^BY5S^:+YQ8,1]?N8!V'S[S6CZ
M/P8*X[O*I)(X71.U[>2&AWYX*4X]B99^OO43_6*( (6'Y=Z,]9L0H=]^.@"1
MFGXGZ0I:I3ZY^]GUPA,O^$H'1!*#8K0?GQ*-6-6YZT;,K7H=TPQ%=Y.FXF#O
M(FL_?+%))CG$39T?<M;DPXUO,TL .2&^ A16K;<97NT9%+SV9&T-2%P>+Z3R
M7DG\M@.WQ'W2HR8RZ:VVB(SPT 6VT(2]NR;[)SACLIX_Q/W;BL4?#?7TYF.%
M3\Z>=RU4R-[Z'R#^'<._01A@?9_]2K4>?=ZQJ;'P^^7\YC798')HNU/ '5G+
M"N>U"('PKQ?T_[#C-W\WX[^L6/#RO7C2=_[]T5W.0MF(7TY"BZ_)U&U9GM9<
M_'H9WM^4S=O(([]G=?XK2N# =+%X1L,H@/;V+I7Y55JWC*3KZ<MS&FR @J&O
M7NA<^_&_%LR7ZMK-ZS,JKGBI9IB;+D$??-U7]P*/>92NWI6=%E)]BMEZ\[FI
MPR.ZR4L:?F' 4B\=<.;ZXG2[;_[VEE[4);7-OA%+H'0#%=UI?_C4B+5GT]-O
MMF+O![IMFU/.0F&O1$Z PHOYC5(;79"SXUF+E;[6^Q4+.O'[K,]6ZT89!ZXF
MW#W&6[<10.W(>=A&_;QXPWZ"C58;^!L^Q6YF%@PWEMBKK>CB ^CBA[#BQOV1
MV2.K#$IW\;6,GLG=B)7?R>CS)?HEY.TGVAK&4YQU'56_Z&X/M=3T5JZP)AE]
MSK-5+6<HB+(*N"_?TR[?U[AA*-=QHXHVFW\YMT\:LY&N$?L54Z3Z8=IP(*%Z
MBLM$%T?'$>>"(H@3.+(3^:S>JC(]?/$])..+,*)S$5A:54NDWR/J8M5S$K21
MBA 44IEVAGX^PAF72?./W;BE^K?M>#;W_\Y^R*1$1-?[M<XJI-DIPNO=594@
M3HJTI<T(%L<!TX?V[HWD"-;G>_PA4OI&+7JSBLTG(O6%= WJ*Q6CZ8#R46>\
MVW1.];;+.0+JUAS,U91UPY9V$HG_.J@B#Q4-(DTB<5S(BE_K-(.>2=]Y%_'[
MNX9 4V1'#7AA%IP*9G\[%GL9,W_Y7PQWVUK*<M',V,,F;MG7NW]<1MD5X%HD
M</ 4^L;4=*+'-0O$WSG2V3 ZBS8EKVDW@<4L"Y9/./C9)4W*=;:(-60II<P'
M2WCHSM_!]=.W94?JOV&+\E\%KSM,'-;6=_%Q#^?N)ZPZ*\'B-Q-PMR;W2-[.
M_\!&6O8O<*A"_T)':.51\1Z?@YKG2DTSBND79E#,V-/[CZ(&+2O:96":8<+1
M16&)](=I'%_5)9=/N.+BA&6"@!=]HCVN^9G^=G1 I\U7V':CG(V^8*L@3_PR
M+ZW S6AR6ML"H:DZ[JQ=DZ*9]$I>DVJ G,ABQ,SIJ[C6N5)/RSV9:JL^^S]!
ML;@L;>^A;ICC*'=;;["IM*@82([\D?_<:1<B?'RF9#=MR+\@6:QHR)",^[+S
M#"R\H:2\(,H4JK>1SJ=/&O2*Z@E*;3VFR8/!SG!WV=GGXN ?U!:AZ]OR&F5]
MCO9FBHZFE5PZ#ALFV5.^<+QRB,V:S7K8AR_>B.HE@\^C0SCQJR=EI/0;+CO?
M&?"(9?1V+$M)RKO,K*TU^6*;Z3709-)+;<-V9YI^HYD1[*'M6EY,3RH(=^)Q
MI3T+[EGV2\B$<I\\,+/VT;^YHDA_)M"RO9[Y= $]#2^Q^S5I"H5#=L]3I'A3
M>]GFP@Q=JY;W7(LW(NO/)USQJ/FH[3N-E7!E%N:QRF\4CI)5+D5"K1,C26^F
MAEO6P++9=I=^:ZOKN$)K0?Z(L#'*SWA*[D-1RD2K"GHON$S#[LB6 X]*Z-!E
M+M=23'P5X;>A0_]]J;7>C^O3=D?KK9?9(LB4?<A,.N![O<$I-(9O*8;[@ B8
M7!JR'9W$Z=7ZBX^DJWS_8#'')D#=7#(= '["\/L^K]W=MGGTB50 =59>V_IS
M]'/6$T2>;;)%8XZ"N6#9\8,EPQ";#RNC0@T]3MPF(XEG&#ON>'\0M$86F,[=
MV=S.5Z67C&9T_X:M?3Q/_](3^SCN, ;/S#I"1G9+M,]MY.-$T8AL!5"=-$XU
M4 7(LRN?>D+?_92(<'E?4Z@'>M_ZWI%]$8Y%\S&";8-2:H^3U'IU<X_NRS.T
MLS95E^F^=M7A&<[&+\:0)]EQ[5M$M#"];IVO;UT!,8/3Q%5%R[/<UA>R-V$$
M[5 FP?G%R)(?8OIDSV!'\.0?_,$0\!>!A C_Q2"9^B&HPY>;$176$X<J" HJ
M5H3(.Z0UO6UEBZ /:4$5_%Q'QZB_V>( .?"<\X&Z>V[$YTA/83[3O,-4.YO4
M%0\/'6/H8*&K48&@<2;%*M="+3-]4>"D%;YB11^U6U\N0*K*BS=QRX41I)B/
M6N\0 M<-MH5.1R/_<]A'QLR[]J)@7K6P+(RVN;:9]YWPG'KT4+6VA:K]&.:A
MB7Z'"IJ@B7O6-A(/B;-54E*2=<L;RH(!<SN:7R.T$HS5^:2TH4BH-+&0F!F>
M,*_W$*?'K14'QY="I:-$CD5&VC(.S?^G;$\&_$VV&6?_(@*6\5_" N)VG_H?
M> ^>EOQ=W*G^TG;;*3O:MA=YW%OFE.U<I;RV6;A2[>A%(,TW$5U'B;.<ZAZT
MHC92V>(>R@$%AE?$$B%:I\D?1IR=BUUYB+.V0 +*#-N&YE;73DL!6P%^\.1<
MW,3,Y]C,BHJ*DJHH7!27%HXR-E@\5XZ'Z76D99RQL0_ML4__LO2M9SWBYUFB
MBA-EIF$YZ/L^L46\GJI-/< BAH3IO,=R0A'4>E7O,WTG'&K,C&U7$=Z9<OQ8
MBRZT4WY'8<-R_(J'>X*VR];:U B.PNRDY6Z;>&-2"&_S++Q!,D7_9,3. NFJ
M?Z-ZXRL.9L#7%8YROOFU=,PW\Q_6P_PC0?AO\PF-^-\)T/\M9/^_&#79)9NW
MWN?3T0ATT&UK^,40;B@$#$9B_--&7Q-&^X(.K%O2;UDCEJH'>\03J@<+<Q,P
MU  .)06K56.SS=1P6):Y1%,ZB,"@I._Q,!++'A@9G_OGC5YC?3B^ISGV0U$(
MD&X:YRT<@])$. J^D(*@QV<,C0QU7P"%K<C^MGXQ/*&BJ$YOFHD5=MD?U'#D
M@4O[3D5?D_WRT95WK1C/4;;6764[SM()[>)O("\N"=DDU,04NZ7I2H/23">T
MHS?<-H=TZB>@M<X]@4"377G[;65.J4->4DWJ+*@_%'[R&:.XHM+/F_K58?#V
M<[\.P6\T)/[#3F"U9^_$I. 8,/E(V(D&UTUZ(O ^;A ,]@V2P"1Y1WL8MLIY
M5?#@CKN,]2Y&&5_$[Y-F@U:K3&= &JZ<7,L#V;,%U=6JO1A#]A6VF.3B4W\_
M88O&)&O$U,%X&2QRT0"Y]9WT6*DH!\-=9&(G05=2*ZX\.&'KSSJIWY ID:<<
M0C<$:*R>T&P_UXP[NQV7Z7ZE*V?0.5!Q<7^%Q#*>8-XO:FQR!CY[C6@?PT3L
ML^BIQS.H& O8E18=Y\5M^G-Y5-FK56N@6'I9M_=D'ZY9RZOV@BY[I8[OTTV\
MW1!,/'K9/&JG?VJO-88TM..H,4\ JP^R5\4;U]GPQ'A@Y ,$+UR9/V]8?+4<
M$AD;IO'QU[EGXE]$"52C;3K6W'1X/\G'>?GXUW<N$75==>=AIK.ZZ8CR2<!0
M @$D4P40G4WIC4(Z(.V41$<2%B%I'DK46N'[2@#V%=:I&,&3?V_HBZ>9CT_K
M/&PL7%W;IF\[HYPE3-,K*S,R1N.W"K8(7W1J1F@?X4;Y1C.]A@O;,U (HQ$L
M++*[NVU4WLPA O&"1.IU)@X2:.C;Q#RH(ZUH@JSH\\*X<N+ ;'$&K";YV&^8
M/P9B,..]KDZPA,+<&@AT89EC/@*YC=QV=I!B^8?'RC3]+2S*_,MGA4790RW%
M;]Y@TK[1BJKGH2T *1M'6>J@/RS?].K]L!PT& A5'Q0<%\N1V-SYCDSRB3 :
M'H8(2SN_Z':EF-C1_X[S3@*NAM) RC&0N'F(X$+:9'PS0-'RF"UN+'(;$Y5H
MBGPBU1C)I14B]8)PIYFZM4:*]7%V*;+J[<2DLX/,>\^^/P97;H?)W'AB((S8
M?J905E 6QG$SRNVTNSM0AJ)-E]D$4,K&#JT=+/SS:#TG&:=@;2N_#BDTHK$R
M"_JW6RE6<G7\MT!L*R_@)-#$SBA[HAR8J)@S"'TUJ&$%=81OV?_^3X)"9OX%
M":7S_X[JA-1O$M%Z>;:],L4CWN?&I6Y+^D4,OY=TNU+9CJ^!C9Y)VLY(,X)D
M\.#1NS@)B,C#(?#ZE-_K\:* C-6!H,.NR8A1#9K;9I60WGL&EMD;$!/QN=(6
MBM<&.T(U[M#XI?TTEU2(:![^/B2*2QOFP"1>S?I'+!"]9?A>Z=>.?YL6"R#Y
ME:=,&S8V<HM7[''O?DU ;>E6U]/<3JZEBT&-\U;HI$"[^9MDWY6^W[M]#K9&
MA3MV,#M:KGHC%1XZ6)@;OEX[,#(IPW.W;*M)N,H]&7//XS&ND<:"\;V_>(_(
MQ8*4.Q56'Q_2\?ZBJPA@(1(W QM1W]Q,FS14MG"0P>.YT9<XQX?/OS] 06\>
ML*&G"/5V$B[VW.[C1XA24YIYI>4FILT!HJQ8!,O='F%^Y8-BD?ATWPP,2+:B
ML_!&O186]N!0_/4>/<-LZ.#@R_:+(0>_D!8_'?^MD:D>:'3X>K]T7V.5!)T&
MU;C$Z6GRJ=L$=F8TG5N*_WBZL>I'-)GUN/%-4>/V5+Y+J]&(&97OCV"2=!6&
M>9VI(*OFR"BO;;F?6/4\K3-,D56TS]W=]&GOK(6DJJO+LDO$VE'HXL$1?] +
MPTRO(G?;]VX;=BY8NGZEX$K.%?7'NAK;R1'WY5RP G%I0KG#<>OY1@V**VVZ
M)K)E*OYE RFND&'N& U$NFL^-Q/DX9%[0_-^MP1OIL"Z/E_>G?Z.Y:-]8-T4
M5@9O:VMK]7[5.TD+871U-B1V0C=,NVZB1S0L?D0$O*HGO^%63WC6(<0H<]+!
MNS;^:3>*41.?&?.6AV[>LYR3XEGB7X(@S:P<N>@5+-7MP]>>>Y!"3GN1?T\J
M&G]S6FJEZ=B5AW<2':I]%O'R_9'AS,SR*'5]UZ9ZL $R<KU7,\W\K19"M=LN
M8V-@Y#BHL!@N5PER#EH@T"U&QFOT*/VV1:4R"^U)YE"HCW\W44M^$ 7Q,F#U
MNE7HW& WK.HD4Y:N.4'1?78D=P<=2:B_#7(QX';W?KN"D*SS[UU=FVK.]W<
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M5"IT\]CEE-5\0J4?" <W%L#__])03T04 /[_ET>T[Z^,:-_?! !02P,$%
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M!Q8]6$M&0U=9VD#P-_T#A#Z&0"G[6@T?KT'N12L::QSA%A1-@J6TX'1'K\!
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M@]_WWWXL/KXKP!7]"/YF05CQ[D-!Q _AQ^+=Z^+C7U\5%[S4<P]U_\7'?)D
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M2&=,)($119^*6Z^:]>0\F?,UP@[0&6."""5YSW2?_EA=^J,5M2V//A=UY<$
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M['[8/=@MSC8-5INC(9>,0O%VO'NM6ER'R]T&8[[\B&QEVK98"JP.;2ZN/D*
M9G):J0TIN1C6SI][\5WX^9K)T6KCU=ETU]T73\J1V!RZ1#V&D)5R"%Y#1 Z[
M #ZYB]ZTE'O=#Z'*38AG__Q:CB)9(,(3ADGQ8IP]H5!\C%4%C[F'1]Y1+DG*
MI,)6H$@QR05_$FG.-%)>&VZ,U\3C5KGT GY\5WT<?UUDKN!@.@('_"ZVM)MT
MOFDL=U4DW<(<(X/W3'&D=$B(:V*1B3P@$8(QBJG<!JM5YC1AS+OJ?37^4HY\
MG^[9Y'3/9E@9F2PWS"4D+#6 7RDA30A&1..0* F$MFQEWH]!!X;_KSQN\J&+
MDW_&&&5]IJ=K\=T/9V*0UPB/*P#)\M@.BW@2_712?LE+AQ#[Q;K/A?2YD'N+
M%(!)D='DUDP!_)N7!M>T)NS1J_)W^TZ/* O!-#*=#Q7W3@G$A870A 2*A.(6
M&PK>%7YR,7?V<_<!:5LR$T\GI1%WU6^O?HP_WL-7?@2_\XFD/E*+G"$2<1K!
M%!J1D#5!<2VH)/K)_/YU#-#U_G \6D2IWV/IF7>,8*)$7^IS"52^%6O]J2XF
M<1B/,]^*4<.X00%6?3C-=J>PH, @%Q>@>?6C+Q[.M0TQ!F_'DV+_.#=RRI9P
M6X7W-83DL6J09]#$Y_"+/7-*[2C,/TK-)J(B[]$"B4ZY8FWT.8+_E0/[8FCK
M25$U>RCZ&K9%[0CFNX*Q]O;R\'E6O<.;H.^<\D-DXAX3OJ\./DGE#O(A9^6D
MA)MG9:&Q D4ZGE;U-->'3L8%W-$L]Q'Z@_LQAX9YO\>^G^QMT:;X-2UT9&97
MR5L*&6\K<B1Z%^O;KN_BVQ[-\2ZY3XFD?EC^YJI,W!1\-^P!:LL;LX/?@_(W
M3+X2FLL;4Q.Z<V;X)L'^6$Z&3?EWM/ZP\& EZ[L2&1?1CY&F4O\>Y,W)C1MI
M6_PA-7\PNYO*ES:47O?^L\^6Q8T%I(H>1^&G"W#72-NJH%>V"7 .3H_@OE[&
M5RWC/2+?%/.=[<=I #F>S**8 EPM>"Q\\LT?6VP91RLV]=J,]LU,ZL+R&D^1
MA4@)LB$W'R$Y"V:L0L3IY)2EDIDGEP><N=>GA+K&_CY<FF[;4 RBTC2$'A3@
M/Q9?[' :BW_?Q23OP2Z:KL"/7&+^+NRY/R;>*0*7RJEV;RNF,NN&<UT@6B?T
MBG 2",>(6F7SD4\1.<$)8L;K?, ,Q]H\5:_.;/S,Q+>G5+^][!6F4X[!.IH5
MICESAB)!0EZ0$0Z90"+RC$7EF?"1/WD[V]RLO#IS&II]V5<*FK)+\=A:IAM]
M%J#>W\?5/V>&IY@/X!'%' ]<]%WC;;*+SR;>F2Q;2B[QS2COPY_$PIT6_C""
M>, H_PG>;&PV#N6\X86MYS^0'XM#6Q>I',90V.'P+&>?$Y'_,RUS&G(R+EP\
MNP&>>9Z)9'E[SJQ!SUD^\D(:<RZ2.4>9+^<&/46 JQ 2YEMAPCXV 2*A1=/T
MK2Y^@.>!]A3U%/SN^G"<][_/&]E,#NWD^[%_M9='F8<X^_+9''X<-.L5/]#9
M'!WH(%QW_X 9Y/N;6^%+>11GS\DMH.IF$,T@\QJ&P46PI_7N8A:.O68^&H)1
M\#2?:<P <WA@2&L@C_=@JWE+/6)>3*L*9C=K:Y6M]L1.'MWZ[4D2^O=8+Z!.
MX&E+GD71--$2SXOB[7C^&U_%(LPZHDC6+E"LHW(R 56,0U"P:CS*'L3PM(C@
M39P6;S+^6]^4L+VT$SMKP/0=R'Q[QL6UCP]3N)-CD7'D0_P\G1T^4AR@C\4/
M&>K5<\KH[MD-D\.R:9YQG)MG+!IQ9N,]!Y)8_[@@F$B2:<EY0$$*4'FI$G+&
M$B1E%$PSGCQY<GW)?'?^.9\RF\Y0HX>)3L/$/Z;UI$RG:X 4H)RV&,),8F&]
M!Z3(*VZA49XJ6^MK/RV ]^B:"_41  R\HYK;--" (YC_Z2"[)O PL.>99I^+
MS]7XZ^1P?GD7/)78C"S$5(Z:CGE-O>U__$%3BI_?-+[F,GD^O^W.&VX>W_S&
M[)Z<W7S#6.=WEJ,9#A+J$)T[7!>]K-TEK@3?(&_]8O"=B\%$[W(A;EW1-?RV
M)5TA=@55M]Q *<3FMST!KE]8-.YHXYP5[)&YWVX0%9F0S"&<#S?DP6+D&!9(
M6NRQUBY1QMKKZ5B] !'\/*Y.KTDK-#<UL.//;FHSP_#K]1#8E<U2;679'NE?
MW]J(5RQ_X_@BR=&MK1EK)0[[-ZK/EA/FJMO<R;X5F]JEH9]_/_]^_AL\_[5R
MZCMJH]Y>EW/H#?B=!GQMR;$.V--1<3BX*=&U65TT[I4A@&"?&(PE2CAG"#SS
MR-'(D7(R8158TK&E?C<-U?\\K<M1K.O6#ZIYVF$SO4N_3K#2S[^??S__3L^_
M=^G72)[Z^??S[Z";_NKZ)>8M=-)3/FZ:88,\)A9QJ04R(1&D@^1.4,D3#NTX
MZ7.:_Z4A^8L9Q=? 65]68?#C2@D>?3+=M;4$H?PRVXJ;9?US1*-QB//OP+CR
MY3D!AO$$A;*:U<#FY?[IT>AY*.OCH3W=RU>_;V"!=T4Y&\Z9M<YJ<3;I^3N:
M+Z(X"L^!^7F"N6;A?!O>R6K*[!_*@?VJM,.' #&0]>SOS(/#ZAO<  MF3HQ-
M,+ ]._QJ3^NS@H6+W+@,3-_1&>]*!I^LA**/Z)30GD1_H^F22]Y76H66;JGW
MR@V7KBU2*]-UE:Q-_6H,Q6C<E)].ZUFM&$QT=@K[-<>LCJOF7</3_/*O);P:
M7EN,8-CCG!7[4M9-!GED1QZT)-=5Y"./\LWUQ(Z"K4)=Y*:W9;BI[P?[P?YX
M;=E77X7XR"K$^C .AW,1*7X QC?5@+,C^&ZOM?MQM_@[#.N,[K-2T,5L#PB8
M4LL-8M)RQ*F2@(DV(4JL$"XID7A+?LI!IL9U[LFL6@[&/:P?VV;P29S]OJ;F
M?@WF-KY _]VHV)]^!HTKZ*"@F/+!52@+Q7@Z:0 F(\W3!/0)3NB99+]NRLH!
MR\Y.3M4A8?#"D<;8(6Y(1#IAB;R(0C L R7D>]&6F,#;K4916X-X<AI9@Q-*
MQ%#F,#COFE^S\Z79I-ULE3O(V['K=]^HLE-,1^7L\;]_:C9KUSN  [X\ GG_
M>0=?5H71] B%\02=W;#SBQ8#+>'_G,P%<S[+%1:ISZ:1<>M^V]-W5S?4F]1W
M:5W@Z"[-_2W"> K!3I>:76VL>]H'7!L:<)$^VEJRQ#SQU._'TN!^9WYO 8QM
M#<??O'WYZK^WB;/KNKL([RI^R]8??=M%L4OOM2VHH?3CUAMA IG,/^_0G?5<
M7.CR.3K?$&.15&G>W@8L-<^$0.KLK->]*03KU; <Q9OMCOT<'[@TOLVRVF:3
MO/?['SX6;PI4O'[S=O_MBS?[OQ9OWKY^]^&W_8]OWKW=!A%?8!E'MVHW-@\_
MMYX 6ZU=3[<$:R-HMCBL<B;S#^<K39^:XQ2;KD8W6X>4;FE)^B +_0;>59!O
M,:!=9[5=.35?GZ\7'IR_MQW2=A\0GK#<P'J[VPVSL_4$Z+Z:]79W(P1MU00X
M-Y7.#L%DQ4_U88RW- UKST:^&(^:WO3-%LT_S]Y>'.2WUX5MUD#_<SJ*!<.S
M1?*FX=++Z&,^AZU@I/F4%3_\/K+3  ,*/_8&MC>PO=JO"0&ZKV:]@=T(05LU
M <X-[+<(]%,Y\N.C6TKR%F1DO\6BV;J^:0;1F-5</%C%PSBJ<X_7LPOS5LH?
M8?RSVP[RNO$XMU^]H^SHIO'?74QT9KK7C3&W=!U])*D>SNI7<,=%.B[\A>%\
M;JN5\:MN8N\9/M@SY+UGV-NK3A"@^VK6>X8;(6BK)L!U5C-WJ)^<KM@S?-4,
MXE8'L,C>1KC1;;NXAT/MTA9KP#M'Q][[:,'[$+WWT6-B)PC0?37KO8^-$+15
M$^ ZJ^EM??@I#<=?EU(D<8L'\@(&4KS. SGW0M;']U@N%7O_HP7_0_;^1X^*
MG2! ]]6L]S\V0M!638!SRSD:3V+]:565FF_SVW.[EDO>R'7UF[U)?9"<JMZD
M]HK>"0)T7\UZD]JJ13D*=FE;)NBF;9E8$O%^LR/[N3&L^9A,HI[7Q<NR]M.Z
MSGV&<AB[/[+#T[IL\@'?[#&8Z3!KX);O^1#KZ7"6,GAW'&<O[S=:W(TAI"\$
M[8AQVGH"=%_/>NO<JH&!^1Q]8DLST&S3#/3RZ/>WW,JTA  X5X5F<PL?#.>_
M9VL]'-?3W*]NWXVGD^(W6_TS3HH/9?W/W@3?"124]":X&Q9HZPG0?3WK37#[
M)H0OS03SC33!2Z$?A+N3:CRL&_/[OAK[&++%[>UK;U_7QKQL/0&ZKV>=MJ]K
MV<[MW%8<VVKRJ2P?;BS::+NWGWN_Y>9O[S[^]=6':QN_;;@%Z9N_K2UL;CT!
MMEJ[MC8N(TN+RS:NW=ORZ/=K_&R'LX LYGGW$=D](C+:6]9N&):M)T#W]:RW
MK NP#,LK"R+[FVE;ET+!O()8O+9^,JYZN]K;U?4Q*UM/@.[K66]7V[<*M*^V
M[3[]?A_-#AB-5=YM:X?Q8JN/@^BG53DIXVRA\?<ZYHMGX6UO@WL;O#XF:.L)
MT'T]ZVUP^S9$+,T&BXVTP4NAW[OF1/LWH]G!U/"=WK+VEG5M#,O6$Z#[>M9;
MUE8M0SPY+%TY^92["9TLS<#*33.P2R?CJ]D+^\#U'N:UWPG:$>NR]03HOIYU
MVKRN=YEL#9_:2=[;L))*V8,W?WF[__'W#Z\.>IMQM\VX];  ^->Z86Q^[ 1N
M???N6U]W7UW.DPOEE\(/;5UG@?@<T6@<XOP[,*Y\>3[[83Q!H:RB;\012#\]
M&CT/97T\M*=[^>JYI,QGNBO*V7#FP "__F-:3\IT.G]'\T441^&Y&Y_D"<+W
M0? JD'5XS,FBI>J;[#Y0K+Z-Q3R2'9=3 D#HL[\S5PZK;UH*3)D!J$TPU#T[
M_&I/Z^<[S\[9=ZT^?T=YO,O@@Y60>*4B_HVDRY"BH@SP_ <U@;M5OBZ:@Q:H
M\_Z.8WR6.9;8H;&$TDZJW)DWAFS]BK]4X^GQ(!\AM?L=6BY-B.YYD.4RJ72Q
MMV"'F/?=J9LK8%B;9'BL,?FA'!63P_&TMJ-0#XIXXN/QI*@/;14+X)C]<5OI
M<DV[R\53X!$F[[$3O-:I:WS7^8O/QIG'M&>GD_'S,].?AY(] 1AYOAV!%S>>
M@C]6GD2(TYI7$0S>_A_G7P .#NUQ'??J>&PA*(ES$LP"@^;9.]^'A%_*NG3E
ML)R<[LV_?TUF9?8ZJ7:I5G\\\VVNN8'L<GG;Y=NNT5UM;GWVRM][2T2=I<-9
M_\_/8)E& 9WI4FK^/"V1_5W(=U2&,(PWN(1FO9(UFSBU:_(CUP?MY_[]/!++
MYB";[V(.P=>,>H&$:<\HW.L,@0?*QMU$F^D:9IT@V^*5Y8P@FS;97GUNI-R5
M4^E[%7I:%OQZF^V! LDOPF9W@:IM"N3^P<&KCP>]D=_8:6[KU+J@J+VX]N*Z
MNJ"SF=K9Z69-TN5NHE[,8C1?N?@,_'PY-'_"<N.+:57!3X6MZSBI][9,RGJ<
MZ*?6[:GUPKG&4VLW"KO=7M&FN.FZ<3_,B-%U-&+Y1-.\MS*?#EKDX\F_V&%>
MW[Y+WAY)K[42PIOF.QIW:K:7V7_3-/^]18YVHU3L,G6?H 0_E2? T]'KRC:%
M4,UR_>M/GD8=A8F(2>L0=X8B%R5&*G&>N%7.8;53-$\YF7S(U8(O/C&E!=,!
M(Z<B03SZ@&S"\*OCE"?LB.+PG9$]@N%/:_39VN.]K(+[HY#_>?5-__8G+VQ5
MG9:CS_]EA].X4TQ'Y>PMOW_Z_> EF#3@"CR%[10A^O+(#NN?=Q#\-MO$]?-.
M>3+9&TV/4!@W-8?YCIU?B!EP3']Z=GG"OZRQ\+>GU2W)?%N3762E[YKPM@>V
MA0";T]+0H S") 4 MAB0(2HB:[D7-%(IJ/L>V# )7 JBD%0A(:X->%F,!Q2Q
M5C[)8(--JP0VQ094Z.T&MG83/[W/?&-1_N&XFB  AZ.B''V)]>2H=Y@W7+5Z
M<W*+.>'2XF0]DBYRQ)/02',6D60L$4P<%8&TX2?O?['E,->UO1Y7N5'0M^9
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M')MZR_$W @P*^,9QA"%^B</3/L[?X$BHC_-OPU=%.4D4>1,9XA(B?JV,!0]
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MG.?C^2M<K5O?CDF8Y\EB_1*7D[_.WDN$DE48L,Z<M54X:X_9*:LX,EE=9&M
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MY:GWMCWR']^(;VZ_S+MBM*\+_RA%#V!SZ6II"0]2J..Z6EK" Q3JN*Z6EO
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MDW.H[%6^>II2(%-1U??[>('A$3EZQQ$,4Z[5D&!*E2Y$5:+JO5/5B52#9]V
M*D,EI/"5JL6!#UIQQ[76>6>>C??>"N<12HZN>K0&JY\::M0>K7-1%5<C^O.@
M*E=ZJN2@G%3B*G%U&%P],/E0JR@1%=B2:ER.HD -JPT@Y\7KPCS:G2/SQ;'
M)=<0-AONW$7P+BDH29N8A0CH]7V3[S/#Z<V4^T$!CX[&'V6S_0FN)[/%:D6&
M8\":06V12-2DLZ,0).GL:$1-.CL009+.CD;4I+,#$23I[&A$33H[$$&>1O[S
MK/>5/)JDL^6 KF5*%0L0C4(HG#D43DC#TLZ^4G;9^NA :)=!>6O!H9<0G!3.
M,*5%41]F5Y_@^O$\+2[PY\5JU?OVD)93)O20LJ6T/414)"K>%Q659\DS[4 S
M(]OY'%'AEAG$H+AF2=NBRNZ>4PQ<)0:"M1WZ$!&<UP$L,PY9-H[GG=UVHB*=
MW#SES:3?YO629_4+YDG;&>WF+R8O0C>?-$69O\+K#N/3R1S7DT69K,-K,DAG
MHTPG9Y HM#Y[49/.#D20I+.C$37I[$ $23H[&E&3S@Y$D*>1K#EP.B6(H'UD
M"51L)QB2<^"X39"Y5LQYCE;O))FU5T%@L& T,E#",W R*W 1;6NU)7).'Z93
MGJY?XK(-LUKB2YRONE>XS:Z\"V/_L8UB?ZI!;$NY/)W_BNEJV:T[7#U<=JOZ
MT/M]MI[@^FEY'E[W5-0K&#44(-B-6)#DH(Q&U*2S Q'D*!P48U)*00L0NHWE
MM,:"5]$ 6NN]K-Y)\+&/_1YR4$Y;1^C$T1XJ]>B] 9R3;M-KL"['C,L)7ES.
M%F\0KQ^[Z64[N9R%.=F: >L1V9I;@N&<LTX<049K:V"+ 2*KL;'!D%U@MI2\
MTQ_%F1A52 DPV1I YZC!RVIU@K4U>$ZYFBCVT?.LV]:?NS,P?[C6S,V3GEWK
MY;.JECU.Q^32C]N:$,[&+<A1X"PA1YY#!A2ENL%1(?@B+3#+>12:1<O- 7&V
M:87_29KUY1<3QXACXQ7D*#A6G(LE>@<N8&O)C@5"C!QR\8;S^J@L.VU&I,Y%
M86!@D]"@C C@)'(HA3/KBV.^M;H['8[Q*5<'G/8Q8!4@E@U$D+0%,1I1D\X.
M1)"DLZ,1->GL0 0YBI@A\UB,S0J"L]7_C\*#SYF!\5Q(8TRL?_2Q;7C?,</(
M\[AT=&P/C6G+=3/U;U$FK3'FLDMKS-N=0#(8 ]86,AB?-A@R8(F.>8A.M8[<
MD4.PN8!/A4<LW%KG#[[WM_GY?9LIVRI1<+X*[1O^M/SP"/+7;?Y-C1QY,0D1
M;=R"' 71LO>:2UE AN2K"^P">.^K=ZNCDT;;G(H]]/;?78'V%4[PR#MQ$\K&
M+<C30-E9MY0Q(8I<_3^P1D909C.<@'OPFA5>#"*W.R-4^]Y?[ 64=VP^,RAB
M4C<N0B=M7I"H26='(4C2V=&(FG1V(((DG3T_4=-QNST6RH^+9<%N?;6LGT][
M:^-2&$K?W%?Z1BLN=.(.O-.M/+QH"$)%0)D"M[J8PN7!=^Y^>:OKFZ<]_",L
M\S4.,'_1WMT=AYD/ZN +)7$(H.1<DJA)9T<A2-+9T8B:='8@@B2='8VH26<'
M(DC2V=&(FG1V(((DG3T_4=,II#T6RB9/"K&5O$W2>S5O$WS=?D>"XX UAN!(
MHB:='84@26='(VK2V8$(\C2J$@Y<-R"8XM%B &ZT;6WE$*(3"G)V$KTT7*B=
MSO+['/MXF/]U=3V.]?GB8<Y=^PYA]BQT^?'\4;CLUF&V*2*('Q[_^ 5_O^I6
M]4)_Q>6K+N&VX. 73(L7\\V[;(Z.]-9-PNM!%140]@A[Y*J0J$_DTDAG26=)
M9TEG29#C""^"5]$::< %V8:)* 5!9P9:9X>\*"UE[J,#'847YZ(M=*9F#^7Z
M!6]F4VVVB=Z.LR*[LJ>FQ+IX</GVJS[0E^O):C'K\N1&/N>@2WN*^O,7?QJV
MZ:P/Y)0@O4S<0_2Z@-(*(5@10.:0C!=&1-M?XZGW^+![*J>_IGD'-%VWK,FM
M 6#RWI%-1W((PR>)X;&$]:<)"0K]B0VGRP9RT3[IHK'B=/', E.1@Y(L0G0H
M@"492TD^YMWDQ-XM[S[AHO6:7>#DGY%_1@P^.0:3?T;^&;%A2*(F-A ;B W$
M!HK=[BEV0^-"%MJ#+;S&;EXK<$S44,Z%F)2I,9D*O8TVH]CMM&(W.FJXAQY]
M'V:;>6=A/?FOJSE.))M.!!.*C%PO:B4>B*97>7$59S@^,_?QRS\-0W=@4^2C
M5:(8"6A3,RM6@HO90.1&&"DY<VDGC1@$0X:8H*0BJOGB!4)6''Q0PA4NL;YR
MQQ1MMFZWO1?[V]-U>FJU/);Q^6"9D.=/4#P=7^,O1,?^Z6A-"KXH"5ZR!(H9
M!3X7!.D%L]'RXHONA8[-47^YF-6[OOKA]ZMN_>;Q/,VN<O/6%\OVA1ZNU\LN
M7JU#E<'SQ9/%O'WH<C&;U:<\;K<?5^N>O'FG'1&5B$I$):(>H-4W8]9&P2#H
M9$!)R<"KDB )%#Y4IS.5G2.[NL+6:XN@@U.@LC?@#4_ M$)MI>;5ASUIHO(I
M8V;*.'&5N$I<'2=7SSIA+16O< X<JL.;JT_K$"*7 J*.417TP3G\D-I<<+32
M"0@A%%!1M0(E72 %*UA]-R6UNV]JWW'<YM1K-3YT4WT2,9P8/AB&<ZN5U\5!
MQ%1Y[)R'X(H"AP59Y+PHN3,CV2OKT(0$F1D+RF)N(WH"9!FL3C'*^D_GP7#A
MW529H^U3$L6)XD3QTZ3XH3F+13-, FPV 532"9R1%D1)%H.O;K$S.X7YUFGI
M,H-HD8/"E"$45O^,2JA2Z6R5O6_.WHI7R\PX\7K?/00^NF!WBT+.I?YC\VE_
M;.]&K&M[^Y9UF2V6FX87W];[@LNZ@/&36BF8D)];=D,T7/7NMD?^XQOQS>V7
M>1+%O0<PV72UM(0'*=1Q72TMX0$*=5Q72TMX@$(=U]72$AZ@4,=UM;2$!RC4
M(5TMG03ZRI- 87X5EF\F?',6Z+-)']K".)FKI3[%?>XXY!(0L\^@F#*@BM<0
M(RN@LC'9HU?&[W1KS-JHK(*'X$5]C;81'(L<&"_!2!XXJG*D,SQBZI4==U]A
MPM1)"O+XNZBCX)7303(F!8B@-2BI0RM"21"UMMG8R*3GO?#JE'9(G?#$.&+<
MR0F2&'>8V1$1O4Z204$C08G,P$G#(?!LA$4?HRD[+3Y\QAQ<]>.L:J<-60)7
M1(3$5,P!@Y0JGS3CO)-3PPY8!4*<(\X1Y\93LRQM\AR9!IE$FT,@2^M.(5N%
MG&8RBAS3SKF3"DKM65$@[*;)+6<0G<D043C%M=*BI/NFZ-UJEN742CTDF%(M
M,E&5J'KO5 U"H^!!@ N\G01A# *+ B3WBDO+2\[B0ZJJG$L-O0.4+$2+V24X
MEWBE:D''D](YA?.@JO-39@[8,^A4E9"P.C2)#@^KAW8GF=0L)P,ZA$T['PO!
MU/"<ZXP!8Y$:=X)RYFT1)C!(UB*HXA3$]AKILI'-.>5H[AM\G^$=GQI)@QMI
M<..7*M$37$^ZNC(OD$S'@'6#QG:3J$EG1R%(TMG1B)IT=B""))T=C:A)9P<B
M2-+9T8B:='8@@AQ%!M1*F:17 8I(K?22<XA!%."J,&ED=,SM9$ Y,B^+*9"C
M5:"$0/ Z)$@ZLJ#1&KW;R/$)KA]O,D<_+U:KOKKHJJE@9MQY3(+4N 4Y"D@E
MKIG2T8*(6"%59( 8O6O[TZ$4J979[38K>512U2=YKCVHQ W$["*$J!,6C4Q;
M39 ZT<T6.M?XS7_^-J^7/*M?,$_:SF$W?S%Y$;KYI&G%_!6NUA?U>:OI9([K
MR:),UN$UV8<!ZQ %GB1JTME1"))T=C2B)IT=B"!)9T<C:M+9@0AR%+D3+8TR
M22I@*4=02B;PQ3FP+JN$G/L4=FK[,4>!K-386ZKZFF@LN.0\<.&89TZ;Z'<2
MO$_7+W'Y:'%1O^9+G*^Z5[A-I;P+8_^QC6)_JD%LRZ\\G?^*Z6K9K3M</5QV
MJ_K0^^/HG^#Z:7D>7O>4AC'L@ -[!JPC!+N!")(<E-&(FG1V(((<A8/B69;<
MA0C&VP1*J@ Q! [6AOJ'Y"A4ZF-SAQR4T]81.I&SATK5]7RQ:&^T2/\SZ3:-
M^":;B2@3O+B<+=X@7C]V>;5,+\,*)Y>S,"=;,V ](EMSRT%W(YW)@8'.HHVM
M506\L1Z**<QDZ?PFL/VSK=&%)<W::V2HK^%)@N.,@V=H4:>0(O_XL/%M7\SW
M3<:V7^8/UYJY>=*S:[U\5M5RU6,/S9%7'!#-QBU(BG9'(VK2V8$(<A0>2$;-
M,A,:9)$U<A75^?"9<TC9,</K(]G)G09F-0)VVO#Z&G2@$.MK@BX@C:[?RN6<
MM;RC!_)_PNP*/^F ]%7R.&5^4&W*B&7$,O(_2-0G<FFDLZ2SI+.DLR3(<<0,
MJD1$C!)LR0R4S1J<R0D\RNB1U_@A^3YVR"AF.*\-,#HE]<U_MN6Z&?^V*)/6
M(W'9I37F[:87&8P!:PL9C$\;#&.44((98"X54.@U!!X9>!D39N>-X^S@VUR;
MG]]7*Y%;T07.5Z%]PY^6'QZM_;I]+DO#18AG(Q;D*'C&M)&!90\\"P?*5%<X
M.JG :R8%3[G4P/> /-LXP'?%V5<,2R*2$<G&*\C3(-E9S_$PW!>1&O-",*!<
MLN"SXL!9=0$ENF#5CM_7]^9B+YR\V^".00&39G80.6GC@D1-.CL*09+.CD;4
MI+,#$23I[/F)FDZ5[;%0?EPL"W;KJV7]?-I7&Y?"4/;FOK(W7ODH,&GP!CDH
MCP:"\AQLB$%FSTPIAS^<]LM;7=\\[>$?89FO<8#YB_;M[I;#$6)0&WB4Q2&"
M$D'OBZ!*QV*SE. K#D$Y%!"=1K"J<)6D$#KO##/H>Y_P%H!>;7C9;PY\4&-<
MB9Y$S[.FYX'Y9DMHK7$*R"Q2995KA<#)@-/:)R\9]_'@AP=[X]MXL$:91J(9
M91I)U"=R::2SI+.DLZ2S)$C2V3,4-1V3VV.A;&(UB*TLL\:'[^HR)_BZ_8X$
MQP%K#,&11$TZ.PI!DLZ.1M2DLP,1Y"BV+C 'X[5BD-!I4.TWGWV"J(1U*DII
M8B]'DQ[F?UU=C\9]OGB8<]>^0Y@]"UU^/'\4+KMUF&TJ7>*'1Y1^P=^ONE6]
MT%]Q^:I+N-WS^ 73XL5\\RZ;[8^>]C?DE+%!'5\B[!'VR%4A49_(I9'.DLZ2
MSI+.DB#'$5XXI8(S7D"(EH-*)4'0W$+Q@6GKN"BIER%B%%Z<B[;0P:\]E.L7
MO)D3MMDF>CM:C.S*GIH2Z^+!Y=NO^D!?KB>KQ:S+DQOYG(,N[2GJSU_\:=BF
M\S[SX)GDFCE(5C-0,4L(DGLHV8K(O'0A]'?FX3T^[!X=ZZ^KHSJ@[;IE46XM
M )/WSFPZ^4 </DD.CR6N/TU(4.Q/;#A=-I"/]DD?33HAHY$62N*B^FAMZ!LW
M C!DX8,H,KF=D_U[G]OZA(_69WK!V@..:CA-]I*#1A ^ PB3@T8.&K%A2*(F
M-A ;B W$!@K>[BEX8X+KY+T'=*H&;Z6&9(&Y -XSKIB6(>XFV/>>OD?!VXD%
M;W3:< ]%^C[,-C/YPGKRSU"7\T3RZ40P(<G,#;CB@NJ3/FU$2BX^,B9!9E,-
M@A8*7 P9-)9@2A#*9/6A$8G.&LY"M3G2UM?$X,';:,&C,LQD5PU)VC$BFVW7
M;>NF'J?LR:F1:MSU1(2IDQ3DW4S[7XA77]B+&(-ELE17UV<$A:Q4WY57?U;S
MG'+VS.>=>LJ]>-6<WI>+674:5S_\?M6MWSR>I]E5;I[O8MF^T,/U>MG%JW6(
M,WR^>+*8MP]=+F:S^I3'[?;C:MV39^RD(<81XTY.D,2XP_AD2I:BBP;#(@>E
MO 2O=/VS%'3"2ZG]#N.TLQJ5KM%>=I5QWF7P3 ;0.GJT5OKD/UXY=RJ,\\Y,
M?0O$B'/$N1,3Y%@Y=];I412%:9,%2(RY4K0&M<X[#LYFK;.5+%C_(45]?8G7
M,@(OS((RSE3RB@0V\FR]DEG8<M\4O5O[=3GED@98$%7/7J)$U9.BJG"%&YDB
M*&$2*(8U$H_"0]2!1UZ,X5%\2-44N.4E"1!*UB"<5=\T:J.JJRK0:B-CL/P\
MJ&K5U&E+6"6LGKM$AX?5 X//1JF8M B!.]=VS@,XE61U$C-SEG.)%G=*I:67
M+&4#4OD *A@+#E4-Z;5U!7V-\EMY]2D'Y<Q/K1V4'TD'MH^RT_X$UY.NKLP+
MZN [9-V@=CTD:M+940B2='8THB:='8@@26=)U,<4-:GQ<&5+:CP:49,:4T'Y
MWAM$6)(4;7>GZGPKT'3@HF7@N<P!/=<?:?N%Q8?DT8,K+(+BON5)HP(N4A#,
M<.1J9]O]":X?;_)+/R]6O0WW=5/A:,(OA0PC%N0H(&4#"]QK QA;G4^V!IQ0
M#)QS0D@OG>$[0S]TT"6XD,$;6R&E5(10I :;LPTN%AO#3M\;@M2);,G0X<=O
M_O.W>;WD6?V">=+V%[OYB\FL+LM)TXKY*[SN'CV=S'$]693).KPF^S!@'3KG
M (5B4?+I2&=)9TG4]W]II+.DLZ2S9R]J4N,!IU/.^L@!,JM\Q  >10;E4X1H
ME0 G(L?,C?0A?YBLR3+::+4";[@&924'+[4#%Z(()>:H=I,U3]<O<=DF(RWQ
M)<Y7W2O<YF[>Q<W_V(;-/X5NWA(Z3^>_8KI:=NL.5P^7W:H^]'YOK">X?EJ>
MA]>]'^UR= *!>'M>0CXYWI+;=/:BIE!G(((D'^FK?:2D-69A'?"@VE"&=L22
MH0991)9*&&&*Z6-#BWRD<_.1Z/32'DKVZ+T1DY-NT[2P+M",RPE>7,X6;Q"O
M'[MIBCNYG(4YV;:S4:B1V;:#EU,D);W/$)2L$;INS:<R,E AN:*S8,;O-!%5
M-K$LL(!V*H!*&B&@-!"-3#P9IF/Z>%.^;0_1W2F//UQKYN9)SZ[U\EE5RQ[G
M/W)!C?@(9R,6Y"AP9HK3V20.!@N"*LR B\F!1LDJZ8J2J ^(LTU/_4_2K*<J
MLI&?Z2>.C5N0H^!8+MHSJZLSIGVISI@JX%C2(+3/1:$/QNUTP,-H,CJ>P"=9
M'3B7*ON<<L""4I['F&7Z> >\^^+85'MJ&DHL&[$@:<N#1$T[ER1;4N-S$369
MWH$(<A1AA(V1<>X4J)0%*,41/,\,LHPR:L^EEZ&/O<7[#B-&/D>*SM3MH3%M
MN6XF"B[*I/7=7'9IC7F[.4@&8\#:0@;CEOPY!M3>2W#):5!!"_"1%4!MA/ :
M$U<[>:?>MP,W/[]O\VI;N0K.5Z%]PY^6'Q[$_JK]0$H]$<[&+,A1X$PKJ454
M#BS/'A3Z!#%Z"]XKQ%A)%7;]W[ZW ^]*,]H0))(1R<Z69&==@UR\-,E;#5YH
M!4KX"+Z-T?):&I:ERD[O--7I>[NQ%T[>K<1X4,"D,3!$3MJW(%&?@:A)C8<K
M6U)C"EI(9TEG!RQJ.H^WQT+Y<;$LV*VOEO7S::=M7 I#"9W[2N@$$[7(/($3
M3(.*Q8+/0@+#PG4RGB>V,_*R]WV\7][J^N9I#_\(RWR- \Q?M)-WQ[0.Y74(
MH"<LT9,#*#F79R]JTMF!"))T=C2B)IT=B"!)9TG4M']"LB4U/A=1D^D=B"!)
M9\]/U'1,:8^%LDF=0FQU<9/T7F'<!%^WWY'@.&"-(3B2J$EG1R%(TMG1B)IT
M=B""/(U"A4.7$G"-.7H&C <)BGD%'E6 Z$LR7F&)V?9Q-N1A_M?5]2#;YXN'
M.7?M.X39L]#EQ_-'X;);A]FFKB!^>$;D%_S]JEO5"_T5EZ^ZA-L:A%\P+5[,
M-^^R.5_2TV$[.:5.PH2]40N27!42-6U[D&Q)C<]%U&1Z!R+(440<2A>A@I<@
M7'0UXM %8JC!!'J=@XHL:[83<>S3M8XBCG/1%CIYLX=R_8(W(ZXV.T=OIV*1
M7=E34V)=/+A\^U4?Z,OU9+68=7ER(Y]ST*4]1?WYBS\-VW36QW9R="5DC( \
M%E!6,W"*2^ IBFBS"YSU-XWK/3[LGMWI<?#6X4S7+6MR:P"8O'=DT\$=PO!)
M8G@L8?UI0H)"?V+#Z;*!7+1/NF@EAR*M$1"3,Z"<]!"21RB<11^4MX6[WEKE
M?<)%ZS.[<,A#TZ>)7O+/B,%GP&#RST;AGYW$<B!<$"X(%^>P8,B5(#90.-?C
M7K-+,EDOP!@?:FC&!?@B6WRF63 A"1-W&F7M/2&-PKG3"N?H0.(>>O1]F&W&
MIH7UY+^NYCB1;#H13$@R<KVHE7@@FE[EQ56<X?C,W,<O_S0,W:$/6@3-$NH(
MR28'RB@-GBL&+C%AC%&A>+VS^:O1QL@UF.+:@*-HZFL$ XO)96YX<3KNF*+-
M;NZV:6-_V[Q.3ITZFO'Y8)F0YT]0/!U?XR]$Q_[I6"''O X*K @)%"NJ@K'Z
M[8$'[;,T5JO4"QV;H_YR,:MW??7#[U?=^LWC>9I=Y>:M+Y;M"SU<KY==O%J'
M*H/GBR>+>?O0Y6(VJT]YW&X_KM8]>?-..B(J$96(2D0]0+&A+#%9Y.U@KP4E
M @?/LH&8 V=8_[^2]D.B2L-9DMQ",5R 2D) A:\#G9UG+$3I)3MIHGK/IT8R
MHBI1E:@Z2JJ>=;K:%)DY,PQ2\0645@8"TP%"0!YDFVGLY(?,YM:9E+D$%61]
M#4<$5V( S:U5QDJ-4M\WL^\VX$%.-1^A0TP%2\1P8OA@&.YSJ9YW3."TJSS.
M(H#W1H%1U1MW64H7=HZWQL*\5(&U0SX*%%,9@K0&?! 8>0@RHST/ABLSU583
MQ GB!/%Q0_S0F$UHT;="?56J[^LK,F/.$;1W: 6F8/7.64K#HG5<2) NNXIF
MIL$%'P&9LP4]XR;X^\;L[>D-):9RC'C=OZ= _6\3S.;70^K G8'YP6??^G%W
MO>H3O#AW+M?V#I%[NZ#^,]>Z?69[XV];TY$N??+JG[_$24BM$7B8OZG\F,P7
MZ_I685G_N9*O/NW%,LPFEV&Y;N-6UR]QA9-'B_FF3BNTL:L_=O,P3UU]TJ_K
M^@^;]B<//KB=N7LU2;.PJLBY#"\0YHN,-U^BWH?V\,W]GN%KR-T2-YSYMMZ5
MJXOY=[E;7<["FV_;H]]=AMQ@^%[=6+>5[G6I%7L@ZS^T5BQ=>7/S*9N7 LYS
M)<[K=A/K.WS[%CZO#VVPCB#S3TE8_PE6]59?_VQR>?FV3&TCEFWQ62CUJWX;
M9G^$-ZOOOOGWMP)\^\SM[=_<CX_?^WNYQ??*PW>W]'17T1];$<7J6O2PK)YA
M[D+U0UY/_EE_JW9]\M-R<74YG51OY4/U/\8]V7AIJ[<$^N\45B__N\P6?ZQ.
MXG;]"9F_?BQ+<#_?:WTZ7^5&=,W./*K2F_S8I'<VAKG?F_'7;EZ-[>)J%>9Y
M];>QWH3?YJ$&/E5ECGD'[MOWW(0/;^.0[?=LW^G;<+5>W 1,[:LT^UJ_>7LZ
M5.]H<56]G.XUYN^V'\49>\#^[>8%58*S<+G";U=8G;FJ:S>W8!-+;]_[FP^+
MUU]UJRYVLQJ#?GOS^H^5I6\^SM@'PME_N_88/O($_D"9VQZ^[3'QP/E;W_O>
M/_>6VG__Y2WE/KK>=N_\9X^ WJSEC^B+/R@P#I"Z^[KSKGU=[L'/N];ET1[Y
MCV_,-[=?^1>=Y[JWA;"/Y?CD[*KF;=:_7JXF/\QS=:1N#HSLMW3N<O[H%&YA
M3ZN+"'6PA3DA=OV978+8]<&=$TPHPA29?%*;+U6;SYX$);79Q[K?>O9X/^O^
MZ;/'?=W"GL\>;]),FR3AI"P7%Y/%)=;0N&V#M'W.5]VZP]6W!*DO@]3@KIRN
M=KA72ZMZ\%?;;]R[:P0WE]'-<]MEWB2A]VG3\7Z>=_,F[[\K^^[D+>D37$_^
M.ENL5G^;=/.TN.ASCOB0%F./(U6.MQ*.46=X&C6$7UR1L6<AN#]$A2+#(K.T
M')0LK>&'MQ!X46#1:9=B"B*4#RL4&9.V".^!L91 *9X@R&"AOH]PKM6(AYU6
MPE77'V]T_.>J[WW7<W/EIMX?\$#EJ2I3GZ7:1,P3%?+PB'E@ILD8N5!*0;8I
M5*9)"=%:"5@9X4/(3GN_TT_/AFP85V"B\J!*=A!=J3!$X:5@UI5L>F+:[4=3
MQ%2Y YXO//XB/Y.TU(Y'/G#G^[W!@Y/U8K+$^E#J9CB95Z]\ZXZW?V]_I4W&
MBW)=E!4@.8_M:FE5#_YJCYGK$GWDNL09FMN_8WU*ZC:3>R=AGB?AHAW,^[^;
M?Z H[IRCN),;TW'6P9N(7$84"#HS"<K:-N7*)]!6:XVN1)9C'PFI]Q6R_C[#
MS2G9>7[XGE[VU0_=3YGWXX[I"&<DVS'B3/*@68D**K<T*.$-N) ]>,>5*\F@
MESL-M??)11T39W;J/*6H>DQ1D<_\\135>VNW'?"K+[CHKBY6TTGN5JG>W?5J
MXTIWJ]759AQ$6JS6*[(^9'W(^ERW:O3%Z*PR&&L9J-: T1M;31!R$:1+S-J=
M5HW[.-/O:^K3<MW=8?[B4=/':H3^?J.N?6V2J$'M]9[<FB>>#5>V9\TSEF+0
MFQ$*Q1103E6>^<)!Q>I*1UV"BJ8/;_K(/+-2CIMGE((^@CO]TV*1_^AFLTEW
M<1FZ9=OZ)=M"MH5LR]:VZ&*2,5F \SF \ADA\.8P%R]C*LBKJ>C#5[Y1P\=O
MM;#'\B&NU52HD5L3(AC)=HP$L]7]=2)D" 41%/H$T2L-*NC(,T;/4B^YYCX)
MMFD^!/\7EXOWQK2/&5Z463Z"*_QC6W63L%KA>O6>.TRY8[(F9$UN1@'SZO5Z
MQ4%Z;JME"-6W-:E *4)FQ85/R/KPA]]9D:?EY\7\Q<_=*\P/-ZKY#YSE'Q?+
MWU9]3:87;,JY&+>!(9Z1;,?(LQ*815T85/?6@$JNG0H*]8=WD?N4ZL,[)QWW
M\8X/R#-REBEO?'QG^?%\'>8ONM9@ECQFLC!D83[I,3.GN94.C$\,5&S&!8.'
M*'VU(P5Y2CO3?K[68WZGG%L3\[ABI735MN"LV9T?7E^/ ;K)V?2U8SDUEBJ:
MB7(DV]%1SF)06:D()K2.(=XAN!3JGQZE0XS5-]ZI*?M:/_HXE"/WFG+1QW>O
MV][)I&I7FU>U6(59JW2.5ZMNCG6IDW]-EH<LS[7ER=7RE"@<6*$1E!"I]75A
MH#'DD*VRW*=>*C1"-V]:^73^:S4:3\OWU]K8>]LJ-G66:C6(923;T;%,&^D-
MINH1!ZM!.6[!H5405)O_&V72>H=E>]5J?#7+R$.F!/3]>LB;Z=80PPI;/YJ+
M2YROMF<"\77[G=K&DETANW)M5Q2J+ Q*2*Z(:B,<@V""KCXRX[$&YU(:[,-'
M_O5E6.+W324?O:>1/667]91QRBX3OTBVH^-75DJZTG+*PH7*(EE9Q%7EEV=H
MLM-2XLX>VCY^\4'Y9:9<ZG'SBU+'1VDJ5W"YK%[Q3;_6\)HRQF1-SLB:G/7L
M!,E\,1(=2!XMJ"1,\YM#=;@%TR'Y:G=Z\;5OU'S;;/QY>/W#-N[]'N=8OV??
M:6E1W6\QJ/Y.-$R!R#DT<AZZRB.Q[$1%%,=V&KJ5L?G<\@C..QY#2"'9?OK6
M]<2V6Y'FIM*:(1&-,M4GZ9 _7;_$)9D1,B-G8T;.V@$O/&-P%D&CEJ",*]5(
M:5ZYSZ7R/JJ2=@;][.. ;]3ZR6+>!J%L#=6UE>JK:\?46'*XB93G)60BY?F0
M4GJ'SJ7*1[0%E#46?+(<;"RN<&7+1YH;[>/.'YJ4G@VJ\^=7</+>AZ2)+QR2
M=H[^_*.78?ZB?G8WOSGZV/I-S[H0NQD-/Z,Q4:.3\[BNEE;UX*_VF&DQV4=:
M3)ZA&7V8KJ<U+#%A]RK$&=5L4NA'H=]10C_/31&FAG'"!P7*,PVA.%-C.6-+
MB<Q@S+UT)9BG"L(5_AVW_WT\OU'[7]YJ?5]1H%04!1(RSTK((T/FH5NM),ZY
M#0**QP!*%PLQ%@?""A.8Y3)PWDL3@EZA=L?Z&S<=6)KKM,M'1^N6/UOB9>CR
MS3&J;7)KT3*XDW2U7-8G76>]R/*0Y2'+<[WGK+0764OP6@M0*7J(J4C(/GLL
MGBGK>]ESWK4\U^IZ4S%UO;'R<)XWFR[;QCA]VR(YM8PZ%!#H2+:C YVT.O&L
M'!B>."@K.$1;O>>B;#2V<B[X7BI 3P-T8LH5'S?H*!5^K K1R6PQ?P&5&Q?D
M8)/=(;OS)[N3I&&Y! DHG&[])=NIJM;&0#B)+L92U$Z?]GX<[+?%2]O@]S"&
MAIMIC1S&;6D(;23;,:+-IJR3JHYT%B*"PBC 1:^A1!=U19O0:N? :#\N]5'0
MIJ=,CWRX#N6MCUE.<AG>A,U8BGF>A)265_@NF4UVA^S.V=B=LRXP8<QFX7SU
MMIUJI[!*!.]"A%#];A&T1UEV&L+W6V#R;,N!A_/\<$N!G]]5:/=MY)R8>FZ'
M9.6H_(2 2D ](:"FPF1&PT"XR$%I9L"G"D=ED7/E97$B'K:XY9A ]78J^: 2
M(L<\U44Y^"_7NL?O=4N[B2'(NI%U.QOK=F#[DSEZ;QV"+SF"2J4YY]4<%>^9
MSHQ[LWM8N#>'OEF;M\V \,82]=5H@4_MV#MS$M5(MB=)M;/VV6.T&+,.4#*V
M7I *(=CB(/O(<S'(O&4'\]F_EIEWW+D4U!>2$OW''8UW4R9SN5P47*WJ>@NS
M]_LOD($C W<V!N[0!STK7Y2+ 003 I0T&7PP DSB1E6OO# ;#N.VWV2'WORX
M6#Z:A>YB]7">KW_)_[I:K=L4U^LRSE]PA<M7?3GT;LHD30HAW)%L1X<[%"5G
M6W2%G.8575C]*BT+&"=9SER&5'8.XO3C<=\C[N2@_&^J43])M_NZ1IV\[$.8
MG5@7'B[??M<'^G(]62UF79[<R.H<]'!/Z7_^XD_#=)UU*BH[+:RI5DV&&@)4
MGSZ#2R% $2XXCED'OI.*ZK& _NDE+L.ZF[\XX)XQYU,C#]@BX99UNC4H3)Y7
MNHIH3;0F6I\DK674H0@%BBD'2GL+/HL 4<92 QG-?3G0,=OCT9I-I3[@^)7!
MT9J&)QXARGF"ZTEK4SZY6FTF*$X6-ZHP:0OTU485)ILI]_R[C0)V\ZOVZ/7S
M%G.*BR@==S[IN+.VDL5SDR1F8"YCM9*Z<LZ@!AYL%"X6GUDOAX(K%!Y5)CQ;
M+EYU&?/W;WY;M:WUMU;RX5LR/'H+A*=O>="[X913X0;5"8Y"& (K@?6$P(K*
M6,6M R9%!B5U (]* )888HE>:+]S>&N?\..TP-JVC0>UDW(F1PXHV+@UV(!)
M[E;7D49]&@4:E-*CE-[YV51O/'>H$%)T$I3C'IQ U>QC<"8K+>7.^;U]@I4[
M&M2_O\>4PYE4-?7^@"<K!I?C(WP3O@G?IXCOHAW6: C!IAH(*89M5F;(8"23
MV1:38M)]A$0GA6\Y=8+P35LTYQ<UD7$EXTK&]5R,:ZQ!CI6)@[:&@1+<@;<U
MV''!&RY3,BZ)XV[D]+YIXZ;"DBFE2(A@3; ^;UBG8BI:E8*H2H5U2AYB#@&D
MR9*I"G"=>NE7>X^PYE-G#CC@9G"P[G>WZ*-K=#<8^DR8<_)Q3%O<DS);_+&:
ME.7BHD8RKW#U01CS+<WBIIGK=+4#O5I:U8._VF-F!'D?&4%^AAG!A^GWJV[5
M;7S4R_"F';1>32=S7$\699LJ#.T92\P4:5()(940'B-*E%H[;44$8W4$Y7F"
M6#"!9H(Q97(K@.@CI??L6M^?+QYN=?S[JU4WQ]4*5S6 ?%J:EWW]2.ZMO0PW
MU.N=X'E>0B9XG@\\76E3,Z0!5*[!4R9P46@(QMC(JX=H52]=;.X!GGQJ")[W
M4&0]VN#@V=4RO0QU1;=@8)MCVZQYLF9DS<B:':7R.2?-@A<@E'3;8YJ>>83
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M=E&^G(!)P#PA8%JI'+K$P07AJK>?)3C&(V1CLVV9BQ1V^F!^33OI@P/3.D/
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M9R)&;25AFB<B'9/$1I<)5]'+Z).RV]$,PXUM&BT(U[8A4@M.O,3SY"$VQH@
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M3*_B6<6S!W=8I#9;(R2Q$K')"$,\LX& N:YXLE0V?LO*#TZ !FTE:2A%(%0
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M#&GVRS+__5W;)OC_^(?[LJ/CG%+PH9&Z5I2L('?0&UI!;G\U<D,R,;M(F):
M=$(E8IG,A$7I;..3CHY=!CG #PKH9XF0+!,9I2 F,D&L,%08D5ER_)! C@YA
M5!7D*L@=](96D-M?:P-'J6UT)(XVDD@3&\"J(.%/1C637@2ZW=H@&*:\\%@M
M/!#IN"(^&TX$9S9ES:A(6]6+G@[D3".'2IL*<A7D#GI#*\CM#>22M533IB'.
M,PZ I0#D8F-(X)Q39I7+#;T,<HPSJ9/2A">+"?.2@R;G'&E43)E3$1M_4" G
MAHVJYNK]?:"U 4*WM/]K>?KOXH3]]F'"*EY>"2M5J?(5J6)4YHQFPGG#B/0Q
M$6L5R)?DE;'1)$WS9:G"5<HR*D^83HE([@PQ*5,BG. 4'J:C8H<C530=VMI5
MIT);W=!7!FW>:)&$4D1G5)@-9\1RAF8^QQ+\#6=NVRN0A4G64**I FCS0A(O
M'25!A*R<9=ER=3C0INRP,;4%8H6VNJ&O"]JBCHW+TA.7A"9@XC?$ABR)$5R#
M:M8P)K9:BV S$D6Y(-Y:3Z3DDM@H!$G"Z.A-X$G0PX$V)OE0,U6QK6);W=!7
MA6W*9-8D9HBS%.U0J8F+(A :6..BEB&(+8LT*N>BE UA/$=L7T&):2PCAB66
M)(LFY'A V"::8:/WW*'BN;!"S?5\  >][ZN UNS.VA;P%;4%W+=VK82@";3K
M2*TD4@@/VC6-A#<T"4=U2&ZK&5+DWF3G'*C3'NZA21//-"6)>L&:1H$(.B#M
MNA%[UJP/LW%?U;XK?E;\W'_.*>CBR21%J-2*R.@:XK-JB [!1ZT!0]-6?VKN
MO7&,6:(Y_)#>!N)30XGBC!F?;"-Y<SCXJ:BM^%GQL^)GQ<\]X"?57@K/&9%<
M A::H(F5H'^&&!P>/DHJN,OXZ9LFAVP]T4W&//\HB9&2D:P"GF?B(M$#RO3B
M0TH?M<M<1="*H!5!7PV"*JMI%":"#JDY6..Z(:X):(UKK[QRV>:M7%G.(FMX
M\"13]#M;"_=04&*-D]1H*87B!V3!\Z&4C]KC^'DC:,VF?01HKN*HMHNN[:)O
M3$L+P32V:8C0)5:90+NG-A/;9*VS!/W=R<NR*1OOF 0!QJEP1#J?B+&-PRPU
MDVA4AD5[.+*IH7+([:-ZF)][%^D*J152*Z3>%U)Y\IXIU.^5LT3*J$'=]Y8X
MK[A7S%N[??ZW<0"TQD5BE<9T.$RFRZ(A.D;MC,_:.W%(D$J'C=[ST;@*J152
M*Z162$5(-5)'R2DE3709#T\$XKT1I$E.!1U-SMN')^[3GNOI(-5:.Q2V0FJ%
MU JI%5(?(ZS'J,J&41(:^"$; 38_E9H(9Y*W(7!+U9:6JEU4E$FB/(8"<S3$
MFPSJ;>)6<*I-C@=T'LU:MO\#:2\+4M<=T_ [=OO[RW+]^H:9?^E;<;ZN?HD[
M;38:N>>2-YJ8+!LB!:@T)LA(:! N:N9YE&D7VLS'<)+B8IS:]QE8#Z%LMFP[
M.FK__.LY_OS983/F/]*=6H_*HT:(S=:CZLB:E]EZU)V=S:9? %+F";M>XS*Z
MX])??')];6/L.CH_/RN7G;GSZ6SPV;4#U_:-3-O:>G1WK4?94[0>%>J(BQM[
M5![MHL>GO5L;RZN&8?A#'\%A'.:A#WGX(!I] (-06M^[ZVIM-_;T[2U>XH1K
MK\3:=O0@F.OYNU<J*]6VHX?95*;J 54/J(VO[@M>M5%<%?:57VJCN,HOE5^J
M?*G\4OGER?FERI=:G.J1BE,MDP]2',"+W3'\-[C9SLI4O=AC5"^BK%NM</B5
MTZF9<]EP;#=J#)%8YM!I*4B,47O-G&WR5O56QZEG*5H"/S21(5!B(VV(-3(X
M'UCP*2RS$4[CFP^KL/G[_%N:?^ABYA^[D'F?(/37\S_.S^#[#Q@MW\@ .EO,
MTBH%B/#U'"!^4[5]]M+*&MXN:^[;FC/Y[':V(MO.4QRIM(!'@1B5 -F,"<0J
MQTC(2E AG'-ZJW:K:;)PE"=B3 )D2SICBF-#=!),"^ZTUOP0D$V]N.Y[%=DJ
MLE5DN^6I;<XSXYX38ZW&^G24.!D5$<DFKXUK0MIN)@+W2"$CB4PPT/.\)X[&
M!O._0],X)VBDAX!L56>KR/9<=K8BV\ZK==J8;'21B&P%D4HY8CDJ84V@40KM
MO;%;UF@P0F?E2:-9 ]:H4)A/[XA/'$;"F=/I,'2V%]=,]('(5NL@/8!__C:%
M&4Q.X8_JPWQ>7%.EQJZE!A,Q.:9 F=69@@30BOC '7$\FA1,ML&SRU(CB81]
MI@S<DT ?=M(2+[DG28G,1.*6!GD(4H/7;J%5#:X;^KH S3H#>BOE)!DN ="8
M)][R1'@CI-, =2EO&?C6R9Q%$$33R(G,7(/J+"+1*C4.%&(C!3L(0*L]0BN@
MU0U]78"6I9>J89'8"# F#5?$IAQ VPI-8S'03/UE0%,N-)%G083*ED@J!2AT
M/!( QJ;Q.2NMXT$ 6FV>5P&M;NCK C0!]S:@;Q%.4R R:@/F8V2$TDRYEE10
MOE7$0P2JE'"*..4PN)P$,=1&8H)QR;,<G'$' 6A50[N_?[(F7*:U;J#SDQ&L
MPYF#N:2V.BI? ]=4J7&]U$B)*4]#(B)I!C9Z PHQLY)D&QR8YY2Z9BLER5IJ
M1<,=:;)W1&IL)!(:31J:O>9.!748:G#5@JL67#?T=>&9:)Q(2CI"H_-$*H.)
MD\$3YF4C>,Y<L*W "VL4;:PWA&O4G'G3$)NQ0YSCRAN6L4?Q(>!958(KGM4-
M?5UX%KV0V6//RH!]&+ABQ%*?"8^22^>MMGZK63 +(E+%%<E:8SE/K8F-$8!0
M&RJ=</#?YA#PK,:1*Y[5#7U=>&:<C]A[DF1)!=B;,A 'YB+1S#)F8W!";*53
M*LTR6*>4)$_!WJ3)$4"]3$0.!MNG&R4.(C%FSRV]G@OYUR3*!W#-A]GHDX/+
MS]SYLI1S]5+6IL</D2NUZ7&7R.\4"!K;D&AE)E)C%S3;6$(3%JOWM+%\2Y-.
M*LKL5$-48R61MM'$,RV)B"%21JW(^B T:5Y;'5=MN^)FQ<U]>""" =S$\$YF
MG$B>%'%.-L0 -FH?C%9AJUE\"-:XQ@L2#6KLR3/B4DJ8*)4:Q6.3N*ZX67&S
MXN8+W/**FP4W06/467!/*)44,) F8B- 8E:&"MID"1KGEJ<C!)5CQ,.F'K"6
M^H3'AC*)PJJ<56Q4J/IFQ<V*FR]QRRMN%MP,QFMEO".">4]D-A++OS$B$NB>
M+"@5\E8$'U1-FT.6)*4&['2%=CK5AK"<$D^4FA1-Q<UGA9LUU?4!G#6H+N/=
M\=&A]"=^0F'TBML26Y^,QV:HF#P&XL@Q4,E!)B5!LX1O?+!;QRHRB"\F R6<
M"D>D S7>V,81395)-"K#HGT,<?3+;S_?() 8I:^S'7$M@56AM$+I(^?F,I&\
M5998 %0B&67$604 *6+0H+X+9[?.&C2NR<ZX2*S"_#<I/7%9-$3'J)WQ67LG
M*I16**U06J'T-4&I9=DK+XE@VA+)!2-&)$JT$X&GY%C8KEY J="96TLH#0&@
ME 7BA-,D"LV-P20(ERN45BBM4%JA]!5!J?>R<8XJPJT"#;,QJ)\VEO@<4E11
M1H]E]RYII=I%19DD ,$ OSD:+,JOB4O<"DZUR5%5*'W.4+KN?H;?'4SG+\N%
M_&UQFF:C '_'T:=K/H5;+V9<ACJ:1'CG&W6DE/[V[1Z8YS\7[7R4SV^%M9M[
M\-47WA:4<,8P\ZMW^6MO6#%FOX++9AE6^\"9PV.8B4@;,_$V1=(DFVF*H6G8
MEK5X%Q5GT9)CY\[>_'71CB:I;7^8GOK1Q"&'_#AJPWC: M_] <_^ZW@:_OQF
MD( #SW S9XMT.QB\<6GOO)?WZ7;W\*UNC@;_;;E*@[5E6B6F/_T0-P(>3[(U
MC\5F%[/KQXC@MT25=:#11TR*70$-XW#O[NCS04ORXV(VFAP/YB=IT(Z^#$[A
MBY-VD&#6<?"_%Y,T$'0X6.]]^N@C');! :? B\\!HD[/Q@G[_.&G+OQS,6I'
M10&9YL%58[S] '9?%<\% >H0)U1S1Z1Q@ACO+ 'JTDY[$>)VAR)0?QKF'"/*
M6BP\Q3* ;FZ(<Y8[(7Q@&TGR@/(^S=[G7QTHE!,W_CG-W?C7%$<! .9#&4Y(
M[3M<IADV#5G3A+I;UQ4@NJ'^D#8%5($PW-NFR3=_F4[2M=K/HU/%X+2?,<DX
MY<%I/^?!63]IG,I@/L7OX*YV!'J56]+)_S@P0I&,1P]J,#%"PJ8G)H@/PI*<
MN4M:AB3T5G;;70CE*]+YA_6U^6/F)FU.,R 5MD$K__CXXTII5NLD0YH;5&9[
M='U;A"<@FM%X#",8(A' .\+)P9$":&8-#32"]1,CD=XY8D%YPQ)" :L%T^CY
M+D@!+"-L+M#^,>W!84D;J?W;;-JV.]I^=71]G8TGV_[!9]<.SMPH#D:307#M
MR<#-!ZBCHB1TD_A0HK@#&6S.^]JZ4@VE7JM K&RP!D%#B7><DD9+(07W+KHM
MJ]HYSU/FGN0FPCU*8*P'=/_(9#2-U""-;J.]_Y["]'@"LXZ_H"(TRB.TWMX!
MG<Q78N7=)/X=/AZ-1U@&#KX#TR/^L  8F<R[*W=$3>+H^IROIZ6F&2S3#'4F
M^-V5G0!:@NLNR9YQOTSG1X,_+JDOZ0M,(/9Z3:_M_,__;CC3;]M!MQ<@RB9I
M#O+X3\2OLY/S%D0>S'HI\N#5 7EW\'D*O+VZ&2DZG(S&<;;V8=OY2]JCP2\3
M'.0D=03W>30_P;)^[?K@-E6PU5SG[@OL7ES G>B@.)Y.XV=8DT.4L-HGY97F
MQ+",!8H%<%!J+&F:G()4/*F\7<]3FT:8"%>6%A(I "AG"G]ZR66F>'917\=!
M[RX6[\-B%DY<"]H8K/>[,=B_93/_UJ_63U_.$O:M_L-]^7&UEN].IXO)?&<B
M^/J>:T\H@O/H2^$7Q(=#))EDC1& H"1:K!ACFD",U HDL1?P"BF8VSKB^A"2
MV07H?IA-S])L?OYA[ !Z)_$GN/8,Y?R.2(D>75\&\.D & %N6NJ1CB9S-SDN
M:-035L'?%M$88!(F,8,W;*(GWGTR;<]&:"JXXUE*13$Z1))TU%"6&TTBJH12
M^@QX%@U)04DM:$K2'!Q)_K+:DEUI ?00M8"CIQO!8#-!^48'^AZ\Y;<.2UYZ
M]WY]Y<7/MOZ*=[.1&U_G(G>-:"+-ABAE >\I'C%SH#'D)N@LI:19;ZD(]W&1
M+P4_<,L%;W2,M"-7^1/Z(G?KB%9/R57_[7 <\DN2&0[^/IT<D[^//H'F5$AF
M\ OHY*-9)[%0DOT=]7\0&$!*9]/6%67\PK1_\^2^[UT&9G;F^ ;9!DOWSX6;
MS4&)@!5#A_>FT5,DTACEWV $2[WR,IY-9_,\!0DP@)>YXZ([#,Y _6J'8"BU
MBW%1/4:@9A01UZ(PGT_!VAO-!VY\.FWQ/V67\+$N9Y">#MW;4_@U)+#S6_AC
M9>$->T5G?@++=8T+M+,M5R/$5\&39_A;9VK@ 'Q:<Z7[\\&/*23T!P\$Z_S]
M1X-W >T\&/[X? C#1[/O$QBRG0%;]*NV+=-%3VMRX02F"3@\B@L8S+9UVGE=
MT@Q7,L5AH59<X00T<%JFG!=S@+[.(Y/'T\]H5H]=/V"\]"J3-X[B8#*=#]K%
M&>Y%N2ZXV>P<U_V3&R\2+F[99I@]Z"V@<H *..JU&-S/BU&/D;W&A;TZ_1%6
MH2USQYV\Q@Q>,V0&HS5V/$ %DC.;*/83I\$SK(*)/7=L!D&GK.&,!\&WRD_<
M1\9=H-+[C)!5$*N3<?\KC>//T]D_VK0C=9#3P[1O+]LBATX;,1D:G+ 8K<+2
M))BU8[!P<XB-=,9&I?6N:>.R O0+2)P\ JI(A0E_^A+&"T2@I0#<$<GH0PQ*
M=&;L67$5 G2-$R#_H.1PD6DFB_:YD)'W+G#A8+5S)$ 1C@ 1))*5-#D'Y;7;
M.G%\'S)ZOURIO^-"71#5WW<7O#"'""R==/\JG:Q3",K]E:1"YRZH(BC%YB74
M5V;?>9:1^D#,@941YIUJM!2^J#9,0-@/QAA?A<F='CT+-?)E)Y$\5T7ZU,54
M/MA2ASN]&GUTYX4:%[,N@H(DW(<K.A+L=&)$3*#13R,88:_AA:).HUX)8T<=
M>3[X/%V,(VJ[L]0YJ8KRNQB-.^43-/4Y<@%^6C#B:%#X:SE:T R!)\K;TE))
MGW^>PCCAQ=-%"YJDZ[U?UXY]35>]=JGPGHMWY?5+UMYZAU>U"]_"C/&;7GE.
MD\M/[E_>(4J7*C'NS<>X9C["'0 J^'Z_,B2+,G]HHB?8)@N7+6E2!NV6"4H,
MJC'PEV,QP_^YK;:Z=SE=O/+@N-$$Q<S[R4>@F/=Y:5_?7NRTP+3PVXWIQD?V
M\ 30NEV;9]/30E%+N@&2Z3)OINNI.$BF0*]_+HE_ FI,[Y_OB',T&V006;V]
M-L;42.3E\G6;P#XNR3PH]XKUNWQPE4-5#MU7#J%6,QNE24#;'=2AT?%Q*@_
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M\&@,;+1BC(2,D4*&H6B1'(G42:]HT_CM!A_W237;$A%?28_95<!0'F("V0Y
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MR#@A(TG4Z)!5=/%&]]F.^48.&V-NS3>'9+<]1XE>O"^M&[O9\OC':(+\AT>
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M,G7O6&;J0[\2'W A=M:0CQY42[X^ON*. =:.T7:Z\', +"TFJR8T:V1R04!
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M<=4$EH%&MBO&62MM2EH3K1O,7_$&;$SJ"6?<*I]]8"Q]+8"(D;)VF1NWJPB
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M2W;>(SG_)S=#,=)^2+./)VZ6:GTK>T#UK0ZIPA4@]&E_\K3_]:=_+D:? '!
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M(3%/)/2(GB7:?N1CBX&L=ITW3!RPPCG[CEG+/%&A.A6#D2N$2P#0Z.*?EK"
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M*V^F+')7?4>F\QQ-MKXP)J/LH+CJ[Q_?_B/7I0%K"CP93A$/#IU6<'1EQD4
M"E%TY9/%0XCA;T3WW\C84OV8Q2E/\X+C^:*35WV)R\!X6XK900_D7 31TB_
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MTJFV\E)]%=W&?'FWD;9GO;]17O*V$R1S] Z&A>WA! ]H#>P2>O1UBQEIX>O
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M;2Z>BTD%J\+7QUI;#J&__;N,9)<KT.OT%ZO:7$>HTYDB#B=.;&L/[/V([7D
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MH@S:_5MQ-*>V[2CSUAK82^>5%(1K->NE^\JB*"34&$$B93+%*$:1M(MEERQ
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M].KF7E4@R,;Z/2*NE<LJ\6B37U-<A6(8&M7=!?TBIB5QBXOJ0Y43M&4^51:
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M#MM??8VB9FOFS=-#77QI;+'73=YIDEVMC-\%H9JMEK=W[Y>:]RKS]Y>\5Q_
M=>C7-9NB-(*W-.7O][X-X'\ /1Z7Q9-P^F8#)YS#E[=T0>2/YF;12-G,C]^Z
M;/U6MGGK>'RI$:#_IU5(%\W!Y__)^!*@M__T5<36&T_"VW<P,OXS8%(&_HDK
M*EL<.,Y2.GV/.E@[S&\_Z!29?L:,79RLZ?J!AH<.N(A&+Z-=<:+A?/M 3_0D
M'3CF"DIM1@X=TVCM?$.W8;"!_V#/;_F-L]!</#&7AB>^$X;!4Y-)]\)0?PO$
M3^0_.#?O?SAY__[D ^+U_U,QW8/9R</]JT%$V[6X@$]83-=Y!AJ7&/BG8DK5
M0U;C+9I[<]%_%*^@3Y> =GGM/- &UQW,M?D9[)@?H=S'^^]QP$74^ACN/0TC
MVNV8\R0/'W@W6/DF8VM1<@$HX:";?]\G%UTAB5=QVFT?@\Y&$;1M*];+"?;)
M9S?Q9E6,=]F#C9GHTDO99%ZZ[Z_?N\Z6!;WZQK0[BGYG5!>VJ68YTVS8%RU3
M"Z#=\U9(;/QOW1YST&.'@\Y3)<Y_JPEI0+E/SFOPSJM8:_2IG;%7XH WXZ$!
MB5YOHFI4[,I[I\FG?8Z]!"*Z:LR5GPPH![82\2R?UT((X88'MN);.Z-O!JW;
MC)M]: TJ6;<4E.VNT'45S&JSA6E 8D 9OI7H;4<J:0J^62V![$>E_Q4IQ9ZL
M7X^:3_L>>RD08]W(:SX<3,)+@ D/EO2R) :3DA0PT<&R4IJ =8FIR?@;?#B@
M]-2$@[U(#/I:[\--0R(#OG:-3L<^) :[LRK#' Z^QAI0'5J7[8#Q5L0'N]D/
M9KPMU<$XK@3A.9CC!E2MOWI[P<WL_30>0'W(&3@43*7-O+3KT_IL'7P7'$IM
M%%[)/*I!)Z[(,K)CX;EY\GY7T[%OC\/9^KH0@PXC.QX+875J2'?6PR;]#*JK
M'+P9NJ \N#VRBVW0DKPMW:!%IE13#:%U%Z.8B]X2@CJ9QIY'-P:K],%74H<=
M#&;+/EQC;4FUFF,/0D7Y3?>;; V,E$:O?BOXA(::.HOA TTFW2M]CJGOIDK8
MZXZ#>:HI_[<3!V'U7*S=O_)G26@D 5S&UX&C PMP#/!-49NWW8V ;\20*PQ<
M0!;_O?+E WGG> [7C6!OG@;^UO#/)4/;Y^-#QYR*ZUXXT0.NWS8Z63K.!C?O
M6^K%D?H-,HC,R5_\54>CP!-XQ7_,,E+1L,.)+K+)@9C^)$44KJ[S<^#S'^>&
MV3L_YP?2&6SZKYGSP#Q^KFF4*-GZ'9D^<*W<F<<E2]+PX\&8 _$I,2Q,GUG9
MWBIH.-B@"T]M1H,L8:/1IX,Q!L_F9V=-SU-)2!D6,HTZ/.'\09-7]6RAY.LS
M9\-BQ[N&R9H]>&R9BAY+3O4>WW8X8M -?^6Z8:(*7@=1=/$\][8NOT?.Z8*&
M7&.X=YY18XS.N&"V++B3#J33R4:)Z/R;9?#XUJ5,[!'^0[(U^#_^>L$OQ7C'
MA0M^948W0<3G]'_8YBQPLYS4-+8Z7!"&PTT0XIKCRW0&YRS<58Z[^JO!#N8M
MA9MO'F_!*"T6O^RB+&PZV, ++$C)\W//!<)3WN]O):PT_+C#\USO_L^?W0;?
M##;]7^X^0KB\#V.YVT"$,;]%^$ZGX29DF"_Q$-^!LP,EA$^I;,[,8AQ$JLNE
M 3?D9[X?>)?4+QQJ6:O!IG_&U>_P<^#/^181RKFTFI7,<7G[P5C04N/I3O_X
M,Z.APS7/W35]I%Z%T-;PXPYWR0UUF1.';/[1X==@ -N *ZG!<L>/Y<>=3^?X
MCQL0>MD<K)F?ME[,KH$ZA"JIK[_P6],'YQ953<LV7-\=#K_P5_YF&T>X6A\J
M;XBJ+X937L$4QE4^B@DE_"P)A2\,'7^)ZMWI+FDB+073)R=T:Y7=]H0'FY3/
M04R51;] +2SAN.ZKX31D+N_'TA8/CKA*]:6D\9@D)$@%@KQ^_,<]WU"1$/_?
M-Y>3RDD,QFA%F&MSD7!/(H,QFS'CG6U#,,:7,%72N-O!1V%L#)S_*QDT_\=?
M;\+ Y5K#+)2>[8)7O;39@-8CL:N%K,2U8\/<]9F637?=5U;G7:3T?:+Q*I!Z
M Z6E)I@&'PRX%IN0SIET.6P\*@VKTW40QNP?16:;O3[MTL[DN S%,KF)N;;B
M@I/L8QAL-V6"7I./!C31I_Q![CEJ_S<T9(&;SD?)F>QK/QS.&JG]-M,YW_0A
M1?6(WT ;&L8[,$."(Q[.PV9=?KGN2\7JZ;\'?QE$6[J,ZZU;ITB9*F\W[':[
MBJ)M>L.@0%@L%_-3$E7NP0.H#6N-8_.8#XHKZB"'I$U Q;^MU)U:D1R1(T2_
MJ?007TCQUP-ZWI*0GTMG#B+"[I;",PNAP0%@;H&-U=GPO\6[4@_<7D0Z?.8N
M(3HB8'Y\_Q3@SS2$F EG2>^HSX(0];GS+>5_OE\%V\CQW?LGWF!WSTF6&CPZ
MH6K5$W#&>P\A),*ES_]%L^M4WFZXZS4!O'ETF(?Z=A!R]8 F!M9:\\1>-#K<
M=<:Z7[(%6&$_!_Z?^9/%%HSFHW3*MMEA9$9T$\XVJ'WCT08O9(VC?@\" WH3
MT",&FC<D=6)@V=WV 602 %.L\Q\T^GA0\X0,K!*"KY!(*NP01:U'M %O0KIQ
MF*NT7>E)X-./ K#P(S?>C(V(]7.+-'B3>GEK"GU0>M7+G('9%L,](LEK7/9$
M&"TZG*0OON^L05X7?G3ZGR L_,)7!2QS3T'9&C;[;,CSQ453'>%6?YL7MAXB
M8 -',0.-]Y'Y\]J0C6SS#G=&+JG,7R9B?JE$L\>'HU2(+]8;+]A1FI-9#E"'
MRVD-?# @7.DR#-;"(K_EHY;B"W_93^DB"*FAVUT\\],0A"Y?RW"'*P<^;_YE
M&'A\:,LK<*)RA;CR</738Y?J5]Y%5A9"4MYT...;,/1#8+VP=^)#7RGA57XR
M&",_4\>+5^!9GX5+QY?F9)7:%_ SQ-75*H?A'@1Z""N_\G/!?^5AY$6-!YOX
MCQ22$C8K-N>[.@[9PQ;M^U537?F)I;<3\45+GO?\WP>;W0LG! -2I+)],!NH
M9%J+VPXV=+CI1+"$YP5/ (.:W;5G*PBBN/*G:PB^+.%J;S(CTLVDQ]=XH61<
MQ3YAXR44AHMV4P8+G1I:+227MQ]PI0S8BP?E&(IWB<VL5O!O3&"XV 0/Z5*W
MV+E2':+8\.-!8X&R&((%$4"ZR8!.I)B_:M15ES,_T-LU)'I2L+*P.2L;?H,/
M!T\@J8@)3349[@R(- H1:5-SIHO;CL%0*2W#P@)Y2R,N=E/W,@@OMV U 1W2
MR6O\A],9P;4,$7L5FZN@X7!!EEP <:(5&E)<ZI[N1-JV?O6F\Y@]XI-0%F_9
MG, 0H6)1HN@5*U#5;8<,S5/W)2JH!4#S8%O@LS];<,&J/&9O+RHCR; L,[+5
MM1Y3>.PMG0=+KH?SP^ "!L""(3()WM(RQL<%A(XDJH__C?/C[ALZ9*?OP::6
M;TMA6JS4R;.MAK1(%<]@>:1GY2='\##4""8'$.K00O5Y"X:]V:)I0HLZ'GGS
MU<&4AD^.,;'B-&I@LRR9JD\'%"X+W&^5_%1],8((&CW=\HY.W<UR"=R9GT9\
M1-M[72I"MWV,09VX<<)9B/X_X6U2]L)Z!:+TRV%3+PMK"(74\> !_SGP(+?^
M(W_40%*;^8:-)F01I-T;[K<:<;"W[H9'?3$J\M6\1Y6?C$0 /J?1/&2;RFR$
MLO:#Y[EHKXZ!27CEQXZ_9%H*K4EZ:41B!)'5>*TT#)DVVPY_7H3!%^Z"P,<\
MM7)S1?4W0P2+R/^ XI?--JQNVV?LUQWX6AO'?IFMCR_M6.P$ VL97Y;[E</%
M>HQM^,A)Q-&5+]Z)LHUEJ_O!)3PH&!L@%F H,1)O6?3;Z0[^]Y*_.T'85([;
MA]* F=M^H-2[)H@2Y>U'8,R-(%X!G62?G/ W&H-$G'.7^>X95^&YU'0?.B!
MB2>J><9P;]UU&5<J'=6W$'H'NQ#BDFZX;LBVZ_R-5]FZPU%=&YDK*;A;",F'
M,#R:0=9JL"J=D;7T.$[YQG%A\UQZSK+@04S_?4B34F)SGL8B= 85S&"OT+K]
MZ8S"T8N9<458;S6)]_O1&#ZP D>F; L[6)%*]NJ_&P4"2>G3%8\@J$7?.#6Z
M;[[=2!3>6CS'TN;#>>@TC/&-P[AV*L^E86\J<\K5?]CA^SCU^06XHM'^6 *-
MOQQ0$=?A]34;OZCE.-[!)F_<@ &<:96_\H@6M[7J]+\%F;-P/V?_.F# L<_?
M.S!H3=TU\R&"V &$^&H-J>ZK#B^,G VNP#14VFQ84\9#O2WA(6=+>-ZP4/KR
MZFP5G= ?[L5ED;-<AG2I# =&K<JR5[?JDR%]['-*74RL 3TM4HI:N8.]I/V0
M+"Q87''_&PU&EAM182FN^&# F9875=.DZ8H/ALMIYW?\'/RS#0*'B]L.B8\D
MQ"Y9D\GQZF2UJB_&ECLIMD=IPN.>8$*UU+J$%]N"/!%2IQ1*+-.@GPSU!-4K
MJK#&U7W0Z=A\?7-%5_Z4N?#LL?7#-HRDVYC?RJKJ7M%0]_J^PY'GTT<+Q?6J
MEL/%=WA.Q)]E7.%*):.@X9!!*=E(BIH C*HOQA!;(RZ@V3:.8L<'QT)]4$W^
MD_% \1E>E?*WIOR3D<@L>P8\-?QXG"]I9[A\]>0&M%H916 :J"_E[0?W:\\6
MOU*V7/'--7VDH;.D*DA63/^>$8K[T!KNMG2B5=FM"'_J%!HO7]1:!6I.L:CU
M#GR_F#=<.=7M:/40C:W#IF?A_2K8@$E9A4U']1'8C;ZV&I>$CD88P2,]=V*G
MV)]7V[Q+Z3Z;?HFZ5%TN4*DJT(;:<.:+)(C5@>M%)<J4&2_*FEO:2>?!'(_E
MG[=.R+>'M^/W?A 6;:*REJ-&+ZDP&S7^O$N4)_9\$#YH991?%T3M^TM*T)R3
MO_51^>9N^Q!M $[=BW>-J]=4?#2@-(>7()>SXUVEYEK0<)2N@#IYK=FWXU$"
MU3U.19HK8E07BQ@'D3B^X-VT7&T"[V+8;-?!NG7=#2K)Y]'**]ZIB@\&#*/1
MF1^ O"_BW2#F$@*"+YXW5:62FGT[,/I%61#-P#D@IJ0"98P"C[GXCX+"S>KZ
M,.9;2-"JD#/_&&H#U=V\_?8Y?(9WQ=%+MQE)T%JEY[R@9:=RE!(M9PO^)MWP
M->?_E#%:\D4^W0&\"-\6SBXHE*KV)3%@P%1IV7/<QSOQOW7G9V\R0^0VG?$?
M9^%]\)25(ZM:CAFFI#(][@C,""*LK<9GG6DT$IS;?!6N*E](LV\'%@<*0&@;
M 6-5?3?H<\(?\D<:1EA4K$G2;W'[X1[O%0N%3HMO1.5A+V[;3US!=3E.=V&K
M462(5,Y>0<,A[0?R$$%J5Z(.2AO'61#%44X;K)5OVU+M1;[*@YIB!4RHG/PK
M_W.57%7WZ?# , :2=\TM6OE)EQXB&0Y1 4E1_I+M__UPQS[!7FF&[UCQ@64'
M!:@$%5X)_+.E(<F4V-W[#P]8?+!@6+DF8[,W:><K'J_]3$^9;SL\AY_XC1OZ
MCG=)8\?#G!_^5-89ZIM\-#STA8P>6_%[@0M2C<3[9M\.QMHGQ]O(688K+BDX
MO9,!M%]\EU_;H/GR9[0R&_,@4I8OH$L^ ,<3]J!+_KOL,U#=MLM#$OAT)]+T
M+[>^6Z1D%!R2!A^-S3%4<SSJONHRW;]1,O3%\]S;PJNOFE\;Z?SY)>F"Z' :
M6.CXT8+?1AJ]%JK,+(H"?N!ICHK_5(VNV647HT@;4FC1LX5.EZA(J6CRY0B0
M2G1 <:F!)]]RN&&O-_SB$V]J%MH+BILNF,]BZK%'J.,G#YY" ROCKPW)L0&M
MBL7J &BUBM (-BU<&&=<NEH&H71M55I!&GPX>.C!91 F62IHRJA!!&CPX7"R
M949<:::OU'UU'*)R+7;)H=2&#;Y/]EB^=E]5E'WE=\.IU:FBY=7)0T5-N]0'
MMC%?\SU4@>KVP]D'\:&\AH<R^XZ62Q<U'PWJ9#&@TS)UQNM\^'5?CB04X3*D
M?]_"O0/1\7 HV5P^*HWB$RH^'Q8;6180RQL_RT)DJC\:A>YAO/8X7%TMMK;6
MRKY4QF#=!I5Q7W-;X\\M&Y[$V;CPW7,N=U88G=+MQJ99--]O>Q 82<0#O)ZB
MU"YUDTJ[RBF4Q@H461-0V0^C:AI%1;2A/USD!._?9=X6\HV2]TRHP-05Y8G7
MFVTLK7?90IR5]2V[H3T@B-O?MM(7>!^4 +,50__<\A>315SBD1%SXLS+RCO0
MH$J<[KW;@:.ELF%#LR>?7]XKMDF<XY6!5$V^[Q(C3P@,_$D%X%"L4\K?G5/J
MTP6+2R2.QI\-?#/R84F0,#FPRGLNW[K+H JI*F,4!$M-5D$8145C2\^^!%>^
MVZT?@JS-,?_WP=:YH !8G:FP\I-AC1,I0:_*&I%N.*R:8@BL]7BWY1\,;KDL
MR'BJPEZH_6RXW-]J3\'P5O\F;J>1.)@2@ 89/1]A(NMUX/B1AD/G]V""L=H<
M\F%_BD.ZQC=!))%O$8:(+=C<J8'$J_MJ0/N10(G93TJH^ZK38-Z0R\2/+-Q&
M-X[OTC6;G\U^N3K_S&^8F%*_$8S_(42L9F#KR*([+M=R02<HR<8N;M?A=-\_
M!?]#P^">-Z#P0T4EFZ)VE@/^N(*)]24 "+PBZ"_5;!3&/[ <?W)B'!V$FG#%
M@<Y1_@*?=2U<U0&4^A#@MYN-)V1RE&8TA+^\#:K$^=I/!Y>C49:)4)F68DTU
M-'W]=\/79"A9F/)V76K74'T$"PY#,32(Y#< ,"X \@G +4M1Z/?Y>OC@4A.?
ML$E-M5S[424%U ERU=]8?4@_.<]LO5V7@K^G_]YEQD+@@Y'\;.6$1>D@Z3^/
MUB-SH"=F4(S$C<-<>6%5>P6+VW:)U%9P#J[+,]"JFP]GN\T8Y\_!KE^*DE+6
MNEN[+&J'B1[(-^%GJL!S&VD !]#HD(,OOL]%3[>P_/3,+TVD:/;9&"Z3^GNC
MT[M6JFWXW]T=>^:WZY^WCL=U:NJ6XF:7S7(K:L._TV9I=OW+GQF7Y/A@JP.A
M]J,Q<,IW]=V>;C,V7WM!\&WKZ-U> 3D_.E$<!A3 @+#LD]+;]D#EK"71X?@_
M\JDSP/7*3GIQL^.#[L+_^45L".'YS=8_[J4+JS@HE\RCH0SLSHJE9:T&]S,4
MU"=O7OQU3R)#@KTT,M:C[V?J><$3),H(<:L.I*,+TB-R7%[Y,K_D!D* ^,$[
MO-II1\0[O'01UP N#!FD JLFQ@2!X7P($!1T+H."+A8+FEOV XGTR<.5+Z+W
MMY#:IB*[&@R[^+M>RWJ4G*7JMI;N<"F(B;3;_Z9.6!XM6=IT9._R7B_L\.9K
M(Z9#AH7]@PN2+I]IKM<X^F51TAB_0TTC3Q1MUSJQNQ*!L;_^.O58L#4_"L(]
M.6?\QU*0X;*6HT 6Q@Q<1[AW3G?F7RJ,S'L0Z$&EJ 2#:(#RW_![J[+I+5UB
MZ4U1@;A4.,TT&T'D1JTZ$)7I U4),MW1'XW-LTY6+V\_DDP@Y1(N>'0;?&#U
M-%VL:;B$'.PP>(I7L'$<OUSC*VX]V*Q7%JLQRF$!-N^\9"'VHS%\('&BA]4%
M$1LMNP3_,  W0(XP8#LJ/ "-ONK2&02E'[ ,!,3(8&T'HQJ$#NHKKPFQ8F%<
M*J=T2GVXI-UL ;GI-EY!(G^INZGJBP%/AM"N9<G2:DMU2>-1A"4EJ"8-T IJ
MOQO>-W+E;_CU><U/A_>^$D^BZHLA+]P,<*2RC\F]HTKCII)<R^_D0X@-*LXT
M!O<M:3QDYGP6]ZA"02MKW644;08QT#?!G*\K0'*;?3<*^"!XT1%W0-@/?J:>
M>QF$7Z)2*:71MQTN M^A4>!M10JD,%HG::4'F(8[(3E^\. '$^:W'H*N#=%A
M70?Y\J7X).UGCMR?T.!>L^0@7I<G&94T'LX+EL$!2;*>TW@A99ZNII\/[>8S
MBL0T<]X5?3!@B%(IX&-ADRYMSBI8*&3S(GSPU)]'Y+.LQ<#M'(:C8/(*2AE5
M2"F5K8</!J^TG:8;C4C74%K CM]09Y[#UB#]R1\T;H&,I;WE$Q\^5IB#.J#=
MJ3LH45W!;8M2$M\T7"=B+N#6LO7#-HRHD@TC%29:Y"\ZE-20(=-&9?B&=I>:
MC\:8CED9^EC_W8 ./]P@>D?QJ_57%J_.^+'@@GVHPSY 5>'_[]X[SZ6>O_TI
M60_R$N;NR@@OV60TWB$TQ&/>6O/*&?O1&+0Z04;IAX0K+J2 ^B3*#Z1_8;04
MND;^NI?;3*5A0FW)PGB@@08QUI->LZ.:?CV:8[/G"1F>@<S.JK0@%[<=7O@T
M0-AO IF6VKC*1?FG@_M:I'18XV11K89/O4W,<B5#+FHYI/(/G@#MR*T#W"QO
M;U6>N%M1SZN+($@U&DFXAEEV6;Q*B3.W'"5M/QI65X+O 17\)Z3J&C&OK/TH
M+;*)["$2MB& B6NR"\H@,Z\\V?MPBATJO_J>T:'U%$N<W$(0RFSQ):*%\9[[
M?#EPIEBC2J##OV0?@T<:^AA[5258Y)I9/<?R&M<@IB <%%9:JFS>X?:]8\\B
M[N4I, )>1)R+#GLI"GAYXLUV&"A3%E/3'>FQW5K"7E-QR93:?5H0'$&\:Y,0
MA_O#H,KV(#F<]R/PE[&*<>/]5,0@%#:UC*N=I( T*^>6M!Q.0Z2A%%F@W-4Y
MO_:XGE2M)U9\,1*3<!5D<5'+0?7S;*9T(J3H3.EBM.X*/?YPFIT"RH3Q:KKF
MU^W<\2%% ["/K_RISR_=%8V84XIGT/##X[0Q:D->RH+/O]A[E:T-8;")!BSZ
M!&+\CL:Q)[(P^%B_^-MHZWBXU:.*F=J/QN!I;R;Z6OEK5];:5G8D>,U#ZIP%
M;F%&I/GGX80'OM3\XE"A$48>0F4E@-K/Q@!74VW,&E/%F!(\D((7J2#_>$^0
MD:9$QW3(4V$T@ @@K$<J6@SLOW"#\UOLG OPG"^0V:OV;[=]=!FTH"UY$%:P
MV/HN 'Q*>^LTOE_!^()0Z&<:,@J2</(I8*W)C<1LFJE250.AT.Q;2V_ =0 %
MJ5>!7^X SS49WHN!]KY&\9J5GPQ^@W21K9Z M-C(C3=[ZQ;O.6W&XB<<].H*
MW.>J]F-:6',.0WZ5^TOE*A?%.>'W>$LG:])\'0\A/FB:'8N5U)X:9.,4F_UH
M#(O=$0F#99DMSVS2+T)+7@,I;]=EHDEA9C<<TX(,DO*V/4!X5EE-=3'NIL[G
M[NB.Y&'58;$UU2VK/QJ);&:ZHS&DQ&WAS\X1&,[%N ;/UC]D(3N-38:91<H$
MM"V'[F_\^>!PJ5/?A%B_9 LD87S9,\#JP?UW>I$*8S>H1 *(KRBFN**A90\*
MPOLP(6>"![;"A9)K:KG>2:J0^$T8+$-GG024"]DIBVJYSY?#2B"Y@HUYR$TS
M Q$]IRDS0RJ37MY[5?),/QT.-XG46_"A5GK2TFTZ//4_!Q&6WHQ46&TIH&QI
MRP'?X$QEIKIZ[14?V"W<P/SJP@VIOP\VOU_\D/+WAU\T'_G]#L:,F5]?L*?N
MJRXS_3&Z_<J7!2<2PXLH/5&4XU_WQ1C@8:I]ZKEV0V?-5BHDS2&!#Z5F]RW7
ML3'%57OSOZ58B:NLQ%D;<B/*G\3<GJ2J9R6(9M.OA]O6Q<6I*T]E]3>#L?(S
MOXGCU1D7B&ZXH(0!?EA"NY*7FH]&CT)0$[V_)Y4!MZ%1,!TLJUQY]F@*].0^
M:.C:K(L2[J.KP9^E#(1Z;5)'U4?#&<W@;I1B:J,RR[FV8WLF$HO> 3A>Y12&
M#4/.*>FW%&PB<#*TMIZT*=;X.R XAFU:8\_--QP<DZ>R"$7-U;D?#;OI#%GX
M2",^J3RIH>JC(9$/G.4RI$MI2Y;IP-<E,"F-/^NGND)-><32EB-*(J@M3MX(
M(GL_:I85.5%3^HL?;>@<;>R%]N[JME:'?,]BF-0K?A:Y$+9U/,B 1[ WB%1;
ML<U](,YP*2/[4AB#,:0J0#_7S.IZ7#QS90'R3F>+!5>/BL-(*AIV:0@32,_\
MJJ.E.7:ES0;UH28*5U8Q:Y2KM!>)X3%Z3W=&]<'+D/Y]2_UY53V+)E^.,=1F
M_\":T<':R^*N=:+3H52Z//W2(4/=3X[/^W;!=E-Z!U0T'I'*#F';>RKLQB=V
M@1C6CN>IL+E2P3K=:CB?SMU]B!?)+KDV*ZV!%1\,:%G0[J2"NM*EQH3*CX:[
M1?%1OG3F&-A4\184-!P2S2GP'B&8)S6HRIU4_<UP=X_GH5%"Q_V?!KY;?28J
M/QE)2)I9X^:<1O.0;2J@E)M].[;,(*U*-K9T'T!H##E<-5P5M1S6["O,&U(_
M$P":*8#V?&$LHVY6E36X'>$!0RDDI 8<M.KWMJ#E\(I+D?*Q=[GU[)>#BYN-
M:MB4-![RO1*E@+F2>QYL'^+%ULL+PS4\[45C+.M4&!*RU^)54BAB$ZB1Y[7'
M?_*7?_J*^B=?[KY*<<YOH& ;%J*>RXH+]P'4W@+SYU^]!T^U"P./BBGB,_3T
M]/0-SA),T(=W[WY\"W]^ZX/EFH\52'[U'XH>"7P"\"7$XR3__6W2ZWC&_ZT8
MOY<9>!P0($6NQSYP5P8.BZ(1_P$B PFV\8*?&F!"S_XW/7)16,0(MNZ=XSDA
M//6^R^7.;42C?=E[I.%#$%&YK[A,1%S9"6$^<40W))+]$,=WR8/HZ3CYE?M0
M]4#>J#Z^!GYE-^3.Y/?TF/G-;-^$;]?DNVJ=>]O8B9-; J]>*V?<ODP"\H+:
MPIH:^0O0(TCP_XZ?!V^(X1<7D<""2D]&79,P\/F/<R$YHR7]0.ZP,Q(LB-D=
M;C;>(4EZ).DNR5^PT^.?ALQI%-,QRTS'M'8ZL.^^M[0A%A48R91R>>!&,(A/
M") G2)\D'9"_J"YZ/[S]<&I>2D8//_7-3=I^ [;! ]<(")&$$E\03JOWQ2@O
MV)AH(^V$9T6/A)K@43'55)(13-Y:8Q)R$2$B7:CT;8X+4") BOQ%$.M]U[4;
MNV=[V/S!NJ4;J=N(,HZ@W\A0<\R/GCUX3 0[=:)J@J:Y$.#'Q,/]%N@.CHO+
MXJ<XZ0C>8^A*Z*>R,X*]D=EQ\RSWZ8AXA9C)7W/E#35T02Z_6(3'M;E;H$<"
M89HDZ9- IX2J7HGJE@M:ST1T3$3/1S\5WNLLY __.&<C"1B8NBYO$]T$$3^>
M_\,V@)!XX,(+@D12G!!!DW"B!*CVSPODD0A7*8-X/?[2G(&@$N[:,Y4B/2%(
MG 0AD1WTRF#BV09Y>1XC:+C,)&UGDT/$@D40KAV158;J<FAVP_^%97[Y;L6R
M+[V9JKID4K]%)B.2UC&,/P[@/:Y@8D+NH4G?O!2 =!6DQAYJKY'$B4$]I:-#
M!P1[Z%U$[X=14S0HXK9/LV]EE?DV9C9T4AB4\<HP:%NPIW7/6Y$CQN1QFN'1
MBI'LRUU2I^1NP[=+P$6$"T!PVH0LRB:2"A]^N^?@DKHTY*_ SP'7,\&A11+Z
MY"^BA][/H@VVY5[^<D>2ODXBU1DQ>B-HJ;(X#1@[^\A<0';R 9_I, [-N^=L
M]LO5^<G['X]E[.JF 5)$TSJ6T6?O$LM<I#(@(3\7\$<POUH6[FMGLD&RXQ][
MP2DXKI%[QJ"))$@$1?)&TOSZ:+@Q!=IJEBQ)MD;"B_[Q9\8?OW"^VEW31^JU
M<&X8/B=-4S@BI[_T[.E %'*7.5!EXZ/#-8< KAT^N&"YXT+,QYU/Y_B/&W [
M ?:Z[W[:>C&[E@CL^NLO7,_P8X3GD$U;7>::+LD."X6K9&!D([O#W^/8B!H<
M2:B(X1$8'U$#M/%"C&QV,X_-BYCEW!F]\C?;.,)3^:'5)DP.YH0(HA."9,D'
M:UPED</5T(*IX&* %KSN)((%2)\@;"$Q^R?& ,C#CICME)<&1V$W\L7Z7'GF
M-)TVG*;3@:<)\]YEZ&E!D$'+L#T@3B3UXG"*(^//*V"L)%"D]^B03(G 5BYB
M(':"SC8@QP4I3M":D[O @G;&U6GFRA(WPM*,7H[W'1H,)R35"S&Z.6:.37EY
M3[:',PUWQWV1W=1)B@<1G!XR-_OKF]]&M1HZL10;/:'2D.KKN-GT&G XE L@
M$Q4MLS7:+.2T*/"9^8 "S1XIW[Z)7'$<S'EIOA0U?AD)>GUQ > F-V$ =<!F
MH42)/$0]3X6!"7JX)I)DSZIY5UQX0S&0!(%FX*V-"-3/M-61T8$03)B%8N>9
M> GU(^/,RS E;5T0Y)&*4>:DCXPS4SYIPE[/0@FB'Y5@&+<2J1.?W\1NS.@Y
MW81TSH0GFFX\*I,&S%HG[?0ZLP>\1!R#]#&RE[Y'7AAS7IZO"='$D<7ID;.8
MOE.:\=GSO0(!LX[+T&(JW]CH$W797-:G[L1FJWM0SWA$9!\$.[%AU>Z!2[EC
M!^<NR:)+P=VZYQA0)2J6"H2'=HY1@S2(]FN^6R/H<D(BI'Y$_&6S!CEA8K(G
M2!-!>R*,H$?(7SJS$Y@,#29=P>1&,FEG$9.4<EFX%)VE7-3GPXAWD ,2\UL6
M1)W->A\%KCC[0O**29,;V0=>L51U<*S\E@,#R'Z(\$*KGB8$^YH@]Q=]<U^(
MD=I"%41:./2;0%K([&B">&I$U4_S.*(5O=AW@VCW;0XJ](:)0GS/8J R XQ!
M<=6^$'9-'U1$1'\3Y;8L]#@E3JD)>:"+@._ORR!<4!9;\&'<ZE6 L$FP&J;#
M,XM_VRXR#")'T'*8#=2TI9_EDRZ-$JA=)9->:2,(WP<;X:@Z-L:*CK#)UI!Y
MLIUPIBT%A:FRB4V$VDR7O68^5!], 2#JR@ZG01@&3Y"=X&SXW^+=P7GV/E[#
MHANB^ID0W1/171'5UW%SGLZ[3[&_T.P["AZ:/#@>O%4]*FZ7[)'>!,R/[Y\"
M_%F7\[VC/@M"='*?;VF^QOPJI ?&')F3 'T2' #A71#Q3ST&(@9!A*N=#P,;
MJ8$0,1*"0[&AY0XQ6=[K/!UB%#F>^3)JFE" O/:X2$^?_XL>>JO*?$-)C" U
MPLGU+MPFY31*2Y=='QI6E38]ZPY.N*AZ$O$N[$:5]<FI-M2FLD8F),WSG2V>
M^6D^J.)WFS?AP[OWWT%\]XGNA CSBNH&E6T;%YD5UI42;MY LC>8!?+[F(7,
M_3W2V2C7!72Q-PE4T04RDZ@"'"$(GDCJA]GP+.(U]<=GM=JC>]&X'_80M[[<
M87(^Q"_=!##/<\>[VSZ G2V"I-LN$B4_;7TV9QO.E^WTP'ZYE*OZY4X '$32
MJ"CI$[.#P3C/E8X3%K*V(7=9?PUA2/9(N/%2C-P)1@3!B30A'@DGIANXBAU+
M<:[Y&_0FI!N'N2KL12:N\7-HU)QLZ9@1/6C(#3R% 3HL9+55^9X<.?.-GA(U
M&;(KG OAO)F^H#DP=_V!$_$R#D1AJ.; QR$M0W=J/_OP[L.WTHQA5Q/HRK U
MJ*&J1P-4.5^"?*\@!/HA/0C,I$"R$;J6!626ED,O$&..8-0YQ =[H]<VK<0P
MV^;I,>VJEMZ3%B/W\H,>\6A3X49BR'Z?0^8;^XOO.VN(2)#UP_X3#.J_\)T*
M23Q/03L=4= FFCA!ZD221XN\A2>@%Q;3ROY+YC1S=35AM=_WSQ S@S75%0O:
MFZG #6\40.C=')5#V,3.9R'6A//G76%L:B!*1;?''9@X3@J*JQ_N,DE=C+(+
M  _6G1B!$Y$MKTE/O'J_#S8SUXIF-UA(H&^!+*H[LE 'ICQT[V*]\8(=I3E/
M2*N :=%9-E9:1O&I+HN<("]B*LJLJ]*J2K:^R]5WJJ9!_$T%7Y,-^()P0':>
M&8!CO@R#M4A$WO(YD0Z,P(].,9[2"!6[>.8/1Q"Z?!^'.SP=@&4%Y:X#CW>Q
MO +,'1JURJE[ R/Z6F5!RI!.9L3-_9[FQ=A*Z7E9\*$!"H <&PGTX'[G4Y:6
M>N2DX6PEPR*SW&R9P8H3DAX*46/I,^XHC^W2"JJV$-+%!D!M9XQDHZ* H4=D
MR$TH]_YXRE3SJ>_*'"XT[':A6@G[=4@?J=__7=\E&YXR3>>2\"?2*&_+'?HS
M=;QX!0AMLW#I^#(Q\E9,Z1U^&;6OFB-Z$4!P9C\0[(L]$=F5M0C\_OCVQL:R
M4<7QRL]5J6@9BJ_K<;HJCQ] %WIWJ'3(4-9_>.6G"VH<$R]E)36SZR.H]W[S
M?Z3!,G0V*S;G+YFH?PX9WVV.54*2F#1[/T1@CSD#L.^6IB2D83&<Z<()(74A
MXEJ:RC%C\W:O+I(XBG$KHY>D!6JT" .9D.-APE3L2CFQY&T!J52 :*K2[-DK
M2P0M7OG3-52VZ>1Q,:L^/ZH!$$>-P.;+8VL>Y,;5W1#=SZ2@VA.@T>9B/B9$
M=#U(_4@ ^#(458F2V5G6WV#)C)VQEA4Z*M+^;NPPJV-N90!.U$4(<Q+(JZ)O
M>H]9[HP/+\N"(FCQ]3:*QD"\K 0SB'=)W&QKSY;N8")"<A6$0;Q+1>=:8QEN
MNCE$,Q:GQ'=0R0&MTQ*<VD115'OT.#E4WH.Z!/\+.TRJZJ"PI]I(/(A*'!NH
MQ#;$G#:#]XQQ:S3E,0\XE90,!5=QMET+H[ZE,5?9J*ND6OZZ;M=;K!?(A1PV
M9ZUX4=1!/@1:Q\>-EV%$2_]O#-I$$N^]FDL/JY6J4]B(24L70/>\"B"HN]@)
MXWTY/J5+Y@L\A'X! ?KF_L)W]^6=?V*1<55JO34ZL*>KK5L!4FHS;F^8(<L2
MR2( OY-LR50L?^]J1B?CEW.O$C 4"_:$;2-T669:BBRI6QK1\)&ZET%XN870
M/86;U5V:7"B[((L@Q+ .&P>\=WZ]%*LR\TPEL4I(KEN3<]$=N;(T 8F^!^4]
M6MP7"2%9*,3*K?&9QH#9A<&*+G5/=U\BL,9H'7TZC]DC:JR'5G6AL4 %4UU
MF9XWT MA_M=&8G+2T_'R;,I?P#A6U-L*7E4T#&?5Z9U5 ]L^2OSK'?B="U'N
M>_84=<J,-QP?1O$')9AA: +8*D*ZHG[$'FD2M<0WT&QQ[SRWQ'8QI$"9HV=V
M1SS>TY$S[.4Y%2$?J7Y(*OH*4? A_)7W=^3LFY?.P7-@20T$<\J5SV4Q=*I?
M=P'JDY"S"EI44&_IELZ#I<_^P1\3%VK*+!BX&80L*F%N77Y_&;48^-_XR-W.
M\'732'#/?!/8\=Z-<C+D)BDNUY4,CYCCDW$<"I78Q??!&".1@YP,A%0\Z@FO
M+Y+6\ZQ;NL3X=2E"]%M)(.!L%F2L"1ZE*]VR2M!-(5;YA/C]U]'IDB4OS8W<
M8]DM9J$X4*?K9!S*>LXLG: N&<S;@9NP:=T$W#W+B?&W"<-V[;[-5>Q.+)6@
M9B^\X"D2215%FG;O]LO^63[<HF+! +IV__IY"P'VLT73"NOJN6^S]*)/4&*$
M<KO&RNF>JIR^T973MZ)R^ARBQW6M=4>.X 5,BI>:C]EBSQKRTY<S$YF0[62'
M'+8W>H_IULE)GZ@#^4,8.W0+D4*0#-H.Y5HG7*'L+2A:! 8L0$9H5V>B! ;!
M6LVJ)#M;+9I4L%**E5Q(=^;K28>88I%RUDE-8C.!VUSD:0)K:NI/:D"$;_MD
M'^"87O24>5W/ELQ5)!;K(!L>MALGG(4(,"&RPU44?'<^Q(TC\QF/D*M"3R$G
M#F <@KS,/=6A_KU'SI98>[_X(74\,(/\''@@EG_DVC^89&>^$8<:LHC_R80$
M:&D@GYU=3;(HL45 Z!.2#)#($1(8HK8;R_SDJ?NWK:K&ZBSXKK)A31_+I)J'
MR)BOE9RO)<P7WX?,C ?VA;T][G^6-++.; &ZPB4H1RWUC@2L!XJL@ *"5"T&
M5Z2]!^<TFH=LT[XT;<J) "=$TST:AHH=(I9YR:1:?@P"]XEY'G_HK[@T[B^9
MMD>W6:^IZV))/<3ZSB;N6*M(W@>7>A%S7$V(Z@:%E:0C2US?ZI)R^*RVAUE-
M""I81DL2?"><> ,SH6]BD58"CV'@PPO3-LQ2IJDD!*W5K>R0(6\87G+X<O(_
MU\RG[SL"EY,_$*!)9GZ?V'(Y*-\[ %GH!&#YCP,"++?@0OGM"H"(D>JQ\=,
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M57<I@0@4]RJV.^GWY!HZ)F\2,4KUW?O)Y/L.#+3\/G]D+G5/=U!^Y4HZ:@$
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M6Y3!9-.1;U@'<6 RB,)T6702MO#&M!9^+>'H=&>&N^+(F<]M6HLY=1!ZTUD
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M"*LWOKT4RSD<ZPG1?1C5GWOT'DHS$=^ ?'@>%TY0%SZE/EVPN O#FD[2%CU
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MN?$ZG19;P O)(PEW2!>8$X:D=!Q,I.WC1\N&EQ[_Q$#Z0)"/WO$L'AWFP0/
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MXU"*!!SI_ ]<?TC_PF@I?*MY+40>THOG^0H\G[=<,VP%8 O=3D@V) W@QM3
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M,]['/NW8/C.5_9*26VRW$K74H20?]_SZ%Z3N$J]JJ0FU7+6;\>D&V00( B
M CP>>>_1?Q->OKX7F8S\2T)9$.F9>LRDRY6C85&"J7[+M0@MDPL>63[HYC+/
M=7N ZV^0[3HB5 7J&HV[QL.V9L#S@KV88;FAI%-I4;?O8\WI7,OS?O:\W4#H
MO78U>^M+%&<:+E!U&*#=#L,\]=-Z$A2H=WA,7"%455O$:@(4*%>^5+[(TAMS
M8)LD1U,[" 5JS0I+8M6:XDIRJD26RD70 T*Q]/957UU36 :+ A&X7 7LD'KA
M@Q? /;XXP@W/G3"HJAWE6CU?1"!DMR2Q+)-B.@S%WC6>GJA.D  ,Q?);.E.K
M5%$LN>-5D9]Y(:#SK)!'9D[W^;[S%0I*?R81Z%SF6[SP=T'$<M\]UE%-<774
M#'$MD7K^TZX/3P:#8C^X-^9%[[!YZ3ELWO<!+>*Y2F_0&).C(!7<R;S75TI>
M2^],_J"F]US*!!X%0@\T7A/B\U=M[(J:E'=42:J&&!@+*IL@E2F<^EL4BQ6_
M_9&Y_N70*)!YH(5L,RKD((=&@4S5TU&7"B\$1(%"<1%,RJY?7J@T(A7@*-"1
M/%+..4?Z2MFF4)MN*M?VQ6/&C!]*/'']Q_:WKA?;N"G691L3F5]4 ^T>F:B2
MM\EM=!'X3(D'NY>,)D5V ^B4M-#K/=QL!KM&M?]>O7\'4H"A$!67H9> 5<+9
M27Z#ZT/A6'P_<TB5;:0 QX).NV#3*DN3U(M8!$N"CQ0>!4*]^JR-,)Y$KTKA
M<2#4LL1LLO_,1J) 4JGRQZGSJIT+!2%:C>-T5STI, I4ZBS<7TCPN@6^NW@C
MU'LE9;)YOB,VZ;P6$Z$@ <NI%$I1^-RU)5$44&*50JM<GC(C^H(E^],#RV+@
M%0CD>W341*Y)4/)/]=!A19^W\9X%&\J'#HGFP83)4.<) 66_OY3PI;V1*R_U
M!%%E':SK_>H]".=W8=WK0O%U[(BI4(B61G:ZQT1C^>1.Z)F2P#IGS*MXS>7%
MWS./ L.%!]!H,>WQI 0,Q3Z8U'"2>0Q-Q[H^=T_!^Z *VO+<W!%FQ!',$W53
MJ+YPO6^5<GK*7I(]ZZD2I@>S/GGR$2A.W2/A<AKN-.E![D+H0Z%8O"K>I#2$
MC0:B0+%WJRY5#LD?^O/^$@++:LAX% @/SJ=OWV&:U>UY(KTT6CO!;Z$@I+CS
MB$R#RJ%1(--X@L:ZZ^29IRR9FCT5N'[?2YLU&@U$@:+\O1JBEVA-\^J2M6$.
M Y__@[_WA5L<D)?9'_RC0M(TMB"_'+#[*_,FP6#6F% IJ2?]010DK:I:R(YF
M"P#%DMMYH/)TD#Z8>T.NM(]7&]!_#\ W\,\B.[*P CX=6*4G8"WO$/?-.LOQ
M*/;K"_G6. 4TCN#/=5ZE@9^)0_Z_RH-H.X?S*W'KY>4E_+FBS_&WEGFK $.Q
M;X-\,M:#4:":IYFJ\C;:$"@6W2Z3WN\D*HV5&0U$@6)N>PB*H>O+'2H&H4"-
MJ2<P*=X(37B#5&U%!"$P"E2>MP'-;^=<Z<B%@A#0M5)NA,+O).TJ1" H*-_,
MAI.3O0^%8O'UP61O4NL;<.'NN8R3-.E=@-7V^I%3NF;%VK[KU]GF?<</<*/X
M!;Z6VH6:<2CV7=3;0B7/5?"N=ZQ, E)4'9(H8^O!*/:N47;+H/"P'-JY?5[&
MHMAE21:G8M\Y7VA1FN#P_0\OO+US=['=[U&PB<2?5V41\.-LX0AL#W1]Z.]!
ME]#("V](ZH7\32,8!<IXC,$(%/O6J"/&K9TMR".P.?77(Z.!*%"\]\)]07@F
M8B]Y=ZE7$JT/13[^U\@'/<-<#6 PR-^R#YG'N3 I)=L-K,P+<[_>#7R6R$1@
M#]#YV8LC<LC+M]QDD2^ZYG7/GGX$"L:41 55ITXSQ/5>F56UN'Y?AQFS>DKP
MNT;UELY>CC CBKU^IEZ4;$! 5N7B67N[C2@%CQDAB?@K1:WJ$>='0;#F:\BR
MC<-J4[T*DST;,QB& KW:S*_>%H@==STP',O?[4&HYNJ_6\*2-;#?!%&0DC!X
M8RV5B[-95KT4XGG$?"@((BE GN_?L67,%;.@0+[=L^02#,/7F!9!5+F32C\*
M!7*ES^@FIO43.NYL4M5YT8]"@5S75#*XL&F&X$#+QE175[ :.!4*,G3>??:;
M$(LO=II!*%#+3;L;;\WKB2D>(PK@7%O)]UD*?&-ZF5$"H]B+&ZZ<[YAR[NIN
MB5FC'H$"*68I-HJ$-E+N6"J^,@=%,PP->K7A?T/)?S(FT]B[&';0@W6AP/1Y
M-O*Q*!#EN0A%R]*^=UJ$GGH$"J2:MYR&I<%77MSK="W9+*= @7:SQU3DV_DK
M3<>B\=CEA^DZ\J_ ,I9YZUI */9(<H4QY$KST2B0;>?5,+7,S4,0'$7ATSBJ
M^N.U:]OF#Z%8YV&>#Z9/VCEB<A2DNH"E^$&8L9>)M8+,+_/$9QBR\'V6%H[-
M;B-Q>5/N42;&02+_7UD1^GV.)85"Q07?'D$%!PF85$5F:"X6BLY]#$!J[4_]
MFR@(*TYX6WV+0/IO@WV=3"&BD/%@U]>*PF0!90[ (6_,#IKN$XG()DA%!H_I
M&!1[6+6;+XI2%FN4"\X>J.O]*:._/#\G:!&ZF]TCAW1NGA1-$IX.NY<X[)HE
MK2]1L,VG?D-3I0=6!8\"H;[E*G7BM*!0+)[?+AJ6N*9XO!0:!3**IX[2$C>Z
M,2@04P5J4 5=M-% ?'&_NB1.\;HEX4_F[V(O2JIF)2!"Z]+CAA5VK*=#00ZX
MU>SCI"@0SPO'!9L@;V(K>YZF&8(#K:)^EX71HAGBVGBYC"G<"]X"FB4/7N23
M7;"^7/U\>_4%I%=*2*1OT3-@!N>5(JHDMR>P\<$4BT55(X1 KO?K^5O\OX3&
MSUM*"/M#UFA/ .3<Q"P37.$.S]M8L<8?74M3!(/BZ#?]JLSE?^^E?*$L>0FN
M6&3-34J6Y:"N;F@_C6N6JVXMV7X?YK<6;L%5/8 *B2:][>C&H=C?TF#C]EO"
M'1V%*:=H9*,=A (UY49)@5RS'>^+1GS@&M:-ECWZ:10?NF9E!UF1:7'/&HNA
M*':H4C7-&KO:CK9=8!2HB-[X*$U=Y0#GEL*]]Q[LLIVX14SK2]?G!6[1+,1R
MN?5H[UE9ZSL4;*(+VPT)]:% [(&2O1?XA115A*.%@*Z92'08[R1O:96P*/:B
M&Q.Z8N$D<7TK":CK_2AO__4]'SC_"RF+W^MO9_83N$;Y:Q2!S0_6,-W'8)&0
M_V%E"7^&L\'> D?B5UE&8U"P9$.&:42<ZWTH[^_\OX>GX!V4R-\S+PPV ?&E
M33^$VW/,5"AVK1)U11GE/*NF_/"G $QG6+<B7=%J A0HYUE["OW5 D"Q9/,L
M>XL4%<%HYR>S6^KZLY>D-":L*AWOTEG>O$U+9>O&NT;X,^Q/HPZM4,8(85"P
MY>#JD/Q_?LZY+\_"^%YX'QQQ?N<^PCRSZ28("2U>CK2N A(0%/M<AM# P.HF
M/VOLM&$SH$#:-#S%HZ 781A_8R_W<AM46?IIA'E1$*A_3;V-BH=N#RR9#TYJ
M*\>/!<-9 ZPXA,E>RTJC9KD 0V9V+=MYG1LFDHI\-+;C.1[LB0HLF^4!7A5Y
M@->;#5EW<YT&S( .Z=LH?X"4L=>]91:H#D_A(->H]1N=B8ZY$M"Y$BJ,VKQD
MPC^(1R79VC(X'()':!:8&Q HD!"D;169J+^"<>X#\>$.Z55:LC1800\TG85)
MDNVJTAWR^LB3_9CK,_E @QT<LCSE8!W G^)> Q(P%)S0;!W BR)X>:CTTZ'Y
MC2QF8C[:]5Z5ES-EH2%=$R2SP<[E;&[)/Y)7WID^2D4) 2(8% Q9IVAI+V")
M[ 8F?6XXVN0H2-5UKBLO05)@%*BTWTB6V1M=XT /C>3L7>\(?64U-VC\+=TR
M#O,BR85;"(IB3Y1-"!OM4%FI_[5HFZPF0(%RE4U8WX1%B G 7.NWNT8%)V8Y
M->I R6)8)D-<H\6;9O$&6BSICG?%:O31JO*5Y=VTM@%-Q6;9F%.C8-Y>R^*+
M+-VR$C'BT*P"' 4ZI2<%="\[8(J0B1@2!1+B^EJZ8CBZ02A0J\)LM]$>9/D=
M'*#P>WGY(@4X"G3ZA:%+7VG!5GFOFDZ5 XEV&# 3"B(PV6_60T ,B0()0:4^
MV?U5 NI:ZW6K^T;-OA-WLAK\1H-0[%"S?!TS.WAEF]RG\Q,)_9N8?DW$AI?)
M0->[!\<BB9E;G+V?ST,G=6T"VZC$&/.AV'/CS@,OS<X#FN*N1\R(@BA<FS,5
M+Z@;9N%HMIX%!?)E6+8^U'>29Z!B2!1(=$M6U24UVJ6MA,%8P[$X$.WUZ3.(
M,PN@42!S)ZF@+/K>M3JI<O=HL.[U-6E^AX*RME7Q4=:5 LH*^E?*#"\5*)(]
M*5ZVR/WB+0@4B^[?HLK+T@'$Y67H!3MFXQ9_5&5YBKS_1]@+^B9SWAT_L6OV
M;+H(6+8"MP&!\>"N&?BLSGVP>\EH0DI3.2DSTWNQR8'SH. 1.'+Y*W!CIY=Z
M! JD% _VY8G0VD$H4"MXIV(VD/._!.GV$HX87&=HE6?%;G3P?_ZS]RZ..EM/
M@R0NQ+(K\S"(.!A4?X]BO[HQ0QZHX8^-#3N364V  F7^GJ_M26&/7<&^8E?*
MO/E2^X,&9'[OZBN8@A_+Q_>LOWD_Y<[-"E 077.@51QF.!0%FKU:BA8G!Q4B
M'::3._V%@"A0:/3CJIS #W%1:\"LCY=T' H$2^=?8;>JXF8%"(IE5_42:A>G
M:.D",!3++^(Z58* LG*V%!B)M?*T)6&H3%YI0J"@?SLSJ&3P6MW5 7Y)^5*K
M"9#L$[!.F4:;F_PJ$U,"C&+W5([LVN3)"W.P5#RXKV](P%XC2RIZ#)[.]?V^
MDF_5\QS"F[@]LHRJU>9K0OKYUA;#4.QVD>ZM;52/2JU^CM\(C7C:H=3JZ<(@
M$1.%<JFJG3-3IM_84@7K^E0\!>]YQM:WN)&JE6=H50E;HE2M;P!VX"E>PE2P
MT>9%P:(2L9<[NQ1R3^PQ&SX;#F+T*GZJDG">!U00-9\/!4%8VD1:IGG"+\E2
M8T1PS@59N^LN>QIFT)RW D-!_TM""]N+=16] @$+ET?%#5H.C@*=MD-=VC=!
M (9B^:+2%+41596F$'<3D7D\!D_H6K]^ 66_O=B!@%][$7NZQ9HVW$87$8CY
M+4D"3UR&QFP4FOT>[%RMW*BM: N,L&./4_T^"H*S9CMUSY0GDJ9A_KP*EOTU
MRI+,"_EQ2604LYH !<J?!-5+)4I6 NI<SUZR3 Q*O,O8[[_.;GR'@MYWP!,@
M<<I\G<;#(GD7)-T8'(@9]=]#VG-/4O=)H L%U19L*DD9SHB"*(+SWDKA8A57
M<J]<F?+(?/-,%8 8O(*+!Z#([AI2OA[U!UR;([6CE66B;++(9P6\"V?Y1?J\
M93C%-+^05D4*V;.\SKO18^="P3MMSW2G=ZBJH(W10.<JYP[X,GS8QI$D0:+[
M/8H]J60/][+J$YE5\"@0&K-61UUK:_*R((V?<BVT>NY!D"', R'K**$ QLH1
M3?I3T#+1:YE^D;=Z9Y]S!5+OIR$##)@9!9'8V\P@+:\EK?6:/:>SF@ %RD6M
M+.X8%CI*&]^[/I."FEB="YD4R/72Q:4NF(SH+%\.Z!H%$T=YWG^6&_$&"12C
M38KB)+6-@BH97=5R73D"!5+R/ J>0>4/S<+HCD:!+.@DF@:_%BV3JW*:_ 5B
MZ9[+))V+3,>Z/L7#BHU?1,T>,3?!AD_1&#EEI?.A/^Z:U&5O.W8SS:O4]O+^
MY5#.+W)E\(W7@PMRLYYE$<B"=%TXY[UI.%? 6BJ_2?Q*O5W]2B2W0%LUHRV&
MH1!8XA;E_=K6S9?3/+C?<B:U:I(4(EEJ"D[R:SB(2<(-K%H>PVT!N!8N/\4)
M[U*?E.GRXKKO,C 4%.\U_\P%X!=BUBJT@G8N:NZ#2-$&J_DE"KI_C2@!U0G"
M[#-H&N:T6D6:QHR:(:Y/PR5_#G,;%9V\:H]<WM.K5V-% XYBEQIB4I%7T@5"
ML7236YUAT?^!4SD7"76"6?X@_IZ  =$HY=/_E/!NKL)6NT?,A8(?^@_9^./!
MNK.]O.JTX5 4:%[X/C> O?#!"V G+CVN>^6G5SD !4H_@=1/MY=@U3V M<>S
M:>D;6'%RG-0C4"!E6K!%]>;';@H<:-?Y-\\Q\[Q':_9.N5F&ZCDV#,TKT_TG
M^!T<!.QU"^3]5=1/PQ0C4"#%Q6EA2E="5>BM% &B0$&B(VKWJFVA1^EP%.B*
M/12/A+F-V.&I7!4UC,#7<?QL*(C1X$J5I[T'A6+Q1AVM5*+6:@+G+L7B35*W
M8'$C:Z_K7-2/0+&/0&OO]962U\+]7U0SN!-5FC(=X_I*W>BGI.J=+0-#L2_]
M5SZZAFD&+2>LID)P#R611X/X:Y3LR9J'2_IA""6@<Q2>@Y31_1;..YB+F1>R
MRB"\.BA+"-T&^^<XEQ-BQ"R'HV#<AL23OL7IPCC?I^MWN/:PE_6KS08N?()4
M*3F4:VE7M$\ >4S$CX)E,"C8I7WG[-Y-]:\A;<:C0+BJ0O_IT&@9?4/)?S(2
MK:5]K@R&H4!/D48FDP02<!3H2!K(\*:3Q%<:@0.G<"Y.BF@;\>^]"-;K,W^8
M6*C((5'L7=^#P=YOV'@\:G@D%Y"GG1>&9=:J^,;1 D&Q#U^?GBD768=:4,N=
ML')H%,@T(H>52*[OJV(?C6H$"J1R\^#&6_,D/ID*ZD.A6#S</N/PC26LM=8G
MYS#E !0H780A=_M4KX ^Q9&O.#,J>!0(R=OE79%D38.]K+& T4 4*$K>!E:W
M:[, A/TL*)!OOII08"< 0['\AB>HN)KF99E;G4WZO3@;K3JESOFC9D5!G*K\
M$#N+"KW=!T.Q_$KGBJY-\G+6!L-0H-=),C$P;Q'VJ&-O@K^Q4G%P;;^*LY=T
MDX5]:UR%F\T$.% V2 XRWTS5\"ZZ__?W-;9W\%?C&_[%OMU%XM_%K_=0WQ$_
M\MY_MXYW@/P/?_RO/__AOWZ?>N]Q%.\.O^=DN&15Z!Z:#RR8/_-OWW5_X;L6
MQ<E[2B+0?=\)=BAN;PY_21Y7XFA+R29?8@)KY%L#,NEWK_';[^%^Q%?)_O@M
M^^-W[XG_?W@Q";;(KM+BQ"F*3;2^%['-!(NJ,M-A1L&:6E^?>$E_SSR:$AH>
MVCGU@M5U(4]-.TGVOXB.7= 3+?4"?MSGFB7T7@7K:W]_8OKES_2O([_9 UM
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ML ?SB'DPP-91)A&;C#^1&'W^%@\1H_6P$=?Y0(.=1P]YK?EU '_*EB:%=%X
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M0YI=GZ9PU2.*_AS)GI:F_4*(.3WO#KD=+^2YS-3$5][0IWA@(J/QR>-[-UY
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M8A$L&&JWS3H)X6A[M2I<<I0EB)F&BNN?N8PJ>,S0-ILI.?2JM)W/HS".4%/
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MC-),\XON8[Y]$TT6Z&U .ENVUA3I+%X.[Y"!!2Y*">/U(5UFQW9NLOU<V!+
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M5/<JD-'FE[ &,$+9;5/DO'SX83X"C9VI8VG#F@*5M\0$>"['N7[ 795=K/U
M_?-L#([L0-<A$LOHMN#.,<Y<",6!M-AL,\P81UE">JF"1D-F(Q"J\&JVWX<Y
M$NVBJV6-M5X\5C\ #1$T%Q:PWG:PM%RPK0/XL_,Z2/H]0LX6=?,IT!!\@V:+
MM+98D81%_'LO OGCLU=6W<>+"A"$.U6FX"H3LJ2)NZ:CFCN,(G57\(RGIWO5
M,,@4KM+P;\=F#"#1>OS%27.Y'5 E7AR?A3=H0HRGF[7.!)OY:P360AC\2OR?
MXI WS:G:M;3:6A6GVW+4;.1W);8,'\Y*Q9[U>'0"L)_)WGX&)_\>(9M76_ $
MO[UG;0O#]*!Y9*T"18AB527 \&V8.3Q"9,N'(_R_!Q#1S8HUU[M]&!\(T92]
M.6X.A$1IY%3TW7["[["9*'E.U"M<RODC\;;=+/X2X3X,8ZR+R#^JBM.I?Q4A
MX9L._L0X1& ["I\C,:\2EJRW9.?]?_\_4$L#!!0    (  DX!EE)+6'>K*T
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M?3.I&,<HUB!$9W,LDZ>CR/0O,A03HT#@"19_)N#4#B$R<Z,$=8=FQM/#K6?
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M.]L_][=O>T\<H;T:[TT?R;NQ_6#40DO8A41- B]7H-&-FV&7JYZXRH+F5^[
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M&)9D"6$0S'A>Y#LE&VJ.S2[X#;B66&U4=;67:_0[N&4=B])BK)J3-:&\*-:
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MVKK1U/@?3=Q]<.*V;[!]J" &V[U@$G#5#A++1$RB,>S]/</>&^VQGS?;. V
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M>60R18SR41E'\SWE+;QN6<LW,-8?]V[S?'-2\6_; P)K*MI$-T-!35"[(H8
M9(I+H\+SLFQO*MI*I53TKI:7N)Y)%+2LJ.@*WB_]C.5YSR6N[4!Q*KEDVT*J
MOWRW2#JEF3K#L@6W+EIM9IC#JZ\?NV#1CJ1Y9,P%&_FZ_FM8M)GF[39LD]L2
MY"=AGRHB1)E*44W"-HDOHW;9Z5'!]*Y@-AN^]8ZK'%%83ZBH0U.?OG,=SW,8
MVL5UK\KFO%%9U@#W=-:J3[BR4F%*$:'1Y85KI[!2 #6A?8I:!S,E9@V?3E>1
M%.7<P!#96:HTF: !L]18NCJ)RN):9=7USJS4V"RJ*+/D"K&ZF9]EY$O##8Y*
M[NB$8_Y(6;  GTJ@4#A<4;-P10,2CNF8.P^3$CT>IXI/MC%_#"JMW@65.C97
MA0E'TCVYWD$\!&)!6(H.N[ !<K(HY1 QQ=,F'%1"O!<7RVL+%R'E>L.\-.9$
M4J7=](!H4$H!';;(8RSX360>HQ[M78]N-LSBM:H4"=SKL):\WPA5[E*_;:;!
MT+429PDANU16V*B%]RJ7C9H0*2'1EK!!-U,@6A4T\2A(TADK^"VQRF1K3D@O
M-I]/:#&<VH#AS9M!:_G/PLJ65>^M66 I8Z<%K!",B9 ^5!*(G,O!!H.7G>%-
M^&B! ?DI()I&3>4EI@+E/^D*?+5?.[&BTJ0=H%O4[,8NBPSA:8:G!'1DJHTC
MN,$\0567A#6\9?[U9P'Y<0MN@7I4BEAWK.HE\)Q&=Y95)K$T+!4R^E&0+ZTX
M&5%B=*[$_9-\TGI)P4+7J%MB@:E_[;#9:UG,-/5LP?@>VLL@;&8E_M=P^,.S
MWGKW+^ZDIL=D]7=.5K\8D]5CLOI',T<V.U?VH8#CWW<2( 6]+QT$CJB6M%?3
MQ)^@ ?#PCD3B'(^]@>JYT=9@QW,0"98;JQ4Z.+Z1957/\,@A1PO+#1\L=I"Q
M^V$CBMGM5M6#!?_A;*UKT^'ZLG<REN.N=%>H>)[J2Q?.:/7RX(KMOJ=YV/-\
M@TZX0$LY)V,[X\9SJ>-D"3GJ^YS=R\%,;GOO4W"FJTU,AXYN]XCIG4Y^.--Z
M)]VPCB$HH/;^=TW,\&-A4,\FHMYH$_%M2@E^$+D3R]T_6,"!Q#&4N6L.X%;K
M4LJ2L:A7=3>2L4^UE8Y85)(51FJIJ$ERL5CJW-CP344XL*V Z96:**\V!?GB
MH6Q[L/\J]V3A8_Z.PW?UHME,V^76BV567%L*99U?@&-N&<2X18-OYL!A+]=)
M)'B/JWE!I<>&LL WD6/>98"N?L<IN58A#Q\C5S0\C-+MQ'59XMU_+Z;1K,YC
MY^8L"P;H&AX>W(;B<ZT.,C>TB/#AP4I]DD80-S0ANL."2V>AKUCW1K^B9E^/
M1M;$KYA=ESFQZ?RA16DX:E1LZPMM#9'GP,]X8=:].?]*H#VMWW$78$MX*H'H
MUMN4&!1-_>O;1N,!&,^W'2$:H;BLB04(7O!^IF!_W8]]!YB;=AYQP1/&L-'=
MU79*:KT%Q5O1^KI,]16;I_)*CJ&S023 %\/>U@V*Z36KT?B!URDTACD?!^P"
MFUN8=SJ<097 !@)9QJ/J4N^X>#VR6MHU6-$KJSV3_)N!]H5MJ+MDG"HJ>>-:
MQH[V/G<,%3BC/DP]ZX"+P3D^IO]Z-Z9F&VU,'7">W4&=6/Q^>G5642T(&2G.
M&1T$CFN_V1*4ZD?6:*\N$($[/X76"C_K!C1-//&IG17#LV(Z9X6?";K\HE1)
M+6=N4L>"C>@B'\.JUEFI\-V+NLJ(Y4T@GK>2OCB 0@>K5X/1*U#O>%K'.KWD
M8P89*NK%NN$U6E:XCG;N7 ^PYJN(LU$G]:N3+C9:)YTH-O(;='2WL @/ 5HJ
M ")$E,)_W?Y;'T6UNW,5C]2@5+PSD[)50)Y+F0%E02%]7*#5/BTN!2*%@_2X
M!-$]S58U05'>\6^1L$5PM(=L),>[ +]>TQ4R=(?P ;;WIA]7V*#RNN#^FF1I
M>>,)78Z+O,FTZ=N)W**<:72,J444[&2%8L(/@&Q7=A5E/E?(N6ZKKFR12Q-&
MP'94",N#'N\^'9$!0T0&_#0B X:)#/!#>?0@K(&G8 T\^:HZLQ>;; *<U:"V
M+U6_@=USPA!;(IF@G:U@Z&B,>L4$QJ,;#>DL4SX'O=( KJ-?F?ZLXQIC#QQ@
M:O[H94C5_!PIF5],(I ._)^?)]$S_!_X&#[\:7=O]S'^Y^DDVGL$_[<'_P<?
M[#V!_\//X#=[<.G>"SJG]GZ^EWS,X#?F=]U^3W>_\>ZCX5_Q 3(MLN0^1![-
MK=/#D]/#L\,/Y_OG1\<?SB;1;_NGI_L?SH\.X=_['UY'!X>GY_M''Z+]7T\/
M#]_#A6</0GH&HM:?[NYMLEK_5>=@!?>KU5'*2XU\  Z:=:5*+J51EN/=]-M\
M2_69^D^M)XNY_IE*L7TWY=$:_>^P2W@SD$Y9L  )W76*]=HU:]IS2[.@+;UE
M<PB)I-7:?!WUH@^AZ!;M#D_,TD\Z@O_FG)+"K)RO6_*N^SLE61E^]$+KJEW6
MZ4K5)0G9REE3H-4S6!S_QL,*9, !Y'U3C"X9H'?%,5AXB40T^FVI%O>[Y8Q8
M?Q0BD0*5ZY497C4E'RK2<ZZ,<)_4U;PHX6:<,,4<G,8<)1:#PB&V+"AOK6*>
MV0>+]4P*X8N^3 M,<#:;GV 0$C0$)P5JK'&WA9L<,L,S,S4VI.5:[C1^[]%B
M/FM@?Y^ZO+/E%S+4L@[+>C"^9N_;,^*N9YQHRBO4"ARB4O>A6&JW9*<\0-OU
MJCN3/F>-T(A.>88T[=>H$< 3F'M(9_LD0B8[F- TH=]-4R9$"/H6V?(YG8,2
MCFUS7Y7FID*I[LB<H7C3QNAU272OMHY+#1XR!NA22P-F4214"3C7H:@SS$+F
M']4+V#]P/U#KV/CUPH565@#1A8OK%W66A' D8J&0=F/P! \@$01>VP#QZW>+
M98OUC&39]+K$LSZ7&!<2SV !%_(,2QX,Y];AGW"^*'O<8NMN+8Y C-'5X/1R
MF$FRX*E6B[7;G U+HH)/9FP</C-EHC?+&(VU_.[$,M018\8\3815;GWGSD;Z
MRS:VCZ:J1)U ,%!W/6'Z;I'HWMO67O0I1+C?L*K)%W&W%Q#%3%I8T'RBR,G?
MB'B43SQUO>_&AR*'[80ORJ)&G-]<QXCGTO[G6"2=2@2@">9R@L>(4RU)P3 5
M&5WIC/Y+-!]K+L-,7[,SNG0((. '?(M OQ:6E=O2YXP?H<II2BU965Y])?++
M1+SY&*.TI17XA^H@!&!A<GNQCY/4O>.V!FWC?%T&@I;I@F@<_0PS7QQ&]BN+
M$VXXU .P5WMM.AW#-LVE49/."6!.VXYYK-9MG9+[4?@]*WC)A-&1'!%I= 5?
M3X03()Y=OYL%O.0<N<<N,;RB=VB/,1Y5= -OKV#\B"W'01A!,"D,)]-F)3#!
M))KI!..6$@8C1@&!#61<Y;;E1_*&KYU$QT>_@@([VY]$9_OOX<\W^P<1L2?2
MUGY- %R"FGZ0FYGH78IL$J\UVJLV-73 02&PH&"P<#47/=AK*8L4O2?T*%BQ
M9\H"RM\1/!O&RU<P71*.#[\PVP\CYS.8J/WC38[:?P!3Z0!,EO_HG!*5(("#
MC> S4%%:X'S</=N-8AZY,^H;JD7P/!]S@M[35NFV)4EO^?AIJ1?(10+_O\T>
M0L],%XOT0N ^%'E%/IDZNU!RCM S\<)?0&FJFK:Y#'.>+NDY1\$MW'"W"-95
M9L+)%UYCE8B]>#O0CDS9'H!FF8R8U"&;JHA$.]KY.3PU86=>"$\^#>B7G;U)
M]!;_YQW^#_S@_$-TF1I%2K(V]P1%'W7*777*1M,('[KSEDY]/J10S.3XC-YJ
ME2$'$>Z[$^R^K1;#UCJ]=FSJ-6'X4%V,.X6YFM:M*_Q$_7F3J-MX.04[L&BL
M:><M^;('G- @KSA,DJ8YGF?7;1=[;=$HEG#-7%N\U37,B7DN8E@M<F\7,W 8
MT1.WK@W=PG<*#3P:>@J=]%(LADOIX@LNJ!SPN7'348WQ(AR<CQF@'/6XR/N]
MKK&ODA._1EM7TI7)L;%&6T6V$S: H-TRYWT5X[Z2#8-?DN?>XY3^TN>4HNWE
M@?ZV%OF@!NN4ZA^=!\D.I.@W<&6Y;09?#^YKL""XK:R2\]O!\':K4DZ\]#C?
M!P.8;R',$/R3-^CW@^)3*]1(M6@G_T0Z#AS:"1YK!097*_#S6"LPU@H,R)5\
M$/WMCIH'S>$0#IK7/])!0^Z*]5"L5S+IN5GN89\S#/^$N:1)QL8[+F&$%#4Y
MY1X=TW-@>3Y<Q"OQ?5".Q5!$EAB>Q9LRSITRDU:J2%RA^_"JNCTJ9'83! \A
M8+%- )X?;,WB/KI#GG8EI$I#M[U?; +WX2):6[SMG_+B*M/)A9[<$#6A;+<D
M"-<@)QKHGS2_Q*Y]%@+B4":P!HD,0,A6OFD0IG<,1Z_PN_7+F<-^DDWIY" @
MS,'B_B8X M%XN7/YW9I9(MP.E_^&Q>-.ET1U=',$A^,)WRAZ,Z'O\#;![ULO
MCN\](T2'M">1^?3M2U@GX4!*_97'T(0;_7+V*EU0=Y$*X58&3.+.U!CENF=1
M5C#]&*;5.GA6Z&N"5A.)U:) ;I'@_K(,# HC=1KPKIQKV%=;Z;;M4.#@P;>)
MR=?MY_9V/EL34\7(YL9(SK>="KB,4-$;,QW># YV4M<1'[(MVFX?(,0U87KA
M_.$6BQ=T\I3<41'/(1UM/=F&RPQX/L909[>)[9_K.IN)XKE]M 0V9**.+]-]
M'H?4.!&#%A6K;^>Y FF/"0<'@75N&*74'O$=&B]J9U?:,AT%TX:G, Z >D;=
M/A-6QP@N-P9E6)77KI52@!(V#M^"V%/-;Q3DU,]$DCV$QKLZQR2T..I#>':Q
M2., +G."C4NN)?.^Y(""PQP'(DWR[DW!B0C^(JWN\J((E%JY0\O@=?M8&D7A
M7(!GMO']SQ]H-.8K$OM/-SFQ?^#P,+UFZ\<NUWUVN089_N:%ZO<@)[=#.AXL
MIB/%0SS-L>.6\:#RD&?0?AVV)W%&O1*CDW*O7B4X\Y-]=:TKLXI%\U7'<JH?
M'_W:NX_=>R0-ZQS C&"*R+M%TAK)V&\11I,"BIN7.F#WM=+#Y'&E5,QTR ^;
MDS$BQJ7"RU)F.J>X9>%2STY?@I3F5+]%O^TBJ.[LI2EU*-8145R5;GW2&]]R
M/'$&<.)\:Y#U?:2MO&?8KS?-)6XSVTK&ME&\FG/D&^OS,NSJ(_3D2G:+H\<.
M8,^I,74CK'-CMR4:HZW6P'T5;*9C.Q'NL$$*$OR][-6#>:IG';^@7NZIB6O+
M3 E;'WQ#1\TY"7B\\)G!Z&W'2NOHQAK>! ?*58,VPHQ^6I*4Z//S?)DEL51R
M:8H,;V520&>[B>8"HF^Z]",X9&C@D,>/1G#(,,$AXU$K1^V#@(O<-<0<=JFX
MJ0?/M8,;$P8XR$,&]<7.QO0QR."$8-7?Z \=G%P#@/./P;[O$>Q[MLG!OGW7
M#N:7HOC$IM$I-=KNMU;G=2O'B.,BLG6TK=*"4J<F_1QM/=^.KK7"POR9K0.8
MU66>FKG4!3>-5^*::75_MU&*,XT4YZJ4VCPT4JL2*2+*24!^Q!V%DAJ)+CQS
ME0M"$09;LC=D!"_4)^QDH]*,LCU"",2-AR;1%&=]XOJQN[X[N  !#Q:L#]6[
M\T!S5=52S BR$21RD!N>W%U?@]WHF-%5%^FS7:U,?U(3GJQ%G=XHJ=QJ:N6S
MX]^V*</MZ>N=Q=S(J5CO06%FR,Z&#Q%<JJPFF_@<%NE\7M0&7_4U+ 4N]-;_
MM_=H N*WC7=:%(CKP5[T*MI[O+. >\U%1*17$'<R](_!P9*>MN_'"74A6T@I
M7;14QC7MQ5<H-;+.H,ZW2K[Q.I+UHB_"%U*H;FON:H84!#1/O.'N('**.?2Q
M?553N"ROE#UXW%C\*=7.6_EOIFZ;BY2U<%#$FHPI.XG;I,934RSKTM0J%[:?
M!+_CY"4O=",&"*NWM_?H,1,4__1BSVU%IG$XLS0.^S!/6T\?4S'MP6ZT]\3^
MYLG/S^;S;3L+&-FI,\$)P7S#+P[>G,)_'NT\>?1H!_Z[^^31T[$F_KN>?,\W
M^>0[]&5E[\EB(YF5.,"A#</V>@@>,128,_*H1(/H,*H][%BAN_@V",J(QTP,
MFQ.N39$,(XB-VM>T]VLVKIP)-DO2UW23\.>M'QL?M?5JYD07RRPX>7PZO]':
M#^LK;>QW7L-T!%T\PNZS&3R<NMBF<1@DAF_:@QF+V+^S$MCH+@6!$D"6AT&7
MIT^( @_^"*"X:<4'="-PV23G-8Z==RW2TZ<'.UDQUK']=N5])BN\Q4'Y;@93
M/ D_F.I<PSQ$("&2I+3!W$EXX,,?=29JK4 =A,,R]].D;-SH=]WH/VWR1O]M
M__0#VII][O#?6LV_&LVQPB-XZIH'D]M;,YDXYBM,BEMJ9D-=C;9EU.DU+_R5
MS/S2:CDV:?AX;>X;W,9VJL(\%-R>/OY05-*+2SKI.LC^-*#N$^?&WF@\DK_S
M3OUYDW?JNZ/W1]*[I-?C^/!_#@Y/SJ/]L^CL\#QZ<WQZ_C8Z^@!_'.#8HJ?1
M\9OH_.W1F>^C,H'O#]Y]?'WTX5?X-79A.7OWK^#7^Q_@+W@UNAA__MOQZ3]X
MW[_?_\?A6?3AV#9K^=>DU<=E$AV?1K]^W,<O#P_QQWBW?QQ]> V#V#^'_SF$
M)YW^\^@ [O/;T;MWT=%K^.W1FW]%!\?O3]X=[7\X.(R.SLX^PO=PJS>G^Q]?
MP[,//QR>PHAX;">'!T=OC@ZBD\-3&/%[_LG[D]/C?\J0X7=''^#CH_UW,+ZS
MC^_.SVA@_&^<GL9]WAW^\_ =CC6\"5QT\.X(_F65T%EPT^#)&(B EX(_#W\]
MQBEM-;:A7C:^MPW]>?[V^.RP<^[MT-K3'^V?X@]@V<Z._GE(-X%+87P?:8YA
M'H]A%*<K#X>7#OOJ_/;VD"Z31^/71SCKAZ]#H<#WD8_#D<.#WA^>'KR%/_=_
M.7IW=/XO&L>;H_,/>"]X@6@_.MD_/3\Z^/AN_S0Z^7AZ N_Y4-3J=U6>SS:Q
M[1/OIYLZ/XV-GWH_EI^-C9_NJ4OOV/MI[/WTW6=U;.\SMO?YKNU]1BC@X*"
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M,45,FM77%1 ]5K$N5 4Z5&=&7R&*8O4$Q1H\Q$Y,V/%CJ@.JL'-4VC<^FR;
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M&[X!'Z,:^^7X+D>!%+T]#;(Z"C?U:]DD<12&X"1V.4:J$!:H A&R;Y*6A43
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MT[\[W!2#=8SAC$F,ED5C:3Q/ 98G@KI1\RGE$6'T<XJ1Q8EP@9':1E0KO/K
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M.9%GL'.DP3%(&!26N!3!0\8PN/4\FWQE24 U)I\J=5[5F[*1H.F\/L!4L(V
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M>[G6(OL2*^].S'.G49)0R+H0\/10 >DH@F&] 8/A(6Z<&^6Z0[:^98 I).]
M^"*K:2?:HNYE<A!\\@P ;01'P.&:K_BEGJ!/UD3-U^0,F/.^3LDC:+^RX,K
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M^0S6$<182TV(JKYP!.G2:KVQN5Q;'"F]N:7TVVGFG&JUX=?9:7U;_%T!)*K
M4CF=K08^JPF2U6LBUT*]8"_I]_YV]_Y.LQ(-<@ROM!\BJD!JX&8+:&!-O.B,
M^$RX1(RN!A]&(,<WS)QLOG6YQQI)UK7ET-Q++@:'JU4.6!?H*W"8]_6 4T,.
M8S1SP 5&&:Q4=,C1*HMH!\]=+#GXHE?#:<](XXCQ-_"^J/(,*J1!O/:-S>),
MW1ZCI]XG(/;;3PH(]1Y9'>VW#,S>*M8C@;3D)9P\;&8G15RPJ'-W%_9NT>YP
M)7&ALAO%(. )PM9$>A81QYWOL/8[.,62?$I(Z!H4K)R@V OT'W_**VCP FD_
MY;E"E#X\,/\R/@ LZ%@0)U!7^VL 9*:#C?<[,?M92X-QRW1XE[!NXD3 P8AJ
M725J&HN-0=".TD7%4(N58(&E)[/L[:  $$],8V+:+W@3YQKQD?Y2JBE\CK0*
MTN?AAHME@ C*QK]FC'F:XIET>9C;S@+"KB\I[FLGH_9#!R>QY&:1:B=WXR[:
M'W2S[I@D.XV+/@:K/1-ND5:-D@\SV-R8$5JFL \F<U!=E-6Y+YGE1/Q D\"
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M5"4#/>]-FDJ\#-%YRKB%@ .,:QDKH'AE@."+E70C$B>Q#+F.^(ZNA72),J[
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M%G'K+)L3P(CEXY%\R(='21RE+L].GL$H12'Y/XP<N0Q/SGX/#@:=_JA;7[)
M=R$QBK2<@W7S#']XG@LS(16"*)W^EO)"&R>4&Q9"2E*3$%X5L^'S2JVDZV;3
M8C5PN@A[G4-2PYQ4D")-4A?V^3+2L\#27UY#I(U$$_ OK&=4-"H2K9P7P;#?
M*]RP=J-6.*S6$I%3-@]_I1PM_()3N-2Y4(U@I)W3.<LZG+E 9#1188:)\S;\
M]L;,-"6'@2U$C&%A,)@:40Q7;'_2'-N:DG1IF) +8I9$Y8V\V.L?]8:CKM][
M,NH6_.'X5'':)D3C([R*,=:9-N%>K_H;WHUX6N<GTIF\%8+C#2-P-DLI(@<U
MR99QV'8$-DCRI@C7<KQM;#';1?,XTCM&XRBA6#C2"BY*8TL^%\!IZ+^"WSI7
MG3%<85PM]@\.>SL:I=:IU(5#"=%\&8[CWA'H!%R*<"5,)!3:X-TLPSF<QLZO
M#'J]P?XNEDSE$RG)LN&@<W3T_7>K1_'7@/M':9FY\TT)\D7XWRC@"[5@PI1<
M6O'@?2D,<S:;PR7Z#NM9<(&2A#,T@W/^%HL,?C:Z+-KP1L4=X-VOM<FAWPO>
M0Z)-I>9#K0:00RCA;:D0#GIMYM/@);2\P(N]V:#7CX>UE?I*#O?;@").&U*6
MO-M8CA3K2-$@4S>NBQUM&XI;E7XO1K=Y73AHT7XEN ":E!FCCG5>9*S^)B(&
M/Y1D,.>P6:_AYBQIB7U@O/W#EMQ?6L6X-.2\AK-9G HUP<9T__C@)0@EV?#"
M,BF.5UZ?6SXS@CQ24O]P2Y#/!F?>>@_:?EED&? V-,2YX(6"7;+M:E="2JC8
M_\X*)56JO4V6*K,:@"[05#;M9Y/[@*5_1RT\5?]6\)_"HJPTWZ<Q9;*:O\2\
M9_:R$'O#!/.D;PI@K7.DPD*$+%H8?4V^SKD0/WU6>"9.B=D;^;I:\)W5?GY7
M4AI%-JV-K!2:7U\6VUCG.5GKG>3:)*8\(TD2* O^Q4-!ZQZ2UX^FI3T0MH>A
M;SGAXH&CNJ,\9?._G<T?YR$T..]IO')?8JSKCA96=PP9'RM?P:VN[<);X65_
MZL#5E!+7AO,.?_]F%Y+R,>0;)NG+G8%=B/@X)4RXD7%C<W2-\"[AAUHTNP"]
M=6&([UH+;OQK^'?R^?/_E%Q_O'<?X?EN-W5J[>W,-KU\C)UQW(%S86*X)+[I
M-M+N1$-<!;T3F*N6]'KY3F&E)3W=!VRY&:Y%WC_K/D5_JR!OHG\:Q[I4CM3D
MKGL1/VB,,V&M'S1.,%!:8J.+G;\UATPRG 623/W^)&0H9:Z&DFR1B7GH5YM!
MYC(<'YM6+MX9-3:JC0$J^>^,,3=[9[<VR3SU[S'O.[^\F6*FYF;8RSF(#(H_
M Y$X-*'(IF)NJZGPJ.MGR2?/1MUJ"OTW4$L! A0#%     @ "3@&6;9M$7.0
M%@0 ?-4$ !(              ( !     &EM9S(V,#(V.3DQ,U\P+FIP9U!+
M 0(4 Q0    (  DX!EFN3(9MB5D! "6"%0 /              "  < 6! !M
M9"TR,#(T,#8S,"YH=&U02P$"% ,4    "  ). 99N';"Z-?J   J#PT #P
M            @ %V< 4 ;60M,C R-# V,S N>'-D4$L! A0#%     @ "3@&
M64DM8=ZLK0  #H<&  T              ( !>EL& &UD+65X,3!?,2YH=&U0
M2P$"% ,4    "  ). 99J+A3A<4'   S-P  #0              @ %1"0<
M;60M97@S,5\Q+FAT;5!+ 0(4 Q0    (  DX!EGH/X0"R@<  #XW   -
M          "  4$1!P!M9"UE>#,Q7S(N:'1M4$L! A0#%     @ "3@&6?I1
MCT56!   C!X   T              ( !-AD' &UD+65X,S)?,2YH=&U02P4&
2      < !P"F 0  MQT'

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>md-20240630_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:md="http://www.mednax.com/20240630"
  xmlns:srt="http://fasb.org/srt/2024"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xhtml="http://www.w3.org/1999/xhtml"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="md-20240630.xsd" xlink:type="simple"/>
    <context id="C_82895573-2795-4732-b42c-4cd5883caf98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">md:UnnamedCorporateJointVentureOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_85f3a02e-88e7-4e7f-b8f5-7e31732a7772">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">md:ContractedManagedCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="C_8693cd13-0631-41d8-8347-98d3ec5b732d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_86bb4acc-ec76-4db5-933a-a771e7cd3750">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_8c03e792-f7c1-4fa1-9f86-8c10e39fa1ac">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_8d682d9c-f4a6-4720-b0e5-6aba644d655b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:HealthCarePatientServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_925f1f8e-686d-4cc3-b111-72650c3e2456">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_9478e6ac-d067-47ed-985a-d3a75cbb347e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">md:RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_9909352a-5fba-478d-bc57-50fb72a6c67d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_9949ee77-7752-43b8-9d0b-21296bfbc11e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_999199c5-cb3d-47a6-abb8-3629d31afbe9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AllOtherCorporateBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_9997289e-fdb8-486e-acac-cb788b4f8239">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">md:RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_9a4ff3c3-70d2-4f27-923d-76e5a8c48431">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:GovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="C_9d8d79b8-258d-4977-8e93-a832860452f4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">md:RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_9f05953b-1f07-4686-942c-7b1d7943d27f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="C_a03ab9fe-6fdf-4312-9317-7df9fc924d88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">md:TwoZeroThreeZeroMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_a04037ee-9a78-4964-9e1c-74fa20cac8af">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_a0685afe-439a-454c-a102-de37c36a07ad">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">md:FivePointThreeSevenFivePercentUnsecuredSeniorNotesDueTwoThousandThirtyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_a20b1ed9-1ed7-4cc0-9d05-984cabc1cbec">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">md:ContractedManagedCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_a20e0eec-fcf2-491f-ad41-9a428f13e263">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_a23f2efb-8927-4491-a7c8-c1b619aa2e83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">md:RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_a24c8561-3fe8-4ee9-9a5f-3650008ddd53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="C_a3930cd6-349a-4a67-8e41-4578fe93ff88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="C_a816572a-ebf4-473a-a445-92cc3d3335f4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_aab2ef2b-f5d5-463b-af2e-d14d85478a3f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">md:MaternalFetalMedicinePracticeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_aacf8890-734e-41da-b969-870124e61507">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_ab52b5b0-1d74-4f4b-8f22-0ab60d83e515">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_ac837f6b-5715-4c36-8c4a-be2ace21a7e2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">md:ContractedManagedCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="C_aea590f4-2725-4610-b86d-be28415452fc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_b2e57193-b6ec-4e23-91dd-bd0d8c1391a7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_b55fcf9b-75fb-43d4-8441-f6cc48e23e07">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_b76e1e1c-7e08-49c4-ba42-36b7776b9c77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">md:RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_b87610a2-4379-4ba9-97b7-9e4606d8ef5c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="C_bbfdd70c-5aff-4803-b853-9aed8b435db7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_bf0934a0-5844-404d-a376-9a2eb1aa3de7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">md:RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="C_c38ac2d9-9615-4715-baeb-08e4368151a9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
        </entity>
        <period>
            <instant>2018-08-31</instant>
        </period>
    </context>
    <context id="C_c4efd93d-fa74-4b60-99aa-628c88395267">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_c97ff8ba-a0bb-4c2f-9d12-7e68bbd283c7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_ca171fc2-2432-408d-b564-cd2e7563ba71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">md:RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="C_ca383e94-5006-4063-9440-291a788feb2a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_cc98a5b3-d80a-4eb1-aeee-1a0e562d5e27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:SelfPayMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="C_cd8a1422-f4cb-4c26-b354-491001ddef25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_d2b8faaa-e3b4-40e7-b170-e0b31556d8c0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_d3b7b754-9615-4731-9358-8ab2afbdb4a3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="C_d408367b-f06f-4217-a293-02fa802d8521">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">md:CreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_d564d4a9-a926-457b-80b1-01fa631a1e4f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_d65f3724-0e7f-4c6c-b50d-444cfddf4c6b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_d6aad445-12fd-4b00-8591-81e1e41d8cfd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">md:HospitalsContractsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="C_d6bf2c94-ac55-40fc-90b0-8184b979a967">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_dc0ea4b3-aac8-4793-b9f2-f1f63e43c02c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">md:NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_dec064d9-341f-4d43-8d13-9380383f1ea2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:HealthCarePatientServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="C_e0420691-52ea-4671-94fc-b8e7b69e3142">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">md:FivePointThreeSevenFivePercentUnsecuredSeniorNotesDueTwoThousandThirtyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-11</startDate>
            <endDate>2022-02-11</endDate>
        </period>
    </context>
    <context id="C_e050a756-0027-4664-943e-74db5426b7c8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">md:CreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_e1d34d08-f45e-4aed-a85a-ba2eecf7da87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_e3eb8c28-c7e1-4a49-b42b-e63f13e290c4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:GovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_e6d4fa65-6594-4957-b174-3dcd01093f75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:SelfPayMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_eb6de81c-9c30-48c6-8848-0a4491bbd3cf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="C_edb2e0fd-b34b-4b67-8c89-128090856b98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="C_ef12bbdb-7da5-4d1d-98f3-f1b0c3da31ba">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_ef9ac9e9-8f0b-4197-8eb4-12ca2061e14f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">md:RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="C_f2de318d-f0fc-45fc-a7dd-1d90eebc8aff">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_f58ff9fd-0a96-40d3-97e1-a038b63ab720">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_f80a1315-a5a6-418b-98c4-fc56bd22ae95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_f8ba14c0-203a-4abe-895a-7068e0d681d9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_f9deda8d-474c-400c-8f2b-c04bdaea334d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_feaa2e55-4022-4e2f-abe1-edb33b1f5e36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_0037f299-00cc-441c-a3a7-d37288934aaf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_01c11cbc-05a6-4e7d-bb87-a2a2acb9a949">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_01d46517-67df-489d-b34d-e087cf6dadaf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_055fb263-9778-4cf7-8395-b3db5ae74ab3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_0971ef72-7587-4d12-8daf-522e84254143">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_097f26a0-c77e-4f84-b663-38d6391e01e6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_0b63294a-0107-49a4-a13e-bda5f278d21c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-11</startDate>
            <endDate>2022-02-11</endDate>
        </period>
    </context>
    <context id="C_0ca0f3da-cd87-48f0-9af2-4b8a86903bc0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">md:AmendedAndRestatedTwoThousandEightPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_12147e67-2e9c-4442-8daa-56def203d5b7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:HealthCarePatientServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="C_121e7382-aaaf-4b4b-b85f-ca7209a14358">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_13c390ad-a46f-4851-8328-8c24f9da6308">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">md:FivePointThreeSevenFivePercentUnsecuredSeniorNotesDueTwoThousandThirtyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_156059b8-27ec-4255-9fd4-8a26b81f0b31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="C_1786cd13-4a3f-41ee-8fba-517746735e35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="C_1c3d0626-f775-4377-9dde-87804a3a8785">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_1e093f6f-db74-422e-95ac-c5b0a5e76558">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">md:RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="C_207dae80-b868-42b4-8f60-529bb2da464b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_21d152cb-f002-4995-a0e6-8a4087443620">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="C_21dc151c-5f14-4067-a9f0-945b9851cd13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-11</instant>
        </period>
    </context>
    <context id="C_2656143a-67b9-4650-b483-9f48b62093d5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_26ef4d6b-17ee-42a8-8ef0-3a3202107d61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">md:HospitalsContractsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_270805f0-aab2-410a-81a6-0fd72e3a746a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_2bb8a119-7219-4b9c-be50-62118be95425">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="C_2d25298d-eb54-4bce-a6ef-521cc063eeb3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">md:NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_31b43498-9159-4c16-bd8b-ab5cef5e0575">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="C_322f434d-d131-49bb-a0d5-c51c55aa30d0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">md:ContractedManagedCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_32a74e36-4b2a-435f-abc7-46f886f94451">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">md:TwoThousandFifteenNonQualifiedStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_35df4ea0-7c25-462a-83e1-ff1079f8091e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_3610c317-f612-4c22-9d38-5d8900ab3930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="C_378538d0-b7e1-4ecd-af00-bb424f0b1747">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_3c0663a6-a6a7-4ee3-809d-8c8aeb1fca8a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:GovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="C_3c7dc91a-a1a8-4164-8011-aa824e2173f1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_3c816b3b-c82c-4a26-bf82-3219ef7103e7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:HealthCarePatientServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_3f38e980-706e-4b34-b4a0-c3cf6a91f926">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">md:HospitalsContractsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="C_407e9c0c-05d2-4164-85d8-d7f2fdffa0b3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">md:SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-11</instant>
        </period>
    </context>
    <context id="C_44713f7f-0be3-44e5-8ff8-456f9638bcb6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AllOtherCorporateBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_4506227b-6467-48fd-bf2a-12d647f3a96a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">md:CreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_45e7bb15-6f89-4eb6-9120-7ec8d161f85b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="C_4753588f-87b9-420c-894d-f10c964db638">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_47c0d2ef-584a-4c5e-ae36-b63c1c605bcc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="C_4ddfa92a-fd22-4353-88c1-befe81c45dca">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">md:RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_4fd51aa1-699c-4d1f-a3f5-aa92a33bc175">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">md:MaternalFetalMedicinePracticeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_51999449-03d0-412b-a0e1-24677d710d3a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">md:FivePointThreeSevenFivePercentUnsecuredSeniorNotesDueTwoThousandThirtyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-11</instant>
        </period>
    </context>
    <context id="C_5207957e-5a84-4d96-961c-054e57351b74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_57ad6014-6b49-4fd8-b8f7-ae2932078fd6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="C_5875e45d-cd89-498d-903a-55b9e7739c94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="C_594a2ea7-65e0-4290-83d4-8be74d122ddc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_5a5fa8ad-967b-444b-af35-7dd7a8bf7ba3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="C_5b39fcf4-ee54-4657-b078-1fee2e008ed8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:SelfPayMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="C_5dea8f8c-6ce2-4ac6-b2b8-2c6020fb27ef">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">md:NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_5f0c50a0-53ad-41c3-8101-90e7e5cacb14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="C_601000a8-e8a9-4fb8-a90f-f1923b0d6484">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
        </entity>
        <period>
            <instant>2024-08-02</instant>
        </period>
    </context>
    <context id="C_60b78123-38d8-4d05-8a9b-e087fe9016a9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="C_671fe710-eb0a-40ea-9b5f-3fc84da58634">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="C_690872af-c97c-4e54-9314-3d7d7de3a6f3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">md:NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_6ac5d2f3-36f9-4043-a22d-1a055bff677d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:GovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_6cc6fddd-3fb2-40be-bc2f-d396ff6d56c5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:SelfPayMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_70422dcf-ff02-49e5-8b94-24099256e942">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">md:AmendedAndRestatedTwoThousandEightPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_73da6023-b99b-4424-9d33-e387db8c2e30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">md:HospitalsContractsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_74e636e1-15c7-4b53-87ca-8d27ceeed147">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">md:TwoZeroThreeZeroMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_7c834d47-d5d5-4daa-8490-432e04b450c3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_7cf5d7c6-f082-42c8-aa0e-fe1ed65ec2d0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <unit id="U_pure">
        <measure>pure</measure>
    </unit>
    <unit id="U_shares">
        <measure>shares</measure>
    </unit>
    <unit id="U_USDollarShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="U_Number">
        <measure>md:Number</measure>
    </unit>
    <unit id="U_USD">
        <measure>iso4217:USD</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf"
      id="F_b8aeeed6-e408-4eb5-973c-15d85dbd4147">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf"
      id="F_fdecb36e-d533-4416-9a31-4b9149c64ca1">0000893949</dei:EntityCentralIndexKey>
    <dei:DocumentFiscalPeriodFocus
      contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf"
      id="F_91680b13-2b28-4ece-b9f1-d83205e91a05">Q2</dei:DocumentFiscalPeriodFocus>
    <dei:CurrentFiscalYearEndDate
      contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf"
      id="F_5a1747dc-191d-4580-8b2a-c28d00f9f79c">--12-31</dei:CurrentFiscalYearEndDate>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_378538d0-b7e1-4ecd-af00-bb424f0b1747"
      id="F_63ef34ef-3859-4003-9f94-acd5a8cf0ae8"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_01d46517-67df-489d-b34d-e087cf6dadaf"
      id="F_2480f1a6-5340-4f8f-9b78-b9de431629ea"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_378538d0-b7e1-4ecd-af00-bb424f0b1747"
      decimals="2"
      id="F_4ef21d0f-768e-4fd9-ac98-0f999e424f57"
      unitRef="U_USDollarShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_01d46517-67df-489d-b34d-e087cf6dadaf"
      decimals="INF"
      id="F_aa5b77d8-2818-431e-b57f-9e1e031ea043"
      unitRef="U_USDollarShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_378538d0-b7e1-4ecd-af00-bb424f0b1747"
      decimals="2"
      id="F_e97295ab-73a6-4c14-8a53-7e8ab77b99d6"
      unitRef="U_USDollarShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_01d46517-67df-489d-b34d-e087cf6dadaf"
      decimals="INF"
      id="F_4b51cbce-e856-447d-8cac-01d0d16055b3"
      unitRef="U_USDollarShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <dei:DocumentType
      contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf"
      id="F_878c859f-ed24-4599-ad73-2b01483005a4">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf"
      id="F_abe76e55-9124-47dc-9414-e810df560035">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf"
      id="F_2815cd63-c384-44bb-81e0-f3796d624791">2024-06-30</dei:DocumentPeriodEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf"
      id="F_f6be0db4-9723-44dc-b4de-370c7e8e016a">2024</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport
      contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf"
      id="F_d441f37b-01bc-41d4-a069-e9759e531b74">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf"
      id="F_2af863cd-0ab4-41cb-9f60-96b99e1d3172">001-12111</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf"
      id="F_a942fa3f-1fd2-4126-92be-4c0b81c647ab">Pediatrix Medical Group, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf"
      id="F_071fb06a-a537-4070-a7b4-3e11c4206a96">FL</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf"
      id="F_72f58580-758b-4312-a3cf-dd7d8917f6f7">26-3667538</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf"
      id="F_f7b1e011-a2c0-4024-a5de-b0bd3cfbec9b">1301 Concord Terrace</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf"
      id="F_623670a5-e201-47d6-8438-7c89499c81c0">Sunrise</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf"
      id="F_96dcc374-78df-481a-9e4d-5dd997370b78">FL</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf"
      id="F_6fa493bf-5a29-47ff-8110-180df21d129b">33323</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf"
      id="F_02e38c25-cb75-45a4-a1d2-574a092dd90a">954</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf"
      id="F_f926ce2a-b916-42ed-b95f-a9d74852618a">384-0175</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf"
      id="F_4fe3de21-ad84-411c-a9a7-1b8fb7a26390">Common Stock, par value $.01 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf"
      id="F_4141d140-2a7a-4e5e-b541-39c8fddd4089">MD</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf"
      id="F_43843b92-51d6-425b-9d1e-c33e7c35ce46">NYSE</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf"
      id="F_c83ce910-dc22-4a3c-a4d3-88cedccc8f42">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf"
      id="F_f638644d-d65c-467f-b9a1-66e53834fc1a">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf"
      id="F_67e3563b-07c6-4da0-b305-6a0c088bf233">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf"
      id="F_03719006-f0c6-4c3c-b2e4-7b6f07d3f8e0">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf"
      id="F_fe810309-c01a-4685-9df1-8d64b5264f0d">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf"
      id="F_cd022a49-36a4-4276-afaf-21a55bf75f4d">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="C_601000a8-e8a9-4fb8-a90f-f1923b0d6484"
      decimals="0"
      id="F_a8df0810-800b-491e-8f06-c5e55306d211"
      unitRef="U_shares">85865841</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_378538d0-b7e1-4ecd-af00-bb424f0b1747"
      decimals="-3"
      id="F_c2e8e59e-36ab-4b92-be60-7f44f4a7bb07"
      unitRef="U_USD">19402000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_01d46517-67df-489d-b34d-e087cf6dadaf"
      decimals="-3"
      id="F_b8692d79-01fd-4bed-917e-aa4c52e2652b"
      unitRef="U_USD">73258000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_378538d0-b7e1-4ecd-af00-bb424f0b1747"
      decimals="-3"
      id="F_b46a0fac-6be4-4f58-843e-633f101b25d1"
      unitRef="U_USD">113795000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_01d46517-67df-489d-b34d-e087cf6dadaf"
      decimals="-3"
      id="F_fa835bb8-9cd5-4c64-b198-45eca3ff8d44"
      unitRef="U_USD">104485000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="C_378538d0-b7e1-4ecd-af00-bb424f0b1747"
      decimals="-3"
      id="F_30b50649-f7f1-461e-937c-471a10b2b5f2"
      unitRef="U_USD">274164000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="C_01d46517-67df-489d-b34d-e087cf6dadaf"
      decimals="-3"
      id="F_1af21e01-0aee-4e25-bfa3-913fe9ca8b6f"
      unitRef="U_USD">272313000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="C_378538d0-b7e1-4ecd-af00-bb424f0b1747"
      decimals="-3"
      id="F_d42ab78d-dbc9-4217-9575-bec6943114a7"
      unitRef="U_USD">11910000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="C_01d46517-67df-489d-b34d-e087cf6dadaf"
      decimals="-3"
      id="F_081afc76-4fe7-403e-98ee-ddb167e3ecc2"
      unitRef="U_USD">13525000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:IncomeTaxReceivable
      contextRef="C_378538d0-b7e1-4ecd-af00-bb424f0b1747"
      decimals="-3"
      id="F_e7b713aa-2910-4e42-b174-ea90897b030e"
      unitRef="U_USD">0</us-gaap:IncomeTaxReceivable>
    <us-gaap:IncomeTaxReceivable
      contextRef="C_01d46517-67df-489d-b34d-e087cf6dadaf"
      decimals="-3"
      id="F_6d2e74c1-5bc3-408c-a4d0-fd9b2f775267"
      unitRef="U_USD">7565000</us-gaap:IncomeTaxReceivable>
    <us-gaap:OtherAssetsCurrent
      contextRef="C_378538d0-b7e1-4ecd-af00-bb424f0b1747"
      decimals="-3"
      id="F_5373c66c-e7ad-4576-8b5b-7a3a2a8f6716"
      unitRef="U_USD">9941000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="C_01d46517-67df-489d-b34d-e087cf6dadaf"
      decimals="-3"
      id="F_e40e0741-b23e-421a-a871-bcd0d9cf6504"
      unitRef="U_USD">12308000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_378538d0-b7e1-4ecd-af00-bb424f0b1747"
      decimals="-3"
      id="F_db316433-c05d-491c-962e-970d6565b2b0"
      unitRef="U_USD">429212000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_01d46517-67df-489d-b34d-e087cf6dadaf"
      decimals="-3"
      id="F_1974b26e-7ad4-4975-a884-5d2e48e32cc5"
      unitRef="U_USD">483454000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_378538d0-b7e1-4ecd-af00-bb424f0b1747"
      decimals="-3"
      id="F_f74107c8-2c3e-4d40-af29-ab56845b1c4b"
      unitRef="U_USD">47893000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_01d46517-67df-489d-b34d-e087cf6dadaf"
      decimals="-3"
      id="F_70ada1f9-6082-44ad-938d-c2842f16c53b"
      unitRef="U_USD">75639000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Goodwill
      contextRef="C_378538d0-b7e1-4ecd-af00-bb424f0b1747"
      decimals="-3"
      id="F_99f608db-5888-447e-b515-1af3e26da74e"
      unitRef="U_USD">1239007000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="C_01d46517-67df-489d-b34d-e087cf6dadaf"
      decimals="-3"
      id="F_36e4179c-fbd1-48c1-8c2c-0cca4a8604f6"
      unitRef="U_USD">1384166000</us-gaap:Goodwill>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="C_378538d0-b7e1-4ecd-af00-bb424f0b1747"
      decimals="-3"
      id="F_f142b4a9-dc90-40fe-a4d9-ba77cdbf4fb8"
      unitRef="U_USD">10193000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="C_01d46517-67df-489d-b34d-e087cf6dadaf"
      decimals="-3"
      id="F_90351aa9-02dc-41c1-aefb-3cebc67eb103"
      unitRef="U_USD">21240000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <md:OperatingAndFinanceLeaseRightOfUseAssets
      contextRef="C_378538d0-b7e1-4ecd-af00-bb424f0b1747"
      decimals="-3"
      id="F_3e55c185-2cdb-4df7-89cc-2982934e7626"
      unitRef="U_USD">65392000</md:OperatingAndFinanceLeaseRightOfUseAssets>
    <md:OperatingAndFinanceLeaseRightOfUseAssets
      contextRef="C_01d46517-67df-489d-b34d-e087cf6dadaf"
      decimals="-3"
      id="F_a6c20bf3-0487-4582-ba9d-9f6ece39edb3"
      unitRef="U_USD">70294000</md:OperatingAndFinanceLeaseRightOfUseAssets>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="C_378538d0-b7e1-4ecd-af00-bb424f0b1747"
      decimals="-3"
      id="F_0fffbc99-02d0-45c0-922e-bf6fda49b41c"
      unitRef="U_USD">124115000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="C_01d46517-67df-489d-b34d-e087cf6dadaf"
      decimals="-3"
      id="F_fb8d8785-2961-4b5d-a92f-5659c91fdfdf"
      unitRef="U_USD">102852000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_378538d0-b7e1-4ecd-af00-bb424f0b1747"
      decimals="-3"
      id="F_e6e4f006-f5aa-4faa-b9f2-adfe5da57721"
      unitRef="U_USD">79539000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_01d46517-67df-489d-b34d-e087cf6dadaf"
      decimals="-3"
      id="F_f1db2186-34ef-4c19-82fe-bbe2d2cde230"
      unitRef="U_USD">82165000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="C_378538d0-b7e1-4ecd-af00-bb424f0b1747"
      decimals="-3"
      id="F_f62b32e2-547e-4159-8b23-22d3ddf4dbd9"
      unitRef="U_USD">1995351000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_01d46517-67df-489d-b34d-e087cf6dadaf"
      decimals="-3"
      id="F_b89edfa6-ed55-4e26-8cfd-c3ee299b6a77"
      unitRef="U_USD">2219810000</us-gaap:Assets>
    <md:AccountsPayableAndAccruedLiabilitiesExcludingAccruedIncomeTaxesCurrent
      contextRef="C_378538d0-b7e1-4ecd-af00-bb424f0b1747"
      decimals="-3"
      id="F_a80a6143-0356-4a77-b74d-f82736dbe1a6"
      unitRef="U_USD">267333000</md:AccountsPayableAndAccruedLiabilitiesExcludingAccruedIncomeTaxesCurrent>
    <md:AccountsPayableAndAccruedLiabilitiesExcludingAccruedIncomeTaxesCurrent
      contextRef="C_01d46517-67df-489d-b34d-e087cf6dadaf"
      decimals="-3"
      id="F_91f483fb-9fec-4275-ab6b-a93480a3c1e2"
      unitRef="U_USD">350798000</md:AccountsPayableAndAccruedLiabilitiesExcludingAccruedIncomeTaxesCurrent>
    <us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent
      contextRef="C_378538d0-b7e1-4ecd-af00-bb424f0b1747"
      decimals="-3"
      id="F_5bcfbc95-3e8d-472d-af31-789e3bc31cab"
      unitRef="U_USD">17730000</us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent>
    <us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent
      contextRef="C_01d46517-67df-489d-b34d-e087cf6dadaf"
      decimals="-3"
      id="F_e02d36ea-f4d6-42f2-9e6c-788f441a5742"
      unitRef="U_USD">14913000</us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_378538d0-b7e1-4ecd-af00-bb424f0b1747"
      decimals="-3"
      id="F_64dd5627-bc84-434c-9b11-00f87addafa8"
      unitRef="U_USD">18764000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_01d46517-67df-489d-b34d-e087cf6dadaf"
      decimals="-3"
      id="F_2c17fb10-ec48-43bb-8711-03e6f156e7e4"
      unitRef="U_USD">21076000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="C_378538d0-b7e1-4ecd-af00-bb424f0b1747"
      decimals="-3"
      id="F_307948ff-9c18-4486-9b5f-7a17a8392a24"
      unitRef="U_USD">6329000</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="C_01d46517-67df-489d-b34d-e087cf6dadaf"
      decimals="-3"
      id="F_9bfb9bde-7f56-4821-a7c9-f5b48c5f10ec"
      unitRef="U_USD">2159000</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_378538d0-b7e1-4ecd-af00-bb424f0b1747"
      decimals="-3"
      id="F_9f237141-6422-41cc-9660-6004ce8a3fe2"
      unitRef="U_USD">310156000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_01d46517-67df-489d-b34d-e087cf6dadaf"
      decimals="-3"
      id="F_74f1a89e-b486-4c99-af1e-8ada466d1c7e"
      unitRef="U_USD">388946000</us-gaap:LiabilitiesCurrent>
    <md:LongTermDebtAndCapitalLeaseObligationsExcludingLongTermLineOfCredit
      contextRef="C_378538d0-b7e1-4ecd-af00-bb424f0b1747"
      decimals="-3"
      id="F_4508757b-5d91-4614-9ef3-50f237cc251f"
      unitRef="U_USD">612640000</md:LongTermDebtAndCapitalLeaseObligationsExcludingLongTermLineOfCredit>
    <md:LongTermDebtAndCapitalLeaseObligationsExcludingLongTermLineOfCredit
      contextRef="C_01d46517-67df-489d-b34d-e087cf6dadaf"
      decimals="-3"
      id="F_ec1e097f-e076-4975-bfb7-18c6acabe253"
      unitRef="U_USD">618421000</md:LongTermDebtAndCapitalLeaseObligationsExcludingLongTermLineOfCredit>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_378538d0-b7e1-4ecd-af00-bb424f0b1747"
      decimals="-3"
      id="F_2bc8b425-5784-455d-bdcc-edb19bdda607"
      unitRef="U_USD">49176000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_01d46517-67df-489d-b34d-e087cf6dadaf"
      decimals="-3"
      id="F_15677f25-a14f-4a9e-8cc1-23388ac597ab"
      unitRef="U_USD">47238000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:MalpracticeLossContingencyAccrualUndiscountedNoncurrent
      contextRef="C_378538d0-b7e1-4ecd-af00-bb424f0b1747"
      decimals="-3"
      id="F_9f84396c-e56f-42aa-babc-ea14c8a12948"
      unitRef="U_USD">254770000</us-gaap:MalpracticeLossContingencyAccrualUndiscountedNoncurrent>
    <us-gaap:MalpracticeLossContingencyAccrualUndiscountedNoncurrent
      contextRef="C_01d46517-67df-489d-b34d-e087cf6dadaf"
      decimals="-3"
      id="F_ce1aede2-1e21-426b-a907-bc5bb4e48d49"
      unitRef="U_USD">251284000</us-gaap:MalpracticeLossContingencyAccrualUndiscountedNoncurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="C_378538d0-b7e1-4ecd-af00-bb424f0b1747"
      decimals="-3"
      id="F_64aaa779-7047-4460-a080-655c8248f00f"
      unitRef="U_USD">30627000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="C_01d46517-67df-489d-b34d-e087cf6dadaf"
      decimals="-3"
      id="F_213330b2-381c-4efc-a96e-1954c84aec33"
      unitRef="U_USD">34308000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="C_378538d0-b7e1-4ecd-af00-bb424f0b1747"
      decimals="-3"
      id="F_81cfc01f-6201-4260-9f25-d871df542b5d"
      unitRef="U_USD">31521000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="C_01d46517-67df-489d-b34d-e087cf6dadaf"
      decimals="-3"
      id="F_d858a81d-f22e-4086-8ca5-4f994c5aabfe"
      unitRef="U_USD">30552000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="C_378538d0-b7e1-4ecd-af00-bb424f0b1747"
      decimals="-3"
      id="F_88e66442-fb90-49b1-ac40-a22d530b6efc"
      unitRef="U_USD">1288890000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="C_01d46517-67df-489d-b34d-e087cf6dadaf"
      decimals="-3"
      id="F_83df0e70-19b3-4ca4-8259-2190aa33c52b"
      unitRef="U_USD">1370749000</us-gaap:Liabilities>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_378538d0-b7e1-4ecd-af00-bb424f0b1747"
      decimals="INF"
      id="F_bd55ad26-5a9e-4558-94c3-c9ce92a3623f"
      unitRef="U_shares">1000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_01d46517-67df-489d-b34d-e087cf6dadaf"
      decimals="INF"
      id="F_ede18482-5037-4758-bf27-bc45801374d1"
      unitRef="U_shares">1000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_378538d0-b7e1-4ecd-af00-bb424f0b1747"
      decimals="INF"
      id="F_5597f6e8-7e8b-41c9-bc08-0640937019a7"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_01d46517-67df-489d-b34d-e087cf6dadaf"
      decimals="INF"
      id="F_fdf94180-3c45-4153-9ee2-2a922a64196b"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue
      contextRef="C_378538d0-b7e1-4ecd-af00-bb424f0b1747"
      decimals="-3"
      id="F_94dc7f69-eb8f-4f47-9e02-e3644eca836a"
      unitRef="U_USD">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="C_01d46517-67df-489d-b34d-e087cf6dadaf"
      decimals="-3"
      id="F_70098b04-9218-40a5-a421-bb200d0acda2"
      unitRef="U_USD">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_378538d0-b7e1-4ecd-af00-bb424f0b1747"
      decimals="INF"
      id="F_ab55feb3-b1a0-4779-abaf-e4b5896c6a5b"
      unitRef="U_shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_01d46517-67df-489d-b34d-e087cf6dadaf"
      decimals="INF"
      id="F_df11290a-b78f-42a9-8e62-d9d100998711"
      unitRef="U_shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_378538d0-b7e1-4ecd-af00-bb424f0b1747"
      decimals="0"
      id="F_bda8fcab-8ebf-4a41-8fc9-7c09217fb7c2"
      unitRef="U_shares">85753258</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_378538d0-b7e1-4ecd-af00-bb424f0b1747"
      decimals="0"
      id="F_c6c38fd1-1148-45cd-a0dc-f49daa9e7740"
      unitRef="U_shares">85753258</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_01d46517-67df-489d-b34d-e087cf6dadaf"
      decimals="0"
      id="F_dd928b24-1e44-4cad-b867-b8fd07c5220a"
      unitRef="U_shares">84018023</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_01d46517-67df-489d-b34d-e087cf6dadaf"
      decimals="0"
      id="F_00e899be-8570-4483-8769-5ab315c30074"
      unitRef="U_shares">84018023</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="C_378538d0-b7e1-4ecd-af00-bb424f0b1747"
      decimals="-3"
      id="F_dd7241f2-c9e3-4604-879a-8f508bac5888"
      unitRef="U_USD">858000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="C_01d46517-67df-489d-b34d-e087cf6dadaf"
      decimals="-3"
      id="F_2164e190-cdbc-44d2-8d37-144992ebe7cf"
      unitRef="U_USD">840000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="C_378538d0-b7e1-4ecd-af00-bb424f0b1747"
      decimals="-3"
      id="F_4205b746-a6f0-4cc8-acbb-5b84312e743a"
      unitRef="U_USD">1006018000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="C_01d46517-67df-489d-b34d-e087cf6dadaf"
      decimals="-3"
      id="F_ac8f8624-5b8f-4b76-8fb7-7bb76f8870cd"
      unitRef="U_USD">999906000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_378538d0-b7e1-4ecd-af00-bb424f0b1747"
      decimals="-3"
      id="F_235e469d-7e70-45c3-8e78-51bf2c89597c"
      unitRef="U_USD">-1954000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_01d46517-67df-489d-b34d-e087cf6dadaf"
      decimals="-3"
      id="F_eb47bcca-6c00-497e-b73e-9a6645745967"
      unitRef="U_USD">-2214000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_378538d0-b7e1-4ecd-af00-bb424f0b1747"
      decimals="-3"
      id="F_1b4ce053-f198-4c6f-974b-ae60d0dd0c30"
      unitRef="U_USD">-298461000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_01d46517-67df-489d-b34d-e087cf6dadaf"
      decimals="-3"
      id="F_882b3d3b-c730-4ca3-ace5-3355bdd629c6"
      unitRef="U_USD">-149471000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="C_378538d0-b7e1-4ecd-af00-bb424f0b1747"
      decimals="-3"
      id="F_8d1cd3d8-af4b-400b-890d-187294727219"
      unitRef="U_USD">706461000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_01d46517-67df-489d-b34d-e087cf6dadaf"
      decimals="-3"
      id="F_51a93754-e687-472f-b524-228ca46d5c0c"
      unitRef="U_USD">849061000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_378538d0-b7e1-4ecd-af00-bb424f0b1747"
      decimals="-3"
      id="F_236ff1e4-252b-4050-a04d-5b0b4ab38629"
      unitRef="U_USD">1995351000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_01d46517-67df-489d-b34d-e087cf6dadaf"
      decimals="-3"
      id="F_21290644-7d18-4df5-95d1-65c51ce5c735"
      unitRef="U_USD">2219810000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="C_f8ba14c0-203a-4abe-895a-7068e0d681d9"
      decimals="-3"
      id="F_7a99f5eb-dbad-498d-96ff-e1e85b535667"
      unitRef="U_USD">504296000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="C_5a5fa8ad-967b-444b-af35-7dd7a8bf7ba3"
      decimals="-3"
      id="F_df6fdb3c-cd6a-4515-afdb-682f761466e2"
      unitRef="U_USD">500577000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf"
      decimals="-3"
      id="F_7e59e707-00a9-468e-9c73-7b5387e79b17"
      unitRef="U_USD">999397000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="C_57ad6014-6b49-4fd8-b8f7-ae2932078fd6"
      decimals="-3"
      id="F_84cd525b-fdff-4089-914c-7ac5dea93791"
      unitRef="U_USD">991585000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <md:PracticeSalariesAndBenefits
      contextRef="C_f8ba14c0-203a-4abe-895a-7068e0d681d9"
      decimals="-3"
      id="F_123572a4-6a0a-425a-b8c6-5a17e52f3ab6"
      unitRef="U_USD">357808000</md:PracticeSalariesAndBenefits>
    <md:PracticeSalariesAndBenefits
      contextRef="C_5a5fa8ad-967b-444b-af35-7dd7a8bf7ba3"
      decimals="-3"
      id="F_6756d97e-afc4-4538-b842-5699c01401c3"
      unitRef="U_USD">354032000</md:PracticeSalariesAndBenefits>
    <md:PracticeSalariesAndBenefits
      contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf"
      decimals="-3"
      id="F_b0e669b1-edd8-43b4-89a4-3381cbc2c50f"
      unitRef="U_USD">726946000</md:PracticeSalariesAndBenefits>
    <md:PracticeSalariesAndBenefits
      contextRef="C_57ad6014-6b49-4fd8-b8f7-ae2932078fd6"
      decimals="-3"
      id="F_c99ba539-c9ba-4630-8009-b998601bcc7e"
      unitRef="U_USD">716267000</md:PracticeSalariesAndBenefits>
    <md:PracticeSuppliesAndOtherOperatingExpenses
      contextRef="C_f8ba14c0-203a-4abe-895a-7068e0d681d9"
      decimals="-3"
      id="F_f6fb2ae4-0509-41b7-8e08-ab66bfcc2ae1"
      unitRef="U_USD">32369000</md:PracticeSuppliesAndOtherOperatingExpenses>
    <md:PracticeSuppliesAndOtherOperatingExpenses
      contextRef="C_5a5fa8ad-967b-444b-af35-7dd7a8bf7ba3"
      decimals="-3"
      id="F_8c269e90-a7b5-4176-b3b1-8a988706c3cc"
      unitRef="U_USD">31089000</md:PracticeSuppliesAndOtherOperatingExpenses>
    <md:PracticeSuppliesAndOtherOperatingExpenses
      contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf"
      decimals="-3"
      id="F_e681b381-dfb0-4a9a-a4a7-8ad1df8f0d3d"
      unitRef="U_USD">63454000</md:PracticeSuppliesAndOtherOperatingExpenses>
    <md:PracticeSuppliesAndOtherOperatingExpenses
      contextRef="C_57ad6014-6b49-4fd8-b8f7-ae2932078fd6"
      decimals="-3"
      id="F_68436388-6382-415d-a62d-ca781144a765"
      unitRef="U_USD">61809000</md:PracticeSuppliesAndOtherOperatingExpenses>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_f8ba14c0-203a-4abe-895a-7068e0d681d9"
      decimals="-3"
      id="F_bfc25329-f6f7-43af-960c-91c8ec6e361e"
      unitRef="U_USD">56565000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_5a5fa8ad-967b-444b-af35-7dd7a8bf7ba3"
      decimals="-3"
      id="F_cc04c812-a8cf-42ea-85c6-b9c136fab7ed"
      unitRef="U_USD">58013000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf"
      decimals="-3"
      id="F_51fd2fb5-fbda-4839-ad20-f952fc00ec1e"
      unitRef="U_USD">116763000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_57ad6014-6b49-4fd8-b8f7-ae2932078fd6"
      decimals="-3"
      id="F_bdd318af-5334-44d3-b3de-6e4c26a16ae4"
      unitRef="U_USD">117072000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="C_f8ba14c0-203a-4abe-895a-7068e0d681d9"
      decimals="-3"
      id="F_02754bcd-2361-4e38-85fb-83532d078c77"
      unitRef="U_USD">8791000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="C_5a5fa8ad-967b-444b-af35-7dd7a8bf7ba3"
      decimals="-3"
      id="F_05d5be3c-5b56-4ad4-a680-24059e51c3c8"
      unitRef="U_USD">8945000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf"
      decimals="-3"
      id="F_902a5ce0-d23c-4e68-b28d-0c90e8663751"
      unitRef="U_USD">19099000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="C_57ad6014-6b49-4fd8-b8f7-ae2932078fd6"
      decimals="-3"
      id="F_3d2f0f91-f696-4176-9426-5419fb92eeb3"
      unitRef="U_USD">17898000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:RestructuringCharges
      contextRef="C_f8ba14c0-203a-4abe-895a-7068e0d681d9"
      decimals="-3"
      id="F_b520e213-257b-476a-8f39-0220ef5c1706"
      unitRef="U_USD">13579000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="C_5a5fa8ad-967b-444b-af35-7dd7a8bf7ba3"
      decimals="-3"
      id="F_c2b58806-7209-4cc0-b156-d32801927f27"
      unitRef="U_USD">0</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf"
      decimals="-3"
      id="F_ca097d32-f358-478e-89f4-de4ca9576aa5"
      unitRef="U_USD">22059000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="C_57ad6014-6b49-4fd8-b8f7-ae2932078fd6"
      decimals="-3"
      id="F_95c0fee6-86ba-4bab-8d9a-4fee96429ac3"
      unitRef="U_USD">0</us-gaap:RestructuringCharges>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="C_f8ba14c0-203a-4abe-895a-7068e0d681d9"
      decimals="-3"
      id="F_b1f8dd9f-1224-4c5f-868c-6b6070dd17a4"
      unitRef="U_USD">154243000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="C_5a5fa8ad-967b-444b-af35-7dd7a8bf7ba3"
      decimals="-3"
      id="F_634b0e25-28f2-4f68-8f8e-22334aa43aef"
      unitRef="U_USD">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf"
      decimals="-3"
      id="F_93907e04-2ae0-426f-8b23-059c667c9689"
      unitRef="U_USD">154243000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="C_57ad6014-6b49-4fd8-b8f7-ae2932078fd6"
      decimals="-3"
      id="F_704e413b-5178-4ef3-a60e-248556431c97"
      unitRef="U_USD">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="C_f8ba14c0-203a-4abe-895a-7068e0d681d9"
      decimals="-3"
      id="F_5991b3ce-bd0b-4db7-ac5a-efd39cb2a2f3"
      unitRef="U_USD">20112000</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="C_5a5fa8ad-967b-444b-af35-7dd7a8bf7ba3"
      decimals="-3"
      id="F_9e112529-f2f0-4d14-9dc1-605ae0e8c03c"
      unitRef="U_USD">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf"
      decimals="-3"
      id="F_32a6ebcd-943b-46e8-87ee-47c5523b0c1c"
      unitRef="U_USD">20112000</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="C_57ad6014-6b49-4fd8-b8f7-ae2932078fd6"
      decimals="-3"
      id="F_ed6da3e4-bccc-4f49-adea-ff314422179e"
      unitRef="U_USD">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="C_f8ba14c0-203a-4abe-895a-7068e0d681d9"
      decimals="-3"
      id="F_e332291b-3797-48f0-805d-20cb8cf1d0dd"
      unitRef="U_USD">7679000</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="C_5a5fa8ad-967b-444b-af35-7dd7a8bf7ba3"
      decimals="-3"
      id="F_3d7c96b9-144f-4c47-8f4a-60fe0aca8a16"
      unitRef="U_USD">0</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf"
      decimals="-3"
      id="F_9a294df7-ad25-4b68-af99-b55023a0b995"
      unitRef="U_USD">7679000</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="C_57ad6014-6b49-4fd8-b8f7-ae2932078fd6"
      decimals="-3"
      id="F_16a409f2-482b-4fb1-971c-51eaa4d32894"
      unitRef="U_USD">0</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:GainLossOnSaleOfBusiness
      contextRef="C_f8ba14c0-203a-4abe-895a-7068e0d681d9"
      decimals="-3"
      id="F_6ab7c523-0812-4136-b585-10f8391fd51d"
      unitRef="U_USD">-10873000</us-gaap:GainLossOnSaleOfBusiness>
    <us-gaap:GainLossOnSaleOfBusiness
      contextRef="C_5a5fa8ad-967b-444b-af35-7dd7a8bf7ba3"
      decimals="-3"
      id="F_21555f8c-440e-420a-a99d-4b0e28dbe4e0"
      unitRef="U_USD">0</us-gaap:GainLossOnSaleOfBusiness>
    <us-gaap:GainLossOnSaleOfBusiness
      contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf"
      decimals="-3"
      id="F_12ed119d-b195-4da1-89bc-1770ffcdfd62"
      unitRef="U_USD">-10873000</us-gaap:GainLossOnSaleOfBusiness>
    <us-gaap:GainLossOnSaleOfBusiness
      contextRef="C_57ad6014-6b49-4fd8-b8f7-ae2932078fd6"
      decimals="-3"
      id="F_5129b3df-8b0d-4e82-9b01-d1eb03d0fc0d"
      unitRef="U_USD">0</us-gaap:GainLossOnSaleOfBusiness>
    <us-gaap:OperatingExpenses
      contextRef="C_f8ba14c0-203a-4abe-895a-7068e0d681d9"
      decimals="-3"
      id="F_16e8b0eb-666a-4a9e-ac31-f1e9104c3e9e"
      unitRef="U_USD">662019000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_5a5fa8ad-967b-444b-af35-7dd7a8bf7ba3"
      decimals="-3"
      id="F_bf324807-47b4-413f-9c37-2555d2081b73"
      unitRef="U_USD">452079000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf"
      decimals="-3"
      id="F_7f9bbb83-605d-498c-a76d-2ed4d06ee97d"
      unitRef="U_USD">1141228000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_57ad6014-6b49-4fd8-b8f7-ae2932078fd6"
      decimals="-3"
      id="F_2a209760-1871-4108-b2a0-922ba1d44853"
      unitRef="U_USD">913046000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_f8ba14c0-203a-4abe-895a-7068e0d681d9"
      decimals="-3"
      id="F_5042a68e-0b92-4be4-8d0a-b12779bc8acc"
      unitRef="U_USD">-157723000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_5a5fa8ad-967b-444b-af35-7dd7a8bf7ba3"
      decimals="-3"
      id="F_2f6967d3-4b02-44cd-8151-5e76cbbbd6c3"
      unitRef="U_USD">48498000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf"
      decimals="-3"
      id="F_c68ef2ad-8ab3-4f0a-a3a8-31f6c94b4d62"
      unitRef="U_USD">-141831000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_57ad6014-6b49-4fd8-b8f7-ae2932078fd6"
      decimals="-3"
      id="F_d4b31528-62cf-42e2-a743-e7194ae6f75f"
      unitRef="U_USD">78539000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeNet
      contextRef="C_f8ba14c0-203a-4abe-895a-7068e0d681d9"
      decimals="-3"
      id="F_84741e03-3176-48bd-8426-042786e57b40"
      unitRef="U_USD">-161000</us-gaap:InvestmentIncomeNet>
    <us-gaap:InvestmentIncomeNet
      contextRef="C_5a5fa8ad-967b-444b-af35-7dd7a8bf7ba3"
      decimals="-3"
      id="F_2f14ea32-1043-4e8f-b7ac-4e334b1a11e9"
      unitRef="U_USD">1189000</us-gaap:InvestmentIncomeNet>
    <us-gaap:InvestmentIncomeNet
      contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf"
      decimals="-3"
      id="F_176fa6e7-7321-451d-b29d-5447eb3d6e53"
      unitRef="U_USD">1852000</us-gaap:InvestmentIncomeNet>
    <us-gaap:InvestmentIncomeNet
      contextRef="C_57ad6014-6b49-4fd8-b8f7-ae2932078fd6"
      decimals="-3"
      id="F_b768e05a-4370-4c5c-a90f-84d0fd92508d"
      unitRef="U_USD">1823000</us-gaap:InvestmentIncomeNet>
    <us-gaap:InterestExpense
      contextRef="C_f8ba14c0-203a-4abe-895a-7068e0d681d9"
      decimals="-3"
      id="F_502a7f02-3d66-40e6-8e99-01d64f45324e"
      unitRef="U_USD">10308000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="C_5a5fa8ad-967b-444b-af35-7dd7a8bf7ba3"
      decimals="-3"
      id="F_2879028f-4f15-4697-8cda-b65ecac77af2"
      unitRef="U_USD">11230000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf"
      decimals="-3"
      id="F_f69147e8-dfa5-4447-81fd-6175cf426a95"
      unitRef="U_USD">20907000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="C_57ad6014-6b49-4fd8-b8f7-ae2932078fd6"
      decimals="-3"
      id="F_73dc6929-83d4-48e5-b791-6ea19d6a6e51"
      unitRef="U_USD">21620000</us-gaap:InterestExpense>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="C_f8ba14c0-203a-4abe-895a-7068e0d681d9"
      decimals="-3"
      id="F_9715b650-b285-47b1-b365-8217b2eece9f"
      unitRef="U_USD">464000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="C_5a5fa8ad-967b-444b-af35-7dd7a8bf7ba3"
      decimals="-3"
      id="F_97f25645-9daf-4c8b-8c7c-4a4072be7758"
      unitRef="U_USD">490000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf"
      decimals="-3"
      id="F_0d1457e0-083b-406d-8617-25e740654e01"
      unitRef="U_USD">982000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="C_57ad6014-6b49-4fd8-b8f7-ae2932078fd6"
      decimals="-3"
      id="F_72761670-756a-489b-9c76-497cc2f9a155"
      unitRef="U_USD">917000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_f8ba14c0-203a-4abe-895a-7068e0d681d9"
      decimals="-3"
      id="F_2286c26b-5142-4e28-a9e2-5daa41ae3984"
      unitRef="U_USD">-10005000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_5a5fa8ad-967b-444b-af35-7dd7a8bf7ba3"
      decimals="-3"
      id="F_71e2ae36-501b-485c-9658-1cbe5ec778f6"
      unitRef="U_USD">-9551000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf"
      decimals="-3"
      id="F_4ff605bf-4f42-41b9-b2b7-3b3205d08e58"
      unitRef="U_USD">-18073000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_57ad6014-6b49-4fd8-b8f7-ae2932078fd6"
      decimals="-3"
      id="F_5ad71eb7-75ea-4d50-80e7-beaf1772b3d4"
      unitRef="U_USD">-18880000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_f8ba14c0-203a-4abe-895a-7068e0d681d9"
      decimals="-3"
      id="F_7411ec82-55a9-489b-9e42-ad195db34aaf"
      unitRef="U_USD">-167728000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_5a5fa8ad-967b-444b-af35-7dd7a8bf7ba3"
      decimals="-3"
      id="F_707e517e-e083-4e05-bc10-1085514c67be"
      unitRef="U_USD">38947000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf"
      decimals="-3"
      id="F_41a37d81-dfdc-49ce-94e3-3860da71ea9e"
      unitRef="U_USD">-159904000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_57ad6014-6b49-4fd8-b8f7-ae2932078fd6"
      decimals="-3"
      id="F_66bc080c-4f7a-4c53-a2f3-e9d98b12854a"
      unitRef="U_USD">59659000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_f8ba14c0-203a-4abe-895a-7068e0d681d9"
      decimals="-3"
      id="F_aceac554-87b6-461d-9530-dd7700fcb291"
      unitRef="U_USD">-14703000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_5a5fa8ad-967b-444b-af35-7dd7a8bf7ba3"
      decimals="-3"
      id="F_8c8aa03f-e8bf-4869-b124-147012ce7967"
      unitRef="U_USD">10665000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf"
      decimals="-3"
      id="F_54e00b57-46f7-4a65-8f21-ff62a16ee4b4"
      unitRef="U_USD">-10914000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_57ad6014-6b49-4fd8-b8f7-ae2932078fd6"
      decimals="-3"
      id="F_1a69a900-b60f-4c10-b64a-335c7116f02e"
      unitRef="U_USD">17171000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ProfitLoss
      contextRef="C_f8ba14c0-203a-4abe-895a-7068e0d681d9"
      decimals="-3"
      id="F_4b4d22e2-1e7d-4da1-83eb-9a82796f3503"
      unitRef="U_USD">-153025000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_5a5fa8ad-967b-444b-af35-7dd7a8bf7ba3"
      decimals="-3"
      id="F_40e0cc12-fd52-4281-b86c-4fb5e14a87e6"
      unitRef="U_USD">28282000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf"
      decimals="-3"
      id="F_e7d0ec2d-bcfd-4733-acbc-7e2b53dc6030"
      unitRef="U_USD">-148990000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_57ad6014-6b49-4fd8-b8f7-ae2932078fd6"
      decimals="-3"
      id="F_93c378de-a8b3-47f7-9f52-d0eb04642ce8"
      unitRef="U_USD">42488000</us-gaap:ProfitLoss>
    <md:NetOfTaxUnrealizedHoldingGainLossOnInvestments
      contextRef="C_f8ba14c0-203a-4abe-895a-7068e0d681d9"
      decimals="-3"
      id="F_18714c5a-15f1-4275-9146-b35258cfc14a"
      unitRef="U_USD">66000</md:NetOfTaxUnrealizedHoldingGainLossOnInvestments>
    <md:NetOfTaxUnrealizedHoldingGainLossOnInvestments
      contextRef="C_5a5fa8ad-967b-444b-af35-7dd7a8bf7ba3"
      decimals="-3"
      id="F_3699bfa2-aab4-49b1-84ef-d34970cf8735"
      unitRef="U_USD">126000</md:NetOfTaxUnrealizedHoldingGainLossOnInvestments>
    <md:NetOfTaxUnrealizedHoldingGainLossOnInvestments
      contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf"
      decimals="-3"
      id="F_39c22187-b770-4405-ac56-9fc664b34869"
      unitRef="U_USD">86000</md:NetOfTaxUnrealizedHoldingGainLossOnInvestments>
    <md:NetOfTaxUnrealizedHoldingGainLossOnInvestments
      contextRef="C_57ad6014-6b49-4fd8-b8f7-ae2932078fd6"
      decimals="-3"
      id="F_56ec7fa3-f3e2-445c-b325-ac6fa53e6bd9"
      unitRef="U_USD">353000</md:NetOfTaxUnrealizedHoldingGainLossOnInvestments>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="C_f8ba14c0-203a-4abe-895a-7068e0d681d9"
      decimals="-3"
      id="F_1dbbcd2b-5c38-4436-ada3-ce8ab4c1825c"
      unitRef="U_USD">200000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="C_5a5fa8ad-967b-444b-af35-7dd7a8bf7ba3"
      decimals="-3"
      id="F_9f567b36-dbe5-47ae-b364-14855618907d"
      unitRef="U_USD">-387000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf"
      decimals="-3"
      id="F_3e3b13c8-956e-4ae9-b897-32cae7773414"
      unitRef="U_USD">260000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="C_57ad6014-6b49-4fd8-b8f7-ae2932078fd6"
      decimals="-3"
      id="F_517364d4-e286-48f9-8165-d870e272fb85"
      unitRef="U_USD">217000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_f8ba14c0-203a-4abe-895a-7068e0d681d9"
      decimals="-3"
      id="F_d5d61069-f94e-42ec-9988-bda22fd027c7"
      unitRef="U_USD">-152825000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_5a5fa8ad-967b-444b-af35-7dd7a8bf7ba3"
      decimals="-3"
      id="F_10e6ea74-ccdd-427a-a3c7-e47df663440b"
      unitRef="U_USD">27895000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf"
      decimals="-3"
      id="F_ce8c60f1-39eb-40a1-9a1d-32b1d0967ab4"
      unitRef="U_USD">-148730000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_57ad6014-6b49-4fd8-b8f7-ae2932078fd6"
      decimals="-3"
      id="F_ecadbb01-4995-4e9c-af96-fd0940cd4bd3"
      unitRef="U_USD">42705000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_f8ba14c0-203a-4abe-895a-7068e0d681d9"
      decimals="2"
      id="F_dfdc46c7-28c7-450f-8353-b481100dfce8"
      unitRef="U_USDollarShare">-1.84</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_5a5fa8ad-967b-444b-af35-7dd7a8bf7ba3"
      decimals="2"
      id="F_cbbe38da-80e1-4b94-94b1-6cad1d25da60"
      unitRef="U_USDollarShare">0.34</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf"
      decimals="2"
      id="F_5ede3980-6d2b-4f06-8c62-ae9f6a425345"
      unitRef="U_USDollarShare">-1.79</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_57ad6014-6b49-4fd8-b8f7-ae2932078fd6"
      decimals="2"
      id="F_61f74dd3-c974-47d0-a457-24acb8fa9bec"
      unitRef="U_USDollarShare">0.52</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_f8ba14c0-203a-4abe-895a-7068e0d681d9"
      decimals="2"
      id="F_7bc7e3d7-ede8-4e2e-b9c1-44ff3561a7f0"
      unitRef="U_USDollarShare">-1.84</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_5a5fa8ad-967b-444b-af35-7dd7a8bf7ba3"
      decimals="2"
      id="F_f436b0ba-4e2e-4ed0-aa50-6973fce2dad1"
      unitRef="U_USDollarShare">0.34</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf"
      decimals="2"
      id="F_ad180b7c-ba85-4b98-8762-7e934cb01fa1"
      unitRef="U_USDollarShare">-1.79</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_57ad6014-6b49-4fd8-b8f7-ae2932078fd6"
      decimals="2"
      id="F_f0bdc3db-b66d-4f08-979f-282474f927d6"
      unitRef="U_USDollarShare">0.52</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_f8ba14c0-203a-4abe-895a-7068e0d681d9"
      decimals="-3"
      id="F_459ab46e-f278-4170-b64f-299825b83f5c"
      unitRef="U_shares">83332000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_5a5fa8ad-967b-444b-af35-7dd7a8bf7ba3"
      decimals="-3"
      id="F_f6aa01f5-614d-45cf-af36-73fb3de81835"
      unitRef="U_shares">82399000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf"
      decimals="-3"
      id="F_2215b0c1-357f-4041-af33-54ce0c944527"
      unitRef="U_shares">83074000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_57ad6014-6b49-4fd8-b8f7-ae2932078fd6"
      decimals="-3"
      id="F_d4bf882d-a5d7-488c-8a66-5a60bd01131e"
      unitRef="U_shares">82033000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_f8ba14c0-203a-4abe-895a-7068e0d681d9"
      decimals="-3"
      id="F_e55ef5ba-2730-42dd-bf00-0c0635e516d7"
      unitRef="U_shares">83332000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_5a5fa8ad-967b-444b-af35-7dd7a8bf7ba3"
      decimals="-3"
      id="F_71fcb6e2-e888-40d7-bd72-9e3946cc8083"
      unitRef="U_shares">82664000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf"
      decimals="-3"
      id="F_84fc3e91-3edd-4bbb-887c-005a36b853a1"
      unitRef="U_shares">83074000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_57ad6014-6b49-4fd8-b8f7-ae2932078fd6"
      decimals="-3"
      id="F_447c0fdb-8b30-46fb-b0d9-529086ad0e3f"
      unitRef="U_shares">82377000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:SharesIssued
      contextRef="C_bbfdd70c-5aff-4803-b853-9aed8b435db7"
      decimals="-3"
      id="F_60cc24cb-8b99-49f4-8b3c-b5f81f707b5d"
      unitRef="U_shares">84018000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_bbfdd70c-5aff-4803-b853-9aed8b435db7"
      decimals="-3"
      id="F_57afd45f-d6ae-4abf-aecf-249dfbd46c8e"
      unitRef="U_USD">840000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_feaa2e55-4022-4e2f-abe1-edb33b1f5e36"
      decimals="-3"
      id="F_3d0b0af1-6f3b-40d4-966e-b59bd57b8a92"
      unitRef="U_USD">999906000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_cd8a1422-f4cb-4c26-b354-491001ddef25"
      decimals="-3"
      id="F_2b6eed39-a5cc-47b4-a78c-818d610432a0"
      unitRef="U_USD">-2214000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_b76e1e1c-7e08-49c4-ba42-36b7776b9c77"
      decimals="-3"
      id="F_d6db44b1-c2c9-4f2e-ab36-5de966351f28"
      unitRef="U_USD">-149471000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_01d46517-67df-489d-b34d-e087cf6dadaf"
      decimals="-3"
      id="F_8d401c0e-cf97-4ab1-aeba-2376b17e7e3b"
      unitRef="U_USD">849061000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="C_a23f2efb-8927-4491-a7c8-c1b619aa2e83"
      decimals="-3"
      id="F_0e662654-6d9c-403c-8991-91ac49c6b6db"
      unitRef="U_USD">4035000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_01c11cbc-05a6-4e7d-bb87-a2a2acb9a949"
      decimals="-3"
      id="F_226a40fc-93f3-4c3d-a22d-bb1855973840"
      unitRef="U_USD">4035000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_a04037ee-9a78-4964-9e1c-74fa20cac8af"
      decimals="-3"
      id="F_8fdb171e-6080-414d-9a60-db90bead08db"
      unitRef="U_USD">60000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_01c11cbc-05a6-4e7d-bb87-a2a2acb9a949"
      decimals="-3"
      id="F_a1f4e6df-134e-4de0-a79b-b206d81d321e"
      unitRef="U_USD">60000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="C_055fb263-9778-4cf7-8395-b3db5ae74ab3"
      decimals="-3"
      id="F_9303bd94-44d7-46f7-bbdd-5f96c0fe50da"
      unitRef="U_shares">108000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_055fb263-9778-4cf7-8395-b3db5ae74ab3"
      decimals="-3"
      id="F_99821ef8-d2d5-4785-8793-5445d2732fce"
      unitRef="U_USD">1000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_207dae80-b868-42b4-8f60-529bb2da464b"
      decimals="-3"
      id="F_bcca2d43-d58a-4769-b2c9-3df615a5a196"
      unitRef="U_USD">859000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_01c11cbc-05a6-4e7d-bb87-a2a2acb9a949"
      decimals="-3"
      id="F_0ef715e2-48dd-4e6c-b6e7-eb3432dc0ed6"
      unitRef="U_USD">860000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited
      contextRef="C_055fb263-9778-4cf7-8395-b3db5ae74ab3"
      decimals="-3"
      id="F_d90e4b4f-6a91-49a4-a2fd-a21be07de954"
      unitRef="U_shares">-21000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_207dae80-b868-42b4-8f60-529bb2da464b"
      decimals="-3"
      id="F_fca8169f-c20a-4c53-bced-5f2f19567fb7"
      unitRef="U_USD">3067000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_01c11cbc-05a6-4e7d-bb87-a2a2acb9a949"
      decimals="-3"
      id="F_02711fa6-8322-41fc-9fc3-4d9f6591f251"
      unitRef="U_USD">3067000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="C_055fb263-9778-4cf7-8395-b3db5ae74ab3"
      decimals="-3"
      id="F_997bbeab-24d9-43c8-93cd-41f54f1a7fd8"
      unitRef="U_shares">97000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="C_055fb263-9778-4cf7-8395-b3db5ae74ab3"
      decimals="-3"
      id="F_ad887e07-059a-4aa2-a05f-598f013a4c6a"
      unitRef="U_USD">1000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="C_207dae80-b868-42b4-8f60-529bb2da464b"
      decimals="-3"
      id="F_2a37c032-62f0-4879-83ad-b60a09976220"
      unitRef="U_USD">886000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="C_01c11cbc-05a6-4e7d-bb87-a2a2acb9a949"
      decimals="-3"
      id="F_b0a23a23-336c-4dfc-9a30-04d12b50fc00"
      unitRef="U_USD">887000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:SharesIssued
      contextRef="C_8693cd13-0631-41d8-8347-98d3ec5b732d"
      decimals="-3"
      id="F_8eb4719d-948c-4a7e-bfcc-a0fb75db0112"
      unitRef="U_shares">84008000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_8693cd13-0631-41d8-8347-98d3ec5b732d"
      decimals="-3"
      id="F_01683239-a700-4526-abec-c31965ac7648"
      unitRef="U_USD">840000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_d6bf2c94-ac55-40fc-90b0-8184b979a967"
      decimals="-3"
      id="F_974567a9-31eb-48fa-87cc-f0295431cda3"
      unitRef="U_USD">1002946000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_7c834d47-d5d5-4daa-8490-432e04b450c3"
      decimals="-3"
      id="F_7c3250cf-40d6-4af1-b0e3-0e4a02ac281e"
      unitRef="U_USD">-2154000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_9997289e-fdb8-486e-acac-cb788b4f8239"
      decimals="-3"
      id="F_82c34756-4a3a-4d29-b0f8-9a54181555d4"
      unitRef="U_USD">-145436000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_f80a1315-a5a6-418b-98c4-fc56bd22ae95"
      decimals="-3"
      id="F_e54b3ee4-7fcb-4e2f-a966-e11f95f09e71"
      unitRef="U_USD">856196000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="C_9d8d79b8-258d-4977-8e93-a832860452f4"
      decimals="-3"
      id="F_9e6c5d71-e8a6-440a-b64e-f108e282360c"
      unitRef="U_USD">-153025000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_f8ba14c0-203a-4abe-895a-7068e0d681d9"
      decimals="-3"
      id="F_490c9058-5063-4a72-a8d0-ba4150c57f4f"
      unitRef="U_USD">-153025000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_594a2ea7-65e0-4290-83d4-8be74d122ddc"
      decimals="-3"
      id="F_a2a59b0c-4b56-4c88-817c-d1540891e75c"
      unitRef="U_USD">200000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_f8ba14c0-203a-4abe-895a-7068e0d681d9"
      decimals="-3"
      id="F_66ccca52-2522-4767-94b6-e7799375ca9b"
      unitRef="U_USD">200000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="C_86bb4acc-ec76-4db5-933a-a771e7cd3750"
      decimals="-3"
      id="F_addd5c1e-3b77-42ea-b00c-6ead8a07ffde"
      unitRef="U_shares">139000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_86bb4acc-ec76-4db5-933a-a771e7cd3750"
      decimals="-3"
      id="F_ce1e1dad-e2fa-4b4e-9f37-0711b250b716"
      unitRef="U_USD">2000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_35df4ea0-7c25-462a-83e1-ff1079f8091e"
      decimals="-3"
      id="F_f88bfb98-8aec-4aef-abb1-df9611f883f1"
      unitRef="U_USD">1147000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_f8ba14c0-203a-4abe-895a-7068e0d681d9"
      decimals="-3"
      id="F_d1bf67d4-a875-4b29-9dd0-69123666bdd0"
      unitRef="U_USD">1149000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross
      contextRef="C_86bb4acc-ec76-4db5-933a-a771e7cd3750"
      decimals="-3"
      id="F_3aefb809-b848-48b1-a7df-9cf1bef17789"
      unitRef="U_shares">1630000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="C_86bb4acc-ec76-4db5-933a-a771e7cd3750"
      decimals="-3"
      id="F_d995133f-3ac9-4b8a-9990-25b83657dcf7"
      unitRef="U_USD">16000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="C_35df4ea0-7c25-462a-83e1-ff1079f8091e"
      decimals="-3"
      id="F_6ab2d3ae-763b-4615-a519-950f1f6ee178"
      unitRef="U_USD">-16000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited
      contextRef="C_86bb4acc-ec76-4db5-933a-a771e7cd3750"
      decimals="-3"
      id="F_54125c18-985c-4af5-a24b-e3ca175f6f13"
      unitRef="U_shares">-22000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_35df4ea0-7c25-462a-83e1-ff1079f8091e"
      decimals="-3"
      id="F_2041b7ea-1657-4aee-b824-dd83e936124b"
      unitRef="U_USD">1952000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_f8ba14c0-203a-4abe-895a-7068e0d681d9"
      decimals="-3"
      id="F_a94b7636-8a37-4244-a5d0-55d8e1f4533d"
      unitRef="U_USD">1952000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="C_86bb4acc-ec76-4db5-933a-a771e7cd3750"
      decimals="-3"
      id="F_fa393c19-b95f-454e-a72a-3dac69262b77"
      unitRef="U_shares">2000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="C_35df4ea0-7c25-462a-83e1-ff1079f8091e"
      decimals="-3"
      id="F_0f85f907-04b1-430b-b8e2-0c3bffc9bd3d"
      unitRef="U_USD">11000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="C_f8ba14c0-203a-4abe-895a-7068e0d681d9"
      decimals="-3"
      id="F_e68ad259-7f11-4954-8027-08abc4683e4a"
      unitRef="U_USD">11000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:SharesIssued
      contextRef="C_a20e0eec-fcf2-491f-ad41-9a428f13e263"
      decimals="-3"
      id="F_9b742f63-e7ca-4a73-8bd6-b162633108cd"
      unitRef="U_shares">85753000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_a20e0eec-fcf2-491f-ad41-9a428f13e263"
      decimals="-3"
      id="F_76ca9f43-930c-4064-9dfe-39207b71f9f5"
      unitRef="U_USD">858000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_5207957e-5a84-4d96-961c-054e57351b74"
      decimals="-3"
      id="F_50077b20-a5c6-4330-94fc-c2e29a162cfb"
      unitRef="U_USD">1006018000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_121e7382-aaaf-4b4b-b85f-ca7209a14358"
      decimals="-3"
      id="F_3419a1a1-f9fd-498e-b132-b5bb4fe9a88e"
      unitRef="U_USD">-1954000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_9478e6ac-d067-47ed-985a-d3a75cbb347e"
      decimals="-3"
      id="F_175495f8-becf-4889-a8f4-8efe0b11f438"
      unitRef="U_USD">-298461000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_378538d0-b7e1-4ecd-af00-bb424f0b1747"
      decimals="-3"
      id="F_1ef50ec2-7d6a-4c5c-8637-2fc7ea912186"
      unitRef="U_USD">706461000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="C_d564d4a9-a926-457b-80b1-01fa631a1e4f"
      decimals="-3"
      id="F_dfaeed9d-4046-4f95-bb0f-4d66d9e94697"
      unitRef="U_shares">82947000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_d564d4a9-a926-457b-80b1-01fa631a1e4f"
      decimals="-3"
      id="F_85a30032-2a55-435a-8efc-b557d67b0391"
      unitRef="U_USD">829000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_f9deda8d-474c-400c-8f2b-c04bdaea334d"
      decimals="-3"
      id="F_abe95c30-fe63-42d0-8361-a1d627e9bb6f"
      unitRef="U_USD">983601000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_aea590f4-2725-4610-b86d-be28415452fc"
      decimals="-3"
      id="F_37c91e05-3c2f-453f-8bd3-4ec503b2dbce"
      unitRef="U_USD">-3735000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_4ddfa92a-fd22-4353-88c1-befe81c45dca"
      decimals="-3"
      id="F_a25e21a2-8a1f-4800-a0b2-31941371fdd2"
      unitRef="U_USD">-89063000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_097f26a0-c77e-4f84-b663-38d6391e01e6"
      decimals="-3"
      id="F_30350dc6-5aac-4067-a663-15deaebf35ef"
      unitRef="U_USD">891632000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="C_1e093f6f-db74-422e-95ac-c5b0a5e76558"
      decimals="-3"
      id="F_733c394a-f2c5-4311-ba2f-14f0363b808f"
      unitRef="U_USD">14206000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_31b43498-9159-4c16-bd8b-ab5cef5e0575"
      decimals="-3"
      id="F_c15045b7-2be5-4f3a-bb98-319aff35468e"
      unitRef="U_USD">14206000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_edb2e0fd-b34b-4b67-8c89-128090856b98"
      decimals="-3"
      id="F_53646c34-0cdb-443c-9f88-78d4ce119ca2"
      unitRef="U_USD">604000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_31b43498-9159-4c16-bd8b-ab5cef5e0575"
      decimals="-3"
      id="F_90d318ab-697c-434a-baa1-77a43431e24c"
      unitRef="U_USD">604000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="C_5f0c50a0-53ad-41c3-8101-90e7e5cacb14"
      decimals="-3"
      id="F_a6386da0-5d2d-494f-9679-f6f06d389b98"
      unitRef="U_shares">86000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_a24c8561-3fe8-4ee9-9a5f-3650008ddd53"
      decimals="-3"
      id="F_de50d025-3f39-4279-9d11-cd8061d02d83"
      unitRef="U_USD">1095000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_31b43498-9159-4c16-bd8b-ab5cef5e0575"
      decimals="-3"
      id="F_4fbeeeb3-7fd0-47d5-86dc-9e3b9e19d1c9"
      unitRef="U_USD">1095000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross
      contextRef="C_5f0c50a0-53ad-41c3-8101-90e7e5cacb14"
      decimals="-3"
      id="F_66424206-08cf-4e95-a1b0-93bced896810"
      unitRef="U_shares">871000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="C_5f0c50a0-53ad-41c3-8101-90e7e5cacb14"
      decimals="-3"
      id="F_0563a0d9-1d28-46b3-b834-950321cdf821"
      unitRef="U_USD">9000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="C_a24c8561-3fe8-4ee9-9a5f-3650008ddd53"
      decimals="-3"
      id="F_619f2ca0-5aa6-48c7-9d41-10e953e8a740"
      unitRef="U_USD">-9000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited
      contextRef="C_5f0c50a0-53ad-41c3-8101-90e7e5cacb14"
      decimals="-3"
      id="F_949b2ec5-96e1-49e6-a491-7aba3d906ff8"
      unitRef="U_shares">-221000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures
      contextRef="C_5f0c50a0-53ad-41c3-8101-90e7e5cacb14"
      decimals="-3"
      id="F_45bf7d33-953a-48e2-b85e-74f14c3225df"
      unitRef="U_USD">-2000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures
      contextRef="C_a24c8561-3fe8-4ee9-9a5f-3650008ddd53"
      decimals="-3"
      id="F_7fabaa1f-3d2c-4185-86c6-8559c93019b3"
      unitRef="U_USD">2000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_a24c8561-3fe8-4ee9-9a5f-3650008ddd53"
      decimals="-3"
      id="F_eda69540-ce85-4540-9d9c-b42784b336b0"
      unitRef="U_USD">3009000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_31b43498-9159-4c16-bd8b-ab5cef5e0575"
      decimals="-3"
      id="F_844a8692-ab71-4cfc-a517-f9a057812fcc"
      unitRef="U_USD">3009000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="C_5f0c50a0-53ad-41c3-8101-90e7e5cacb14"
      decimals="-3"
      id="F_49031508-c750-4bd3-a319-fd72b0938aaf"
      unitRef="U_shares">49000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="C_a24c8561-3fe8-4ee9-9a5f-3650008ddd53"
      decimals="-3"
      id="F_3823b637-fc12-4b79-9162-ead29a2f3c88"
      unitRef="U_USD">775000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="C_31b43498-9159-4c16-bd8b-ab5cef5e0575"
      decimals="-3"
      id="F_0215c999-e842-4f61-a08a-99014053abaf"
      unitRef="U_USD">775000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:SharesIssued
      contextRef="C_b87610a2-4379-4ba9-97b7-9e4606d8ef5c"
      decimals="-3"
      id="F_fdf9b003-3d69-4524-8bad-5efa6fa246d4"
      unitRef="U_shares">83634000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_b87610a2-4379-4ba9-97b7-9e4606d8ef5c"
      decimals="-3"
      id="F_9ea703f1-a9de-4e0f-ab18-951dcdd909dc"
      unitRef="U_USD">836000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_5875e45d-cd89-498d-903a-55b9e7739c94"
      decimals="-3"
      id="F_f43ff5f5-60b1-4493-9455-6ffe8293359c"
      unitRef="U_USD">986923000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_9f05953b-1f07-4686-942c-7b1d7943d27f"
      decimals="-3"
      id="F_e2f056d2-3ebd-44ad-8981-87d55d730a79"
      unitRef="U_USD">-3131000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_ca171fc2-2432-408d-b564-cd2e7563ba71"
      decimals="-3"
      id="F_28f163cb-426c-40e1-ab29-b5a1b1f661b2"
      unitRef="U_USD">-74857000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_a3930cd6-349a-4a67-8e41-4578fe93ff88"
      decimals="-3"
      id="F_7b34037e-a188-4c1a-84c3-46d087113e7e"
      unitRef="U_USD">909771000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="C_ef9ac9e9-8f0b-4197-8eb4-12ca2061e14f"
      decimals="-3"
      id="F_2efc3264-c821-4e08-8b70-913dae915aaf"
      unitRef="U_USD">28282000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_5a5fa8ad-967b-444b-af35-7dd7a8bf7ba3"
      decimals="-3"
      id="F_7a0a1956-eb07-4d76-8240-888223938610"
      unitRef="U_USD">28282000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_d3b7b754-9615-4731-9358-8ab2afbdb4a3"
      decimals="-3"
      id="F_e0749bea-9e2d-49cb-b742-82b1ed1639ad"
      unitRef="U_USD">-387000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_5a5fa8ad-967b-444b-af35-7dd7a8bf7ba3"
      decimals="-3"
      id="F_c55ed278-1a48-4e8d-b0e5-3f2d342626f6"
      unitRef="U_USD">-387000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="C_47c0d2ef-584a-4c5e-ae36-b63c1c605bcc"
      decimals="-3"
      id="F_7ac4399d-a43d-458d-9de0-4ac8f5d20694"
      unitRef="U_shares">126000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_47c0d2ef-584a-4c5e-ae36-b63c1c605bcc"
      decimals="-3"
      id="F_6f85d6c1-6efe-4f06-8bc8-5e30ac4f43e5"
      unitRef="U_USD">1000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_eb6de81c-9c30-48c6-8848-0a4491bbd3cf"
      decimals="-3"
      id="F_df59075d-959f-4a4f-80c5-259df4e9a689"
      unitRef="U_USD">1593000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_5a5fa8ad-967b-444b-af35-7dd7a8bf7ba3"
      decimals="-3"
      id="F_7bb01184-4cd2-441e-91d0-d3b3b591393a"
      unitRef="U_USD">1594000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross
      contextRef="C_47c0d2ef-584a-4c5e-ae36-b63c1c605bcc"
      decimals="-3"
      id="F_6eae5993-8c85-4a52-9b0f-e562295ec149"
      unitRef="U_shares">93000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="C_47c0d2ef-584a-4c5e-ae36-b63c1c605bcc"
      decimals="-3"
      id="F_54352b48-71d9-4e9c-bb97-994eebc5ea3a"
      unitRef="U_USD">1000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="C_eb6de81c-9c30-48c6-8848-0a4491bbd3cf"
      decimals="-3"
      id="F_f936c975-9254-429b-9f07-95360d34d850"
      unitRef="U_USD">-1000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited
      contextRef="C_47c0d2ef-584a-4c5e-ae36-b63c1c605bcc"
      decimals="-3"
      id="F_a6b52d1c-8205-4bf7-9d23-0ef15c691c0e"
      unitRef="U_shares">-11000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_eb6de81c-9c30-48c6-8848-0a4491bbd3cf"
      decimals="-3"
      id="F_a15edb90-01a3-4094-9e4a-b9fc694efbd7"
      unitRef="U_USD">3126000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_5a5fa8ad-967b-444b-af35-7dd7a8bf7ba3"
      decimals="-3"
      id="F_45f24a93-28b8-405f-ba1c-e95da4b0d507"
      unitRef="U_USD">3126000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="C_47c0d2ef-584a-4c5e-ae36-b63c1c605bcc"
      decimals="-3"
      id="F_db8fadeb-e1bf-4750-8413-1cb2b7d8a104"
      unitRef="U_shares">1000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="C_eb6de81c-9c30-48c6-8848-0a4491bbd3cf"
      decimals="-3"
      id="F_fdaf3762-bc86-4839-ac9e-f10b9a497f18"
      unitRef="U_USD">11000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="C_5a5fa8ad-967b-444b-af35-7dd7a8bf7ba3"
      decimals="-3"
      id="F_48c3c792-669a-4812-9f36-8850a6ac26be"
      unitRef="U_USD">11000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:SharesIssued
      contextRef="C_45e7bb15-6f89-4eb6-9120-7ec8d161f85b"
      decimals="-3"
      id="F_aa50ce5b-c7c8-4645-9140-8c026664af95"
      unitRef="U_shares">83841000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_45e7bb15-6f89-4eb6-9120-7ec8d161f85b"
      decimals="-3"
      id="F_b15095a4-72ac-40f4-8c92-a1a59d36754c"
      unitRef="U_USD">838000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_3610c317-f612-4c22-9d38-5d8900ab3930"
      decimals="-3"
      id="F_d3fbc7e1-01a7-42a1-90d6-bda10ea1072a"
      unitRef="U_USD">991630000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_1786cd13-4a3f-41ee-8fba-517746735e35"
      decimals="-3"
      id="F_6f3d1060-cf9f-4546-a05a-aae1a3eebc83"
      unitRef="U_USD">-3518000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_bf0934a0-5844-404d-a376-9a2eb1aa3de7"
      decimals="-3"
      id="F_9df3fbbc-858f-4d2a-9964-64c7e8d338a7"
      unitRef="U_USD">-46575000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_60b78123-38d8-4d05-8a9b-e087fe9016a9"
      decimals="-3"
      id="F_9ce7e962-b4f3-494d-bddb-598e72eca754"
      unitRef="U_USD">942375000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf"
      decimals="-3"
      id="F_0ef3d371-43f8-4697-a1f4-7e858cbca2af"
      unitRef="U_USD">-148990000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_57ad6014-6b49-4fd8-b8f7-ae2932078fd6"
      decimals="-3"
      id="F_3bb12444-d7ca-4633-b773-e9909aad8599"
      unitRef="U_USD">42488000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf"
      decimals="-3"
      id="F_2b13be2e-5d03-4772-bc9c-57555e8fb0db"
      unitRef="U_USD">19099000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="C_57ad6014-6b49-4fd8-b8f7-ae2932078fd6"
      decimals="-3"
      id="F_31a50fb4-b0d5-4296-8ad9-98148fc6e935"
      unitRef="U_USD">17898000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf"
      decimals="-3"
      id="F_69f65d4d-6770-4d13-9676-8e12a38c0773"
      unitRef="U_USD">440000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="C_57ad6014-6b49-4fd8-b8f7-ae2932078fd6"
      decimals="-3"
      id="F_0cba5eb6-9f6f-4843-99f1-4bfc6b5fa4b6"
      unitRef="U_USD">733000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf"
      decimals="-3"
      id="F_5f6c66d2-89da-49de-a113-9f93bcfe1078"
      unitRef="U_USD">154243000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="C_57ad6014-6b49-4fd8-b8f7-ae2932078fd6"
      decimals="-3"
      id="F_7a4b82ad-afee-4e9c-b945-4a5b1deb90c5"
      unitRef="U_USD">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf"
      decimals="-3"
      id="F_a1bcf941-3917-4fac-a6cf-ff23d4129ce0"
      unitRef="U_USD">20112000</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="C_57ad6014-6b49-4fd8-b8f7-ae2932078fd6"
      decimals="-3"
      id="F_fa07e5f0-8f76-4c83-b7a3-b98b19cca07f"
      unitRef="U_USD">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf"
      decimals="-3"
      id="F_a0851738-69c0-4ba3-bea9-b397adfe1cc4"
      unitRef="U_USD">7679000</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="C_57ad6014-6b49-4fd8-b8f7-ae2932078fd6"
      decimals="-3"
      id="F_7ea4d44b-6af8-498e-8cab-69e38eebae23"
      unitRef="U_USD">0</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:GainLossOnSaleOfBusiness
      contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf"
      decimals="-3"
      id="F_dea4fb28-725e-422c-b770-5eadad74719c"
      unitRef="U_USD">-10873000</us-gaap:GainLossOnSaleOfBusiness>
    <us-gaap:GainLossOnSaleOfBusiness
      contextRef="C_57ad6014-6b49-4fd8-b8f7-ae2932078fd6"
      decimals="-3"
      id="F_56396ec4-6a75-4817-8e74-a460b7b3c55c"
      unitRef="U_USD">0</us-gaap:GainLossOnSaleOfBusiness>
    <us-gaap:ShareBasedCompensation
      contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf"
      decimals="-3"
      id="F_4e4d26e3-c8f2-4f80-a6a5-5e01bf0f336e"
      unitRef="U_USD">5019000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_57ad6014-6b49-4fd8-b8f7-ae2932078fd6"
      decimals="-3"
      id="F_d4438f8e-828a-443c-a145-590e6d8533e4"
      unitRef="U_USD">6135000</us-gaap:ShareBasedCompensation>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf"
      decimals="-3"
      id="F_309f63e8-31b7-4c26-a3aa-a6205ac98fde"
      unitRef="U_USD">-25028000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="C_57ad6014-6b49-4fd8-b8f7-ae2932078fd6"
      decimals="-3"
      id="F_7c0d82cc-1eda-4ea9-9da5-58981baacac7"
      unitRef="U_USD">8376000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf"
      decimals="-3"
      id="F_f1dea87e-5e53-468f-9d51-de13499b4fc9"
      unitRef="U_USD">1678000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="C_57ad6014-6b49-4fd8-b8f7-ae2932078fd6"
      decimals="-3"
      id="F_398e88cf-9e7f-4767-9c71-7bf8f147f078"
      unitRef="U_USD">900000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf"
      decimals="-3"
      id="F_916f2614-29a4-4905-af86-b867ffb06ebd"
      unitRef="U_USD">934000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="C_57ad6014-6b49-4fd8-b8f7-ae2932078fd6"
      decimals="-3"
      id="F_ac1117a2-f9ea-45f7-bbf8-2726a0713a11"
      unitRef="U_USD">-28900000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf"
      decimals="-3"
      id="F_f4592d53-9552-4cb9-bcf3-d9d9ef904799"
      unitRef="U_USD">-3703000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_57ad6014-6b49-4fd8-b8f7-ae2932078fd6"
      decimals="-3"
      id="F_375c1d48-61c1-4721-b714-f47b67047a97"
      unitRef="U_USD">-2141000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf"
      decimals="-3"
      id="F_c360dfa3-e285-4986-a380-a283e8bbff4f"
      unitRef="U_USD">-16955000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="C_57ad6014-6b49-4fd8-b8f7-ae2932078fd6"
      decimals="-3"
      id="F_7cd5c421-d22b-4eb2-8b95-fb8b58bb254e"
      unitRef="U_USD">-5052000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf"
      decimals="-3"
      id="F_007d2897-d843-46fb-98ab-a9342a59e3f3"
      unitRef="U_USD">-82917000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="C_57ad6014-6b49-4fd8-b8f7-ae2932078fd6"
      decimals="-3"
      id="F_cf03de60-28b1-4506-9ca7-47e11493f82b"
      unitRef="U_USD">-97315000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable
      contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf"
      decimals="-3"
      id="F_d1e9978e-9fdb-4cfc-a360-f9905d019678"
      unitRef="U_USD">11735000</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable
      contextRef="C_57ad6014-6b49-4fd8-b8f7-ae2932078fd6"
      decimals="-3"
      id="F_bb7ebd5a-fde7-4c4e-a7f8-d9b1df6e0970"
      unitRef="U_USD">-12028000</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <us-gaap:IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve
      contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf"
      decimals="-3"
      id="F_90fc48ba-2022-436d-9a62-6c1640ccf07a"
      unitRef="U_USD">8039000</us-gaap:IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve>
    <us-gaap:IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve
      contextRef="C_57ad6014-6b49-4fd8-b8f7-ae2932078fd6"
      decimals="-3"
      id="F_e2fdd7f5-9a51-44ed-b53f-6830dd13acf9"
      unitRef="U_USD">838000</us-gaap:IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf"
      decimals="-3"
      id="F_d85276f7-3a6d-441d-8caa-f28a81ed5a10"
      unitRef="U_USD">-11630000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="C_57ad6014-6b49-4fd8-b8f7-ae2932078fd6"
      decimals="-3"
      id="F_d3b5af24-4048-4597-9d2a-b3bf30d519f7"
      unitRef="U_USD">-10356000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
      contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf"
      decimals="-3"
      id="F_f916c3ed-08de-455d-b6e5-1a7b28bf9d0f"
      unitRef="U_USD">-13280000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
    <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
      contextRef="C_57ad6014-6b49-4fd8-b8f7-ae2932078fd6"
      decimals="-3"
      id="F_e4674178-032d-435a-9e42-efbabfb92593"
      unitRef="U_USD">-8038000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
    <us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
      contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf"
      decimals="-3"
      id="F_96918e4e-cb83-4819-82e4-ae2a86d4533b"
      unitRef="U_USD">-4995000</us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations>
    <us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
      contextRef="C_57ad6014-6b49-4fd8-b8f7-ae2932078fd6"
      decimals="-3"
      id="F_f58e032e-7c42-40e7-9cad-6303d7f6cbc5"
      unitRef="U_USD">-3825000</us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf"
      decimals="-3"
      id="F_bf2973c1-5760-4218-971c-8a9613cc68c2"
      unitRef="U_USD">-18275000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_57ad6014-6b49-4fd8-b8f7-ae2932078fd6"
      decimals="-3"
      id="F_cf6aaf44-b4f0-4cc9-bdaa-36d3047605ce"
      unitRef="U_USD">-11863000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf"
      decimals="-3"
      id="F_3558572b-675b-491c-bfec-5020046d4819"
      unitRef="U_USD">8167000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="C_57ad6014-6b49-4fd8-b8f7-ae2932078fd6"
      decimals="-3"
      id="F_8fd84336-e48b-493c-8b25-a667b1ff0749"
      unitRef="U_USD">1667000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf"
      decimals="-3"
      id="F_9dc50a92-2438-455d-909e-a0219af75749"
      unitRef="U_USD">39915000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="C_57ad6014-6b49-4fd8-b8f7-ae2932078fd6"
      decimals="-3"
      id="F_64f93a36-6e2b-4941-ad65-3390834a83ee"
      unitRef="U_USD">17761000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments
      contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf"
      decimals="-3"
      id="F_142e6a30-222c-44e2-803a-b6c0951913d2"
      unitRef="U_USD">31244000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments
      contextRef="C_57ad6014-6b49-4fd8-b8f7-ae2932078fd6"
      decimals="-3"
      id="F_0204ae7d-6e7a-4c7f-9f80-1bd09ff62393"
      unitRef="U_USD">12810000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
    <us-gaap:PaymentsToAcquireOtherPropertyPlantAndEquipment
      contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf"
      decimals="-3"
      id="F_b6b925aa-8183-4b87-863d-dfd5ada2b71c"
      unitRef="U_USD">12292000</us-gaap:PaymentsToAcquireOtherPropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireOtherPropertyPlantAndEquipment
      contextRef="C_57ad6014-6b49-4fd8-b8f7-ae2932078fd6"
      decimals="-3"
      id="F_b421386a-df24-432a-8325-594362717ec8"
      unitRef="U_USD">15130000</us-gaap:PaymentsToAcquireOtherPropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf"
      decimals="-3"
      id="F_1cc0cf80-648b-4b56-88ff-c42d17990e15"
      unitRef="U_USD">-29130000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_57ad6014-6b49-4fd8-b8f7-ae2932078fd6"
      decimals="-3"
      id="F_b4933d93-b065-422a-b1d1-973c5bf21686"
      unitRef="U_USD">-21748000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromLinesOfCredit
      contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf"
      decimals="-3"
      id="F_9608bbf4-df42-4425-9e93-c8be5777238b"
      unitRef="U_USD">235500000</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:ProceedsFromLinesOfCredit
      contextRef="C_57ad6014-6b49-4fd8-b8f7-ae2932078fd6"
      decimals="-3"
      id="F_6681bcf3-e46f-4f14-b476-5698ab88091a"
      unitRef="U_USD">421000000</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:RepaymentsOfLinesOfCredit
      contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf"
      decimals="-3"
      id="F_94c0c0b8-afb3-427a-b32e-bff19e1c99b7"
      unitRef="U_USD">235500000</us-gaap:RepaymentsOfLinesOfCredit>
    <us-gaap:RepaymentsOfLinesOfCredit
      contextRef="C_57ad6014-6b49-4fd8-b8f7-ae2932078fd6"
      decimals="-3"
      id="F_9d913398-bd89-4e47-bd01-105496b19426"
      unitRef="U_USD">384000000</us-gaap:RepaymentsOfLinesOfCredit>
    <md:PaymentsToTermLoan
      contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf"
      decimals="-3"
      id="F_b1747f6f-5eaf-475f-8462-103d0f9dddf9"
      unitRef="U_USD">6250000</md:PaymentsToTermLoan>
    <md:PaymentsToTermLoan
      contextRef="C_57ad6014-6b49-4fd8-b8f7-ae2932078fd6"
      decimals="-3"
      id="F_c39d3bd9-9eac-42e1-a64a-2dce0b8679a6"
      unitRef="U_USD">6250000</md:PaymentsToTermLoan>
    <md:RepaymentsOfLongTermCapitalLeaseObligation
      contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf"
      decimals="-3"
      id="F_12494ae0-58b1-4e99-b4e8-c1f20559a02e"
      unitRef="U_USD">1391000</md:RepaymentsOfLongTermCapitalLeaseObligation>
    <md:RepaymentsOfLongTermCapitalLeaseObligation
      contextRef="C_57ad6014-6b49-4fd8-b8f7-ae2932078fd6"
      decimals="-3"
      id="F_a5e7464d-b3b6-4225-93fc-a27ece47701a"
      unitRef="U_USD">1404000</md:RepaymentsOfLongTermCapitalLeaseObligation>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf"
      decimals="-3"
      id="F_89cf1579-e4b3-4b2c-9633-54763cba71d3"
      unitRef="U_USD">2009000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_57ad6014-6b49-4fd8-b8f7-ae2932078fd6"
      decimals="-3"
      id="F_15ab3ad9-cb65-43f6-93ff-69e6ee0898c0"
      unitRef="U_USD">2689000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf"
      decimals="-3"
      id="F_05f2fb56-cf34-4d34-91ea-84f5c2fe82ba"
      unitRef="U_USD">898000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="C_57ad6014-6b49-4fd8-b8f7-ae2932078fd6"
      decimals="-3"
      id="F_7348e8c1-8a28-43d3-801b-d67d73cbaca5"
      unitRef="U_USD">786000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf"
      decimals="-3"
      id="F_84e30022-f56f-4411-b957-3275e11f8030"
      unitRef="U_USD">79000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="C_57ad6014-6b49-4fd8-b8f7-ae2932078fd6"
      decimals="-3"
      id="F_5df6c633-112c-4562-a186-06cc3efa1825"
      unitRef="U_USD">-1613000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf"
      decimals="-3"
      id="F_e7e3720d-7f81-4395-887b-b73d55979c5d"
      unitRef="U_USD">-6451000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_57ad6014-6b49-4fd8-b8f7-ae2932078fd6"
      decimals="-3"
      id="F_22cc7ff5-7b2c-40b8-91c3-68ab561d5799"
      unitRef="U_USD">29636000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf"
      decimals="-3"
      id="F_3a25cdf7-f3f9-4869-90c4-bc1c9862419c"
      unitRef="U_USD">-53856000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_57ad6014-6b49-4fd8-b8f7-ae2932078fd6"
      decimals="-3"
      id="F_13314506-0f00-4566-8811-20a6022487c6"
      unitRef="U_USD">-3975000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_01d46517-67df-489d-b34d-e087cf6dadaf"
      decimals="-3"
      id="F_98db8ff0-8ff3-4b1d-84ef-90372180f23f"
      unitRef="U_USD">73258000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_097f26a0-c77e-4f84-b663-38d6391e01e6"
      decimals="-3"
      id="F_7af69c6a-54fe-4f68-969c-740c94ac3a9e"
      unitRef="U_USD">9824000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_378538d0-b7e1-4ecd-af00-bb424f0b1747"
      decimals="-3"
      id="F_aa36d916-d9d6-492c-8d5a-3f341075667f"
      unitRef="U_USD">19402000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_60b78123-38d8-4d05-8a9b-e087fe9016a9"
      decimals="-3"
      id="F_d85f4650-cf5d-476e-a1e2-80a593cdf4f2"
      unitRef="U_USD">5849000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock
      contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf"
      id="F_5b9af3b4-638d-487c-baf9-b73ff9e3fdf9">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;1.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;            Basis of Presentation:&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;The accompanying unaudited Consolidated Financial Statements of the Company and the notes thereto presented in this Form 10-Q have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission ("SEC") applicable to interim financial statements, and do not include all disclosures required by accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;) for complete financial statements. In the opinion of management, these financial statements include all adjustments, consisting only of normal recurring adjustments, necessary for a fair statement of the results of interim periods. The financial statements include all the accounts of Pediatrix Medical Group, Inc. and its consolidated subsidiaries (collectively, &#x201c;PMG&#x201d;) together with the accounts of PMG&#x2019;s affiliated business corporations or professional associations, professional corporations, limited liability companies and partnerships (the &#x201c;affiliated professional contractors&#x201d;). Certain subsidiaries of PMG have contractual management arrangements with its affiliated professional contractors, which are separate legal entities that provide physician services in certain states. The terms &#x201c;Pediatrix&#x201d; and the &#x201c;Company&#x201d; refer collectively to Pediatrix Medical Group Inc., its subsidiaries and the affiliated professional contractors.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Compan&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;y is a party to a joint venture in which it owns a &lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;37.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;% economic interest.  The Company accounts for this joint venture under the equity method of accounting because the Company exercises significant influence over, but does not control, this entity.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;The consolidated results of operations for the interim periods presented are not necessarily indicative of the results to be experienced for the entire fiscal year. In addition, the accompanying unaudited Consolidated Financial Statements and the notes thereto should be read in conjunction with the Consolidated Financial Statements and the notes thereto included in the Company&#x2019;s most recent Annual Report on Form 10-K (the &#x201c;Form 10-K&#x201d;).&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="C_82895573-2795-4732-b42c-4cd5883caf98"
      decimals="3"
      id="F_b13dd794-172e-4a14-9daf-26db4dbe69f2"
      unitRef="U_pure">0.375</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock
      contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf"
      id="F_4cb3b5d4-4bb4-4aa1-9aa3-a1f44ea421d4">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;2.            Cash Equivalents and Investments:&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of June 30, 2024 and December 31, 2023, the Company's cash equivalents consisted entirely of money market funds totaling $&lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;white-space:pre-wrap;min-width:fit-content;color:#000000;"&gt;0.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;white-space:pre-wrap;min-width:fit-content;color:#000000;"&gt;2.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, respectively.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:9pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;Investments held are all classified as current and at &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;June 30, 2024 and December 31, 2023 are summarized as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:72.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:56.529%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.42%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:18.316%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.42%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:18.316%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;June 30, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Corporate securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;55,777&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;57,878&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;31,456&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;22,674&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Municipal debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;17,377&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14,649&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Federal home loan securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,503&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,670&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Certificates of deposit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,682&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,614&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;113,795&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;104,485&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <us-gaap:MoneyMarketFundsAtCarryingValue
      contextRef="C_e1d34d08-f45e-4aed-a85a-ba2eecf7da87"
      decimals="-5"
      id="F_35fb877b-dea8-40ea-9b4e-55aa647760b6"
      unitRef="U_USD">400000</us-gaap:MoneyMarketFundsAtCarryingValue>
    <us-gaap:MoneyMarketFundsAtCarryingValue
      contextRef="C_a816572a-ebf4-473a-a445-92cc3d3335f4"
      decimals="-5"
      id="F_19594a85-17cf-4463-829d-7b9d59dd19b7"
      unitRef="U_USD">2800000</us-gaap:MoneyMarketFundsAtCarryingValue>
    <us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock
      contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf"
      id="F_7ab42ddb-a8c9-4967-abd3-5bf9d0b0f37f">&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;Investments held are all classified as current and at &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;June 30, 2024 and December 31, 2023 are summarized as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:72.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:56.529%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.42%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:18.316%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.42%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:18.316%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;June 30, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Corporate securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;55,777&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;57,878&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;31,456&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;22,674&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Municipal debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;17,377&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14,649&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Federal home loan securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,503&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,670&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Certificates of deposit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,682&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,614&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;113,795&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;104,485&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_44713f7f-0be3-44e5-8ff8-456f9638bcb6"
      decimals="-3"
      id="F_b07f34e9-1160-425b-8bca-c12ec196d133"
      unitRef="U_USD">55777000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_999199c5-cb3d-47a6-abb8-3629d31afbe9"
      decimals="-3"
      id="F_8483e884-ff5c-4840-af93-a548c984a45e"
      unitRef="U_USD">57878000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_2656143a-67b9-4650-b483-9f48b62093d5"
      decimals="-3"
      id="F_463e3c56-407b-4dfc-bab6-dc85982a49d1"
      unitRef="U_USD">31456000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_ca383e94-5006-4063-9440-291a788feb2a"
      decimals="-3"
      id="F_209f9834-94b9-4838-b19c-f9662e9045b3"
      unitRef="U_USD">22674000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_8c03e792-f7c1-4fa1-9f86-8c10e39fa1ac"
      decimals="-3"
      id="F_854a8efb-9223-45f8-895f-7e6bd5181543"
      unitRef="U_USD">17377000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_925f1f8e-686d-4cc3-b111-72650c3e2456"
      decimals="-3"
      id="F_0533f1f7-324b-4384-a009-1f96b15940bf"
      unitRef="U_USD">14649000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_aacf8890-734e-41da-b969-870124e61507"
      decimals="-3"
      id="F_bb2b6ccf-3f66-4e90-bb7a-53245f44a8e6"
      unitRef="U_USD">6503000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_d65f3724-0e7f-4c6c-b50d-444cfddf4c6b"
      decimals="-3"
      id="F_be926a33-3e20-4433-8de8-6db44e48efe3"
      unitRef="U_USD">5670000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_4753588f-87b9-420c-894d-f10c964db638"
      decimals="-3"
      id="F_969cc16a-41e1-4aeb-934c-d1843f4ebfc8"
      unitRef="U_USD">2682000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_3c7dc91a-a1a8-4164-8011-aa824e2173f1"
      decimals="-3"
      id="F_f8596908-8b5a-40b8-91b0-6870e6c6973a"
      unitRef="U_USD">3614000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_378538d0-b7e1-4ecd-af00-bb424f0b1747"
      decimals="-3"
      id="F_f366eeaf-2431-428f-9d33-710f08b964b5"
      unitRef="U_USD">113795000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_01d46517-67df-489d-b34d-e087cf6dadaf"
      decimals="-3"
      id="F_cb9de403-5ef7-4933-be70-956fc29a75ea"
      unitRef="U_USD">104485000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf"
      id="F_dba11174-e972-44db-801a-d9eaa9996247">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;3.            Fair Value Measurements:&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;The accounting guidance establishes a fair value hierarchy that prioritizes valuation inputs into three levels based on the extent to which inputs used in measuring fair value are observable in the market. Each fair value measurement is reported in one of three levels:&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;Level 1 &#x2013; inputs are based upon unadjusted quoted prices for identical instruments traded in active markets.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;Level 2 &#x2013; inputs are based upon quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, and model-based valuation techniques for which all significant assumptions are observable in the market or can be corroborated by observable market data for substantially the full term of the assets or liabilities.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;Level 3 &#x2013; inputs are generally unobservable and typically reflect management&#x2019;s estimates of assumptions that market participants would use in pricing the asset or liability. The fair values are therefore determined using model-based techniques that include option pricing models, discounted cash flow models, and similar techniques.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Arial;"&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table presents information about the Company&#x2019;s financial instruments that are accounted for at fair value on a recurring basis at &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;June 30, 2024 and December 31, 2023 (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.54%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.32%;"&gt;&lt;/td&gt;
        &lt;td style="width:13%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.26%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.54%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.26%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:15.08%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Fair Value&lt;br/&gt;Category&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;June 30, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;397&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,814&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Short-term investments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;113,795&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;104,485&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Mutual Funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;19,002&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;17,687&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:9pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table presents information about the Company&#x2019;s financial instruments that are not carried at fair value at &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;June 30, 2024 and December 31, 2023 (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.72%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.08%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.24%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.08%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.24%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.08%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.24%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.08%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.24%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;June 30, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2030 Notes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;400,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;353,760&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;400,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;357,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;The carrying amounts of cash equivalents, accounts receivable and accounts payable and accrued expenses approximate fair value due to the short maturities of the respective instruments. The carrying value of the line of credit approximates fair value.  If the Company&#x2019;s line of credit was measured at fair value, it would be categorized as Level 2 in the fair value hierarchy.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf"
      id="F_e54c1428-2fa5-4a79-a91b-f188e87f6a95">&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table presents information about the Company&#x2019;s financial instruments that are accounted for at fair value on a recurring basis at &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;June 30, 2024 and December 31, 2023 (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.54%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.32%;"&gt;&lt;/td&gt;
        &lt;td style="width:13%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.26%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.54%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.26%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:15.08%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Fair Value&lt;br/&gt;Category&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;June 30, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;397&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,814&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Short-term investments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;113,795&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;104,485&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Mutual Funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;19,002&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;17,687&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <md:MoneyMarketFundsFairValueDisclosure
      contextRef="C_c97ff8ba-a0bb-4c2f-9d12-7e68bbd283c7"
      decimals="-3"
      id="F_286113c8-8f62-45aa-ae27-79eb7696ffb6"
      unitRef="U_USD">397000</md:MoneyMarketFundsFairValueDisclosure>
    <md:MoneyMarketFundsFairValueDisclosure
      contextRef="C_f2de318d-f0fc-45fc-a7dd-1d90eebc8aff"
      decimals="-3"
      id="F_2b16a090-0d2f-4849-8d39-e78d861216ca"
      unitRef="U_USD">2814000</md:MoneyMarketFundsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="C_b2e57193-b6ec-4e23-91dd-bd0d8c1391a7"
      decimals="-3"
      id="F_1e8ce852-712f-4695-a1c1-a567a82147e9"
      unitRef="U_USD">113795000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="C_c4efd93d-fa74-4b60-99aa-628c88395267"
      decimals="-3"
      id="F_3d2f8051-defe-471e-9c6e-d991a22071a9"
      unitRef="U_USD">104485000</us-gaap:InvestmentsFairValueDisclosure>
    <md:MutualFundsFairValueDisclosure
      contextRef="C_c97ff8ba-a0bb-4c2f-9d12-7e68bbd283c7"
      decimals="-3"
      id="F_590490bc-d30f-4e9d-bf6a-790f4f5c84a1"
      unitRef="U_USD">19002000</md:MutualFundsFairValueDisclosure>
    <md:MutualFundsFairValueDisclosure
      contextRef="C_f2de318d-f0fc-45fc-a7dd-1d90eebc8aff"
      decimals="-3"
      id="F_7eead798-0e0b-43ef-9faa-86ca2c83a83b"
      unitRef="U_USD">17687000</md:MutualFundsFairValueDisclosure>
    <md:FinancialInstrumentsMeasuredAtCarryingAmountTableTextBlock
      contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf"
      id="F_94814d31-db0d-4a40-a22b-1a17460c49ea">&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table presents information about the Company&#x2019;s financial instruments that are not carried at fair value at &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;June 30, 2024 and December 31, 2023 (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.72%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.08%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.24%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.08%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.24%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.08%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.24%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.08%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.24%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;June 30, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2030 Notes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;400,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;353,760&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;400,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;357,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</md:FinancialInstrumentsMeasuredAtCarryingAmountTableTextBlock>
    <us-gaap:NotesPayable
      contextRef="C_74e636e1-15c7-4b53-87ca-8d27ceeed147"
      decimals="-3"
      id="F_e69dcac9-4c18-4922-af5f-7cbf0f8e8c4b"
      unitRef="U_USD">400000000</us-gaap:NotesPayable>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="C_74e636e1-15c7-4b53-87ca-8d27ceeed147"
      decimals="-3"
      id="F_bb9f78db-30d1-4380-b8a3-c491cae73812"
      unitRef="U_USD">353760000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayable
      contextRef="C_a03ab9fe-6fdf-4312-9317-7df9fc924d88"
      decimals="-3"
      id="F_08769550-9557-4fa6-9a43-0366f5205a51"
      unitRef="U_USD">400000000</us-gaap:NotesPayable>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="C_a03ab9fe-6fdf-4312-9317-7df9fc924d88"
      decimals="-3"
      id="F_fb70aac4-8b07-44ed-a727-bbdde9ac8108"
      unitRef="U_USD">357000000</us-gaap:NotesPayableFairValueDisclosure>
    <md:AccountsReceivableAndNetRevenueDisclosureTextBlock
      contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf"
      id="F_fb3b0887-1b33-435d-8ce8-93bddcd8c4ac">&lt;p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;4. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Arial;min-width:fit-content;"&gt;            &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;Accounts Receivable and Net Revenue:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:9pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;Accounts receivable, net consists of the following (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:93.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:63.441%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.151%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:14.128%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.151%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:14.128%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;June 30, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Gross accounts receivable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,490,865&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,379,213&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Allowance for contractual adjustments and uncollectibles&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,216,701&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,106,900&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;274,164&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;272,313&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;Patient service revenue is recognized at the time services are provided by the Company&#x2019;s affiliated physicians. The Company&#x2019;s performance obligations related to the delivery of services to patients are satisfied at the time of service. Accordingly, there are no performance obligations that are unsatisfied or partially unsatisfied at the end of the reporting period with respect to patient service revenue. Almost all of the Company&#x2019;s patient service revenue is reimbursed by government-sponsored healthcare programs (&#x201c;GHC Programs&#x201d;) and third-party insurance payors. Payments for services rendered to the Company&#x2019;s patients are generally less than billed charges. The Company monitors its revenue and receivables from these sources and records an estimated contractual allowance to properly account for the anticipated differences between billed and reimbursed amounts.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;Accordingly, patient service revenue is presented net of an estimated provision for contractual adjustments and uncollectibles. The Company estimates allowances for contractual adjustments and uncollectibles on accounts receivable based upon historical experience and other factors, including days sales outstanding (&#x201c;DSO&#x201d;) for accounts receivable, evaluation of expected adjustments and delinquency rates, past adjustments and collection experience in relation to amounts billed, an aging of accounts receivable, current contract and reimbursement terms, changes in payor mix and other relevant information. Contractual adjustments result from the difference between the physician rates for services performed and the reimbursements by GHC Programs and third-party insurance payors for such services.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;Collection of patient service revenue the Company expects to receive is normally a function of providing complete and correct billing information to the GHC Programs and third-party insurance payors within the various filing deadlines and typically occurs within 30 to 60 days of billing.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;Some of the Company&#x2019;s hospital agreements require hospitals to pay the Company administrative fees. Some agreements provide for fees if the hospital does not generate sufficient patient volume in order to guarantee that the Company receives a specified minimum revenue level. The Company also receives fees from hospitals for administrative services performed by its affiliated physicians providing medical director or other services at the hospital.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:9pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table summarizes the Company&#x2019;s net revenue by category (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:29.984%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.111%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.136000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.223%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.113999999999999%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.623%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:14.914%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.623%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:14.27%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net patient service revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;432,847&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;430,383&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;854,678&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;853,567&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Hospital contract administrative fees&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;70,913&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;69,585&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;142,716&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;135,574&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;536&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;609&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,003&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,444&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;504,296&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;500,577&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;999,397&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;991,585&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:9pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:4.533%;text-indent:6.983%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;The approximate percentage of net patient service revenue by type of payor was as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:91.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:36.233%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.3%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.197%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.82%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.198%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.578%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.677999999999999%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Contracted managed care&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;71&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;68&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;71&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;67&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Government&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;23&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;25&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;24&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;25&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other third-parties&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Private-pay patients&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;100&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;100&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;100&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;100&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</md:AccountsReceivableAndNetRevenueDisclosureTextBlock>
    <us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock
      contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf"
      id="F_70c6d452-0446-46b8-8fe8-713a0e488152">&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;Accounts receivable, net consists of the following (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:93.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:63.441%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.151%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:14.128%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.151%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:14.128%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;June 30, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Gross accounts receivable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,490,865&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,379,213&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Allowance for contractual adjustments and uncollectibles&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,216,701&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,106,900&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;274,164&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;272,313&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock>
    <us-gaap:AccountsReceivableGrossCurrent
      contextRef="C_378538d0-b7e1-4ecd-af00-bb424f0b1747"
      decimals="-3"
      id="F_bb38042d-bf48-4a9e-a198-dc394e8549cd"
      unitRef="U_USD">1490865000</us-gaap:AccountsReceivableGrossCurrent>
    <us-gaap:AccountsReceivableGrossCurrent
      contextRef="C_01d46517-67df-489d-b34d-e087cf6dadaf"
      decimals="-3"
      id="F_a4602581-9452-49eb-ac14-c8287c3d3112"
      unitRef="U_USD">1379213000</us-gaap:AccountsReceivableGrossCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="C_378538d0-b7e1-4ecd-af00-bb424f0b1747"
      decimals="-3"
      id="F_c88a9ef5-5c5b-4c48-b2ec-2561b6709e75"
      unitRef="U_USD">1216701000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="C_01d46517-67df-489d-b34d-e087cf6dadaf"
      decimals="-3"
      id="F_7e73daa0-bdc1-4407-a729-8b836acbabfc"
      unitRef="U_USD">1106900000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="C_378538d0-b7e1-4ecd-af00-bb424f0b1747"
      decimals="-3"
      id="F_5da3b66c-1e23-4b04-be1f-181274cd2917"
      unitRef="U_USD">274164000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="C_01d46517-67df-489d-b34d-e087cf6dadaf"
      decimals="-3"
      id="F_4ba4dcf8-791e-4870-a71d-2ebbd60658db"
      unitRef="U_USD">272313000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf"
      id="F_61d48caf-d913-45c5-9480-673d400103f2">&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table summarizes the Company&#x2019;s net revenue by category (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:29.984%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.111%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.136000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.223%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.113999999999999%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.623%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:14.914%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.623%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:14.27%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net patient service revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;432,847&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;430,383&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;854,678&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;853,567&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Hospital contract administrative fees&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;70,913&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;69,585&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;142,716&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;135,574&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;536&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;609&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,003&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,444&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;504,296&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;500,577&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;999,397&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;991,585&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="C_8d682d9c-f4a6-4720-b0e5-6aba644d655b"
      decimals="-3"
      id="F_f3989a8b-4566-4732-bdd7-c48e41e64df8"
      unitRef="U_USD">432847000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="C_dec064d9-341f-4d43-8d13-9380383f1ea2"
      decimals="-3"
      id="F_ace8dfad-174b-436e-914f-1d4a95be7da1"
      unitRef="U_USD">430383000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="C_3c816b3b-c82c-4a26-bf82-3219ef7103e7"
      decimals="-3"
      id="F_ba00957d-a054-48d5-93c4-a010714b3c0d"
      unitRef="U_USD">854678000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="C_12147e67-2e9c-4442-8daa-56def203d5b7"
      decimals="-3"
      id="F_e9907055-ab12-4a65-9d58-c2220196af50"
      unitRef="U_USD">853567000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="C_26ef4d6b-17ee-42a8-8ef0-3a3202107d61"
      decimals="-3"
      id="F_e86f210f-2251-4bde-9962-4eb689d8e70f"
      unitRef="U_USD">70913000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="C_3f38e980-706e-4b34-b4a0-c3cf6a91f926"
      decimals="-3"
      id="F_b873e366-7f12-4821-9216-bf28b83521ad"
      unitRef="U_USD">69585000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="C_73da6023-b99b-4424-9d33-e387db8c2e30"
      decimals="-3"
      id="F_d7d5af4b-ae37-47e5-9cf4-8327f4d5113c"
      unitRef="U_USD">142716000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="C_d6aad445-12fd-4b00-8591-81e1e41d8cfd"
      decimals="-3"
      id="F_68f15e18-a902-4e47-ad3c-0c15ad74cc3f"
      unitRef="U_USD">135574000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="C_d2b8faaa-e3b4-40e7-b170-e0b31556d8c0"
      decimals="-3"
      id="F_d6330e4b-d094-433b-9c0d-250e3a07cea7"
      unitRef="U_USD">536000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="C_2bb8a119-7219-4b9c-be50-62118be95425"
      decimals="-3"
      id="F_aad4e8e6-0476-4da5-bf65-7ccbd77e3ae5"
      unitRef="U_USD">609000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="C_b55fcf9b-75fb-43d4-8441-f6cc48e23e07"
      decimals="-3"
      id="F_07b43b21-4249-48c7-940d-cdca2d9ce6ca"
      unitRef="U_USD">2003000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="C_21d152cb-f002-4995-a0e6-8a4087443620"
      decimals="-3"
      id="F_6970d38d-be72-4075-a5c0-e07b6b6af9f0"
      unitRef="U_USD">2444000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="C_f8ba14c0-203a-4abe-895a-7068e0d681d9"
      decimals="-3"
      id="F_bcc85955-37fd-4be7-909f-95f77f475fa4"
      unitRef="U_USD">504296000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="C_5a5fa8ad-967b-444b-af35-7dd7a8bf7ba3"
      decimals="-3"
      id="F_2ebb16c0-e6a9-44d7-a5b9-ab62b61b990d"
      unitRef="U_USD">500577000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf"
      decimals="-3"
      id="F_847d4200-5daf-482c-bb83-5ea6c7d8ffad"
      unitRef="U_USD">999397000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="C_57ad6014-6b49-4fd8-b8f7-ae2932078fd6"
      decimals="-3"
      id="F_0106f810-c510-453f-9047-3a8eb9cc2906"
      unitRef="U_USD">991585000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock
      contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf"
      id="F_d2b24257-8f45-43af-8c4d-0c3ad71b2d4e">&lt;p style="margin-left:4.533%;text-indent:6.983%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;The approximate percentage of net patient service revenue by type of payor was as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:91.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:36.233%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.3%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.197%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.82%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.198%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.578%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.677999999999999%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Contracted managed care&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;71&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;68&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;71&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;67&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Government&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;23&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;25&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;24&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;25&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other third-parties&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Private-pay patients&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;100&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;100&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;100&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;100&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock>
    <md:PercentageOfNetPatientServiceRevenueByTypeOfPayor
      contextRef="C_a20b1ed9-1ed7-4cc0-9d05-984cabc1cbec"
      decimals="2"
      id="F_6f224522-bd88-4902-a743-ddd7b71a95fc"
      unitRef="U_pure">0.71</md:PercentageOfNetPatientServiceRevenueByTypeOfPayor>
    <md:PercentageOfNetPatientServiceRevenueByTypeOfPayor
      contextRef="C_85f3a02e-88e7-4e7f-b8f5-7e31732a7772"
      decimals="2"
      id="F_00494cac-86e8-488c-96a1-cf63033aaa7f"
      unitRef="U_pure">0.68</md:PercentageOfNetPatientServiceRevenueByTypeOfPayor>
    <md:PercentageOfNetPatientServiceRevenueByTypeOfPayor
      contextRef="C_322f434d-d131-49bb-a0d5-c51c55aa30d0"
      decimals="2"
      id="F_b22f12b2-8997-4b90-a4d6-3e9eb78a5ced"
      unitRef="U_pure">0.71</md:PercentageOfNetPatientServiceRevenueByTypeOfPayor>
    <md:PercentageOfNetPatientServiceRevenueByTypeOfPayor
      contextRef="C_ac837f6b-5715-4c36-8c4a-be2ace21a7e2"
      decimals="2"
      id="F_a9de9dad-3f93-466a-927f-b5c0d437bb89"
      unitRef="U_pure">0.67</md:PercentageOfNetPatientServiceRevenueByTypeOfPayor>
    <md:PercentageOfNetPatientServiceRevenueByTypeOfPayor
      contextRef="C_e3eb8c28-c7e1-4a49-b42b-e63f13e290c4"
      decimals="2"
      id="F_13dea165-c7f0-4c76-bc2a-a2d8ec8f9cb1"
      unitRef="U_pure">0.23</md:PercentageOfNetPatientServiceRevenueByTypeOfPayor>
    <md:PercentageOfNetPatientServiceRevenueByTypeOfPayor
      contextRef="C_9a4ff3c3-70d2-4f27-923d-76e5a8c48431"
      decimals="2"
      id="F_9a821a02-e824-4c1b-b92e-2534a7a16efd"
      unitRef="U_pure">0.25</md:PercentageOfNetPatientServiceRevenueByTypeOfPayor>
    <md:PercentageOfNetPatientServiceRevenueByTypeOfPayor
      contextRef="C_6ac5d2f3-36f9-4043-a22d-1a055bff677d"
      decimals="2"
      id="F_f4b4651d-9d2e-4826-9efc-e6c5597b710b"
      unitRef="U_pure">0.24</md:PercentageOfNetPatientServiceRevenueByTypeOfPayor>
    <md:PercentageOfNetPatientServiceRevenueByTypeOfPayor
      contextRef="C_3c0663a6-a6a7-4ee3-809d-8c8aeb1fca8a"
      decimals="2"
      id="F_3ace5ff3-20ec-4d78-b4d1-00f02740302e"
      unitRef="U_pure">0.25</md:PercentageOfNetPatientServiceRevenueByTypeOfPayor>
    <md:PercentageOfNetPatientServiceRevenueByTypeOfPayor
      contextRef="C_9909352a-5fba-478d-bc57-50fb72a6c67d"
      decimals="2"
      id="F_ee16b0ce-3e71-4f5d-9194-f9ca43100a5f"
      unitRef="U_pure">0.04</md:PercentageOfNetPatientServiceRevenueByTypeOfPayor>
    <md:PercentageOfNetPatientServiceRevenueByTypeOfPayor
      contextRef="C_156059b8-27ec-4255-9fd4-8a26b81f0b31"
      decimals="2"
      id="F_35a3e64a-0dab-468e-88cb-1b4532ff2311"
      unitRef="U_pure">0.05</md:PercentageOfNetPatientServiceRevenueByTypeOfPayor>
    <md:PercentageOfNetPatientServiceRevenueByTypeOfPayor
      contextRef="C_1c3d0626-f775-4377-9dde-87804a3a8785"
      decimals="2"
      id="F_db34fbfb-4c7b-4261-90bf-2d424ab979b5"
      unitRef="U_pure">0.03</md:PercentageOfNetPatientServiceRevenueByTypeOfPayor>
    <md:PercentageOfNetPatientServiceRevenueByTypeOfPayor
      contextRef="C_671fe710-eb0a-40ea-9b5f-3fc84da58634"
      decimals="2"
      id="F_8abd0d38-f403-4f4c-a67d-719119dca339"
      unitRef="U_pure">0.06</md:PercentageOfNetPatientServiceRevenueByTypeOfPayor>
    <md:PercentageOfNetPatientServiceRevenueByTypeOfPayor
      contextRef="C_e6d4fa65-6594-4957-b174-3dcd01093f75"
      decimals="2"
      id="F_aa667d95-d94f-47d7-a959-0e934ab05925"
      unitRef="U_pure">0.02</md:PercentageOfNetPatientServiceRevenueByTypeOfPayor>
    <md:PercentageOfNetPatientServiceRevenueByTypeOfPayor
      contextRef="C_cc98a5b3-d80a-4eb1-aeee-1a0e562d5e27"
      decimals="2"
      id="F_dc867d57-5f12-42e6-aa45-86d47bc876c0"
      unitRef="U_pure">0.02</md:PercentageOfNetPatientServiceRevenueByTypeOfPayor>
    <md:PercentageOfNetPatientServiceRevenueByTypeOfPayor
      contextRef="C_6cc6fddd-3fb2-40be-bc2f-d396ff6d56c5"
      decimals="2"
      id="F_5947f32b-0040-4e0e-9db3-f680305f4059"
      unitRef="U_pure">0.02</md:PercentageOfNetPatientServiceRevenueByTypeOfPayor>
    <md:PercentageOfNetPatientServiceRevenueByTypeOfPayor
      contextRef="C_5b39fcf4-ee54-4657-b078-1fee2e008ed8"
      decimals="2"
      id="F_c8b768ba-31bb-4f84-a741-3e42e1c66cf1"
      unitRef="U_pure">0.02</md:PercentageOfNetPatientServiceRevenueByTypeOfPayor>
    <md:PercentageOfNetPatientServiceRevenueByTypeOfPayor
      contextRef="C_f8ba14c0-203a-4abe-895a-7068e0d681d9"
      decimals="INF"
      id="F_9be8bc4d-2ff2-4fa1-bc84-e30f48bcbc9e"
      unitRef="U_pure">1</md:PercentageOfNetPatientServiceRevenueByTypeOfPayor>
    <md:PercentageOfNetPatientServiceRevenueByTypeOfPayor
      contextRef="C_5a5fa8ad-967b-444b-af35-7dd7a8bf7ba3"
      decimals="INF"
      id="F_313eb969-9bc4-4101-a96a-43dc7fcf3a9f"
      unitRef="U_pure">1</md:PercentageOfNetPatientServiceRevenueByTypeOfPayor>
    <md:PercentageOfNetPatientServiceRevenueByTypeOfPayor
      contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf"
      decimals="INF"
      id="F_391fb6b4-3179-4231-83e0-7a3c2eea1c0b"
      unitRef="U_pure">1</md:PercentageOfNetPatientServiceRevenueByTypeOfPayor>
    <md:PercentageOfNetPatientServiceRevenueByTypeOfPayor
      contextRef="C_57ad6014-6b49-4fd8-b8f7-ae2932078fd6"
      decimals="INF"
      id="F_bb45aa06-296b-4589-9b59-bfced6d4dbc4"
      unitRef="U_pure">1</md:PercentageOfNetPatientServiceRevenueByTypeOfPayor>
    <us-gaap:BusinessCombinationDisclosureTextBlock
      contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf"
      id="F_097bc21a-8a2e-49df-b9ed-5e9f0edc551f">&lt;p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;5. 	Business Combinations&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;During the six months ended June 30, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;, the Company completed the acquisition of &lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;one&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt; maternal-fetal medicine practice for total consideration of $&lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, of which $&lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt; million was paid in cash at closing and $&lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;white-space:pre-wrap;min-width:fit-content;color:#000000;"&gt;3.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt; million was recorded as a contingent consideration liability. The acquisition expanded the Company&#x2019;s national network of physician practices across women&#x2019;s and children&#x2019;s services. In connection with this acquisition, the Company recorded tax deductible goodwill of $&lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, fixed assets of $&lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and other intangible assets consisting primarily of physician and hospital agreements of $&lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt; million.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;   &lt;/span&gt;&lt;/p&gt;</us-gaap:BusinessCombinationDisclosureTextBlock>
    <md:NumberOfMaternalFetalMedicinePracticesAcquired
      contextRef="C_4fd51aa1-699c-4d1f-a3f5-aa92a33bc175"
      decimals="0"
      id="F_fac345a2-072a-48a3-8ba9-6677a7b3cd7f"
      unitRef="U_Number">1</md:NumberOfMaternalFetalMedicinePracticesAcquired>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="C_4fd51aa1-699c-4d1f-a3f5-aa92a33bc175"
      decimals="-5"
      id="F_412db57a-834c-4e13-bc39-ff2ae74ce379"
      unitRef="U_USD">9700000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="C_4fd51aa1-699c-4d1f-a3f5-aa92a33bc175"
      decimals="-5"
      id="F_9df50c0d-aedd-4baa-9097-f9cce8240db2"
      unitRef="U_USD">6500000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets
      contextRef="C_aab2ef2b-f5d5-463b-af2e-d14d85478a3f"
      decimals="-5"
      id="F_e500b76c-9455-4350-ba20-5743432bada4"
      unitRef="U_USD">3200000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets>
    <us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount
      contextRef="C_378538d0-b7e1-4ecd-af00-bb424f0b1747"
      decimals="-5"
      id="F_7be6b672-81fe-4830-be59-55fec462e6fe"
      unitRef="U_USD">9100000</us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment
      contextRef="C_378538d0-b7e1-4ecd-af00-bb424f0b1747"
      decimals="-5"
      id="F_e9883ef2-d9fb-485c-8476-f9b3000431a5"
      unitRef="U_USD">400000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="C_378538d0-b7e1-4ecd-af00-bb424f0b1747"
      decimals="-5"
      id="F_a0801f57-d097-44bf-81d8-ec64730ee485"
      unitRef="U_USD">200000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock
      contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf"
      id="F_a535d0f8-669b-400e-9a72-f5c7f4440f7e">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;6.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;  	&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;Goodwill, Long-Lived Asset Impairments and Loss on Disposal of Businesses:&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;During the second quarter of 2024, the Company formalized its practice portfolio management plans, resulting in a decision to exit almost all of its affiliated office-based practices, other than maternal-fetal medicine. The practice exits are expected to be completed by December 31, 2024. Accordingly, a recoverability assessment for each individual physician practice was performed, and the estimated future cash flows related to the physician practices did not support the carrying value of the specifically identified individual long-lived assets. As a result, the Company recorded fixed asset impairments of $&lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;20.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, intangible asset impairments of $&lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and operating lease right-of-use asset impairments of $&lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt; million. The operating lease right-of-use impairments are recorded within the transformational and restructuring related expenses line item.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;During the second quarter of 2024, the Company made the decision to exit its primary and urgent care service line based on a review of the cost and time that would be required to build the platform to scale.  The Company divested one of its two previously acquired primary and urgent care practices during the second quarter and divested of the second of its two acquired primary and urgent care practices subsequent to the end of the second quarter. The total loss on disposal of these two businesses was $&lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, resulting from the loss on sale for one practice and marking the net assets to their fair value less costs to sell for the other practice.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;During the second quarter of 2024, the Company experienced a triggering event, due to a sustained decline in its stock price and a market capitalization below the Company's book equity value. As the Company consists of only one reporting unit, and is publicly traded, management estimates the fair value of its reporting unit utilizing the Company&#x2019;s market capitalization, multiplying the number of actual shares outstanding on June 30, 2024 by its stock price on June 30, 2024 and applying an additional premium to give effect to the Company&#x2019;s best estimate of a control premium. With respect to the estimated control premium used in its analysis, the Company believes that it is reasonable to expect that a market participant would pay a premium to obtain a controlling interest in the Company. The Company considered information from the public markets for premiums on acquisitions in its industry and also considered other factors, such as the value that may arise from the ability to take advantage of synergies and other benefits that flow from control over another entity.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;This assessment resulted in a non-cash impairment charge of $&lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;130.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, representing the amount by which the Company's book value exceeded its implied fair value, based on its market capitalization plus an estimated control premium. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"&gt;Consideration was first given to other individual and group long-lived assets, and no impairment was considered necessary on such assets.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;Recognition of this non-cash charge against goodwill resulted in a tax benefit which generated an additional deferred tax asset of $&lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;24.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt; million &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;that increased the Company's book value. An incremental non-cash charge was required to reduce the&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;Company's &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;book value to its previously determined fair value. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;Accordingly, the Company recorded the incremental non-cash charge of $&lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;24.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt; million for a total non-cash charge of $&lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;154.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt; million. A &lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;% change in the control premium used would have impacted the non-cash impairment charge by approximately $&lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt; million.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf"
      decimals="-5"
      id="F_219e0b90-0cb1-4c73-a29f-9a698212c320"
      unitRef="U_USD">20100000</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf"
      decimals="-5"
      id="F_de80ca39-0722-4259-b8d4-8cd54a89d677"
      unitRef="U_USD">7700000</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:OperatingLeaseImpairmentLoss
      contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf"
      decimals="-5"
      id="F_dbbac23a-defd-41ca-aafe-f648ffc6b7a1"
      unitRef="U_USD">8100000</us-gaap:OperatingLeaseImpairmentLoss>
    <us-gaap:GainLossOnSaleOfBusiness
      contextRef="C_f8ba14c0-203a-4abe-895a-7068e0d681d9"
      decimals="-5"
      id="F_c95f3af9-5ef1-4130-8259-ef1a1dfdfdad"
      unitRef="U_USD">-10900000</us-gaap:GainLossOnSaleOfBusiness>
    <md:GoodWillImpairmentLossExcludingDeferredTaxAssetsCharge
      contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf"
      decimals="-5"
      id="F_86122c08-6c66-4208-a394-9b8cdd42b5ae"
      unitRef="U_USD">130000000</md:GoodWillImpairmentLossExcludingDeferredTaxAssetsCharge>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets
      contextRef="C_378538d0-b7e1-4ecd-af00-bb424f0b1747"
      decimals="-5"
      id="F_58143611-cfb1-41ce-b3ea-d0a4b6055b25"
      unitRef="U_USD">24200000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <md:IncrementalNonCashCharge
      contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf"
      decimals="-5"
      id="F_eb4e19d7-4d4f-4b61-a931-8c9327bc50d0"
      unitRef="U_USD">24200000</md:IncrementalNonCashCharge>
    <md:NonCashCharge
      contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf"
      decimals="-5"
      id="F_488f9313-f9c0-48a8-8854-2543a5518a26"
      unitRef="U_USD">154200000</md:NonCashCharge>
    <md:ChangeInRateOfControlPremium
      contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf"
      decimals="2"
      id="F_f9978919-1c95-4639-9374-402445d5a5a7"
      unitRef="U_pure">0.01</md:ChangeInRateOfControlPremium>
    <md:ChangeInNonCashImpairmentCharges
      contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf"
      decimals="-5"
      id="F_780b40fe-6768-43c9-b129-9e5b6efc1823"
      unitRef="U_USD">6500000</md:ChangeInNonCashImpairmentCharges>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock
      contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf"
      id="F_74911537-1f1b-4802-981b-570817718b71">&lt;p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;7.            Accounts Payable and Accrued Expenses:	&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:9pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;Accounts payable and accrued expenses consist of the following (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:60.048%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.56%;"&gt;&lt;/td&gt;
        &lt;td style="width:18.416%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.56%;"&gt;&lt;/td&gt;
        &lt;td style="width:18.416%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;June 30, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accounts payable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;32,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;34,588&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accrued salaries and incentive compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;115,093&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;193,112&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accrued payroll taxes and benefits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;28,034&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;36,545&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accrued professional liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;28,966&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;32,039&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accrued interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8,258&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8,262&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other accrued expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;54,982&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;46,252&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;267,333&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;350,798&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;The net decrease in accrued salaries and incentive compensation of $&lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;78.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, from December 31, 2023 to June 30, 2024, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;is primarily due to the payment of performance-based incentive compensation, principally to the Company&#x2019;s affiliated physicians, partially offset by performance-based incentive compensation accrued during the six months ended June 30, 2024. A majority of the Company&#x2019;s payments for performance-based incentive compensation is paid annually during the first quarter.&lt;/span&gt;&lt;/p&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock
      contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf"
      id="F_87997623-1279-494d-a76c-9345e2cd119e">&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;Accounts payable and accrued expenses consist of the following (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:60.048%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.56%;"&gt;&lt;/td&gt;
        &lt;td style="width:18.416%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.56%;"&gt;&lt;/td&gt;
        &lt;td style="width:18.416%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;June 30, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accounts payable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;32,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;34,588&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accrued salaries and incentive compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;115,093&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;193,112&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accrued payroll taxes and benefits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;28,034&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;36,545&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accrued professional liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;28,966&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;32,039&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accrued interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8,258&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8,262&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other accrued expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;54,982&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;46,252&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;267,333&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;350,798&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_378538d0-b7e1-4ecd-af00-bb424f0b1747"
      decimals="-3"
      id="F_3f4c3b28-6ccd-4a26-ab76-ed9340cdd6e6"
      unitRef="U_USD">32000000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_01d46517-67df-489d-b34d-e087cf6dadaf"
      decimals="-3"
      id="F_1b8948e3-945f-43d8-ba05-8dfb310c8476"
      unitRef="U_USD">34588000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedSalariesCurrent
      contextRef="C_378538d0-b7e1-4ecd-af00-bb424f0b1747"
      decimals="-3"
      id="F_c8eb22a5-5b56-416a-a0bb-65e7a1b35f38"
      unitRef="U_USD">115093000</us-gaap:AccruedSalariesCurrent>
    <us-gaap:AccruedSalariesCurrent
      contextRef="C_01d46517-67df-489d-b34d-e087cf6dadaf"
      decimals="-3"
      id="F_8ad2efc0-efcf-46c3-924c-5e019667f20d"
      unitRef="U_USD">193112000</us-gaap:AccruedSalariesCurrent>
    <md:AccruedPayrollTaxesAndBenefitsCurrent
      contextRef="C_378538d0-b7e1-4ecd-af00-bb424f0b1747"
      decimals="-3"
      id="F_24cdbe20-98cb-4faf-8b30-a24f4b2c1db7"
      unitRef="U_USD">28034000</md:AccruedPayrollTaxesAndBenefitsCurrent>
    <md:AccruedPayrollTaxesAndBenefitsCurrent
      contextRef="C_01d46517-67df-489d-b34d-e087cf6dadaf"
      decimals="-3"
      id="F_499907f5-b3c0-42f6-a2be-9a68a5792517"
      unitRef="U_USD">36545000</md:AccruedPayrollTaxesAndBenefitsCurrent>
    <us-gaap:MalpracticeLossContingencyAccrualUndiscountedCurrent
      contextRef="C_378538d0-b7e1-4ecd-af00-bb424f0b1747"
      decimals="-3"
      id="F_61372d17-ef8b-477e-b4db-310322945176"
      unitRef="U_USD">28966000</us-gaap:MalpracticeLossContingencyAccrualUndiscountedCurrent>
    <us-gaap:MalpracticeLossContingencyAccrualUndiscountedCurrent
      contextRef="C_01d46517-67df-489d-b34d-e087cf6dadaf"
      decimals="-3"
      id="F_554dc2b3-9e3c-474c-8555-bae2a37f9552"
      unitRef="U_USD">32039000</us-gaap:MalpracticeLossContingencyAccrualUndiscountedCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="C_378538d0-b7e1-4ecd-af00-bb424f0b1747"
      decimals="-3"
      id="F_68886411-1bc2-43fe-b3ca-d3005cb571a7"
      unitRef="U_USD">8258000</us-gaap:InterestPayableCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="C_01d46517-67df-489d-b34d-e087cf6dadaf"
      decimals="-3"
      id="F_504dcf7d-7b3b-4f37-8bfd-3eee28629e3f"
      unitRef="U_USD">8262000</us-gaap:InterestPayableCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_378538d0-b7e1-4ecd-af00-bb424f0b1747"
      decimals="-3"
      id="F_a14d5d34-effd-43f5-8428-e13b06374aa9"
      unitRef="U_USD">54982000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_01d46517-67df-489d-b34d-e087cf6dadaf"
      decimals="-3"
      id="F_295e0391-b0c1-4c45-9d41-ca5e835ba35f"
      unitRef="U_USD">46252000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="C_378538d0-b7e1-4ecd-af00-bb424f0b1747"
      decimals="-3"
      id="F_3db53c5c-d6a0-4de0-a52e-d32dfb9c3b6c"
      unitRef="U_USD">267333000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="C_01d46517-67df-489d-b34d-e087cf6dadaf"
      decimals="-3"
      id="F_8ca75e4c-571c-4581-94a3-f45672b27f59"
      unitRef="U_USD">350798000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <md:IncreaseDecreaseInAccruedSalariesAndBonuses
      contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf"
      decimals="-5"
      id="F_4fbc0680-dcf0-45c4-90d9-e517928e69e4"
      unitRef="U_USD">78000000</md:IncreaseDecreaseInAccruedSalariesAndBonuses>
    <md:LineOfCreditAndLongTermDebtTextBlock
      contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf"
      id="F_4f046ff6-2573-41a7-91ca-aa26d423dc12">&lt;p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;8.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Arial;min-width:fit-content;"&gt;          &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;Line of Credit and Long-Term Debt:&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;On February 11, 2022, the Company issued $&lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;400.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt; million of &lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.375&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;% unsecured senior notes due 2030 (the &#x201c;2030 Notes&#x201d;).  The Company used the net proceeds from the issuance of the &lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;2030&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt; Notes, together with $&lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;100.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt; million drawn under the Revolving Credit Line (as defined below), $&lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;250.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt; million of Term A Loan (as defined below) and approximately $&lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;308.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt; million of cash on hand, to redeem (the &#x201c;Redemption&#x201d;) the 2027 Notes, which had an outstanding principal balance of $&lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt; billion, and to pay costs, fees and expenses associated with the Redemption and the Credit Agreement Amendment (as defined below).&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;Interest on the 2030 Notes accrues at the rate of &lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.375&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;% per annum, or $&lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, and is &lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;payable semi-annually in arrears on February 15 and August 15, beginning on August 15, 2022&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;. The Company's obligations under the 2030 &lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;Notes are guaranteed on an unsecured senior basis by the same subsidiaries and affiliated professional contractors that guarantee the Amended Credit Agreement (as defined below). The indenture under which the 2030 Notes are issued, among other things, limits the Company's ability to (1) incur liens and (2) enter into sale and lease-back transactions, and also limits the Company's ability to merge or dispose of all or substantially all of its assets, in all cases, subject to a number of customary exceptions&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;. Although the Company is not required to make mandatory redemption or sinking fund payments with respect to the 2030 Notes, upon the occurrence of a change in control, the Company may be required to repurchase the 2030 Notes at a purchase price equal to &lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;101&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;% of the aggregate principal amount of the 2030 Notes repurchased plus accrued and unpaid interest.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;Also in connection with the Redemption, the Company amended its credit agreement (the &#x201c;Credit Agreement&#x201d;, and such amendment, the "Credit Agreement Amendment"), concurrently with the issuance of the 2030 Notes. The Credit Agreement Amendment, among other things, (i) refinanced the prior unsecured revolving credit facility with a $&lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;450&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt; million unsecured revolving credit facility, including a $&lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;37.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt; million sub-facility for the issuance of letters of credit (the &#x201c;Revolving Credit Line&#x201d;), and a $&lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;250&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt; million term A loan facility (&#x201c;Term A Loan&#x201d;) and (ii) removed JPMorgan Chase Bank, N.A., as the administrative agent under the Credit Agreement and appointed Bank of America, N.A. as the administrative agent for the lenders.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Credit Agreement, as amended by the Credit Agreement Amendment (the &#x201c;Amended Credit Agreement&#x201d;) matures on February 11, 2027 and is guaranteed on an unsecured basis by substantially all of the Company's subsidiaries and affiliated professional contractors. At the Company's option, borrowings under the Amended Credit Agreement bear interest at &lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;(i) the Alternate Base Rate (defined as the highest of (a) the prime rate as announced by Bank of America, N.A., (b) the Federal Funds Rate plus 0.50% and (c) Term Secured Overnight Financing Rate ("SOFR") for an interest period of one month plus 1.00% with a 1.00% floor) plus an applicable margin rate of 0.50% for the first two fiscal quarters after the date of the Credit Agreement Amendment, and thereafter at an applicable margin rate ranging from 0.125% to 0.750% based on the Company's consolidated net leverage ratio or (ii) Term SOFR rate (calculated as the Secured Overnight Financing Rate published on the applicable Reuters screen page plus a spread adjustment of 0.10%, 0.15% or 0.25% depending on if the Company selects a one-month, three-month or six-month interest period, respectively, for the applicable loan with a 0% floor), plus an applicable margin rate of 1.50% for the first two full fiscal quarters after the date of the Credit Agreement Amendment, and thereafter at an applicable margin rate ranging from 1.125% to 1.750% based on the Company's consolidated net leverage ratio. The Amended Credit Agreement also provides for other customary fees and charges, including an unused commitment fee with respect to the Revolving Credit Line ranging from 0.150% to 0.200% of the unused lending commitments under the Revolving Credit Line&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;, based on the Company's consolidated net leverage ratio.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Amended Credit Agreement contains customary covenants and restrictions, including covenants that require the Company to maintain a minimum interest coverage ratio, a maximum consolidated total consolidated net leverage ratio and to comply with laws, and restrictions on the ability to pay dividends, incur indebtedness or liens and make certain other distributions subject to baskets and exceptions, in each case, as specified therein. Failure to comply with these covenants would constitute an event of default under the Amended Credit Agreement, notwithstanding the ability of the Company to meet its debt service obligations. The Amended Credit Agreement includes various customary remedies for the lenders following an event of default, including the acceleration of repayment of outstanding amounts under the Amended Credit Agreement. In addition, the Company may increase the principal amount of the Revolving Credit Line or incur additional term loans under the Amended Credit Agreement in an aggregate principal amount such that on a pro forma basis after giving effect to such increase or additional term loans, the Company would be in compliance with the financial covenants, subject to the satisfaction of specified conditions and additional caps in the event that the Amended Credit Agreement is secured.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;At June 30, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;, the Company had an outstanding principal balance on the Amended Credit Agreement of $&lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;221.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, composed of the Term A Loan.  There was no outstanding balance under the Revolving Credit Line. The Company had $&lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;450.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt; million available on its Amended Credit Agreement at June 30, 2024.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;At June 30, 2024, the Company had an outstanding principal balance of $&lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;400.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt; million on the 2030 Notes.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</md:LineOfCreditAndLongTermDebtTextBlock>
    <us-gaap:SeniorNotes
      contextRef="C_51999449-03d0-412b-a0e1-24677d710d3a"
      decimals="-5"
      id="F_86a95aa3-4702-43d6-a656-a164556360d5"
      unitRef="U_USD">400000000</us-gaap:SeniorNotes>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="C_51999449-03d0-412b-a0e1-24677d710d3a"
      decimals="5"
      id="F_b1f3f3bc-a244-4d1e-9f64-fd211b06a4ab"
      unitRef="U_pure">0.05375</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <md:DebtInstrumentMaturityYear
      contextRef="C_e0420691-52ea-4671-94fc-b8e7b69e3142"
      id="F_c0927320-9210-47fa-9ded-084486911614">2030</md:DebtInstrumentMaturityYear>
    <us-gaap:ProceedsFromIssuanceOfUnsecuredDebt
      contextRef="C_0b63294a-0107-49a4-a13e-bda5f278d21c"
      decimals="-5"
      id="F_09cc41a9-2814-480c-8650-20b250422e84"
      unitRef="U_USD">100000000</us-gaap:ProceedsFromIssuanceOfUnsecuredDebt>
    <us-gaap:UnsecuredLongTermDebt
      contextRef="C_21dc151c-5f14-4067-a9f0-945b9851cd13"
      decimals="-5"
      id="F_6397d8d9-97e9-4a29-bd2b-c1914e85ca55"
      unitRef="U_USD">250000000</us-gaap:UnsecuredLongTermDebt>
    <us-gaap:Cash
      contextRef="C_21dc151c-5f14-4067-a9f0-945b9851cd13"
      decimals="-5"
      id="F_2c32a91f-50c0-4566-9fcd-fd5c4c7e4f32"
      unitRef="U_USD">308000000</us-gaap:Cash>
    <us-gaap:LongTermDebt
      contextRef="C_407e9c0c-05d2-4164-85d8-d7f2fdffa0b3"
      decimals="-8"
      id="F_51e6d9c6-a488-4403-839d-8613aa9fb524"
      unitRef="U_USD">1000000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="C_378538d0-b7e1-4ecd-af00-bb424f0b1747"
      decimals="5"
      id="F_2c438d09-2dda-42a3-989e-51ebfbe30c3c"
      unitRef="U_pure">0.05375</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentPeriodicPaymentInterest
      contextRef="C_13c390ad-a46f-4851-8328-8c24f9da6308"
      decimals="-5"
      id="F_1540b4fc-4e0a-45a5-9379-6478109f8ff1"
      unitRef="U_USD">21500000</us-gaap:DebtInstrumentPeriodicPaymentInterest>
    <us-gaap:DebtInstrumentFrequencyOfPeriodicPayment
      contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf"
      id="F_ed7a63d7-af86-4731-9d4f-fee4585befb2">payable semi-annually in arrears on February 15 and August 15, beginning on August 15, 2022</us-gaap:DebtInstrumentFrequencyOfPeriodicPayment>
    <us-gaap:DebtInstrumentDescription
      contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf"
      id="F_a9f2d720-e082-4058-8be9-cf973f4eda1a">Notes are guaranteed on an unsecured senior basis by the same subsidiaries and affiliated professional contractors that guarantee the Amended Credit Agreement (as defined below). The indenture under which the 2030 Notes are issued, among other things, limits the Company's ability to (1) incur liens and (2) enter into sale and lease-back transactions, and also limits the Company's ability to merge or dispose of all or substantially all of its assets, in all cases, subject to a number of customary exceptions</us-gaap:DebtInstrumentDescription>
    <md:PurchasePrice
      contextRef="C_378538d0-b7e1-4ecd-af00-bb424f0b1747"
      decimals="2"
      id="F_d78da273-1bab-47c9-8dcc-681a2c4c4604"
      unitRef="U_pure">1.01</md:PurchasePrice>
    <us-gaap:UnsecuredDebt
      contextRef="C_d408367b-f06f-4217-a293-02fa802d8521"
      decimals="-6"
      id="F_65f78bb1-1abd-4690-8cf6-5fb833cc8fe8"
      unitRef="U_USD">450000000</us-gaap:UnsecuredDebt>
    <us-gaap:ProceedsFromLinesOfCredit
      contextRef="C_9949ee77-7752-43b8-9d0b-21296bfbc11e"
      decimals="-5"
      id="F_f016b171-191d-445e-8a70-d365c1f46917"
      unitRef="U_USD">37500000</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:UnsecuredLongTermDebt
      contextRef="C_ef12bbdb-7da5-4d1d-98f3-f1b0c3da31ba"
      decimals="-6"
      id="F_3842249f-0548-4a87-846d-72f8d14bf642"
      unitRef="U_USD">250000000</us-gaap:UnsecuredLongTermDebt>
    <us-gaap:DescriptionOfInterestRateRiskExposure
      contextRef="C_e050a756-0027-4664-943e-74db5426b7c8"
      id="F_6ef581d0-45b5-41de-b5d0-32415546f2fa">(i) the Alternate Base Rate (defined as the highest of (a) the prime rate as announced by Bank of America, N.A., (b) the Federal Funds Rate plus 0.50% and (c) Term Secured Overnight Financing Rate ("SOFR") for an interest period of one month plus 1.00% with a 1.00% floor) plus an applicable margin rate of 0.50% for the first two fiscal quarters after the date of the Credit Agreement Amendment, and thereafter at an applicable margin rate ranging from 0.125% to 0.750% based on the Company's consolidated net leverage ratio or (ii) Term SOFR rate (calculated as the Secured Overnight Financing Rate published on the applicable Reuters screen page plus a spread adjustment of 0.10%, 0.15% or 0.25% depending on if the Company selects a one-month, three-month or six-month interest period, respectively, for the applicable loan with a 0% floor), plus an applicable margin rate of 1.50% for the first two full fiscal quarters after the date of the Credit Agreement Amendment, and thereafter at an applicable margin rate ranging from 1.125% to 1.750% based on the Company's consolidated net leverage ratio. The Amended Credit Agreement also provides for other customary fees and charges, including an unused commitment fee with respect to the Revolving Credit Line ranging from 0.150% to 0.200% of the unused lending commitments under the Revolving Credit Line</us-gaap:DescriptionOfInterestRateRiskExposure>
    <us-gaap:LongTermDebt
      contextRef="C_4506227b-6467-48fd-bf2a-12d647f3a96a"
      decimals="-5"
      id="F_85534152-90e1-4704-82c1-00f2091d5142"
      unitRef="U_USD">221900000</us-gaap:LongTermDebt>
    <us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity
      contextRef="C_4506227b-6467-48fd-bf2a-12d647f3a96a"
      decimals="-5"
      id="F_af04071e-f98d-4278-9dfe-ff78a0d71c82"
      unitRef="U_USD">450000000</us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity>
    <us-gaap:LongTermDebt
      contextRef="C_a0685afe-439a-454c-a102-de37c36a07ad"
      decimals="-5"
      id="F_2413387c-dd28-4747-8e62-383ae7b014fa"
      unitRef="U_USD">400000000</us-gaap:LongTermDebt>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf"
      id="F_571b7f60-ca82-44e7-bcf9-40c5976684d9">&lt;p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;9.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Arial;min-width:fit-content;"&gt;            &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;Common and Common Equivalent Shares:&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;Basic net income per common share is calculated by dividing net income by the weighted average number of common shares outstanding during the period. Diluted net income per common share is calculated by dividing net income by the weighted average number of common and potential common shares outstanding during the period. Potential common shares consist of outstanding restricted stock and stock options and is calculated using the treasury stock method.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:9pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;The calculation of shares used in the basic and diluted net income per common share calculation for the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;three and six months ended June 30, 2024 and 2023 is as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:49.07%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.498%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.88%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.178%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:8.978%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.398%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Weighted average number of common shares outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;83,332&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;82,399&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;83,074&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;82,033&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Weighted average number of dilutive common share&lt;br/&gt;&#160;&#160;&#160;equivalents (a)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;265&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;344&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Weighted average number of common and common&lt;br/&gt;&#160;&#160;&#160;equivalent shares outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;83,332&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;82,664&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;83,074&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;82,377&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Antidilutive securities (restricted stock and stock options) not included in the diluted net income per common share calculation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;916&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,338&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;661&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,358&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;"&gt;(a) &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;"&gt;Due to a loss for the three and six months ended June 30, 2024, &lt;/span&gt;&lt;span style="font-size:8.5pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and &lt;/span&gt;&lt;span style="font-size:8.5pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;"&gt; million incremental shares, respectively, are not included because the effect would be antidilutive.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock
      contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf"
      id="F_80381e4f-a1c2-4b7b-9497-1ae07de4f0f2">&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;The calculation of shares used in the basic and diluted net income per common share calculation for the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;three and six months ended June 30, 2024 and 2023 is as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:49.07%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.498%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.88%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.178%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:8.978%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.398%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Weighted average number of common shares outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;83,332&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;82,399&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;83,074&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;82,033&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Weighted average number of dilutive common share&lt;br/&gt;&#160;&#160;&#160;equivalents (a)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;265&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;344&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Weighted average number of common and common&lt;br/&gt;&#160;&#160;&#160;equivalent shares outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;83,332&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;82,664&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;83,074&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;82,377&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Antidilutive securities (restricted stock and stock options) not included in the diluted net income per common share calculation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;916&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,338&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;661&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,358&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;"&gt;(a) &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;"&gt;Due to a loss for the three and six months ended June 30, 2024, &lt;/span&gt;&lt;span style="font-size:8.5pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and &lt;/span&gt;&lt;span style="font-size:8.5pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;"&gt; million incremental shares, respectively, are not included because the effect would be antidilutive.&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_f8ba14c0-203a-4abe-895a-7068e0d681d9"
      decimals="-3"
      id="F_24204417-d660-4713-bd7d-dc0d69f64459"
      unitRef="U_shares">83332000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_5a5fa8ad-967b-444b-af35-7dd7a8bf7ba3"
      decimals="-3"
      id="F_506620dc-b993-4f5d-b4a7-519d111a2803"
      unitRef="U_shares">82399000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf"
      decimals="-3"
      id="F_ab0f7450-5aa9-4f30-bf43-47992e4823e3"
      unitRef="U_shares">83074000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_57ad6014-6b49-4fd8-b8f7-ae2932078fd6"
      decimals="-3"
      id="F_4ffc61a8-526e-46dc-9164-dd5498f886b2"
      unitRef="U_shares">82033000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="C_f8ba14c0-203a-4abe-895a-7068e0d681d9"
      decimals="INF"
      id="F_66ce8c6b-bf02-4620-aebb-b797c84e03c0"
      unitRef="U_shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="C_5a5fa8ad-967b-444b-af35-7dd7a8bf7ba3"
      decimals="INF"
      id="F_366def61-6f60-45f1-ba3d-c025beb3a2f3"
      unitRef="U_shares">265000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf"
      decimals="INF"
      id="F_76080b36-bd54-43be-8e29-8555378a28cc"
      unitRef="U_shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="C_57ad6014-6b49-4fd8-b8f7-ae2932078fd6"
      decimals="INF"
      id="F_57572a1b-018e-4ddb-a8a8-a910ae1e8652"
      unitRef="U_shares">344000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_f8ba14c0-203a-4abe-895a-7068e0d681d9"
      decimals="-3"
      id="F_27617bf4-843f-42ab-bd4f-d87a00af5dc3"
      unitRef="U_shares">83332000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_5a5fa8ad-967b-444b-af35-7dd7a8bf7ba3"
      decimals="-3"
      id="F_4de0b138-dce2-485d-97c7-44272da7deca"
      unitRef="U_shares">82664000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf"
      decimals="-3"
      id="F_889191eb-a96d-4e00-a5d4-c5d53b72846d"
      unitRef="U_shares">83074000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_57ad6014-6b49-4fd8-b8f7-ae2932078fd6"
      decimals="-3"
      id="F_c4d4c140-d72f-419b-988c-2aca845b915a"
      unitRef="U_shares">82377000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_f8ba14c0-203a-4abe-895a-7068e0d681d9"
      decimals="INF"
      id="F_a3b39698-cc60-4981-9a80-dbdfad3aa137"
      unitRef="U_shares">916000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_5a5fa8ad-967b-444b-af35-7dd7a8bf7ba3"
      decimals="INF"
      id="F_653049d4-bed2-4fa8-a155-329545114a13"
      unitRef="U_shares">1338000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf"
      decimals="INF"
      id="F_0e86b410-6079-4bc8-8f4d-5716d7e8d799"
      unitRef="U_shares">661000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_57ad6014-6b49-4fd8-b8f7-ae2932078fd6"
      decimals="INF"
      id="F_f1a5e710-1ebb-4866-998b-2a772ec0690c"
      unitRef="U_shares">1358000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <md:IncrementalSharesNotIncludedDueToAntiDilutiveEffect
      contextRef="C_f8ba14c0-203a-4abe-895a-7068e0d681d9"
      decimals="-5"
      id="F_181412ae-4e8f-4c1f-92c6-af668cc6bb09"
      unitRef="U_shares">100000</md:IncrementalSharesNotIncludedDueToAntiDilutiveEffect>
    <md:IncrementalSharesNotIncludedDueToAntiDilutiveEffect
      contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf"
      decimals="-5"
      id="F_19a0a234-01ed-4015-825b-870ed9d5bb52"
      unitRef="U_shares">300000</md:IncrementalSharesNotIncludedDueToAntiDilutiveEffect>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf"
      id="F_004b56ee-63da-41b7-9a30-480dc24698f0">&lt;p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;10.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Arial;min-width:fit-content;"&gt;            &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;Stock Incentive Plans and Stock Purchase Plans:&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company&#x2019;s Amended and Restated 2008 Incentive Compensation Plan (the &#x201c;Amended and Restated 2008 Incentive Plan&#x201d;) provides for grants of stock options, stock appreciation rights, restricted stock, deferred stock, and other stock-related awards and performance awards that may be settled in cash, stock or other property.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;Under the Amended and Restated 2008 Incentive Plan, options to purchase shares of common stock may be granted at a price not less than the fair market value of the shares on the date of grant. The options must be exercised within &lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;10 years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt; from the date of grant and generally become exercisable on a pro rata basis over a &lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;three-year&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt; period from the date of grant. The Company issues new shares of its common stock upon exercise of its stock options. Restricted stock awards generally vest over periods of &lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;three years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt; upon the fulfillment of specified service-based conditions and in certain instances performance-based conditions. Deferred stock awards generally vest upon the satisfaction of specified performance-based conditions and service-based conditions. The Company recognizes compensation expense related to its restricted stock and deferred stock awards ratably over the corresponding vesting periods. During the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;six months ended June 30, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;, the Company granted &lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt; million shares of restricted stock to its employees and non-employee directors under the Amended and Restated 2008 Incentive Plan. At June 30, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;, the Company had &lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt; million shares available for future grants and awards under the Amended and Restated 2008 Incentive Plan.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;   &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;Under the Company&#x2019;s Amended and Restated 1996 Non-Qualified Employee Stock Purchase Plan, as amended (the &#x201c;ESPP&#x201d;), employees are permitted to purchase the Company's common stock at &lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;85&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;% of market value on January 1st, April 1st, July 1st and October 1st of each year. Under the Company&#x2019;s 2015 Non-Qualified Stock Purchase Plan (the &#x201c;SPP&#x201d;), certain eligible non-employee service providers are permitted to purchase the Company&#x2019;s common stock at &lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;90&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;% of market value on January 1st, April 1st, July 1st and October 1st of each year.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company recognizes stock-based compensation expense for the discount received by participating employees and non-employee service providers. During the six months ended June 30, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;, approximately &lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt; million shares were issued under the ESPP. At June 30, 2024, the Company had approximately &lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt; million shares reserved for issuance under the ESPP. At June 30, 2024, the Company had approximately &lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;61,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares in the aggregate reserved for issuance under the SPP.  &lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;No&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares have been issued under the SPP since 2020.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;During the three and six months ended June 30, 2024 and 2023, the Company recognized stock-based compensation expense of $&lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, respectively.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="C_270805f0-aab2-410a-81a6-0fd72e3a746a"
      id="F_48e02f9c-80b0-4dee-81c9-bae010472edd">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_ab52b5b0-1d74-4f4b-8f22-0ab60d83e515"
      id="F_c38c526a-9750-4ff5-8557-8b0cdcbffedf">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_7cf5d7c6-f082-42c8-aa0e-fe1ed65ec2d0"
      id="F_594a1192-7cd8-47c5-8fcb-79ec5eabc3a8">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="C_0ca0f3da-cd87-48f0-9af2-4b8a86903bc0"
      decimals="-5"
      id="F_4f968453-9d20-44a6-86b9-3523e1b4e653"
      unitRef="U_shares">1400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_70422dcf-ff02-49e5-8b94-24099256e942"
      decimals="-5"
      id="F_38c7607e-83f7-4ea7-81ac-11970a17267e"
      unitRef="U_shares">6300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="C_2d25298d-eb54-4bce-a6ef-521cc063eeb3"
      decimals="2"
      id="F_f22ed4c3-d8a7-4326-a97d-9f456348f59e"
      unitRef="U_pure">0.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="C_32a74e36-4b2a-435f-abc7-46f886f94451"
      decimals="2"
      id="F_1ac5c239-2459-496f-926c-2c87f35233b7"
      unitRef="U_pure">0.90</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="C_ab52b5b0-1d74-4f4b-8f22-0ab60d83e515"
      decimals="-5"
      id="F_e8a9f8c3-2877-44ad-a895-8f623d7ffa28"
      unitRef="U_shares">200000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_690872af-c97c-4e54-9314-3d7d7de3a6f3"
      decimals="-5"
      id="F_8bf964f2-0952-4ce6-9630-92021394ff61"
      unitRef="U_shares">1800000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_5dea8f8c-6ce2-4ac6-b2b8-2c6020fb27ef"
      decimals="-3"
      id="F_1d5a86e1-1b50-4b16-853f-1ded171d5022"
      unitRef="U_shares">61000000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="C_dc0ea4b3-aac8-4793-b9f2-f1f63e43c02c"
      decimals="-6"
      id="F_6fce273e-733d-4533-8a7a-1172ffb059a4"
      unitRef="U_shares">0</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_f8ba14c0-203a-4abe-895a-7068e0d681d9"
      decimals="-5"
      id="F_f78f5d6b-c5cc-4114-9373-cbfc89493e16"
      unitRef="U_USD">2000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_5a5fa8ad-967b-444b-af35-7dd7a8bf7ba3"
      decimals="-5"
      id="F_e547d652-a034-400b-837b-f025d05483ca"
      unitRef="U_USD">4900000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf"
      decimals="-5"
      id="F_545508f3-2d60-406c-8bdb-163c74485e54"
      unitRef="U_USD">3100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_57ad6014-6b49-4fd8-b8f7-ae2932078fd6"
      decimals="-5"
      id="F_57897584-9fe7-4903-b71c-5c602e446b65"
      unitRef="U_USD">6100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <md:CommonStockRepurchasesTextBlock
      contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf"
      id="F_05c93d01-3c3e-45fd-8125-f1328991bf46">&lt;p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;11.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Arial;min-width:fit-content;"&gt;            &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;Common Stock Repurchase Programs:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;In July 2013, the Company&#x2019;s Board of Directors authorized the repurchase of shares of the Company&#x2019;s common stock up to an amount sufficient to offset the dilutive impact from the issuance of shares under the Company&#x2019;s equity compensation programs. The share repurchase program allows the Company to make open market purchases from time-to-time based on general economic and market conditions and trading restrictions. The repurchase program also allows for the repurchase of shares of the Company&#x2019;s common stock to offset the dilutive impact from the issuance of shares, if any, related to the Company&#x2019;s acquisition program. &lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;No&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares were purchased under this program during the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;six months ended June 30, 2024.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;In August 2018, the Company announced that its Board of Directors had authorized the repurchase of up to $&lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;500.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt; million of the Company&#x2019;s common stock in addition to its existing share repurchase program, of which $&lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt; million remained available for repurchase as of December 31, 2023. Under this share repurchase program, during the six months ended June 30, 2024, the Company purchased a nominal number of shares of its common stock for $&lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt; million representing shares withheld to satisfy minimum statutory withholding obligations in connection with the vesting of restricted stock, resulting in $&lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt; million remaining available for repurchase under this authorization as of June 30, 2024.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company intends to utilize various methods to effect any future share repurchases, including, among others, open market purchases and accelerated share repurchase programs. The amount and timing of repurchases will depend upon several factors, including general economic and market conditions and trading restrictions.&lt;/span&gt;</md:CommonStockRepurchasesTextBlock>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf"
      decimals="INF"
      id="F_db755eae-a413-40de-beb8-7b3a4f44d139"
      unitRef="U_shares">0</us-gaap:StockRepurchasedDuringPeriodShares>
    <srt:StockRepurchaseProgramAuthorizedAmount1
      contextRef="C_c38ac2d9-9615-4715-baeb-08e4368151a9"
      decimals="-5"
      id="F_ca315e02-a0ef-4df3-b5f2-927fcdf53091"
      unitRef="U_USD">500000000</srt:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1
      contextRef="C_01d46517-67df-489d-b34d-e087cf6dadaf"
      decimals="-5"
      id="F_400d3bc6-d503-499a-b3b2-cf774d58f11a"
      unitRef="U_USD">4600000</us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="C_0971ef72-7587-4d12-8daf-522e84254143"
      decimals="-5"
      id="F_4944c6ac-3ceb-4db8-a510-2517baa60588"
      unitRef="U_USD">900000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1
      contextRef="C_f58ff9fd-0a96-40d3-97e1-a038b63ab720"
      decimals="-5"
      id="F_809bd645-0ac7-4981-8361-e54525932844"
      unitRef="U_USD">3700000</us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="C_0037f299-00cc-441c-a3a7-d37288934aaf"
      id="F_822c3995-8358-44aa-b217-3574aaff9dd7">&lt;p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;12.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Arial;min-width:fit-content;"&gt;            &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;Commitments and Contingencies:	&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company expects that audits, inquiries and investigations from government authorities and agencies will occur in the ordinary course of business. Such audits, inquiries and investigations and their ultimate resolutions, individually or in the aggregate, could have a material adverse effect on the Company's business, financial condition, results of operations, cash flows and the trading price of its securities. The Company has not included an accrual for these matters as of June 30, 2024 in its Consolidated Financial Statements, as the variables affecting any potential eventual liability depend on the currently unknown facts and circumstances that arise out of, and are specific to, any particular future audit, inquiry and investigation and cannot be reasonably estimated at this time.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;In the ordinary course of business, the Company becomes involved in pending and threatened legal actions and proceedings, most of which involve claims of medical malpractice related to medical services provided by the Company's affiliated physicians. The Company's contracts with hospitals generally require the Company to indemnify them and their affiliates for losses resulting from the negligence of the Company's affiliated physicians. The Company may also become subject to other lawsuits which could involve large claims and significant costs. The Company believes, based upon a review of pending actions and proceedings, that the outcome of such legal actions and proceedings will not have a material adverse effect on its business, financial condition, results of operations, cash flows and the trading price of its securities. The outcome of such actions and proceedings, however, cannot be predicted with certainty and an unfavorable resolution of one or more of them could have a material adverse effect on the Company's business, financial condition, results of operations, cash flows and the trading price of its securities.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;Although the Company currently maintains liability insurance coverage intended to cover professional liability and certain other claims, the Company cannot assure that its insurance coverage will be adequate to cover liabilities arising out of claims asserted against it in the future where the outcomes of such claims are unfavorable. With respect to professional liability risk, the Company generally self-insures a portion of this risk through its wholly owned captive insurance subsidiary. Liabilities in excess of the Company's insurance coverage, including coverage for professional liability and certain other claims, could have a material adverse effect on the Company's business, financial condition, results of operations, cash flows and the trading price of its securities.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <ecd:Rule10b51ArrAdoptedFlag
      contextRef="C_f8ba14c0-203a-4abe-895a-7068e0d681d9"
      id="F_6fcdac8a-10fb-4404-834f-c4d1f4fea0d3">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrAdoptedFlag
      contextRef="C_f8ba14c0-203a-4abe-895a-7068e0d681d9"
      id="F_bac399c8-c17a-4d2f-87d7-9613da402582">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrTrmntdFlag
      contextRef="C_f8ba14c0-203a-4abe-895a-7068e0d681d9"
      id="F_1c553998-bee3-4ea1-a87f-96e9a93dc9f7">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:Rule10b51ArrTrmntdFlag
      contextRef="C_f8ba14c0-203a-4abe-895a-7068e0d681d9"
      id="F_109f24c6-b24c-4c79-b699-6e8f793328e9">false</ecd:Rule10b51ArrTrmntdFlag>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#F_57572a1b-018e-4ddb-a8a8-a910ae1e8652"
          xlink:label="F_57572a1b-018e-4ddb-a8a8-a910ae1e8652"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_366def61-6f60-45f1-ba3d-c025beb3a2f3"
          xlink:label="F_366def61-6f60-45f1-ba3d-c025beb3a2f3"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_76080b36-bd54-43be-8e29-8555378a28cc"
          xlink:label="F_76080b36-bd54-43be-8e29-8555378a28cc"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_66ce8c6b-bf02-4620-aebb-b797c84e03c0"
          xlink:label="F_66ce8c6b-bf02-4620-aebb-b797c84e03c0"
          xlink:type="locator"/>
        <link:footnote id="FNT_744c8b1e-b9b8-41e6-bb9a-b20ca1c97fb6" xlink:label="FNT_744c8b1e-b9b8-41e6-bb9a-b20ca1c97fb6" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;">Due to a loss for the three and six months ended June 30, 2024, </xhtml:span><xhtml:span style="font-size:8.5pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.1</xhtml:span><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;"> million and </xhtml:span><xhtml:span style="font-size:8.5pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.3</xhtml:span><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;"> million incremental shares, respectively, are not included because the effect would be antidilutive.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_57572a1b-018e-4ddb-a8a8-a910ae1e8652"
          xlink:to="FNT_744c8b1e-b9b8-41e6-bb9a-b20ca1c97fb6"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_366def61-6f60-45f1-ba3d-c025beb3a2f3"
          xlink:to="FNT_744c8b1e-b9b8-41e6-bb9a-b20ca1c97fb6"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_76080b36-bd54-43be-8e29-8555378a28cc"
          xlink:to="FNT_744c8b1e-b9b8-41e6-bb9a-b20ca1c97fb6"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_66ce8c6b-bf02-4620-aebb-b797c84e03c0"
          xlink:to="FNT_744c8b1e-b9b8-41e6-bb9a-b20ca1c97fb6"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
